FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Guy, GP Berkowitz, Z Ekwueme, DU Rim, SH Yabroff, KR AF Guy, Gery P., Jr. Berkowitz, Zahava Ekwueme, Donatus U. Rim, Sun Hee Yabroff, K. Robin TI Annual Economic Burden of Productivity Losses Among Adult Survivors of Childhood Cancers SO PEDIATRICS LA English DT Article ID HEALTH-INSURANCE COVERAGE; AFFORDABLE CARE ACT; UNITED-STATES; COHORT; AGREEMENT; OUTCOMES AB BACKGROUND AND OBJECTIVES: Although adult survivors of childhood cancers have poorer health and greater health limitations than other adults, substantial gaps remain in understanding the economic consequences of surviving childhood cancer. Therefore, we estimated the economic burden of productivity losses among adult survivors of childhood cancers. METHODS: We examined health status, functional limitations, and productivity loss among adult survivors of childhood cancers (n = 239) diagnosed at = 14 years of age compared with adults without a history of cancer (n = 304 265) by using the 2004-2014 National Health Interview Survey. We estimated economic burden using the productivity loss from health-related unemployment, missed work days, missed household productivity, and multivariable regression models controlling for age, sex, race/ethnicity, education, comorbidities, and survey year. RESULTS: Childhood cancer survivorship is associated with a substantial economic burden. Adult survivors of childhood cancers are more likely to be in poorer health, need assistance with personal care and routine needs, have work limitations, be unable to work because of health, miss more days of work, and have greater household productivity loss compared with adults without a history of cancer (all P < .05). The annual productivity loss for adult survivors of childhood cancer is $8169 per person compared with $3083 per person for individuals without a history of cancer. CONCLUSIONS: These findings underscore the importance of efforts to reduce the health and economic burden among adult survivors of childhood cancer. In addition, this study highlights the potential productivity losses that could be avoided during adulthood from the prevention of childhood cancer in the United States. C1 [Guy, Gery P., Jr.; Berkowitz, Zahava; Ekwueme, Donatus U.; Rim, Sun Hee] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA USA. [Yabroff, K. Robin] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. RP Guy, GP (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,MS F-76, Chamblee, GA 30341 USA. EM irm2@cdc.gov FU US Government FX All authors are federal government employees, and the preparation of the manuscript was entirely funded by the US Government. NR 34 TC 0 Z9 0 U1 1 U2 1 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD NOV PY 2016 VL 138 SU 1 BP S15 EP S21 DI 10.1542/peds.2015-4268D PG 7 WC Pediatrics SC Pediatrics GA EE2LA UT WOS:000389414300003 PM 27940973 ER PT J AU Holman, DM Buchanan, ND AF Holman, Dawn M. Buchanan, Natasha D. CA Canc Prevention During Early Life TI Opportunities During Early Life for Cancer Prevention: Highlights From a Series of Virtual Meetings With Experts SO PEDIATRICS LA English DT Article ID LEUKEMIA-INTERNATIONAL-CONSORTIUM; ACUTE LYMPHOBLASTIC-LEUKEMIA; PARENTAL OCCUPATIONAL-EXPOSURE; ENVIRONMENTAL-HEALTH SCIENCE; NERVOUS-SYSTEM TUMORS; CHILDHOOD-LEUKEMIA; BREAST-CANCER; BIRTH-WEIGHT; ATAXIA-TELANGIECTASIA; RADIATION-EXPOSURE AB Compelling evidence suggests that early life exposures can affect lifetime cancer risk. In 2014, the Centers for Disease Control and Prevention's (CDC's) Cancer Prevention Across the Lifespan Workgroup hosted a series of virtual meetings with select experts to discuss the state of the evidence linking factors during the prenatal period and early childhood to subsequent risk of both pediatric and adult cancers. In this article, we present the results from a qualitative analysis of the meeting transcripts and summarize themes that emerged from our discussions with meeting participants. Themes included the state of the evidence linking early life factors to cancer risk, research gaps and challenges, the level of evidence needed to support taking public health action, and the challenges of communicating complex, and sometimes conflicting, scientific findings to the public. Opportunities for collaboration among public health agencies and other stakeholders were identified during these discussions. Potential next steps for the CDC and its partners included advancing and building upon epidemiology and surveillance work, developing and using evidence from multiple sources to inform decision-making, disseminating and communicating research findings in a clear and effective way, and expanding collaborations with grantees and other partners. As the science on early life factors and cancer risk continues to evolve, there are opportunities for collaboration to translate science into actionable public health practice. C1 [Holman, Dawn M.; Buchanan, Natasha D.; Canc Prevention During Early Life] Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,Mailstop F76, Atlanta, GA 30327 USA. RP Holman, DM (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,Mailstop F76, Atlanta, GA 30327 USA. EM dholman@cdc.gov RI Heck, Julia/B-5230-2009 OI Heck, Julia/0000-0001-8713-8413 FU US government FX Ms Holman and Dr Buchanan are federal government employees and preparation of this manuscript was entirely funded by the US government. NR 119 TC 0 Z9 0 U1 6 U2 6 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD NOV PY 2016 VL 138 SU 1 BP S3 EP S14 DI 10.1542/peds.2015-4268C PG 12 WC Pediatrics SC Pediatrics GA EE2LA UT WOS:000389414300002 PM 27940972 ER PT J AU Holman, DM Ports, KA Buchanan, ND Hawkins, NA Merrick, MT Metzler, M Trivers, KF AF Holman, Dawn M. Ports, Katie A. Buchanan, Natasha D. Hawkins, Nikki A. Merrick, Melissa T. Metzler, Marilyn Trivers, Katrina F. TI The Association Between Adverse Childhood Experiences and Risk of Cancer in Adulthood: A Systematic Review of the Literature SO PEDIATRICS LA English DT Review ID CERVICAL-CANCER; PHYSICAL ABUSE; LIFE; DISEASE; VIOLENCE; STRESS; STATES; INFLAMMATION; MORTALITY; FRAMEWORK AB CONTEXT: Adverse childhood experiences (ACEs) can affect health and well-being across the life course. OBJECTIVE: This systematic review summarizes the literature on associations between ACEs and risk of cancer in adulthood. DATA SOURCES: We searched PubMed to identify relevant publications published on or before May 31, 2015. STUDY SELECTION: We included original research quantifying the association between ACEs and adult cancer incidence. Case reports and reviews were excluded. DATA ABSTRACTION: Two reviewers independently abstracted and summarized key information (eg, ACE type, cancer type, risk estimates) from included studies and resolved all discrepancies. RESULTS: Twelve studies were included in the review. In studies in which ACE summary scores were calculated, significant associations were observed between the scores and an increased risk of cancer in adulthood. Of the different types of ACEs examined, physical and psychological abuse victimization were associated with risk of any cancer in 3 and 2 studies, respectively. Two studies also reported significant associations with regard to sexual abuse victimization (1 for cervical cancer and 1 for any cancer). However, 2 other studies reported no significant associations between childhood sexual or physical abuse and incidence of cervical or breast cancer. LIMITATIONS: Because of heterogeneity across studies, we were unable to compute a summary effect estimate. CONCLUSIONS: These findings suggest that childhood adversity in various forms may increase a person's cancer risk. Further research is needed to understand the mechanisms driving this relationship and to identify opportunities to prevent and mitigate the deleterious effects of early adversity on long-term health. C1 [Holman, Dawn M.; Buchanan, Natasha D.; Hawkins, Nikki A.; Trivers, Katrina F.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,Mailstop F76, Atlanta, GA 30327 USA. [Ports, Katie A.; Merrick, Melissa T.; Metzler, Marilyn] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. RP Holman, DM (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,Mailstop F76, Atlanta, GA 30327 USA. EM dholman@cdc.gov FU US government FX All authors are federal government employees, and the preparation of the manuscript was entirely funded by the US government. NR 43 TC 0 Z9 0 U1 3 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD NOV PY 2016 VL 138 SU 1 BP S81 EP S91 DI 10.1542/peds.2015-4268 PG 11 WC Pediatrics SC Pediatrics GA EE2LA UT WOS:000389414300011 PM 27940981 ER PT J AU Massetti, GM Thomas, CC Ragan, KR AF Massetti, Greta M. Thomas, Cheryll C. Ragan, Kathleen R. TI Disparities in the Context of Opportunities for Cancer Prevention in Early Life SO PEDIATRICS LA English DT Article ID ADVERSE CHILDHOOD EXPERIENCES; ACUTE LYMPHOBLASTIC-LEUKEMIA; NUTRITION EXAMINATION SURVEY; ENVIRONMENTAL TOBACCO-SMOKE; DAY-CARE ATTENDANCE; OF-THE-LITERATURE; UNITED-STATES; TESTICULAR CANCER; SECONDHAND SMOKE; BIRTH-WEIGHT AB Persistent health disparities are a major contributor to disproportionate burden of cancer for some populations. Health disparities in cancer incidence and mortality may reflect differences in exposures to risk factors early in life. Understanding the distribution of exposures to early life risk and protective factors for cancer across different populations can shed light on opportunities to promote health equity at earlier developmental stages. Disparities may differentially influence risk for cancer during early life and create opportunities to promote health equity. Potential risk and protective factors for cancer in early life reveal patterns of disparities in their exposure. These disparities in exposures can manifest in downstream disparities in risk for cancer. These risk and protective factors include adverse childhood experiences; maternal alcohol consumption in pregnancy; childhood obesity; high or low birth weight; benzene exposure; use of assisted reproductive technologies; pesticide and insecticide exposure; isolated cryptorchidism; early pubertal timing; exposure to radiation; exposure to tobacco in utero and in early life; allergies, asthma, and atopy; and early exposure to infection. Disparities on the basis of racial and ethnic minority status, economic disadvantage, disability status, sex, geography, and nation of origin can occur in these risk and protective factors. Vulnerable populations experience disproportionally greater exposure to risk factors in early life. Addressing disparities in risk factors in early life can advance opportunities for prevention, promote health equity, and possibly reduce risk for subsequent development of cancer. C1 [Massetti, Greta M.; Thomas, Cheryll C.; Ragan, Kathleen R.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Massetti, GM (reprint author), Div Canc Prevent & Control, 4770 Buford Hwy NE,MS K76, Atlanta, GA 30341 USA. EM gmassetti@cdc.gov FU Intramural CDC HHS [CC999999] NR 110 TC 0 Z9 0 U1 4 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD NOV PY 2016 VL 138 SU 1 BP S65 EP S77 DI 10.1542/peds.2015-4268J PG 13 WC Pediatrics SC Pediatrics GA EE2LA UT WOS:000389414300009 PM 27940979 ER PT J AU White, MC Peipins, LA Holman, DM AF White, Mary C. Peipins, Lucy A. Holman, Dawn M. TI Labeling Cancer Risk Factors as Lifestyle Limits Prevention Activities Across the Life Span SO PEDIATRICS LA English DT Editorial Material ID HEALTH C1 [White, Mary C.; Peipins, Lucy A.; Holman, Dawn M.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA USA. RP White, MC (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA USA.; White, MC (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,MS F76, Atlanta, GA 30341 USA. EM mxw5@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD NOV PY 2016 VL 138 SU 1 BP S95 EP S97 DI 10.1542/peds.2015-4268N PG 3 WC Pediatrics SC Pediatrics GA EE2LA UT WOS:000389414300013 PM 27940983 ER PT J AU White, MC Holman, DM Massetti, GM AF White, Mary C. Holman, Dawn M. Massetti, Greta M. TI Foreword: Cancer Prevention Can Start Early and Last a Lifetime SO PEDIATRICS LA English DT Editorial Material ID EXPOSURES; DEATH C1 [White, Mary C.; Holman, Dawn M.; Massetti, Greta M.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP White, MC (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,MS F76, Atlanta, GA 30341 USA. EM mxw5@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD NOV PY 2016 VL 138 SU 1 BP S1 EP S2 DI 10.1542/peds.2015-4268B PG 2 WC Pediatrics SC Pediatrics GA EE2LA UT WOS:000389414300001 PM 27940971 ER PT J AU Wright, TE Terplan, M Ondersma, SJ Boyce, C Yonkers, K Chang, G Creanga, AA AF Wright, Tricia E. Terplan, Mishka Ondersma, Steven J. Boyce, Cheryl Yonkers, Kimberly Chang, Grace Creanga, Andreea A. TI The role of screening, brief intervention, and referral to treatment in the perinatal period SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE alcohol; brief intervention; opioid use; pregnancy; referral to treatment; screening; substance use disorders; tobacco ID ILLICIT DRUG-USE; SUBSTANCE-USE; ALCOHOL-USE; PREGNANT-WOMEN; RANDOMIZED-TRIAL; MECONIUM ANALYSIS; POSTPARTUM WOMEN; CLINICAL CARE; UNITED-STATES; ABUSE AB Substance use during pregnancy is at least as common as many of the medical conditions screened for and managed during pregnancy. While harmful and costly, it is often ignored or managed poorly. Screening, brief intervention, and referral to treatment is an evidence-based approach to manage substance use. In September 2012, the US Centers for Disease Control and Prevention convened an Expert Meeting on Perinatal Illicit Drug Abuse to help address key issues around drug use in pregnancy in the United States. This article reflects the formal conclusions of the expert panel that discussed the use of screening, brief intervention, and referral to treatment during pregnancy. Screening for substance use during pregnancy should be universal. It allows stratification of women into zones of risk given their pattern of use. Low-risk women should receive brief advice, those classified as moderate risk should receive a brief intervention, whereas those who are high risk need referral to specialty care. A brief intervention is a patient-centered form of counseling using the principles of motivational interviewing. Screening, brief intervention, and referral to treatment has the potential to reduce the burden of substance use in pregnancy and should be integrated into prenatal care. C1 [Wright, Tricia E.] Univ Hawaii, John A Burns Sch Med, Dept Obstet Gynecol & Womens Hlth, Honolulu, HI 96822 USA. [Wright, Tricia E.] Univ Hawaii, John A Burns Sch Med, Dept Psychiat, Honolulu, HI 96822 USA. [Terplan, Mishka] Behav Hlth Syst, Baltimore, MD USA. [Ondersma, Steven J.] Wayne State Univ, Merrill Palmer Skillman Inst, Dept Psychiat & Behav Neurosci, Detroit, MI USA. [Ondersma, Steven J.] Wayne State Univ, Merrill Palmer Skillman Inst, Dept Obstet & Gynecol, Detroit, MI USA. [Boyce, Cheryl] NIDA, Div Clin Neurosci & Behav Res, NIH, Bethesda, MD 20892 USA. [Yonkers, Kimberly] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Yonkers, Kimberly] Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06510 USA. [Yonkers, Kimberly] Yale Univ, Sch Med, Sch Epidemiol & Publ Hlth, New Haven, CT 06510 USA. [Chang, Grace] Harvard Med Sch, Dept Psychiat, Boston, MA USA. [Chang, Grace] Boston Healthcare Syst, Dept Vet Affairs, Dept Psychiat, Brockton, MA USA. [Creanga, Andreea A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Creanga, Andreea A.] Johns Hopkins Bloomberg Sch Publ Hlth, Int Ctr Maternal & Newborn Hlth, Baltimore, MD USA. [Creanga, Andreea A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Wright, TE (reprint author), Univ Hawaii, John A Burns Sch Med, Dept Obstet Gynecol & Womens Hlth, Honolulu, HI 96822 USA.; Wright, TE (reprint author), Univ Hawaii, John A Burns Sch Med, Dept Psychiat, Honolulu, HI 96822 USA. EM tewright@hawaii.edu NR 65 TC 3 Z9 3 U1 3 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD NOV PY 2016 VL 215 IS 5 BP 539 EP 547 DI 10.1016/j.ajog.2016.06.038 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EE3RK UT WOS:000389513700002 PM 27373599 ER PT J AU Van Epps, P Tumpey, T Higgins, P Hornick, T Burant, C Wilson, B Gravenstein, S Canaday, DH AF Van Epps, P. Tumpey, T. Higgins, P. Hornick, T. Burant, C. Wilson, B. Gravenstein, S. Canaday, D. H. TI PREEXISTING IMMUNITY NOT FRAILTY PREDICTS INFLUENZA VACCINE RESPONSES AMONG OLDER VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Van Epps, P.; Higgins, P.; Hornick, T.; Burant, C.; Wilson, B.; Canaday, D. H.] Cleveland VA, GRECC, Cleveland, VA USA. [Van Epps, P.; Higgins, P.; Burant, C.; Gravenstein, S.; Canaday, D. H.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Tumpey, T.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 184 EP 184 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585000672 ER PT J AU Snyder, GM Patel, PR Kallen, AJ Strom, JA Tucker, JK D'Agata, EMC AF Snyder, Graham M. Patel, Priti R. Kallen, Alexander J. Strom, James A. Tucker, J. Kevin D'Agata, Erika M. C. TI Factors associated with the receipt of antimicrobials among chronic hemodialysis patients SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Hemodialysis; antimicrobial stewardship; multidrug-resistant organism ID INFECTIOUS-DISEASES-SOCIETY; RESISTANT BACTERIA; AMERICA GUIDELINES; VASCULAR ACCESS; RESIDENTS; DIAGNOSIS; MANAGEMENT; CONVERSION; MORTALITY; ADULTS AB Background: Antimicrobial use is common among patients receiving chronic hemodialysis (CHD) and may represent an important antimicrobial stewardship opportunity. The objective of this study is to characterize CHD patients at increased risk of receiving antimicrobials, including not indicated antimicrobials. Methods: We conducted a prospective cohort study over a 12-month period among patients receiving CHD in 2 outpatient dialysis units. Each parenteral antimicrobial dose administered was characterized as indicated or not indicated based on national guidelines. Patient factors associated with receipt of antimicrobials and receipt of >= 1 inappropriate antimicrobial dose were analyzed. Results: A total of 89 of 278 CHD patients (32%) received >= 1 antimicrobial doses and 52 (58%) received >= 1 inappropriately indicated dose. Patients with tunneled catheter access, a history of colonization or infection with a multidrug-resistant organism, and receiving CHD sessions during daytime shifts were more likely to receive antimicrobials (odds ratio [OR], 5.16; 95% confidence interval [CI], 2.72-9.80; OR, 5.43; 95% CI, 1.84-16.06; OR, 4.59; 95% CI, 1.20-17.52, respectively). Patients with tunneled catheter access, receiving CHD at dialysis unit B, and with a longer duration of CHD prior to enrollment were at higher risk of receiving an inappropriately indicated antimicrobial dose (incidence rate ratio, 2.23; 95% CI, 1.16-4.29; incidence rate ratio, 2.67; 95% CI, 1.34-5.35; incidence rate ratio, 1.11; 95% CI, 1.01-1.23, respectively). Conclusions: This study of all types of antimicrobials administered in 2 outpatient dialysis units identified several important factors to consider when developing antimicrobial stewardship programs in this health care setting. (C) 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Snyder, Graham M.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Patel, Priti R.; Kallen, Alexander J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Strom, James A.] Tufts Univ, Sch Med, St Elizabeths Med Ctr, Boston, MA 02111 USA. [Tucker, J. Kevin] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA. [D'Agata, Erika M. C.] Brown Univ, Sch Med, Rhode Isl Hosp, Providence, RI 02912 USA. RP Snyder, GM (reprint author), Beth Israel Deaconess Med Ctr, Div Infect Dis, 330 Brookline Ave,Mailstop SL 435, Boston, MA 02215 USA. EM gsnyder@bidmc.harvard.edu FU Centers for Disease Control and Prevention Division of Healthcare Quality Promotion [10IPA1004108]; Agency for Healthcare Research and Quality [R18HS021666] FX Supported by the Centers for Disease Control and Prevention Division of Healthcare Quality Promotion (intergovernmental personnel agreement no. 10IPA1004108) and the Agency for Healthcare Research and Quality (grant no. R18HS021666 to E.M.C.D.). NR 32 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD NOV 1 PY 2016 VL 44 IS 11 BP 1269 EP 1274 DI 10.1016/j.ajic.2016.03.034 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EE3QQ UT WOS:000389510700032 PM 27184209 ER PT J AU Talaat, M El-Shokry, M El-Kholy, J Ismail, G Kotb, S Hafez, S Attia, E Lessa, FC AF Talaat, Maha El-Shokry, Mona El-Kholy, Jehan Ismail, Ghada Kotb, Sara Hafez, Soad Attia, Ehab Lessa, Fernanda C. TI National surveillance of health care-associated infections in Egypt: Developing a sustainable program in a resource-limited country SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Health care-associated infections; antimicrobial resistance; surveillance in intensive care units ID BLOOD-STREAM INFECTION; RISK-FACTORS; UNITS; PREVALENCE; RATES; HOSPITALS AB Background: Health care-associated infections (HAIs) are a major global public health concern. The lack of surveillance systems in developing countries leads to an underestimation of the global burden of HAI. We describe the process of developing a national HAI surveillance program and the magnitude of HAI rates in Egypt. Methods: The detailed process of implementation of a national HAI surveillance program is described. A 3-phase surveillance approach was implemented in intensive care units (ICUs). This article focuses on results from the phase 2 surveillance. Standard surveillance definitions were used, clinical samples were processed by the hospital laboratories, and results were confirmed by a reference laboratory. Results: Ninety-one ICUs in 28 hospitals contributed to 474,544 patient days and 2,688 HAIs. Of these, 30% were bloodstream infections, 29% were surgical site infections, 26% were pneumonia, and 15% were urinary tract infections. Ventilator-associated pneumonia had the highest incidence of device-associated infections (4.3/1,000 ventilator days). The most common pathogens reported were Klebsiella spp (28.7%) and Acinetobacter spp (13.7%). Of the Acinetobacter spp, 92.8% (157/169) were multidrug resistant, whereas 42.5% (151/355) of the Klebsiella spp and 54% (47/87) of Escherichia coli were extended-spectrum beta-lactamase producers. Conclusions: Implementation of a sustainable surveillance system in a resource-limited country was possible following a stepwise approach with continuous evaluation. Enhancing infection prevention and control programs should be an infection control priority in Egypt. (C) 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. C1 [Talaat, Maha; El-Shokry, Mona; Kotb, Sara] US Ctr Dis Control & Prevent, Global Dis Detect Ctr, Cairo, Egypt. [Talaat, Maha; El-Shokry, Mona; Kotb, Sara] US Naval Med Res Unit, Cairo, Egypt. [El-Shokry, Mona; Ismail, Ghada] Ain Shams Univ Hosp, Cairo, Egypt. [El-Kholy, Jehan] Cairo Univ Hosp, Cairo, Egypt. [Hafez, Soad] Alexandria Univ Hosp, Alexandria, Egypt. [Attia, Ehab] Minist Hlth & Populat, Cairo, Egypt. [Lessa, Fernanda C.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Talaat, M (reprint author), Abbassia Fever Hosp, 3A Imtidad Ramses St, Cairo 11517, Egypt. EM maha.m.talaat.ctr@mail.mil FU U.S. Agency for International Development (USAID-Egypt) [263-T-14-0001] FX Supported by the U.S. Agency for International Development (USAID-Egypt), Work Unit 263-T-14-0001. NR 31 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD NOV 1 PY 2016 VL 44 IS 11 BP 1296 EP 1301 DI 10.1016/j.ajic.2016.04.212 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EE3QQ UT WOS:000389510700037 PM 27339791 ER PT J AU Conwell, Y Van Orden, K Stone, DM Rowe, J McIntosh, WL Tu, X Podgorski, C AF Conwell, Y. Van Orden, K. Stone, D. M. Rowe, J. McIntosh, W. LikamWa Tu, X. Podgorski, C. TI THE SENIOR CONNECTION: A RANDOMIZED TRIAL OF PEER COMPANIONSHIP TO REDUCE SUICIDE RISK IN LATER LIFE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Conwell, Y.; Van Orden, K.; Tu, X.; Podgorski, C.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Stone, D. M.; McIntosh, W. LikamWa] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rowe, J.] Lifespan Greater Rochester Inc, Rochester, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 121 EP 121 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585000443 ER PT J AU French, M Bouldin, E Edwards, V McGuire, L AF French, M. Bouldin, E. Edwards, V. McGuire, L. TI SUBJECTIVE COGNITIVE DECLINE: DISCUSSIONS WITH HEALTH CARE PROFESSIONALS, 2013 BRFSS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Edwards, V.; McGuire, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bouldin, E.] Univ Washington, Seattle, WA 98195 USA. [French, M.] Alzheimers Assoc, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 249 EP 250 PG 2 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001177 ER PT J AU Taylor, C Bouldin, E Edwards, V McGuire, L AF Taylor, C. Bouldin, E. Edwards, V. McGuire, L. TI SUBJECTIVE COGNITIVE DECLINE: POPULATION CHARACTERISTICS, 2013 BRFSS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Taylor, C.; Edwards, V.; McGuire, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bouldin, E.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 249 EP 249 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001176 ER PT J AU Bouldin, E Edwards, V French, M Taylor, C McGuire, L AF Bouldin, E. Edwards, V. French, M. Taylor, C. McGuire, L. TI SUBJECTIVE COGNITIVE DECLINE: CHRONIC HEALTH CONDITIONS, 2013 BRFSS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Bouldin, E.] Univ Washington, Seattle, WA 98195 USA. [Edwards, V.; Taylor, C.; McGuire, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [French, M.] Alzheimers Assoc, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 250 EP 250 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001178 ER PT J AU Edwards, V Thompson, W Bouldin, E McGuire, L AF Edwards, V. Thompson, W. Bouldin, E. McGuire, L. TI GENDER AS A MODIFIER OF SUBJECTIVE COGNITIVE DECLINE AND HEALTH-RELATED QUALITY OF LIFE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Edwards, V.; Thompson, W.; Bouldin, E.; McGuire, L.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 250 EP 250 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001179 ER PT J AU McGuire, L Bouldin, E Taylor, C Edwards, V French, M AF McGuire, L. Bouldin, E. Taylor, C. Edwards, V. French, M. TI SUBJECTIVE COGNITIVE DECLINE: CARE NEEDS AND UNMET CARE NEEDS, 2013 BRFSS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [McGuire, L.; Taylor, C.; Edwards, V.] CDC, Atlanta, GA 30333 USA. [Bouldin, E.] Univ Washington, Seattle, WA 98195 USA. [French, M.] Alzheimers Assoc, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 250 EP 250 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001180 ER PT J AU Courtney-Long, EA Stevens, AC Carroll, DD AF Courtney-Long, E. A. Stevens, A. C. Carroll, D. D. TI USE OF ASSISTIVE TECHNOLOGY AMONG OLDER ADULTS IN THE US WITH SERIOUS DIFFICULTY HEARING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Courtney-Long, E. A.; Stevens, A. C.; Carroll, D. D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 334 EP 334 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585001524 ER PT J AU Grosch, J AF Grosch, J. TI AN OVERVIEW OF THE AGING WORKFORCE FROM AN OCCUPATIONAL HEALTH PERSPECTIVE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Grosch, J.] NIOSH, CDC, Cincinnati, OH 45226 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 454 EP 454 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002145 ER PT J AU Sengupta, M Zimmerman, S Park-Lee, E Harris-Kojetin, L AF Sengupta, M. Zimmerman, S. Park-Lee, E. Harris-Kojetin, L. TI SOCIAL ENGAGEMENT IN RELATION TO COGNITIVE STATUS IN RESIDENTIAL CARE/ASSISTED LIVING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Sengupta, M.; Harris-Kojetin, L.] CDC, NCHS, Hyattsville, MD USA. [Zimmerman, S.] UNC, Chapel Hill, NC USA. [Park-Lee, E.] SAHMSA, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 490 EP 490 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002295 ER PT J AU Lendon, JP Rome, V Sengupta, M AF Lendon, J. P. Rome, V. Sengupta, M. TI CHARACTERISTICS ASSOCIATED WITH ADULT DAY CENTERS MOSTLY SERVING RACIAL/ ETHNIC MINORITY PARTICIPANTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Lendon, J. P.; Rome, V.; Sengupta, M.] CDC, Long Term Care Stat, Natl Ctr Hlth Stat, Silver Spring, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 521 EP 521 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002427 ER PT J AU Sengupta, M Valverde, R Lendon, JP Rome, V Harris-Kojetin, L Caffrey, C AF Sengupta, M. Valverde, R. Lendon, J. P. Rome, V. Harris-Kojetin, L. Caffrey, C. TI STATE PROFILES FROM THE 2014 NATIONAL STUDY OF LONG-TERM CARE PROVIDERS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Sengupta, M.; Valverde, R.; Lendon, J. P.; Rome, V.; Harris-Kojetin, L.; Caffrey, C.] CDC, NCHS, Hyattsville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 521 EP 521 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002426 ER PT J AU Bobitt, J Lehning, A Ulin, B Dicocco, C Kung, J AF Bobitt, J. Lehning, A. Ulin, B. Dicocco, C. Kung, J. TI PROMISING STRATEGIES TO PROMOTE HEALTHY AGING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Bobitt, J.] Univ Illinois, Urbana, IL USA. [Lehning, A.] Univ Maryland, Baltimore, MD 21201 USA. [Ulin, B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dicocco, C.] Adm Community Living, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 618 EP 618 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002790 ER PT J AU Lehning, A Bobitt, J Ulin, B Dicocco, C Kung, J AF Lehning, A. Bobitt, J. Ulin, B. Dicocco, C. Kung, J. TI THE NEED FOR HEALTHY AGING IN ACTION SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Lehning, A.] Univ Maryland, Baltimore, MD 21201 USA. [Bobitt, J.] Univ Illinois, Urbana, IL USA. [Ulin, B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dicocco, C.] Adm Community Living, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 618 EP 618 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002789 ER PT J AU McGuire, L AF McGuire, L. TI CDC'S HEALTHY BRAIN INITIATIVE: THE NATION'S PUBLIC HEALTH ROAD MAP TO MAINTAINING COGNITIVE HEALTH SO GERONTOLOGIST LA English DT Meeting Abstract C1 [McGuire, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2016 VL 56 SU 3 BP 618 EP 618 PG 1 WC Gerontology SC Geriatrics & Gerontology GA ED1DT UT WOS:000388585002791 ER PT J AU Kruger, J Jama, A Kegler, M Holmes, CB Hu, S King, B AF Kruger, Judy Jama, Amal Kegler, Michelle Holmes, Carissa Baker Hu, Sean King, Brian TI Smoke-Free Rules and Secondhand Smoke Exposure in Vehicles among US Adults-National Adult Tobacco Survey, 2009-2010 and 2013-2014 SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article DE tobacco products; secondhand smoke exposure; vehicles; policy ID CARS; CHILDREN AB In the United States (U.S.), secondhand smoke (SHS) exposure causes more than 41,000 deaths among nonsmoking adults annually. Adoption of smoke-free laws in public areas has increased, but private settings such as vehicles remain a source of SHS exposure. This study assessed change in voluntary smoke-free vehicle rules and SHS exposure in personal vehicles among U.S. adults between two periods, 2009-2010 and 2013-2014, using data from the National Adult Tobacco Survey (NATS). NATS is a national landline and cellular telephone survey of non-institutionalized adults aged >= 18 years in the 50 U.S. states and the District of Columbia. We assessed percentage change in the prevalence of smoke-free vehicle rules among all adults and SHS exposure in vehicles among nonsmoking adults, overall, by sociodemographic factors (sex, age, race/ethnicity, education, marital status, annual household income, U.S. region), and by cigarette smoking status. During 2009-2010 to 2013-2014, the percentage of adults with a 100% smoke-free vehicle rule increased from 73.6% to 79.5% (% change = +8.0%; p < 0.05). Among nonsmokers, SHS exposure in vehicles in the previous 7 days decreased from 9.2% to 8.2% (% change = 10.9%; p < 0.05). Smoke-free rules in private settings such as vehicles, in coordination with comprehensive smoke-free policies in indoor public settings, can help reduce SHS exposure and promote smoke-free norms. C1 [Kruger, Judy; Holmes, Carissa Baker; Hu, Sean; King, Brian] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30329 USA. [Jama, Amal] DB Consulting Grp, Atlanta, GA 30329 USA. [Kegler, Michelle] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Kruger, J (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30329 USA. EM jkruger@cdc.gov; amal.o.jama@gmail.com; mkegler@emory.edu; ipz3@cdc.gov; fik4@cdc.gov; iyn3@cdc.gov FU National Cancer Institute under the State and Community Tobacco Control Initiative [UO1-CA154282] FX Funding for Michelle Kegler's contribution to this work was provided by the National Cancer Institute under the State and Community Tobacco Control Initiative, Grant Number UO1-CA154282. There were no sources of funding, direct or indirect, for other authors in regards to the reported research. The findings and conclusions in this report are those of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. NR 19 TC 0 Z9 0 U1 0 U2 0 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD NOV PY 2016 VL 13 IS 11 AR 1048 DI 10.3390/ijerph13111048 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA EE4KR UT WOS:000389571300007 ER PT J AU Balisanga, H Mutagoma, M Remera, E Kayitesi, C Kayirangwa, E Dee, J Malamba, S Boer, KR Hedt-Gauthier, B Umugwaneza, P Nsanzimana, S AF Balisanga, Helene Mutagoma, Mwumvaneza Remera, Eric Kayitesi, Catherine Kayirangwa, Eugenie Dee, Jacob Malamba, Samuel Boer, Kimberly R. Hedt-Gauthier, Bethany Umugwaneza, Placidie Nsanzimana, Sabin TI HIV surveillance in Rwanda: readiness assessment to transition from antenatal care-based to prevention of mother-to-child transmission program-based HIV surveillance SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV prevalence; Routine data; Sentinel surveillance; Prevention of mother-to-child transmission; HIV diagnostic tests ID HUMAN-IMMUNODEFICIENCY-VIRUS; SENTINEL SURVEILLANCE; PREVALENCE DATA; PREGNANT-WOMEN; SYPHILIS; UGANDA; POPULATION; VOLUNTARY; SERVICES; UTILITY AB Background: In 2013, the World Health Organization (WHO) recommended that for efficiency and ethical considerations, transitioning from antenatal clinic-based surveillance to prevention of mother-to-child transmission (PMTCT)-based routine data should be investigated. An assessment of the readiness for this transition was carried out in Rwanda in 2011 and 2013. Methods: This assessment applied the WHO recommended method. Individual HIV rapid testing at site was compared to antenatal surveillance results at all existing 30 sites, involving 13 292 women. In addition, PMTCT HIV testing quality assurance and PMTCT routine data quality were assessed at 27 out of the 30 sites. Results: All sentinel sites provided PMTCT services and had a high uptake of HIV testing (more than 90%). At all sites, PMTCT data were recorded in longitudinal and standardized antenatal clinic registers. Twenty-six out of 27 sites had HIV result completeness above 90%. A positive percentage agreement of 97.5% and negative percentage agreement of 99.9% were observed between routine PMTCT and sero-surveillance HIV test results. Of 27 sites, 25 scored more than 80% in all phases of HIV testing quality assurance. Conclusions: According to WHO standards, Rwanda antenatal care HIV sero-surveillance is ready to transition to PMTCT-based sero-surveillance. (C) 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. C1 [Balisanga, Helene; Mutagoma, Mwumvaneza; Remera, Eric; Kayitesi, Catherine; Umugwaneza, Placidie; Nsanzimana, Sabin] Minist Hlth, Rwanda Biomed Ctr, POB 7162, Kigali, Rwanda. [Kayirangwa, Eugenie; Dee, Jacob; Malamba, Samuel; Boer, Kimberly R.] US Ctr Dis Control & Prevent CDC, Ctr Global Hlth CGH, Div Global HIV AIDS DGHA, Atlanta, GA USA. [Hedt-Gauthier, Bethany] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USA. RP Balisanga, H (reprint author), Minist Hlth, Rwanda Biomed Ctr, POB 7162, Kigali, Rwanda. EM bahelene@gmail.com FU PEPFAR; USG Center for Disease Control and Prevention COAG [5U2GPS002048]; World Health Organization; Government of Rwanda FX We acknowledge the contribution from PEPFAR, USG Center for Disease Control and Prevention COAG# 5U2GPS002048, World Health Organization, the Government of Rwanda, and other partners for their financial and technical support. We recognize the technical working group, participants in the survey, and sentinel site staff for their collaboration. NR 29 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD NOV PY 2016 VL 52 BP 62 EP 67 DI 10.1016/j.ijid.2016.08.029 PG 6 WC Infectious Diseases SC Infectious Diseases GA EE3RZ UT WOS:000389516600013 PM 27616035 ER PT J AU Perelygina, L Plotkin, S Russo, P Hautala, T Bonilla, F Ochs, HD Joshi, A Routes, J Patel, K Wehr, C Icenogle, J Sullivan, KE AF Perelygina, Ludmila Plotkin, Stanley Russo, Pierre Hautala, Timo Bonilla, Francisco Ochs, Hans D. Joshi, Avni Routes, John Patel, Kiran Wehr, Claudia Icenogle, Joseph Sullivan, Kathleen E. TI Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Letter ID MEASLES C1 [Perelygina, Ludmila; Icenogle, Joseph] Ctr Dis Control & Prevent, Div Viral Dis, Measles Mumps Rubella & Herpesvirus Lab Branch, Atlanta, GA 30333 USA. [Plotkin, Stanley] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Russo, Pierre] Univ Penn, Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Hautala, Timo] Oulu Univ Hosp, Dept Internal Med, Oulu, Finland. [Bonilla, Francisco] Boston Childrens Hosp, Div Immunol, Boston, MA USA. [Ochs, Hans D.] Univ Washington, Seattle, WA 98195 USA. [Ochs, Hans D.] Seattle Childrens Hosp, Seattle, WA USA. [Joshi, Avni] Mayo Clin, Childrens Ctr, Div Allergy Immunol, Rochester, MN USA. [Routes, John] Med Coll Wisconsin, Childrens Hosp Wisconsin, Div Allergy Immunol, Dept Pediat, Milwaukee, WI 53226 USA. [Patel, Kiran] Childrens Healthcare Atlanta, Div Pulm Allergy & Immunol Cyst Fibrosis & Sleep, Atlanta, GA USA. [Wehr, Claudia] Univ Freiburg, Univ Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany. [Wehr, Claudia] Univ Freiburg, Univ Med Ctr Freiburg, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany. [Sullivan, Kathleen E.] Childrens Hosp Philadelphia, Div Allergy Immunol, Philadelphia, PA 19104 USA. RP Sullivan, KE (reprint author), Childrens Hosp Philadelphia, Div Allergy Immunol, Philadelphia, PA 19104 USA. EM sullivak@mail.med.upenn.edu FU NIAID NIH HHS [U24 AI086037] NR 9 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD NOV PY 2016 VL 138 IS 5 BP 1436 EP 1439 DI 10.1016/j.jaci.2016.06.030 PG 4 WC Allergy; Immunology SC Allergy; Immunology GA EE4AA UT WOS:000389542700025 PM 27613149 ER PT J AU Hsu, J Wilhelm, N Lewis, L Herman, E AF Hsu, Joy Wilhelm, Natalie Lewis, Lillianne Herman, Elizabeth TI Economic Evidence for US Asthma Self-Management Education and Home-Based Interventions SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE LA English DT Review DE Asthma; Education; Home; Control; Cost; Return on investment; Community health worker ID INNER-CITY ASTHMA; PEDIATRIC ASTHMA; DISEASE MANAGEMENT; ENVIRONMENTAL INTERVENTION; OUTREACH PROGRAM; CONTROLLED-TRIAL; ADULT ASTHMA; RESPIRATORY THERAPISTS; COST-EFFECTIVENESS; HEALTH-EDUCATION AB The health and economic burden of asthma in the United States is substantial. Asthma self-management education (AS-ME) and home-based interventions for asthma can improve asthma control and prevent asthma exacerbations, and interest in health care-public health collaboration regarding asthma is increasing. However, outpatient AS-ME and home-based asthma intervention programs are not widely available; economic sustainability is a common concern. Thus, we conducted a narrative review of existing literature regarding economic outcomes of outpatient AS-ME and home-based intervention programs for asthma in the United States. We identified 9 outpatient AS-ME programs and 17 home-based intervention programs with return on investment (ROI) data. Most programs were associated with a positive ROI; a few programs observed positive ROIs only among selected populations (eg, higher health care utilization). Interpretation of existing data is limited by heterogeneous ROI calculations. Nevertheless, the literature suggests promise for sustainable opportunities to expand access to outpatient AS-ME and home-based asthma intervention programs in the United States. More definitive knowledge about how to maximize program benefit and sustainability could be gained through more controlled studies of specific populations and increased uniformity in economic assessments. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. C1 [Hsu, Joy; Herman, Elizabeth] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Hwy,Mailstop F-60, Atlanta, GA 30341 USA. [Wilhelm, Natalie] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Lewis, Lillianne] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Publ Hlth Sci Serv, Atlanta, GA USA. RP Hsu, J (reprint author), Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Hwy,Mailstop F-60, Atlanta, GA 30341 USA. EM xdd6@cdc.gov FU Intramural CDC HHS [CC999999] NR 122 TC 1 Z9 1 U1 6 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2198 EI 2213-2201 J9 J ALLER CL IMM-PRACT JI J. Allergy Clin. Immunol.-Pract. PD NOV-DEC PY 2016 VL 4 IS 6 BP 1123 EP + DI 10.1016/j.jaip.2016.05.012 PG 39 WC Allergy; Immunology SC Allergy; Immunology GA EE4ZA UT WOS:000389613300012 PM 27658535 ER PT J AU Neven, D Paulozzi, L Howell, D McPherson, S Murphy, SM Grohs, B Marsh, L Lederhos, C Roll, J AF Neven, Darin Paulozzi, Leonard Howell, Donelle McPherson, Sterling Murphy, Sean M. Grohs, Becky Marsh, Linda Lederhos, Crystal Roll, John TI A RANDOMIZED CONTROLLED TRIAL OF A CITYWIDE EMERGENCY DEPARTMENT CARE COORDINATION PROGRAM TO REDUCE PRESCRIPTION OPIOID RELATED EMERGENCY DEPARTMENT VISITS SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE frequent ED users; ED care coordination; prescription opioid abuse; prescription drug monitoring program; opioid prescribing ID CLINICAL CASE-MANAGEMENT; DRUG-SEEKING BEHAVIOR; ED FREQUENT USERS; CHRONIC PAIN; PATIENT; US AB Background: Increasing prescription overdose deaths have demonstrated the need for safer emergency department (ED) prescribing practices for patients who are frequent ED users. Objectives: We hypothesized that the care of frequent ED users would improve using a citywide care coordination program combined with an ED care coordination information system, as measured by fewer ED visits by and decreased controlled substance prescribing to these patients. Methods: We conducted a multisite randomized controlled trial (RCT) across all EDs in a metropolitan area; 165 patients with the most ED visits for complaints of pain were randomized. For the treatment arm, drivers of ED use were identified by medical record review. Patients and their primary care providers were contacted by phone. Each patient was discussed at a community multidisciplinary meeting where recommendations for ED care were formed. The ED care recommendations were stored in an ED information exchange system that faxed them to the treating ED provider when the patient presented to the ED. The control arm was subjected to treatment as usual. Results: The intervention arm experienced a 34% decrease (incident rate ratios = 0.66, p < 0.001; 95% confidence interval 0.57-0.78) in ED visits and an 80% decrease (odds ratio = 0.21, p = 0.001) in the odds of receiving an opioid prescription from the ED relative to the control group. Declines of 43.7%, 53.1%, 52.9%, and 53.1% were observed in the treatment group for morphine milligram equivalents, controlled substance pills, prescriptions, and prescribers, respectively. Conclusion: This RCT showed the effectiveness of a citywide ED care coordination program in reducing ED visits and controlled substance prescribing. (C) 2016 The Author(s). Published by Elsevier Inc. C1 [Neven, Darin; Howell, Donelle; Murphy, Sean M.; Grohs, Becky; Lederhos, Crystal; Roll, John] Washington State Univ, Coll Nursing, Program Excellence Addict Res, Spokane, WA USA. [Neven, Darin; McPherson, Sterling] Washington State Univ, Elson S Floyd Coll Med, Spokane, WA USA. [Paulozzi, Leonard] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Murphy, Sean M.] Washington State Univ, Coll Nursing, Dept Hlth Policy & Adm, Spokane, WA USA. [Marsh, Linda] Providence Sacred Heart Med Ctr, Spokane, WA USA. [Marsh, Linda] Childrens Hosp, Spokane, WA USA. RP Neven, D (reprint author), Washington State Univ, Elson S Floyd Coll Med, Program Excellence Addict Res, POB 1495, Spokane, WA 99210 USA. OI Smith, Crystal/0000-0002-5095-2822 FU Centers for Disease Control and Prevention [BAA 2011-N-13277]; Washington State University Program of Excellence in Addictions Research FX This project was funded by the Centers for Disease Control and Prevention under contract #BAA 2011-N-13277 with the Washington State University Program of Excellence in Addictions Research, Principal Investigator: Darin Neven. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Agency for Toxic Substances and Disease Registry. NR 28 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 EI 1090-1280 J9 J EMERG MED JI J. Emerg. Med. PD NOV PY 2016 VL 51 IS 5 BP 498 EP 506 DI 10.1016/j.jemermed.2016.06.057 PG 9 WC Emergency Medicine SC Emergency Medicine GA EE3TB UT WOS:000389520200008 PM 27624507 ER PT J AU Ponce-Garcia, G Del Rio-Galvan, S Barrera, R Saavedra-Rodriguez, K Villanueva-Segura, K Felix, G Amador, M Flores, AE AF Ponce-Garcia, Gustavo Del Rio-Galvan, Samantha Barrera, Roberto Saavedra-Rodriguez, Karla Villanueva-Segura, Karina Felix, Gilberto Amador, Manuel Flores, Adriana E. TI Knockdown Resistance Mutations in Aedes aegypti (Diptera: Culicidae) From Puerto Rico SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE permethrin resistance; kdr; Aedes aegypti; Puerto Rico ID SODIUM-CHANNEL GENE; INSECTICIDE RESISTANCE; PYRETHROID RESISTANCE; NATURAL-POPULATIONS; KDR MUTATIONS; MECHANISMS; MEXICO; STATE AB Permethrin resistance is widespread in Aedes aegypti (L.), the main dengue, zika, and chikungunya virus vector in Latin America and the Caribbean. A common mechanism of resistance to pyrethroids-knockdown resistance (kdr)-is conferred through mutations in the insect's voltage-dependent sodium channel. In this mosquito, around 10 replacement substitutions in the voltage-gated sodium channel gene (vgsc) have been reported in pyrethroid-resistant strains. Two of these mutations, named Ile1,016 and Cys1,534, are widespread in mosquito populations from Latin America and the Caribbean. This study assessed the levels of permethrin resistance and the frequency of two kdr mutations in eight Ae. aegypti populations collected in Puerto Rico in 2013. Permethrin resistance factors ranged from 33-214-fold relative to the New Orleans reference strain. The frequency of kdr mutation Ile1,016 ranged from 0.65 to fixation (1.0), and for Cys1,534 frequencies varied from 0.8 to fixation. Alarmingly, two populations-Carolina and Caguas-reached fixation at both loci. Our results suggest that permethrin effectiveness for Ae. aegypti control is compromised in these collections from Puerto Rico. C1 [Ponce-Garcia, Gustavo; Del Rio-Galvan, Samantha; Villanueva-Segura, Karina; Flores, Adriana E.] Univ Autonoma Nuevo Leon, Fac Ciencias Biol, San Nicolas De Los Garza 66455, Nuevo Leon, Mexico. [Barrera, Roberto; Felix, Gilberto; Amador, Manuel] Ctr Dis Control & Prevent, Dengue Branch, Entomol & Ecol Act, San Juan, PR USA. [Saavedra-Rodriguez, Karla] Colorado State Univ, Lab Insect Genet Microbiol Immunol & Pathol, Ft Collins, CO 80521 USA. RP Ponce-Garcia, G (reprint author), Univ Autonoma Nuevo Leon, Fac Ciencias Biol, San Nicolas De Los Garza 66455, Nuevo Leon, Mexico. EM gponcealfa@gmail.com; samdelriog@hotmail.com; amz9@cdc.gov; karlasaav@gmail.com; karinaypwm@gmail.com; ckn5@cdc.gov; maa4@cdc.gov; adriana.floressr@uanl.edu.mx NR 27 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD NOV PY 2016 VL 53 IS 6 BP 1410 EP 1414 DI 10.1093/jme/tjw115 PG 5 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA EF3IH UT WOS:000390217500020 PM 27493252 ER PT J AU Hecht, JA Allerdice, MEJ Krawczak, FS Labruna, MB Paddock, CD Karpathy, SE AF Hecht, Joy A. Allerdice, Michelle E. J. Krawczak, Felipe S. Labruna, Marcelo B. Paddock, Christopher D. Karpathy, Sandor E. TI Development of a Rickettsia bellii-Specific TaqMan Assay Targeting the Citrate Synthase Gene SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE Rickettsia bellii; spotted fever group Rickettsia; real-time PCR; citrate synthase gene ID FEVER GROUP RICKETTSIAE; TICKS ACARI IXODIDAE; SPOTTED-FEVER; SAO-PAULO; DERMACENTOR-VARIABILIS; AMBLYOMMA-DUBITATUM; MOLECULAR-DETECTION; UNITED-STATES; BRAZIL; INFECTION AB Rickettsia bellii is a rickettsial species of unknown pathogenicity that infects argasid and ixodid ticks throughout the Americas. Many molecular assays used to detect spotted fever group (SFG) Rickettsia species do not detect R. bellii, so that infection with this bacterium may be concealed in tick populations when assays are used that screen specifically for SFG rickettsiae. We describe the development and validation of a R. bellii-specific, quantitative, real-time PCR TaqMan assay that targets a segment of the citrate synthase (gltA) gene. The specificity of this assay was validated against a panel of DNA samples that included 26 species of Rickettsia, Orientia, Ehrlichia, Anaplasma, and Bartonella, five samples of tick and human DNA, and DNA from 20 isolates of R. bellii, including 11 from North America and nine from South America. A R. bellii control plasmid was constructed, and serial dilutions of the plasmid were used to determine the limit of detection of the assay to be one copy per 4 ml of template DNA. This assay can be used to better determine the role of R. bellii in the epidemiology of tickborne rickettsioses in the Western Hemisphere. C1 [Hecht, Joy A.; Allerdice, Michelle E. J.; Paddock, Christopher D.; Karpathy, Sandor E.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Krawczak, Felipe S.; Labruna, Marcelo B.] Univ Sao Paulo, Dept Prevent Vet Med & Anim Hlth, Fac Vet Med, Sao Paulo, SP, Brazil. RP Hecht, JA (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM jhecht@cdc.gov; mallerdice@cdc.gov; felipekvet@gmail.com; labruna@usp.br; CPaddock@cdc.gov; skarpathy@cdc.gov FU appointment of J. Hecht to the Research Participation Program at the Centers for Disease Control and Prevention FX The research reported here was supported in part by an appointment of J. Hecht to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the CDC. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 20 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD NOV PY 2016 VL 53 IS 6 BP 1492 EP 1495 DI 10.1093/jme/tjw111 PG 4 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA EF3IH UT WOS:000390217500032 PM 27473178 ER PT J AU Suda, KJ Roberts, RM Hunkler, RJ Taylor, TH AF Suda, Katie J. Roberts, Rebecca M. Hunkler, Robert J. Taylor, Thomas H. TI Antibiotic prescriptions in the community by type of provider in the United States, 2005-2010 SO JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION LA English DT Article ID INFECTIOUS-DISEASES SOCIETY; PNEUMOCOCCAL CONJUGATE VACCINE; QUALITY-OF-CARE; ANTIMICROBIAL STEWARDSHIP; STAPHYLOCOCCUS-AUREUS; RETAIL CLINICS; TRENDS; IMPACT; GUIDELINES; AMERICA AB Objectives: Although antibiotic prescriptions are decreasing in the United States, broad-spectrum prescribing is increasing. It is unknown if decreases observed in national antibiotic prescribing differ by provider group. Understanding prescribing trends over time by provider group can be helpful for customizing antimicrobial stewardship efforts. Therefore, the purposes of this study were to describe outpatient antibiotic prescribing by provider group overall and adjusted for population and number of providers. In addition, trends in prescribing by class and seasonal variation are described by provider group over 6 years. Design: Cross-sectional observation of outpatient antibiotic prescriptions. Setting and participants: A population-level analysis of U.S. prescribing from 2005 to 2010 with the use of the IMS Health Xponent dataset. Main outcome measures: Number and rates of prescriptions dispensed overall and by provider group. Results: The majority (81.0%) of antibiotics were prescribed by physicians, followed by dentists (10.4%), nurse practitioners (NPs; 4.5%), and physician assistants (PAs; 4.2%). The percentage of antibiotic prescriptions decreased for physicians, but increased significantly for NPs and PAs. Provider-based and population-based prescribing rates decreased for physicians and dentists and increased for NPs and PAs. Penicillins were prescribed most frequently by all provider groups, decreasing for physicians and dentists. Increased prescribing of broad-spectrum agents was observed for NPs and PAs. With the exception of dentists, antibiotic prescriptions were higher in winter than in summer, with the largest seasonal increase by NPs. Conclusion: Over 6 years, antibiotic prescriptions overall and for broad-spectrum agents decreased for physicians and increased for NPs and PAs. Thus, increasing trends in the US of broad-spectrum antibiotic prescriptions can be attributed to midlevel providers. Interventions should be designed to reverse increasing prescribing trends, especially of broad-spectrum agents prescribed by NPs and PAs. Stewardship efforts should also be targeted towards dentists, since this group prescribes a higher proportion of antibiotics compared with midlevel providers. Published by Elsevier Inc. on behalf of the American Pharmacists Association. C1 [Suda, Katie J.] Univ Illinois, Hines VA Hosp, Dept Vet Affairs Ctr Innovat Complex Chron Care, Chicago, IL USA. [Roberts, Rebecca M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Hunkler, Robert J.] IMS Hlth, Profess Relat, Plymouth Meeting, PA USA. [Taylor, Thomas H.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA. RP Suda, KJ (reprint author), Univ Illinois, 833 S Wood St,Suite 287,MC 871, Chicago, IL 60612 USA. EM katiesuda@gmail.com NR 44 TC 0 Z9 0 U1 0 U2 0 PU AMER PHARMACEUTICAL ASSOC PI WASHINGTON PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037 USA SN 1544-3191 EI 1544-3450 J9 J AM PHARM ASSOC JI J. Am. Pharm. Assoc. PD NOV-DEC PY 2016 VL 56 IS 6 BP 621 EP + DI 10.1016/j.japh.2016.08.015 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EE6XZ UT WOS:000389758900006 PM 27745794 ER PT J AU Johansson, MA Mier-Y-Teran-Romero, L Reefhuis, J Gilboa, SM Hills, SL AF Johansson, Michael A. Mier-y-Teran-Romero, Luis Reefhuis, Jennita Gilboa, Suzanne M. Hills, Susan L. TI Zika and the Risk of Microcephaly EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Johansson, Michael A.; Mier-y-Teran-Romero, Luis; Hills, Susan L.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Atlanta, GA 30333 USA. [Reefhuis, Jennita; Gilboa, Suzanne M.] Ctr Dis Control & Prevent, Div Congenital & Dev Disorders, Atlanta, GA 30333 USA. [Johansson, Michael A.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Johansson, MA (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD NOV PY 2016 VL 71 IS 11 BP 635 EP 636 DI 10.1097/OGX.0000000000000386 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EE0DY UT WOS:000389245100001 ER PT J AU Pinto, TCA Kegele, FCO Dias, CAG Barros, RR Peralta, JM Merquior, VLC Carvalho, MD Chochua, S Hawkins, P McGee, L Teixeira, LM AF Pinto, Tatiana C. A. Kegele, Fabiola C. O. Dias, Cicero A. G. Barros, Rosana R. Peralta, Jose M. Merquior, Vania L. C. Carvalho, Maria da Gloria Chochua, Sopio Hawkins, Paulina McGee, Lesley Teixeira, Lucia M. TI Streptococcus pneumoniae Serotypes 9 and 14 Circulating in Brazil over a 23-Year Period Prior to Introduction of the 10-Valent Pneumococcal Conjugate Vaccine: Role of International Clones in the Evolution of Antimicrobial Resistance and Description of a Novel Genotype SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID RIO-DE-JANEIRO; MULTIPLEX PCR; UNITED-STATES; SUSCEPTIBILITY; STRAINS; MENINGITIS; CHILDREN; PREVALENCE; MECHANISMS; DISEASE AB Antimicrobial-resistant pneumococcal strains have been detected worldwide since the 1960s. In Brazil, the first penicillin-nonsusceptible pneumococci (PNSP) were reported in the 1980s, and their emergence and dissemination have been mainly attributed to serogroup 9 and serotype 14 strains, especially those highly related to recognized international clones. In the present study, antimicrobial susceptibility testing and multilocus sequence typing were performed on 315 pneumococcal isolates belonging to serogroup 9 (n = 99) or serotype 14 (n = 216), recovered from patients or asymptomatic carriers between 1988 and 2011 in Brazil, in order to trace changes in antimicrobial resistance and genotypes prior to the full introduction of the pneumococcal conjugate vaccine in the country. Over the 23-year study period, the PNSP levels increased, and four clonal complexes (CC156, CC66, CC15, and CC5401) have played important roles in the evolution and dissemination of pneumococcal isolates belonging to serogroup 9 and serotype 14, as well as in the emergence of antimicrobial resistance, in the pre-pneumococcal-vaccination era. The earliest PNSP strains detected in this study belonged to serotype 9N/ ST66 and were single locus variants of the international clone Tennessee(14)- 18 ST67 (CC66). The first serotype 14 PNSP isolates were identified in 1990 and were related to the England(14)- 9 ST9 (CC15) clone. Serotype 14 PNSP variants of the Spain(9V)- 3 ST156 clone with elevated penicillin MICs and nonsusceptibility to other beta-lactams were detected in 1995 and showed an increasing trend over the years. The results also indicated that introduction of ST156 in our region was preceded by the emergence of trimethoprim-sulfamethoxazole resistance and by the dissemination of ST162. In addition to the presence of successful international clones, a novel regional serotype 14 genotype (CC5401) has emerged in 1996. C1 [Pinto, Tatiana C. A.; Peralta, Jose M.; Teixeira, Lucia M.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Rio De Janeiro, Brazil. [Kegele, Fabiola C. O.] Fundacao Oswaldo Cruz, Inst Fernandes Figueira, Rio De Janeiro, Brazil. [Dias, Cicero A. G.] Univ Fed Ciencias Saude Porto Alegre, Dept Microbiol & Parasitol, Porto Alegre, RS, Brazil. [Barros, Rosana R.] Univ Fed Fluminense, Inst Biomed, Niteroi, RJ, Brazil. [Merquior, Vania L. C.] Univ Estado Rio de Janeiro, Dept Microbiol Imunol & Parasitol, Rio De Janeiro, Brazil. [Carvalho, Maria da Gloria; Chochua, Sopio; Hawkins, Paulina; McGee, Lesley] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. [Hawkins, Paulina] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Teixeira, LM (reprint author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Rio De Janeiro, Brazil. EM lmt2@micro.ufrj.br FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) FX This study was supported in part by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), and Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ). NR 43 TC 1 Z9 1 U1 2 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD NOV PY 2016 VL 60 IS 11 BP 6664 EP 6672 DI 10.1128/AAC.00673-16. PG 9 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA ED7QH UT WOS:000389063500024 PM 27572394 ER PT J AU Roberts, ST Haberer, J Celum, C Mugo, N Ware, NC Cohen, CR Tappero, JW Kiarie, J Ronald, A Mujugira, A Tumwesigye, E Were, E Irungu, E Baeten, JM AF Roberts, Sarah T. Haberer, Jessica Celum, Connie Mugo, Nelly Ware, Norma C. Cohen, Craig R. Tappero, Jordan W. Kiarie, James Ronald, Allan Mujugira, Andrew Tumwesigye, Elioda Were, Edwin Irungu, Elizabeth Baeten, Jared M. CA Partners PrEP Study Team TI Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE intimate partner violence; pre-exposure prophylaxis; adherence; HIV prevention ID TENOFOVIR DISOPROXIL FUMARATE; POISSON REGRESSION APPROACH; CHILD SEXUAL-ABUSE; SUB-SAHARAN AFRICA; OF-THE-LITERATURE; ANTIRETROVIRAL PROPHYLAXIS; MEDICATION ADHERENCE; HEALTHY-VOLUNTEERS; DOMESTIC VIOLENCE; MICROBICIDE TRIAL AB Background: Intimate partner violence (IPV) is associated with higher HIV incidence, reduced condom use, and poor adherence to antiretroviral therapy and other medications. IPV may also affect adherence to pre-exposure prophylaxis (PrEP). Methods: We analyzed data from 1785 HIV-uninfected women enrolled in a clinical trial of PrEP among African HIV serodiscordant couples. Experience of verbal, physical, or economic IPV was assessed at monthly visits by face-to-face interviews. Low PrEP adherence was defined as clinic-based pill count coverage <80% or plasma tenofovir levels <40 ng/mL. The association between IPV and low adherence was analyzed using generalized estimating equations, adjusting for potential confounders. In-depth interview transcripts were examined to explain how IPV could impact adherence. Results: Sixteen percent of women reported IPV during a median of 34.8 months of follow-up (interquartile range 27.0-35.0). Overall, 7% of visits had pill count coverage <80%, and 32% had plasma tenofovir <40 ng/mL. Women reporting IPV in the past 3 months had increased risk of low adherence by pill count (adjusted risk ratio 1.49, 95% confidence interval: 1.17 to 1.89) and by plasma tenofovir (adjusted risk ratio 1.51, 95% confidence interval: 1.06 to 2.15). Verbal, economic, and physical IPV were all associated with low adherence. However, the impact of IPV diminished and was not statistically significant 3 months after the reported exposure. In qualitative interviews, women identified several ways in which IPV affected adherence, including stress and forgetting, leaving home without pills, and partners throwing pills away. Conclusions: Women who reported recent IPV in the Partners PrEP Study were at increased risk of low PrEP adherence. Strategies to mitigate PrEP nonadherence in the context of IPV should be evaluated. C1 [Roberts, Sarah T.; Celum, Connie; Mujugira, Andrew; Baeten, Jared M.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA. [Haberer, Jessica] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Haberer, Jessica] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA. [Haberer, Jessica; Ware, Norma C.] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USA. [Celum, Connie; Mugo, Nelly; Baeten, Jared M.] Univ Washington, Dept Global Hlth, Seattle, WA 98104 USA. [Celum, Connie; Baeten, Jared M.] Univ Washington, Dept Med, Seattle, WA 98104 USA. [Mugo, Nelly] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Ware, Norma C.] Brigham & Womens Hosp, Dept Med, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA. [Cohen, Craig R.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA. [Tappero, Jordan W.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kiarie, James] Univ Nairobi, Dept Obstet & Gynaecol, Nairobi, Kenya. [Ronald, Allan] Univ Manitoba, Dept Med, Winnipeg, MB, Canada. [Tumwesigye, Elioda] Kabwohe Clin Res Ctr, Kabwohe, Uganda. [Were, Edwin] Moi Univ, Dept Reprod Hlth, Eldoret, Kenya. [Irungu, Elizabeth] Kenyatta Natl Hosp, Nairobi, Kenya. RP Roberts, ST (reprint author), Univ Washington, Int Clin Res Ctr, 325 Ninth Ave,Box 359927, Seattle, WA 98104 USA. EM str24@uw.edu FU Bill & Melinda Gates Foundation [OPP47674]; US National Institutes of Health [R01 MH095507, T32 AI007140, F31 MH107258]; ARCS Foundation Seattle Chapter Endowment Fund FX Supported by research Grants from the Bill & Melinda Gates Foundation (OPP47674), the US National Institutes of Health (R01 MH095507, T32 AI007140, F31 MH107258), and the ARCS Foundation Seattle Chapter Endowment Fund. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the National Institutes of Health or Centers for Disease Control and Prevention. NR 70 TC 2 Z9 2 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2016 VL 73 IS 3 BP 313 EP 322 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA ED7KV UT WOS:000389044000018 PM 27243900 ER PT J AU Van Handel, MM Rose, CE Hallisey, EJ Kolling, JL Zibbell, JE Lewis, B Bohm, MK Jones, CM Flanagan, BE Siddiqi, AEA Iqbal, K Dent, AL Mermin, JH McCray, E Ward, JW Brooks, JT AF Van Handel, Michelle M. Rose, Charles E. Hallisey, Elaine J. Kolling, Jessica L. Zibbell, Jon E. Lewis, Brian Bohm, Michele K. Jones, Christopher M. Flanagan, Barry E. Siddiqi, Azfar-E-Alam Iqbal, Kashif Dent, Andrew L. Mermin, Jonathan H. McCray, Eugene Ward, John W. Brooks, John T. TI County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT National HIV Prevention Conference CY DEC 06-09, 2015 CL Atlanta, GA DE human immunodeficiency virus (HIV); hepatitis C virus (HCV); persons who inject drugs; opioid epidemic; vulnerability analysis ID C VIRUS-INFECTIONS; HEROIN USERS; OXYMORPHONE; EPIDEMIC; INDIANA AB Objective: A recent HIV outbreak in a rural network of persons who inject drugs (PWID) underscored the intersection of the expanding epidemics of opioid abuse, unsterile injection drug use (IDU), and associated increases in hepatitis C virus (HCV) infections. We sought to identify US communities potentially vulnerable to rapid spread of HIV, if introduced, and new or continuing high rates of HCV infections among PWID. Design: We conducted a multistep analysis to identify indicator variables highly associated with IDU. We then used these indicator values to calculate vulnerability scores for each county to identify which were most vulnerable. Methods: We used confirmed cases of acute HCV infection reported to the National Notifiable Disease Surveillance System, 2012-2013, as a proxy outcome for IDU, and 15 county-level indicators available nationally in Poisson regression models to identify indicators associated with higher county acute HCV infection rates. Using these indicators, we calculated composite index scores to rank each county's vulnerability. Results: A parsimonious set of 6 indicators were associated with acute HCV infection rates (proxy for IDU): drug-overdose deaths, prescription opioid sales, per capita income, white, non-Hispanic race/ethnicity, unemployment, and buprenorphine prescribing potential by waiver. Based on these indicators, we identified 220 counties in 26 states within the 95th percentile of most vulnerable. Conclusions: Our analysis highlights US counties potentially vulnerable to HIV and HCV infections among PWID in the context of the national opioid epidemic. State and local health departments will need to further explore vulnerability and target interventions to prevent transmission. C1 [Van Handel, Michelle M.; Rose, Charles E.; Siddiqi, Azfar-E-Alam; Iqbal, Kashif; McCray, Eugene; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd NE,Mail Stop E-59, Atlanta, GA 30333 USA. [Hallisey, Elaine J.; Dent, Andrew L.] Ctr Dis Control & Prevent, Geospatial Res Anal & Serv Program, Div Toxicol & Human Hlth Sci, Agcy Toxic Subst & Dis Registry, Atlanta, GA 30333 USA. [Kolling, Jessica L.] Ctr Dis Control & Prevent, DRT Strategies Geospatial Res Anal & Serv Program, Div Toxicol & Human Hlth Sci, Agcy Toxic Subst & Dis Registry, Atlanta, GA 30333 USA. [Zibbell, Jon E.; Ward, John W.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Lewis, Brian; Flanagan, Barry E.] Ctr Dis Control & Prevent, KHP Enterprise Serv Geospatial Res Anal & Serv Pr, Div Toxicol & Human Hlth Sci, Agcy Toxic Subst & Dis Registry, Atlanta, GA 30333 USA. [Bohm, Michele K.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Jones, Christopher M.] US Dept HHS, Div Sci Policy, Off Assistant Secretary Planning & Evaluat, Washington, DC 20201 USA. [Mermin, Jonathan H.] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Van Handel, MM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd NE,Mail Stop E-59, Atlanta, GA 30333 USA. EM ioq4@cdc.gov NR 33 TC 1 Z9 1 U1 6 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2016 VL 73 IS 3 BP 323 EP 331 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA ED7KV UT WOS:000389044000019 PM 27763996 ER PT J AU Karita, E Nsanzimana, S Ndagije, F Wall, KM Mukamuyango, J Mugwaneza, P Remera, E Raghunathan, PL Bayingana, R Kayitenkore, K Bekan-Homawoo, B Tichacek, A Allen, S AF Karita, Etienne Nsanzimana, Sabin Ndagije, Felix Wall, Kristin M. Mukamuyango, Jeannine Mugwaneza, Placidie Remera, Eric Raghunathan, Pratima L. Bayingana, Roger Kayitenkore, Kayitesi Bekan-Homawoo, Brigitte Tichacek, Amanda Allen, Susan TI Evolution of Couples' Voluntary Counseling and Testing for HIV in Rwanda: From Research to Public Health Practice SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE couples' HIV testing; Rwanda; implementing WHO guidelines ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; DISCORDANT COUPLES; RANDOMIZED-TRIAL; ANTIRETROVIRAL THERAPY; REPRESENTATIVE SAMPLE; CHILDBEARING WOMEN; SEXUAL-BEHAVIOR; PREVENTION; INFECTION AB Background: Couples' voluntary HIV counseling and testing (CVCT) is a WHO-recommended intervention for prevention of heterosexual HIV transmission which very few African couples have received. We report the successful nationwide implementation of CVCT in Rwanda. Methods: From 1988 to 1994 in Rwanda, pregnant and postpartum women were tested for HIV and requested testing for their husbands. Partner testing was associated with more condom use and lower HIV and sexually transmitted infection rates, particularly among HIV-discordant couples. After the 1994 genocide, the research team continued to refine CVCT procedures in Zambia. These were reintroduced to Rwanda in 2001 and continually tested and improved. In 2003, the Government of Rwanda (GoR) established targets for partner testing among pregnant women, with the proportion rising from 16% in 2003 to 84% in 2008 as the prevention of mother-to-child transmission program expanded to >400 clinics. In 2009, the GoR adopted joint posttest counseling procedures, and in 2010 a quarterly follow-up program for discordant couples was established in government clinics with training and technical assistance. An estimated 80%-90% of Rwandan couples have now been jointly counseled and tested resulting in prevention of >70% of new HIV infections. Conclusions: Rwanda is the first African country to have established CVCT as standard of care in antenatal care. More than 20 countries have sent providers to Rwanda for CVCT training. To duplicate Rwanda's success, training and technical assistance must be part of a coordinated effort to set national targets, timelines, indicators, and budgets. Governments, bilateral, and multilateral funding agencies must jointly prioritize CVCT for prevention of new HIV infections. C1 [Karita, Etienne; Mukamuyango, Jeannine; Bayingana, Roger; Kayitenkore, Kayitesi; Bekan-Homawoo, Brigitte] PSF, Kigali, Rwanda. [Karita, Etienne; Mukamuyango, Jeannine; Bayingana, Roger; Kayitenkore, Kayitesi; Bekan-Homawoo, Brigitte; Tichacek, Amanda; Allen, Susan] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Nsanzimana, Sabin; Mugwaneza, Placidie; Remera, Eric] RBC, Kigali, Rwanda. [Ndagije, Felix] US Ctr Dis Control & Prevent CDC, Kigali, Rwanda. [Wall, Kristin M.] Emory Univ, Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Raghunathan, Pratima L.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. RP Wall, KM (reprint author), Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, 1518 Clifton Rd NE,GCR 457, Atlanta, GA 30322 USA. EM kmwall@emory.edu FU Centers for Disease Control and Prevention (CDC) [U2GPS001839]; NIAID [R01 AI23980, R01 AI40951]; NIMH [R01_MH66767, R01 MH95503]; NICHD [R01 HD40125, R01 HD072659]; CDC [U2GPS 1839, U2GPS 1904]; Emory AITRP Fogarty [5D43TW001042]; Emory Center for AIDS Research (CFAR) [P30 AI050409]; International AIDS Vaccine Initiative (IAVI) [SOW2166]; United States Agency for International Development (USAID) FX Supported by the Centers for Disease Control and Prevention (CDC) (U2GPS001839), NIAID (R01 AI23980, R01 AI40951), NIMH (R01_MH66767, R01 MH95503), NICHD (R01 HD40125, R01 HD072659), CDC (U2GPS 1839), CDC (U2GPS 1904), Emory AITRP Fogarty (5D43TW001042), Emory Center for AIDS Research (CFAR) (P30 AI050409), and the International AIDS Vaccine Initiative (IAVI) (SOW2166) with the support of the United States Agency for International Development (USAID). The contents of this manuscript are the responsibility of the authors and do not necessarily reflect the views of USAID or the US Government. NR 65 TC 0 Z9 0 U1 4 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2016 VL 73 IS 3 BP E51 EP E58 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA ED7KV UT WOS:000389044000003 PM 27741033 ER PT J AU Ethier, KA Harper, CR Hoo, E Dittus, PJ AF Ethier, Kathleen A. Harper, Christopher R. Hoo, Elizabeth Dittus, Patricia J. TI The Longitudinal Impact of Perceptions of Parental Monitoring on Adolescent Initiation of Sexual Activity SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Parental monitoring; Sexual behavior; Adolescents ID HEALTH-RISK BEHAVIORS; RANDOMIZED-TRIAL; YOUTH; REINTERPRETATION; COMMUNICATION; INTERVENTION; ASSOCIATION; INTERCOURSE; TRUST; TIME AB Purpose: The association between parental monitoring and adolescent behavior is well established. Past research suggests that parents monitor adolescent activities through parental control, solicitation of information, and youth disclosure, which increase parents' knowledge of youth activity leading to decreased risk behavior. However, there is mixed evidence of the impact of these efforts on sexual behavior. We examined these strategies from the adolescent perspective and assessed their impact on the initiation of sexual activity across the transition from middle school to high school. Methods: Analyses include 533 primarily Latino adolescents, who had not yet had sex in eighth grade and were surveyed yearly through 10th grade. Results: Adolescents who in eighth grade reported greater parental knowledge and more family rules about dating were less likely to initiate sex between eighth and 10th grade. Exchange of information, through parental solicitation and youth disclosure, and parental control, through rules about friends and dating, as well as maternal relationship satisfaction were significant predictors of parental knowledge. There were no gender differences in the impact of dating rules and parental knowledge on sexual initiation, but the paths to acquiring knowledge did differ by gender. Conclusions: Results suggest that parental monitoring at earlier ages has an impact on sexual initiation. Effective monitoring is an active process within a family that includes setting boundaries and exchanging information. Interventions that encourage family rules, provide strategies for improving parental solicitation of information, and increase youth disclosure by enhancing the maternal-child relationship may be more likely to impact sexual initiation. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Ethier, Kathleen A.; Hoo, Elizabeth] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS-D37, Atlanta, GA 30329 USA. [Harper, Christopher R.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. [Dittus, Patricia J.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA USA. RP Ethier, KA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS-D37, Atlanta, GA 30329 USA. EM KEthier@cdc.gov NR 34 TC 0 Z9 0 U1 9 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD NOV PY 2016 VL 59 IS 5 BP 570 EP 576 DI 10.1016/j.jadohealth.2016.06.011 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA EE3RC UT WOS:000389512700014 PM 27567066 ER PT J AU Zong, G Zhang, ZF Yang, QH Wu, HY Hu, FB Sun, Q AF Zong, Geng Zhang, Zefeng Yang, Quanhe Wu, Hongyu Hu, Frank B. Sun, Qi TI Total and Regional Adiposity Measured by Dual-Energy X-Ray Absorptiometry and Mortality in NHANES 1999-2006 SO Obesity LA English DT Article ID ALL-CAUSE MORTALITY; BODY-MASS INDEX; FAT DISTRIBUTION; VISCERAL FAT; FOLLOW-UP; METABOLIC IMPLICATIONS; POSTMENOPAUSAL WOMEN; INSULIN-RESISTANCE; OLDER-ADULTS; OBESITY AB Objective: Associations of overall and regional body fat measured by dual-energy X-ray absorptiometry with total and cause-specific mortality in the National Health and Nutrition Examination Survey (NHANES) 1999-2006 were investigated. Methods: This study included 9,471 participants (>= 20 years) free of major chronic diseases at baseline. Death information was obtained from the National Death Index (mean follow-up duration: 8.8 years). Results: A total of 682 participants died after 12 months since baseline, with 206 and 170 deaths attributed to cardiovascular diseases (CVD) and cancer, respectively. The second quartile of fat mass percentages (FM%) was used as the reference to account for potential nonlinearity. In the multivariate-adjusted model, participants in the highest quartile of total FM% had increased total mortality; hazard ratio (HR; 95% confidence interval, 95% CI) was 1.48 (1.07-2.04; P<0.05). Higher total and trunk FM%, but not leg FM%, were significantly associated with an increased CVD mortality; HRs (95% CIs) in the highest quartiles of total, trunk, and leg FM% were 2.24 (1.17-4.31), 1.93 (1.02-3.66), and 1.50 (0.77-2.94), respectively. Conclusions: Higher total body fat was associated with increased total mortality in U.S. adults. Higher total and trunk fat contents were also associated with increased CVD mortality, although fat accumulation in the lower body was not an independent predictor of mortality. C1 [Zong, Geng; Hu, Frank B.; Sun, Qi] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Zhang, Zefeng; Yang, Quanhe] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Wu, Hongyu] Icahn Sch Med Mt Sinai, Inst Translat Epidemiol, New York, NY 10029 USA. [Hu, Frank B.; Sun, Qi] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA USA. [Hu, Frank B.; Sun, Qi] Harvard Med Sch, Boston, MA USA. RP Sun, Q (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. EM qisun@hsph.harvard.edu FU NIH [ES022981, ES021372, P30-DK-46200]; National Heart, Lung, and Blood Institute [R00-HL098459] FX QS is supported by NIH grants ES022981 and ES021372 and a career development award, R00-HL098459, from the National Heart, Lung, and Blood Institute. FH is supported by NIH grant P30-DK-46200. NR 40 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD NOV PY 2016 VL 24 IS 11 BP 2414 EP 2421 DI 10.1002/oby.21659 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA ED8VG UT WOS:000389148400023 PM 27667735 ER PT J AU Bhandari, D Ruhl, J Murphy, A McGahee, E Chambers, D Blount, BC AF Bhandari, Deepak Ruhl, John Murphy, Anthony McGahee, Ernest Chambers, David Blount, Benjamin C. TI Isotope Dilution UPLC-APCI-MS/MS Method for the Quantitative Measurement of Aromatic Diamines in Human Urine: Biomarkers of Diisocyanate Exposure SO ANALYTICAL CHEMISTRY LA English DT Article ID 4,4'-METHYLENEDIPHENYL DIISOCYANATE; OCCUPATIONAL-EXPOSURE; TOLUENE DIISOCYANATE; HEMOGLOBIN ADDUCTS; MASS-SPECTROMETRY; ISOCYANATES; PLASMA; CHROMATOGRAPHY; METABOLITES; ALBUMIN AB Urinary diamines are biomarkers of diisocyanate exposure. Diisocyanates are considered as skin and respiratory sensitizers and are the most frequently reported cause of occupational asthma. Herein we report on the development and validation of an ultraperformance liquid chromatographytandem mass spectrometry (UPLC-MS/MS) method for the measurement of five aromatic diamines, 4,4'-methylenedianiline (MDA), 2,4-toluenediamine (4TDA), 2,6-toluenediamine (6TDA), 1,5-naphthalenediamine (NDA), and p-phenylenediamine (PPDA) in human urine. The method incorporates sample preparation steps, which include a 4 h acid hydrolysis followed by high-throughput solid-phase extraction prior to chromatographic separation. Chromatographic separation was achieved using a C18 reversed phase column with gradient elution of basic mobile phases (pH 9.2). The duty cycle of the method was less than 5 min, including both the column equilibration and autosampler movement. Analytical detection was performed using positive ion atmospheric pressure chemical ionization tandem mass spectrometry (APCI-MS/MS) in scheduled multiple reaction monitoring (sMRM) mode. Excellent linearity was observed over standard calibration curve concentration ranges of 3 orders of magnitude with method detection limit ranging from 10 to 100 pg/mL. The interday and intraday reproducibility and accuracy were within +/- 15%. This method is fast, accurate, and reproducible and is suitable for assessment of exposure to the most common aromatic diisocyanates within targeted groups as well as larger population studies such as the National Health and Nutrition Examination Survey (NHANES). C1 [Bhandari, Deepak; Ruhl, John; Murphy, Anthony; McGahee, Ernest; Chambers, David; Blount, Benjamin C.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Bhandari, D (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. EM dbhandari@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 0 Z9 0 U1 4 U2 4 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD NOV 1 PY 2016 VL 88 IS 21 BP 10687 EP 10692 DI 10.1021/acs.analchem.6b03191 PG 6 WC Chemistry, Analytical SC Chemistry GA EA9UW UT WOS:000386991200051 PM 27690384 ER PT J AU Mazurek, JM Weissman, DN AF Mazurek, Jacek M. Weissman, David N. TI Occupational Respiratory Allergic Diseases in Healthcare Workers SO CURRENT ALLERGY AND ASTHMA REPORTS LA English DT Review DE Healthcare workers; Rhinitis; Asthma; Occupational allergy; Occupational exposures; Allergy prevention and control ID DIPHENYL DIISOCYANATE MDI; UNITED AIRWAYS DISEASE; IN-HOSPITAL WORKERS; RISK-FACTORS; CHRONIC RHINOSINUSITIS; ORTHO-PHTHALALDEHYDE; IGE SENSITIZATION; CLEANING PRODUCTS; MEDICAL DOCTORS; NATIONAL-HEALTH AB Healthcare workers (HCWs) are exposed to a range of high and low molecular weight agents that are allergic sensitizers or irritants including cleaners and disinfectants, natural rubber latex, and various medications. Studies have shown that exposed HCWs are at risk for work-related rhinitis and asthma (WRA). Work-related rhinitis may precede development of WRA and should be considered as an early marker of WRA. Avoidance of causative exposures through control strategies such as elimination, substitution, engineering controls, and process modification is the preferred primary prevention strategy for preventing development of work-related allergic diseases. There is limited evidence for the effectiveness of respirators in preventing occupational asthma. If sensitizer-induced WRA is diagnosed, it is important to avoid further exposure to the causative agent, preferably by more rigorous application of exposure control strategies to the workplace. This review focuses on allergic occupational respiratory diseases in HCWs. C1 [Mazurek, Jacek M.; Weissman, David N.] NIOSH, Resp Hlth Div, Ctr Dis Control & Prevent, Mailstop HG 900-2,1095 Willowdale Rd, Morgantown, WV 26505 USA. RP Mazurek, JM (reprint author), NIOSH, Resp Hlth Div, Ctr Dis Control & Prevent, Mailstop HG 900-2,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM JMazurek1@cdc.gov; DWeissman@cdc.gov NR 94 TC 0 Z9 0 U1 4 U2 4 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1529-7322 EI 1534-6315 J9 CURR ALLERGY ASTHM R JI Curr. Allergy Asthma Rep. PD NOV PY 2016 VL 16 IS 11 AR 77 DI 10.1007/s11882-016-0657-y PG 10 WC Allergy; Immunology SC Allergy; Immunology GA ED1GG UT WOS:000388592200001 PM 27796792 ER PT J AU Gardner, EE Walker, SE Gardner, LI AF Gardner, Eleanor E. Walker, Sally E. Gardner, Lytt I. TI Palaeoclimate, environmental factors, and bird body size: A multivariable analysis of avian fossil preservation SO EARTH-SCIENCE REVIEWS LA English DT Review DE Avian fossils; Depositional environment; Climate; Bird body size ID MESOZOIC BIRDS; NORTH-AMERICA; BONE-DENSITY; EARLY EOCENE; LAS HOYAS; RECORD; TAPHONOMY; QUALITY; ISOTOPE; SPAIN AB For this study, we abstracted data on 693 avian fossil specimens from 398 publications to determine preservation biases in the avian fossil record. Our results show that dissociated wing and leg bones are the most commonly preserved avian skeletal elements and they are preferentially preserved in environments of high erosion and reworking potential notably continental shelf marine environments. Using bivariate descriptive displays and multivariable regression analyses, we investigated the trends and associations between well-preserved avian specimens (i.e., fully- or partially-articulated) and a variety of taphonomic factors, including depositional environment, body size, and palaeoclimate. The regression model shows that well-preserved specimens are independently associated with depositional environments of low reworking potential commensurate with low energy systems, warm and humid climates, and smaller bird body size. Our results also indicate that fossils of smaller birds are less common than those of larger birds, but they are more often well-preserved. Bivariate analyses revealed that five times as many articulated specimens are found in warm and humid climates as in cool or dry climates, and this association persists in the multivariable regression model. Warm climates, the strongest predictor of better skeletal preservation, may be underestimated as a source of taphonomic bias in the avian fossil record, possibly because of the indirect nature of climate effects. Rapid burial events, such as volcanic ash accumulations and mudflows, are recognised for their influence on preservation, but climate-related storm events may be more important to avian taphonomy than previously understood. Our analyses indicate that geologic processes leading to high quality preservation of avian fossils are closely associated with climate. Additional studies, based both on fossils and modern taphonomic experiments, with improved collection of climate-related data, are needed to advance our understanding of avian taphonomy. (C) 2016 Elsevier B.V. All rights reserved. C1 [Gardner, Eleanor E.; Walker, Sally E.] Univ Georgia, Dept Geol, 210 Field St, Athens, GA 30602 USA. [Gardner, Lytt I.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Gardner, EE (reprint author), Univ Florida, Florida Museum Nat Hist, 1659 Museum Rd,POB 117800, Gainesville, FL 32611 USA. EM egardner@flmnh.ufl.edu; swalker@gly.uga.edu; lig0@cdc.gov FU National Science Foundation [ANT-0739512] FX This work was supported, in part, by National Science Foundation grant ANT-0739512. This organisation played no part in study design, data collection, analysis and interpretation of data, or in the writing of this report. NR 84 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0012-8252 EI 1872-6828 J9 EARTH-SCI REV JI Earth-Sci. Rev. PD NOV PY 2016 VL 162 BP 177 EP 197 DI 10.1016/j.earscirev.2016.07.001 PG 21 WC Geosciences, Multidisciplinary SC Geology GA ED3VN UT WOS:000388776700010 ER PT J AU Lindsey, NP Fischer, M Neitzel, D Schiffman, E Salas, ML Glaser, CA Sylvester, T Kretschmer, M Bunko, A Staples, JE AF Lindsey, N. P. Fischer, M. Neitzel, D. Schiffman, E. Salas, M. L. Glaser, C. A. Sylvester, T. Kretschmer, M. Bunko, A. Staples, J. E. TI Hospital-based enhanced surveillance for West Nile virus neuroinvasive disease SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Arbovirus; encephalitis; meningitis; surveillance; West Nile virus ID UNITED-STATES; ENCEPHALITIS; MENINGITIS AB Accurate data on the incidence of West Nile virus (WNV) disease are important for directing public health education and control activities. The objective of this project was to assess the underdiagnosis of WNV neuroinvasive disease through laboratory testing of patients with suspected viral meningitis or encephalitis at selected hospitals serving WNV-endemic regions in three states. Of the 279 patients with cerebrospinal fluid (CSF) specimens tested for WNV immunoglobulin M (IgM) antibodies, 258 (92%) were negative, 19 (7%) were positive, and two (1%) had equivocal results. Overall, 63% (12/19) of patients with WNV IgM-positive CSF had WNV IgM testing ordered by their attending physician. Seven (37%) cases would not have been identified as probable WNV infections without the further testing conducted through this project. These findings indicate that over a third of WNV infections in patients with clinically compatible neurological illness might be undiagnosed due to either lack of testing or inappropriate testing, leading to substantial underestimates of WNV neuroinvasive disease burden. Efforts should be made to educate healthcare providers and laboratorians about the local epidemiology of arboviral diseases and the optimal tests to be used in different clinical situations. C1 [Lindsey, N. P.; Fischer, M.; Staples, J. E.] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO USA. [Neitzel, D.; Schiffman, E.] Minnesota Dept Hlth, Foodborne Waterborne Vectorborne & Zoonot Dis Sec, St Paul, MN USA. [Salas, M. L.; Glaser, C. A.] Calif Dept Publ Hlth, Viral & Rickettsial Dis Lab, Richmond, CA USA. [Sylvester, T.; Kretschmer, M.; Bunko, A.] Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA. RP Lindsey, NP (reprint author), CDC, Arboviral Dis Branch, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM nplindsey@cdc.gov NR 13 TC 0 Z9 0 U1 2 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD NOV PY 2016 VL 144 IS 15 BP 3170 EP 3175 DI 10.1017/S0950268816001138 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA ED1QM UT WOS:000388620000006 PM 27311302 ER PT J AU Crowe, SJ Newton, AE Gould, LH Parsons, MB Stroika, S Bopp, CA Freeman, M Greene, K Mahon, BE AF Crowe, S. J. Newton, A. E. Gould, L. H. Parsons, M. B. Stroika, S. Bopp, C. A. Freeman, M. Greene, K. Mahon, B. E. TI Vibriosis, not cholera: toxigenic Vibrio cholerae non-O1, non-O139 infections in the United States, 1984-2014 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Oysters; post-harvest processing; toxigenic serogroups O75 and O141; Vibrio cholerae; vibriosis ID VULNIFICUS; PARAHAEMOLYTICUS; OYSTERS; BACTERIA; DIARRHEA; STORAGE; GENES AB Toxigenic strains of Vibrio cholerae serogroups O1 and O139 have caused cholera epidemics, but other serogroups - such as O75 or O141 - can also produce cholera toxin and cause severe watery diarrhoea similar to cholera. We describe 31 years of surveillance for toxigenic non-O1, non-O139 infections in the United States and map these infections to the state where the exposure probably originated. While serogroups O75 and O141 are closely related pathogens, they differ in how and where they infect people. Oysters were the main vehicle for O75 infection. The vehicles for O141 infection include oysters, clams, and freshwater in lakes and rivers. The patients infected with serogroup O75 who had food traceback information available ate raw oysters from Florida. Patients infected with O141 ate oysters from Florida and clams from New Jersey, and those who only reported being exposed to freshwater were exposed in Arizona, Michigan, Missouri, and Texas. Improving the safety of oysters, specifically, should help prevent future illnesses from these toxigenic strains and similar pathogenic Vibrio species. Post-harvest processing of raw oysters, such as individual quick freezing, heat-cool pasteurization, and high hydrostatic pressurization, should be considered. C1 [Crowe, S. J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Crowe, S. J.; Newton, A. E.; Gould, L. H.; Mahon, B. E.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA USA. [Parsons, M. B.; Stroika, S.; Bopp, C. A.; Freeman, M.; Greene, K.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA USA. RP Crowe, SJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A38, Atlanta, GA 30329 USA. EM yeo2@cdc.gov NR 23 TC 0 Z9 0 U1 2 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD NOV PY 2016 VL 144 IS 15 BP 3335 EP 3341 DI 10.1017/S0950268816001783 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA ED1QM UT WOS:000388620000023 PM 27510301 ER PT J AU Cogliati, M D'Amicis, R Zani, A Montagna, MT Caggiano, G De Giglio, O Balbino, S De Donno, A Serio, F Susever, S Ergin, C Velegraki, A Ellabib, MS Nardoni, S Macci, C Oliveri, S Trovato, L Dipineto, L Rickerts, V McCormick-Smith, I Akcaglar, S Tore, O Mlinaric-Missoni, E Bertout, S Mallie, M Martins, MD Venca, ACF Vieira, ML Sampaio, AC Pereira, C Criseo, G Romeo, O Ranque, S Al-Yasiri, MHY Kaya, M Cerikcioglu, N Marchese, A Vezzulli, L Ilkit, M Desnos-Ollivier, M Pasquale, V Korem, M Polacheck, I Scopa, A Meyer, W Ferreira-Paim, K Hagen, F Theelen, B Boekhout, T Lockhart, SR Tintelnot, K Tortorano, AM Dromer, F Varma, A Kwon-Chung, KJ Inacio, J Alonso, B Colom, MF AF Cogliati, Massimo D'Amicis, Roberta Zani, Alberto Montagna, Maria Teresa Caggiano, Giuseppina De Giglio, Osvalda Balbino, Stella De Donno, Antonella Serio, Francesca Susever, Serdar Ergin, Cagri Velegraki, Aristea Ellabib, Mohamed S. Nardoni, Simona Macci, Cristina Oliveri, Salvatore Trovato, Laura Dipineto, Ludovico Rickerts, Volker McCormick-Smith, Ilka Akcaglar, Sevim Tore, Okan Mlinaric-Missoni, Emilija Bertout, Sebastien Mallie, Michele Martins, Maria da Luz Venca, Ana C. F. Vieira, Maria L. Sampaio, Ana C. Pereira, Cheila Criseo, Giuseppe Romeo, Orazio Ranque, Stephane Al-Yasiri, Mohammed H. Y. Kaya, Meltem Cerikcioglu, Nilgun Marchese, Anna Vezzulli, Luigi Ilkit, Macit Desnos-Ollivier, Marie Pasquale, Vincenzo Korem, Maya Polacheck, Itzhack Scopa, Antonio Meyer, Wieland Ferreira-Paim, Kennio Hagen, Ferry Theelen, Bart Boekhout, Teun Lockhart, Shawn R. Tintelnot, Kathrin Tortorano, Anna Maria Dromer, Francoise Varma, Ashok Kwon-Chung, Kyung J. Inacio, Joao Alonso, Beatriz Colom, Maria F. TI Environmental distribution of Cryptococcus neoformans and C. gattii around the Mediterranean basin (vol 16, 2016 ) SO FEMS YEAST RESEARCH LA English DT Correction C1 [Cogliati, Massimo; D'Amicis, Roberta; Zani, Alberto; Tortorano, Anna Maria] Univ Milan, Dip Sci Biomed Salute, Via Pascal 36, I-20133 Milan, Italy. [Montagna, Maria Teresa; Caggiano, Giuseppina; De Giglio, Osvalda; Balbino, Stella] Univ Bari Aldo Moro, Dip Sci Biomed & Oncol Umana, Piazza Giulio Cesare 11, I-70124 Bari, Italy. [De Donno, Antonella; Serio, Francesca] Univ Salento, Dip Sci & Tecnol Biol & Ambientali, Via Monteroni, I-73100 Lecce, Italy. [Susever, Serdar] Cyprus Near East Univ, Dept Nutr & Dietet, Near East Blvd, CY-99138 Nicosia, Cyprus. [Ergin, Cagri] Pamukkale Univ, Sch Med, Klin Kampusu, TR-20160 Denizli, Turkey. [Velegraki, Aristea] Univ Athens, Sch Med, Mikras Asias 75, Athens 11527, Greece. [Ellabib, Mohamed S.] Univ Tripoli, Coll Med, Tripoli Univ Rd, Tripoli, Libya. [Nardoni, Simona] Univ Pisa, Dip Sci Vet, Via Piagge 2, I-56124 Pisa, Italy. [Macci, Cristina] CNR, ISE, Via Moruzzi 1, I-56124 Pisa, Italy. [Oliveri, Salvatore; Trovato, Laura] Univ Catania, Dip Sci Microbiol & Sci Ginecol, Via Androne 81, I-95124 Catania, Italy. [Dipineto, Ludovico] Univ Naples Federico II, Dip Med Vet & Prod Anim, Cso Umberto 1 40, I-80138 Naples, Italy. [Rickerts, Volker; McCormick-Smith, Ilka; Tintelnot, Kathrin] Robert Koch Inst, Dept Infeciuos Dis, D-13302 Berlin, Germany. [Akcaglar, Sevim; Tore, Okan] Uludag Univ, Sch Med, Gorukle Kampusu, TR-16059 Bursa, Turkey. [Mlinaric-Missoni, Emilija] Croatian Natl Inst Publ Hlth, Rockefellerova 7, Zagreb 10000, Croatia. [Bertout, Sebastien; Mallie, Michele] Univ Montpellier, Unite Mixte Int Rech Translat lnfect VIH & Malad, 15 Ave Charles Flahault, F-34093 Montpellier, France. [Martins, Maria da Luz; Venca, Ana C. F.; Vieira, Maria L.] Inst Higiene & Med Trop, Rua Junqueira 100, P-1349008 Lisbon, Portugal. [Sampaio, Ana C.; Pereira, Cheila] Univ Tras Os Montes & Alto Douro, CITAB, P-5000801 Quinta Dos Prados, Vila Real, Portugal. [Criseo, Giuseppe; Romeo, Orazio] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Piazza Pugliatti 1, I-98122 Messina, Italy. [Ranque, Stephane; Al-Yasiri, Mohammed H. Y.] Aix Marseille Univ, IP TPT Infect Parasitaires Transmiss Pphysiopatho, 27 Blvd Jean Moulin, F-13005 Marseille, France. [Kaya, Meltem; Cerikcioglu, Nilgun] Marmara Univ, Sch Med, MU Goztepe Kampusu, TR-34722 Istanbul, Turkey. [Marchese, Anna] Univ Genoa, IRCCS San Martino IST Genova, Sez Microbiol DISC, Largo Benzi 10, I-16132 Genoa, Italy. [Vezzulli, Luigi] Univ Genoa, Dipartimento Sci Terra Ambiente & Vita DISTAV, Cso Europa 26, I-16132 Genoa, Italy. [Ilkit, Macit] Cukurova Univ Rektorlugu, Univ Cukurova Saricam, Dept Microbiol, TR-01330 Adana, Turkey. [Desnos-Ollivier, Marie; Dromer, Francoise] Inst Pasteur, CNRS, Unite Mycol Mol, 25-28 Rue Dr Roux, F-75015 Paris, France. [Pasquale, Vincenzo] Univ Napoli Parthenope, Dip Sci & Tecnol, Via Amm F Acton 38, I-80133 Naples, Italy. [Korem, Maya; Polacheck, Itzhack] Hadassah Hebrew Univ, Med Ctr, Div Microbiol & Infect Dis, POB 12271, Jerusalem, Israel. [Scopa, Antonio] Univ Basilicata, Fac Sci Agr Forestali & Ambientali, Via Nazario Sauro 85, I-85100 Potenza, Italy. [Meyer, Wieland; Ferreira-Paim, Kennio] Univ Sydney, Westmead Millennium Inst, Mol Mycol Res Lab, CIDM,MBI,Sydney Med Sch,Westmead Hosp, 176 Hawkesbury Rd, Westmead, NSW 2145, Australia. [Hagen, Ferry] Canisius Wilhelmina Hosp, Weg Door Jonkerbos 100, NL-6532 SZ Nijmegen, Netherlands. [Theelen, Bart; Boekhout, Teun] CBS KNAW Fungal Biodivers Ctr, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands. [Lockhart, Shawn R.] Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. [Varma, Ashok; Kwon-Chung, Kyung J.] NIAID, 31 Ctr Dr, Bethesda, MD 20892 USA. [Inacio, Joao; Alonso, Beatriz] Univ Brighton, Sch Pharm & Biomol Sci, Lewes Rd, Brighton BN2 4GJ, E Sussex, England. [Colom, Maria F.] Univ Miguel Hernandez, Sch Med, Ave Univ, Alicante 03202, Spain. RP Cogliati, M (reprint author), Univ Milan, Dip Sci Biomed Salute, Lab Micol Med, Via Pascal 36, I-20133 Milan, Italy. EM massimo.cogliati@unimi.it RI Hagen, Ferry/B-9044-2009 OI Hagen, Ferry/0000-0002-5622-1916 NR 1 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1567-1356 EI 1567-1364 J9 FEMS YEAST RES JI FEMS Yeast Res. PD NOV PY 2016 VL 16 IS 7 AR fow086 DI 10.1093/femsyr/fow086 PG 2 WC Biotechnology & Applied Microbiology; Microbiology; Mycology SC Biotechnology & Applied Microbiology; Microbiology; Mycology GA ED0VO UT WOS:000388560700012 ER PT J AU Tang, Y Li, N Song, MX Roellig, DM Feng, YY Xiao, LH AF Tang, Ying Li, Na Song, Mingxin Roellig, Dawn M. Feng, Yaoyu Xiao, Lihua TI Development of a multilocus sequence typing tool for high-resolution subtyping and genetic structure characterization of Cryptosporidium ubiquitum SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Cryptosporidium ubiquitum; Multilocus sequence typing; Zoonotic transmission; Host adaptation ID NEW-YORK; HOMINIS; GENOTYPES; PARVUM; POPULATION; HUMANS; RECOMBINATION; TRANSMISSION; CHILDREN; SPAIN AB Cryptosporidium ubiquitum is an emerging zoonotic pathogen in humans. Recently, a subtyping tool targeting the 60-kDa glycoprotein (gp60) gene was developed for C. ubiquitum, and identified six subtype families (XIIa-XIIf). In this study, we selected five genetic loci known to be polymorphic in C. hominis and C. parvum for the development of a multilocus subtyping tool for C. ubiquitum, including CP47 (cgd6_1590), MSC6-5 (cgd6_4290), cgd6_60, cgd2_3690, and cgd4_370. PCR primers for these targets were designed based on whole genome sequence data from C. ubiquitum. DNA sequence analyses of 24 C. ubiquitum specimens showed the presence of 18, 1, 5, 4, and 5 subtypes at the CP47, MSC6-5, cgd6_60, cgd2_3690, and cgd4_370 loci, respectively. Altogether, 18 multilocus sequence typing (MLST) subtypes were detected among the 19 specimens successfully sequenced at all polymorphic loci. Phylogenetic analyses of the MLST data indicated that the rodent subtype families of XIIe and XIIf were highly divergent from others, and the ruminant XIIa subtype family formed a monophyletic group genetically distant from other rodent subtype families XIIb, XIIc, and XIId. The latter showed no consistent grouping of specimens and formed one large cluster in phylogenetic analysis of concatenated multilocus sequences. This was supported by results of STRUCTURE and F-ST analyses, which further suggested that XIIa originated from one common ancestor whereas XIIb, XIIc, and XIId contained mixed ancestral types, reflecting a close relatedness of the three subtype families and the likely occurrence of genetic recombination among them. Thus, an MLST tool was developed for high-resolution subtyping of C. ubiquitum and results of preliminary characterizations of specimens from humans and animals supported the conclusion on the existence of ruminant and rodent-adapted C. ubiquitum groups. (C) 2016 Elsevier B.V. All rights reserved. C1 [Tang, Ying; Roellig, Dawn M.; Xiao, Lihua] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. [Tang, Ying; Song, Mingxin] Northeast Agr Univ, Coll Vet Med, Harbin 150030, Heilongjiang, Peoples R China. [Li, Na; Feng, Yaoyu] East China Univ Sci & Technol, Sch Resources & Environm Engn, Shanghai 200237, Peoples R China. RP Xiao, LH (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA.; Feng, YY (reprint author), East China Univ Sci & Technol, Sch Resources & Environm Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn; lxiao@cdc.gov OI Xiao, Lihua/0000-0001-8532-2727 FU National Natural Science Foundation of China [31425025, 31229005, 3110103901, 31302078]; Open Funding Project of the State Key Laboratory of Veterinary Etiological Biology, Lanzhou, China [SKLVEB2014KFKT008]; Fundamental Research Funds for the Central Universities, China; U.S. Centers for Disease Control and Prevention FX This work was supported by the National Natural Science Foundation of China (grant numbers 31425025, 31229005, 3110103901, and 31302078); Open Funding Project of the State Key Laboratory of Veterinary Etiological Biology, Lanzhou, China (grant number SKLVEB2014KFKT008); Fundamental Research Funds for the Central Universities, China; and the U.S. Centers for Disease Control and Prevention. NR 26 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 EI 1567-7257 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD NOV PY 2016 VL 45 BP 256 EP 261 DI 10.1016/j.meegid.2016.09.011 PG 6 WC Infectious Diseases SC Infectious Diseases GA ED0ZY UT WOS:000388574400035 PM 27633152 ER PT J AU Mac Kenzie, WR Davidson, AJ Wiesenthal, A Engel, JP Turner, K Conn, L Becker, SJ Moffatt, S Groseclose, SL Jellison, J Stinn, J Garrett, NY Helmus, L Harmon, B Richards, CL Lumpkin, JR Iademarco, MF AF Mac Kenzie, William R. Davidson, Arthur J. Wiesenthal, Andrew Engel, Jeffrey P. Turner, Kathryn Conn, Laura Becker, Scott J. Moffatt, Sharon Groseclose, Samuel L. Jellison, Jim Stinn, John Garrett, Nedra Y. Helmus, Lesliann Harmon, Bob Richards, Chesley L. Lumpkin, John R. Iademarco, Michael F. TI The Promise of Electronic Case Reporting SO PUBLIC HEALTH REPORTS LA English DT Editorial Material ID HEALTH C1 [Mac Kenzie, William R.; Conn, Laura; Garrett, Nedra Y.; Helmus, Lesliann; Iademarco, Michael F.] Ctr Dis Control & Prevent, Ctr Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd NE,MS-E94, Atlanta, GA 30329 USA. [Davidson, Arthur J.] Denver Publ Hlth, Denver, CO USA. [Wiesenthal, Andrew; Stinn, John] Deloitte Consulting, San Francisco, CA USA. [Wiesenthal, Andrew; Stinn, John] Deloitte Consulting, Atlanta, GA USA. [Engel, Jeffrey P.] Council State & Terr Epidemiol, Atlanta, GA USA. [Turner, Kathryn] Idaho Dept Hlth & Welf, Boise, ID USA. [Becker, Scott J.] Assoc Publ Hlth Labs, Silver Spring, MD USA. [Moffatt, Sharon] Assoc State & Terr Hlth Officials, Arlington, VA USA. [Groseclose, Samuel L.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Jellison, Jim] Publ Hlth Informat Inst, Atlanta, GA USA. [Harmon, Bob] Cerner Corp, Kansas City, MO USA. [Richards, Chesley L.] Ctr Dis Control & Prevent, Off Publ Hlth Sci Serv, Atlanta, GA USA. [Lumpkin, John R.] Robert Wood Johnson Fdn, Princeton, NJ 08540 USA. RP Mac Kenzie, WR (reprint author), Ctr Dis Control & Prevent, Ctr Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd NE,MS-E94, Atlanta, GA 30329 USA. EM wmackenzie@cdc.gov NR 11 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2016 VL 131 IS 6 BP 742 EP 746 DI 10.1177/0033354916670871 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ED2FN UT WOS:000388659400002 PM 28123218 ER PT J AU Burris, S Ashe, M Blanke, D Ibrahim, J Levin, DE Matthews, G Penn, M Katz, M AF Burris, Scott Ashe, Marice Blanke, Doug Ibrahim, Jennifer Levin, Donna E. Matthews, Gene Penn, Matthew Katz, Martha TI Better Health Faster: The 5 Essential Public Health Law Services SO PUBLIC HEALTH REPORTS LA English DT Editorial Material DE law; evidence-based policy; translation; public health law research; metrics; legal epidemiology; public health law practice ID KNOWLEDGE TRANSFER; POLICY-MAKERS; OPPORTUNITIES; ADVOCACY; SYSTEMS C1 [Burris, Scott; Ibrahim, Jennifer] Robert Wood Johnson Fdn, Publ Hlth Law Res Program, Natl Program Off, Philadelphia, PA USA. [Burris, Scott; Ibrahim, Jennifer] Temple Univ, 1719 N Broad St, Philadelphia, PA 19122 USA. [Ashe, Marice] ChangeLab Solut, Oakland, CA USA. [Blanke, Doug] Mitchell Hamline Sch Law, Publ Hlth Law Ctr, St Paul, MN USA. [Levin, Donna E.] Network Publ Hlth Law, St Paul, MN USA. [Matthews, Gene] Network Publ Hlth Law, Chapel Hill, NC USA. [Matthews, Gene] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Penn, Matthew] Ctr Dis Control & Prevent, Publ Hlth Law Program, Off State Tribal Local & Terr Support, Atlanta, GA USA. [Katz, Martha] Georgia Hlth Fdn, Atlanta, GA USA. RP Burris, S (reprint author), Temple Univ, 1719 N Broad St, Philadelphia, PA 19122 USA. EM scott.burris@temple.edu FU Robert Wood Johnson Foundation; Centers for Disease Control and Prevention [CDC-RFA-OT13-1302] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Work on this article was supported by grants from the Robert Wood Johnson Foundation and by collaborating agreement CDC-RFA-OT13-1302 from the Centers for Disease Control and Prevention. The opinions expressed in this article are those of the authors and are not necessarily those of the funding agencies. NR 37 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2016 VL 131 IS 6 BP 747 EP 753 DI 10.1177/0033354916667496 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ED2FN UT WOS:000388659400003 PM 28123219 ER PT J AU de Moor, JS Virgo, KS Li, CY Chawla, N Han, XS Blanch-Hartigan, D Ekwueme, DU McNeel, TS Rodriguez, JL Yabroff, KR AF de Moor, Janet S. Virgo, Katherine S. Li, Chunyu Chawla, Neetu Han, Xuesong Blanch-Hartigan, Danielle Ekwueme, Donatus U. McNeel, Timothy S. Rodriguez, Juan L. Yabroff, K. Robin TI Access to Cancer Care and General Medical Care Services Among Cancer Survivors in the United States: An Analysis of 2011 Medical Expenditure Panel Survey Data SO PUBLIC HEALTH REPORTS LA English DT Article DE cancer care; access to care; health services ID QUALITY-OF-CARE; BREAST-CANCER; HEALTH-CARE; LONG-TERM; RECEIPT; PATIENT; EXPERIENCES; DISPARITIES; CHALLENGE; PATTERNS AB Objectives: Cancer survivors require appropriate health care to manage their unique health needs. This study describes access to cancer care among cancer survivors in the United States and compares access to general medical care between cancer survivors and people who have no history of cancer. Methods: We assessed access to general medical care using the core 2011 Medical Expenditure Panel Survey (MEPS). We assessed access to cancer care using the MEPS Experiences With Cancer Survey. We used multivariable logistic regression to compare access to general medical care among 2 groups of cancer survivors (those who reported having access to all necessary cancer care [n = 1088] and those who did not [n = 70]) with self-reported access to general medical care among people who had no history of cancer (n = 22434). Results: Of the 1158 cancer survivors, 70 (6.0%) reported that they did not receive all necessary cancer care. Adjusted analyses found that cancer survivors who reported not receiving all necessary cancer care were also less likely to report receiving general medical care (78.0%) than cancer survivors who reported having access to necessary cancer care (87.1%) and people who had no history of cancer (87.8%). Conclusions: This study provides nationally representative data on the proportion of cancer survivors who have access to necessary cancer care and yields insight into factors that impede survivors' access to both cancer care and general medical care. This study is a reference for future work on access to care. C1 [de Moor, Janet S.; Yabroff, K. Robin] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Virgo, Katherine S.] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. [Li, Chunyu; Ekwueme, Donatus U.; Rodriguez, Juan L.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Chawla, Neetu] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Han, Xuesong] Amer Canc Soc, Surveillance & Hlth Serv Res, Atlanta, GA 30329 USA. [Blanch-Hartigan, Danielle] Bentley Univ, Dept Nat & Appl Sci, Waltham, MA USA. [McNeel, Timothy S.] Informat Management Serv Inc, Calverton, MD USA. RP de Moor, JS (reprint author), NCI, Healthcare Assessment Res Branch, Healthcare Delivery Res Program, Div Canc Control & Populat Sci, 9609 Med Ctr Dr, Rockville, MD 20850 USA. EM demoorjs@mail.nih.gov NR 41 TC 0 Z9 0 U1 3 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2016 VL 131 IS 6 BP 783 EP 790 DI 10.1177/0033354916675852 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ED2FN UT WOS:000388659400008 PM 28123224 ER PT J AU Byrd, KK Furtado, M Bush, T Gardner, L AF Byrd, Kathy K. Furtado, Melissa Bush, Tim Gardner, Lytt TI Reengagement in Care After a Gap in HIV Care Among a Population of Privately Insured Persons with HIV in the United States SO AIDS PATIENT CARE AND STDS LA English DT Article DE gaps in care; HIV; reengagement in care; retention in care ID MEDICAL-CARE; INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; VIRAL SUPPRESSION; MISSED VISITS; FOLLOW-UP; RETENTION; SERVICES; HEALTH; IMPACT AB The HIV care continuum illustrates steps needed to reach HIV viral suppression, including retention in care. The continuum's retention measure does not account for gaps or reengagement in care and thus provides an incomplete picture of long-term engagement. We used a claims database to determine the proportion of privately insured persons with HIV who experienced a gap in care and subsequently reengaged between 2008 and 2012. A gap was defined as no office visit claim in >6 months and reengagement as >= 1 office visit claim after a gap. Cox proportional hazards models were conducted to determine factors associated with time to first gap and time to reengagement. Of 5142 persons in the study, 79% were males and median age was 46 years (range, 19-64 years). No race/ethnicity data were available. Thirty percent (n = 1555) experienced a gap. Median time to first gap was 15 months (IQR: 6-30). Median gap length was 3.2 months. Seventy percent with a gap reengaged; 22% reengaged more than once. Of 1086 patients who reengaged, 224 (21%) eventually had a terminal gap. Residence in the North Central region (HR 0.73, 95% CI 0.62-0.87) and having >= 1 Charlson comorbidities (HR 0.85, 95% CI 0.73-0.99) were associated with shorter time to reengagement. The majority who experienced a gap reengaged within a relatively short period and remained in the cohort at 60 months. However, 21% of those reengaging had a terminal gap by 60 months, which should alert providers to the eventual potential for loss to follow-up. The analysis was limited by inability to distinguish between HIV-specific and non-HIV-specific care visits. C1 [Byrd, Kathy K.; Bush, Tim; Gardner, Lytt] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, MS E-45 1600 Clifton Rd, Atlanta, GA 30333 USA. [Furtado, Melissa] Engility Corp, Atlanta, GA USA. RP Byrd, KK (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, MS E-45 1600 Clifton Rd, Atlanta, GA 30333 USA. EM gdn8@cdc.gov NR 39 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 EI 1557-7449 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD NOV PY 2016 VL 30 IS 11 BP 491 EP 496 DI 10.1089/apc.2016.0188 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EC5OC UT WOS:000388184400001 PM 27849370 ER PT J AU Ahrens, KA Haley, BA Rossen, LM Lloyd, PC Aoki, Y AF Ahrens, Katherine A. Haley, Barbara A. Rossen, Lauren M. Lloyd, Patricia C. Aoki, Yutaka TI Housing Assistance and Blood Lead Levels: Children in the United States, 2005-2012 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HEALTH; US; ASSOCIATION AB Objectives. To compare blood lead levels (BLLs) among US children aged 1 to 5 years according to receipt of federal housing assistance. Methods. In our analyses, we used 2005 to 2012 data for National Health and Nutrition Examination Survey (NHANES) respondents that were linked to 1999 to 2014 administrative records from the US Department of Housing and Urban Development (HUD). After we restricted the analysis to children with family income-to-poverty ratios below 200%, we compared geometric mean BLLs and the prevalence of BLLs of 3 micrograms per deciliter or higher among children who were living in assisted housing at the time of their NHANES blood draw (n = 151) with data for children who did not receive housing assistance (n = 1099). Results. After adjustment, children living in assisted housing had a significantly lower geometric mean BLL (1.44 mu g/dL; 95% confidence interval [CI] = 1.31, 1.57) than comparable children who did not receive housing assistance (1.79 mu g/dL; 95% CI = 1.59, 2.01; P < .01). The prevalence ratio for BLLs of 3 micrograms per deciliter or higher was 0.51 (95% CI = 0.33, 0.81; P < .01). Conclusions. Children aged 1 to 5 years during 2005 to 2012 who were living in HUD-assisted housing had lower BLLs than expected given their demographic, socioeconomic, and family characteristics. C1 [Ahrens, Katherine A.; Rossen, Lauren M.; Lloyd, Patricia C.] Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, US Dept Hlth & Human Serv, Hyattsville, MD USA. [Haley, Barbara A.] US Dept Housing & Urban Dev, Off Policy Dev & Res, Washington, DC USA. [Aoki, Yutaka] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, US Dept Hlth & Human Serv, Hyattsville, MD USA. RP Ahrens, KA (reprint author), Off Populat Affairs, 1101 Wootton Pkwy,Suite 700, Rockville, MD 20852 USA. EM kate.ahrens@hhs.gov NR 22 TC 1 Z9 1 U1 2 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD NOV PY 2016 VL 106 IS 11 BP 2049 EP 2056 DI 10.2105/AJPH.2016.303432 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EC4IE UT WOS:000388090200043 PM 27631737 ER PT J AU Spengler, JR Estrada-Pena, A Garrison, AR Schmaljohn, C Spiropoulou, CF Bergeron, E Bente, DA AF Spengler, Jessica R. Estrada-Pena, Agustin Garrison, Aura R. Schmaljohn, Connie Spiropoulou, Christina F. Bergeron, Eric Bente, Dennis A. TI A chronological review of experimental infection studies of the role of wild animals and livestock in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus SO ANTIVIRAL RESEARCH LA English DT Review DE Crimean-Congo hemorrhagic fever; Bunyavirus; Tick-borne; Viral hemorrhagic fever; Transmission ID BORNE ENCEPHALITIS-VIRUS; HYALOMMA-TRUNCATUM TICKS; FAMILY BUNYAVIRIDAE; ANTIBODY-RESPONSE; RISK-FACTORS; HOST; DISEASES; AFRICAN; BIRDS; EPIDEMIOLOGY AB This article provides a definitive review of experimental studies of the role of wild animals and livestock in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus (CCHFV), the etiologic agent of Crimean-Congo hemorrhagic fever (CCHF), beginning with the first recognized outbreak of the human disease in Crimea in 1944. Published reports by researchers in the former Soviet Union, Bulgaria, South Africa, and other countries where CCHF has been observed show that CCHFV is maintained in nature in a tick-vertebrate-tick enzootic cycle. Human disease most commonly results from the bite of an infected tick, but may also follow crushing of infected ticks or exposure to the blood and tissues of infected animals during slaughter. Wild and domestic animals are susceptible to infection with CCHFV, but do not develop clinical illness. Vertebrates are important in CCHF epidemiology, as they provide blood meals to support tick populations, transport ticks across wide geographic areas, and transmit CCHFV to ticks and humans during the period of viremia. Many aspects of vertebrate involvement in the maintenance and spread of CCHFV are still poorly understood. Experimental investigations in wild animals and livestock provide important data to aid our understanding of CCHFV ecology. This article is the second in a series of reviews of more than 70 years of research on CCHF, summarizing important findings, identifying gaps in knowledge, and suggesting directions for future research. (C) 2016 Elsevier B.V. All rights reserved. C1 [Spengler, Jessica R.; Spiropoulou, Christina F.; Bergeron, Eric] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Estrada-Pena, Agustin] Univ Zaragoza, Dept Anim Pathol, Zaragoza, Spain. [Garrison, Aura R.; Schmaljohn, Connie] US Army, Med Res Inst Infect Dis, Frederick, MD USA. [Bente, Dennis A.] Dept Microbiol & Immunol, Galveston, TX USA. [Bente, Dennis A.] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA. RP Spengler, JR (reprint author), 1600 Clifton Rd,MS G-14, Atlanta, GA 30333 USA. EM JSpengler@cdc.gov OI Spengler, Jessica R./0000-0002-5383-0513; Bergeron, Eric/0000-0003-3398-8628 FU Oak Ridge Institute for Science and Education; National Institutes of Health Loan Repayment Award; National Institutes of Health [R01AI109008]; Canadian Institute of Health FX This work was supported in part by an appointment to the Research Participation Program at CDC by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC (to J.R.S.); by the National Institutes of Health Loan Repayment Award (to J.R.S.); by the National Institutes of Health grant R01AI109008 (to E.B.); and by the Canadian Institute of Health (to E.B.). NR 111 TC 1 Z9 1 U1 4 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 EI 1872-9096 J9 ANTIVIR RES JI Antiviral Res. PD NOV PY 2016 VL 135 BP 31 EP 47 DI 10.1016/j.antivira1.2016.09.013 PG 17 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA ED0QV UT WOS:000388547900004 PM 27713073 ER PT J AU Wilson, JR Guo, Z Reber, A Kamal, RP Music, N Gansebom, S Bai, YH Levine, M Carney, P Tzeng, WP Stevens, J York, IA AF Wilson, Jason R. Guo, Zhu Reber, Adrian Kamal, Ram P. Music, Nedzad Gansebom, Shane Bai, Yaohui Levine, Min Carney, Paul Tzeng, Wen-Pin Stevens, James York, Ian A. TI An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo SO ANTIVIRAL RESEARCH LA English DT Article DE Influenza; H7N9; Monoclonal antibody; Antiviral; Neuraminidase; NA epitope ID STRUCTURAL-CHARACTERIZATION; HUMAN SERA; HEMAGGLUTININ; EPITOPE; H5N1; RESISTANCE; INFECTION; H1N1; ASSOCIATION; PROTECTION AB Zoonotic A(H7N9) avian influenza viruses emerged in China in 2013 and continue to be a threat to human public health, having infected over 800 individuals with a mortality rate approaching 40%. Treatment options for people infected with A(H7N9) include the use of neuraminidase (NA) inhibitors. However, like other influenza viruses, A(H7N9) can become resistant to these drugs. The use of monoclonal antibodies is a rapidly developing strategy for controlling influenza virus infection. Here we generated a murine monoclonal antibody (3c10-3) directed against the NA of A(H7N9) and show that prophylactic systemic administration of 3c10-3 fully protected mice from lethal challenge with wild-type A/Anhui/1/2013 (H7N9). Further, post-infection treatment with a single systemic dose of 3c10-3 at either 24, 48 or 72 h post A(H7N9) challenge resulted in both dose- and time-dependent protection of up to 100% of mice, demonstrating therapeutic potential for 3c10-3. Epitope mapping revealed that 3c10-3 binds near the enzyme active site of NA, and functional characterization showed that 3c10-3 inhibits the enzyme activity of NA and restricts the cell-to-cell spread of the virus in cultured cells. Affinity analysis also revealed that 3c10-3 binds equally well to recombinant NA of wild-type A/Anhui/1/2013 and to a variant NA carrying a R289k mutation known to infer NAI resistance. These results suggest that 3c10-3 has the potential to be used as a therapeutic to treat A(H7N9) infections either as an alternative to, or in combination with, current NA antiviral inhibitors. (C) 2016 Elsevier B.V. All rights reserved. C1 [Wilson, Jason R.; Guo, Zhu; Reber, Adrian; Kamal, Ram P.; Music, Nedzad; Gansebom, Shane; Bai, Yaohui; Levine, Min; Carney, Paul; Tzeng, Wen-Pin; Stevens, James; York, Ian A.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Wilson, Jason R.; Gansebom, Shane] Carter Consulting Inc, Atlanta, GA USA. [Kamal, Ram P.; Music, Nedzad] Battelle Mem Inst, Atlanta, GA USA. RP York, IA (reprint author), Influenza Div, MS G-16,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM ite1@cdc.gov OI York, Ian/0000-0002-3478-3344 FU Centers for Disease Control and Prevention FX We thank Lee Pitts, Joo Lee and Jason Goldstein for performing the fusion and subsequent ClonePix selection of hybridoma clones. This work was supported by the Centers for Disease Control and Prevention. NR 48 TC 0 Z9 0 U1 8 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 EI 1872-9096 J9 ANTIVIR RES JI Antiviral Res. PD NOV PY 2016 VL 135 BP 48 EP 55 DI 10.1016/j.antiviral.2016.10.001 PG 8 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA ED0QV UT WOS:000388547900005 PM 27713074 ER PT J AU Coetzer, A Kidane, AH Bekele, M Hundera, AD Pieracci, EG Shiferaw, ML Wallace, R Nel, LH AF Coetzer, A. Kidane, A. H. Bekele, M. Hundera, A. D. Pieracci, E. G. Shiferaw, M. L. Wallace, R. Nel, L. H. TI The SARE tool for rabies control: Current experience in Ethiopia SO ANTIVIRAL RESEARCH LA English DT Article DE Rabies; Elimination; Stepwise approach; One health; Ethiopia ID ELIMINATING CANINE RABIES; AFRICA AB The Stepwise Approach towards Rabies Elimination (SARE) tool was developed through a joint effort of the Food and Agriculture Organization (FAO) of the United Nations and the Global Alliance for Rabies Control (GARC), to provide a standard mechanism for countries to assess their rabies situation and measure progress in eliminating the disease. Because the African continent has the highest per capita death rate from rabies, and Ethiopia is estimated to have the second largest number of rabies deaths of all African countries, Ethiopia undertook a self-assessment by means of the Stepwise Approach towards Rabies Elimination (SARE) tool. In February 2016, the Ethiopian government hosted an intersectoral consultative meeting in an effort to assess the progress that has been made towards the control and elimination of canine rabies. The SARE assessment identified a number of critical gaps, including poor inter-sectoral collaboration and limited availability and access to dog vaccine, while the existence of a surveillance system for rabies and legislation for outbreak declaration and response were among the strengths identified. The SARE tool enabled key criteria to be prioritized, thereby accelerating the National Strategy and ensuring that Ethiopia will progress rapidly in line with the goals set by the global community for the elimination of human rabies deaths by 2030. Although the analysis showed that Ethiopia is still in the early stages of rabies control (Stage 0.5/5), the country shows great promise in terms of developing a SARE-guided National Rabies Prevention and Control Strategy. (C) 2016 Elsevier B.V. All rights reserved. C1 [Coetzer, A.; Nel, L. H.] Univ Pretoria, Fac Nat & Agr Sci, Dept Microbiol & Plant Pathol, Pretoria, South Africa. [Coetzer, A.; Nel, L. H.] Global Alliance Rabies Control SA NPC, Erasmus Forum A434, ZA-0181 Pretoria, South Africa. [Kidane, A. H.; Hundera, A. D.] Ethiopian Publ Hlth Inst, POB 1242, Addis Ababa, Ethiopia. [Bekele, M.] Minist Livestock & Fishery, POB 170042, Addis Ababa, Ethiopia. [Pieracci, E. G.; Shiferaw, M. L.; Wallace, R.] US Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA USA. RP Nel, LH (reprint author), Univ Pretoria, Fac Nat & Agr Sci, Dept Microbiol & Plant Pathol, Pretoria, South Africa. EM louis.nel@rabiesalliance.org OI Coetzer, Andre/0000-0003-0581-7207 FU United States Centers for Disease Control and Prevention; Ethiopian Public Health Institute FX This work was supported by the United States Centers for Disease Control and Prevention and the Ethiopian Public Health Institute. The authors would like to thank all of the national and regional participants at the consultative meeting, with special thanks to the event organisers and Meseret Birhane & Jesse Blanton for their work preparing the workshop materials and developing the regional-specific SARE tool. We would also like to thank colleagues from GARC and the CDC for their contributions to the success of the meeting. NR 22 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 EI 1872-9096 J9 ANTIVIR RES JI Antiviral Res. PD NOV PY 2016 VL 135 BP 74 EP 80 DI 10.1016/j.antivira1.2016.09.011 PG 7 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA ED0QV UT WOS:000388547900008 PM 27746249 ER PT J AU Poirier, MJP Moss, DM Feeser, KR Streit, TG Chang, GJJ Whitney, M Russell, BJ Johnson, BW Basile, AJ Goodman, CH Barry, AK Lammie, PJ AF Poirier, Mathieu J. P. Moss, Delynn M. Feeser, Karla R. Streit, Thomas G. Chang, Gwong-Jen J. Whitney, Matthew Russell, Brandy J. Johnson, Barbara W. Basile, Alison J. Goodman, Christin H. Barry, Amanda K. Lammie, Patrick J. TI Measuring Haitian children's exposure to chikungunya, dengue and malaria SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Article ID LINKED-IMMUNOSORBENT-ASSAY; MULTIPLEX BEAD ASSAY; FLAVIVIRAL INFECTIONS; ANTIBODY-RESPONSES; HEMORRHAGIC-FEVER; IMMUNOGLOBULIN-M; VIRUS-INFECTION; PROTEIN; QUANTITATION; TRANSMISSION AB Objective To differentiate exposure to the newly introduced chikungunya virus-from exposure to endemic dengue virus and other pathogens in Haiti. Methods We used a multiplex bead assay to detect immunoglobulin G (IgG) responses to a recombinant chikungunya virus antigen, two dengue virus-like particles and three recombinant Plasmodium falciparum antigens. Most (217) of the blood samples investigated were collected longitudinally, from each of 61 children, between 2011 and 2014 but another 127 were collected from a cross-sectional sample of children in 2014. Findings Of the samples from the longitudinal cohort, none of the 153 collected between 2011 and 2013 but 78.7% (48/61) of those collected in 2014 were positive for IgG responses to the chikungunya virus antigen. In the cross-sectional sample, such responses were detected in 96 (75.6%) of the children and occurred at similar prevalence across all age groups. In the same sample, responses to malarial antigen were only detected in eight children (6.3%) but the prevalence of IgG responses to dengue virus antigens was 60.6% (77/127) overall and increased steadily with age. Spatial analysis indicated that the prevalence of IgG responses to the chikungunya virus and one of the dengue virus-like particles decreased as the sampling site moved away from the city of Leogane and towards the ocean. Conclusion Serological evidence indicates that there had been a rapid and intense dissemination of chikungunya virus in Haiti. The multiplex bead assay appears to be an appropriate serological platform to monitor the seroprevalence of multiple pathogens simultaneously. C1 [Poirier, Mathieu J. P.; Streit, Thomas G.] Hop St Croix, Univ Notre Dame Haiti Program, Rue Accenil 1, Leogane, Haiti. [Moss, Delynn M.; Feeser, Karla R.; Barry, Amanda K.; Lammie, Patrick J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Chang, Gwong-Jen J.; Whitney, Matthew; Russell, Brandy J.; Johnson, Barbara W.; Basile, Alison J.; Goodman, Christin H.] Ctr Dis Control & Prevent, Ft Collins, CO USA. RP Poirier, MJP (reprint author), Hop St Croix, Univ Notre Dame Haiti Program, Rue Accenil 1, Leogane, Haiti. EM poiriemj@mcmaster.ca FU Bill & Melinda Gates Foundation [402.01]; Abbott/AbbVie FX This work was supported by the Bill & Melinda Gates Foundation (grant number 402.01), Abbott/AbbVie and a donor who wishes to remain anonymous. NR 43 TC 0 Z9 0 U1 0 U2 0 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 EI 1564-0604 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD NOV PY 2016 VL 94 IS 11 BP 817 EP 825 DI 10.2471/BLT.16.173252 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EC3XP UT WOS:000388060700008 PM 27821884 ER PT J AU Sharp, TM Munoz-Jordan, J Perez-Padilla, J Bello-Pagan, MI Rivera, A Pastula, DM Salinas, JL Mendez, JHM Mendez, M Powers, AM Waterman, S Rivera-Garcia, B AF Sharp, Tyler M. Munoz-Jordan, Jorge Perez-Padilla, Janice Bello-Pagan, Melissa I. Rivera, Aidsa Pastula, Daniel M. Salinas, Jorge L. Mendez, Jose H. Martinez Mendez, Mnica Powers, Ann M. Waterman, Stephen Rivera-Garcia, Brenda TI Zika Virus Infection Associated With Severe Thrombocytopenia SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE Zika virus; thrombocytopenia; fatal; Puerto Rico ID FEVER AB We report two patients that developed severe thrombocytopenia after Zika virus ( ZIKV) infection. The first patient had 1000 platelets/mu L and died after multiple hemorrhages. The second patient had 2000 platelets/mu L, had melena and ecchymoses, and recovered after receiving intravenous immunoglobulin. ZIKV may be associated with immune-mediated severe thrombocytopenia. C1 [Sharp, Tyler M.; Munoz-Jordan, Jorge; Perez-Padilla, Janice; Rivera, Aidsa; Waterman, Stephen] Ctr Dis Control & Prevent, Dengue Branch, 1324 Calle Canada, San Juan, PR 00920 USA. [Pastula, Daniel M.] Ctr Dis Control & Prevent, Div Vector Borne Dis, San Juan, PR USA. [Salinas, Jorge L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, San Juan, PR USA. [Powers, Ann M.] Ctr Dis Control & Prevent, Arboviral Dis Branch, San Juan, PR USA. [Bello-Pagan, Melissa I.; Rivera-Garcia, Brenda] Puerto Rico Dept Hlth, San Juan, PR USA. [Mendez, Jose H. Martinez] San Juan City Hosp, San Juan, PR USA. [Mendez, Mnica] Hosp HIMA San Pablo, Bayamon, PR USA. [Pastula, Daniel M.] Univ Colorado, Denver, CO 80202 USA. RP Sharp, TM (reprint author), Ctr Dis Control & Prevent, Dengue Branch, 1324 Calle Canada, San Juan, PR 00920 USA. EM tsharp@cdc.gov FU Intramural CDC HHS [CC999999] NR 14 TC 1 Z9 1 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2016 VL 63 IS 9 BP 1198 EP 1201 DI 10.1093/cid/ciw476 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EC2WY UT WOS:000387986200013 PM 27418575 ER PT J AU Spradling, PR Xing, J Rupp, LB Moorman, AC Gordon, SC Teshale, ET Lu, M Boscarino, JA Trinacty, CM Schmidt, MA Holmberg, SD AF Spradling, Philip R. Xing, Jian Rupp, Loralee B. Moorman, Anne C. Gordon, Stuart C. Teshale, Eyasu T. Lu, Mei Boscarino, Joseph A. Trinacty, Connie M. Schmidt, Mark A. Holmberg, Scott D. CA Chronic Hepatitis Cohort Study TI Infrequent Clinical Assessment of Chronic Hepatitis B Patients in United States General Healthcare Settings SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE chronic hepatitis B; clinical assessment; monitoring; general healthcare ID AASLD GUIDELINES; MANAGEMENT; COHORT AB Among 2338 chronic hepatitis B patients followed during 2006-2013 in the Chronic Hepatitis Cohort Study, 78% had >= 1 alanine aminotransferase and 37% had >= 1 hepatitis B virus DNA level assessed annually. Among cirrhotic patients, 46% never had hepatic imaging. Patients in this cohort were insufficiently monitored for disease activity and hepatocellular carcinoma. C1 [Spradling, Philip R.; Xing, Jian; Rupp, Loralee B.; Moorman, Anne C.; Gordon, Stuart C.; Teshale, Eyasu T.; Lu, Mei; Boscarino, Joseph A.; Trinacty, Connie M.; Schmidt, Mark A.; Holmberg, Scott D.; Chronic Hepatitis Cohort Study] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. RP Spradling, PR (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS G37, Atlanta, GA 30333 USA. EM pspradling@cdc.gov NR 13 TC 2 Z9 2 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2016 VL 63 IS 9 BP 1205 EP 1208 DI 10.1093/cid/ciw516 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EC2WY UT WOS:000387986200015 PM 27486115 ER PT J AU Baggs, J Fridkin, SK Pollack, LA Srinivasan, A Jernigan, JA AF Baggs, James Fridkin, Scott K. Pollack, Lori A. Srinivasan, Arjun Jernigan, John A. TI Estimating National Trends in Inpatient Antibiotic Use Among US Hospitals From 2006 to 2012 SO JAMA INTERNAL MEDICINE LA English DT Article ID CLOSTRIDIUM-DIFFICILE INFECTION; ACADEMIC HEALTH CENTERS; ANTIBACTERIAL DRUG-USE; UNITED-STATES; ANTIMICROBIAL USE; DISEASES-SOCIETY; RESEARCH NETWORK; SURVEILLANCE; STEWARDSHIP; GUIDELINES AB IMPORTANCE The rising threat of antibiotic resistance and other adverse consequences resulting from the misuse of antibiotics requires a better understanding of antibiotic use in hospitals in the United States. OBJECTIVE To use proprietary administrative data to estimate patterns of US inpatient antibiotic use in recent years. DESIGN, SETTING, AND PARTICIPANTS For this retrospective analysis, adult and pediatric in-patient antibiotic use data was obtained from the Truven Health MarketScan Hospital Drug Database (HDD) from January 1, 2006, to December 31, 2012. Data from adult and pediatric patients admitted to 1 of approximately 300 participating acute care hospitals provided antibiotic use data for over 34 million discharges representing 166 million patient-days. MAIN OUTCOMES AND MEASURES We retrospectively estimated the days of therapy (DOT) per 1000 patient-days and the proportion of hospital discharges in which a patient received at least 1 dose of an antibiotic during the hospital stay. We calculated measures of antibiotic usage stratified by antibiotic class, year, and other patient and facility characteristics. We used data submitted to the Centers for Medicare and Medicaid Services Healthcare Cost Report Information System to generate estimated weights to apply to the HDD data to create national estimates of antibiotic usage. A multivariate general estimating equation model to account for interhospital covariance was used to assess potential trends in antibiotic DOT over time. RESULTS During the years 2006 to 2012, 300 to 383 hospitals per year contributed antibiotic data to the HDD. Across all years, 55.1% of patients received at least 1 dose of antibiotics during their hospital visit. The overall national DOT was 755 per 1000 patient-days. Overall antibiotic use did not change significantly over time. The multivariable trend analysis of data from participating hospitals did not show a statistically significant change in overall use (total DOT increase, 5.6; 95% CI, -18.9 to 30.1; P = .65). However, the mean change (95% CI) for the following antibiotic classes increased significantly: third-and fourth-generation cephalosporins, 10.3 (3.1-17.5); macrolides, 4.8 (2.0-7.6); glycopeptides, 22.4 (17.5-27.3); beta-lactam/beta-lactamase inhibitor combinations, 18.0 (13.3-22.6); carbapenems, 7.4 (4.6-10.2); and tetracyclines, 3.3 (2.0-4.7). CONCLUSIONS AND RELEVANCE Overall DOT of all antibiotics among hospitalized patients in US hospitals has not changed significantly in recent years. Use of some antibiotics, especially broad spectrum agents, however, has increased significantly. This trend is worrisome in light of the rising challenge of antibiotic resistance. Our findings can help inform national efforts to improve antibiotic use by suggesting key targets for improvement interventions. C1 [Baggs, James; Fridkin, Scott K.; Pollack, Lori A.; Srinivasan, Arjun; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Baggs, J (reprint author), 1600 Clifton Rd,MS A31, Atlanta, GA 30333 USA. EM jbaggs@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX This study was funded by the Centers for Disease Control and Prevention (CDC). NR 38 TC 1 Z9 1 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV PY 2016 VL 176 IS 11 BP 1639 EP 1648 DI 10.1001/jamainternmed.2016.5651 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA EC4KK UT WOS:000388097700015 PM 27653796 ER PT J AU Tepper, NK Curtis, KM Jatlaoui, TC Whiteman, MK AF Tepper, Naomi K. Curtis, Kathryn M. Jatlaoui, Tara C. Whiteman, Maura K. TI Updated Guidance for Safe and Effective Use of Contraception SO JOURNAL OF WOMENS HEALTH LA English DT Article DE contraception; guidelines; CDC ID UNINTENDED PREGNANCY AB Progress has been made in efforts to reduce unintended pregnancy; however, unintended pregnancy remains a public health issue in the United States. A key component of reducing unintended pregnancy is to increase correct and consistent use of contraception by reducing barriers to access and use. The CDC has recently updated its guidance for the safe and effective use of contraception. The U.S. Medical Eligibility Criteria for Contraceptive Use (US MEC), 2016, and U.S. Selected Practice Recommendations for Contraceptive Use (US SPR), 2016, are intended for healthcare providers to help patients choose a method that is safe and can be used effectively. The recommendations aim to reduce certain barriers to contraception and thus help women, men, and couples to control timing of pregnancies. C1 [Tepper, Naomi K.; Curtis, Kathryn M.; Jatlaoui, Tara C.; Whiteman, Maura K.] Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,Mailstop F-74, Atlanta, GA 30341 USA. RP Tepper, NK (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,Mailstop F-74, Atlanta, GA 30341 USA. EM ntepper@cdc.gov NR 18 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD NOV PY 2016 VL 25 IS 11 BP 1097 EP 1101 DI 10.1089/jwh.2016.6191 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA EC9SE UT WOS:000388483700005 PM 27841957 ER PT J AU Verani, JR Groome, MJ Zar, HJ Zell, ER Kapongo, CN Nzenze, SA Mulligan, C Moore, DP Whitney, CG Madhi, SA AF Verani, Jennifer R. Groome, Michelle J. Zar, Heather J. Zell, Elizabeth R. Kapongo, Constant N. Nzenze, Susan A. Mulligan, Christine Moore, David P. Whitney, Cynthia G. Madhi, Shabir A. TI Risk Factors for Presumed Bacterial Pneumonia Among HIV-uninfected Children Hospitalized in Soweto, South Africa SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE pneumonia; risk factors; South Africa; HIV ID PNEUMOCOCCAL CONJUGATE VACCINE; LOWER RESPIRATORY-INFECTIONS; CHILDHOOD PNEUMONIA; 1ST YEAR; INFANTS; TRANSMISSION; POPULATION; ANTIBODIES; EXPOSURE; ETIOLOGY AB Background: Pneumonia is a leading cause of child morbidity and death. Data on risk factors can guide prevention efforts. Within a study on pneumococcal conjugate vaccine effectiveness, we investigated risk factors for presumed bacterial pneumonia (PBP). Methods: PBP cases were human immunodeficiency virus (HIV) uninfected children with lower respiratory tract infection and consolidation on chest radiograph or nonconsolidated infiltrate with C-reactive protein >= 40 mg/L hospitalized at Chris Hani Baragwanath Academic Hospital (CHBAH) in Soweto. Age-matched community controls were identified using CHBAH birth records +/- 1 week of case birth date. Data were analyzed using conditional logistic regression. Results: A total of 889 PBP cases (median age 9 months) were matched to 2628 controls. Crowding was a significant risk factor among well-nourished children (adjusted odds ratio [aOR]: 2.29, 95% confidence interval [CI]: 1.89-2.78), but not in those with low weight-for-age. Malnutrition was associated with PBP; strength of association was highest in the absence of crowding (aOR: 6.68, 95% CI: 4.74-9.42). Exclusive breastfeeding was protective only among HIV-unexposed children (aOR: 0.65, 95% CI: 0.54-0.78). Self-reported maternal HIV infection was a risk factor among children exclusively breastfeed up to 4 months (aOR: 2.33, 95% CI: 1.53-3.55). Having indoor tap water was protective (aOR: 0.65, 95% CI: 0.54-0.78), whereas a primary care giver who smoked was a risk factor (aOR: 5.15, 95% CI: 2.94-9.03). Conclusions: Our findings confirm several known pneumonia risk factors and highlight complex interactions between factors, including HIV exposure, breastfeeding, malnutrition and crowding. Improved housing, reduced secondhand smoke exposure and HIV prevention among women of reproductive age could lessen the child pneumonia burden. C1 [Verani, Jennifer R.; Zell, Elizabeth R.; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30333 USA. [Groome, Michelle J.; Nzenze, Susan A.; Moore, David P.; Madhi, Shabir A.] Univ Witwatersrand, Fac Hlth Sci, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Groome, Michelle J.; Mulligan, Christine; Madhi, Shabir A.] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, Dept Sci & Technol, Johannesburg, South Africa. [Zar, Heather J.] Univ Cape Town, Red Cross War Mem Childrens Hosp, Dept Pediat & Child Hlth, Cape Town, South Africa. [Zar, Heather J.] Univ Cape Town, MRC Unit Child & Adolescent Hlth, Cape Town, South Africa. [Kapongo, Constant N.] Ngwelezane Hosp, Dept Pediat, Empangeni, South Africa. [Madhi, Shabir A.] Natl Inst Communicable Dis, Div Natl Hlth Lab Serv, Johannesburg, South Africa. RP Verani, JR (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30333 USA. EM jverani@cdc.gov FU PATH from the GAVI Alliance Accelerated Vaccine Initiative: Special Studies Program FX Supported by PATH through funding from the GAVI Alliance Accelerated Vaccine Initiative: Special Studies Program. M.J.G. reports personal fees from GlaxoSmithKline and from Sanofi Pasteur, outside the submitted work. S.A.M. reports personal fees from Pfizer, grants and personal fees from GSK, grants from Novartis, personal fees from Medscape, outside the submitted work. The other authors have no conflicts of interest to disclose. NR 34 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD NOV PY 2016 VL 35 IS 11 BP 1169 EP 1174 DI 10.1097/INF.0000000000001264 PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA EC5ZQ UT WOS:000388216200006 PM 27276181 ER PT J AU Dziuban, EJ Rivadeneira, ED AF Dziuban, Eric J. Rivadeneira, Emilia D. TI Universal Antiretroviral Treatment Eligibility for Children and Adolescents Living With HIV A New Era SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE antiretroviral therapy; children; eligibility determination; guidelines; HIV ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; INFECTED CHILDREN; THERAPY; CARE; INITIATION; AGE; NEURODEVELOPMENT; RETENTION; IMPACT AB Antiretroviral treatment coverage for children living with HIV is low, and new efforts are underway to expand eligibility so that all children and adolescents qualify for the treatment regardless of immune suppression or clinical stage. Although recent trials provide direct evidence of the benefit of this approach in adults, no such studies have been performed in children. This report examines the available body of evidence regarding universal HIV treatment for children and adolescents and assesses the benefits and challenges both at individual patient health, as well as at programmatic level. Universal treatment eligibility for children with HIV has great potential for improved growth and neurodevelopment and fewer morbidities for children, and treatment coverage would be expected to increase through guideline simplification. However, concerns regarding toxicities, drug resistance and costs require careful planning. Successful implementation will depend on effective strategies for case-finding, treatment adherence support and program monitoring that will contribute to the growing evidence base for this pivotal pediatric HIV policy shift. C1 [Dziuban, Eric J.; Rivadeneira, Emilia D.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. RP Dziuban, EJ (reprint author), 1600 Clifton Rd NE,Mailstop E-88, Atlanta, GA 30333 USA. EM esv8@cdc.gov FU US President's Emergency Plan for AIDS Relief (PEPFAR) through the US Centers for Disease Control and Prevention (CDC) FX Supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the US Centers for Disease Control and Prevention (CDC). The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the CDC. NR 48 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD NOV PY 2016 VL 35 IS 11 BP 1225 EP 1228 DI 10.1097/INF.0000000000001276 PG 4 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA EC5ZQ UT WOS:000388216200016 PM 27294308 ER PT J AU Gonzalez-Diaz, M Urrea-Quezada, A Villegas-Gomez, I Durazo, M Garibay-Escobar, A Hernandez, J Xiao, LH Valenzuela, O AF Gonzalez-Diaz, Mariana Urrea-Quezada, Alejandro Villegas-Gomez, Isaac Durazo, Maria Garibay-Escobar, Adriana Hernandez, Jesus Xiao, Lihua Valenzuela, Olivia TI CRYPTOSPORIDIUM CANIS IN TWO MEXICAN TODDLERS SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE Cryptosporidium; genotype; diarrhea; toddlers; children; Mexico ID CHILDREN AB Cryptosporidium canis is reported for the first time in 2 toddlers in Northwestern Mexico. The 2 toddlers (33 and 34 months old) were symptomatic at diagnosis, presenting diarrhea and fever, and 1 case presented chronic malnutrition. Both toddlers were HIV-negative. C. canis was identified by SspI and VspI restriction enzyme digestion of the 18S rRNA polymerase chain reaction products and confirmed by sequence analysis. C1 [Gonzalez-Diaz, Mariana; Urrea-Quezada, Alejandro; Villegas-Gomez, Isaac; Garibay-Escobar, Adriana; Valenzuela, Olivia] Univ Sonora, Dept Ciencias Quim Biol, Blvd Luis Encinas & Rosales S-N, Hermosillo 83000, Sonora, Mexico. [Durazo, Maria] Hosp Infantil Estado Sonora, Serv Infectiol, Hermosillo, Sonora, Mexico. [Hernandez, Jesus] Ctr Invest Alimentac & Desarrollo AC, Lab Inmunol, Hermosillo, Sonora, Mexico. [Xiao, Lihua] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Valenzuela, O (reprint author), Univ Sonora, Dept Ciencias Quim Biol, Blvd Luis Encinas & Rosales S-N, Hermosillo 83000, Sonora, Mexico. EM o_valen-zuela@guayacan.uson.mx NR 10 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD NOV PY 2016 VL 35 IS 11 BP 1265 EP 1266 DI 10.1097/INF.0000000000001287 PG 2 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA EC5ZQ UT WOS:000388216200023 PM 27341498 ER PT J AU Spradling, PR Xing, J Rupp, LB Moorman, AC Gordon, SC Teshale, ET Lu, M Boscarino, JA Schmidt, MA Trinacty, CM Holmberg, SD AF Spradling, P. R. Xing, J. Rupp, L. B. Moorman, A. C. Gordon, S. C. Teshale, E. T. Lu, M. Boscarino, J. A. Schmidt, M. A. Trinacty, C. M. Holmberg, S. D. CA Chronic Hepatitis Cohort Study Inv TI Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013 SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID VIRUS-INFECTION; UNITED-STATES; TRANSIENT ELASTOGRAPHY; AASLD GUIDELINES; RISK-FACTORS; FIBROSIS; MANAGEMENT; PREVALENCE; CHECS; POPULATION AB Background Limited information exists regarding the distribution of disease phases, treatment prescription and severe liver disease among patients with chronic hepatitis B (CHB) in US general healthcare settings. Aim To determine the distribution of disease phases, treatment prescription and severe liver disease among patients with CHB in general US healthcare settings. Methods We analysed demographic and clinical data collected during 2006-2013 from patients with confirmed CHB in the Chronic Hepatitis Cohort Study, an observational cohort study involving patients from healthcare organisations in Michigan, Pennsylvania, Oregon and Hawaii. CHB phases were classified according to American Association for the Study of Liver Disease guidelines. Results Of 1598 CHB patients with >= 12 months of follow-up (median 6.3 years), 457 (29%) were immune active during follow-up [11% hepatitis B e antigen (HBeAg)-positive, 16% HBeAg-negative, and 2% HBeAg status unknown], 10 (0.6%) were immune tolerant, 112 (7%) were inactive through the duration of follow-up and 886 (55%) were phase indeterminate. Patients with cirrhosis were identified within each group (among 21% of immune active, 3% of inactive and 9% of indeterminate phase patients) except among those with immune-tolerant CHB. Prescription of treatment was 59% among immune active patients and 84% among patients with cirrhosis and hepatitis B virus (HBV) DNA > 2000 IU/mL. Conclusions Approximately, one-third of the cohort had active disease during follow-up; 60% of eligible patients were prescribed treatment. Our findings underscore the importance of ascertainment of fibrosis status in addition to regular assessment of ALT and HBV DNA levels. C1 [Spradling, P. R.; Xing, J.; Moorman, A. C.; Teshale, E. T.; Holmberg, S. D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Mailstop G37,1600 Clifton Rd NE, Atlanta, GA 30333 USA. [Rupp, L. B.; Gordon, S. C.; Lu, M.] Henry Ford Hlth Syst, Detroit, MI USA. [Boscarino, J. A.] Geisinger Hlth Syst, Ctr Hlth Res, Danville, PA USA. [Schmidt, M. A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Trinacty, C. M.] Kaiser Permanente Hawaii, Ctr Hlth Res, Honolulu, HI USA. RP Spradling, PR (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Mailstop G37,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM pspradling@cdc.gov FU CDC Foundation; AbbVie; Genentech; Roche Group; Gilead Sciences; Janssen Pharmaceuticals, Inc.; Vertex Pharmaceuticals; Bristol-Myers Squibb; Henry Ford Health System FX CHeCS was funded through May 2016 by the CDC Foundation, which received grants from AbbVie; Genentech, A Member of the Roche Group; Gilead Sciences; Janssen Pharmaceuticals, Inc. and Vertex Pharmaceuticals. Past partial funders include Bristol-Myers Squibb. Currently CHeCS is funded by the Henry Ford Health System, which receives grants from Gilead Sciences. Granting corporations do not have access to CHeCS data and do not contribute to data analysis or writing of manuscripts. NR 31 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD NOV PY 2016 VL 44 IS 10 BP 1080 EP 1089 DI 10.1111/apt.13802 PG 10 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA EB7UP UT WOS:000387596600008 PM 27640985 ER PT J AU Lucas, CE Cooley, LA Kunz, JM Garrison, LE AF Lucas, Claressa E. Cooley, Laura A. Kunz, Jasen M. Garrison, Laurel E. TI Legionnaires' Outbreaks Preventable with Water Management Programs SO ASHRAE JOURNAL LA English DT Article AB The first documented outbreak of Legionnaires' disease was investigated by the Centers for Disease Control and Prevention (CDC) in 1976. Researchers of the time identified a novel bacterial agent responsible for causing the severe pneumonia that sickened or killed several of the American Legionnaires who attended a convention in Pennsylvania. In the ensuing years, scientists characterized the newly discovered bacterium, called Legionella in tribute to the first known victims. Since then we have discovered where the bacteria live, how they cause disease, and the ways they can be transmitted to humans. Most importantly, we learned that most of the disease caused by Legionella is preventable. C1 [Lucas, Claressa E.; Cooley, Laura A.; Kunz, Jasen M.; Garrison, Laurel E.] Ctr Dis Control & Prevent CDC, Atlanta, GA 30329 USA. RP Lucas, CE (reprint author), Ctr Dis Control & Prevent CDC, Atlanta, GA 30329 USA. NR 6 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEATING REFRIGERATING AIR-CONDITIONING ENG, INC, PI ATLANTA PA 1791 TULLIE CIRCLE NE, ATLANTA, GA 30329 USA SN 0001-2491 EI 1943-6637 J9 ASHRAE J JI ASHRAE J. PD NOV PY 2016 VL 58 IS 11 BP 84 EP 86 PG 3 WC Thermodynamics; Construction & Building Technology; Engineering, Mechanical SC Thermodynamics; Construction & Building Technology; Engineering GA EB8JT UT WOS:000387638000016 ER PT J AU Taylan-Ozkan, A Yasa-Duru, S Usluca, S Lysen, C Ye, JB Roellig, DM Feng, YY Xiao, LH AF Taylan-Ozkan, Aysegul Yasa-Duru, Sibel Usluca, Selma Lysen, Colleen Ye, Jianbin Roellig, Dawn M. Feng, Yaoyu Xiao, Lihua TI Cryptosporidium species and Cryptosporidium parvum subtypes in dairy calves and goat kids reared under traditional farming systems in Turkey SO EXPERIMENTAL PARASITOLOGY LA English DT Article DE Cryptosporidium; Cryptosporidiosis; Genotype; Subtype; Cattle; Goat; Turkey ID EASTERN UNITED-STATES; MOLECULAR CHARACTERIZATION; NORTHWESTERN CHINA; GIARDIA-DUODENALIS; PREVALENCE; CATTLE; SPP.; GENOTYPES; HUMANS; SPAIN AB Molecular characterizations of Cryptosporidium spp. in ruminants reared under traditional animal management systems are scarce and studies conducted thus far have revealed largely an absence of the pathogenic and zoonotic species Cryptosporidium parvum in pre-weaned animals. In this study, we examined Cryptosporidium species and subtype distribution in free-range pre-weaned dairy calves and goat kids with diarrhea. Cryptosporidium-positive specimens from pre-weaned calves on 10 farms and goat kids on 4 farms in Ankara, Balikesir, Corum, Kirikkale, and Kirsehir Provinces, Turkey were genotyped by PCR-restriction length polymorphism analysis of the small subunit rRNA gene, which identified C. parvum in 27 calves and 9 goat kids and Cryptosporidium ryanae in 1 calf. Among the C. parvum isolates successfully subtyped by DNA sequence analysis of the 60 kDa glycoprotein gene, three subtypes were detected in calves, including IlaA13G2R1 (20/23), IldA18G1 (2/23), and IldA20G1b (1/23), and four subtypes were detected in goat kids, including IlaA13G2R1 (3/8), IlaA15G1R1 (2/8), IldA22G1 (2/8), and IldA18G1 (1/8). Data of the study suggest that dairy calves reared in a traditional cow-calf system in Turkey are mainly infected with a C. parvum subtype rarely seen elsewhere, whereas goat kids are infected with diverse subtypes. As all five C. parvum subtypes found in this study are known human pathogens, pre-weaned farm animals could play a potential role in the transmission of human cryptosporidiosis. (C) 2016 Elsevier Inc. All rights reserved. C1 [Taylan-Ozkan, Aysegul] Hitit Univ, Fac Med, Dept Med Microbiol, TR-19200 Comm, Turkey. [Yasa-Duru, Sibel] Kirikkale Univ, Fac Vet Med, Dept Internal Med, TR-71450 Kirikkale, Turkey. [Usluca, Selma] Turkish Natl Publ Hlth Agcy, Natl Parasitol Lab, TR-16100 Ankara, Turkey. [Lysen, Colleen; Ye, Jianbin; Roellig, Dawn M.; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd, Atlanta, GA 30329 USA. [Ye, Jianbin; Feng, Yaoyu] East China Univ Sci & Technol, State Environm Protect Key Lab Environm Risk Asse, Sch Resources & Environm Engn, Shanghai 200237, Peoples R China. RP Feng, YY (reprint author), East China Univ Sci & Technol, State Environm Protect Key Lab Environm Risk Asse, Sch Resources & Environm Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn OI Taylan Ozkan, Aysegul/0000-0001-8421-3625; Xiao, Lihua/0000-0001-8532-2727 FU National Natural Science Foundation of China [31229005, 31110103901]; Centers for Disease Control and Prevention FX This research was supported by the National Natural Science Foundation of China (Project No. 31229005 and 31110103901) and Centers for Disease Control and Prevention. NR 51 TC 1 Z9 1 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4894 EI 1090-2449 J9 EXP PARASITOL JI Exp. Parasitol. PD NOV PY 2016 VL 170 BP 16 EP 20 DI 10.1016/j.exppara.2016.06.014 PG 5 WC Parasitology SC Parasitology GA EC3XC UT WOS:000388059400003 PM 27373430 ER PT J AU Zhong, VW Obeid, JS Craig, JB Pfaff, ER Thomas, J Jaacks, LM Beavers, DP Carey, TS Lawrence, JM Dabelea, D Hamman, RF Bowlby, DA Pihoker, C Saydah, SH Mayer-Davis, EJ AF Zhong, Victor W. Obeid, Jihad S. Craig, Jean B. Pfaff, Emily R. Thomas, Joan Jaacks, Lindsay M. Beavers, Daniel P. Carey, Timothy S. Lawrence, Jean M. Dabelea, Dana Hamman, Richard F. Bowlby, Deborah A. Pihoker, Catherine Saydah, Sharon H. Mayer-Davis, Elizabeth J. TI An efficient approach for surveillance of childhood diabetes by type derived from electronic health record data: the SEARCH for Diabetes in Youth Study SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article DE automated algorithm; ascertainment and classification; childhood diabetes; electronic health records; surveillance ID REGRESSION TREE ANALYSIS; HISPANIC WHITE YOUTH; CASE ASCERTAINMENT; CLASSIFICATION; CHILDREN; PREVALENCE; ADOLESCENTS; VALIDATION; ALGORITHMS; MELLITUS AB Objective To develop an efficient surveillance approach for childhood diabetes by type across 2 large US health care systems, using phenotyping algorithms derived from electronic health record (EHR) data. Materials and Methods Presumptive diabetes cases < 20 years of age from 2 large independent health care systems were identified as those having >= 1 of the 5 indicators in the past 3.5 years, including elevated HbA1c, elevated blood glucose, diabetes-related billing codes, patient problem list, and outpatient anti-diabetic medications. EHRs of all the presumptive cases were manually reviewed, and true diabetes status and diabetes type were determined. Algorithms for identifying diabetes cases overall and classifying diabetes type were either prespecified or derived from classification and regression tree analysis. Surveillance approach was developed based on the best algorithms identified. Results We developed a stepwise surveillance approach using billing code-based prespecified algorithms and targeted manual EHR review, which efficiently and accurately ascertained and classified diabetes cases by type, in both health care systems. The sensitivity and positive predictive values in both systems were approximately >= 90% for ascertaining diabetes cases overall and classifying cases with type 1 or type 2 diabetes. About 80% of the cases with "other" type were also correctly classified. This stepwise surveillance approach resulted in a > 70% reduction in the number of cases requiring manual validation compared to traditional surveillance methods. Conclusion EHR data may be used to establish an efficient approach for large-scale surveillance for childhood diabetes by type, although some manual effort is still needed. C1 [Zhong, Victor W.; Thomas, Joan; Mayer-Davis, Elizabeth J.] Univ N Carolina, Dept Nutr, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27514 USA. [Obeid, Jihad S.; Craig, Jean B.] Med Univ South Carolina, Biomed Informat Ctr, Charleston, SC USA. [Pfaff, Emily R.] Univ N Carolina, North Carolina TraCS Inst, Chapel Hill, NC USA. [Jaacks, Lindsay M.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA USA. [Beavers, Daniel P.] Wake Forest Univ, Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Carey, Timothy S.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA. [Lawrence, Jean M.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA. [Dabelea, Dana; Hamman, Richard F.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Bowlby, Deborah A.] Med Univ South Carolina, Div Pediat Endocrinol, Charleston, SC USA. [Pihoker, Catherine] Univ Washington, Dept Washington, Seattle, WA USA. [Saydah, Sharon H.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27514 USA. RP Mayer-Davis, EJ (reprint author), Univ N Carolina, Dept Nutr, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27514 USA.; Mayer-Davis, EJ (reprint author), Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27514 USA.; Mayer-Davis, EJ (reprint author), Univ N Carolina, Dept Nutr, Sch Publ Hlth, 245C Rosenau Hall,CB 7461, Chapel Hill, NC 27599 USA. EM ejmayer_davis@unc.edu OI Obeid, Jihad/0000-0002-7193-7779 FU Centers for Disease Control and Prevention [00097, DP-05-069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases [U58/CCU019235-4, U01-DP-000244, U18-DP-002710-01, U01-DP-000250, 200-2010-35171]; National Institutes of Health Clinical and Translational Science Awards [UL1 TR00423]; University of Colorado Pediatric Clinical and Translational Research Center [UL1 TR000154]; National Center for Advancing Translational Sciences, National Institutes of Health [8 UL1 TR000077]; NIH - National Center for Advancing Translational Sciences [UL1 TR000062]; The National Institute of Diabetes and Digestive and Kidney Diseases [U48/CCU919219, U01-DP-000246, U18-DP-002714, U48/CCU819241-3, U01-DP-000247, U18-DP-000247-06A1, U48/CCU519239, U01-DP-000248, 1U18-DP-002709, U48/CCU419249, U01-DP-000254, U18-DP-002708-01] FX Grant Support: SEARCH for Diabetes in Youth Study is funded by the Centers for Disease Control and Prevention (PA numbers 00097, DP-05-069, and DP-10-001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases. Contract numbers: Kaiser Permanente Southern California (U48/CCU919219, U01-DP-000246, and U18-DP-002714), University of Colorado Denver (U48/CCU819241-3, U01-DP-000247, and U18-DP-000247-06A1), Children's Hospital Medical Center (Cincinnati) (U48/CCU519239, U01-DP-000248, and 1U18-DP-002709), University of North Carolina at Chapel Hill (U48/CCU419249, U01-DP-000254, and U18-DP-002708-01), University of Washington School of Medicine (U58/CCU019235-4, U01-DP-000244, and U18-DP-002710-01), and Wake Forest School of Medicine (U48/CCU919219, U01-DP-000250, and 200-2010-35171). The authors wish to acknowledge the involvement of Seattle Children's Hospital (National Institutes of Health Clinical and Translational Science Awards grant UL1 TR00423 of the University of Washington); University of Colorado Pediatric Clinical and Translational Research Center (grant number UL1 TR000154); the Barbara Davis Center at the University of Colorado Denver (DERC NIH P30 DK57516); the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through grant 8 UL1 TR000077; and the Children with Medical Handicaps program managed by the Ohio Department of Health. The MUSC effort was supported by the NIH - National Center for Advancing Translational Sciences: Grant Number UL1 TR000062. NR 29 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD NOV PY 2016 VL 23 IS 6 BP 1060 EP 1067 DI 10.1093/jamia/ocv207 PG 8 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA EC3DZ UT WOS:000388006800005 PM 27107449 ER PT J AU Nelson, JM Perrine, CG Scanlon, KS Li, RW AF Nelson, Jennifer M. Perrine, Cria G. Scanlon, Kelley S. Li, Ruowei TI Provision of Non-breast Milk Supplements to Healthy Breastfed Newborns in US Hospitals, 2009 to 2013 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Breastfeeding; Hospital supplementation; Infant formula ID FED INFANTS; MOTHERS AB Introduction Breastfed newborns are often given non-breast milk supplements in the hospital, which can negatively impact breastfeeding outcomes. Efforts to improve maternity care practices include reducing supplementation of breastfed newborns. Methods The Maternity Practices in Infant Nutrition and Care (mPINC) survey is administered every 2 years to all hospitals in the United States and territories with registered maternity beds. We examined provision of non-breast milk supplements to healthy, full-term breastfed newborns from 2009 to 2013. Results Hospitals that provided non-breast milk supplements to at least 50 % of breastfed newborns decreased from 31.5 % in 2009 to 23.3 % in 2013. Among hospitals providing any supplements, there was no change in the percent that supplemented with infant formula; whereas, supplementing with water declined from 8.8 % in 2009 to 4.2 % in 2013 and with glucose water from 23.4 % to 12.5 %, respectively. In 2013, 64.9 % of breastfed infants were supplemented with formula for "mother's choice," 25.0 % for "doctor's orders," and 8.7 % for "nurse's recommendation." Discussion Despite improvements in maternity care practices, nearly one-fourth of hospitals are still providing at least 50 % of healthy, full-term breastfed newborns with non-breast milk supplements. While there has been no change in the proportion of hospitals providing infant formula supplements, the proportion supplementing with water and glucose water have declined. Additional education and support of mothers during the early post-partum period and training of physicians may address reasons breastfed infants are supplemented. C1 [Nelson, Jennifer M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30341 USA. [Nelson, Jennifer M.; Perrine, Cria G.; Scanlon, Kelley S.; Li, Ruowei] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Hwy NE,Mailstop F-77, Atlanta, GA 30341 USA. RP Nelson, JM (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30341 USA.; Nelson, JM (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Hwy NE,Mailstop F-77, Atlanta, GA 30341 USA. EM jmnelson@cdc.gov NR 17 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD NOV PY 2016 VL 20 IS 11 BP 2228 EP 2232 DI 10.1007/s10995-016-2095-9 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EB8VV UT WOS:000387670300002 PM 27439419 ER PT J AU Rankin, KM Gavin, L Moran, JW Kroelinger, CD Vladutiu, CJ Goodman, DA Sappenfield, WM AF Rankin, Kristin M. Gavin, Loretta Moran, John W., Jr. Kroelinger, Charlan D. Vladutiu, Catherine J. Goodman, David A. Sappenfield, William M. TI Importance of Performance Measurement and MCH Epidemiology Leadership to Quality Improvement Initiatives at the National, State and Local Levels SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Quality improvement; Performance measurement; MCH epidemiologists; Contraceptive services; Peripartum hemorrhage ID UNITED-STATES; UNINTENDED PREGNANCY; PUBLIC-HEALTH; CHILD AB Purpose In recognition of the importance of performance measurement and MCH epidemiology leadership to quality improvement (QI) efforts, a plenary session dedicated to this topic was presented at the 2014 CityMatCH Leadership and MCH Epidemiology Conference. This paper summarizes the session and provides two applications of performance measurement to QI in MCH. Description Performance measures addressing processes of care are ubiquitous in the current health system landscape and the MCH community is increasingly applying QI processes, such as Plan-Do-Study-Act (PDSA) cycles, to improve the effectiveness and efficiency of systems impacting MCH populations. QI is maximally effective when well-defined performance measures are used to monitor change. Assessment MCH epidemiologists provide leadership to QI initiatives by identifying population-based outcomes that would benefit from QI, defining and implementing performance measures, assessing and improving data quality and timeliness, reporting variability in measures throughout PDSA cycles, evaluating QI initiative impact, and translating findings to stakeholders. MCH epidemiologists can also ensure that QI initiatives are aligned with MCH priorities at the local, state and federal levels. Two examples of this work, one highlighting use of a contraceptive service performance measure and another describing QI for peripartum hemorrhage prevention, demonstrate MCH epidemiologists' contributions throughout. Challenges remain in applying QI to complex community and systems-level interventions, including those aimed at improving access to quality care. Conclusion MCH epidemiologists provide leadership to QI initiatives by ensuring they are data-informed and supportive of a common MCH agenda, thereby optimizing the potential to improve MCH outcomes. C1 [Rankin, Kristin M.] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, 1603 Taylor St M-C 923, Chicago, IL 60612 USA. [Gavin, Loretta] US Dept HHS, Off Populat Affairs, Rockville, MD USA. [Moran, John W., Jr.] Publ Hlth Fdn, Washington, DC USA. [Kroelinger, Charlan D.; Goodman, David A.] Ctr Dis Control & Prevent, Maternal & Child Hlth Epidemiol Program, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Vladutiu, Catherine J.] Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, Rockville, MD USA. [Sappenfield, William M.] Univ S Florida, Dept Community & Family Hlth, Coll Publ Hlth, Lawton & Rhea Chiles Ctr Hlth Mothers & Babies, Tampa, FL USA. RP Rankin, KM (reprint author), Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, 1603 Taylor St M-C 923, Chicago, IL 60612 USA. EM krankin@uic.edu FU Centers for Disease Control and Prevention Division of Reproductive Health; Maternal and Child Health Bureau of the Health Services and Resources Administration FX Funding for the 2014 CityMatCH Leadership and MCH Epidemiology Conference was provided by the Centers for Disease Control and Prevention Division of Reproductive Health and the Maternal and Child Health Bureau of the Health Services and Resources Administration. The authors would like to sincerely thank the other members of the conference planning committee, especially Caroline Stampfel, Russell Kirby, Laurin Kasehagen, and Mary Balluff for their input on this plenary session. NR 28 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD NOV PY 2016 VL 20 IS 11 BP 2239 EP 2246 DI 10.1007/s10995-016-2105-y PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EB8VV UT WOS:000387670300004 PM 27423235 ER PT J AU Chesson, HW Patel, CG Gift, TL Aral, SO AF Chesson, Harrell W. Patel, Chirag G. Gift, Thomas L. Aral, Sevgi O. TI Trends in Selected Measures of Racial and Ethnic Disparities in Gonorrhea and Syphilis in the United States, 1981-2013 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; HEALTH INEQUALITIES; USA; PERSISTENCE; DISEASES AB Background The purpose of this study was to examine selected measures of racial and ethnic disparities in the reported incidence of syphilis and gonorrhea from 1981 to 2013 in the United States. Methods For each year, from 1981 to 2013, we calculated values for 5 disparity measures (Gini coefficient, 2 versions of the index of disparity, population attributable proportion, and the black-to-white rate ratio) for 5 racial/ethnic categories (non-Hispanic white, non-Hispanic black, Hispanic, American Indian/Alaska Native, and Asian/Pacific Islander). We also examined annual and 5-year changes to see if the disparity measures agreed on the direction of change in disparity. Results With a few exceptions, the disparity measures increased from 1981 to 1993 and decreased from 1993 to 2013, whereas syphilis and gonorrhea rates decreased for most groups from 1981 to 1993 and increased from 1993 to 2013. Overall, the disparity measures we examined were highly correlated with one another, particularly when examining 5-year changes rather than annual changes in disparity. For example, all 5 measures agreed on the direction of change in the disparity of syphilis in 56% of the annual comparisons and in 82% of the 5-year comparisons. Conclusions Although the disparity measures we examined were generally consistent with one another, these measures can sometimes yield divergent assessments of whether racial/ethnic disparities are increasing or decreasing for a given sexually transmitted disease from one point in time to another, as well as divergent assessments of the relative magnitude of the change. C1 [Chesson, Harrell W.; Patel, Chirag G.; Gift, Thomas L.; Aral, Sevgi O.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Chesson, HW (reprint author), CDC, Mailstop E-80,1600 Clifton Rd, Atlanta, GA 30329 USA. EM hbc7@cdc.gov NR 25 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2016 VL 43 IS 11 BP 661 EP 667 DI 10.1097/OLQ.0000000000000518 PG 7 WC Infectious Diseases SC Infectious Diseases GA EA6FS UT WOS:000386722600001 PM 27893593 ER PT J AU Carter, MW Hsu, KK Loosier, PS Maddox, BLP Doshi, SR Kroeger, K Cranston, K AF Carter, Marion W. Hsu, Katherine K. Loosier, Penny S. Maddox, Brandy L. Peterson Doshi, Sonal R. Kroeger, Karen Cranston, Kevin TI Sexually Transmitted Disease Program Evolution in Response to Changes in the Public Health Environment: A Massachusetts Example SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID DEPARTMENTS; REFORM AB Background In 2008, the line item supporting sexually transmitted disease (STD) services in the Massachusetts state budget was cut as a result of budget shortfalls. Shortly thereafter, direct provision of STD clinical services supported by the Massachusetts Department of Public Health (MDPH) was suspended. Massachusetts Department of Public Health requested an initial assessment of its internal response and impact in 2010. A follow-up assessment occurred in September 2013. Methods In 2010 and 2013, 39 and 46 staff, respectively, from MDPH and from clinical partner agencies, were interviewed about changes in the role of the MDPH, partnerships, STD services, challenges, and recommendations. Interview notes were summarized, analyzed, and synthesized by coauthors using qualitative analysis techniques and NVivo software. Results The withdrawal of state funding for STD services, and the subsequent reduction in clinical service hours, erected numerous barriers for Disease Intervention Specialists (DIS) seeking to ensure timely STD treatment for index cases and their partners. After initial instability, MDPH operations stabilized due partly to strong management, new staff, and intensified integration with human immunodeficiency virus services. Existing contracts with human immunodeficiency virus providers were leveraged to support alternative STD testing and care sites. Massachusetts Department of Public Health strengthened its clinical and epidemiologic expertise. The DIS expanded their scope of work and were outposted to select new sites. Challenges remained, however, such as a shortage of DIS staff to meet the needs. Conclusions Although unique in many ways, MA offers experiences and lessons for how a state STD program can adapt to a changing public health context. C1 [Carter, Marion W.; Loosier, Penny S.; Maddox, Brandy L. Peterson; Doshi, Sonal R.; Kroeger, Karen] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Hsu, Katherine K.; Cranston, Kevin] Massachusetts Dept Publ Hlth, Boston, MA USA. RP Carter, MW (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS-E-80, Atlanta, GA 30333 USA. EM acq0@cdc.gov NR 7 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2016 VL 43 IS 11 BP 668 EP 672 DI 10.1097/OLQ.0000000000000509 PG 5 WC Infectious Diseases SC Infectious Diseases GA EA6FS UT WOS:000386722600002 PM 27893594 ER PT J AU Reid, A Rogers, ME Arya, V Edelstein, ZR Schillinger, JA AF Reid, Amanda Rogers, Meighan E. Arya, Vibhuti Edelstein, Zoe R. Schillinger, Julia A. TI Pharmacists' Knowledge and Practices Surrounding Expedited Partner Therapy for Chlamydia trachomatis, New York City, 2012 and 2014 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article AB Background Health care providers in New York City can prescribe treatment for Chlamydia trachomatis (Ct) for a patient's partner without the partner having a medical evaluation (prescription-expedited partner therapy [EPT]), and use of prescription-EPT is common. However, there is little known about pharmacists' knowledge and practices surrounding EPT. Methods Two cross-sectional surveys, in 2012 and 2014, were conducted with representative samples of supervising pharmacists in NYC neighborhoods with high rates of Ct infection. Results In both survey years, the majority of pharmacists who agreed to participate returned a survey (2012: 81% [83/103], 2014: 61% [106/173]), and pharmacist and pharmacy characteristics were similar across the 2 surveys. Pharmacists' EPT-related knowledge and practice was generally low, with little change between 2012 and 2014. In both years, fewer than half of pharmacists knew EPT was legal (2012, 46%; 2014, 42%). There were even decreases in specific content knowledge; in 2014, significantly fewer of the pharmacists who knew EPT was legal, knew that the initials EPT must be written in the body of the prescription (2012: 58%; 2014: 36%, P < 0.05). Most pharmacists in both survey years reported they had never received an EPT prescription, and those who had reported only infrequent receipt. Conclusions NYC pharmacists had low levels of knowledge and familiarity with EPT law and reported infrequent receipt of EPT prescriptions. Pharmacists and providers should be further educated about EPT laws and regulations so that prescription-EPT use can be accurately monitored, and to assure the success of this partner treatment strategy. C1 [Reid, Amanda] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Reid, Amanda; Edelstein, Zoe R.] Bur HIV AIDS Prevent & Control, Dept Hlth & Mental Hyg, New York, NY USA. [Reid, Amanda; Rogers, Meighan E.; Schillinger, Julia A.] Bur STD Prevent & Control, Dept Hlth & Mental Hyg, New York, NY USA. [Arya, Vibhuti] Bur Policy Community Resilience & Response, Dept Hlth & Mental Hyg, New York, NY USA. [Schillinger, Julia A.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Schillinger, JA (reprint author), New York City Dept Hlth & Mental Hyg, 42-09 28th St CN 73, Long Isl City, NY 11101 USA. EM jschilli@health.nyc.gov FU New York City Department of Health and Mental Hygiene FX The first author was supported by a stipend from the New York City Department of Health and Mental Hygiene during the time the analysis for this paper was completed. NR 16 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2016 VL 43 IS 11 BP 679 EP 684 DI 10.1097/OLQ.0000000000000520 PG 6 WC Infectious Diseases SC Infectious Diseases GA EA6FS UT WOS:000386722600004 PM 27893596 ER PT J AU Ford, CL Mesfin, MS Gaines, TL Godette, DC AF Ford, Chandra L. Mesfin, Mulatu S. Gaines, Tommi L. Godette, Dionne C. TI How Underestimates of Need Contribute to Biased Conclusions SO SEXUALLY TRANSMITTED DISEASES LA English DT Letter ID COST-EFFECTIVENESS; HIV; OLDER; AGE; COMORBIDITIES; DISPARITIES; PREVALENCE; ADULTS; STATES C1 [Ford, Chandra L.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. [Mesfin, Mulatu S.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Gaines, Tommi L.] Univ Calif San Diego, Dept Med, Div Global Publ Hlth, San Diego, CA 92103 USA. [Godette, Dionne C.] NIAAA, Div Epidemiol & Prevent Res, NIH, Rockville, MD 20852 USA. RP Ford, CL (reprint author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. FU NICHD NIH HHS [P2C HD041022]; NINR NIH HHS [R01 NR014789] NR 13 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2016 VL 43 IS 11 BP 696 EP 697 DI 10.1097/OLQ.0000000000000526 PG 2 WC Infectious Diseases SC Infectious Diseases GA EA6FS UT WOS:000386722600007 PM 27893599 ER PT J AU Djomand, G Schlefer, M Gutreuter, S Tobias, S Patel, R DeLuca, N Hood, J Sawadogo, S Chen, C Muadinohamba, A Lowrance, DW Bock, N AF Djomand, Gaston Schlefer, Madeleine Gutreuter, Steve Tobias, Sarah Patel, Roopal DeLuca, Nickolas Hood, Julia Sawadogo, Souleymane Chen, Cheng Muadinohamba, Alexinah Lowrance, David W. Bock, Naomi TI Prevalence and Correlates of Genital Infections Among Newly Diagnosed Human Immunodeficiency Virus-Infected Adults Entering Human Immunodeficiency Virus Care in Windhoek, Namibia SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; TRICHOMONAS-VAGINALIS INFECTION; SOUTH-AFRICA; DISCHARGE SYNDROMES; PREGNANT-WOMEN; HIV; RISK; PREVENTION; TRANSMISSION; PARTNERS AB Background Identifying and treating genital infections, including sexually transmitted infections (STI), among newly diagnosed human immunodeficiency virus (HIV)-infected individuals may benefit both public and individual health. We assessed prevalence of genital infections and their correlates among newly diagnosed HIV-infected individuals enrolling in HIV care services in Namibia. Methods Newly diagnosed HIV-infected adults entering HIV care at 2 health facilities in Windhoek, Namibia, were recruited from December 2012 to March 2014. Participants provided behavioral and clinical data including CD4+ T lymphocyte counts. Genital and blood specimens were tested for gonorrhea, Chlamydia, trichomoniasis, Mycoplasma genitalium, syphilis, bacterial vaginosis, and vulvovaginal candidiasis. Results Among 599 adults, 56% were women and 15% reported consistent use of condoms in the past 6 months. The most common infections were bacterial vaginosis (37.2%), trichomoniasis (34.6%) and Chlamydia (14.6%) in women and M. genitalium (11.4%) in men. Correlates for trichomoniasis included being female (adjusted relative risk, [aRR], 7.18; 95% confidence interval [CI], 4.07-12.65), higher education (aRR, 0.58; 95% CI, 0.38-0.89), and lower CD4 cell count (aRR, 1.61; 95% CI, 1.08-2.40). Being female (aRR, 2.39; 95% CI, 1.27-4.50), nonmarried (aRR, 2.30; (95% CI, 1.28-4.14), and having condomless sex (aRR, 2.72; 95% CI, 1.06-7.00) were independently associated with chlamydial infection. Across all infections, female (aRR, 2.31; 95% CI, 1.79-2.98), nonmarried participants (aRR, 1.29; 95% CI, 1.06-1.59), had higher risk to present with any STI, whereas pregnant women (aRR, 1.16, 95% CI 1.03-1.31) were at increased risk of any STI or reproductive tract infection. C1 [Djomand, Gaston; Schlefer, Madeleine; Gutreuter, Steve; Hood, Julia; Chen, Cheng; Bock, Naomi] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Tobias, Sarah] Minist Hlth & Social Serv, Windhoek, Namibia. [Muadinohamba, Alexinah] Namibian Inst Pathol, Windhoek, Namibia. [Patel, Roopal; DeLuca, Nickolas; Sawadogo, Souleymane; Lowrance, David W.] US Ctr Dis Control & Prevent, Windhoek, Namibia. RP Djomand, G (reprint author), 1600 Clifton Rd,MS E-04, Atlanta, GA 30333 USA. EM gdd7@cdc.gov FU U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS and TB [U36/CCU300430] FX This research has been supported by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention, Division of Global HIV/AIDS and TB under the terms of a cooperative agreement [U36/CCU300430]. NR 29 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2016 VL 43 IS 11 BP 698 EP 705 DI 10.1097/OLQ.0000000000000513 PG 8 WC Infectious Diseases SC Infectious Diseases GA EA6FS UT WOS:000386722600008 PM 27893600 ER PT J AU Nadol, P O'Connor, S Duong, H Mixson-Hayden, T Tram, TH Xia, GL Kaldor, J Law, M Nguyen, T AF Nadol, Patrick O'Connor, Siobhan Duong, Hao Mixson-Hayden, Tonya Tran Hong Tram Xia, Guo-Liang Kaldor, John Law, Matthew Tuan Nguyen TI High hepatitis C virus (HCV) prevalence among men who have sex with men (MSM) in Vietnam and associated risk factors: 2010 Vietnam Integrated Behavioural and Biologic Cross-Sectional Survey SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article ID SUBSTANCE USE; INFECTION; EPIDEMIOLOGY; DISEASE; BURDEN AB Background Hepatitis C virus (HCV) is an increasing health issue among key populations such as men who have sex with men (MSM). We sought to assess the burden of and risk factors for HCV among MSM in Vietnam. Methods We analysed behavioural and demographic data and stored specimens from MSM surveyed in four provinces through Vietnam's 2009-2010 Integrated Biologic and Behavioural Survey, which used probability-based, respondent-driven sampling. Commercial hepatitis B surface antigen (HBsAg) and HCV/antibody (HCV Ag/Ab) testing were performed on archived sera with follow-up PCR for HCV RNA and genotype determination. Results Among the 1588 MSM surveyed, the median (range) frequency, by province, of HCV Ag/Ab detection was 28.4% (13.7%-38.8%); 84.5% (83.1%-100%) among HIV-infected and 21.9% (8.9%-28.2%) among HIV-uninfected. HCV prevalence was higher in northern Hanoi and Hai Phong provinces than in southern Ho Chi Minh City and Chan Tho provinces. Among a convenience sample of 67 HCV Ag/Ab+ MSM, 67.2% were HCV RNA +; of 41 genotyped, 73.2% were genotype 1. HBsAg prevalence varied from 8.5% to 27.4%. In the multivariable logistic regression analysis, being HIV-infected (adjusted OR (aOR) 19.0; 7.0-51.9), ever having used injected drugs (aOR 4.4; 1.6-12.4) and age > 25 years were significant risk factors for testing HCV Ag/Ab+. Conclusions HCV infection in Vietnam appears to be high among MSM, particularly among HIV-infected MSM, with a north-south gradient. Given overlapping risk behaviours and associations between HCV and HIV, integrating HIV and HCV programme services to prevent both HIV and HCV transmission among MSM is indicated. C1 [Nadol, Patrick; Duong, Hao] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Hanoi, Vietnam. [Nadol, Patrick; Kaldor, John; Law, Matthew] Univ New South Wales, Kirby Inst Infect & Immun, Sydney, NSW 2052, Australia. [O'Connor, Siobhan; Mixson-Hayden, Tonya; Xia, Guo-Liang] US Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Tran Hong Tram; Tuan Nguyen] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam. RP Nadol, P (reprint author), Univ New South Wales, Kirby Inst Infect & Immun, Sydney, NSW 2052, Australia.; Nadol, P (reprint author), 9300 Pretoria Pl, Dulles, VA USA. EM pcvnadol@gmail.com FU President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention [5U2GGH000116-03] FX This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention under the terms of project 5U2GGH000116-03. NR 29 TC 1 Z9 1 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 EI 1472-3263 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD NOV PY 2016 VL 92 IS 7 BP 542 EP U104 DI 10.1136/sextrans-2015-052518 PG 8 WC Infectious Diseases SC Infectious Diseases GA EC3EF UT WOS:000388007400015 ER PT J AU Marcus, PM Pashayan, N Church, TR Doria-Rose, VP Gould, MK Hubbard, RA Marrone, M Miglioretti, DL Pharoah, PD Pinsky, PF Rendle, KA Robbins, HA Roberts, MC Rolland, B Schiffman, M Tiro, JA Zauber, AG Winn, DM Khoury, MJ AF Marcus, Pamela M. Pashayan, Nora Church, Timothy R. Doria-Rose, V. Paul Gould, Michael K. Hubbard, Rebecca A. Marrone, Michael Miglioretti, Diana L. Pharoah, Paul D. Pinsky, Paul F. Rendle, Katherine A. Robbins, Hilary A. Roberts, Megan C. Rolland, Betsy Schiffman, Mark Tiro, Jasmin A. Zauber, Ann G. Winn, Deborah M. Khoury, Muin J. TI Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Editorial Material ID PROSTATE-CANCER; COLORECTAL-CANCER; LUNG-CANCER; SUSCEPTIBILITY LOCI; CERVICAL-CANCER; BREAST-CANCER; HUMAN-PAPILLOMAVIRUS; COST-EFFECTIVENESS; UNITED-STATES; TASK-FORCE AB Precision medicine, an emerging approach for disease treatment that takes into account individual variability in genes, environment, and lifestyle, is under consideration for preventive interventions, including cancer screening. On September 29, 2015, the National Cancer Institute sponsored a symposium entitled "Precision Cancer Screening in the General Population: Evidence, Epidemiology, and Next Steps". The goal was two-fold: to share current information on the evidence, practices, and challenges surrounding precision screening for breast, cervical, colorectal, lung, and prostate cancers, and to allow for in-depth discussion among experts in relevant fields regarding how epidemiology and other population sciences can be used to generate evidence to inform precision screening strategies. Attendees concluded that the strength of evidence for efficacy and effectiveness of precision strategies varies by cancer site, that no one research strategy or methodology would be able or appropriate to address the many knowledge gaps in precision screening, and that issues surrounding implementation must be researched as well. Additional discussion needs to occur to identify the high priority research areas in precision cancer screening for pertinent organs and to gather the necessary evidence to determine whether further implementation of precision cancer screening strategies in the general population would be feasible and beneficial. (C) 2016 AACR C1 [Marcus, Pamela M.; Doria-Rose, V. Paul; Rendle, Katherine A.; Roberts, Megan C.; Winn, Deborah M.; Khoury, Muin J.] NCI, Div Canc Control & Populat Studies, Bethesda, MD 20892 USA. [Pashayan, Nora] UCL, Dept Appl Hlth Res, London, England. [Church, Timothy R.] Univ Minnesota, Sch Publ Hlth, Div Environm Hlth Sci, Minneapolis, MN USA. [Gould, Michael K.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA. [Hubbard, Rebecca A.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Marrone, Michael; Robbins, Hilary A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Miglioretti, Diana L.] Univ Calif Davis, Dept Publ Hlth Sci, Sacramento, CA 95817 USA. [Pharoah, Paul D.] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England. [Pharoah, Paul D.] Univ Cambridge, Dept Oncol, Cambridge, England. [Pinsky, Paul F.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA. [Rolland, Betsy] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Schiffman, Mark] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Tiro, Jasmin A.] UT Southwestern Med Ctr, Dept Clin Sci, Dallas, TX USA. [Zauber, Ann G.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. RP Marcus, PM (reprint author), NCI, 9609 Med Ctr Dr,Room 4E-608, Bethesda, MD 20892 USA. EM marcusp@mail.nih.gov FU Cancer Research UK [10119, 10124]; Intramural NIH HHS [Z99 CA999999]; NCI NIH HHS [P30 CA008748, P01 CA154292, T32 CA009314] NR 46 TC 0 Z9 0 U1 4 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD NOV PY 2016 VL 25 IS 11 BP 1449 EP 1455 DI 10.1158/1055-9965.EPI-16-0555 PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA EB7AI UT WOS:000387537000001 PM 27507769 ER PT J AU Dirks, NF Vesper, HW van Herwaarden, AE van den Ouweland, JMW Kema, IP Krabbe, JG Heijboer, AC AF Dirks, Niek F. Vesper, Hubert W. van Herwaarden, Antonius E. van den Ouweland, Jody M. W. Kema, Ido P. Krabbe, Johannes G. Heijboer, Annemieke C. TI Various calibration procedures result in optimal standardization of routinely used 25(OH)D ID-LC-MS/MS methods SO CLINICA CHIMICA ACTA LA English DT Article DE Mass spectrometry; Method comparison; Standardization; Vitamin D ID TANDEM MASS-SPECTROMETRY; 25-HYDROXYVITAMIN D ASSAYS; HUMAN SERUM; D-3; ACCURACY AB Background: The variety of LC-MS/MS methods measuring total 25(OH)D used today is vast and the comparability among these methods is still not well assessed. Methods: Here, we performed a comparison in samples of healthy donors between the currently routinely used 25(OH)D LC-MS/MS methods in the Netherlands and the Ghent University reference measurement procedure to address this issue (n = 40). Additionally, an interlaboratory comparison in patient serum samples assessed agreement between the Dutch diagnostic methods (n = 37). Results: The overall correlation of the routine methods for 25(OH)D-3 with the reference measurement procedures and with the mean of all diagnostic methods was excellent (r > 0.993 and r > 0.989, respectively). Three out of five methods aligned perfectly with both the reference measurement procedure and the median of all methods. One of the routine methods showed a small positive bias, while another showed a small negative bias consistently in both comparisons. Conclusion: The biases most probably originated from differences in calibration procedure and may be obviated by reassessing calibration of stock standards and/or calibrator matrices. In conclusion, five diagnostic centers have performed a comparison with the 25(OH)D Ghent University reference measurement procedure in healthy donor serum samples and a comparison among themselves in patient serum samples. Both analyses showed a high correlation and specificity of the routine LC-MS/MS methods, yet did reveal some small standardization issues that could not be traced back to the technical details of the different methods. Hence, this study indicates various calibration procedures can result in perfect alignment. (C) 2016 Elsevier B.V. All rights reserved. C1 [Dirks, Niek F.; Heijboer, Annemieke C.] Vrije Univ Amsterdam, Med Ctr, Endocrine Lab, Dept Clin Chem, Amsterdam, Netherlands. [Vesper, Hubert W.] Ctr Dis Control & Prevent CDC, Div Sci Lab, Atlanta, GA USA. [van Herwaarden, Antonius E.] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Nijmegen, Netherlands. [van den Ouweland, Jody M. W.] Canisius Wilhelmina Hosp, Dept Clin Chem, Nijmegen, Netherlands. [Kema, Ido P.] Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, Groningen, Netherlands. [Krabbe, Johannes G.] Med Spectrum Twente, Dept Clin Chem & Lab Med, Medlon Bv, Netherlands. RP Heijboer, AC (reprint author), Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, De Boelelaan 1118, NL-1081 HV Amsterdam, Netherlands. EM a.heijboer@vumc.nl OI Heijboer, Annemieke/0000-0002-6712-9955 FU Dutch Foundation for Quality Assessment in Medical Laboratories (SKML), section Endocrinology FX This study was financially supported by the Dutch Foundation for Quality Assessment in Medical Laboratories (SKML), section Endocrinology. NR 15 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 EI 1873-3492 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD NOV 1 PY 2016 VL 462 BP 49 EP 54 DI 10.1016/j.cca.2016.08.016 PG 6 WC Medical Laboratory Technology SC Medical Laboratory Technology GA EB2MB UT WOS:000387195400009 PM 27570062 ER PT J AU Schantz, MM Powers, CD Schleicher, RL Betz, JM Wise, SA AF Schantz, Michele M. Powers, Carissa D. Schleicher, Rosemary L. Betz, Joseph M. Wise, Stephen A. TI Interlaboratory analytical comparison of fatty acid concentrations in serum or plasma SO CLINICA CHIMICA ACTA LA English DT Article DE Fatty acids; Serum; Plasma; Interlaboratory study; SRM 2378; SRM 1950 ID QUALITY-ASSURANCE PROGRAM; MEASUREMENT PERFORMANCE; ASSOCIATION; ADULTS; TIME AB Background: There are a large number of clinical studies focusing on the measurement of individual fatty acids in serum or plasma; however, few studies have focused on the interlaboratory comparisons of these measurements. The National Institutes of Standards and Technology (NIST), in collaboration with the National Institutes of Health Office of Dietary Supplements (NIH-ODS) and the Centers for Disease Control and Prevention (CDC), has initiated a quality assurance program for assessing and improving the comparability of individual fatty acid measurements in serum and plasma. Methods: This is a performance-based study so participants are encouraged to use their laboratory's methods for the quantification of the individual fatty acids that they typically measure in the unknown serum or plasma samples along with a control material. The control materials used to date are SRM 1950 Metabolites in Human Plasma and SRM 2378 Fatty Acids in Frozen Human Serum. Results: To date, two studies of the Fatty Acid Quality Assurance Program (FAQAP) have been completed with 11 and 14 participants, respectively. The agreement among the laboratories for individual fatty acids was within 20% for 70% of the data submitted. Laboratories were also requested to run triplicate analyses for each unknown sample. The precision of the individual laboratory data was generally good, with relative standard deviations <20%. Conclusions: The results from the first two exercises indicate the need for additional assessment of the comparability among laboratories doing these measurements. Future studies will be conducted with the goals of increasing the number of participating laboratories, increasing awareness of the need to use control materials, and improving the comparability among laboratories. Published by Elsevier B.V. C1 [Schantz, Michele M.; Wise, Stephen A.] NIST, Div Chem Sci, Gaithersburg, MD 20899 USA. [Powers, Carissa D.; Schleicher, Rosemary L.] Ctr Dis Control & Prevent, Nutr Biomarkers Branch, Div Lab Sci, Atlanta, GA 30341 USA. [Betz, Joseph M.; Wise, Stephen A.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. RP Schantz, MM (reprint author), NIST, Div Chem Sci, Gaithersburg, MD 20899 USA. EM Michele.schantz@nist.gov FU National Institutes of Health (NIH), Office of Dietary Supplements (ODS) [AOD 14043-001] FX The financial support for these intercomparison exercises was provided by the National Institutes of Health (NIH) (grant number AOD 14043-001), Office of Dietary Supplements (ODS). The time and effort of the analysts and management of the participating laboratories are gratefully acknowledged. Certain commercial equipment, instruments, or materials are identified in this report to specify adequately the experimental procedure. Such identification does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment identified are the best available for the purpose. The findings and conclusions in this article are those of the authors and do not necessarily represent the official views or positions of the CDC/Agency for Toxic Substance and Disease Registry or the Department of Health and Human Services. NR 19 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 EI 1873-3492 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD NOV 1 PY 2016 VL 462 BP 148 EP 152 DI 10.1016/j.cca.2016.09.013 PG 5 WC Medical Laboratory Technology SC Medical Laboratory Technology GA EB2MB UT WOS:000387195400026 PM 27662814 ER PT J AU Nelson, NP Easterbrook, PJ McMahon, BJ AF Nelson, Noele P. Easterbrook, Philippa J. McMahon, Brian J. TI Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease SO CLINICS IN LIVER DISEASE LA English DT Article DE Hepatitis B virus; Hepatitis B vaccine; Birth dose; Perinatal transmission; Vaccine impact ID UNITED-STATES; HEPATOCELLULAR-CARCINOMA; CARRIER STATE; ANTIVIRAL THERAPY; ALASKAN NATIVES; SURFACE-ANTIGEN; CHILDREN; IMMUNIZATION; PROGRAM; TRANSMISSION AB Integration of hepatitis B vaccination into national immunization programs has resulted in substantial reductions of hepatitis B virus (HBV) transmission in previously high endemic countries. The key strategy for control of the HBV epidemic is birth dose and infant vaccination. Additional measures include use of hepatitis B immunoglobulin (HBIG) and diagnosis of mothers at high risk of transmitting HBV and use of antiviral agents during pregnancy to decrease maternal DNA concentrations to undetectable concentrations. Despite the substantial decrease in HBV cases since vaccination introduction, implementation of birth dose vaccination in low-income and middle-income countries and vaccination of high-risk adults remain challenging. C1 [Nelson, Noele P.] Ctr Dis Control & Prevent, Clin Intervent Team, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS G37, Atlanta, GA 30329 USA. [Easterbrook, Philippa J.] World Hlth Org, HIV Dept, Global Hepatitis Programme, 20 Via Appia, CH-1211 Geneva, Switzerland. [McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Alaska Native Med Ctr, Liver Dis & Hepatitis Program, 4315 Diplomacy Dr, Anchorage, AK 99508 USA. RP Nelson, NP (reprint author), Ctr Dis Control & Prevent, Clin Intervent Team, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS G37, Atlanta, GA 30329 USA. EM nnelson@cdc.gov NR 68 TC 0 Z9 0 U1 8 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1089-3261 EI 1557-8224 J9 CLIN LIVER DIS JI Clin. Liver Dis. PD NOV PY 2016 VL 20 IS 4 BP 607 EP + DI 10.1016/j.cld.2016.06.006 PG 23 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EB2OS UT WOS:000387202300002 PM 27742003 ER PT J AU Ribot, EM Hise, KB AF Ribot, Efrain M. Hise, Kelley B. TI Future challenges for tracking foodborne diseases: PulseNet, a 20-year-old US surveillance system for foodborne diseases, is expanding both globally and technologically SO EMBO REPORTS LA English DT Editorial Material ID UNITED-STATES; PATHOGENS; NETWORK C1 [Ribot, Efrain M.; Hise, Kelley B.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Ribot, EM (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM eyr4@cdc.gov NR 10 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-221X EI 1469-3178 J9 EMBO REP JI EMBO Rep. PD NOV PY 2016 VL 17 IS 11 BP 1499 EP 1505 DI 10.15252/embr.201643128 PG 7 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA EB1XD UT WOS:000387148700001 PM 27644260 ER PT J AU Hasle, H Friedman, JM Olsen, JH Rasmussen, SA AF Hasle, Henrik Friedman, Jan M. Olsen, Jurgen H. Rasmussen, Sonja A. TI Low risk of solid tumors in persons with Down syndrome SO GENETICS IN MEDICINE LA English DT Article DE cancer; Down syndrome; tumor-suppressor genes ID CANCER INCIDENCE; BREAST-CANCER; ADULTS; INDIVIDUALS; MORTALITY; WOMEN; SUPPRESSION; SURVIVAL; LEUKEMIA; DENMARK AB Purpose: The aim of this study was to investigate cancer incidence in a large cohort of persons with Down syndrome. Methods: Down syndrome was identified from the Danish Cytogenetic Register. Cancer occurrence was identified by linkage to the Danish Cancer Registry. Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated based on observed and expected numbers from rates for all Danish residents. The cohort consisted of 3,530 persons with Down syndrome contributing 89,570 person-years at risk. Results: Acute leukemia risk was highest from 1-4 years of age and remained elevated until age 30. The overall risk of solid tumors was decreased (SIR 0.45; 95% CI 0.34-0.59), especially in persons 50 years or older (SIR 0.27; 95% CI 0.16-0.43). We found a significantly lower risk of lung cancer (SIR 0.10; 95% CI 0.00-0.56), breast cancer (SIR 0.16; 95% CI 0.03-0.47), and cervical cancer (SIR 0.0; 95% CI 0.00-0.77). Testicular cancer was the only solid tumor with an increased SIR (2.9; 95% CI 1.6-4.8). Conclusions: The risk of all major groups of solid tumors was decreased, except testicular cancer. Altered screening strategies should be considered for persons with Down syndrome. This unusual pattern of cancer occurrence may help understanding carcinogenesis in the general population. C1 [Hasle, Henrik] Aarhus Univ Hosp, Dept Pediat, Aarhus, Denmark. [Friedman, Jan M.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. [Olsen, Jurgen H.] Danish Canc Soc, Res Ctr, Copenhagen, Denmark. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Hasle, H (reprint author), Aarhus Univ Hosp, Dept Pediat, Aarhus, Denmark. EM hasle@dadlnet.dk OI Friedman, Jan/0000-0002-7482-9570; Hasle, Henrik/0000-0003-3976-9231; Rasmussen, Sonja/0000-0002-0574-4928 NR 39 TC 2 Z9 2 U1 5 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD NOV PY 2016 VL 18 IS 11 BP 1151 EP 1157 DI 10.1038/gim.2016.23 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA EA8DR UT WOS:000386866000013 PM 27031084 ER PT J AU Schaffner, W Gravenstein, S Hopkins, RH Jernigan, DB AF Schaffner, William Gravenstein, Stefan Hopkins, Robert H. Jernigan, Daniel B. TI Reinvigorating Influenza Prevention in US Adults Aged 65 Years and Older SO INFECTIOUS DISEASES IN CLINICAL PRACTICE LA English DT Article DE influenza; immunosenescence; cardiovascular outcomes; vaccines ID SEASONAL INFLUENZA; UNITED-STATES; VACCINES RECOMMENDATIONS; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; ELDERLY SUBJECTS; VACCINATION; IMMUNOGENICITY; MORTALITY; INFECTION AB Adults aged 65 years and older are disproportionately impacted by influenza, accounting for more influenza-related deaths and hospitalizations than any other age group by far. The increasing likelihood of chronic conditions with age and age-related gradual decline in the immune system (immunosenescence) result in an elevated risk of complications from infections, including influenza. Immunosenescence is also a factor in reduced vaccine efficacy in older adults. Newer vaccines approved specifically for adults aged 65 years and older are designed to provide better immune response and better efficacy. Improving immunization coverage rates among this population using new and existing influenza vaccines is essential to reduce the annual impact of influenza infections in the United States. C1 [Schaffner, William] Vanderbilt Univ, Sch Med, Suite 2600,1500 21st Ave S, Nashville, TN 37212 USA. [Schaffner, William] Natl Fdn Infect Dis, Bethesda, MD USA. [Gravenstein, Stefan] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Hopkins, Robert H.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Jernigan, Daniel B.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Schaffner, W (reprint author), Vanderbilt Univ, Sch Med, Suite 2600,1500 21st Ave S, Nashville, TN 37212 USA. EM william.schaffner@vanderbilt.edu NR 41 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1056-9103 EI 1536-9943 J9 INFECT DIS CLIN PRAC JI Infect. Dis. Clin. Pract. PD NOV PY 2016 VL 24 IS 6 BP 303 EP 309 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EB6CJ UT WOS:000387468200021 ER PT J AU Valverde, EE DiNenno, EA Schulden, JD Oster, A Painter, T AF Valverde, Eduardo E. DiNenno, Elizabeth A. Schulden, Jeffrey D. Oster, Alexandra Painter, Thomas TI Sexually transmitted infection diagnoses among Hispanic immigrant and migrant men who have sex with men in the United States SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE Bacterial disease; sexually transmitted infection; high-risk behaviour; MSM; men; Hispanic immigrant ID RISK BEHAVIORS; COMMERCIAL SEX; NORTH-CAROLINA; DAY LABORERS; SELF-REPORT; HIV RISK; CALIFORNIA; MIGRATION; SYPHILIS; FARMWORKERS AB Hispanic immigrant/migrant men who have sex with men (MSM) should be at higher risk for sexually transmitted infections/human immunodeficiency virus (STIs/HIV) given individual-level factors associated with the migration process that have been theorised to increase susceptibility to STIs/HIV among migrant populations. However, relatively little is known if these individual level factors are actually associated with the STI prevalence among this population. During 2005-2007, 2576 men and women foreign-born Hispanics were surveyed at three community-based organisations offering services to immigrant/migrant communities in the US. We analysed demographic characteristics, sexual risk behaviours, migration patterns, and factors associated with STI diagnoses (syphilis, chlamydia, and gonorrhoea) in the past 12 months among Hispanic immigrant/migrant MSM. Of 1482 Hispanic immigrant/migrant men surveyed who reported having sex in the past 12 months, 353 (24%) reported sex with a man, and of these, 302 answered questions regarding whether or not they had been diagnosed with a bacterial STI in the past year. Of these 302 men, 25% reported being married; 42% self-identified as being heterosexual and 20% as bisexual. Twenty-nine (9.6%) men reported that they had received an STI diagnosis in the past year. In the multivariate logistic regression model, men who reported receiving money or goods for sex had increased odds of a self-reported STI diagnosis. The prevalence of bacterial STIs among Hispanic immigrant/migrant MSM is lower than the prevalence of bacterial STIs among other MSM in the United States. Nevertheless, receiving money or goods for sex was significantly associated with a self-reported STI diagnosis among Hispanic immigrant/migrant MSM. It is important to understand factors contributing to participation in exchange sex among this population. HIV/STI prevention interventions tailored to non-gay identifying MSM are important for Hispanic immigrant/migrant MSM. C1 [Valverde, Eduardo E.; DiNenno, Elizabeth A.; Oster, Alexandra; Painter, Thomas] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Schulden, Jeffrey D.] NIDA, NIH, Neurosci Ctr, Bethesda, MD 20892 USA. RP Valverde, EE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-47, Atlanta, GA 30329 USA. EM evalverde@cdc.gov NR 28 TC 0 Z9 0 U1 3 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD NOV PY 2016 VL 27 IS 13 BP 1162 EP 1169 DI 10.1177/0956462415610679 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EA9XX UT WOS:000386999100003 PM 26464501 ER PT J AU Hosey, GM Rengiil, A Maddison, R Agapito, AU Lippwe, K Wally, OD Agapito, DD Seremai, J Primo, S Luther, XN Ikerdeu, E Satterfield, D AF Hosey, Gwendolyn M. Rengiil, Augusta Maddison, Robert Agapito, Angelica U. Lippwe, Kipier Wally, Omengkar Damien Agapito, Dennis D. Seremai, Johannes Primo, Selma Luther, X-ner Ikerdeu, Edolem Satterfield, Dawn TI US Associated Pacific Islands Health Care Teams Chart a Course for Improved Health Systems: Implementation and Evaluation of a Non-communicable Disease Collaborative Model SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Micronesia; US Associated Pacific Islands; chronic disease; chronic care model; diabetes; cardiovascular disease; system change; consolidated framework for implementation research; quality improvement; indigenous knowledge ID COUNTRIES AB The burden of non-communicable disease (NCD) is increasing in the U.S. Associated Pacific Islands (USAPI). We describe the implementation and evaluation of a NCD Collaborative pilot, using local trainers, as an evidence-based strategy to systematically strengthen NCD health care quality and outcomes, focusing on diabetes preventive care across five health systems in the region. C1 [Hosey, Gwendolyn M.; Rengiil, Augusta] Natl Assoc Chron Dis Directors, Atlanta, GA USA. [Maddison, Robert] Belau Natl Hosp, Internal Med, Koror, Palau. [Satterfield, Dawn] Ctr Dis Control & Prevent, Tribal Terr & Reg Support Team, Div Diabet Translat, Atlanta, GA USA. RP Hosey, GM (reprint author), Natl Assoc Chron Dis Directors, POB 402, Wellington, NV 89444 USA. EM akapacific@hughes.net FU Centers for Disease Control and Prevention; U.S. Department of the Interior, Office of Insular Affair FX Funding to support the pilot learning sessions was supported in part by the Centers for Disease Control and Prevention and the U.S. Department of the Interior, Office of Insular Affairs. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention; U.S. Departing of the Interior; National Association of Chronic Disease Directors; the Federated States of Micronesia; the Republic of the Marshall Islands; or the Republic of Palau. NR 22 TC 0 Z9 0 U1 1 U2 1 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD NOV PY 2016 VL 27 IS 4 SU S BP 19 EP 38 PG 20 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EB1ES UT WOS:000387093000006 PM 27818410 ER PT J AU Dopson, SA AF Dopson, Stephanie A. TI Improving the Public Health Infrastructure Capacity in the US Pacific Territories SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Editorial Material DE Infrastructure; epidemiology; surveillance; US Pacific territories AB The public health emergency of 2009 pandemic influenza A (H1N1) virus resulted in supplemental funding provided by Congress to the 62 states and territories. The CDC's response included deployment of personnel to the U.S. Pacific territories, who provided technical assistance on laboratory capacity, infbrmation technology, surveillance, planning, and continuity of operations. C1 [Dopson, Stephanie A.] Ctr Dis Control & Prevent, Influenza Coordinat Unit, Off Infect Dis, MS A-28, Atlanta, GA 30329 USA. RP Dopson, SA (reprint author), Ctr Dis Control & Prevent, Influenza Coordinat Unit, Off Infect Dis, MS A-28, Atlanta, GA 30329 USA. EM sld9@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 0 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD NOV PY 2016 VL 27 IS 4 BP 1632 EP 1637 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EB1EQ UT WOS:000387092800002 PM 27818427 ER PT J AU Raphael, JL Tapia, C Fischer, LS McKeever, J Giardino, AP AF Raphael, Jean L. Tapia, Carl Fischer, Leah S. McKeever, John Giardino, Angelo P. TI The Medical Home Experience of Low-income Children with Non-Urgent Encounters in Acute Care Settings SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Medical home; primary care; pediatrics; disparities ID EMERGENCY-DEPARTMENT UTILIZATION; HEALTH-CARE; HOSPITAL EMERGENCY; UNITED-STATES; NONURGENT; ASSOCIATION; PREDICTORS; PHYSICIAN; OUTCOMES; QUALITY AB Purpose. Assess relationships between having a medical home and health care seeking behavior attitudes among parents of low-income children with non-urgent encounters in acute settings (emergency, urgent care centers). Methods. We analyzed data from 1,743 publicly insured children within non-urgent encounters. Parents completed surveys assessing medical home access and attitudes regarding health care-seeking behavior. Multivariate logistic regression analyses were conducted to investigate relationships between medical home access and attitudes. Results. Forty percent of children with non-urgent acute care encounters had medical homes. Having a medical home was positively associated with always calling the doctor before going to acute care settings and preference to take a child to their doctor if the doctor's office was open evenings and weekends. Conclusions. Although having a medical home is associated with positive attitudes regarding health care-seeking behavior, it may not suffice to overcome other barriers that precipitate non-urgent encounters. C1 [Raphael, Jean L.; Tapia, Carl; Giardino, Angelo P.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Fischer, Leah S.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Atlanta, GA USA. [McKeever, John] Gelb Consulting, Houston, TX USA. RP Raphael, JL (reprint author), Suite 1540-00,6701 Fannin St, Houston, TX 77030 USA. EM raphael@bcm.edu NR 49 TC 0 Z9 0 U1 6 U2 6 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD NOV PY 2016 VL 27 IS 4 BP 1885 EP 1898 PG 14 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EB1EQ UT WOS:000387092800020 PM 27818445 ER PT J AU Lockhart, E Lubin, L Greene, C See, V Vashist, S AF Lockhart, E. Lubin, L. Greene, C. See, V. Vashist, S. TI Long QT Syndrome: A Genetic Test in the Context of a Diagnostic Algorithm SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Meeting of the Association-for-Molecular-Pathology CY NOV 10-12, 2016 CL Charlotte, NC SP Assoc Mol Pathol C1 [Lockhart, E.; Lubin, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lockhart, E.; Greene, C.; See, V.; Vashist, S.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2016 VL 18 IS 6 MA G38 BP 945 EP 945 PG 1 WC Pathology SC Pathology GA EB2OF UT WOS:000387201000056 ER PT J AU Faroon, O Ruiz, P AF Faroon, Obaid Ruiz, Patricia TI Polychlorinated biphenyls: New evidence from the last decade SO TOXICOLOGY AND INDUSTRIAL HEALTH LA English DT Article DE cancer; developmental neurotoxicity; diabetes mellitus; endocrine disrupters; PCB congeners; Polychlorinated biphenyls ID IN-UTERO EXPOSURE; PERSISTENT ORGANIC POLLUTANTS; SPRAGUE-DAWLEY RATS; DIOXIN-LIKE COMPOUNDS; BONE-MINERAL DENSITY; HUDSON RIVER COMMUNITIES; 2-YEAR ORAL TREATMENT; PCB EXPOSURE; PROSTATE-CANCER; SERUM CONCENTRATIONS AB Millions of pounds of polychlorinated biphenyl (PCB) compounds have been produced in multiple countries for industrial applications over the last several decades. PCB exposure induces various adverse health effects in animals and humans. Environmental and occupational exposures to PCBs have been associated with liver, kidney, endocrine, and neurodevelopmental adverse effects. We have collected and reviewed animal and human data cited in the US National Library of Medicine from 2000 to 2010. In brief, our review shows new evidence, that is, in animal studies, exposure to one of the PCBs, A1221, induces a significant alteration of serum luteinizing hormone. The effects were more profound in the F2 generation, particularly with respect to fluctuations in hormones and reproductive tract tissues across the estrous cycle. Morphological analyses of brain tissue from rats exposed to A1254 confirmed the results of an earlier work which showed that the relative size of the intra- and infrapyramidal (II-P) mossy fibers was smaller than that in the controls and also reduction in growth was selective for the II-P mossy fibers. PCB exposure increased anogenital distance and prostate size but decreased epididymal weight, epididymal sperm count, and motile epididymal sperm count. No effects were observed on testicular weight or size. The epidemiological data showed an association between diabetes mellitus prevalence and elevated concentrations of PCB 153. Additionally, prenatal PCB exposure studies were associated with a smaller thymic index at birth and could adversely affect immune responses to childhood vaccinations and resistance to respiratory infections. PCB exposure was also reported to adversely affect enamel development in children in a dose-dependent manner. Because PCBs and their metabolites are potential health hazards, understanding the risk factors associated with individual PCBs, PCB mixtures, and PCB metabolites is important. PCB exposures of vulnerable populations (pregnant women, fetuses, infants, and children) are of particular concern because of heightened sensitivity during this period of brain development. C1 [Faroon, Obaid; Ruiz, Patricia] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, 1600 Clifton Rd,MS F57, Atlanta, GA 30333 USA. RP Faroon, O (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, 1600 Clifton Rd,MS F57, Atlanta, GA 30333 USA. EM oxs0@cdc.gov NR 97 TC 6 Z9 6 U1 25 U2 25 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0748-2337 EI 1477-0393 J9 TOXICOL IND HEALTH JI Toxicol. Ind. Health PD NOV PY 2016 VL 32 IS 11 BP 1825 EP 1847 DI 10.1177/0748233715587849 PG 23 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA EA8CL UT WOS:000386862800001 ER PT J AU Engelman, D Fuller, LC Solomon, AW McCarthy, JS Hay, RJ Lammie, PJ Steer, AC AF Engelman, Daniel Fuller, L. Claire Solomon, Anthony W. McCarthy, James S. Hay, Roderick J. Lammie, Patrick J. Steer, Andrew C. TI Opportunities for Integrated Control of Neglected Tropical Diseases That Affect the Skin SO TRENDS IN PARASITOLOGY LA English DT Review ID SUB-SAHARAN AFRICA; RESISTANT STREPTOCOCCUS-PNEUMONIAE; REMOTE ABORIGINAL COMMUNITIES; LYMPHATIC FILARIASIS; DERMATOLOGICAL CARE; NORTHERN AUSTRALIA; SARCOPTES-SCABIEI; TRACHOMA CONTROL; CONTROL PROGRAMS; SOLOMON-ISLANDS AB Many neglected tropical diseases (NTDs) affect the skin, causing considerable disability, stigma, and exacerbation of poverty. However, there has been relatively little investment into laboratory research, epidemiology, diagnostic tools or management strategies to control tropical skin disease. Integration may advance the control of skin disease across a range of domains, including mapping, diagnosis, clinical management, and community control measures such as mass drug administration. Examples of successful integration strategies include programs targeting scabies, impetigo, yaws, and diseases causing lymphoedema. Future strategies should build on these experiences and the experience of integration of other NTDs, strengthen existing health systems, and contribute toward the attainment of Universal Health Coverage. Strong Partnerships and political support and will be necessary to achieve these goals. C1 [Engelman, Daniel; Steer, Andrew C.] Univ Melbourne, Ctr Int Child Hlth, Melbourne, Vic, Australia. [Engelman, Daniel; Steer, Andrew C.] Murdoch Childrens Res Inst, Grp Streptococcal Res A, Melbourne, Vic, Australia. [Fuller, L. Claire] Chelsea & Westminster Hosp, London, England. [Fuller, L. Claire; Hay, Roderick J.] Int Fdn Dermatol, London, England. [Solomon, Anthony W.] World Hlth Org, Dept Control Neglected Trop Dis, Geneva, Switzerland. [McCarthy, James S.] Univ Queensland, Queensland Inst Med Res Berghofer, Med Res Inst, Brisbane, Qld, Australia. [Hay, Roderick J.] Kings Coll London, Kings Coll Hosp Natl Hlth Serv Trust, London, England. [Lammie, Patrick J.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Engelman, D (reprint author), Univ Melbourne, Ctr Int Child Hlth, Melbourne, Vic, Australia.; Engelman, D (reprint author), Murdoch Childrens Res Inst, Grp Streptococcal Res A, Melbourne, Vic, Australia. EM Daniel.Engelman@rch.org.au OI Solomon, Anthony/0000-0001-7101-6649; Engelman, Daniel/0000-0002-4909-1287 FU Australian National Health and Medical Research Council research fellowships; National Heart Foundation of Australia FX This manuscript emerged from presentations made at, and discussions arising from, Symposium 57 (Neglected Tropical Diseases and the Skin: Integration, Surveillance and Control') of the 64th Annual Meeting of the American Society of Tropical Medicine and Hygiene, held in October 2015 in Philadelphia, USA. D.E., J.S.M., and A.C.S. are supported by Australian National Health and Medical Research Council research fellowships. D.E. and A.C.S. are additionally supported by the National Heart Foundation of Australia. A.W.S. is an employee of the WHO. The views expressed in this article are the views of the authors alone and do not necessarily reflect the decisions or the stated policy of the WHO. NR 86 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1471-4922 EI 1471-5007 J9 TRENDS PARASITOL JI Trends Parasitol. PD NOV PY 2016 VL 32 IS 11 BP 843 EP 854 DI 10.1016/j.pt.2016.08.005 PG 12 WC Parasitology SC Parasitology GA EB2LZ UT WOS:000387195200005 PM 27638231 ER PT J AU Qi, CL Kulkarni, P AF Qi, Chaolong Kulkarni, Pramod TI Miniature differential mobility analyzer for compact field-portable spectrometers SO AEROSOL SCIENCE AND TECHNOLOGY LA English DT Article ID PARTICLE CLASSIFICATION; SIZE RANGE; DMA; DESIGN; NM AB A low-flow miniature differential mobility analyzer (mDMA) has been developed for compact field-portable mobility spectrometers to classify the submicrometer aerosol. The mDMA was designed for an ultra-low aerosol flow rate of 0.05 L/min. At a sheath flow rate of 0.2 L/min, the mDMA's upper size limit was estimated to be about 921 nm. The mDMA has a classification zone of 2.54 cm long, an outer diameter of 2.54 cm, and an inner diameter of 1.778 cm. The design allows low-cost fabrication and easy assembly. Tandem DMA measurements were carried out to evaluate the performance of the mDMA. Its transfer function was described using Stolzenburg's model. The experimentally measured transfer function shows close agreement with the theory. The transmission efficiency was comparable to that of the Knutson-Whitby DMA for particles in the range of 10-1000 nm. The mobility resolution was comparable to that of the TSI 3085 nanoDMA at the same aerosol flow rate. The design features and performance of the mDMA make it suitable for compact field portable mobility size spectrometers for measurement of nanoparticles and submicrometer aerosol. C1 [Qi, Chaolong; Kulkarni, Pramod] NIOSH, Ctr Dis Control & Prevent, 1090 Tusculum Ave,MS R7, Cincinnati, OH 45226 USA. RP Kulkarni, P (reprint author), NIOSH, Ctr Dis Control & Prevent, 1090 Tusculum Ave,MS R7, Cincinnati, OH 45226 USA. EM PSKulkarni@cdc.gov NR 25 TC 1 Z9 1 U1 5 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0278-6826 EI 1521-7388 J9 AEROSOL SCI TECH JI Aerosol Sci. Technol. PD NOV PY 2016 VL 50 IS 11 BP 1145 EP 1154 DI 10.1080/02786826.2016.1221500 PG 10 WC Engineering, Chemical; Engineering, Mechanical; Environmental Sciences; Meteorology & Atmospheric Sciences SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA EA3BN UT WOS:000386473200001 ER PT J AU Zheng, LN Kulkarni, P Birch, ME Deye, G Dionysiou, DD AF Zheng, Lina Kulkarni, Pramod Birch, M. Eileen Deye, Gregory Dionysiou, Dionysios D. TI Near real-time measurement of carbonaceous aerosol using microplasma spectroscopy: Application to measurement of carbon nanomaterials SO AEROSOL SCIENCE AND TECHNOLOGY LA English DT Article ID INDUCED BREAKDOWN SPECTROSCOPY; AERODYNAMIC DIAMETER MEASUREMENTS; ATOMIC-EMISSION-SPECTROMETRY; SECONDARY ORGANIC AEROSOL; THERMAL-OPTICAL METHOD; ELEMENTAL CARBON; SPARK DISCHARGE; THERMOGRAVIMETRIC ANALYSIS; SPECTROCHEMICAL ANALYSIS; DENSITY CHARACTERIZATION AB A sensitive, field-portable microplasma spectroscopy method has been developed for real-time measurement of carbon nanomaterials. The method involves microconcentration of aerosol on a microelectrode tip for subsequent analysis for atomic carbon using spark emission spectroscopy (SES). The spark-induced microplasma was characterized by measuring the excitation temperature (15,000-35,000 K), electron density (1.0 x 10(17)-2.2 x 10(17) cm(-3)), and spectral responses as functions of time and interelectrode distance. The system was calibrated and detection limits were determined for total atomic carbon (TAC) using a carbon emission line at 247.856 nm (C I) for various carbonaceous materials including sucrose, EDTA, caffeine, sodium carbonate, carbon black, and carbon nanotubes. The limit of detection for total atomic carbon was 1.61 ng, equivalent to 238 ng m(-3) when sampling at 1.5 L min(-1) for 5 min. To improve the selectivity for carbon nanomaterials, which mainly consist of elemental carbon (EC), the cathode was heated to 300 degrees C to reduce the contribution of organic carbon to the total atomic carbon. Measurements of carbon nanotube aerosol at elevated electrode temperature showed improved selectivity to elemental carbon and compared well with the measurements from the thermal optical method (NIOSH Method 5040). The study shows the SES method to be an excellent candidate for development of low-cost, hand-portable, real-time instrument for measurement of carbonaceous aerosols and nanomaterials. C1 [Zheng, Lina; Kulkarni, Pramod; Birch, M. Eileen; Deye, Gregory] NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,MS R7, Cincinnati, OH 45226 USA. [Zheng, Lina; Dionysiou, Dionysios D.] Univ Cincinnati, Dept Biomed Chem & Environm Engn, Environm Engn & Sci Program, Cincinnati, OH USA. RP Kulkarni, P (reprint author), NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,MS R7, Cincinnati, OH 45226 USA. EM PSKulkarni@cdc.gov NR 50 TC 1 Z9 1 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0278-6826 EI 1521-7388 J9 AEROSOL SCI TECH JI Aerosol Sci. Technol. PD NOV PY 2016 VL 50 IS 11 BP 1155 EP 1166 DI 10.1080/02786826.2016.1224804 PG 12 WC Engineering, Chemical; Engineering, Mechanical; Environmental Sciences; Meteorology & Atmospheric Sciences SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA EA3BN UT WOS:000386473200002 ER PT J AU Kulkarni, P Qi, CL Fukushima, N AF Kulkarni, Pramod Qi, Chaolong Fukushima, Nobuhiko TI Development of portable aerosol mobility spectrometer for personal and mobile aerosol measurement SO AEROSOL SCIENCE AND TECHNOLOGY LA English DT Article ID EXPOSURE; CARBON; NANOMATERIALS; CHARGE; PART AB We describe development of a portable aerosol mobility spectrometer (PAMS) for size distribution measurement of submicrometer aerosol. The spectrometer is designed for use in personal or mobile aerosol characterization studies and measures approximately 22.5x22.5x15 cm and weighs about 4.5 kg including the battery. PAMS uses electrical mobility technique to measure number-weighted particle size distribution of aerosol in the 10-855 nm range. Aerosol particles are electrically charged using a dual-corona bipolar corona charger, followed by classification in a cylindrical miniature differential mobility analyzer. A condensation particle counter is used to detect and count particles. The mobility classifier was operated at an aerosol flow rate of 0.05 L/min, and at two different user-selectable sheath flows of 0.2 L/min (for wider size range 15-855 nm) and 0.4 L/min (for higher size resolution over the size range of 10.6-436 nm). The instrument was operated in voltage stepping mode to retrieve the size distribution in approximately 1-2 min. Sizing accuracy and resolution were probed and found to be within the 25% limit of NIOSH criterion for direct-reading instruments. Comparison of size distribution measurements from PAMS and other commercial mobility spectrometers showed good agreement. The instrument offers unique measurement capability for on-person or mobile size distribution measurement of ultrafine and nanoparticle aerosol. C1 [Kulkarni, Pramod; Qi, Chaolong] NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. [Fukushima, Nobuhiko] Kanomax Japan Inc, Osaka, Japan. RP Kulkarni, P (reprint author), NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM PSKulkarni@cdc.gov NR 17 TC 0 Z9 0 U1 8 U2 8 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0278-6826 EI 1521-7388 J9 AEROSOL SCI TECH JI Aerosol Sci. Technol. PD NOV PY 2016 VL 50 IS 11 BP 1167 EP 1179 DI 10.1080/02786826.2016.1230662 PG 13 WC Engineering, Chemical; Engineering, Mechanical; Environmental Sciences; Meteorology & Atmospheric Sciences SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA EA3BN UT WOS:000386473200003 ER PT J AU Hubbs, AF Fluharty, KL Edwards, RJ Barnabei, JL Grantham, JT Palmer, SM Kelly, F Sargent, LM Reynolds, SH Mercer, RR Goravanahally, MP Kashon, ML Honaker, JC Jackson, MC Cumpston, AM Goldsmith, WT McKinney, W Fedan, JS Battelli, LA Munro, T Bucklew-Moyers, W McKinstry, K Schwegler-Berry, D Friend, S Knepp, AK Smith, SL Sriram, K AF Hubbs, Ann F. Fluharty, Kara L. Edwards, Rebekah J. Barnabei, Jamie L. Grantham, John T. Palmer, Scott M. Kelly, Francine Sargent, Linda M. Reynolds, Steven H. Mercer, Robert R. Goravanahally, Madhusudan P. Kashon, Michael L. Honaker, John C. Jackson, Mark C. Cumpston, Amy M. Goldsmith, William T. McKinney, Walter Fedan, Jeffrey S. Battelli, Lori A. Munro, Tiffany Bucklew-Moyers, Winnie McKinstry, Kimberly Schwegler-Berry, Diane Friend, Sherri Knepp, Alycia K. Smith, Samantha L. Sriram, Krishnan TI Accumulation of Ubiquitin and Sequestosome-1 Implicate Protein Damage in Diacetyl-Induced Cytotoxicity SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID BRONCHIOLITIS OBLITERANS SYNDROME; SPRAGUE-DAWLEY RATS; FLAVORING MANUFACTURING WORKERS; N-ALPHA-ACETYLARGININE; KAPPA-B ACTIVATION; MICROGLIAL PHAGOCYTOSIS; CIGARETTE-SMOKE; LUNG-DISEASES; NOBEL LECTURE; NEURODEGENERATIVE DISEASES AB Inhaled diacetyl vapors are associated with flavorings-related lung disease, a potentially fatal airway disease. The reactive alpha-dicarbonyl group in diacetyl causes protein damage in vitro. Dicarbonyl/L-xylulose reductase (DCXR) metabolizes diacetyl into acetoin, which lacks this alpha-dicarbonyl group. To investigate the hypothesis that flavorings-related lung disease is caused by in vivo protein damage, we correlated diacetyl-induced airway damage in mice with immunofluorescence for markers of protein turnover and autophagy. Western immunoblots identified shifts in ubiquitin pools. Diacetyl inhalation caused dose-dependent increases in bronchial epithelial cells with puncta of both total ubiquitin and K63-ubiquitin, central mediators of protein turnover. This response was greater in Dcxr-knockout mice than in wild-type controls inhaling 200 ppm diacetyl, further implicating the alpha-dicarbonyl group in protein damage. Western immunoblots demonstrated decreased free ubiquitin in airway-enriched fractions. Transmission electron microscopy and colocalization of ubiquitin-positive puncta with lysosomal-associated membrane proteins 1 and 2 and with the multifunctional scaffolding protein sequestosome-1 (SQSTM1/p62) confirmed autophagy. Surprisingly, immunoreactive SQSTM1 also accumulated in the olfactory bulb of the brain. Olfactory bulb SQSTM1 often congregated in activated microglial cells that also contained olfactory marker protein, indicating neuronophagia within the olfactory bulb. This suggests the possibility that SQSTM1 or damaged proteins may be transported from the nose to the brain. Together, these findings strongly implicate widespread protein damage in the etiology of flavorings-related lung disease. C1 [Hubbs, Ann F.; Fluharty, Kara L.; Edwards, Rebekah J.; Barnabei, Jamie L.; Grantham, John T.; Sargent, Linda M.; Reynolds, Steven H.; Mercer, Robert R.; Goravanahally, Madhusudan P.; Kashon, Michael L.; Honaker, John C.; Jackson, Mark C.; Cumpston, Amy M.; Goldsmith, William T.; McKinney, Walter; Fedan, Jeffrey S.; Battelli, Lori A.; Munro, Tiffany; Bucklew-Moyers, Winnie; McKinstry, Kimberly; Schwegler-Berry, Diane; Friend, Sherri; Knepp, Alycia K.; Smith, Samantha L.; Sriram, Krishnan] NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. [Edwards, Rebekah J.; Knepp, Alycia K.; Smith, Samantha L.] West Virginia Univ, Dept Forens & Invest Sci, Morgantown, WV USA. [Grantham, John T.] West Virginia Univ, Sch Med, Morgantown, WV USA. [Goravanahally, Madhusudan P.] West Virginia Univ, Ctr Neurosci, Morgantown, WV USA. [Barnabei, Jamie L.] Univ Georgia, Coll Vet Med, Athens, GA USA. [Palmer, Scott M.; Kelly, Francine] Duke Univ, Sch Med, Durham, NC USA. [Barnabei, Jamie L.] Gryphon Sci, Takoma Pk, MD USA. [Goravanahally, Madhusudan P.] Covance, Madison, WI USA. RP Hubbs, AF (reprint author), NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM ahubbs@cdc.gov FU National Institute for Occupational Safety and Health; Centers for Disease Control and Prevention; Intramural National Occupational Research Agenda [6927ZKQC]; Causes of Flavorings-Related Lung Disease; West Virginia University under a National Institute for Occupational Safety and Health project, Pathophysiology of Popcorn Workers' Lung FX Supported by National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Intramural National Occupational Research Agenda Project 6927ZKQC, Causes of Flavorings-Related Lung Disease. M.P.G. was supported in part by a contract to West Virginia University under a National Institute for Occupational Safety and Health project, Pathophysiology of Popcorn Workers' Lung. NR 104 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD NOV PY 2016 VL 186 IS 11 BP 2887 EP 2908 DI 10.1016/j.ajpath.2016.07.018 PG 22 WC Pathology SC Pathology GA EA9TG UT WOS:000386987000011 PM 27643531 ER PT J AU Sliwa, SA Must, A Perea, FC Boulos, RJ Economos, CD AF Sliwa, Sarah A. Must, Aviva Perea, Flavia C. Boulos, Rebecca J. Economos, Christina D. TI Occupational Physical Activity and Weight-Related Outcomes in Immigrant Mothers SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID CHOICE COPING STRATEGIES; WORK-FAMILY CONFLICT; UNITED-STATES; EMPLOYED PARENTS; MENTAL-HEALTH; LIFE-STYLE; LIVE WELL; US WOMEN; DEPRESSION; OBESITY AB Introduction: New immigrants are likely to be employed in occupations that provide physical activity; however, these positions may place workers at risk for adverse health outcomes. Relationships between occupational physical activity (OPA); weight-related behaviors; obesity; and depression remain underexplored among recent immigrants. Methods: Participants (N=385) were Brazilian, Haitian, and Latino mothers enrolled in a community-based participatory research lifestyle intervention among immigrant mothers (<10 years in U.S.). Baseline BMI was calculated using objectively measured height and weight. Self-reported baseline data included sociodemographics; physical activity (Pregnancy Physical Activity Questionnaire); depressive symptoms (Center for Epidemiological Studies-Depression Scale); and prepared food purchasing frequency. Logistic regression models estimated the odds of obesity (BMI >= 30.0); high depressive symptoms (score >= 16); and purchasing prepared foods (>= 1 times/week) by OPA quartile. Models adjusted for covariates, including household composition, origin group, maternal age, education, household income, and recruitment year (2010, 2011). Data were analyzed in 2013. Results: Employed participants (49%) primarily worked as domestic workers, nursing assistants, and food service staff. In adjusted models, women in the highest OPA quartile versus lowest had 65% lower obesity odds (95% CI=0.16, 0.76) and approximately twice the odds of presenting high depressive symptoms (2.01, 95% CI=1.02, 4.27) and purchasing takeout food (1.85, 95% CI=0.90, 3.90), which was attenuated after adjusting for income and education (unadjusted OR=1.98, 95% CI=1.10, 3.52). Conclusions: OPA contributes to energy expenditure and may protect against obesity among new immigrant mothers; however, it is also associated with high depressive symptoms. Implications for physical and psychosocial well-being are mixed. (C) 2016 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved. C1 [Sliwa, Sarah A.; Boulos, Rebecca J.; Economos, Christina D.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA. [Must, Aviva; Perea, Flavia C.] Tufts Univ, Sch Med, Dept Publ Hlth & Community Med, Boston, MA 02111 USA. [Boulos, Rebecca J.] Univ New England, Sch Community & Populat Hlth, Portland, ME USA. RP Sliwa, SA (reprint author), US Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway, Atlanta, GA 30341 USA. EM ssliwa@cdc.gov FU NIH [5R01HD057841]; New Balance Foundation; Boston Nutrition Obesity Research Center [DK46200] FX NIH provided funding for the parent study [PI Economos, 5R01HD057841]. Sarah Sliwa's efforts were supported by a doctoral fellowship from the New Balance Foundation. Aviva Must's efforts on this study were supported, in part, through the Boston Nutrition Obesity Research Center (DK46200). NR 62 TC 0 Z9 0 U1 11 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2016 VL 51 IS 5 BP 637 EP 646 DI 10.1016/j.amepre.2016.04.017 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7CG UT WOS:000386785100006 PM 27291074 ER PT J AU Sumner, SA Maenner, MJ Socias, CM Mercy, JA Silverman, P Medinilla, SP Martin, SS Xu, LK Hillis, SD AF Sumner, Steven A. Maenner, Matthew J. Socias, Christina M. Mercy, James A. Silverman, Paul Medinilla, Sandra P. Martin, Steven S. Xu, Likang Hillis, Susan D. TI Sentinel Events Preceding Youth Firearm Violence An Investigation of Administrative Data in Delaware SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID CHILD MALTREATMENT; UNITED-STATES; FOLLOW-UP; RISK; TRIAL; HOSPITALIZATION; POPULATION; PREVENTION; BEHAVIOR; COHORT AB Introduction: Accurately identifying youth at highest risk of firearm violence involvement could permit delivery of focused, comprehensive prevention services. This study explored whether readily available city and state administrative data covering life events before youth firearm violence could elucidate patterns preceding such violence. Methods: Four hundred twenty-one individuals arrested for homicide, attempted homicide, aggravated assault, or robbery with a firearm committed in Wilmington, Delaware, from January 1, 2009 to May 21, 2014, were matched 1: 3 to 1,259 Wilmington resident controls on birth year and sex. In 2015, descriptive statistics and a conditional logistic regression model using Delaware healthcare, child welfare, juvenile services, labor, and education administrative data examined associations between preceding life events and subsequent firearm violence. Results: In a multivariable adjusted model, experiencing a prior gunshot wound injury (AOR=11.4, 95% CI=2.7, 48.1) and being subject to community probation (AOR=13.2, 95% CI=5.7, 30.3) were associated with the highest risk of subsequent firearm violence perpetration, though multiple other sentinel events were informative. The mean number of sentinel events experienced by youth committing firearm violence was 13.0 versus 1.9 among controls (p<0.0001). Within the sample, 84.1% of youth experiencing a sentinel event in all five studied domains ultimately committed firearm violence. Conclusions: Youth who commit firearm violence have preceding patterns of life events that markedly differ from youth not involved in firearm violence. This information is readily available from administrative data, demonstrating the potential of data sharing across city and state institutions to focus prevention strategies on those at greatest risk. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Sumner, Steven A.; Maenner, Matthew J.; Socias, Christina M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Sumner, Steven A.; Mercy, James A.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Maenner, Matthew J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Socias, Christina M.] NIOSH, Div Safety Res, Morgantown, WV 26505 USA. [Silverman, Paul] Delaware Div Publ Hlth, Delaware, OH USA. [Medinilla, Sandra P.] Christiana Care Hlth Syst, Trauma Dept, Newark, DE USA. [Martin, Steven S.] Univ Delaware, Ctr Drug & Hlth Studies, Newark, DE USA. [Xu, Likang] Ctr Dis Control & Prevent, Div Anal Res & Practice Integrat, Atlanta, GA USA. [Hillis, Susan D.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Sumner, SA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, 4770 Buford Highway NE,Mailstop F-63, Atlanta, GA 30341 USA. EM hvo5@cdc.gov FU National Institute of General Medical Sciences of NIH [U54-GM104941] FX Dr. Martin's work was supported in part by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of NIH under grant number U54-GM104941 (Principal Investigator: Binder-Macleod). No other financial disclosures were reported by the authors of this paper. NR 32 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2016 VL 51 IS 5 BP 647 EP 655 DI 10.1016/j.amepre.2016.08.002 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7CG UT WOS:000386785100007 ER PT J AU Nguyen, KH Gomez, Y Homa, DM King, BA AF Nguyen, Kimberly H. Gomez, Yessica Homa, David M. King, Brian A. TI Tobacco Use, Secondhand Smoke, and Smoke-Free Home Rules in Multiunit Housing SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID FREE POLICIES; UNITED-STATES; EXPOSURE; ATTITUDES; NONSMOKERS; EXPERIENCES; POPULATION; RESIDENTS; CESSATION; ADULTS AB Introduction: Multiunit housing (MUH) residents are particularly susceptible to involuntary secondhand smoke (SHS) exposure in their home, which can enter their living units from nearby units and shared areas where smoking occurs. To date, no study has assessed non-cigarette tobacco use among MUH residents. This study assessed the prevalence and sociodemographic correlates of tobacco use (combustible, noncombustible, any tobacco use including electronic cigarettes), smoke-free home rules, and SHS incursions among U.S. MUH residents. Methods: Data came from the 2013-2014 National Adult Tobacco Survey, a telephone survey of U.S. adults aged >= 18 years. Analyses were conducted in 2015. Prevalence of current tobacco use and smoke-free home rules were assessed overall and by sociodemographics, stratified by housing type (single family versus MUH). Prevalence and adjusted odds of SHS incursions among MUH residents with smoke-free home rules were assessed. Results: Tobacco use was higher among adults living in MUH (24.7%) than those in single-family housing (18.9%, p < 0.05). Smoke-free home rules were higher among adults living in single-family housing (86.7%) than those in MUH (80.9%, p < 0.05). Among MUH residents with smoke-free homes, 34.4% experienced SHS incursions. Adjusted odds of SHS incursions were greater among women, younger adults, non-Hispanic blacks, Hispanics, and those with lower income. Conclusions: One quarter of MUH residents use tobacco, and one third of MUH residents with smoke-free rules experience SHS incursions. Interventions are warranted to promote tobacco cessation and smoke-free building policies to protect all MUH residents, employees, and visitors from the dangers of tobacco use and SHS. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Nguyen, Kimberly H.; Gomez, Yessica; Homa, David M.; King, Brian A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F-79, Atlanta, GA 30341 USA. RP Nguyen, KH (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F-79, Atlanta, GA 30341 USA. EM uxp1@cdc.gov NR 34 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2016 VL 51 IS 5 BP 682 EP 692 DI 10.1016/j.amepre.2016.05.009 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7CG UT WOS:000386785100011 PM 27423656 ER PT J AU Tansil, KA Esser, MB Sandhu, P Reynolds, JA Elder, RW Williamson, RS Chattopadhyay, SK Bohm, MK Brewer, RD McKnight-Eily, LR Hungerford, DW Toomey, TL Hingson, RW Fielding, JE AF Tansil, Kristin A. Esser, Marissa B. Sandhu, Paramjit Reynolds, Jeffrey A. Elder, Randy W. Williamson, Rebecca S. Chattopadhyay, Sajal K. Bohm, Michele K. Brewer, Robert D. McKnight-Eily, Lela R. Hungerford, Daniel W. Toomey, Traci L. Hingson, Ralph W. Fielding, Jonathan E. CA Community Preventive Serv Task For TI Alcohol Electronic Screening and Brief Intervention A Community Guide Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; INTERACTIVE VOICE RESPONSE; TELEPHONE BRIEF INTERVENTION; CONTROLLED CLINICAL-TRIAL; IDENTIFICATION TEST AUDIT; REDUCING HEAVY DRINKING; WEB-BASED FEEDBACK; UNIVERSITY-STUDENTS; PRIMARY-CARE; PROBLEM DRINKERS AB Context: Excessive drinking is responsible for one in ten deaths among working-age adults in the U.S. annually. Alcohol screening and brief intervention is an effective but underutilized intervention for reducing excessive drinking among adults. Electronic screening and brief intervention (e-SBI) uses electronic devices to deliver key elements of alcohol screening and brief intervention, with the potential to expand population reach. Evidence acquisition: Using Community Guide methods, a systematic review of the scientific literature on the effectiveness of e-SBI for reducing excessive alcohol consumption and related harms was conducted. The search covered studies published from 1967 to October 2011. A total of 31 studies with 36 study arms met quality criteria and were included in the review. Analyses were conducted in 2012. Evidence synthesis: Twenty-four studies (28 study arms) provided results for excessive drinkers only and seven studies (eight study arms) reported results for all drinkers. Nearly all studies found that e-SBI reduced excessive alcohol consumption and related harms: nine study arms reported a median 23.9% reduction in binge-drinking intensity (maximum drinks/binge episode) and nine study arms reported a median 16.5% reduction in binge-drinking frequency. Reductions in drinking measures were sustained for up to 12 months. Conclusions: According to Community Guide rules of evidence, e-SBI is an effective method for reducing excessive alcohol consumption and related harms among intervention participants. Implementation of e-SBI could complement population-level strategies previously recommended by the Community Preventive Services Task Force for reducing excessive drinking (e.g., increasing alcohol taxes and regulating alcohol outlet density). Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Tansil, Kristin A.; Esser, Marissa B.; Sandhu, Paramjit; Reynolds, Jeffrey A.; Elder, Randy W.; Williamson, Rebecca S.; Chattopadhyay, Sajal K.; Bohm, Michele K.] Ctr Dis Control & Prevent CDC, Community Guide Branch, Div Publ Hlth Informat Disseminat, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Brewer, Robert D.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [McKnight-Eily, Lela R.; Hungerford, Daniel W.] CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Toomey, Traci L.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Hingson, Ralph W.] NIAAA, Bethesda, MD USA. [Fielding, Jonathan E.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. RP Elder, RW (reprint author), Ctr Dis Control & Prevent, Community Guide Branch, Div Publ Hlth Informat Disseminat, Ctr Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd,MS E-69, Atlanta, GA 30329 USA. EM rfe3@cdc.gov FU Intramural CDC HHS [CC999999] NR 77 TC 0 Z9 0 U1 7 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2016 VL 51 IS 5 BP 801 EP 811 DI 10.1016/j.amepre.2016.04.013 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7CG UT WOS:000386785100023 PM 27745678 ER PT J AU Elder, RW AF Elder, Randy W. CA Community Preventive Serv Task For TI Alcohol Electronic Screening and Brief Intervention Recommendation of the Community Preventive Services Task Force SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material C1 [Elder, Randy W.] Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-69, Atlanta, GA 30329 USA. RP Elder, RW (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-69, Atlanta, GA 30329 USA. EM rfe3@cdc.gov NR 2 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2016 VL 51 IS 5 BP 812 EP 813 DI 10.1016/j.amepre.2016.04.012 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7CG UT WOS:000386785100024 ER PT J AU Austin, AE Vladutiu, CJ Jones-Vessey, KA Norwood, TS Proescholdbell, SK Menard, MK AF Austin, Anna E. Vladutiu, Catherine J. Jones-Vessey, Kathleen A. Norwood, Tammy S. Proescholdbell, Scott K. Menard, M. Kathryn TI Improved Ascertainment of Pregnancy-Associated Suicides and Homicides in North Carolina SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID DEATH-REPORTING-SYSTEM; UNITED-STATES; MATERNAL MORTALITY; POSTPARTUM WOMEN; HEALTH AB Introduction: Injuries, including those resulting from violence, are a leading cause of death during pregnancy and the postpartum period. North Carolina, along with other states, has implemented surveillance systems to improve reporting of maternal deaths, but their ability to capture violent deaths is unknown. The purpose of this study was to quantify the improvement in ascertainment of pregnancy-associated suicides and homicides by linking data from the North Carolina Violent Death Reporting System (NC-VDRS) to traditional maternal mortality surveillance files. Methods: Enhanced case ascertainment was used to identify suicides and homicides that occurred during or up to 1 year after pregnancy from 2005 to 2011 in North Carolina. NC-VDRS data were linked to traditional maternal mortality surveillance files (i.e., death certificates with any mention of pregnancy or matched to a live birth or fetal death record and hospital discharge records for women who died in the hospital with a pregnancy-related diagnosis). Mortality ratios were calculated by case ascertainment method. Analyses were conducted in 2015. Results: A total of 29 suicides and 55 homicides were identified among pregnant and postpartum women through enhanced case ascertainment as compared with 20 and 34, respectively, from traditional case ascertainment. Linkage to NC-VDRS captured 55.6% more pregnancy-associated violent deaths than traditional surveillance alone, resulting in higher mortality ratios for suicide (2.3 vs 3.3 deaths per 100,000 live births) and homicide (3.9 vs 6.2 deaths per 100,000 live births). Conclusions: Linking traditional maternal mortality files to NC-VDRS provided a notable improvement in ascertainment of pregnancy-associated violent deaths. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine. C1 [Austin, Anna E.] Ctr Dis Control & Prevent, CSTE Appl Epidemiol Fellowship, Atlanta, GA USA. [Austin, Anna E.; Norwood, Tammy S.; Proescholdbell, Scott K.] North Carolina Dept Hlth & Human Serv, Injury & Violence Prevent Branch, Div Publ Hlth, Raleigh, NC USA. [Vladutiu, Catherine J.; Menard, M. Kathryn] Univ N Carolina, Sch Med, Dept Obstet & Gynecol, Chapel Hill, NC USA. [Vladutiu, Catherine J.] Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, Rockville, MD USA. [Jones-Vessey, Kathleen A.] North Carolina State Ctr Hlth Stat, Div Publ Hlth, Raleigh, NC USA. RP Vladutiu, CJ (reprint author), HRSA Maternal & Child Hlth Bur, Off Epidemiol & Res, Div Epidemiol, 5600 Fishers Lane, Rockville, MD 20857 USA. EM cvladutiu@hrsa.gov FU Centers for Disease Control and Prevention FX Publication of this article was supported by the Centers for Disease Control and Prevention. The findings and conclusions in this article are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention, Health Resourcees and Services Administration, or the U. S. DHHS. NR 22 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2016 VL 51 IS 5 SU 3 BP S234 EP S240 DI 10.1016/j.amepre.2016.04.023 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7CB UT WOS:000386784600008 PM 27745612 ER PT J AU Blair, JM Fowler, KA Betz, CJ Baumgardner, JL AF Blair, Janet M. Fowler, Katherine A. Betz, Carter J. Baumgardner, Jason L. TI Occupational Homicides of Law Enforcement Officers, 2003-2013 Data From the National Violent Death Reporting System SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID POLICE; SURVEILLANCE; INJURIES; US AB Introduction: Law enforcement officers (LEOs) in the U.S. are at an increased risk for homicide. The purpose of this study is to describe the characteristics of homicides of LEOs in 17 U.S. states participating in the National Violent Death Reporting System. This active surveillance system uses data from death certificates, coroner/medical examiner reports, and law enforcement reports. Methods: This study used quantitative and qualitative methods to analyze National Violent Death Reporting System data for 2003-2013. Deaths of LEOs feloniously killed in the line of duty were selected for analysis. LEO homicides and the circumstances preceding or occurring during the incident were characterized. Analyses were conducted October 2015-June 2016. Results: A total of 128 officer homicides from 121 incidents were identified. Most (93.7%) LEO victims were male, 60.9% were aged 30-49 years (average age, 40.9 years). Approximately 21.9% of LEOs were killed during an ambush, and 19.5% were killed during traffic stops or pursuits. Of the 14.1% of LEOs killed responding to domestic disturbances, most disturbances were intimate partner violence related. More than half (57.0%) of homicides were precipitated by another crime, and of these, 71.2% involved crimes in progress. Most suspects were male. Ninety-one percent of homicides of LEOs were committed with a firearm. Conclusions: This information is critical to help describe encounter situations faced by LEOs. The results of this study can be used to help educate and train LEOs on hazards, inform prevention efforts designed to promote LEO safety, and prevent homicide among this population. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine. C1 [Blair, Janet M.; Fowler, Katherine A.; Betz, Carter J.; Baumgardner, Jason L.] Ctr Dis Control & Prevent, Div Violence Prevent, 4770 Buford Highway NE,MS F63, Atlanta, GA 30341 USA. RP Blair, JM (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, 4770 Buford Highway NE,MS F63, Atlanta, GA 30341 USA. EM jblair@cdc.gov FU Centers for Disease Control and Prevention FX Publication of this article was supported by the Centers for Disease Control and Prevention. The findings and conclusions in this article are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 45 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2016 VL 51 IS 5 SU 3 BP S188 EP S196 DI 10.1016/j.amepre.2016.08.019 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7CB UT WOS:000386784600003 PM 27745607 ER PT J AU Crosby, AE Mercy, JA Houry, D AF Crosby, Alex E. Mercy, James A. Houry, Debra TI The National Violent Death Reporting System Past, Present, and Future SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID PRECIPITATING CIRCUMSTANCES; UNITED-STATES; HOMICIDE; SUICIDE C1 [Crosby, Alex E.; Mercy, James A.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS F-63, Atlanta, GA 30341 USA. [Houry, Debra] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Crosby, AE (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS F-63, Atlanta, GA 30341 USA. EM aec1@cdc.gov NR 21 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2016 VL 51 IS 5 SU 3 BP S169 EP S172 DI 10.1016/j.amepre.2016.07.022 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7CB UT WOS:000386784600001 PM 27745605 ER PT J AU DeGue, S Fowler, KA Calkins, C AF DeGue, Sarah Fowler, Katherine A. Calkins, Cynthia TI Deaths Due to Use of Lethal Force by Law Enforcement Findings From the National Violent Death Reporting System, 17 US States, 2009-2012 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SEVERE MENTAL-ILLNESS; POLICE OFFICERS; LEGAL INTERVENTION; PUBLIC-HEALTH; UNITED-STATES; DEADLY FORCE; PEOPLE; ENCOUNTERS; ILL; HOMICIDES AB Introduction: Several high-profile cases in the U.S. have drawn public attention to the use of lethal force by law enforcement (LE), yet research on such fatalities is limited. Using data from a public health surveillance system, this study examined the characteristics and circumstances of these violent deaths to inform prevention. Methods: All fatalities (N=812) resulting from use of lethal force by on-duty LE from 2009 to 2012 in 17 U.S. states were examined using National Violent Death Reporting System data. Case narratives were coded for additional incident circumstances. Results: Victims were majority white (52%) but disproportionately black (32%) with a fatality rate 2.8 times higher among blacks than whites. Most victims were reported to be armed (83%); however, black victims were more likely to be unarmed (14.8%) than white (9.4%) or Hispanic (5.8%) victims. Fatality rates among military veterans/active duty service members were 1.4 times greater than among their civilian counterparts. Four case subtypes were examined based on themes that emerged in incident narratives: about 22% of cases were mental health related; 18% were suspected "suicide by cop" incidents, with white victims more likely than black or Hispanic victims to die in these circumstances; 14% involved intimate partner violence; and about 6% were unintentional deaths due to LE action. Another 53% of cases were unclassified and did not fall into a coded subtype. Regression analyses identified victim and incident characteristics associated with each case subtype and unclassified cases. Conclusions: Knowledge about circumstances of deaths due to the use of lethal force can inform the development of prevention strategies, improve risk assessment, and modify LE response to increase the safety of communities and officers and prevent fatalities associated with LE intervention. (C) 2016 Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine. C1 [DeGue, Sarah; Fowler, Katherine A.] Ctr Dis Control & Prevent, Div Violence Prevent, 4770 Buford Highway NE,MS-F64, Atlanta, GA 30341 USA. [Calkins, Cynthia] CUNY, John Jay Coll Criminal Justice, Dept Psychol, New York, NY 10021 USA. RP DeGue, S (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, 4770 Buford Highway NE,MS-F64, Atlanta, GA 30341 USA. EM sdegue@cdc.gov FU Centers for Disease Control and Prevention FX Publication of this article was supported by the Centers for Disease Control and Prevention. The findings and conclusions in this article are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 78 TC 1 Z9 1 U1 15 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2016 VL 51 IS 5 SU 3 BP S173 EP S187 DI 10.1016/j.amepre.2016.08.027 PG 15 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7CB UT WOS:000386784600002 PM 27745606 ER PT J AU Logan, JE Fowler, KA Patel, NP Holland, KM AF Logan, Joseph E. Fowler, Katherine A. Patel, Nimeshkumar P. Holland, Kristin M. TI Suicide Among Military Personnel and Veterans Aged 18-35 Years by County-16 States SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SERVICEMEMBERS ARMY STARRS; RANDOMIZED CLINICAL-TRIAL; RISK-FACTORS; US ARMY; RESILIENCE; SOLDIERS; SAMPLE; INTERVENTION; PREVALENCE; MORTALITY AB Introduction: Suicide among military personnel and young Veterans remains a health concern. This study examined stateside distribution of suicides by U.S. county to help focus prevention efforts. Methods: Using 2005-2012 National Violent Death Reporting System data from 16 states (963 counties, or county-equivalent entities), this study mapped the county-level distribution of suicides among current military and Veteran decedents aged 18-35 years. This study also compared incident circumstances of death between decedents in high-density counties (i.e., counties with the highest proportion of deaths) versus those in medium/low-density counties to better understand the precipitators of suicide in counties most affected. Last, this study identified potential military and Veteran Health Administration intervention sites. All analyses were conducted in 2015. Results: Within the National Violent Death Reporting System participating states, an estimated 262 (33%) current military suicides occurred in just ten (1.0%) counties, and 391 (33%) Veteran suicides occurred in 33 (3.4%) counties. Mental health and intimate partner problems were common precipitating circumstances, and some circumstances differed between cases in high-versus those in medium/low-density counties. Multiple potential intervention sites were identified in high-density counties. Conclusions: These findings suggest that military and Veteran suicides are concentrated in a small number of counties. Increased efforts at these locales might be beneficial. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine. C1 [Logan, Joseph E.; Fowler, Katherine A.; Holland, Kristin M.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, 4770 Buford Highway,MS-F63, Atlanta, GA 30341 USA. [Patel, Nimeshkumar P.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Anal Res & Practice Integrat, Atlanta, GA USA. RP Logan, JE (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, 4770 Buford Highway,MS-F63, Atlanta, GA 30341 USA. EM ffa3@cdc.gov FU Centers for Disease Control and Prevention FX Publication of this article was supported by the Centers for Disease Control and Prevention. The findings and conclusions in this article are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 47 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2016 VL 51 IS 5 SU 3 BP S197 EP S208 DI 10.1016/j.amepre.2016.06.001 PG 12 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7CB UT WOS:000386784600004 PM 27745608 ER PT J AU Stone, DM Holland, KM Schiff, LB McIntosh, WL AF Stone, Deborah M. Holland, Kristin M. Schiff, Lara B. McIntosh, Wendy LiKamWa TI Mixed Methods Analysis of Sex Differences in Life Stressors of Middle-Aged Suicides SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID DEATH REPORTING SYSTEM; PSYCHOLOGICAL AUTOPSY; RISK-FACTORS; PSYCHIATRIC-DISORDER; ADOLESCENT SUICIDE; PREVENTION PROGRAM; COMPLETED SUICIDE; MENTAL-DISORDERS; OLDER-PEOPLE; HONG-KONG AB Introduction: Between 1999 and 2013, rates of suicide in mid-life increased more than 30%. The purpose of this study is to examine life stressors impacting middle-aged suicide, to determine whether these stressors vary by sex, and to explore their co-occurrence. Methods: A random sample of 315 men and 315 women aged 35-64 years was selected from 17 states implementing the National Violent Death Reporting System from its inception in 2003 to 2011. Data collection took place between 2003 and 2011 and analysis occurred in 2015. Analysis included coding circumstances of death noted in the law enforcement and coroner/medical examiner reports using an investigator-designed coding instrument. Using the most commonly cited life stressors as a basis, thematic analyses were conducted for cases. Quantitative comparisons of the most common circumstances by sex were calculated via multivariable logistic regression. Results: The five most common life stressors of suicide included intimate partner, job/financial, health, family, and criminal/legal problems. In adjusted analyses, job/financial problems and criminal/legal problems were more common among men, whereas health and family problems were more common among women. Men and women had similar rates of intimate partner problems. Life stressors also co-occurred, as found per qualitative and quantitative analyses. Conclusions: Men and women in mid-life have both common and unique circumstances preceding suicide. Prevention strategies that consider these circumstances and co-occurring circumstances are warranted. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine. C1 [Stone, Deborah M.; Holland, Kristin M.; McIntosh, Wendy LiKamWa] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS F-64, Atlanta, GA 30341 USA. [Schiff, Lara B.] Univ Washington, Div Hematol, Seattle, WA 98195 USA. RP Stone, DM (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS F-64, Atlanta, GA 30341 USA. EM dstone3@cdc.gov FU Centers for Disease Control and Prevention FX Publication of this article was supported by the Centers for Disease Control and Prevention. The findings and conclusions in this article are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 41 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2016 VL 51 IS 5 SU 3 BP S209 EP S218 DI 10.1016/j.amepre.2016.07.021 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7CB UT WOS:000386784600005 PM 27745609 ER PT J AU Zhang, L Xia, Y Xia, BY Nicodemus, KJ McGuffey, J McGahee, E Blount, B Wang, LQ AF Zhang, Li Xia, Yang Xia, Baoyun Nicodemus, Keegan J. McGuffey, James McGahee, Ernest Blount, Benjamin Wang, Lanqing TI High-throughput and sensitive analysis of urinary heterocyclic aromatic amines using isotope-dilution liquid chromatography-tandem mass spectrometry and robotic sample preparation system SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY LA English DT Article DE Heterocyclic aromatic amines; Urine; Automation; High throughput; LC-MS/MS ID CIGARETTE-SMOKE CONDENSATE; DNA ADDUCT FORMATION; COLORECTAL-CANCER; COOKED FOODS; METABOLISM; PHIP; MEAT; CONSUMPTION; CARBOLINES; EXTRACTION AB Heterocyclic aromatic amines (HCAA) are listed by the US Food and Drug Administration (FDA) as harmful or potentially harmful constituents of tobacco smoke. However, quantifying HCAA exposure is challenging. In this study, we developed a sensitive, precise, and accurate isotope dilution, liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to quantify urinary HCAAs in smokers and nonsmokers. The high-throughput robotic sample preparation system could handle a throughput of over 300 samples per day, while maintaining intra-day and inter-day imprecision and bias aecurrency sign10 %. The limits of detection of carcinogenic HCAAs ranged from 0.31 to 0.83 pg/mL. The validated method was applied to measure HCAAs in urine collected from smokers and non-smokers. This sensitive and efficient analytical method is ideal to support large-scale biomonitoring studies of HCAA exposure. C1 [Zhang, Li; Xia, Yang; Xia, Baoyun; Nicodemus, Keegan J.; McGuffey, James; McGahee, Ernest; Blount, Benjamin; Wang, Lanqing] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway Mail Stop F47, Atlanta, GA 30341 USA. [Zhang, Li] Battelle Mem Inst, 2987 Clairmont Rd, Atlanta, GA 30329 USA. RP Zhang, L; Xia, Y (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway Mail Stop F47, Atlanta, GA 30341 USA.; Zhang, L (reprint author), Battelle Mem Inst, 2987 Clairmont Rd, Atlanta, GA 30329 USA. EM lzhang6@cdc.gov; yxia@cdc.gov FU Center for Tobacco Products, Food and Drug Administration FX The authors would like to thank the Center for Tobacco Products, Food and Drug Administration, for providing funds for this project. We also thank Tonya Guillot, Katie Wozniak, Dana Freeman, Jason Terranova, Binnian Wei, John Lee, Justin Brown, and Christina Brosius for their suggestions and support during this study. NR 30 TC 0 Z9 0 U1 11 U2 11 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1618-2642 EI 1618-2650 J9 ANAL BIOANAL CHEM JI Anal. Bioanal. Chem. PD NOV PY 2016 VL 408 IS 28 BP 8149 EP 8161 DI 10.1007/s00216-016-9917-x PG 13 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA EA5VS UT WOS:000386693000027 PM 27687186 ER PT J AU Nakamura, M Iso, H Kitamura, A Imano, H Noda, H Kiyama, M Sato, S Yamagishi, K Nishimura, K Nakai, M Vesper, HW Teramoto, T Miyamoto, Y AF Nakamura, Masakazu Iso, Hiroyasu Kitamura, Akihiko Imano, Hironori Noda, Hiroyuki Kiyama, Masahiko Sato, Shinichi Yamagishi, Kazumasa Nishimura, Kunihiro Nakai, Michikazu Vesper, Hubert W. Teramoto, Tamio Miyamoto, Yoshihiro TI Comparison between the triglycerides standardization of routine methods used in Japan and the chromotropic acid reference measurement procedure used by the CDC Lipid Standardization Programme SO ANNALS OF CLINICAL BIOCHEMISTRY LA English DT Article DE Centers for Disease Control and Prevention standardization; triglycerides; fluorometric method; enzymatic method; chromotropic acid reference measurement procedure; GC-IDMS ID ISCHEMIC-HEART-DISEASE; CHROMATOGRAPHY MASS-SPECTROMETRY; NONFASTING TRIGLYCERIDES; SERUM TRIGLYCERIDES; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; TOTAL GLYCERIDES; RISK-FACTOR; WOMEN; MEN AB Background The US Centers for Disease Control and Prevention ensured adequate performance of the routine triglycerides methods used in Japan by a chromotropic acid reference measurement procedure used by the Centers for Disease Control and Prevention lipid standardization programme as a reference point. We examined standardized data to clarify the performance of routine triglycerides methods. Methods The two routine triglycerides methods were the fluorometric method of Kessler and Lederer and the enzymatic method. The methods were standardized using 495 Centers for Disease Control and Prevention reference pools with 98 different concentrations ranging between 0.37 and 5.15mmol/L in 141 survey runs. The triglycerides criteria for laboratories which perform triglycerides analyses are used: accuracy, as bias 5% from the Centers for Disease Control and Prevention reference value and precision, as measured by CV, 5%. Results The correlation of the bias of both methods to the Centers for Disease Control and Prevention reference method was: y (%bias)=0.516x(Centers for Disease Control and Prevention reference value) -1.292 (n=495, R-2=0.018). Triglycerides bias at medical decision points of 1.13, 1.69 and 2.26mmol/L was -0.71%, -0.42% and -0.13%, respectively. For the combined precision, the equation y (CV)=-0.398x(triglycerides value)+1.797 (n=495, R-2=0.081) was used. Precision was 1.35%, 1.12% and 0.90%, respectively. It was shown that triglycerides measurements at Osaka were stable for 36 years. Conclusions The epidemiologic laboratory in Japan met acceptable accuracy goals for 88.7% of all samples, and met acceptable precision goals for 97.8% of all samples measured through the Centers for Disease Control and Prevention lipid standardization programme and demonstrated stable results for an extended period of time. C1 [Nakamura, Masakazu] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Lipid Reference Lab, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan. [Iso, Hiroyasu; Kitamura, Akihiko; Imano, Hironori; Noda, Hiroyuki] Osaka Univ, Grad Sch Med, Dept Social Med, Publ Hlth, Osaka, Japan. [Kiyama, Masahiko] Osaka Ctr Canc & Cardiovasc Dis Prevent, Osaka, Japan. [Sato, Shinichi] Osaka Prefecture Univ, Inst Publ Nutr Practice, Chiba Prefectural Inst Publ Hlth, Chiba, Japan. [Yamagishi, Kazumasa] Univ Tsukuba, Dept Publ Hlth Med, Fac Med, Ibaraki, Japan. [Nishimura, Kunihiro; Nakai, Michikazu] Natl Cerebral & Cardiovasc Ctr, Ctr Cerebral & Cardiovasc Dis Informat, Dept Stat & Data Anal, Suita, Osaka, Japan. [Vesper, Hubert W.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Teramoto, Tamio] Teikyo Univ, Teikyo Acad Res Ctr, Tokyo, Japan. [Miyamoto, Yoshihiro] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, Japan. RP Nakamura, M (reprint author), Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Lipid Reference Lab, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan. EM nakamura.masakazu.hp@ncvc.go.jp OI yamagishi, kazumasa/0000-0003-3301-5519 FU Ministry of Health, Labour, and Welfare of Japan FX This work was supported by 'Health and Labor Science Research Grants, Comprehensive Research on Life-Style Related Diseases including Cardiovascular Diseases and Diabetes Mellitus. 015' from the Ministry of Health, Labour, and Welfare of Japan. NR 40 TC 0 Z9 0 U1 4 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0004-5632 EI 1758-1001 J9 ANN CLIN BIOCHEM JI Ann. Clin. Biochem. PD NOV PY 2016 VL 53 IS 6 BP 632 EP 639 DI 10.1177/0004563215624461 PG 8 WC Medical Laboratory Technology SC Medical Laboratory Technology GA DZ3JW UT WOS:000385743900002 PM 26680645 ER PT J AU Harris, AM Hicks, LA Qaseem, A AF Harris, Aaron M. Hicks, Lauri A. Qaseem, Amir TI Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Harris, Aaron M.; Hicks, Lauri A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA USA. RP Harris, AM (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 1 PY 2016 VL 165 IS 9 BP 674 EP 674 DI 10.7326/L16-0284 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA EA8SJ UT WOS:000386908600015 PM 27802463 ER PT J AU Girard, V Mailler, S Welker, M Arsac, M Celliere, B Cotte-Pattat, PJ Chatellier, S Durand, G Beni, AM Schrenzel, J Miller, E Dussoulier, R Dunne, WM Butler-Wu, S Saubolle, MA Sussland, D Bell, M van Belkum, A Deol, P AF Girard, Victoria Mailler, Sandrine Welker, Martin Arsac, Maud Celliere, Beatrice Cotte-Pattat, Pierre-Jean Chatellier, Sonia Durand, Geraldine Beni, Anne-Marie Schrenzel, Jacques Miller, Elizabeth Dussoulier, Rahima Dunne, W. Michael, Jr. Butler-Wu, Susan Saubolle, Michael A. Sussland, Den Bell, Melissa van Belkum, Alex Deol, Parampal TI Identification of mycobacterium spp. and nocardia spp. from solid and liquid cultures by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE Mycobacteria; Nocardiae; MALDI TOE MS; Solid and liquid cultures ID NONTUBERCULOUS MYCOBACTERIA; VITEK MS; MULTICENTER EVALUATION; CLINICAL MICROBIOLOGY; RAPID IDENTIFICATION; INFECTIONS; BACTERIA; SYSTEM; REPRODUCIBILITY; INACTIVATION AB Identification of microorganisms by MALDI-TOF MS has been widely accepted in clinical microbiology. However, for Mycobacterium spp. and Nocardia spp. such identification has not yet reached the optimal level of routine testing. Here we describe the development of an identification tool for 49 and 15 species of Mycobacterium spp. and Nocardia spp., respectively. During database construction, a number of ambiguous reference identifications were revealed and corrected via molecular analyses. Eventually, more than 2000 individual mass spectra acquired from 494 strains were included in a reference database and subjected to bio-statistical analyses. This led to correct species identification and correct combination of species into several complexes or groups, such as the Mycobacterium tuberculosis complex. With the Advanced Spectrum Classifier algorithm, class-specific bin weights were determined and tested by cross-validation experiments with good results. When challenged with independent isolates, overall identification performance was 90% for identification of Mycobacterium spp. and 88% for Nocardia spp. However, for a number of Mycobacterium sp. isolates, no identification could be achieved and in most cases, this could be attributed to the production of polymers that masked the species-specific protein peak patterns. For the species where >20 isolates were tested, correct identification reached 95% or higher. With the current spectral database, the identification of Mycobacterium spp. and Nocardia spp. by MALDI-TOF MS can be performed in routine clinical diagnostics although in some complicated cases verification by sequencing remains mandatory. (C) 2016 Elsevier Inc. All rights reserved. C1 [Girard, Victoria; Mailler, Sandrine; Welker, Martin; Arsac, Maud; Celliere, Beatrice; Cotte-Pattat, Pierre-Jean; Chatellier, Sonia; Durand, Geraldine; van Belkum, Alex] BioMerieux, Microbiol R&D, Route Port Michaud, F-38390 La Balme, Les Grottes, France. [Beni, Anne-Marie; Schrenzel, Jacques] Hop Univ Geneve, Lab Bacteriol, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland. [Miller, Elizabeth; Dussoulier, Rahima; Dunne, W. Michael, Jr.; Deol, Parampal] BioMerieux Inc, Microbiol R&D, 100 Rodolphe St, Durham, NC 27712 USA. [Butler-Wu, Susan] Univ Washington, Clin Microbiol Lab, 1959 NE Pacific St, Seattle, WA 98195 USA. [Butler-Wu, Susan] Univ Southern Calif, Keck Sch Med, 1975 Zonal Ave, Los Angeles, CA 90033 USA. [Saubolle, Michael A.; Sussland, Den] Banner Univ, Med Ctr, 1111 E McDowell Rd, Phoenix, AZ 85006 USA. [Bell, Melissa] Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30329 USA. RP van Belkum, A (reprint author), BioMerieux, Microbiol R&D, Route Port Michaud, F-38390 La Balme, Les Grottes, France. EM alex.vanbelkum@biomerieux.com NR 44 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 EI 1879-0070 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD NOV PY 2016 VL 86 IS 3 BP 277 EP 283 DI 10.1016/j.diagmicrobio.2016.07.027 PG 7 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA EA3WJ UT WOS:000386539700008 PM 27567285 ER PT J AU Brennan, MB Herwaldt, BL Kazmierczak, JJ Weiss, JW Klein, CL Leith, CP He, R Oberley, MJ Tonnetti, L Wilkins, PP Gauthier, GM AF Brennan, Meghan B. Herwaldt, Barbara L. Kazmierczak, James J. Weiss, John W. Klein, Christina L. Leith, Catherine P. He, Rong Oberley, Matthew J. Tonnetti, Laura Wilkins, Patricia P. Gauthier, Gregory M. TI Transmission of Babesia microti Parasites by Solid Organ Transplantation SO EMERGING INFECTIOUS DISEASES LA English DT Article ID TRANSFUSION-ASSOCIATED BABESIOSIS; HUMAN GRANULOCYTIC ANAPLASMOSIS; WEST-NILE-VIRUS; IMMUNOCOMPROMISED PATIENTS; HEMOPHAGOCYTIC SYNDROME; BLOOD-TRANSFUSION; LYME-DISEASE; INFECTION; ATOVAQUONE; AZITHROMYCIN AB Babesia microti, an intraerythrocytic parasite, is tickborne in nature. In contrast to transmission by blood transfusion, which has been well documented, transmission associated with solid organ transplantation has not been reported. We describe parasitologically confirmed cases of babesiosis diagnosed approximate to 8 weeks posttransplantation in 2 recipients of renal allografts from an organ donor who was multiply transfused on the day he died from traumatic injuries. The organ donor and recipients had no identified risk factors for tick borne infection. Antibodies against B. microti parasites were not detected by serologic testing of archived pretransplant specimens. However, 1 of the organ donor's blood donors was seropositive when tested postdonation and had risk factors for tick exposure. The organ donor probably served as a conduit of Babesia parasites from the seropositive blood donor to both kidney recipients. Babesiosis should be included in the differential diagnosis of unexplained fever and hemolytic anemia after blood transfusion or organ transplantation. C1 [Brennan, Meghan B.; Weiss, John W.; Klein, Christina L.; Leith, Catherine P.; He, Rong; Oberley, Matthew J.; Gauthier, Gregory M.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Herwaldt, Barbara L.; Wilkins, Patricia P.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kazmierczak, James J.] Wisconsin Div Publ Hlth, Madison, WI USA. [Weiss, John W.] Amer Red Cross Badger Hawkeye Blood Serv Reg, Madison, WI USA. [Tonnetti, Laura] Amer Red Cross Jerome H Holland Labs Biomed Sci, Rockville, MD USA. RP Brennan, MB (reprint author), Univ Wisconsin, Med Fdn Centennial Bldg,5th Fl,1685 Highland Ave, Madison, WI 53705 USA. EM mbbrennan@medicine.wisc.edu FU National Institutes of Health to the Wisconsin Institute for Clinical and Translational Research [UL1TR000427, KL2TR000428] FX This work was supported by grants (UL1TR000427 and KL2TR000428) from the National Institutes of Health to the Wisconsin Institute for Clinical and Translational Research. NR 36 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2016 VL 22 IS 11 BP 1869 EP 1876 DI 10.3201/eid2211.151028 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EA3XS UT WOS:000386543200001 ER PT J AU Alraddadi, BM Al-Salmi, HS Jacobs-Slifka, K Slayton, RB Estivariz, CF Geller, AI Al-Turkistani, HH Al-Rehily, SS Alserehi, HA Wali, GY Alshukairi, AN Azhar, EI Haynes, L Swerdlow, DL Jernigan, JA Madani, TA AF Alraddadi, Basem M. Al-Salmi, Hanadi S. Jacobs-Slifka, Kara Slayton, Rachel B. Estivariz, Concepcion F. Geller, Andrew I. Al-Turkistani, Hanan H. Al-Rehily, Sanaa S. Alserehi, Haleema A. Wali, Ghassan Y. Alshukairi, Abeer N. Azhar, Esam I. Haynes, Lia Swerdlow, David L. Jernigan, John A. Madani, Tariq A. TI Risk Factors for Middle East Respiratory Syndrome Coronavirus Infection among Healthcare Personnel SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SAUDI-ARABIA; MERS-COV; TRANSMISSION; OUTBREAK; JEDDAH AB Healthcare settings can amplify transmission of Middle East respiratory syndrome coronavirus (MERS-CoV), but knowledge gaps about the epidemiology of transmission remain. We conducted a retrospective cohort study among healthcare personnel in hospital units that treated MERS-CoV patients. Participants were interviewed about exposures to MERS-CoV patients, use of personal protective equipment, and signs and symptoms of illness after exposure. Infection status was determined by the presence of antibodies against MERS-CoV. To assess risk factors, we compared infected and uninfected participants. Healthcare personnel caring for MERS-CoV patients were at high risk for infection, but infection most often resulted in a relatively mild illness that might be unrecognized. In the healthcare personnel cohort reported here, infections occurred exclusively among those who had close contact with MERS-CoV patients. C1 [Alraddadi, Basem M.; Al-Salmi, Hanadi S.; Al-Turkistani, Hanan H.; Al-Rehily, Sanaa S.; Alserehi, Haleema A.; Wali, Ghassan Y.; Alshukairi, Abeer N.] King Faisal Specialist Hosp & Res Ctr, Jeddah, Saudi Arabia. [Alraddadi, Basem M.; Azhar, Esam I.; Madani, Tariq A.] Minist Hlth, Jeddah, Saudi Arabia. [Jacobs-Slifka, Kara; Slayton, Rachel B.; Estivariz, Concepcion F.; Geller, Andrew I.; Haynes, Lia; Swerdlow, David L.; Jernigan, John A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Azhar, Esam I.; Madani, Tariq A.] King Abdulaziz Univ, Jeddah, Saudi Arabia. RP Madani, TA (reprint author), King Abdulaziz Univ, Dept Med, Fac Med, POB 80215, Jeddah 21589, Saudi Arabia. EM tmadani@kau.edu.sa FU Ministry of Health of Saudi Arabia and the US Centers for Disease Control and Prevention FX This study was funded by the Ministry of Health of Saudi Arabia and the US Centers for Disease Control and Prevention. NR 23 TC 0 Z9 0 U1 5 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2016 VL 22 IS 11 BP 1915 EP 1920 DI 10.3201/eid2211.160920 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EA3XS UT WOS:000386543200007 PM 27767011 ER PT J AU Eberhard, ML Cleveland, CA Zirimwabagabo, H Yabsley, MJ Ouakou, PT Ruiz-Tiben, E AF Eberhard, Mark L. Cleveland, Christopher A. Zirimwabagabo, Hubert Yabsley, Michael J. Ouakou, Philippe Tchindebet Ruiz-Tiben, Ernesto TI Guinea Worm (Dracunculus medinensis) Infection in a Wild-Caught Frog, Chad SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INSIGNIS NEMATODA; PARATENIC HOSTS AB A third-stage (infective) larva of Dracunculus medinensis, the causative agent of Guinea worm disease, was recovered from a wild-caught Phrynobatrachus francisci frog in Chad. Although green frogs (Lithobates clamitans) have been experimentally infected with D. medinensis worms, our findings prove that frogs can serve as natural paratenic hosts. C1 [Eberhard, Mark L.] Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Cleveland, Christopher A.; Yabsley, Michael J.] Univ Georgia, Athens, GA 30602 USA. [Zirimwabagabo, Hubert; Ruiz-Tiben, Ernesto] Carter Ctr, Atlanta, GA USA. [Ouakou, Philippe Tchindebet] Minist Publ Hlth, Ndjamena, Chad. RP Eberhard, ML (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D64, Atlanta, GA 30329 USA. EM mlel@cdc.gov FU Carter Center FX This work was supported by The Carter Center, whose work during 2008-2015 to eradicate Guinea worm disease was made possible by financial and in-kind contributions from many donors. A full listing of supporters can be found at The Carter Center website (http://www.cartercenter.org/donate/corporate-government-foundation-part ners/index.html). NR 8 TC 2 Z9 2 U1 4 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2016 VL 22 IS 11 BP 1961 EP 1962 DI 10.3201/eid2211.161332 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EA3XS UT WOS:000386543200016 PM 27560598 ER PT J AU Wallace, RM Etheart, MD Doty, J Monroe, B Crowdis, K Augustin, PD Blanton, J Fenelon, N AF Wallace, Ryan M. Etheart, Melissa D. Doty, Jeff Monroe, Ben Crowdis, Kelly Augustin, Pierre Dilius Blanton, Jesse Fenelon, Natael TI Dog-Mediated Human Rabies Death, Haiti, 2016 SO EMERGING INFECTIOUS DISEASES LA English DT Article AB Haiti has experienced numerous barriers to rabies control over the past decades and is one of the few remaining Western Hemisphere countries to report dog-mediated human rabies deaths. We describe the circumstances surrounding a reported human rabies death in 2016 as well as barriers to treatment and surveillance reporting. C1 [Wallace, Ryan M.] Ctr Dis Control & Prevent, Rabies Epidemiol Unit, Poxvirus & Rabies Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Doty, Jeff; Monroe, Ben; Blanton, Jesse] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G-43, Atlanta, GA 30329 USA. [Etheart, Melissa D.] Ctr Dis Control & Prevent, Port Au Prince, Haiti. [Crowdis, Kelly] Christian Vet Mission, Port Au Prince, Haiti. [Augustin, Pierre Dilius] Minist Agr Nat Resources & Rural Dev, Port Au Prince, Haiti. [Fenelon, Natael] Pan Amer Hlth Org, Port Au Prince, Haiti. RP Wallace, RM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G-43, Atlanta, GA 30329 USA. EM euk5@cdc.go NR 5 TC 0 Z9 0 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2016 VL 22 IS 11 BP 1963 EP 1965 DI 10.3201/eid2211.160826 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EA3XS UT WOS:000386543200017 PM 27767911 ER PT J AU Alhakeem, RF Midgley, CM Assiri, AM Alessa, M Al Hawaj, H Bin Saeed, A Almasri, MM Lu, XY Abedi, GR Abdalla, O Mohammed, M Algarni, HS Al-Abdely, HM Alsharef, AA Nooh, R Erdman, DD Gerber, SI Watson, JT AF Alhakeem, Raafat F. Midgley, Claire M. Assiri, Abdullah M. Alessa, Mohammed Al Hawaj, Hassan Bin Saeed, Abdulaziz Almasri, Malak M. Lu, Xiaoyan Abedi, Glen R. Abdalla, Osman Mohammed, Mutaz Algarni, Homoud S. Al-Abdely, Hail M. Alsharef, Ali Abraheem Nooh, Randa Erdman, Dean D. Gerber, Susan I. Watson, John T. TI Exposures among MERS Case-Patients, Saudi Arabia, January-February 2016 SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID EAST RESPIRATORY SYNDROME; SYNDROME CORONAVIRUS; OUTBREAK; HUMANS C1 [Alhakeem, Raafat F.; Assiri, Abdullah M.; Alessa, Mohammed; Al Hawaj, Hassan; Bin Saeed, Abdulaziz; Almasri, Malak M.; Abdalla, Osman; Mohammed, Mutaz; Algarni, Homoud S.; Al-Abdely, Hail M.; Alsharef, Ali Abraheem; Nooh, Randa] Minist Hlth, Riyadh, Saudi Arabia. [Midgley, Claire M.; Lu, Xiaoyan; Abedi, Glen R.; Erdman, Dean D.; Gerber, Susan I.; Watson, John T.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Midgley, CM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM ydk5@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2016 VL 22 IS 11 BP 2020 EP 2022 DI 10.3201/eid2211.161042 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EA3XS UT WOS:000386543200037 PM 27606432 ER PT J AU Breedlove, B AF Breedlove, Byron TI A Simple Sketch Symbolizing Self-Reliance SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Breedlove, Byron] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C19, Atlanta, GA 30329 USA. RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C19, Atlanta, GA 30329 USA. EM wbb1@cdc.gov OI Breedlove, Byron/0000-0002-1026-1963 NR 9 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2016 VL 22 IS 11 BP 2031 EP 2032 DI 10.3201/eid2211.AC2211 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EA3XS UT WOS:000386543200042 ER PT J AU Cote, I Andersen, ME Ankley, GT Barone, S Birnbaum, LS Boekelheide, K Bois, F Burgoon, LD Chiu, WA Crawford-Brown, D Crofton, KM DeVito, M Devlin, RB Edwards, SW Guyton, KZ Hattis, D Judson, RS Knight, D Krewski, D Lambert, J Maull, EA Mendrick, D Paoli, GM Patel, CJ Perkins, EJ Poje, G Portier, CJ Rusyn, I Schulte, PA Simeonov, A Smith, MT Thayer, KA Thomas, RS Thomas, R Tice, RR Vandenberg, JJ Villeneuve, DL Wesselkamper, S Whelan, M Whittaker, C White, R Xia, M Yauk, C Zeise, L Zhao, J DeWoskin, RS AF Cote, Ila Andersen, Melvin E. Ankley, Gerald T. Barone, Stanley Birnbaum, Linda S. Boekelheide, Kim Bois, FredericY. Burgoon, Lyle D. Chiu, Weihsueh A. Crawford-Brown, Douglas Crofton, Kevin M. DeVito, Michael Devlin, Robert B. Edwards, Stephen W. Guyton, Kathryn Z. Hattis, Dale Judson, Richard S. Knight, Derek Krewski, Daniel Lambert, Jason Maull, Elizabeth Anne Mendrick, Donna Paoli, Gregory M. Patel, Chirag Jagdish Perkins, Edward J. Poje, Gerald Portier, Christopher J. Rusyn, Ivan Schulte, Paul A. Simeonov, Anton Smith, Martyn T. Thayer, Kristina A. Thomas, Russell S. Thomas, Reuben Tice, Raymond R. Vandenberg, John J. Villeneuve, Daniel L. Wesselkamper, Scott Whelan, Maurice Whittaker, Christine White, Ronald Xia, Menghang Yauk, Carole Zeise, Lauren Zhao, Jay DeWoskin, Robert S. TI The Next Generation of Risk Assessment Multi-Year Study-Highlights of Findings, Applications to Risk Assessment, and Future Directions SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Review ID ADVERSE OUTCOME PATHWAYS; BRONCHIAL EPITHELIAL-CELLS; THROUGHPUT SCREENING DATA; IN-VIVO HAZARD; ENVIRONMENTAL CHEMICALS; HUMAN HEALTH; GENE-EXPRESSION; POPULATION VARIABILITY; PREDICTIVE TOXICOLOGY; ESTROGEN-RECEPTOR AB BACKGROUND: The Next Generation (NexGen) of Risk Assessment effort is a multi-year collaboration among several organizations evaluating new, potentially more efficient molecular, computational, and systems biology approaches to risk assessment. This article summarizes our findings, suggests applications to risk assessment, and identifies strategic research directions. OBJECTIVE: Our specific objectives were to test whether advanced biological data and methods could better inform our understanding of public health risks posed by environmental exposures. METHODS: New data and methods were applied and evaluated for use in hazard identification and dose-response assessment. Biomarkers of exposure and effect, and risk characterization were also examined. Consideration was given to various decision contexts with increasing regulatory and public health impacts. Data types included transcriptomics, genomics, and proteomics. Methods included molecular epidemiology and clinical studies, bioinformatic knowledge mining, pathway and network analyses, short-duration in vivo and in vitro bioassays, and quantitative structure activity relationship modeling. DISCUSSION: NexGen has advanced our ability to apply new science by more rapidly identifying chemicals and exposures of potential concern, helping characterize mechanisms of action that influence conclusions about causality, exposure-response relationships, susceptibility and cumulative risk, and by elucidating new biomarkers of exposure and effects. Additionally, NexGen has fostered extensive discussion among risk scientists and managers and improved confidence in interpreting and applying new data streams. CONCLUSIONS: While considerable uncertainties remain, thoughtful application of new knowledge to risk assessment appears reasonable for augmenting major scope assessments, forming the basis for or augmenting limited scope assessments, and for prioritization and screening of very data limited chemicals. C1 [Cote, Ila; Vandenberg, John J.; DeWoskin, Robert S.] US EPA, Natl Ctr Environm Assessment, Washington, DC 20460 USA. [Andersen, Melvin E.] ScitoVation, Res Triangle Pk, NC USA. [Ankley, Gerald T.; Villeneuve, Daniel L.] US EPA, Natl Hlth & Environm Effects Res Lab, Duluth, MN USA. [Barone, Stanley] US EPA, Off Chem Safety & Pollut Prevent, Washington, DC 20460 USA. [Birnbaum, Linda S.; DeVito, Michael; Maull, Elizabeth Anne; Thayer, Kristina A.; Tice, Raymond R.] NIEHS, POB 12233, Res Triangle Pk, NC 27709 USA. [Birnbaum, Linda S.; DeVito, Michael; Maull, Elizabeth Anne; Thayer, Kristina A.; Tice, Raymond R.] NIH, Natl Toxicol Program, DHHS, Res Triangle Pk, NC USA. [Boekelheide, Kim] Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA. [Bois, FredericY.] Inst Natl Environm Ind & Risques, Unite Modeles Icotoxicol & Toxicol, Verneuil En Halatte, France. [Burgoon, Lyle D.] US Army, Engineer Res & Dev Ctr, Res Triangle Pk, NC USA. [Chiu, Weihsueh A.; Rusyn, Ivan] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Integrat Biosci, College Stn, TX USA. [Crawford-Brown, Douglas] Univ Cambridge, Dept Land Econ, Cambridge, England. [Crofton, Kevin M.; Judson, Richard S.; Thomas, Russell S.] Natl Ctr Computat Toxicol, Res Triangle Pk, NC USA. [Devlin, Robert B.; Edwards, Stephen W.] US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA. [Guyton, Kathryn Z.] Int Agcy Res Canc, Lyon, France. [Hattis, Dale] Clark Univ, George Perkins Marsh Inst, Worcester, MA 01610 USA. [Knight, Derek] European Chem Agcy, Helsinki, Finland. [Krewski, Daniel] Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON, Canada. [Lambert, Jason; Wesselkamper, Scott; Zhao, Jay] US EPA, Natl Ctr Environm Assessment, Cincinnati, OH 45268 USA. [Mendrick, Donna] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA. [Paoli, Gregory M.] Risk Sci Int, Ottawa, ON, Canada. [Patel, Chirag Jagdish] Harvard Med Sch, Dept Biomed Informat, Boston, MA USA. [Perkins, Edward J.] US Army, Engineer Res & Dev Ctr, Vicksburg, MS USA. [Poje, Gerald] Grant Consulting Grp, Washington, DC USA. [Portier, Christopher J.] Environm Def Fund, Washington, DE USA. [Schulte, Paul A.; Whittaker, Christine] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Educ & Informat Div, Cincinnati, OH USA. [Simeonov, Anton; Xia, Menghang] NIH, Natl Ctr Adv Translat Sci, DHHS, Bethesda, MD USA. [Smith, Martyn T.] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA. [Thomas, Reuben] Univ Calif San Francisco, Gladstone Inst, San Francisco, CA 94143 USA. [Whelan, Maurice] European Commiss Joint Res Ctr, Syst Toxicol Unit, Ispra, Italy. [White, Ronald] Ctr Effect Govt, Washington, DE USA. [Yauk, Carole] Hlth Canada, Environm Hlth Sci & Res Bur, Ottawa, ON, Canada. [Zeise, Lauren] Calif EPA, Off Environm Hlth Hazard Assessment, Oakland, CA USA. RP Cote, I (reprint author), US EPA, Reg 8,Room 8152,1595 Wynkoop St, Denver, CO 80202 USA. EM cote.ila@epa.gov RI Bois, Frederic/E-9241-2012; Rusyn, Ivan/S-2426-2016; OI Bois, Frederic/0000-0002-4154-0391; Vandenberg, John/0000-0003-2619-9460; Burgoon, Lyle/0000-0003-4977-5352 FU NIEHS NIH HHS [P42 ES005948, R00 ES023504, K99 ES023504, R21 ES025052] NR 152 TC 0 Z9 0 U1 30 U2 30 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD NOV PY 2016 VL 124 IS 11 BP 1671 EP 1682 DI 10.1289/EHP233 PG 12 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA EA8UF UT WOS:000386913800010 PM 27091369 ER PT J AU Azofeifa, A Mattson, ME Grant, A AF Azofeifa, Alejandro Mattson, Margaret E. Grant, Althea TI Monitoring Marijuana Use in the United States Challenges in an Evolving Environment SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID HEALTH C1 [Azofeifa, Alejandro; Mattson, Margaret E.] Subst Abuse & Mental Hlth Serv Adm, 5600 Fisher Ln,Room 15E-29D, Rockville, MD 20857 USA. [Grant, Althea] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Azofeifa, A (reprint author), Subst Abuse & Mental Hlth Serv Adm, 5600 Fisher Ln,Room 15E-29D, Rockville, MD 20857 USA. EM alejandro.azofeifa@samhsa.hhs.gov NR 8 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 1 PY 2016 VL 316 IS 17 BP 1765 EP 1766 DI 10.1001/jama.2016.13696 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EA4GP UT WOS:000386569300012 PM 27583699 ER PT J AU DeSilva, M Vazquez-Benitez, G Nordin, JD Lipkind, HS Romitti, PA DeStefano, F Kharbanda, EO AF DeSilva, Malini Vazquez-Benitez, Gabriela Nordin, James D. Lipkind, Heather S. Romitti, Paul A. DeStefano, Frank Kharbanda, Elyse O. TI Tdap Vaccination During Pregnancy and Microcephaly and Other Structural Birth Defects in Offspring SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID SAFETY; IMMUNIZATION; OUTCOMES; DATALINK C1 [DeSilva, Malini; Vazquez-Benitez, Gabriela; Nordin, James D.; Kharbanda, Elyse O.] HealthPartners Inst, POB 1524,MS 21111R, Minneapolis, MN 55440 USA. [Lipkind, Heather S.] Yale Univ, Obstet & Gynecol, New Haven, CT USA. [Romitti, Paul A.] Univ Iowa, Iowa City, IA USA. [DeStefano, Frank] Ctr Dis Control & Prevent, Atlanta, GA USA. RP DeSilva, M (reprint author), HealthPartners Inst, POB 1524,MS 21111R, Minneapolis, MN 55440 USA. EM malini.b.desilva@healthpartners.com NR 6 TC 0 Z9 0 U1 11 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 1 PY 2016 VL 316 IS 17 BP 1823 EP 1825 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA EA4GP UT WOS:000386569300023 PM 27802536 ER PT J AU Soke, GN Rosenberg, SA Hamman, RF Fingerlin, T Robinson, C Carpenter, L Giarelli, E Lee, LC Wiggins, LD Durkin, MS DiGuiseppi, C AF Soke, Gnakub N. Rosenberg, Steven A. Hamman, Richard F. Fingerlin, Tasha Robinson, Cordelia Carpenter, Laura Giarelli, Ellen Lee, Li-Ching Wiggins, Lisa D. Durkin, Maureen S. DiGuiseppi, Carolyn TI Brief Report: Prevalence of Self-injurious Behaviors among Children with Autism Spectrum Disorder-A Population-Based Study SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Self-injurious behaviors; Autism; Autism spectrum disorder; Prevalence; Challenging behaviors ID RISK-FACTORS; CHALLENGING BEHAVIORS; DEVELOPMENTAL-DISABILITIES; YOUNG-CHILDREN; AGE; INDIVIDUALS; ADOLESCENTS; REGRESSION; DIAGNOSIS; PEOPLE AB Self-injurious behaviors (SIB) have been reported in more than 30 % of children with an autism spectrum disorder (ASD) in clinic-based studies. This study estimated the prevalence of SIB in a large population-based sample of children with ASD in the United States. A total of 8065 children who met the surveillance case definition for ASD in the Autism and Developmental Disabilities Monitoring (ADDM) Network during the 2000, 2006, and 2008 surveillance years were included. The presence of SIB was reported from available health and/or educational records by an expert clinician in ADDM Network. SIB prevalence averaged 27.7 % across all sites and surveillance years, with some variation between sites. Clinicians should inquire about SIB during assessments of children with ASD. C1 [Soke, Gnakub N.; Hamman, Richard F.; Fingerlin, Tasha; DiGuiseppi, Carolyn] Univ Colorado, Colorado Sch Publ Heath, Dept Epidemiol, Anschutz Med Campus, Aurora, CO 80045 USA. [Rosenberg, Steven A.; Robinson, Cordelia] Univ Colorado, Sch Med, Dept Psychiat, Anschutz Med Campus, Aurora, CO 80045 USA. [Robinson, Cordelia] Univ Colorado, Sch Med, Dept Pediat, Anschutz Med Campus, Aurora, CO 80045 USA. [Carpenter, Laura] Med Univ South Carolina, Dept Pediat, Charleston, SC 29425 USA. [Giarelli, Ellen] Drexel Univ, Coll Nursing & Hlth Profess, Philadelphia, PA 19102 USA. [Lee, Li-Ching] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA. [Lee, Li-Ching] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA. [Wiggins, Lisa D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Durkin, Maureen S.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53726 USA. RP Soke, GN (reprint author), Univ Colorado, Colorado Sch Publ Heath, Dept Epidemiol, Anschutz Med Campus, Aurora, CO 80045 USA. EM Gnakub.soke@ucdenver.edu OI Carpenter, Laura/0000-0002-6448-9242 NR 39 TC 2 Z9 2 U1 5 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 EI 1573-3432 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD NOV PY 2016 VL 46 IS 11 BP 3607 EP 3614 DI 10.1007/s10803-016-2879-1 PG 8 WC Psychology, Developmental SC Psychology GA EA7BI UT WOS:000386782700018 PM 27565654 ER PT J AU Dawson, AL Tinker, SC Jamieson, DJ Hobbs, CA Berry, RJ Rasmussen, SA Anderka, M Keppler-Noreuil, KM Lin, AE Reefhuis, J AF Dawson, April L. Tinker, Sarah C. Jamieson, Denise J. Hobbs, Charlotte A. Berry, R. J. Rasmussen, Sonja A. Anderka, Marlene Keppler-Noreuil, Kim M. Lin, Angela E. Reefhuis, Jennita CA Natl Birth Defects Prevention TI Twinning and major birth defects, National Birth Defects Prevention Study, 1997-2007 SO JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH LA English DT Article ID ASSISTED REPRODUCTIVE TECHNOLOGY; MULTIPLE BIRTHS; INCREASED RISK; UNITED-STATES; MATERNAL AGE; YOUNG TWINS; QUESTIONNAIRE; EPIDEMIOLOGY; ASSOCIATION; ANOMALIES AB Background Twinning has been associated with many types of birth defects, although previous studies have had inconsistent findings. Many studies lack information about potential confounders, particularly use of fertility treatment. Our objective was to assess the association between twinning and birth defects in the National Birth Defects Prevention Study (NBDPS). Methods We used data from the NBDPS, a population-based, case-control study of major birth defects in the USA, to evaluate associations between twinning and birth defects. The study population included mothers of twin and singleton controls (live-born infants without major birth defects), and cases (fetuses or infants with a major birth defect) born October 1997-December 2007. Adjusted ORs and 95% CIs were estimated using multivariable logistic regression stratified by use of fertility treatment. Twin sex-pairing data and a simulation approach were used to estimate the zygosity of twins. Results In the unassisted conception stratum, we observed significant positive associations between twinning and 29 of 45 defect groups. The largest effect estimates were observed for multiple ventricular septal defects and cloacal exstrophy. Among mothers reporting any use of fertility treatments, we observed a significant association with twinning for 5 of 25 defect groups, with the largest effect estimates for hypoplastic left heart syndrome and omphalocele. OR estimates in the estimated monozygotic stratum were generally further from the null than in the dizygotic stratum. Conclusions Compared with singletons, a wide range of birth defects are significantly more common among twins. Birth defect risk in twins may be differential by use of fertility treatment. C1 [Dawson, April L.; Tinker, Sarah C.; Berry, R. J.; Reefhuis, Jennita] CDC, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS-E86, Atlanta, GA 30333 USA. [Jamieson, Denise J.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Hobbs, Charlotte A.] Univ Arkansas Med Sci, Coll Med, Fayetteville, AR USA. [Rasmussen, Sonja A.] CDC, Off Infect Dis, Atlanta, GA 30333 USA. [Anderka, Marlene; Lin, Angela E.] Massachusetts Ctr Birth Defects Res & Prevent, Boston, MA USA. [Keppler-Noreuil, Kim M.] NHGRI, NIH, Bethesda, MD 20892 USA. [Lin, Angela E.] MassGen Hosp Children, Genet Unit, Boston, MA USA. RP Dawson, AL (reprint author), CDC, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS-E86, Atlanta, GA 30333 USA. EM isp3@cdc.gov FU Intramural CDC HHS [CC999999] NR 27 TC 0 Z9 0 U1 5 U2 5 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0143-005X EI 1470-2738 J9 J EPIDEMIOL COMMUN H JI J. Epidemiol. Community Health PD NOV PY 2016 VL 70 IS 11 BP 1114 EP 1121 DI 10.1136/jech-2015-206302 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA3PP UT WOS:000386516300009 PM 27325867 ER PT J AU LaKind, JS Overpeck, J Breysse, PN Backer, L Richardson, SD Sobus, J Sapkota, A Upperman, CR Jiang, CS Ben Beard, C Brunkard, JM Bell, JE Harris, R Chretien, JP Peltier, RE Chew, GL Blount, BC AF LaKind, Judy S. Overpeck, Jonathan Breysse, Patrick N. Backer, Lorrie Richardson, Susan D. Sobus, Jon Sapkota, Amir Upperman, Crystal R. Jiang, Chengsheng Ben Beard, C. Brunkard, J. M. Bell, Jesse E. Harris, Ryan Chretien, Jean-Paul Peltier, Richard E. Chew, Ginger L. Blount, Benjamin C. TI Exposure science in an age of rapidly changing climate: challenges and opportunities SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Review DE climate change; exposure science; extreme events; indoor environments; non-targeted analysis; sensors ID DISINFECTION BY-PRODUCTS; SALINE WASTE-WATER; CANADIAN FOREST-FIRES; WEST NILE VIRUS; DRINKING-WATER; UNITED-STATES; MASS-SPECTROMETRY; AIR-POLLUTION; EPIDEMIOLOGIC EVIDENCE; EMERGING CONTAMINANTS AB Climate change is anticipated to alter the production, use, release, and fate of environmental chemicals, likely leading to increased uncertainty in exposure and human health risk predictions. Exposure science provides a key connection between changes in climate and associated health outcomes. The theme of the 2015 Annual Meeting of the International Society of Exposure Science Exposures in an Evolving Environment-brought this issue to the fore. By directing attention to questions that may affect society in profound ways, exposure scientists have an opportunity to conduct "consequential science"-doing science that matters, using our tools for the greater good and to answer key policy questions, and identifying causes leading to implementation of solutions. Understanding the implications of changing exposures on public health may be one of the most consequential areas of study in which exposure scientists could currently be engaged. In this paper, we use a series of case studies to identify exposure data gaps and research paths that will enable us to capture the information necessary for understanding climate change-related human exposures and consequent health impacts. We hope that paper will focus attention on under-developed areas of exposure science that will likely have broad implications for public health. C1 [LaKind, Judy S.] LaKind Associates LLC, 106 Oakdale Ave, Catonsville, MD 21228 USA. [LaKind, Judy S.] Univ Maryland, Dept Epidemiol & Publ Hlth, Sch Med, Baltimore, MD 21201 USA. [LaKind, Judy S.] Penn State U Coll Med, Hershey Med Ctr, Dept Pediat, Hershey, PA 17033 USA. [Overpeck, Jonathan] Univ Arizona, Inst Environm, ENR2 Bldg,Room N523,1064 East Lowell St, Tucson, AZ 85721 USA. [Breysse, Patrick N.] Natl Ctr Environm Hlth, Agcy Tox Subst & Dis Registry, 4770 Buford Highway NE,MS-F60, Atlanta, GA 30341 USA. [Backer, Lorrie] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS-F60, Atlanta, GA 30341 USA. [Richardson, Susan D.] Univ South Carolina, Dept Chem & Biochem, JM Palms Ctr GSR, 631 Sumter St, Columbia, SC 29208 USA. [Sobus, Jon] US EPA, Natl Exposure Res Lab, Mail Code E205-04, Res Triangle Pk, NC 27711 USA. [Sapkota, Amir; Upperman, Crystal R.; Jiang, Chengsheng] Univ Maryland, Sch Publ Hlth, Maryland Inst Appl Environm Hlth, College Pk, MD 20742 USA. [Ben Beard, C.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Mail Stop P-02,3156 Rampart Rd, Ft Collins, CO 80521 USA. [Brunkard, J. M.] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Mail Stop C-09,1600 Clifton Rd NE, Asheville, NC 28801 USA. [Bell, Jesse E.] North Carolina State Univ, Cooperat Inst Climate & Satellites NC, 151 Patton Ave, Asheville, NC 28801 USA. [Harris, Ryan] USAF, Weather Squadron DOD Appl Climate Serv 14, Asheville, NC USA. [Chretien, Jean-Paul] Def Hlth Agcy, Armed Forces Hlth Surveillance Branch, Silver Spring, MD USA. [Peltier, Richard E.] Univ Massachusetts, Dept Environm Hlth Sci, 149 Goessmann Lab,686 North Pleasant St, Amherst, MA 01003 USA. [Chew, Ginger L.] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS-F60, Atlanta, GA 30341 USA. [Blount, Benjamin C.] Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F47, Atlanta, GA 30341 USA. RP LaKind, JS (reprint author), Univ Maryland, Sch Med, LaKind Associates LLC, Dept Epidemiol & Publ Hlth, 106 Oakdale Ave, Catonsville, MD 21228 USA. EM lakindassoc@gmail.com RI Sapkota, Amir/A-5968-2011 FU CDC Foundation FX The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry, the US Air Force or Navy, or the US Environmental Protection Agency. The United States Environmental Protection Agency through its Office of Research and Development collaborated in the research described here. It has been subjected to Agency administrative review and approved for publication. Dr. LaKind received support from the CDC Foundation and Dr. LaKind consults to both governmental agencies and private clients. NR 112 TC 1 Z9 1 U1 10 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 EI 1559-064X J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD NOV-DEC PY 2016 VL 26 IS 6 BP 529 EP 538 DI 10.1038/jes.2016.35 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA EA3WH UT WOS:000386539500001 PM 27485992 ER PT J AU Harvey, RR Zakhour, CM Gould, LH AF Harvey, R. Reid Zakhour, Christine M. Gould, L. Hannah TI Foodborne Disease Outbreaks Associated with Organic Foods in the United States SO JOURNAL OF FOOD PROTECTION LA English DT Article DE Disease outbreak; Foodborne illness; Organic ID PRODUCE; CONSUMPTION; SAFETY; RISKS; MEAT AB Consumer demand for organically produced foods is increasing in the United States as well as globally. Consumer perception often credits organic foods as being safer than conventionally produced foods, although organic standards do not directly address safety issues such as microbial or chemical hazards. We reviewed outbreaks reported to the Centers for Disease Control and Prevention's Foodborne Disease Outbreak Surveillance System where the implicated food was reported to be organic. Information collected for each outbreak included the year, state, number of illnesses, pathogen, and implicated food. We identified 18 outbreaks caused by organic foods from 1992 to 2014, resulting in 779 illnesses, 258 hospitalizations, and 3 deaths; 56% of outbreaks occurred from 2010 to 2014. Nine outbreaks occurred in a single state, and nine outbreaks were multistate. Salmonella sp. (44% of outbreaks) and Escherichia coli O157:H7 (33%) were the most commonly occurring pathogens. Eight of the outbreaks were attributed to produce items, four to unpasteurized dairy products, two to eggs, two to nut and seed products, and two to multi ingredient foods. Fifteen (83%) outbreaks were associated with foods that were definitely or likely U.S. Department of Agriculture certified. More foodbome outbreaks associated with organic foods in the United States have been reported in recent years, in parallel with increases in organic food production and consumption. We are unable to assess risk of outbreaks due to organic foods compared with conventional foods because foodbome outbreak surveillance does not systematically collect food production method. Food safety requires focused attention by consumers, regardless of whether foods are produced organically or conventionally. Consumers should be aware of the risk of milk and produce consumed raw, including organic. C1 [Harvey, R. Reid; Zakhour, Christine M.; Gould, L. Hannah] Ctr Dis Control & Prevent CDC, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd NE,Mail Stop A-38, Atlanta, GA 30329 USA. [Harvey, R. Reid] NIOSH, 1095 Willowdale Rd,M-S H2800, Morgantown, WV 26505 USA. [Zakhour, Christine M.] Massachusetts Dept Publ Hlth, 1 Ashburton Pl 17, Boston, MA 02108 USA. [Gould, L. Hannah] New York City Dept Hlth & Mental Hyg, 42-09 28th St, Queens, NY 11101 USA. RP Harvey, RR (reprint author), Ctr Dis Control & Prevent CDC, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd NE,Mail Stop A-38, Atlanta, GA 30329 USA.; Harvey, RR (reprint author), NIOSH, 1095 Willowdale Rd,M-S H2800, Morgantown, WV 26505 USA. EM iez1@cdc.gov NR 26 TC 0 Z9 0 U1 26 U2 26 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD NOV PY 2016 VL 79 IS 11 BP 1953 EP 1958 DI 10.4315/0362-028X.JFP-16-204 PG 6 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA EB1FG UT WOS:000387094400018 PM 28221898 ER PT J AU Rohan, EA Slotman, B DeGroff, A Morrissey, KG Murillo, J Schroy, P AF Rohan, Elizabeth A. Slotman, Beth DeGroff, Amy Morrissey, Kerry Grace Murillo, Jennifer Schroy, Paul TI Refining the Patient Navigation Role in a Colorectal Cancer Screening Program: Results From an Intervention Study SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID RANDOMIZED-CONTROLLED-TRIAL; BREAST-CANCER; UNITED-STATES; FOLLOW-UP; CARE; DISPARITIES; COMMUNITY; DIAGNOSIS; IMPACT; IMPLEMENTATION AB Background: Oncology patient navigators help individuals overcome barriers to increase access to cancer screening, diagnosis, and timely treatment. This study, part of a randomized intervention trial investigating the efficacy of patient navigation in increasing colonoscopy completion, examined navigators' activities to ameliorate barriers to colonoscopy screening in a medically disadvantaged population. Methods: This study was conducted from 2012 through 2014 at Boston Medical Center. We analyzed navigator service delivery and survey data collected on 420 participants who were navigated for colonoscopy screening after randomization to this intervention. Key variables under investigation included barriers to colonoscopy, activities navigators undertook to reduce barriers, time navigators spent on each activity and per contact, and patient satisfaction with navigation services. Descriptive analysis assessed how navigators spent their time and examined what aspects of patient navigation were most valued by patients. Results: Navigators spent the most time assessing patient barriers/needs; facilitating appointment scheduling; reminding patients of appointments; educating patients about colorectal cancer, the importance of screening, and the colonoscopy preparation and procedures; and arranging transportation. Navigators spent an average of 44 minutes per patient. Patients valued the navigators, especially for providing emotional/peer support and explaining screening procedures and bowel preparation clearly. Conclusions: Our findings help clarify the role of the navigator in colonoscopy screening within a medically disadvantaged community. These findings may help further refine the navigator role in cancer screening and treatment programs as facilities strive to effectively and efficiently integrate navigation into their services. C1 [Rohan, Elizabeth A.; DeGroff, Amy] Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway,NE,Chamblee Bldg 107,MS F76, Atlanta, GA 30341 USA. [Slotman, Beth; Morrissey, Kerry Grace] Westat Corp, Rockville, MD USA. [Murillo, Jennifer; Schroy, Paul] Boston Med Ctr, Dept Gastroenterol, Boston, MA USA. RP Rohan, EA (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway,NE,Chamblee Bldg 107,MS F76, Atlanta, GA 30341 USA. EM erohan@cdc.gov NR 41 TC 0 Z9 0 U1 0 U2 0 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD NOV 1 PY 2016 VL 14 IS 11 BP 1371 EP + PG 19 WC Oncology SC Oncology GA EA8JE UT WOS:000386880300008 PM 27799508 ER PT J AU Wong, IS Smith, PM Ibrahim, S Mustard, CA Gignac, MAM AF Wong, Imelda S. Smith, Peter M. Ibrahim, Selahadin Mustard, Cameron A. Gignac, Monique A. M. TI Mediating pathways and gender differences between shift work and subjective cognitive function SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CARDIOVASCULAR-DISEASE; OCCUPATIONAL INJURY; SLEEP-DEPRIVATION; RISK-FACTORS; HEALTH; PERFORMANCE; NURSES; INSOMNIA; STRESS; AGE AB Objectives Increased injury risk among shift workers is often attributed to cognitive function deficits that come about as a result of sleep disruptions. However, little is known about the intermediate influences of other factors (eg, work stress, health) which may affect this relationship. In addition, gender differences in these the complex relationships have not been fully explored. The purpose of this study is to (1) identify the extent to which work and non-work factors mediate the relationship between shift work, sleep and subsequent subjective cognitive function; and (2) determine if the mediating pathways differ for men and women. Methods Data from the 2010 National Population Health Survey was used to create a cross-sectional sample of 4255 employed Canadians. Using path modelling, we examined the direct and indirect relationships between shift work, sleep duration, sleep quality and subjective cognitive function. Multigroup analyses tested for significantly different pathways between men and women. Potential confounding effects of age and self-reported health and potential mediating effects of work stress were simultaneously examined. Results Work stress and sleep quality significantly mediated the effects of shift work on cognition. Age and health confounded the relationship between sleep quality and subjective cognition. No differences were found between men and women. Conclusions Occupational health and safety programmes are needed to address stress and health factors, in addition to sleep hygiene, to effectively address cognitive function among shift workers. C1 [Wong, Imelda S.] NIOSH, Cincinnati, OH 45226 USA. [Smith, Peter M.; Ibrahim, Selahadin; Mustard, Cameron A.; Gignac, Monique A. M.] Inst Work & Hlth, Toronto, ON, Canada. [Smith, Peter M.; Mustard, Cameron A.; Gignac, Monique A. M.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. RP Wong, IS (reprint author), NIOSH, Div Appl Res & Technol, 1150 Tusculum Ave,MS C-24, Cincinnati, OH USA. EM IWong@cdc.gov OI Smith, Peter/0000-0001-8286-4563 FU Institute for Work Health (IWH); Oak Ridge Institute for Science and Education (ORISE); National Institute for Occupational Safety and Health (NIOSH); Chair in Gender, Work & Health from the Canadian Institutes of Health Research FX Funding for ISW was provided by the Mustard Post-doctoral Fellowship from the Institute for Work & Health (IWH), and the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement with the National Institute for Occupational Safety and Health (NIOSH). PMS is supported by a Chair in Gender, Work & Health from the Canadian Institutes of Health Research. IWH operates with the support of the Province of Ontario. NR 56 TC 0 Z9 0 U1 2 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 EI 1470-7926 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD NOV PY 2016 VL 73 IS 11 BP 753 EP 760 DI 10.1136/oemed-2016-103774 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA2ZA UT WOS:000386465000008 PM 27421746 ER PT J AU Chan, HT Xiao, YH Weldon, WC Oberste, SM Chumakov, K Daniell, H AF Chan, Hui-Ting Xiao, Yuhong Weldon, William C. Oberste, Steven M. Chumakov, Konstantin Daniell, Henry TI Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes SO PLANT BIOTECHNOLOGY JOURNAL LA English DT Article DE human infectious diseases; molecular farming; chloroplast transformation; bioencapsulation; oral delivery; mucosal immunity ID TOXIN B-SUBUNIT; ORAL DELIVERY; PLANT-CELLS; TOBACCO CHLOROPLASTS; INHIBITOR FORMATION; TRANSGENIC PLANTS; UNITED-STATES; HEMOPHILIA-B; HEPATITIS-B; EXPRESSION AB The WHO recommends complete withdrawal of oral polio vaccine (OPV) type 2 by April 2016 globally and replacing with at least one dose of inactivated poliovirus vaccine (IPV). However, high-cost, limited supply of IPV, persistent circulating vaccine-derived polioviruses transmission and need for subsequent boosters remain unresolved. To meet this critical need, a novel strategy of a low-cost cold chain-free plant-made viral protein 1 (VP1) subunit oral booster vaccine after single IPV dose is reported. Codon optimization of the VP1 gene enhanced expression by 50-fold in chloroplasts. Oral boosting of VP1 expressed in plant cells with plant-derived adjuvants after single priming with IPV significantly increased VP1-IgG1 and VP1-IgA titres when compared to lower IgG1 or negligible IgA titres with IPV injections. IgA plays a pivotal role in polio eradication because of its transmission through contaminated water or sewer systems. Neutralizing antibody titres (similar to 3.17-10.17 log(2) titre) and seropositivity (70-90%) against all three poliovirus Sabin serotypes were observed with two doses of IPV and plant-cell oral boosters but single dose of IPV resulted in poor neutralization. Lyophilized plant cells expressing VP1 stored at ambient temperature maintained efficacy and preserved antigen folding/assembly indefinitely, thereby eliminating cold chain currently required for all vaccines. Replacement of OPV with this booster vaccine and the next steps in clinical translation of FDA-approved antigens and adjuvants are discussed. C1 [Chan, Hui-Ting; Xiao, Yuhong; Daniell, Henry] Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA. [Weldon, William C.; Oberste, Steven M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Chumakov, Konstantin] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA. RP Daniell, H (reprint author), Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA. EM hdaniell@upenn.edu FU Bill and Melinda Gates Foundation [OPP1031406]; NIH [R01 HL107904, R01 HL109442] FX This study was supported by Bill and Melinda Gates Foundation (OPP1031406), NIH grants R01 HL107904 and R01 HL109442 to Henry Daniell. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 57 TC 6 Z9 6 U1 16 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1467-7644 EI 1467-7652 J9 PLANT BIOTECHNOL J JI Plant Biotechnol. J. PD NOV PY 2016 VL 14 IS 11 BP 2190 EP 2200 DI 10.1111/pbi.12575 PG 11 WC Biotechnology & Applied Microbiology; Plant Sciences SC Biotechnology & Applied Microbiology; Plant Sciences GA DZ8TB UT WOS:000386143400010 PM 27155248 ER PT J AU Osikowicz, LM Billeter, SA Rizzo, MF Rood, MP Freeman, AN Burns, JE Hu, RJ Juieng, P Loparev, V Kosoy, M AF Osikowicz, Lynn M. Billeter, Sarah A. Rizzo, Maria Fernanda Rood, Michael P. Freeman, Ashley N. Burns, Joseph E. Hu, Renjie Juieng, Phalasy Loparev, Vladimir Kosoy, Michael TI Distribution and Diversity of Bartonella washoensis Strains in Ground Squirrels from California and Their Potential Link to Human Cases SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Bartonella washoensis; California; ground squirrel; Oropsylla montana; Otospermophilus beecheyi ID PHYLOGENETIC ANALYSIS; LOS-ANGELES; ENDOCARDITIS; RESERVOIRS; RODENTS; PATIENT; FLEAS; GENE; DIFFERENTIATION; CLASSIFICATION AB We investigated the prevalence of Bartonella washoensis in California ground squirrels (Otospermophilus beecheyi) and their fleas from parks and campgrounds located in seven counties of California. Ninety-seven of 140 (69.3%) ground squirrels were culture positive and the infection prevalence by location ranged from 25% to 100%. In fleas, 60 of 194 (30.9%) Oropsylla montana were found to harbor Bartonella spp. when screened using citrate synthase (gltA) specific primers, whereas Bartonella DNA was not found in two other flea species, Hoplopsyllus anomalus (n = 86) and Echidnophaga gallinacea (n = 6). The prevalence of B. washoensis in O. montana by location ranged from 0% to 58.8%. A majority of the gltA sequences (92.0%) recovered from ground squirrels and fleas were closely related (similarity 99.4-100%) to one of two previously described strains isolated from human patients, B. washoensis NVH1 (myocarditis case in Nevada) and B. washoensis 08S-0475 (meningitis case in California). The results from this study support the supposition that O. beecheyi and the flea, O. montana, serve as a vertebrate reservoir and a vector, respectively, of zoonotic B. washoensis in California. C1 [Osikowicz, Lynn M.; Rizzo, Maria Fernanda; Kosoy, Michael] Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. [Billeter, Sarah A.; Freeman, Ashley N.; Burns, Joseph E.; Hu, Renjie] Calif Dept Publ Hlth, Vector Borne Dis Sect, Ontario, CA USA. [Rood, Michael P.] Los Angeles Cty Dept Publ Hlth, Div Environm Hlth, Vector Management Program, Baldwin Pk, CA USA. [Juieng, Phalasy; Loparev, Vladimir] Ctr Dis Control & Prevent, Div Sci Resources, Atlanta, GA USA. RP Osikowicz, LM (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM vir5@cdc.gov NR 35 TC 0 Z9 0 U1 3 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD NOV PY 2016 VL 16 IS 11 BP 683 EP 690 DI 10.1089/vbz.2016.2009 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EA7BG UT WOS:000386782500001 PM 27705539 ER PT J AU Murphy, JL Ayers, TL Knee, J Oremo, J Odhiambo, A Faith, SH Nyagol, RO Stauber, CE Lantagne, DS Quick, RE AF Murphy, Jennifer L. Ayers, Tracy L. Knee, Jacqueline Oremo, Jared Odhiambo, Aloyce Faith, Sitnah H. Nyagol, Ronald O. Stauber, Christine E. Lantagne, Daniele S. Quick, Robert E. TI Evaluating four measures of water quality in clay pots and plastic safe storage containers in Kenya SO WATER RESEARCH LA English DT Article DE Chlorination; Household water treatment; Safe water storage ID POINT-OF-USE; HOUSEHOLD DRINKING-WATER; WESTERN KENYA; MICROBIOLOGICAL CONTAMINATION; DEVELOPING-COUNTRIES; USE CHLORINATION; NYANZA PROVINCE; CHILD DIARRHEA; IMPACT; DISINFECTION AB Household water treatment with chlorine can improve microbiological' quality and reduce diarrhea. Chlorination is typically assessed using free chlorine residual (FCR), with a lower acceptable limit of 0.2 mg/L, however, accurate measurement of FCR is challenging with turbid water. To compare potential measures of adherence to treatment and water quality, we chlorinated recently-collected water in rural Kenyan households and measured total chlorine residual (TCR), FCR, oxidation reduction potential (ORP), and E. coli concentration over 72 h in clay and plastic containers. Results showed that 1) ORP served as a useful proxy for chlorination in plastic containers up to 24 h; 2) most stored water samples disinfected by chlorination remained significantly less contaminated than source water for up to 72 h, even in the absence of FCR; 3) TCR may be a useful proxy indicator of microbiologic water quality because it confirms previous chlorination and is associated with a lower risk of E. coli contamination compared to untreated source water; and 4) chlorination is more effective in plastic than clay containers presumably because of lower chlorine demand in plastic. Published by Elsevier Ltd. C1 [Murphy, Jennifer L.; Ayers, Tracy L.; Knee, Jacqueline; Quick, Robert E.] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. [Oremo, Jared; Odhiambo, Aloyce; Faith, Sitnah H.; Nyagol, Ronald O.] Safe Water & AIDS Project, Kisumu, Kenya. [Stauber, Christine E.] Georgia State Univ, Atlanta, GA 30303 USA. [Lantagne, Daniele S.] Tufts Univ, Dept Civil & Environm Engn, Boston, MA 02111 USA. RP Murphy, JL (reprint author), Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. EM iod7@cdc.gov OI Ayers, Tracy/0000-0003-4140-3263 FU Clorox Company FX We thank our colleagues at the Safe Water and AIDS Project (SWAP) in Kisumu for their diligent work, including field supervisor Owiti Maurice Owiti and field research assistants Juma Grace Akinyi, Okuttah Paul Omondi, Okello Lydia Akoth, and Okoth A Rosemary. We are grateful to study participants in project villages for their gracious willingness to interrupt their daily activities to help in this research. We also thank William J. Murphy for preparing the photographs for publication. This study was supported by a grant from the Clorox Company. We appreciate the interest in this topic and support of Alexis Limberakis and Elias Shaheen. The use of trade names and commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services. The findings and conclusions in this presentation are those of the authors and do not necessarily represent those of the CDC. NR 37 TC 0 Z9 0 U1 7 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0043-1354 J9 WATER RES JI Water Res. PD NOV 1 PY 2016 VL 104 BP 312 EP 319 DI 10.1016/j.watres.2016.08.022 PG 8 WC Engineering, Environmental; Environmental Sciences; Water Resources SC Engineering; Environmental Sciences & Ecology; Water Resources GA EA2DB UT WOS:000386401900032 PM 27565116 ER PT J AU Guerin, RJ Okun, AH Kelley, P AF Guerin, Rebecca J. Okun, Andrea H. Kelley, Patricia TI Development and validation of an assessment tool for a national young worker curriculum SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE National Institute for Occupational Safety and Health (U.S); Centers for Disease Control and Prevention (U.S); assessment; measurement; work; safety; adolescent; occupational injuries; young workers; curriculum ID INJURIES; HEALTH AB BackgroundAn online, multiple-choice assessment was developed and validated for Youth@Work-Talking Safety, a NIOSH curriculum that equips middle and high school students with foundational workplace safety and health knowledge and skills. MethodsClassical Test Theory was used for the test development and validation; the Jaeger method was used for cut score determination. A total of 118 multiple-choice items were developed to measure the acquisition of knowledge and skills taught through the NIOSH curriculum. Pilot testing was conducted with 192 8-12th grade students and a cut score was determined. ResultsThe mean score for all test-takers on the Talking Safety assessment was 80.9%; total test reliability measured using an Alpha/KR20 statistic was 0.93. A minimum passing (cut) score of 74% was established. ConclusionsThe assessment provides an objective measure of students' acquisition of the foundational workplace safety and health competencies taught through the Talking Safety curriculum. Am. J. Ind. Med. 59:969-978, 2016. (c) 2016 Wiley Periodicals, Inc. C1 [Guerin, Rebecca J.; Okun, Andrea H.] NIOSH, US Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Kelley, Patricia] NOCTI, Big Rapids, MI USA. RP Guerin, RJ (reprint author), NIOSH, Educ & Informat Div, 1090 Tusculum Ave,MS C-10, Cincinnati, OH 45226 USA. EM rguerin@cdc.gov FU Intramural CDC HHS [CC999999] NR 28 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD NOV PY 2016 VL 59 IS 11 BP 969 EP 978 DI 10.1002/ajim.22610 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ7KF UT WOS:000386043600006 PM 27711978 ER PT J AU Bertke, SJ Lehman, EJ Wurzelbacher, SJ Hein, MJ AF Bertke, Stephen J. Lehman, Everett J. Wurzelbacher, Steven J. Hein, Misty J. TI Mortality of lead smelter workers: A follow-up study with exposure assessment SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE mortality cohort study; lead exposure ID TABLE ANALYSIS SYSTEM; BLOOD LEAD; UNITED-STATES; CARDIOVASCULAR-DISEASE; CIGARETTE-SMOKING; PRESSURE; METAANALYSIS; ASSOCIATION; POPULATION; UPDATE AB BackgroundLead exposure has been linked to impaired renal function and kidney failure. High lead exposures have been associated with increased mortality from certain cancers, hypertension, cardiovascular disease, and amyotrophic lateral sclerosis (ALS). MethodsWe extended vital status follow-up on a cohort of 1,990 lead smelter workers by 25 years and computed standardized mortality ratios and rate ratios (RR) stratified by cumulative lead exposure. ResultsThe update added 13,823 person-years at risk and 721 deaths. Increased risk of mortality was observed for the a priori outcomes of lung cancer, cardiovascular disease (including cerebrovascular disease), chronic kidney disease, and ALS. However, of these outcomes, only cardiovascular, cerebrovascular, and chronic kidney diseases were associated with a positive exposure-response in RR analyses. ConclusionsThis study reaffirms the association of lead exposure with cardiovascular and kidney diseases; however, increased mortality observed for certain cancers is not likely to be due to lead exposure. Am. J. Ind. Med. 59:979-986, 2016. Published 2016. This article is a U.S. Government work and is in the public domain in the USA. C1 [Bertke, Stephen J.; Lehman, Everett J.; Wurzelbacher, Steven J.; Hein, Misty J.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Industrywide Studies Branch, 5555 Ridge Rd, Cincinnati, OH 45213 USA. RP Bertke, SJ (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Industrywide Studies Branch, 5555 Ridge Rd, Cincinnati, OH 45213 USA. EM inh4@cdc.gov FU National Institute for Occupational Safety and Health FX Funded by the National Institute for Occupational Safety and Health. Approved by the CDC Human Subjects Review Board (#07-DSHEFS-01XP). NR 26 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD NOV PY 2016 VL 59 IS 11 BP 979 EP 986 DI 10.1002/ajim.22618 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ7KF UT WOS:000386043600007 PM 27350012 ER PT J AU Charles, LE Zhao, SZ Fekedulegn, D Violanti, JM Andrew, ME Burchfiel, CM AF Charles, Luenda E. Zhao, Songzhu Fekedulegn, Desta Violanti, John M. Andrew, Michael E. Burchfiel, Cecil M. TI Shiftwork and decline in endothelial function among police officers SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE endothelial function; flow-mediated dilation; police officers; shiftwork; brachial artery reactivity; law enforcement officers ID FLOW-MEDIATED DILATION; BRACHIAL-ARTERY REACTIVITY; CARDIOVASCULAR-DISEASE; MORNING ATTENUATION; NIGHT SHIFTS; DYSFUNCTION; EVENTS; INFLAMMATION; EXERCISE; MARKERS AB BackgroundOur objective was to assess the influence of shiftwork on change in endothelial function. MethodsThis longitudinal study was conducted in 188 police officers (78.2% men). Shiftwork status (day, afternoon, night) was assessed objectively using daily Buffalo, NY payroll work history records. Brachial artery flow-mediated dilation (FMD) was assessed using ultrasound. Mean change in FMD% between 2004-2009 and 2010-2015 was compared across shiftwork using analysis of variance/covariance. ResultsOverall, mean FMD% decreased from 5.742.83 to 3.88 +/- 2.11 over an average of 7 years among all officers; P<0.0001. Effect modification by gender was significant. Among men (but not women), those who worked day shifts had a smaller mean (+/- SE) decrease in FMD% (-0.89 +/- 0.35) compared with those who worked the afternoon (-2.69 +/- 0.39; P=0.001) or night shifts (-2.31 +/- 0.45; P=0.020) after risk factor adjustment. ConclusionsLarger declines in endothelial function were observed among men who worked afternoon or night shifts. Further investigation is warranted. Am. J. Ind. Med. 59:1001-1008, 2016. Published 2016. This article is a U.S. Government work and is in the public domain in the USA C1 [Charles, Luenda E.; Zhao, Songzhu; Fekedulegn, Desta; Andrew, Michael E.; Burchfiel, Cecil M.] NIOSH, Hlth Effects Lab Div, Biostat & Epidemiol Branch, Ctr Dis Control & Prevent, Morgantown, WV USA. [Violanti, John M.] SUNY Buffalo, Dept Epidemiol & Environm Hlth, Sch Publ Hlth & Hlth Profess, Buffalo, NY USA. RP Charles, LE (reprint author), NIOSH, US Ctr Dis Control & Prevent, HELD, BEB, MS L-4050,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM lcharles@cdc.gov FU National Institute for Occupational Safety and Health (NIOSH) [200-2003-01580, 1R01OH 009640-01A1] FX This work was supported by the National Institute for Occupational Safety and Health (NIOSH), contract no. 200-2003-01580 and grant no. (1R01OH 009640-01A1). NR 28 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD NOV PY 2016 VL 59 IS 11 BP 1001 EP 1008 DI 10.1002/ajim.22611 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ7KF UT WOS:000386043600009 PM 27245641 ER PT J AU Steege, AL Boiano, JM Sweeney, MH AF Steege, Andrea L. Boiano, James M. Sweeney, Marie H. TI Secondhand smoke in the operating room? Precautionary practices lacking for surgical smoke SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE surgical smoke; local exhaust ventilation (LEV); electrosurgery; smoke evacuators; laser surgery; engineering controls; healthcare workers ID LASER; PAPILLOMAVIRUS; MUTAGENICITY; HEALTH AB BackgroundConsensus organizations, government bodies, and healthcare organization guidelines recommend that surgical smoke be evacuated at the source by local exhaust ventilation (LEV) (i.e., smoke evacuators or wall suctions with inline filters). MethodsData are from NIOSH's Health and Safety Practices Survey of Healthcare Workers module on precautionary practices for surgical smoke. ResultsFour thousand five hundred thirty-three survey respondents reported exposure to surgical smoke: 4,500 during electrosurgery; 1,392 during laser surgery procedures. Respondents were mainly nurses (56%) and anesthesiologists (21%). Only 14% of those exposed during electrosurgery reported LEV was always used during these procedures, while 47% reported use during laser surgery. Those reporting LEV was always used were also more likely to report training and employer standard procedures addressing the hazards of surgical smoke. Few respondents reported use of respiratory protection. ConclusionsStudy findings can be used to raise awareness of the marginal use of exposure controls and impediments for their use. Am. J. Ind. Med. 59:1020-1031, 2016. Published 2016. This article is a U.S. Government work and is in the public domain in the USA C1 [Steege, Andrea L.; Boiano, James M.; Sweeney, Marie H.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 1090 Tusculum Ave,MS R-18, Cincinnati, OH 45226 USA. RP Steege, AL (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 1090 Tusculum Ave,MS R-18, Cincinnati, OH 45226 USA. EM asteege@cdc.gov FU National Institute for Occupational Safety and Health FX This project was supported by the National Institute for Occupational Safety and Health. NR 35 TC 3 Z9 3 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD NOV PY 2016 VL 59 IS 11 BP 1020 EP 1031 DI 10.1002/ajim.22614 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ7KF UT WOS:000386043600011 PM 27282626 ER PT J AU Perera, F Nolte, ELR Wang, Y Margolis, AE Calafat, AM Wang, S Garcia, W Hoepner, LA Peterson, BS Rauh, V Herbstman, J AF Perera, Frederica Nolte, Emily L. Roen Wang, Ya Margolis, Amy E. Calafat, Antonia M. Wang, Shuang Garcia, Wanda Hoepner, Lori A. Peterson, Bradley S. Rauh, Virginia Herbstman, Julie TI Bisphenol A exposure and symptoms of anxiety and depression among inner city children at 10-12 years of age SO ENVIRONMENTAL RESEARCH LA English DT Article DE Prenatal; Bisphenol A; Child behavior; Sex-specific ID URINARY PHTHALATE METABOLITE; MANIFEST ANXIETY; TEMPORAL VARIABILITY; PRENATAL EXPOSURE; PREGNANT-WOMEN; DEVELOPMENTAL EXPOSURE; SEXUAL-DIFFERENTIATION; PSYCHIATRIC-DISORDERS; NEONATAL EXPOSURE; RATING-SCALE AB Background: Experimental and epidemiological studies suggest that gestational exposure to Bisphenol A (BPA), an ubiquitous endocrine disrupting chemical, may lead to neurobehavioral problems in childhood; however, not all results have been consistent. We previously reported a positive association between prenatal BPA exposure and symptoms of anxiety/depression reported by the mother at child age 7-9 years in boys, but not girls. Objectives: Here, in the same birth cohort, we investigated the association of prenatal BPA exposure with symptoms of depression and anxiety self-reported by the 10-12 year olds; hypothesizing that we would observe sex-specific differences in anxiety and depressive symptoms. Methods: African-American and Dominican women living in Northern Manhattan and their children were followed from mother's pregnancy through children's age 10-12 years. BPA was quantified in maternal urine collected during the third trimester of pregnancy and in child urine collected at ages 3 and 5 years. Children were evaluated using the Revised Children's Manifest Anxiety Scale (RCMAS) and Children's Depression Rating Scale (CDRS). We compared the children in the highest tertile of BPA concentration to those in the lower two tertiles. Associations between behavior and prenatal (maternal) BPA concentration or postnatal (child) BPA concentration were assessed in regression models stratified by sex. Results: Significant positive associations between prenatal BPA and symptoms of depression and anxiety were observed among boys. Postnatal BPA exposure was not significantly associated with outcomes. There was substantial co-occurrence of anxiety and depressive symptoms in this sample. Conclusion: These results provide evidence that prenatal BPA exposure is associated with more symptoms of anxiety and depression in boys but not in girls at age 10-12 years. 2016 Elsevier Inc. All rights reserved. C1 [Perera, Frederica; Nolte, Emily L. Roen; Hoepner, Lori A.; Herbstman, Julie] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, 722 W 168th St, New York, NY 10032 USA. [Perera, Frederica; Nolte, Emily L. Roen; Wang, Ya; Margolis, Amy E.; Wang, Shuang; Garcia, Wanda; Hoepner, Lori A.; Rauh, Virginia; Herbstman, Julie] Columbia Univ, Columbia Ctr Childrens Environm Hlth, 722 W 168th St, New York, NY 10032 USA. [Wang, Ya; Wang, Shuang] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, 722 W 168th St, New York, NY 10032 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Hwy,MS F17, Atlanta, GA 30341 USA. [Margolis, Amy E.] Columbia Univ, Div Child & Adolescent Psychiat, 1051 Riverside Dr, New York, NY 10032 USA. [Margolis, Amy E.] Columbia Univ, Ctr Dev Neuropsychiat, Dept Psychiat, New York State Psychiat Inst, 1051 Riverside Dr, New York, NY 10032 USA. [Margolis, Amy E.] Columbia Univ, Coll Phys & Surg, 1051 Riverside Dr, New York, NY 10032 USA. [Peterson, Bradley S.] Univ Southern Calif, Childrens Hosp Los Angeles, Inst Developing Mind, Los Angeles, CA 90089 USA. [Peterson, Bradley S.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Garcia, Wanda; Rauh, Virginia] Columbia Univ, Heilbrunn Dept Populat & Family Hlth, 60 Haven Ave, New York, NY 10032 USA. RP Perera, F (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, 722 W 168th St, New York, NY 10032 USA. EM fpp1@columbia.edu FU National Institute for Environmental Health Sciences (NIEHS); U.S. Environmental Protection Agency (US EPA) [NIEHS/EPA P01ES09600/R82702701, NIEHS/EPA P01ES09600/RD83214101, NIEHS/EPA P01ES09600/RD83450901, NIEHS R01ES08977, NIEHS R01ES015579, NIDA R01DA027100] FX Funding was provided by the National Institute for Environmental Health Sciences (NIEHS) and the U.S. Environmental Protection Agency (US EPA): NIEHS/EPA P01ES09600/R82702701, NIEHS/EPA P01ES09600/RD83214101, NIEHS/EPA P01ES09600/RD83450901, NIEHS R01ES08977, NIEHS R01ES015579, and NIDA R01DA027100. This publication was also made possible in part by the John and Wendy Neu Family Foundation, the New York Community Trust, and the Trustees of the Blanchette Hooker Rockefeller Fund. NR 81 TC 0 Z9 0 U1 13 U2 13 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD NOV PY 2016 VL 151 BP 195 EP 202 DI 10.1016/j.envres.2016.07.028 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA EA2HO UT WOS:000386413600022 PM 27497082 ER PT J AU Minguez-Alarcon, L Souter, I Chiu, YH Williams, PL Ford, JB Ye, X Calafat, AM Hauser, R AF Minguez-Alarcon, Lidia Souter, Irene Chiu, Yu -Han Williams, Paige L. Ford, Jennifer B. Ye, Xiaoyun Calafat, Antonia M. Hauser, Russ CA Earth Study Team TI Urinary concentrations of cyclohexane-1,2-dicarboxylic acid monohydroxy isononyl ester, a metabolite of the non-phthalate plasticizer di(isononyl)cyclohexane-1,2-dicarboxylate (DINCH), and markers of ovarian response among women attending a fertility center SO ENVIRONMENTAL RESEARCH LA English DT Article DE DINCH metabolites; Epidemiology; Markers of ovarian response; Phthalates; Reproductive health ID VASCULAR FRACTION DIFFERENTIATION; DIISONONYL ESTER; ADIPOSE-TISSUE; EXPOSURE; HEALTH; POPULATION; CARE AB Di(isononyl)cyclohexane-1,2-dicarboxylate (DINCH), a non-phthalate plasticizer, was introduced commercially in 2002 as an alternative to ortho-phthalate esters because of its favorable toxicological profile. However, the potential health effects from DINCH exposure remain largely unknown. We explored the associations between urinary concentrations of metabolites of DINCH on markers of ovarian response among women undergoing in vitro fertilization (IVF) treatments. Between 2011 and 2015, 113 women enrolled a prospective cohort study at the Massachusetts General Hospital Fertility Center and provided up to two urine samples prior to oocyte retrieval. The urinary concentrations of two DINCH metabolites, cyclohexane-1,2-dicarboxylic acid monohydroxy isononyl ester (MHiNCH) and cyclohexane-1,2-dicarboxylic acid monocarboxyisooctyl ester (MCOCH), were quantified by isotope dilution tandem mass spectrometry. We used generalized linear mixed models to evaluate the association between urinary metabolite concentrations and markers of ovarian response, accounting for multiple IVF cycles per woman via random intercepts. On average, women with detectable urinary MHiNCH concentrations, as compared to those below LOD, had a lower estradiol levels (-325 pmol/l, p=0.09) and number of retrieved oocytes (-1.8, p=0.08), with a stronger association among older women. However, urinary MHiNCH concentrations were unrelated to mature oocyte yield and endometrial wall thickness. In conclusion, we found suggestive negative associations between urinary MHiNCH concentrations and peak estradiol levels and number of total oocyte yields. This is the first study evaluating the effect of DINCH exposure on human reproductive health and raises the need for further experimental and epidemiological studies to better understand the potential effects of this chemical on health. (C) 2016 Elsevier Inc. All rights reserved. C1 [Minguez-Alarcon, Lidia; Ford, Jennifer B.; Hauser, Russ] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Chiu, Yu -Han] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Williams, Paige L.; Hauser, Russ] Dept Epidemiol, Boston, MA USA. [Williams, Paige L.; Hauser, Russ] Harvard TH Chan Sch Publ Hlth, Boston, MA USA. [Williams, Paige L.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Souter, Irene; Hauser, Russ] Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA. [Souter, Irene; Hauser, Russ] Harvard Med Sch, Boston, MA USA. [Ye, Xiaoyun; Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Minguez-Alarcon, L (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. EM lminguez@hsph.harvard.edu FU NIH from the National Institute of Environmental Health Sciences (NIEHS) [R01ES022955, R01ES009718, R01ES000002] FX NIH grants R01ES022955, R01ES009718, and R01ES000002 from the National Institute of Environmental Health Sciences (NIEHS). NR 30 TC 0 Z9 0 U1 8 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD NOV PY 2016 VL 151 BP 595 EP 600 DI 10.1016/j.envres.2016.08.012 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA EA2HO UT WOS:000386413600063 PM 27591839 ER PT J AU Botton, J Philippat, C Calafat, AM Caries, S Charles, MA Slama, R AF Botton, Jeremie Philippat, Claire Calafat, Antonia M. Caries, Sophie Charles, Marie-Aline Slama, Remy CA EDEN mother-child cohort study gro TI Phthalate pregnancy exposure and male offspring growth from the intra-uterine period to five years of age SO ENVIRONMENTAL RESEARCH LA English DT Article DE Body Mass Index; Endocrine Disruptors; Epidemiology; Fetal growth; Infant growth; Phthalates ID BODY-MASS INDEX; PRENATAL EXPOSURE; BIRTH OUTCOMES; TEMPORAL VARIABILITY; POSTNATAL WEIGHT; PHENOLS; COHORT; DETERMINANTS; METABOLITES; ENDOCRINE AB Objective: To study associations between prenatal exposure to phthalates and fetal and postnatal growth up to age 5 years in male offspring. Methods: Eleven phthalate metabolites were quantified in spot maternal urine samples collected during gestation among 520 women of the EDEN mother-child cohort who gave birth to a boy. Fetal growth was assessed from repeated ultrasound measurements and measurements at birth. We used repeated measures of weight and height in the first 5 years of life to model individual postnatal growth trajectories. We estimated adjusted variations in pre and postnatal growth parameters associated with an inter quartile range increase in In-transformed phthalate metabolite concentrations. Results: Monocarboxyisononyl phthalate (MCNP) was positively associated with femoral length during gestation and length at birth. High molecular weight phthalate metabolites were negatively associated with estimated fetal weight throughout pregnancy. Monoethyl phthalate (MEP) showed positive association with weight growth velocity from two to five years and with body mass index at five years (beta=0.17 kg/m(2), 95% confidence interval, 0.04, 0.30). Conclusions: We highlighted associations between gestational exposure to some phthalates and growth in boys. The positive association between MEP and postnatal growth in boys was also reported in several previous human studies. (C) 2016 Elsevier Inc. All rights reserved. C1 [Botton, Jeremie; Caries, Sophie; Charles, Marie-Aline; EDEN mother-child cohort study gro] Paris Descartes Univ, Sorbonne Paris Cite Ctr CRESS, Team Early Origin Childs Hlth & Dev ORCHAD, INSERM,Epidemiol & Biostat UMR1153, Paris, France. [Botton, Jeremie] Univ Paris Saclay, Univ Paris 11, Fac Pharm, F-92296 Chatenay Malabry, France. [Philippat, Claire; Slama, Remy] Univ Grenoble Alpes, Team Environm Epidemiol Appl Reprod & Resp Hlth, Res Ctr, Inserm,CNRS,IAB, F-38000 Grenoble, France. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Caries, Sophie; Charles, Marie-Aline] Paris Descartes Univ, F-75005 Paris, France. RP Botton, J (reprint author), INSERM, UMR 1153, Equipe ORCHAD, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France. EM jeremie.botton@inserm.fr OI Slama, Remy/0000-0002-8980-8529; Botton, Jeremie/0000-0002-4814-6370 FU ANSES (PEnDevE project for Perturbateurs Endocriniens et Developpement de l'Enfant) [EST-2010/2/126]; European Research Council [311765-E-DOHaD]; FRM; Inserm; IReSP; Nestle; French Ministry of Health; ANR; Univ. Paris-Sud; InVS; ANSES; MGEN FX This research was supported by ANSES (PEnDevE project for Perturbateurs Endocriniens et Developpement de l'Enfant, EST-2010/2/126) and by the European Research Council (consolidator grant No 311765-E-DOHaD, PI, R. Slama). The EDEN cohort is supported by grants from FRM, Inserm, IReSP, Nestle, French Ministry of Health, ANR, Univ. Paris-Sud, InVS, ANSES and MGEN. NR 33 TC 0 Z9 0 U1 8 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD NOV PY 2016 VL 151 BP 601 EP 609 DI 10.1016/j.envres.2016.08.033 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA EA2HO UT WOS:000386413600064 PM 27596487 ER PT J AU Levin, ML Schumacher, LBM AF Levin, Michael L. Schumacher, Lauren B. M. TI Manual for maintenance of multi-host ixodid ticks in the laboratory SO EXPERIMENTAL AND APPLIED ACAROLOGY LA English DT Review DE Tick colony; Colony maintenance; Ixodid ticks; Rearing ID HAEMAPHYSALIS-LEPORIS-PALUSTRIS; HYALOMMA-TRUNCATUM ACARI; AMBLYOMMA-PARVUM ARAGAO; LIFE-CYCLE; RHIPICEPHALUS-SANGUINEUS; FEEDING PERFORMANCE; HOST-SPECIFICITY; SCAPULARIS ACARI; PACIFICUS ACARI; IMMATURE STAGES AB Use of laboratory animals as hosts for blood-sucking arthropods remains a time-proven and the most efficient method for establishment and propagation of slowly feeding ixodid ticks, despite introduction of techniques involving artificial feeding on either animal skins or synthetic membranes. New Zealand White rabbits are usually the most accessible and most suitable hosts routinely used for establishment and maintenance of a large variety of multi-host tick species. Here we describe standard procedures for maintaining colonies of multi-host ixodid ticks by feeding all developmental stages (larvae, nymphs, and adults) upon New Zealand White rabbits. When needed, the same procedures can be easily adapted to other species of laboratory or domestic animals from mice to dogs and goats. A summary of our experience in maintaining laboratory colonies of Ixodes scapularis, Ixodes pacificus, Amblyomma americanum, Dermacentor variabilis, Dermacentor occidentalis, Haemaphysalis leporispalustris, and Rhipicephalus sanguineus with descriptions of the complete laboratory life cycles and reliable production of uninfected ticks under standardized conditions has been published by Troughton and Levin (J Med Entomol 44:732-740, 2007). Here we provide step-by-step recommendations for various procedures used in the maintenance of ixodid tick colonies based on over 20 years of experience. C1 [Levin, Michael L.; Schumacher, Lauren B. M.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, 1600 Clifton Rd NE,MS G-13, Atlanta, GA 30329 USA. RP Levin, ML (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, 1600 Clifton Rd NE,MS G-13, Atlanta, GA 30329 USA. EM MLevin@cdc.gov NR 81 TC 0 Z9 0 U1 8 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0168-8162 EI 1572-9702 J9 EXP APPL ACAROL JI Exp. Appl. Acarol. PD NOV PY 2016 VL 70 IS 3 BP 343 EP 367 DI 10.1007/s10493-016-0084-8 PG 25 WC Entomology SC Entomology GA DZ7VL UT WOS:000386075800007 PM 27651325 ER PT J AU Almli, LM Jenkins, MM Bay, CP Romitti, PA Moreno-Uribe, L Wehby, GL AF Almli, Lynn M. Jenkins, Mary M. Bay, Camden P. Romitti, Paul A. Moreno-Uribe, Lina Wehby, George L. CA Natl Birth Defects Prevention Stud TI Socioeconomic Status, Genetic Risk, and How their Interactions Affect Risk of Oral Clefts SO GENETIC EPIDEMIOLOGY LA English DT Meeting Abstract CT Annual Meeting of the International-Genetic-Epidemiology-Society CY OCT 24-26, 2016 CL Toronto, CANADA SP Int Genet Epidemiol Soc C1 [Almli, Lynn M.] Carter Consulting Inc, Atlanta, GA USA. [Jenkins, Mary M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bay, Camden P.; Romitti, Paul A.; Moreno-Uribe, Lina; Wehby, George L.] Univ Iowa, Iowa City, IA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0741-0395 EI 1098-2272 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PD NOV PY 2016 VL 40 IS 7 MA 36 BP 621 EP 622 PG 2 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA DZ7HF UT WOS:000386034800043 ER PT J AU Whelton, PK Einhorn, PT Muntner, P Appel, LJ Cushman, WC Roux, AVD Ferdinand, KC Rahman, M Taylor, HA Ard, J Arnett, DK Carter, BL Davis, BR Freedman, BI Cooper, LA Cooper, R Desvigne-Nickens, P Gavini, N Go, AS Hyman, DJ Kimmel, PL Margolis, KL Miller, ER Mills, KT Mensah, GA Navar, AM Ogedegbe, G Rakotz, MK Thomas, G Tobin, JN Wright, JT Yoon, SS Cutler, JA AF Whelton, Paul K. Einhorn, Paula T. Muntner, Paul Appel, Lawrence J. Cushman, William C. Roux, Ana V. Diez Ferdinand, Keith C. Rahman, Mahboob Taylor, Herman A. Ard, Jamy Arnett, Donna K. Carter, Barry L. Davis, Barry R. Freedman, Barry I. Cooper, Lisa A. Cooper, Richard Desvigne-Nickens, Patrice Gavini, Nara Go, Alan S. Hyman, David J. Kimmel, Paul L. Margolis, Karen L. Miller, Edgar R., III Mills, Katherine T. Mensah, George A. Navar, Ann M. Ogedegbe, Gbenga Rakotz, Michael K. Thomas, George Tobin, Jonathan N. Wright, Jackson T. Yoon, Sung Sug (Sarah) Cutler, Jeffrey A. CA Natl Heart Lung Blood Inst Working TI Research Needs to Improve Hypertension Treatment and Control in African Americans SO HYPERTENSION LA English DT Review ID HIGH BLOOD-PRESSURE; LIPID-LOWERING TREATMENT; ATTACK TRIAL ALLHAT; INFLUENCING ANTIHYPERTENSIVE RESPONSE; GENOMIC ASSOCIATION ANALYSIS; RANDOMIZED CLINICAL-TRIAL; CHRONIC KIDNEY-DISEASE; TEAM-BASED CARE; CARDIOVASCULAR-DISEASE; HIGH-RISK C1 [Whelton, Paul K.; Ferdinand, Keith C.] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 8318,1440 Canal St,Room 2018, New Orleans, LA 70112 USA. [Whelton, Paul K.; Ferdinand, Keith C.] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA. [Einhorn, Paula T.; Desvigne-Nickens, Patrice; Mensah, George A.; Cutler, Jeffrey A.] NHLBI, Div Cardiovasc Sci, Bldg 10, Bethesda, MD 20892 USA. [Gavini, Nara; Mensah, George A.] NHLBI, Ctr Translat Res & Implementat Sci, Bldg 10, Bethesda, MD 20892 USA. [Muntner, Paul] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Appel, Lawrence J.; Cooper, Lisa A.; Miller, Edgar R., III] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA. [Cushman, William C.] Vet Affairs Med Ctr, Prevent Med Sect, Memphis, TN USA. [Roux, Ana V. Diez] Drexel Univ, Dornsife Sch Publ Hlth, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Rahman, Mahboob; Wright, Jackson T.] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Louis Stokes Cleveland VA Med Ctr, Dept Med, Cleveland, OH 44106 USA. [Taylor, Herman A.] Morehouse Sch Med, Cardiovasc Res Inst, Atlanta, GA 30310 USA. [Ard, Jamy] Wake Forest Univ, Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA. [Ard, Jamy; Freedman, Barry I.] Wake Forest Univ, Wake Forest Sch Med, Dept Med, Winston Salem, NC 27109 USA. [Arnett, Donna K.] Univ Kentucky, Deans Off, Coll Publ Hlth, Lexington, KY 40506 USA. [Carter, Barry L.] Univ Iowa, Coll Pharm, Dept Pharm Practice & Sci, Iowa City, IA 52242 USA. [Davis, Barry R.] Univ Texas Sch Publ Hlth, Dept Biostat, Houston, TX USA. [Cooper, Richard] Loyola Univ Chicago, Stritch Sch Med, Dept Publ Hlth Sci, Maywood, IL USA. [Go, Alan S.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Hyman, David J.] Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USA. [Kimmel, Paul L.] NIDDK, Bethesda, MD 20892 USA. [Margolis, Karen L.] HealthPartners Inst, Minneapolis, MN USA. [Navar, Ann M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Ogedegbe, Gbenga] NYU Sch Med, Dept Populat Hlth, New York, NY USA. [Rakotz, Michael K.] Amer Med Assoc, 515 N State St, Chicago, IL 60610 USA. [Thomas, George] Cleveland Clin, Dept Hypertens & Nephrol, Cleveland, OH USA. [Tobin, Jonathan N.] Clin Directors Network, New York, NY USA. [Tobin, Jonathan N.] Rockefeller Univ, Ctr Clin & Translat Sci, 1230 York Ave, New York, NY 10021 USA. [Yoon, Sung Sug (Sarah)] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Whelton, PK (reprint author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 8318,1440 Canal St,Room 2018, New Orleans, LA 70112 USA. EM pkwhelton@gmail.com FU NHLBI; National Institutes of Health (NIH) [T32HL069749-12]; National Institute of Diabetes and Digestive and Kidney Diseases FX This work was supported by the NHLBI with a contribution from the National Institute of Diabetes and Digestive and Kidney Diseases. A.M. Navar was supported by National Institutes of Health (NIH) training grant T32HL069749-12. NR 76 TC 1 Z9 1 U1 8 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0194-911X EI 1524-4563 J9 HYPERTENSION JI Hypertension PD NOV PY 2016 VL 68 IS 5 BP 1066 EP 1072 DI 10.1161/HYPERTENSIONAHA.116.07905 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DZ9VE UT WOS:000386227500003 PM 27620388 ER PT J AU Weiner, LM Webb, AK Limbago, B Dudeck, MA Patel, J Kallen, AJ Edwards, JR Sievert, DM AF Weiner, Lindsey M. Webb, Amy K. Limbago, Brandi Dudeck, Margaret A. Patel, Jean Kallen, Alexander J. Edwards, Jonathan R. Sievert, Dawn M. TI Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014 SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article AB OBJECTIVE. To describe antimicrobial resistance patterns for healthcare-associated infections (HAIs) that occurred in 2011-2014 and were reported to the Centers for Disease Control and Prevention's National Healthcare Safety Network. METHODS. Data from central line associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated pneumonias, and surgical site infections were analyzed. These HAIs were reported from acute care hospitals, long-term acute care hospitals, and inpatient rehabilitation facilities. Pooled mean proportions of pathogens that tested resistant (or nonsusceptible) to selected antimicrobials were calculated by year and HAI type. RESULTS. Overall, 4,515 hospitals reported that at least 1 HAI occurred in 2011-2014. There were 408,151 pathogens from 365,490 HAIs reported to the National Healthcare Safety Network, most of which were reported from acute care hospitals with greater than 200 beds. Fifteen pathogen groups accounted for 87% of reported pathogens; the most common included Escherichia coli (15%), Staphylococcus aureus (12%), Klebsiella species (8%), and coagulase-negative staphylococci (8%). In general, the proportion of isolates with common resistance phenotypes was higher among device-associated HAIs compared with surgical site infections. Although the percent resistance for most phenotypes was similar to earlier reports, an increase in the magnitude of the resistance percentages among E. coli pathogens was noted, especially related to fluoroquinolone resistance. CONCLUSION. This report represents a national summary of antimicrobial resistance among select HAIs and phenotypes. The distribution of frequent pathogens and some resistance patterns appear to have changed from 2009-2010, highlighting the need for continual, careful monitoring of these data across the spectrum of HAI types. C1 [Weiner, Lindsey M.; Webb, Amy K.; Limbago, Brandi; Dudeck, Margaret A.; Patel, Jean; Kallen, Alexander J.; Edwards, Jonathan R.; Sievert, Dawn M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Sievert, Dawn M.] Lantana Consulting Grp, East Thetford, VT USA. RP Weiner, LM (reprint author), 1600 Clifton Rd,MS A-24, Atlanta, GA 30329 USA. EM Lweiner@cdc.gov FU Division of Healthcare Quality Promotion, CDC FX The NHSN surveillance system is supported by the Division of Healthcare Quality Promotion, CDC. NR 16 TC 1 Z9 1 U1 7 U2 7 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD NOV PY 2016 VL 37 IS 11 BP 1288 EP 1301 DI 10.1017/ice.2016.174 PG 14 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EA2EA UT WOS:000386404400004 PM 27573805 ER PT J AU Molins, CR Delorey, MJ Sexton, C Schriefer, ME AF Molins, Claudia R. Delorey, Mark J. Sexton, Christopher Schriefer, Martin E. TI Lyme Borreliosis Serology: Performance of Several Commonly Used Laboratory Diagnostic Tests and a Large Resource Panel of Well-Characterized Patient Samples SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID DISEASE; BURGDORFERI; SERODIAGNOSIS; ANTIGEN; VLSE AB The current recommendation for the laboratory confirmation of Lyme disease is serology-based diagnostics. Specifically, a standardized two-tiered testing (STTT) algorithm is applied that utilizes a first-tier immunofluorescence assay or enzyme immunoassay (EIA) that, if the result is positive or equivocal, is followed by second-tier immunoblotting. Despite the standardization and performance achievements, STTT is considered technically complex and subjective, as well as insensitive for early acute infection. These issues have prompted development of novel algorithms and testing platforms. In this study, we evaluated the performance of several commonly used assays for STTT. Several modified two-tiered testing (MTTT) algorithms, including a 2-EIA algorithm and modified criteria for second-tier IgG immunoblots, were also evaluated. All tests were performed on sera from a recently available, well-defined archive of positive-and negative-control patients. Our study demonstrates differences in the results between individual first-and second-tier tests, although the overall agreement of the different STTT algorithms used was strong. In addition, the MTTT algorithm utilizing 2-EIAs was found to be equivalent to all STTT algorithms tested, with agreement ranging from 94 to 97%. The 2-EIA MTTT algorithm slightly enhanced sensitivity in early disease compared to the STTT algorithms evaluated. Furthermore, these data add to the mounting evidence that a 2-EIA-based MTTT algorithm, where immunoblotting is replaced by the C6 EIA, performs as well or better than STTT. C1 [Molins, Claudia R.; Delorey, Mark J.; Sexton, Christopher; Schriefer, Martin E.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. RP Schriefer, ME (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. EM mms7@cdc.gov NR 15 TC 1 Z9 1 U1 3 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD NOV PY 2016 VL 54 IS 11 BP 2726 EP 2734 DI 10.1128/JCM.00874-16 PG 9 WC Microbiology SC Microbiology GA DZ8ID UT WOS:000386113200016 PM 27558183 ER PT J AU Hayden, MK Lolans, K Haffenreffer, K Avery, TR Kleinman, K Li, HY Kaganov, RE Lankiewicz, J Moody, J Septimus, E Weinstein, RA Hickok, J Jernigan, J Perlin, JB Platt, R Huang, SS AF Hayden, Mary K. Lolans, Karen Haffenreffer, Katherine Avery, Taliser R. Kleinman, Ken Li, Haiying Kaganov, Rebecca E. Lankiewicz, Julie Moody, Julia Septimus, Edward Weinstein, Robert A. Hickok, Jason Jernigan, John Perlin, Jonathan B. Platt, Richard Huang, Susan S. CA AHRQ DEcIDE Network Healthcare-Asso Ctr Dis Control Prevention's CDC Prevention Epicenters Program TI Chlorhexidine and Mupirocin Susceptibility of Methicillin-Resistant Staphylococcus aureus Isolates in the REDUCE-MRSA Trial SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article AB Whether targeted or universal decolonization strategies for the control of methicillin-resistant Staphylococcus aureus (MRSA) select for resistance to decolonizing agents is unresolved. The REDUCE-MRSA trial (ClinicalTrials registration no. NCT00980980) provided an opportunity to investigate this question. REDUCE-MRSA was a 3-arm, cluster-randomized trial of either screening and isolation without decolonization, targeted decolonization with chlorhexidine and mupirocin, or universal decolonization without screening to prevent MRSA infection in intensive-care unit (ICU) patients. Isolates from the baseline and intervention periods were collected and tested for susceptibility to chlorhexidine gluconate (CHG) by microtiter dilution; mupirocin susceptibility was tested by Etest. The presence of the qacA or qacB gene was determined by PCR and DNA sequence analysis. A total of 3,173 isolates were analyzed; 2 were nonsusceptible to CHG (MICs, 8 mu g/ml), and 5/814 (0.6%) carried qacA or qacB. At baseline, 7.1% of MRSA isolates expressed low-level mupirocin resistance, and 7.5% expressed high-level mupirocin resistance. In a mixed-effects generalized logistic regression model, the odds of mupirocin resistance among clinical MRSA isolates or MRSA isolates acquired in an ICU in intervention versus baseline periods did not differ across arms, although estimates were imprecise due to small numbers. Reduced susceptibility to chlorhexidine and carriage of qacA or qacB were rare among MRSA isolates in the REDUCE-MRSA trial. The odds of mupirocin resistance were no different in the intervention versus baseline periods across arms, but the confidence limits were broad, and the results should be interpreted with caution. C1 [Hayden, Mary K.; Weinstein, Robert A.] Rush Univ, Med Ctr, Dept Med Infect Dis, Chicago, IL 60612 USA. [Hayden, Mary K.; Lolans, Karen; Li, Haiying] Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA. [Haffenreffer, Katherine; Avery, Taliser R.; Kleinman, Ken; Kaganov, Rebecca E.; Lankiewicz, Julie; Platt, Richard] Harvard Med Sch, Dept Populat Med, Boston, MA USA. [Haffenreffer, Katherine; Avery, Taliser R.; Kleinman, Ken; Kaganov, Rebecca E.; Lankiewicz, Julie; Platt, Richard] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Moody, Julia; Hickok, Jason; Perlin, Jonathan B.] Hosp Corp Amer, Nashville, TN USA. [Septimus, Edward] Texas A&M Hlth Sci Ctr, Coll Med, Div Internal Med, Houston, TX USA. [Weinstein, Robert A.] Cook Cty Hlth & Hosp Syst, Chicago, IL USA. [Jernigan, John] Ctr Dis Control & Prevent, Off HAI Prevent Res & Evaluat, Atlanta, GA USA. [Huang, Susan S.] Univ Calif Irvine, Sch Med, Div Infect Dis, Orange, CA 92668 USA. RP Hayden, MK (reprint author), Rush Univ, Med Ctr, Dept Med Infect Dis, Chicago, IL 60612 USA.; Hayden, MK (reprint author), Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA. EM mhayden@rush.edu FU HHS | Centers for Disease Control and Prevention (CDC) [1U01 CI00034]; HHS | Agency for Healthcare Research and Quality (AHRQ) [HHSA290201000008I, HHSA29032007T]; HAI Program from AHRQ [HHSA290201000008I, HHSA29032007T]; U.S. Department of Health and Human Services, as part of Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program; CDC Prevention Epicenters Program [1U01 CI000344] FX This work, including the efforts of Richard Platt, was funded by HHS | Centers for Disease Control and Prevention (CDC) (1U01 CI00034). This work, including the efforts of Richard Platt, was funded by HHS | Agency for Healthcare Research and Quality (AHRQ) (HHSA290201000008I). This work, including the efforts of Richard Platt, was funded by HHS | Agency for Healthcare Research and Quality (AHRQ) (HHSA29032007T).; This project was funded by the HAI Program under contract no. HHSA290201000008I and HHSA29032007T from AHRQ, the U.S. Department of Health and Human Services, as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program, and the CDC Prevention Epicenters Program (1U01 CI000344) (principal investigator, R.P.). NR 48 TC 1 Z9 1 U1 4 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD NOV PY 2016 VL 54 IS 11 BP 2735 EP 2742 DI 10.1128/JCM.01444-16 PG 8 WC Microbiology SC Microbiology GA DZ8ID UT WOS:000386113200017 PM 27558180 ER PT J AU Hakovirta, JR Prezioso, S Hodge, D Pillai, SP Weigel, LM AF Hakovirta, Janetta R. Prezioso, Samantha Hodge, David Pillai, Segaran P. Weigel, Linda M. TI Identification and Analysis of Informative Single Nucleotide Polymorphisms in 16S rRNA Gene Sequences of the Bacillus cereus Group SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article AB Analysis of 16S rRNA genes is important for phylogenetic classification of known and novel bacterial genera and species and for detection of uncultivable bacteria. PCR amplification of 16S rRNA genes with universal primers produces a mixture of amplicons from all rRNA operons in the genome, and the sequence data generally yield a consensus sequence. Here we describe valuable data that are missing from consensus sequences, variable effects on sequence data generated from nonidentical 16S rRNA amplicons, and the appearance of data displayed by different software programs. These effects are illustrated by analysis of 16S rRNA genes from 50 strains of the Bacillus cereus group, i.e., Bacillus anthracis, Bacillus cereus, Bacillus mycoides, and Bacillus thuringiensis. These species have 11 to 14 rRNA operons, and sequence variability occurs among the multiple 16S rRNA genes. A single nucleotide polymorphism (SNP) previously reported to be specific to B. anthracis was detected in some B. cereus strains. However, a different SNP, at position 1139, was identified as being specific to B. anthracis, which is a biothreat agent with high mortality rates. Compared with visual analysis of the electropherograms, basecaller software frequently missed gene sequence variations or could not identify variant bases due to overlapping basecalls. Accurate detection of 16S rRNA gene sequences that include intragenomic variations can improve discrimination among closely related species, improve the utility of 16S rRNA databases, and facilitate rapid bacterial identification by targeted DNA sequence analysis or by whole-genome sequencing performed by clinical or reference laboratories. C1 [Hakovirta, Janetta R.; Prezioso, Samantha; Weigel, Linda M.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Hodge, David] US Dept Homeland Secur, Sci & Technol Directorate, Washington, DC USA. [Pillai, Segaran P.] US FDA, Off Lab Sci & Safety, Silver Spring, MD USA. [Prezioso, Samantha] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA. RP Weigel, LM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM lweigel@cdc.gov FU Department of Homeland Security USA [HSHQDC-09-X-00240] FX This work was funded by Department of Homeland Security USA (HSHQDC-09-X-00240). NR 33 TC 0 Z9 0 U1 6 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD NOV PY 2016 VL 54 IS 11 BP 2749 EP 2756 DI 10.1128/JCM.01267-16 PG 8 WC Microbiology SC Microbiology GA DZ8ID UT WOS:000386113200019 PM 27582514 ER PT J AU Bartsch, SM Huang, SS Wong, KF Slayton, RB McKinnell, JA Sahm, DF Kazmierczak, K Mueller, LE Jernigan, JA Lee, BY AF Bartsch, Sarah M. Huang, Susan S. Wong, Kim F. Slayton, Rachel B. McKinnell, James A. Sahm, Daniel F. Kazmierczak, Krystyna Mueller, Leslie E. Jernigan, John A. Lee, Bruce Y. TI Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article AB Delays often occur between CLSI and FDA revisions of antimicrobial interpretive criteria. Using our Regional Healthcare Ecosystem Analyst (RHEA) simulation model, we found that the 32-month delay in changing carbapenem-resistant Enterobacteriaceae (CRE) breakpoints might have resulted in 1,821 additional carriers in Orange County, CA, an outcome that could have been avoided by identifying CRE and initiating contact precautions. Policy makers should aim to minimize the delay in the adoption of new breakpoints for antimicrobials against emerging pathogens when containment of spread is paramount; delays of < 1.5 years are ideal. C1 [Bartsch, Sarah M.; Mueller, Leslie E.; Lee, Bruce Y.] Johns Hopkins Bloomberg Sch Publ Hlth, Publ Hlth Computat & Operat Res PHICOR, Baltimore, MD USA. [Huang, Susan S.] Univ Calif Irvine, Sch Med, Div Infect Dis, Orange, CA 92668 USA. [Huang, Susan S.] Univ Calif Irvine, Hlth Policy Res Inst, Sch Med, Orange, CA 92668 USA. [Wong, Kim F.] Univ Pittsburgh, Ctr Simulat & Modeling, Pittsburgh, PA USA. [Slayton, Rachel B.; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [McKinnell, James A.] Harbor UCLA Med Ctr, Infect Dis Clin Outcomes Res Unit ID CORE, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. [McKinnell, James A.] Torrance Mem Med Ctr, Torrance, CA USA. [Sahm, Daniel F.; Kazmierczak, Krystyna] Int Hlth Management Associates Inc, Schaumburg, IL USA. RP Lee, BY (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Publ Hlth Computat & Operat Res PHICOR, Baltimore, MD USA. EM brucelee@jhu.edu FU Agency for Healthcare Research and Quality (AHRQ) [R01HS023317]; National Institute of Child Health and Human Development (NICHD); Global Obesity Prevention Center (GOPC) [U54HD070725]; NICHD [U01 HD086861]; CDC under an intergovernmental personnel act FX This work was supported by the Agency for Healthcare Research and Quality (AHRQ) via grant R01HS023317, by the National Institute of Child Health and Human Development (NICHD) and the Global Obesity Prevention Center (GOPC) via grant U54HD070725, and by NICHD via grant U01 HD086861. The University of Pittsburgh Center for Simulation and Modeling provided supercomputing resources for the project. Programmer analyst time was supported in part by the CDC under an intergovernmental personnel act. The funders had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript. NR 34 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD NOV PY 2016 VL 54 IS 11 BP 2757 EP 2762 DI 10.1128/JCM.00635-16 PG 6 WC Microbiology SC Microbiology GA DZ8ID UT WOS:000386113200020 PM 27582516 ER PT J AU Nascimento, FS Wei-Pridgeon, Y Arrowood, MJ Moss, D da Silva, AJ Talundzic, E Qvarnstrom, Y AF Nascimento, Fernanda S. Wei-Pridgeon, Yuping Arrowood, Michael J. Moss, Delynn da Silva, Alexandre J. Talundzic, Eldin Qvarnstrom, Yvonne TI Evaluation of library preparation methods for Illumina next generation sequencing of small amounts of DNA from foodborne parasites SO JOURNAL OF MICROBIOLOGICAL METHODS LA English DT Article DE Next generation sequencing; Illumina; MiSeq; Library preparation; Angiostrongylus cantonensis; Cyclospora cayetanensis ID ANGIOSTRONGYLUS-CANTONENSIS; CYCLOSPORA-CAYETANENSIS; CRYPTOSPORIDIUM-PARVUM; GENOME; CONSTRUCTION; OOCYSTS; BIAS AB Illumina library preparation methods for ultra-low input amounts were compared using genomic DNA from two foodborne parasites (Angiostrongylus cantonensis and Cyclospora cayetanensis) as examples. The Ovation Ultralow method resulted in libraries with the highest concentration and produced quality sequencing data, even when the input DNA was in the picogram range. Published by Elsevier B.V. C1 [Nascimento, Fernanda S.; Wei-Pridgeon, Yuping; da Silva, Alexandre J.; Qvarnstrom, Yvonne] Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. [Wei-Pridgeon, Yuping] IHRC Inc, 2 Ravinia Dr,Suite 1750, Atlanta, GA 30346 USA. [Arrowood, Michael J.; Moss, Delynn] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Enter & Zoonot Infect Dis, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. [Talundzic, Eldin] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. [Talundzic, Eldin] Atlanta Res & Educ Fdn, 1670 Clairmont Rd,Suite 5A104, Decatur, GA 30033 USA. [da Silva, Alexandre J.] US FDA, Off Appl Res & Safety Assessment, Ctr Food Safety & Nutr, Laurel, MD 20708 USA. RP Qvarnstrom, Y (reprint author), Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM yeb7@cdc.gov; saaspservices@gmail.com; mja0@cdc.gov; dmm3@cdc.gov; Alexandre.DaSilva@fda.hhs.gov; wrj5@cdc.gov; bvp2@cdc.gov NR 23 TC 1 Z9 1 U1 16 U2 16 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-7012 EI 1872-8359 J9 J MICROBIOL METH JI J. Microbiol. Methods PD NOV PY 2016 VL 130 BP 23 EP 26 DI 10.1016/j.mimet.2016.08.020 PG 4 WC Biochemical Research Methods; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA EA2EZ UT WOS:000386406900004 PM 27553132 ER PT J AU Curtis, KA Rudolph, DL Morrison, D Guelig, D Diesburg, S McAdams, D Burton, RA LaBarre, P Owen, M AF Curtis, Kelly A. Rudolph, Donna L. Morrison, Daphne Guelig, Dylan Diesburg, Steven McAdams, David Burton, Robert A. LaBarre, Paul Owen, Michele TI Single-use, electricity-free amplification device for detection of HIV-1 SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE HIV-1; Diagnosis; Point-of-care; RNA; Nucleic acid amplification ID MEDIATED ISOTHERMAL AMPLIFICATION; NUCLEIC-ACID AMPLIFICATION; REVERSE-TRANSCRIPTION; VISUAL DETECTION; INFECTION; LAMP; DIAGNOSIS AB Early and accurate diagnosis of HIV is key for the reduction of transmission and initiation of patient care. The availability of a rapid nucleic acid test (NAT) for use at the point-of-care (POC) will fill a gap in HIV diagnostics, improving the diagnosis of acute infection and HIV in infants born to infected mothers. In this study, we evaluated the performance of non-instrumented nucleic acid amplification, single-use disposable (NINA-SUD) devices for the detection of HIV-1 in whole blood using reverse-transcription, loop-mediated isothermal amplification (RT-LAMP) with lyophilized reagents. The NINA-SUD heating device harnesses the heat from an exothermic chemical reaction initiated by the addition of saline to magnesium iron powder. Reproducibility was demonstrated between NINA-SUD units and comparable, if not superior, performance for detecting clinical specimens was observed as compared to the thermal cycler. The stability of the lyophilized HIV-1 RT-LAMP reagents was also demonstrated following storage at -20, 4, 25, and 30 degrees C for up to one month. The single-use, disposable NAT minimizes hands-on time and has the potential to facilitate HIV-1 testing in resource-limited settings or at the POC. Published by Elsevier B.V. C1 [Curtis, Kelly A.; Rudolph, Donna L.; Morrison, Daphne; Owen, Michele] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. [Guelig, Dylan; Diesburg, Steven; McAdams, David; Burton, Robert A.; LaBarre, Paul] PATH, 2201 Westlake Ave,Suite 200, Seattle, WA 98121 USA. RP Curtis, KA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS-A25, Atlanta, GA 30329 USA. EM czv2@cdc.gov FU University of Washington Center for AIDS Research (CFAR); NIH - NIH (NIAID) [AI027757]; NIH (NCI); NIH (NIMH); NIH (NIDA); NIH (NICHD); NIH (NHLBI); NIH (NIA); NIH (NIGMS); NIH (NIDDK); NIH - NIBIB [R01EB012641] FX The authors would like to acknowledge Michalina Montano at the University of Washington for coordinating the enrollment of study subjects through CFAR, the sample and data collection from study participants, and shipment of samples to the CDC. This research was funded in part by a 2013 developmental grant from the University of Washington Center for AIDS Research (CFAR), an NIH funded program under award number AI027757 which is supported by the following NIH Institutes and Centers (NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA, NIGMS, NIDDK). Funding for the research and development of the NINA-SUD was provided under the NIH grantR01EB012641 to PATH supported by the NIBIB. NR 23 TC 1 Z9 1 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD NOV PY 2016 VL 237 BP 132 EP 137 DI 10.1016/j.jviromet.2016.09.007 PG 6 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA DZ9JH UT WOS:000386190700021 PM 27616198 ER PT J AU Lu, XY Erdman, DD AF Lu, Xiaoyan Erdman, Dean D. TI Quantitative real-time PCR assays for detection and type-specific identification of the endemic species C human adenoviruses SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article ID RAPID DETECTION; DNA; INFECTIONS; PREVALENCE; SPECIMENS AB Human adenoviruses (HAdVs) are medically important respiratory pathogens. Among the 7 recognized species (A-G), species C HAdVs (serotypes 1, 2, 5 and 6) are globally endemic and infect most people early in life. Species C HAdV infections are most often subclinical or mild and can lead to persistent shedding from the gastrointestinal and upper respiratory tracts. They can also cause severe disseminated disease in newborn and immunocompromised persons, where rapid and quantitative detection and identification of the virus would help guide therapeutic intervention. To this end, we developed quantitative type specific real-time PCR (qPCR) assays for HAdV-1, -2, -5 and -6 targeting the HAdV hexon gene. All type specific qPCR assays reproducibly detected as few as 5 copies/reaction of quantified hexon recombinant plasmids with a linear dynamic range of 8 log units (5-5 x 10(7) copies). No non-specific amplifications were observed with concentrated nucleic acid from other HAdV types or other common respiratory pathogens. Of 199 previously typed HAdV field isolates and positive clinical specimens, all were detected and correctly identified to type by the qPCR assays; 10 samples had 2 HAdV types and 1 sample had 3 types identified which were confirmed by amplicon sequencing. The species C HAdV qPCR assays permit rapid, sensitive, specific and quantitative detection and identification of four recognized endemic HAdVs. Together with our previously developed qPCR assays for the epidemic respiratory HAdVs, these assays provide a convenient alternative to classical typing methods. Published by Elsevier B.V. C1 [Lu, Xiaoyan; Erdman, Dean D.] Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, Atlanta, GA USA. RP Erdman, DD (reprint author), 1600 Clifton Rd,NE,Mailstop G04, Atlanta, GA 30329 USA. EM dde1@cdc.gov NR 24 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD NOV PY 2016 VL 237 BP 174 EP 178 DI 10.1016/j.jviromet.2016.05.020 PG 5 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA DZ9JH UT WOS:000386190700028 PM 27363737 ER PT J AU Kuiper, NM Marshall, LL Lavinghouze, SR King, BA AF Kuiper, Nicole M. Marshall, LaTisha L. Lavinghouze, S. Rene King, Brian A. TI State Tobacco Control Program Implementation Strategies for Smoke-Free Multiunit Housing SO HEALTH PROMOTION PRACTICE LA English DT Article DE tobacco control; secondhand smoke; smoke-free policy; multiunit housing; public housing; subsidized housing; smoke-free housing ID PUBLIC-HEALTH ACTION; FREE POLICIES; RESIDENTS AB Multiunit housing residents are at risk of secondhand smoke exposure from adjoining units and common areas. We developed this case study to document state-level strategies undertaken to address this risk. We explored program documents to identify facilitators, barriers, and outcomes. Three states (Montana, Michigan, and Nebraska) provided detailed information on multiunit housing efforts in the study time frame. We conducted a qualitative analysis using inductive coding to develop themes. Several facilitators relating to existing infrastructure included traditional and nontraditional partnerships, leadership and champions, collecting and using data, efficient use of resources, and strategic plans. We also report external catalysts, barriers, and outcomes. Significant state leadership and effort were required to provide local-level technical assistance to engage traditional and nontraditional partners. Information needs were identified and varied by stakeholder type (i.e., health vs. housing). States recommend starting with public housing authorities, so they can become resources for affordable and subsidized housing. These lessons and resources can be used to inform smoke-free multiunit housing initiatives in other states and localities. C1 [Kuiper, Nicole M.; Marshall, LaTisha L.; Lavinghouze, S. Rene; King, Brian A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Kuiper, NM (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, 4770 Buford Highway MS F79, Atlanta, GA 30341 USA. EM nkuiper@cdc.gov FU Intramural CDC HHS [CC999999] NR 27 TC 0 Z9 0 U1 4 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1524-8399 EI 1552-6372 J9 HEALTH PROMOT PRACT JI Health Promot. Pract. PD NOV PY 2016 VL 17 IS 6 BP 836 EP 844 DI 10.1177/1524839916655082 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ4GQ UT WOS:000385817100009 PM 27402719 ER PT J AU Brady, TJ Brick, M Berktold, J Sonnefeld, J Gaddes, R Bartenfeld, T AF Brady, Teresa J. Brick, Mari Berktold, Jennifer Sonnefeld, Joseph Gaddes, Rachel Bartenfeld, Thomas TI Expanding the Reach of Evidence-Based Self-Management Education and Physical Activity Interventions: Results of a Cross-Site Evaluation of State Health Departments SO HEALTH PROMOTION PRACTICE LA English DT Article DE dissemination; self-management education; physical activity; arthritis; chronic disease; community health programs; aging ID PUBLIC-HEALTH; ARTHRITIS; FRAMEWORK; PROGRAM AB Participation in community-based self-management education and physical activity interventions has been demonstrated to improve quality of life for those who have arthritis and other chronic diseases. The Centers for Disease Control and Prevention Arthritis Program funded 21 state health departments to expand the reach (defined as the number of people who participate in interventions) of 10 evidence-based interventions in community settings. The Arthritis Centralized Evaluation assessed the strategies and tactics used by state health departments to expand the reach of these evidence-based interventions. The evaluation compared and contrasted processes used by the states to expand reach. Engaging multisite delivery system partners, prioritizing reach, embedding interventions within partners' routine operations, and collaborating across chronic disease program areas were all dissemination strategies that were correlated with expanded intervention reach. However, states also encountered challenges that limited their ability to successfully engage delivery systems as partners. These barriers included difficulty identifying delivery system partners and the lengthy time periods partners needed to adopt and embed the interventions. C1 [Brady, Teresa J.; Bartenfeld, Thomas] Ctr Dis Control & Prevent, Atlanta, GA USA. [Brick, Mari] Natl Assoc Chron Dis Directors, Atlanta, GA USA. [Berktold, Jennifer; Sonnefeld, Joseph; Gaddes, Rachel] WESTAT Corp, Rockville, MD 20850 USA. RP Brady, TJ (reprint author), Ctr Dis Control & Prevent, Arthrit Program, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. EM tob9@cdc.gov NR 25 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1524-8399 EI 1552-6372 J9 HEALTH PROMOT PRACT JI Health Promot. Pract. PD NOV PY 2016 VL 17 IS 6 BP 871 EP 879 DI 10.1177/1524839916652844 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ4GQ UT WOS:000385817100013 PM 27402720 ER PT J AU Horton, K Kaye, W Wagner, L AF Horton, Kevin Kaye, Wendy Wagner, Laurie TI Integrating a Biorepository Into the National Amyotrophic Lateral Sclerosis Registry SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material AB As part of our continuing effort to highlight innovative approaches to improving the health and environment of communities, the Journal is pleased to publish a bimonthly column from the Agency for Toxic Substances and Disease Registry (ATSDR). ATSDR is a federal public health agency of the U.S. Department of Health and Human. Services (HHS) and shares a common office of the Director with the National Center for Environmental Health (NCEH) at the Centers for Disease Control and Prevention (CDC). ATSDR serves the public by using the best science, taking responsive public health actions, and providing trusted health information to prevent harmful exposures and diseases related to toxic substances. The purpose of this column is to inform readers of ATSDR's activities and initiatives to better understand the relationship between exposure to hazardous substances in the environment and their impact on human health and how to protect public health. We believe that the column will provide a valuable resource to our readership by helping to make known the considerable resources and expertise that ATSDR has available to assist communities, states, and others to assure good environmental health practice for all is served. The conclusions of this column are those of the author(s) and do not necessarily represent the views of ATSDR, CDC, or HHS. Kevin Horton is chief of the Environmental Health Surveillance Branch within the Division of Toxicology and Human Health Sciences at ATSDR. Wendy Kaye is a senior epidemiologist at McKing Consulting Corporation. Laurie Wagner is a research associate at McKing Consulting Corporation. C1 [Horton, Kevin] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Environm Hlth Surveillance Branch, 4770 Buford Highway NE,MS F-57, Atlanta, GA 30341 USA. [Kaye, Wendy; Wagner, Laurie] McKing Consulting Corp, Atlanta, GA USA. RP Horton, K (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Environm Hlth Surveillance Branch, 4770 Buford Highway NE,MS F-57, Atlanta, GA 30341 USA. EM dhorton@cdc.gov NR 13 TC 0 Z9 0 U1 1 U2 1 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD NOV PY 2016 VL 79 IS 4 BP 38 EP 40 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA DY7WM UT WOS:000385340000007 ER PT J AU Curtiss, E AF Curtiss, Elaine TI Environmental Health Resources by Essential Services SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material AB NEHA strives to provide up-to-date and relevant information on environmental health and to build partnerships in the profession. In pursuit of these goals, we feature a column from the Environmental Health Services Branch (EHSB) of the Centers for Disease Control and Prevention (CDC) in every issue of the Journal. In these columns, EHSB and guest authors share insights and information about environmental health programs, trends, issues, and resources. The conclusions in this article are those of the author(s) and do not necessarily represent the views of CDC. Elaine Curtiss is a contract public health analyst working on communications projects within EHSB. C1 [Curtiss, Elaine] Carter Consulting Inc, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-58, Atlanta, GA 30341 USA. RP Curtiss, E (reprint author), Carter Consulting Inc, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-58, Atlanta, GA 30341 USA. EM ECurtiss@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD NOV PY 2016 VL 79 IS 4 BP 42 EP 43 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA DY7WM UT WOS:000385340000008 ER PT J AU Hoss, A Menon, A Corso, L AF Hoss, Aila Menon, Akshara Corso, Liza TI State Public Health Enabling Authorities: Results of a Fundamental Activities Assessment Examining Core and Essential Services SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE core public health functions; essential public health services; local health department; public health law; state health department ID LAW RESEARCH AB Context: Public health enabling authorities establish the legal foundation for financing, organizing, and delivering public health services. State laws vary in terms of the content, depth, and breadth of these fundamental public health activities. Given this variance, the Institute of Medicine has identified state public health laws as an area that requires further examination. To respond to this call for further examination, the Centers for Disease Control and Prevention's Public Health Law Program conducted a fundamental activities legal assessment on state public health laws. Objective: The goal of the legal assessment was to examine state laws referencing frameworks representing public health department fundamental activities (ie, core and essential services) in an effort to identify, catalog, and describe enabling authorities of state governmental public health systems. Design: In 2013, Public Health Law Program staff compiled a list of state statutes and regulations referencing different commonly-recognized public health frameworks of fundamental activities. The legal assessment included state fundamental activities laws available on WestlawNext as of July 2013. The results related to the 10 essential public health services and the 3 core public health functions were confirmed and updated in June 2016. Results: Eighteen states reference commonly-recognized frameworks of fundamental activities in their laws. Thirteen states have listed the 10 essential public health services in their laws. Eight of these states have also referenced the 3 core public health functions in their laws. Five states reference only the core public health functions. Conclusions: Several states reference fundamental activities in their state laws, particularly through use of the essential services framework. Further work is needed to capture the public health laws and practices of states that may be performing fundamental activities but without reference to a common framework. C1 [Hoss, Aila; Menon, Akshara] Carter Consulting Inc, Atlanta, GA USA. [Corso, Liza] Ctr Dis Control & Prevent, Div Publ Hlth Performance Improvement, Off State Tribal Local & Terr Support, Atlanta, GA USA. RP Hoss, A (reprint author), Ctr Dis Control & Prevent, Publ Hlth Law Program, Off State Tribal Local & Terr Support, 4770 Buford Hwy NE,Mailstop E70, Atlanta, GA 30341 USA. EM ahoss@cdc.gov FU Oak Ridge Institute for Science and Education FX Research conducted for this article was supported by the Oak Ridge Institute for Science and Education. The authors thank Duiona Baker, Lindsay Culp, Lorre Cuzze, Matthew Penn, and Tara Ramanathan for their research and editorial assistance. NR 21 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD NOV-DEC PY 2016 VL 22 IS 6 BP 529 EP 536 DI 10.1097/PHH.0000000000000347 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DY9KL UT WOS:000385452400009 PM 27682724 ER PT J AU Yaylali, E Farnham, PG Schneider, KL Landers, SJ Kouzouian, O Lasry, A Purcell, DW Green, TA Sansom, SL AF Yaylali, Emine Farnham, Paul G. Schneider, Karen L. Landers, Stewart J. Kouzouian, Oskian Lasry, Arielle Purcell, David W. Green, Timothy A. Sansom, Stephanie L. TI From Theory to Practice: Implementation of a Resource Allocation Model in Health Departments SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE HIV/AIDS; HIV prevention; resource allocation modeling ID NATIONAL PROBABILITY SAMPLE; HIV-INFECTED PERSONS; UNITED-STATES; SEXUAL-BEHAVIORS; CONCURRENT PARTNERSHIPS; ANTIRETROVIRAL THERAPY; MEDICATION ADHERENCE; PERCEIVED HEALTH; CONDOM USE; CARE AB Objective: To develop a resource allocation model to optimize health departments' Centers for Disease Control and Prevention (CDC)-funded HIV prevention budgets to prevent the most new cases of HIV infection and to evaluate the model's implementation in 4 health departments. Design, Settings, and Participants: We developed a linear programming model combined with a Bernoulli process model that allocated a fixed budget among HIV prevention interventions and risk subpopulations to maximize the number of new infections prevented. The model, which required epidemiologic, behavioral, budgetary, and programmatic data, was implemented in health departments in Philadelphia, Chicago, Alabama, and Nebraska. Main Outcome Measures: The optimal allocation of funds, the site-specific cost per case of HIV infection prevented rankings by intervention, and the expected number of HIV cases prevented. Results: The model suggested allocating funds to HIV testing and continuum-of-care interventions in all 4 health departments. The most cost-effective intervention for all sites was HIV testing in nonclinical settings for men who have sex with men, and the least cost-effective interventions were behavioral interventions for HIV-negative persons. The pilot sites required 3 to 4 months of technical assistance to develop data inputs and generate and interpret the results. Although the sites found the model easy to use in providing quantitative evidence for allocating HIV prevention resources, they criticized the exclusion of structural interventions and the use of the model to allocate only CDC funds. Conclusions: Resource allocation models have the potential to improve the allocation of limited HIV prevention resources and can be used as a decision-making guide for state and local health departments. Using such models may require substantial staff time and technical assistance. These model results emphasize the allocation of CDC funds toward testing and continuum-of-care interventions and populations at highest risk of HIV transmission. C1 [Yaylali, Emine; Farnham, Paul G.; Lasry, Arielle; Purcell, David W.; Green, Timothy A.; Sansom, Stephanie L.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, 1600 Clifton Rd,MS E-48, Atlanta, GA 30319 USA. [Schneider, Karen L.; Landers, Stewart J.] John Snow Inc, Boston, MA USA. [Kouzouian, Oskian] US Dept HHS, Off HIV AIDS & Infect Dis, Washington, DC USA. RP Yaylali, E (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, 1600 Clifton Rd,MS E-48, Atlanta, GA 30319 USA. EM Wqq3@cdc.gov FU Intramural CDC HHS [CC999999] NR 37 TC 2 Z9 2 U1 7 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD NOV-DEC PY 2016 VL 22 IS 6 BP 567 EP 575 DI 10.1097/PHH.0000000000000332 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DY9KL UT WOS:000385452400014 PM 26352385 ER PT J AU Penman-Aguilar, A Talih, M Moonesinghe, R Huang, D AF Penman-Aguilar, Ana Talih, Makram Moonesinghe, Ramal Huang, David TI Response to Scanlan Concerning: Measurement of Health Disparities, Health Inequities, and Social Determinants of Health to Support the Advancement of Health Equity SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Letter ID RELATIVE DISPARITIES C1 [Penman-Aguilar, Ana; Moonesinghe, Ramal] Ctr Dis Control & Prevent, Off Minor Hlth & Hlth Equ, Atlanta, GA 30333 USA. [Talih, Makram; Huang, David] Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Penman-Aguilar, A (reprint author), Ctr Dis Control & Prevent, Off Minor Hlth & Hlth Equ, Atlanta, GA 30333 USA. EM bpv4@cdc.gov NR 8 TC 0 Z9 0 U1 6 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD NOV-DEC PY 2016 VL 22 IS 6 BP 614 EP 615 DI 10.1097/PHH.0000000000000494 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DY9KL UT WOS:000385452400023 PM 27682733 ER PT J AU August, EM Hayek, S Casillas, D Wortley, P Collins, CB AF August, Euna M. Hayek, Samah Casillas, Daniel Wortley, Pascale Collins, Charles B., Jr. TI Evaluation of the Dissemination, Implementation, and Sustainability of the "Partnership for Health" Intervention SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE clinician training; evaluation; HIV prevention ID CARE; PREVENTION; RISK AB Partnership for Health (PfH) is an evidence-based, clinician-delivered HIV prevention program conducted in the United States for HIV-positive patients. This intervention strives to reduce risky sexual behaviors through provider-patient discussions on safer sex and HIV status disclosure. A cross-sectional, mixed-methods design was used to evaluate the dissemination and implementation of PfH, including training evaluations, an online trainee survey, and interviews with national trainers for PfH. Descriptive statistics were calculated with the categorical data, whereas thematic analysis was completed with the qualitative data. Between 2007 and 2013, PfH was disseminated to 776 individuals from 104 different organizations in 21 states/territories. The smallest proportion of trainees was physicians (6.9%). More than three-fourths of survey respondents (78.6%) reported using PfH, but less than one-third (31.8%) used the intervention with every patient. The PfH training supports the implementation of the intervention; however, challenges were experienced in clinician engagement. Tailored strategies to recruit and train clinicians providing care to HIV-positive patients are required. C1 [August, Euna M.] Ctr Dis Control & Prevent, Prevent Commun Branch, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. [Hayek, Samah] Ctr Dis Control & Prevent, Program Evaluat Branch, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. [Wortley, Pascale] Ctr Dis Control & Prevent, Off Director, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. [Collins, Charles B., Jr.] Ctr Dis Control & Prevent, Capac Bldg Branch, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, 1600 Clifton Rd NE,MS E-40, Atlanta, GA 30333 USA. [Casillas, Daniel] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. RP Collins, CB (reprint author), Ctr Dis Control & Prevent, Capac Bldg Branch, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, 1600 Clifton Rd NE,MS E-40, Atlanta, GA 30333 USA. EM cwc4@cdc.gov NR 12 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD NOV-DEC PY 2016 VL 22 IS 6 BP E14 EP E18 DI 10.1097/PHH.0000000000000340 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DY9KL UT WOS:000385452400003 PM 26485697 ER PT J AU Thomas, MJ AF Thomas, Mathew J. TI Accomplishments and Opportunities in Biosurveillance SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Editorial Material ID SURVEILLANCE C1 [Thomas, Mathew J.] Ctr Dis Control & Prevent, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Thomas, Mathew J.] US PHS, Commissioned Corps, Rockville, MD USA. RP Thomas, MJ (reprint author), Ctr Dis Control & Prevent, Ctr Surveillance Epidemiol & Lab Serv, Off Publ Hlth Sci Serv, 1600 Clifton Rd NE,MS-E94, Atlanta, GA 30329 USA. EM dvz5@cdc.gov NR 2 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD NOV-DEC PY 2016 VL 22 SU 6 BP S81 EP S82 DI 10.1097/PHH.0000000000000461 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DY9MO UT WOS:000385458200015 PM 27684624 ER PT J AU Eberhard, ML Ruiz-Tiben, E Hopkins, DR AF Eberhard, Mark L. Ruiz-Tiben, Ernesto Hopkins, Donald R. TI Dogs and Guinea worm eradication SO LANCET INFECTIOUS DISEASES LA English DT Letter ID DRACUNCULUS-INSIGNIS NEMATODA; PARATENIC HOSTS; FROGS; CHAD C1 [Eberhard, Mark L.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. Carter Ctr, Atlanta, GA USA. RP Eberhard, ML (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM mle1@cdc.gov NR 10 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD NOV PY 2016 VL 16 IS 11 BP 1225 EP 1226 PG 2 WC Infectious Diseases SC Infectious Diseases GA DZ5PP UT WOS:000385914300021 PM 27788982 ER PT J AU Sidikou, F Zaneidou, M Alkassoum, I Schwartz, S Issaka, B Obama, R Lingani, C Tate, A Ake, F Sakande, S Ousmane, S Zanguina, J Seidou, I Nzeyimana, I Mounkoro, D Abodji, O Wang, X Taha, MK Moulia-Pelat, JP Pana, A Kadade, G Ronveaux, O Novak, R Oukem-Boyer, OOM Meyer, S AF Sidikou, Fati Zaneidou, Maman Alkassoum, Ibrahim Schwartz, Stephanie Issaka, Bassira Obama, Ricardo Lingani, Clement Tate, Ashley Ake, Flavien Sakande, Souleymane Ousmane, Sani Zanguina, Jibir Seidou, Issaka Nzeyimana, Innocent Mounkoro, Didier Abodji, Oubote Wang, Xin Taha, Muhamed-Kheir Moulia-Pelat, Jean Paul Pana, Assimawe Kadade, Goumbi Ronveaux, Olivier Novak, Ryan Oukem-Boyer, Odile Ouwe Missi Meyer, Sarah CA MenAfriNet Consortium TI Emergence of epidemic Neisseria meningitidis serogroup C in Niger, 2015: an analysis of national surveillance data SO LANCET INFECTIOUS DISEASES LA English DT Article ID MENINGOCOCCAL MENINGITIS; W135; AFRICA AB Background To combat Neisseria meningitidis serogroup A epidemics in the meningitis belt of sub-Saharan Africa, a meningococcal serogroup A conjugate vaccine (MACV) has been progressively rolled out since 2010. We report the first meningitis epidemic in Niger since the nationwide introduction of MACV. Methods We compiled and analysed nationwide case-based meningitis surveillance data in Niger. Cases were confirmed by culture or direct real-time PCR, or both, of cerebrospinal fluid specimens, and whole-genome sequencing was used to characterise isolates. Information on vaccination campaigns was collected by the Niger Ministry of Health and WHO. Findings From Jan 1 to June 30,2015,9367 suspected meningitis cases and 549 deaths were reported in Niger. Among 4301 cerebrospinal fluid specimens tested, 1603 (37.3%) were positive for a bacterial pathogen, including 1147 (71.5%) that were positive for N meningitidis serogroup C (NmC). Whole-genome sequencing of 77 NmC isolates revealed the strain to be ST-10217. Although vaccination campaigns were limited in scope because of a global vaccine shortage, 1.4 million people were vaccinated from March to June, 2015. Interpretation This epidemic represents the largest global NmC outbreak so far and shows the continued threat of N meningitidis in sub-Saharan Africa. The risk of further regional expansion of this novel clone highlights the need for continued strengthening of case-based surveillance. The availability of an affordable, multivalent conjugate vaccine may be important in future epidemic response. Copyright (C) 2016. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. C1 [Sidikou, Fati; Issaka, Bassira; Ousmane, Sani; Zanguina, Jibir; Seidou, Issaka; Moulia-Pelat, Jean Paul; Oukem-Boyer, Odile Ouwe Missi] Inst Pasteur Int Network, Minist Publ Hlth, Ctr Rech Med & Sanit CERMES, Niamey, Niger. [Zaneidou, Maman; Alkassoum, Ibrahim; Kadade, Goumbi] Minist Hlth, Direct Surveillance & Riposte Epidemies, Niamey, Niger. [Schwartz, Stephanie; Tate, Ashley; Wang, Xin; Novak, Ryan; Meyer, Sarah] US Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Obama, Ricardo; Nzeyimana, Innocent; Pana, Assimawe] World Hlth Org Niger, Niamey, Niger. [Lingani, Clement] World Hlth Org, Intercountry Support Team West Africa, Ouagadougou, Burkina Faso. [Ake, Flavien] Davycas Consulting, Gounghin Petit Paris, Ouagadougou, Burkina Faso. [Sakande, Souleymane] Agence Med Prevent Ouagadougou, Ouagadougou, Burkina Faso. [Mounkoro, Didier; Abodji, Oubote] Agence Med Prevent Togo, Dapaong, Togo. [Taha, Muhamed-Kheir] Inst Pasteur, Paris, France. [Ronveaux, Olivier] World Hlth Org, Geneva, Switzerland. RP Meyer, S (reprint author), US Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM SMeyer@cdc.gov FU US Centers for Disease Control and Prevention; WHO; Agence de Medecine Preventive through Bill & Melinda Gates Foundation FX MenAfriNet consortium, a partnership between the US Centers for Disease Control and Prevention, WHO, and Agence de Medecine Preventive, through a grant from the Bill & Melinda Gates Foundation. NR 31 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD NOV PY 2016 VL 16 IS 11 BP 1288 EP 1294 DI 10.1016/S1473-3099(16)30253-5 PG 7 WC Infectious Diseases SC Infectious Diseases GA DZ5PP UT WOS:000385914300042 PM 27567107 ER PT J AU Kalman, LV Datta, V Williams, M Zook, JM Salit, ML Han, JY AF Kalman, Lisa V. Datta, Vivekananda Williams, Mickey Zook, Justin M. Salit, Marc L. Han, Jin-Yeong TI Development and Characterization of Reference Materials for Genetic Testing: Focus on Public Partnerships SO ANNALS OF LABORATORY MEDICINE LA English DT Review DE Reference materials; Genetic tests; DNA sequencing; Next generation sequencing; Molecular oncology; Quality control; Assay validation; Genomics; Genome sequencing ID REFERENCE-MATERIAL-PANEL; GENOMIC REFERENCE MATERIALS; DNA REFERENCE MATERIALS; COLLABORATIVE-PROJECT; MOLECULAR-PATHOLOGY; QUALITY; ASSOCIATION; STANDARDS AB Characterized reference materials (RMs) are needed for clinical laboratory test development and validation, quality control procedures, and proficiency testing to assure their quality. In this article, we review the development and characterization of RMs for clinical molecular genetic tests. We describe various types of RMs and how to access and utilize them, especially focusing on the Genetic Testing Reference Materials Coordination Program (Get-RM) and the Genome in a Bottle (GIAB) Consortium. This review also reinforces the need for collaborative efforts in the clinical genetic testing community to develop additional RMs. C1 [Kalman, Lisa V.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Datta, Vivekananda; Williams, Mickey] NCI, Frederick Natl Lab Canc Res, Gaithersburg, MD USA. [Zook, Justin M.; Salit, Marc L.] NIST, Gaithersburg, MD 20899 USA. [Han, Jin-Yeong] Dong A Univ, Coll Med, Dept Lab Med, 26 Daesingongwon Ro, Busan 49201, South Korea. RP Han, JY (reprint author), Dong A Univ, Coll Med, Dept Lab Med, 26 Daesingongwon Ro, Busan 49201, South Korea. EM jyhan@dau.ac.kr FU Dong-A University research fund FX This work was supported by the Dong-A University research fund (JY Han). Certain commercial equipment, instruments, or materials are identified in this paper only to specify the experimental procedure adequately. Such identification is not intended to imply recommendation or endorsement by the NIST, nor is it intended to imply that the materials or equipment identified are necessarily the best available for the intended purpose. NR 31 TC 0 Z9 0 U1 8 U2 8 PU KOREAN SOC LABORATORY MEDICINE PI SEOUL PA A505-ASTERIUM SEOUL, 372 HANGANG-DAERO, YONGSAN-GU, SEOUL, 04323, SOUTH KOREA SN 2234-3806 EI 2234-3814 J9 ANN LAB MED JI Ann. Lab. Med. PD NOV PY 2016 VL 36 IS 6 BP 513 EP 520 DI 10.3343/alm.2016.36.6.513 PG 8 WC Medical Laboratory Technology SC Medical Laboratory Technology GA DV9GP UT WOS:000383248900002 PM 27578503 ER PT J AU Ondoa, P Datema, T Keita-Sow, MS Ndihokubwayo, JB Isadore, J Oskam, L Nkengasong, J Lewis, K AF Ondoa, Pascale Datema, Tjeerd Keita-Sow, Mah-Sere Ndihokubwayo, Jean-Bosco Isadore, Jocelyn Oskam, Linda Nkengasong, John Lewis, Kim TI A new matrix for scoring the functionality of national laboratory networks in Africa: introducing the LABNET scorecard SO AFRICAN JOURNAL OF LABORATORY MEDICINE LA English DT Article ID HEALTH SYSTEMS; ACCREDITATION; SETTINGS; QUALITY AB Background: Functional national laboratory networks and systems are indispensable to the achievement of global health security targets according to the International Health Regulations. The lack of indicators to measure the functionality of national laboratory network has limited the efficiency of past and current interventions to enhance laboratory capacity in resource-limited-settings. Scorecard for laboratory networks: We have developed a matrix for the assessment of national laboratory network functionality and progress thereof, with support from the African Society of Laboratory Medicine and the Association of Public Health Laboratories. The laboratory network (LABNET) scorecard was designed to: (1) Measure the status of nine overarching core capabilities of laboratory network required to achieve global health security targets, as recommended by the main normative standards; (2) Complement the World Health Organization joint external evaluation tool for the assessment of health system preparedness to International Health Regulations (2005) by providing detailed information on laboratory systems; and (3) Serve as a clear roadmap to guide the stepwise implementation of laboratory capability to prevent, detect and act upon infectious threats. Conclusions: The application of the LABNET scorecard under the coordination of the African Society of Laboratory Medicine and the Association of Public Health Laboratories could contribute to the design, monitoring and evaluation of upcoming Global Health Security Agenda-supported laboratory capacity building programmes in sub Saharan-Africa and other resource-limited settings, and inform the development of national laboratory policies and strategic plans. Endorsement by the World Health Organization Regional Office for Africa is foreseen. C1 [Ondoa, Pascale] Acad Med Ctr, Dept Global Hlth, AIGHD, Amsterdam, Netherlands. [Datema, Tjeerd; Oskam, Linda] Royal Trop Inst Biomed Res KIT, Amsterdam, Netherlands. [Datema, Tjeerd; Oskam, Linda] DATOS, Amsterdam, Netherlands. [Keita-Sow, Mah-Sere] ASLM, Addis Ababa, Ethiopia. [Ndihokubwayo, Jean-Bosco] WHO, Reg Off Africa, Brazzaville, Rep Congo. [Isadore, Jocelyn; Lewis, Kim] Assoc Publ Hlth Labs, Silver Spring, MD 20910 USA. [Nkengasong, John] US Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV & TB, Atlanta, GA USA. RP Ondoa, P (reprint author), Acad Med Ctr, Dept Global Hlth, AIGHD, Amsterdam, Netherlands. EM p.ondoa@aighd.org NR 40 TC 0 Z9 0 U1 0 U2 0 PU AOSIS PI CAPE TOWN PA POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA SN 2225-2002 EI 2225-2010 J9 AFR J LAB MED JI Afr. J. Lab. Med. PD OCT 31 PY 2016 VL 5 IS 3 AR a498 DI 10.4102/ajlm.v5i3.498 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA ED1LO UT WOS:000388607200006 ER PT J AU Peter, T Keita, MS Nkengasong, J AF Peter, Trevor Keita, Mah-Sere Nkengasong, John TI Building laboratory capacity to combat disease outbreaks in Africa SO AFRICAN JOURNAL OF LABORATORY MEDICINE LA English DT Editorial Material C1 [Peter, Trevor] Clinton Hlth Access Initiat, Gaborone, Botswana. [Keita, Mah-Sere] African Soc Lab Med, Addis Ababa, Ethiopia. [Nkengasong, John] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Peter, T (reprint author), Clinton Hlth Access Initiat, Gaborone, Botswana. EM tpeter@clintonhealthaccess.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU AOSIS PI CAPE TOWN PA POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA SN 2225-2002 EI 2225-2010 J9 AFR J LAB MED JI Afr. J. Lab. Med. PD OCT 31 PY 2016 VL 5 IS 3 AR a579 DI 10.4102/ajlm.v5i3.579 PG 2 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA ED1LO UT WOS:000388607200010 ER PT J AU Nkengasong, JN AF Nkengasong, John N. TI The diagnostic-clinical chasm: Work in progress? SO AFRICAN JOURNAL OF LABORATORY MEDICINE LA English DT Editorial Material C1 [Nkengasong, John N.] US Ctr Dis Control & Prevent, Int Lab Branch, Div HIV & TB, Atlanta, GA 30333 USA. RP Nkengasong, JN (reprint author), US Ctr Dis Control & Prevent, Int Lab Branch, Div HIV & TB, Atlanta, GA 30333 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU AOSIS PI CAPE TOWN PA POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA SN 2225-2002 EI 2225-2010 J9 AFR J LAB MED JI Afr. J. Lab. Med. PD OCT 31 PY 2016 VL 5 IS 1 AR a586 DI 10.4102/ajlm.v5i1.586 PG 2 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA ED1LJ UT WOS:000388606700001 ER PT J AU Alymova, IV York, IA Air, GM Cipollo, JF Gulati, S Baranovich, T Kumar, A Zeng, H Gansebom, S McCullers, JA AF Alymova, Irina V. York, Ian A. Air, Gillian M. Cipollo, John F. Gulati, Shelly Baranovich, Tatiana Kumar, Amrita Zeng, Hui Gansebom, Shane McCullers, Jonathan A. TI Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence Irina SO SCIENTIFIC REPORTS LA English DT Article ID A VIRUS; UNITED-STATES; CELLS; EVOLUTION; SITES; HOST; SPECIFICITY; GLYCANS; ENTRY; GENE AB Since the emergence of human H3N2 influenza A viruses in the pandemic of 1968, these viruses have become established as strains of moderate severity. A decline in virulence has been accompanied by glycan accumulation on the hemagglutinin globular head, and hemagglutinin receptor binding has changed from recognition of a broad spectrum of glycan receptors to a narrower spectrum. The relationship between increased glycosylation, binding changes, and reduction in H3N2 virulence is not clear. We evaluated the effect of hemagglutinin glycosylation on receptor binding and virulence of engineered H3N2 viruses. We demonstrate that low-binding virus is as virulent as higher binding counterparts, suggesting that H3N2 infection does not require either recognition of a wide variety of, or high avidity binding to, receptors. Among the few glycans recognized with low-binding virus, there were two structures that were bound by the vast majority of H3N2 viruses isolated between 1968 and 2012. We suggest that these two structures support physiologically relevant binding of H3N2 hemagglutinin and that this physiologically relevant binding has not changed since the 1968 pandemic. Therefore binding changes did not contribute to reduced severity of seasonal H3N2 viruses. This work will help direct the search for factors enhancing influenza virulence. C1 [Alymova, Irina V.; York, Ian A.; Kumar, Amrita; Zeng, Hui; Gansebom, Shane] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Air, Gillian M.; Gulati, Shelly] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA. [Cipollo, John F.] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA. [Baranovich, Tatiana; McCullers, Jonathan A.] St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA. [Kumar, Amrita] Battelle Mem Inst, Atlanta, GA USA. [McCullers, Jonathan A.] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA. RP Alymova, IV (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. EM xeq3@cdc.gov FU American Lebanese Syrian Associated Charities (ALSAC); NIH [A1050933]; NIGMS [GM98791]; National Center for Functional Glycomics - Glycan Array Synthesis Core (The Scripps Research Institute, La Jolla, CA) [P41GM103694] FX This work was supported by the American Lebanese Syrian Associated Charities (ALSAC) and NIH (A1050933). The authors would like to acknowledge The Consortium for Functional Glycomics funded by the NIGMS GM98791 and the National Center for Functional Glycomics funded by P41GM103694 for services provided by the Glycan Array Synthesis Core (The Scripps Research Institute, La Jolla, CA) that produced the mammalian glycan microarray and Drs. Dave Smith and Jamie Heimburg-Molinaro of the Protein-Glycan Interaction Core (Emory University School of Medicine, Atlanta, GA), who assisted with analysis of samples on the array. We also thank Dr. John Nicholls of University of Hong Kong for providing information on the structures of glycans of human RT and helpful discussion, and Drs. James Stevens and Terry Tumpey of Influenza Division of National Center for Immunization & Respiratory Diseases, Centers for Disease Control & Prevention for helpful discussions. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or funding agency. NR 50 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD OCT 31 PY 2016 VL 6 AR 36216 DI 10.1038/srep36216 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EA3MA UT WOS:000386505500001 PM 27796371 ER PT J AU Schicker, RS Rossow, J Eckel, S Fisher, N Bidol, S Tatham, L Matthews-Greer, J Sohner, K Bowman, AS Avrill, J Forshey, T Blanton, L Davis, CT Schiltz, J Skorupski, S Berman, L Jang, YH Bresee, JS Lindstrom, S Trock, SC Wentworth, D Fry, AM de Fijter, S Signs, K DiOrio, M Olsen, SJ Biggerstaff, M AF Schicker, Rebekah S. Rossow, John Eckel, Seth Fisher, Nicolas Bidol, Sally Tatham, Lilith Matthews-Greer, Janice Sohner, Kevin Bowman, Andrew S. Avrill, James Forshey, Tony Blanton, Lenee Davis, C. Todd Schiltz, John Skorupski, Susan Berman, LaShondra Jang, Yunho Bresee, Joseph S. Lindstrom, Stephen Trock, Susan C. Wentworth, David Fry, Alicia M. de Fijter, Sietske Signs, Kimberly DiOrio, Mary Olsen, Sonja J. Biggerstaff, Matthew TI Outbreak of Influenza A(H3N2) Variant Virus Infections Among Persons Attending Agricultural Fairs Housing Infected Swine - Michigan and Ohio, July-August 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; PIGS; H3N2 C1 [Schicker, Rebekah S.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Schicker, Rebekah S.; Rossow, John; Blanton, Lenee; Davis, C. Todd; Berman, LaShondra; Jang, Yunho; Bresee, Joseph S.; Lindstrom, Stephen; Trock, Susan C.; Wentworth, David; Fry, Alicia M.; Olsen, Sonja J.; Biggerstaff, Matthew] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Rossow, John] CDC, Epidemiol Elective Program, Div Sci Educ & Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Eckel, Seth; Bidol, Sally; Matthews-Greer, Janice; Signs, Kimberly] Michigan Dept Hlth & Human Serv, Lansing, MI USA. [Fisher, Nicolas; Tatham, Lilith; Sohner, Kevin; de Fijter, Sietske; DiOrio, Mary] Ohio Dept Hlth, Columbus, OH 43266 USA. [Bowman, Andrew S.] Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA. [Avrill, James] Michigan Dept Agr & Rural Dev, Anim Ind Div, Lansing, MI USA. [Forshey, Tony] Ohio Dept Agr, Div Anim Hlth, Reynoldsburg, OH USA. [Schiltz, John] USDA, Natl Vet Serv Labs, Washington, DC 20250 USA. [Skorupski, Susan] USDA, Anim & Plant Hlth Inspect Serv, Washington, DC 20250 USA. RP Schicker, RS (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Schicker, RS (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM rschicker@cdc.gov NR 9 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 28 PY 2016 VL 65 IS 42 BP 1157 EP 1160 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA5EZ UT WOS:000386643500001 PM 27787493 ER PT J AU Dahlhamer, JM Zammitti, EP Ward, BW Wheaton, AG Croft, JB AF Dahlhamer, James M. Zammitti, Emily P. Ward, Brian W. Wheaton, Anne G. Croft, Janet B. TI Prevalence of Inflammatory Bowel Disease Among Adults Aged >= 18 Years - United States, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CROHNS-DISEASE; ULCERATIVE-COLITIS; TRENDS C1 [Dahlhamer, James M.; Zammitti, Emily P.; Ward, Brian W.] CDC, Div Hlth Interview Stat, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. [Wheaton, Anne G.; Croft, Janet B.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Dahlhamer, JM (reprint author), CDC, Div Hlth Interview Stat, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. EM jdahlhamer@cdc.gov NR 10 TC 1 Z9 1 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 28 PY 2016 VL 65 IS 42 BP 1166 EP 1169 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA5EZ UT WOS:000386643500003 PM 27787492 ER PT J AU Lupcho, T Harrist, A Van Houten, C AF Lupcho, Tiffany Harrist, Alexia Van Houten, Clay TI Gastrointestinal Illness Associated with Rancid Tortilla Chips at a Correctional Facility - Wyoming, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID OUTBREAK C1 [Lupcho, Tiffany; Harrist, Alexia; Van Houten, Clay] Wyoming Dept Hlth, Cheyenne, WY 82002 USA. [Harrist, Alexia] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. RP Lupcho, T (reprint author), Wyoming Dept Hlth, Cheyenne, WY 82002 USA. EM tiffany.lupcho@wyo.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 28 PY 2016 VL 65 IS 42 BP 1170 EP 1173 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA5EZ UT WOS:000386643500004 PM 27787491 ER PT J AU Matthias, J Dwiggins, P Totten, Y Blackmore, C Wilson, C Peterman, TA AF Matthias, James Dwiggins, Patty Totten, Yolanda Blackmore, Carina Wilson, Craig Peterman, Thomas A. TI Evaluation of the Sensitivity and Specificity of a Commercially Available Rapid Syphilis Test - Escambia County, Florida, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Matthias, James; Peterman, Thomas A.] CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Matthias, James; Blackmore, Carina; Wilson, Craig] Florida Dept Hlth, Tallahassee, FL 32399 USA. [Dwiggins, Patty] Florida Dept Hlth Escambia Cty, Pensacola, FL USA. [Totten, Yolanda] Bur Publ Hlth Labs, Florida Dept Hlth, Jacksonville, FL USA. RP Matthias, J (reprint author), CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.; Matthias, J (reprint author), Florida Dept Hlth, Tallahassee, FL 32399 USA. EM lnk1@cdc.gov NR 2 TC 0 Z9 0 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 28 PY 2016 VL 65 IS 42 BP 1174 EP 1175 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA5EZ UT WOS:000386643500005 PM 27787496 ER PT J AU Choi, YH Jin, N Kelly, F Sakthivel, SK Yu, TW AF Choi, Youkyung H. Jin, Nancy Kelly, Fiona Sakthivel, SenthilKumar K. Yu, Tianwei TI Elevation of Alanine Aminotransferase Activity Occurs after Activation of the Cell-Death Signaling Initiated by Pattern-Recognition Receptors but before Activation of Cytolytic Effectors in NK or CD8+T Cells in the Liver During Acute HCV Infection SO PLoS One LA English DT Article ID HEPATITIS-C VIRUS; INTERFERON REGULATORY FACTOR-3; ANTIVIRAL IMMUNITY; III INTERFERONS; APOPTOSIS; MECHANISMS; DISEASE; HEPATOCYTES; CHIMPANZEES; BIOMARKERS AB Pattern-recognition receptors (PRRs) promote host defenses against HCV infection by binding to their corresponding adapter molecules leading to the initiation of innate immune responses including cell death. We investigated the expression of PRR genes, biomarkers of liver cell-death, and T cell and NK cell activation/inhibition-related genes in liver and serum obtained from three experimentally infected chimpanzees with acute HCV infection, and analyzed the correlation between gene expression levels and clinical profiles. Our results showed that expression of hepatic RIG-I, TLR3, TLR7, 2OAS1, and CXCL10 mRNAs was upregulated as early as 7 days post-inoculation and peaked 12 to 83 days post-inoculation. All of the three HCV infected chimpanzees exhibited significant elevations of serum alanine aminotransferase (ALT) activity between 70 and 95 days after inoculation. Elevated levels of serum cytokeratin 18 (CK-18) and caspases 3 and 7 activity coincided closely with the rise of ALT activity, and were preceded by significant increases in levels of caspase 3 and caspase 7 mRNAs in the liver. Particularly we found that significant positive auto-correlations were observed between RIG-I, TLR3, CXCL10, 2OAS1, and PD-L1 mRNA and ALT activity at 3 to 12 days before the peak of ALT activity. However, we observed substantial negative auto-correlations between T cell and NK cell activation/inhibition-related genes and ALT activity at 5 to 32 days after the peak of ALT activity. Our results indicated cell death signaling is preceded by early induction of RIG-I, TLR3, 2OAS1, and CXCL10 mRNAs which leads to elevation of ALT activity and this signaling pathway occurs before the activation of NK and T cells during acute HCV infection. Our study suggests that PRRs and type I IFN response may play a critical role in development of liver cell injury related to viral clearance during acute HCV infection. C1 [Choi, Youkyung H.; Kelly, Fiona; Sakthivel, SenthilKumar K.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Jin, Nancy; Yu, Tianwei] Emory Univ, Dept Biostat & Bioinformat, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Choi, YH (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM brt5@cdc.gov FU CDC FX Funding for the study was provided by CDC.; We are very grateful to Dr. Kris Krawczynski (deceased) for his contribution of this study. We also thank Dr. Michael A. Purdy (Division of Viral Hepatitis, CDC) for critical reviews of the manuscript and helpful discussions. This study was funded by CDC. This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy. Use of trade names is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services, the Public Health Service, or the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 48 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 27 PY 2016 VL 11 IS 10 AR e0165533 DI 10.1371/journal.pone.0165533 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EE4VY UT WOS:000389604900105 PM 27788241 ER PT J AU Stehling-Ariza, T Rosewell, A Moiba, SA Yorpie, BB Ndomaina, KD Jimissa, KS Leidman, E Rijken, DJ Basler, C Wood, J Manso, D AF Stehling-Ariza, Tasha Rosewell, Alexander Moiba, Sahr A. Yorpie, Brima Berthalomew Ndomaina, Kai David Jimissa, Kai Samuel Leidman, Eva Rijken, Dingeman J. Basler, Colin Wood, James Manso, Dumbuya TI The impact of active surveillance and health education on an Ebola virus disease cluster - Kono District, Sierra Leone, 2014-2015 SO BMC INFECTIOUS DISEASES LA English DT Article DE Ebola virus disease; Sierra Leone; Surveillance; Health education ID TRANSMISSION; LIBERIA AB Background: During December 2014-February 2015, an Ebola outbreak in a village in Kono district, Sierra Leone, began following unsafe funeral practices after the death of a person later confirmed to be infected with Ebola virus. In response, disease surveillance officers and community health workers, in collaboration with local leadership and international partners, conducted 1 day of active surveillance and health education for all households in the village followed by ongoing outreach. This study investigated the impact of these interventions on the outbreak. Methods: Fifty confirmed Ebola cases were identified in the village between December 1, 2014 and February 28, 2015. Data from case investigations, treatment facility and laboratory records were analyzed to characterize the outbreak. The reproduction number (R) was estimated by fitting to the observed distribution of secondary cases. The impact of the active surveillance and health education was evaluated by comparing two outcomes before and after the day of the interventions: 1) the number of days from symptom onset to case-patient isolation or death and 2) a reported epidemiologic link to a prior Ebola case. Results: The case fatality ratio among the 50 confirmed Ebola cases was 64.0 %. Twenty-three cases occurred among females (46.0 %); the mean age was 39 years (median: 37 years; range: 5 months to 75 years). Forty-three (87.8 %) cases were linked to the index case; 30 (61.2 %) were either at the funeral of Patient 1 or had contact with him while he was ill. R was 0.93 (95 % CI: 0.15-2.3); excluding the funeral, R was 0.29 (95 % CI: 0.11-0.53). The mean number of days in the community after onset of Ebola symptoms decreased from 4.0 days (median: 3 days; 95 % CI: 3.2-4.7) before the interventions to 2.9 days (median: 2 days; 95 % CI: 1.6-4.3) afterward. An epidemiologic link was reported in 47.6 % of case investigations prior to and 100 % after the interventions. Conclusions: Initial case investigation and contact tracing were hindered by delayed reporting and under-reporting of symptomatic individuals from the community. Active surveillance and health education contributed to quicker identification of suspected cases, interrupting further transmission. C1 [Stehling-Ariza, Tasha; Leidman, Eva; Basler, Colin] Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. [Rosewell, Alexander; Wood, James] Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia. [Moiba, Sahr A.; Yorpie, Brima Berthalomew; Ndomaina, Kai David; Jimissa, Kai Samuel; Manso, Dumbuya] Minist Hlth & Sanitat, Dist Hlth Management Team, Koidu, Sierra Leone. [Rijken, Dingeman J.] Int Federat Red Cross & Red Crescent Soc, Geneva, Switzerland. RP Stehling-Ariza, T (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. EM ydi9@cdc.gov NR 12 TC 0 Z9 0 U1 9 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD OCT 27 PY 2016 VL 16 AR 611 DI 10.1186/s12879-016-1941-0 PG 7 WC Infectious Diseases SC Infectious Diseases GA EA0XU UT WOS:000386313700001 PM 27784275 ER PT J AU Auld, AF Agizew, T Pals, S Finlay, A Ndwapi, N Boyd, R Alexander, H Mathoma, A Basotli, J Gwebe-Nyirenda, S Shepherd, J Ellerbrock, TV Date, A AF Auld, Andrew F. Agizew, Tefera Pals, Sherri Finlay, Alyssa Ndwapi, Ndwapi Boyd, Rosanna Alexander, Heather Mathoma, Anikie Basotli, Joyce Gwebe-Nyirenda, Sambayawo Shepherd, James Ellerbrock, Tedd V. Date, Anand TI Implementation of a pragmatic, stepped-wedge cluster randomized trial to evaluate impact of Botswana's Xpert MTB/RIF diagnostic algorithm on TB diagnostic sensitivity and early antiretroviral therapy mortality SO BMC INFECTIOUS DISEASES LA English DT Article DE Xpert MTB/RIF; Diagnostic accuracy; Sensitivity; Antiretroviral therapy; People living with HIV; Mortality; Stepped-wedge cluster randomized trial; Botswana ID HIV-INFECTED PATIENTS; SUB-SAHARAN AFRICA; RESOURCE-LIMITED SETTINGS; FOLLOW-UP; IMMUNE RECONSTITUTION; PREVENTIVE THERAPY; TREATMENT PROGRAMS; INCOME COUNTRIES; SOUTH-AFRICA; TUBERCULOSIS AB Background: In 2012, as a pilot for Botswana's national Xpert MTB/RIF (Xpert) rollout plans, intensified tuberculosis (TB) case finding (ICF) activities were strengthened at 22 HIV treatment clinics prior to phased activation of 13 Xpert instruments. Together, the strengthened ICF intervention and Xpert activation are referred to as the "Xpert package". Methods: The evaluation, called the Xpert Package Rollout Evaluation using a Stepped-wedge design (XPRES), has two key objectives: (1) to compare sensitivity of microscopy-based and Xpert-based pulmonary TB diagnostic algorithms in diagnosing sputum culture-positive TB; and (2) to evaluate impact of the "Xpert package" on all-cause, 6-month, adult antiretroviral therapy (ART) mortality. A pragmatic, stepped-wedge cluster-randomized trial design was chosen. The design involves enrollment of three cohorts: (1) cohort R, a retrospective cohort of all study clinic ART enrollees in the 24 months before study initiation (July 31, 2012); (2) cohort A, a prospective cohort of all consenting patients presenting to study clinics after study initiation, who received the ICF intervention and the microscopy-based TB diagnostic algorithm; and (3) cohort B, a prospective cohort of all consenting patients presenting to study clinics after Xpert activation, who received the ICF intervention and the Xpert-based TB diagnostic algorithm. TB diagnostic sensitivity will be compared between TB culture-positive enrollees in cohorts A and B. All-cause, 6-month ART-mortality will be compared between cohorts R and B. With anticipated cohort R, A, and B sample sizes of about 10,131, 1,878, and 4,258, respectively, the study is estimated to have > 80 % power to detect differences in pre-versus post-Xpert TB diagnostic sensitivity if pre-Xpert sensitivity is <= 52.5 % and post-Xpert sensitivity >= 82.5 %, and > 80 % power to detect a 40 % reduction in all-cause, 6-month, ART mortality between cohorts R and B if cohort R mortality is <= 13/100 person-years. Discussion: Only one small previous trial (N = 424) among ART enrolees in Zimbabwe evaluated, in a secondary analysis, Xpert impact on all-cause 6-month ART mortality. No mortality impact was observed. This Botswana trial, with its larger sample size and powered specifically to detect differences in all-cause 6-month ART mortality, remains well-positioned to contribute understanding of Xpert impact. C1 [Auld, Andrew F.; Pals, Sherri; Alexander, Heather; Ellerbrock, Tedd V.; Date, Anand] US Ctr Dis Control & Prevent CDC, Div Global HIV & TB, Ctr Global Hlth, 1600 Clifton Rd, Atlanta, GA 30333 USA. [Agizew, Tefera; Finlay, Alyssa; Boyd, Rosanna; Mathoma, Anikie; Basotli, Joyce; Gwebe-Nyirenda, Sambayawo; Shepherd, James] Ctr Dis Control & Prevent Botswana, Plot 14818 Lebatlane Rd, Gaborone, Botswana. [Finlay, Alyssa; Boyd, Rosanna] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV Hepatitis & STD Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. [Ndwapi, Ndwapi] Minist Hlth, Ministerial Strategy Off, 24 Amos St, Gaborone, Botswana. [Shepherd, James] Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06510 USA. RP Auld, AF (reprint author), US Ctr Dis Control & Prevent CDC, Div Global HIV & TB, Ctr Global Hlth, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM aauld@cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention FX This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention. NR 59 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD OCT 26 PY 2016 VL 16 AR 606 DI 10.1186/s12879-016-1905-4 PG 14 WC Infectious Diseases SC Infectious Diseases GA DZ7GE UT WOS:000386032100002 PM 27782821 ER PT J AU Chiang, CF Flint, M Lin, JMS Spiropoulou, CF AF Chiang, Cheng-Feng Flint, Mike Lin, Jin-Mann S. Spiropoulou, Christina F. TI Endocytic Pathways Used by Andes Virus to Enter Primary Human Lung Endothelial Cells SO PLOS ONE LA English DT Article ID HANTAVIRUS PULMONARY SYNDROME; MEDIATED ENDOCYTOSIS; WORLD HANTAVIRUSES; HEMORRHAGIC-FEVER; ENTRY; MACROPINOCYTOSIS; NEUTRALIZATION; TRANSMISSION; PATHOGENESIS; REPLICATION AB Andes virus (ANDV) is the major cause of hantavirus pulmonary syndrome (HPS) in South America. Despite a high fatality rate (up to 40%), no vaccines or antiviral therapies are approved to treat ANDV infection. To understand the role of endocytic pathways in ANDV infection, we used 3 complementary approaches to identify cellular factors required for ANDV entry into human lung microvascular endothelial cells. We screened an siRNA library targeting 140 genes involved in membrane trafficking, and identified 55 genes required for ANDV infection. These genes control the major endocytic pathways, endosomal transport, cell signaling, and cytoskeleton rearrangement. We then used infectious ANDV and retroviral pseudovirions to further characterize the possible involvement of 9 of these genes in the early steps of ANDV entry. In addition, we used markers of cellular endocytosis along with chemical inhibitors of known endocytic pathways to show that ANDV uses multiple routes of entry to infect target cells. These entry mechanisms are mainly clathrin-, dynamin-, and cholesterol-dependent, but can also occur via a clathrin-independent manner. C1 [Chiang, Cheng-Feng; Flint, Mike; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Lin, Jin-Mann S.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Spiropoulou, CF (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. EM css8@cdc.gov OI Chiang, Cheng-Feng/0000-0002-3617-9124 FU Centers for Disease Control and Prevention (CDC) FX This work was funded by Centers for Disease Control and Prevention (CDC) core funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 0 Z9 0 U1 5 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 25 PY 2016 VL 11 IS 10 AR e0164768 DI 10.1371/journal.pone.0164768 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA ED7LQ UT WOS:000389046900017 PM 27780263 ER PT J AU Keddy, KH Sooka, A Smith, AM Musekiwa, A Tau, NP Kingman, KP Angulo, FJ AF Keddy, Karen H. Sooka, Arvinda Smith, Anthony M. Musekiwa, Alfred Tau, Nomsa P. Kingman, Keith P. Angulo, Frederick J. CA GERMS-SA TI Typhoid Fever in South Africa in an Endemic HIV Setting SO PLOS ONE LA English DT Article ID ENTERICA SEROVAR TYPHI; SALMONELLA-TYPHI; OUTBREAK; TRANSMISSION; INFECTION; BACTERIAL; FEATURES; DISEASE; BURDEN; SEX AB Background Typhoid fever remains an important disease in Africa, associated with outbreaks and the emerging multidrug resistant Salmonella enterica serotype Typhi (Salmonella Typhi) haplotype, H58. This study describes the incidence of, and factors associated with mortality due to, typhoid fever in South Africa, where HIV prevalence is high. Methods and Findings Nationwide active laboratory-based surveillance for culture-confirmed typhoid fever was undertaken from 2003-2013. At selected institutions, additional clinical data from patients were collected including age, sex, HIV status, disease severity and outcome. HIV prevalence among typhoid fever patients was compared to national HIV seroprevalence estimates. The national reference laboratory tested Salmonella Typhi isolates for antimicrobial susceptibility and haplotype. Unadjusted and adjusted logistic regression analyses were conducted determining factors associated with typhoid fever mortality. We identified 855 typhoid fever cases: annual incidence ranged from 0.11 to 0.39 per 100,000 population. Additional clinical data were available for 369 (46.8%) cases presenting to the selected sites. Among typhoid fever patients with known HIV status, 19.3% (29/150) were HIV-infected. In adult females, HIV prevalence in typhoid fever patients was 43.2% (19/44) versus 15.7% national HIV seroprevalence (P < .001); in adult males, 16.3% (7/43) versus 12.3% national HIV seroprevalence (P = .2). H58 represented 11.9% (22/185) of Salmonella Typhi isolates tested. Increased mortality was associated with HIV infection (AOR 10.7; 95% CI 2.3-50.3) and disease severity (AOR 9.8; 95% CI 1.6-60.0) on multivariate analysis. Conclusions Typhoid fever incidence in South Africa was largely unchanged from 2003-2013. Typhoid fever mortality was associated disease severity. HIV infection may be a contributing factor. Interventions mandate improved health care access, including to HIV management programmes as well as patient education. Further studies are necessary to clarify relationships between HIV infection and typhoid fever in adults. C1 [Keddy, Karen H.; Sooka, Arvinda; Smith, Anthony M.; Tau, Nomsa P.] Natl Inst Communicable Dis, Ctr Enter Dis, Johannesburg, South Africa. [Keddy, Karen H.; Smith, Anthony M.; Kingman, Keith P.] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa. [Musekiwa, Alfred] Ctr Dis Control & Prevent, South Africa Global Dis Detect Ctr, Int Emerging Infect Programme, Pretoria, South Africa. [Kingman, Keith P.] Bill & Melinda Gates Fdn, Seattle, WA USA. [Angulo, Frederick J.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global Hlth Protect, Atlanta, GA USA. RP Keddy, KH; Smith, AM (reprint author), Natl Inst Communicable Dis, Ctr Enter Dis, Johannesburg, South Africa.; Keddy, KH; Smith, AM (reprint author), Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa. EM karenk@nicd.ac.za; anthonys@nicd.ac.za FU National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) [5U2GPS001328]; United States Agency for International Development's Antimicrobial Resistance Initiative, transferred via Centers for Disease Control and Prevention (CDC), Atlanta, Georgia [U60/CCU022088]; HHS Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Global AIDS Program (GAP) [U62/PS0022901] FX This research has been supported by National Institute for Communicable Diseases (www.nicd.ac.za) of the National Health Laboratory Service, Johannesburg, South Africa and the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) (www.cdc.gov) under the terms of [5U2GPS001328] and, in part, for 2003-2006 by funds from the United States Agency for International Development's Antimicrobial Resistance Initiative, transferred via a cooperative agreement [number U60/CCU022088] from the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia (www.cdc.gov). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NICD/NHLS or CDC. For 2007-2009, it was supported by the HHS Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Global AIDS Program (GAP) Cooperative Agreement [U62/PS0022901]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 34 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 25 PY 2016 VL 11 IS 10 AR e0164939 DI 10.1371/journal.pon.0164939 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA ED7LQ UT WOS:000389046900025 PM 27780232 ER PT J AU Nannei, C Chadwick, C Fatima, H Goldin, S Grubo, M Ganim, A AF Nannei, Claudia Chadwick, Christopher Fatima, Hiba Goldin, Shoshanna Grubo, Myriam Ganim, Alexandra TI Considerations for sustainable influenza vaccine production in developing countries SO VACCINE LA English DT Article DE Sustainability; Vaccine manufacturing; Pandemic influenza preparedness; Policy coherence ID BURDEN AB Through its Global Action Plan for Influenza Vaccines (GAP), the World Health Organization (WHO) in collaboration with the United States Department of Health and Human Services has produced a checklist to support policy-makers and influenza vaccine manufacturers in identifying key technological, political, financial, and logistical issues affecting the sustainability of influenza vaccine production. This checklist highlights actions in five key areas that are beneficial for establishing successful local vaccine manufacturing. These five areas comprise: (1) the policy environment and health-care systems; (2) surveillance systems and influenza evidence; (3) product development and manufacturing; (4) product approval and regulation; and (5) communication to support influenza vaccination. Incorporating the checklist into national vaccine production programmes has identified the policy gaps and next steps for countries involved in GAP's Technology Transfer Initiative. Lessons learnt from country experiences provide context and insight that complement the checldist's goal of simplifying the complexities of influenza prevention, preparedness, and vaccine manufacturing. (C) 2016 The Authors. Published by Elsevier Ltd. C1 [Nannei, Claudia; Grubo, Myriam] WHO, Hlth Syst & Innovat Cluster, CH-1211 Geneva 27, Switzerland. [Chadwick, Christopher] US Dept Hlth & Human Serv, Off Pandem & Emerging Threats, Off Global Affairs, Washington, DC 20201 USA. [Fatima, Hiba] Duke Global Hlth Inst, Durham, NC 27710 USA. [Goldin, Shoshanna] Yale Sch Publ Hlth, New Haven, CT 06520 USA. [Ganim, Alexandra] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Nannei, C (reprint author), WHO, WHO Secretariat GAP, Hlth Syst & Innovat Cluster, 20 Ave Appia, CH-1211 Geneva 27, Switzerland. EM nanneic@who.int FU WHO; US Centers for Disease Control and Prevention; U.S. Department of Health and Human Services, Office of Global Affairs FX Funding for this study was provided by WHO, US Centers for Disease Control and Prevention, and the U.S. Department of Health and Human Services, Office of Global Affairs. The authors state they have no conflict of interest. NR 11 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 25 PY 2016 VL 34 IS 45 SI SI BP 5425 EP 5429 DI 10.1016/j.vaccine.2016.08.056 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EA5EK UT WOS:000386642000008 PM 27614783 ER PT J AU Friedman, EE Duffus, WA AF Friedman, Eleanor E. Duffus, Wayne A. TI Chronic health conditions in Medicare beneficiaries 65 years old, and older with HIV infection SO AIDS LA English DT Article DE chronic conditions; HIV; Medicare; older ID UNITED-STATES; DRUG-INTERACTIONS; DISEASE; AGE; POPULATION; PREVALENCE; CARE; COMORBIDITY; DISPARITIES; MORBIDITY AB Objectives:To examine sociodemographic factors and chronic health conditions of people living with HIV (PLWHIV/HIV+) at least 65 years old and compare their chronic disease prevalence with beneficiaries without HIV.Design:National fee-for-service Medicare claims data (parts A and B) from 2006 to 2009 were used to create a retrospective cohort of beneficiaries at least 65 years old.Methods:Beneficiaries with an inpatient or skilled nursing facility claim, or outpatient claims with HIV diagnosis codes were considered HIV+. HIV+ beneficiaries were compared with uninfected beneficiaries on demographic factors and on the prevalence of hypertension, hyperlipidemia, ischemic heart disease, rheumatoid arthritis/osteoarthritis, and diabetes. Odds ratios (OR), 95% confidence intervals (CIs), and P values were calculated. Adjustment variables included age, sex, race/ethnicity, end stage renal disease (ESRD), and dual Medicare-Medicaid enrollment. Chronic conditions were examined individually and as an index from zero to all five conditions.Results:Of 29060418 eligible beneficiaries, 24735 (0.09%) were HIV+. HIV+ beneficiaries were more likely to be Hispanic, African-American, male, and younger (P>0.0001) and were 1.5-2.1 times as likely to have a chronic disease [diabetes (adjusted OR) 1.51, 95% CI (1.47, 1.55): rheumatoid arthritis/osteoarthritis 2.14, 95% CI (2.08, 2.19)], and 2.4-7 times as likely to have 1-5 comorbid chronic conditions [1 condition (adjusted OR) 2.38, 95% CI (2.21, 2.57): 5 conditions 7.07, 95% CI (6.61, 7.56)].Conclusion:Our results show that PLWHIV at least 65 years old are at higher risk of comorbidities than other fee-for-service Medicare beneficiaries. This finding has implications for the cost and health management of PLWHIV 65 years and older. C1 [Friedman, Eleanor E.; Duffus, Wayne A.] Ctr Dis Control & Prevent, Off Hlth Equ, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Friedman, EE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop E-07, Atlanta, GA 30329 USA. EM Uvv8@cdc.gov FU Centers for Disease Control and Prevention [U36/CCU300430]; Association of Schools and Programs of Public Health FX The work was supported by Cooperative Agreement Number U36/CCU300430 from the Centers for Disease Control and Prevention and the Association of Schools and Programs of Public Health. The findings and conclusions of this publication do not necessarily represent the official views of CDC or ASPPH. NR 40 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD OCT 23 PY 2016 VL 30 IS 16 BP 2529 EP 2536 DI 10.1097/QAD.0000000000001215 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DZ0KV UT WOS:000385528600014 PM 27776013 ER PT J AU Mirkovic, KR Rivadeneira, ED Broyles, LN AF Mirkovic, Kelsey R. Rivadeneira, Emilia D. Broyles, Laura N. TI Children and alternative service delivery models: a case for inclusion SO AIDS LA English DT Letter ID AFRICA C1 [Mirkovic, Kelsey R.; Rivadeneira, Emilia D.; Broyles, Laura N.] Ctr Dis Control & Prevent, Div Global HIV & TB, Ctr Global Hlth, 1600 Clifton Rd NE,Mailstop E-30, Atlanta, GA 30333 USA. RP Mirkovic, KR (reprint author), Ctr Dis Control & Prevent, Div Global HIV & TB, Ctr Global Hlth, 1600 Clifton Rd NE,Mailstop E-30, Atlanta, GA 30333 USA. EM kmirkovic@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD OCT 23 PY 2016 VL 30 IS 16 BP 2569 EP 2570 DI 10.1097/QAD.0000000000001265 PG 2 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DZ0KV UT WOS:000385528600021 PM 27753682 ER PT J AU Irish, SR Al-Amin, HM Alam, MS Harbach, RE AF Irish, Seth R. Al-Amin, Hasan Mohammad Alam, Mohammad Shafiul Harbach, Ralph E. TI A review of the mosquito species (Diptera: Culicidae) of Bangladesh SO PARASITES & VECTORS LA English DT Article DE Species list; Mosquitoes; Bangladesh; Culicidae ID ANOPHELES-SUBPICTUS COMPLEX; PLASMODIUM INFECTION STATUS; MALARIA-ENDEMIC AREA; SOUTHEAST-ASIA; EAST PAKISTAN; POPULATION-STRUCTURE; AEDES-ALBOPICTUS; FOREST MALARIA; IDENTIFICATION; TRANSMISSION AB Background: Diseases caused by mosquito-borne pathogens remain an important source of morbidity and mortality in Bangladesh. To better control the vectors that transmit the agents of disease, and hence the diseases they cause, and to appreciate the diversity of the family Culicidae, it is important to have an up-to-date list of the species present in the country. Original records were collected from a literature review to compile a list of the species recorded in Bangladesh. Results: Records for 123 species were collected, although some species had only a single record. This is an increase of ten species over the most recent complete list, compiled nearly 30 years ago. Collection records of three additional species are included here: Anopheles pseudowillmori, Armigeres malayi and Mimomyia luzonensis. Conclusions: While this work constitutes the most complete list of mosquito species collected in Bangladesh, further work is needed to refine this list and understand the distributions of those species within the country. Improved morphological and molecular methods of identification will allow the refinement of this list in years to come. C1 [Irish, Seth R.] Ctr Dis Control & Prevent, Entomol Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. [Al-Amin, Hasan Mohammad; Alam, Mohammad Shafiul] Int Ctr Diarrhoeal Dis Res, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh. [Harbach, Ralph E.] Nat Hist Museum, Dept Life Sci, Cromwell Rd, London SW7 5BD, England. RP Irish, SR (reprint author), Ctr Dis Control & Prevent, Entomol Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM sirish@cdc.gov FU Governments of Bangladesh, Canada, Sweden; UK; President's Malaria Initiative (USAID/CDC) FX International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) is grateful to the Governments of Bangladesh, Canada, Sweden and the UK for providing core/unrestricted support. The publishing costs for this manuscript were paid by the President's Malaria Initiative (USAID/CDC). NR 146 TC 0 Z9 0 U1 4 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD OCT 22 PY 2016 VL 9 AR 559 DI 10.1186/s13071-016-1848-z PG 9 WC Parasitology SC Parasitology GA DZ5ES UT WOS:000385885400001 PM 27770829 ER PT J AU Garcia, MC Dodek, AB Kowalski, T Fallon, J Lee, SH Iademarco, MF Auerbach, J Bohm, MK AF Garcia, Macarena C. Dodek, Anton B. Kowalski, Tom Fallon, John Lee, Scott H. Iademarco, Michael F. Auerbach, John Bohm, Michele K. TI Declines in Opioid Prescribing After a Private Insurer Policy Change - Massachusetts, 2011-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID OVERDOSE DEATHS; DRUG C1 [Garcia, Macarena C.; Lee, Scott H.; Iademarco, Michael F.] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Dodek, Anton B.; Kowalski, Tom; Fallon, John] Blue Cross & Blue Shield Massachusetts, Boston, MA USA. [Auerbach, John] CDC, Off Associate Director Policy, Off Director, Atlanta, GA 30333 USA. [Bohm, Michele K.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Garcia, MC (reprint author), CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. EM mcgarcia@cdc.gov NR 10 TC 0 Z9 0 U1 3 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 21 PY 2016 VL 65 IS 41 BP 1125 EP 1131 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA5EX UT WOS:000386643300001 PM 27764082 ER PT J AU Gvinjilia, L Nasrullah, M Sergeenko, D Tsertsvadze, T Kamkamidze, G Butsashvili, M Gamkrelidze, A Imnadze, P Kvaratskhelia, V Chkhartishvili, N Sharvadze, L Drobeniuc, J Hagan, L Ward, JW Morgan, J Averhoff, F AF Gvinjilia, Lia Nasrullah, Muazzam Sergeenko, David Tsertsvadze, Tengiz Kamkamidze, George Butsashvili, Maia Gamkrelidze, Amiran Imnadze, Paata Kvaratskhelia, Valeri Chkhartishvili, Nikoloz Sharvadze, Lali Drobeniuc, Jan Hagan, Liesl Ward, John W. Morgan, Juliette Averhoff, Francisco TI National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID FIBROSIS C1 [Gvinjilia, Lia] CDC Fdn, Tbilisi, Rep of Georgia. [Nasrullah, Muazzam; Drobeniuc, Jan; Hagan, Liesl; Ward, John W.; Averhoff, Francisco] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Sergeenko, David; Kvaratskhelia, Valeri] Minist Labor Hlth & Social Affairs Georgia, Tbilisi, Rep of Georgia. [Tsertsvadze, Tengiz; Chkhartishvili, Nikoloz] Infect Dis AIDS & Clin Immunol Res Ctr, Tbilisi, Rep of Georgia. [Kamkamidze, George; Butsashvili, Maia] Neolab, Tbilisi, Rep of Georgia. [Gamkrelidze, Amiran; Imnadze, Paata] Natl Ctr Dis Control & Publ Hlth Georgia, Tbilisi, Rep of Georgia. [Sharvadze, Lali] Joint Georgian French Hepatol Clin Hepa, Tbilisi, Rep of Georgia. [Morgan, Juliette] South Caucasus CDC Off, Div Global Hlth Protect, Global Dis Detect, Tbilisi, Rep of Georgia. RP Nasrullah, M (reprint author), CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM snasrullah@cdc.gov NR 8 TC 0 Z9 0 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 21 PY 2016 VL 65 IS 41 BP 1132 EP 1135 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA5EX UT WOS:000386643300002 PM 27764081 ER PT J AU Loharikar, A Dumolard, L Chu, S Hyde, T Goodman, T Mantel, C AF Loharikar, Anagha Dumolard, Laure Chu, Susan Hyde, Terri Goodman, Tracey Mantel, Carsten TI Status of New Vaccine Introduction - Worldwide, September 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CHILDREN YOUNGER; BURDEN C1 [Loharikar, Anagha; Chu, Susan; Hyde, Terri] CDC, Global Immunizat Div, Atlanta, GA 30333 USA. [Dumolard, Laure; Goodman, Tracey; Mantel, Carsten] World Hlth Org, Expanded Program Immunizat, Geneva, Switzerland. RP Loharikar, A (reprint author), CDC, Global Immunizat Div, Atlanta, GA 30333 USA. EM igd2@cdc.gov NR 10 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 21 PY 2016 VL 65 IS 41 BP 1136 EP 1140 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA5EX UT WOS:000386643300003 PM 27764083 ER PT J AU Griffin, SO Wei, L Gooch, BF Weno, K Espinoza, L AF Griffin, Susan O. Wei, Liang Gooch, Barbara F. Weno, Katherine Espinoza, Lorena TI Vital Signs: Dental Sealant Use and Untreated Tooth Decay Among US School-Aged Children SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PROGRAMS; CARIES AB Background: Tooth decay is one of the greatest unmet treatment needs among children. Pain and suffering associated with untreated dental disease can lead to problems with eating, speaking, and learning. School-based dental sealant programs (SBSP) deliver a highly effective intervention to prevent tooth decay in children who might not receive regular dental care. SBSPs benefits exceed their costs when they target children at high risk for tooth decay. Methods: CDC used data, from the National Health and Nutrition Examination Survey (NHANES) 2011-2014 to estimate current prevalences of sealant use and untreated tooth decay among low-income (<= 185% of federal poverty level) and higher-income children aged 6-11 years and compared these estimates with 1999-2004 NHANES data. The mean number of decayed and filled first molars (DFFM) was estimated for children with and without sealants. Averted tooth decay resulting from increasing sealant use prevalence was also estimated. All reported differences are significant at p<0.05. Results: From 1999-2004 to 2011-2014, among low- and higher-income children, sealant use prevalence increased by 16.2 and 8.8 percentage points to 38.7% and 47.8%, respectively. Among low-income children aged 7-11 years, the mean DFFM was almost three times higher among children without sealants (0.82) than among children with sealants. Approximately 6.5 million low-income children could potentially benefit from the delivery of sealants through SBSP. Conclusions and Implications for Public Health Practice: The prevalence of dental sealant use has increased; however, most children have not received sealants. Increasing sealant use prevalence could substantially reduce untreated decay, associated problems, and dental treatment costs. C1 [Griffin, Susan O.; Wei, Liang; Weno, Katherine; Espinoza, Lorena] CDC, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Griffin, SO (reprint author), CDC, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM sgriffin2@cdc.gov NR 15 TC 0 Z9 0 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 21 PY 2016 VL 65 IS 41 BP 1141 EP 1145 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA5EX UT WOS:000386643300004 PM 27764075 ER PT J AU Healy, JM Burgess, MC Chen, TH Hancock, WT Toews, KAE Anesi, MS Tulafono, RT Mataia, MA Sili, B Solaita, J Whelen, AC Sciulli, R Gose, RB Uluiviti, V Hennessey, M Utu, F Nua, MT Fischer, M AF Healy, Jessica M. Burgess, M. Catherine Chen, Tai-Ho Hancock, W. Thane Toews, Karrie-Ann E. Anesi, Magele Scott Tulafono, Ray T., Jr. Mataia, Mary Aseta Sili, Benjamin Solaita, Jacqueline Whelen, A. Christian Sciulli, Rebecca Gose, Remedios B. Uluiviti, Vasiti Hennessey, Morgan Utu, Fara Nua, Motusa Tuileama Fischer, Marc TI Outbreak of Zika Virus Disease - American Samoa, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Healy, Jessica M.; Hennessey, Morgan] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Healy, Jessica M.] Cty San Diego Hlth & Human Serv Agcy, Epidemiol & Immunizat Serv Branch, San Diego, CA USA. [Healy, Jessica M.; Chen, Tai-Ho] CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Burgess, M. Catherine; Hancock, W. Thane; Toews, Karrie-Ann E.] CDC, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Anesi, Magele Scott; Mataia, Mary Aseta; Sili, Benjamin; Solaita, Jacqueline; Utu, Fara; Nua, Motusa Tuileama] Amer Samoa Govt, Dept Hlth, Utulei, AS USA. [Tulafono, Ray T., Jr.] Lyndon B Johnson Trop Med Ctr, Pago Pago, AS USA. [Whelen, A. Christian; Sciulli, Rebecca; Gose, Remedios B.] Hawaii Dept Hlth State Labs Div, Honolulu, HI USA. [Uluiviti, Vasiti] Pacific Isl Hlth Officers Assoc, Honolulu, HI USA. [Hennessey, Morgan; Fischer, Marc] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Healy, JM (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Healy, JM (reprint author), Cty San Diego Hlth & Human Serv Agcy, Epidemiol & Immunizat Serv Branch, San Diego, CA USA.; Healy, JM (reprint author), CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM jhealy@cdc.gov NR 3 TC 1 Z9 1 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 21 PY 2016 VL 65 IS 41 BP 1146 EP 1147 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA5EX UT WOS:000386643300005 PM 27764076 ER PT J AU Budnitz, DS Lovegrove, MC Sapiano, MRP Mathew, J Kegler, SR Geller, AI Hampp, C AF Budnitz, Daniel S. Lovegrove, Maribeth C. Sapiano, Mathew R. P. Mathew, Justin Kegler, Scott R. Geller, Andrew I. Hampp, Christian TI Pediatric Emergency Department Visits for Buprenorphine/Naloxone Ingestion - United States, 2008-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID YOUNG-CHILDREN; EXPOSURES C1 [Budnitz, Daniel S.; Lovegrove, Maribeth C.; Sapiano, Mathew R. P.; Geller, Andrew I.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Mathew, Justin; Hampp, Christian] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA. [Kegler, Scott R.] CDC, Div Res Anal & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Budnitz, DS (reprint author), CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM dbudnitz@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 21 PY 2016 VL 65 IS 41 BP 1148 EP 1149 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA5EX UT WOS:000386643300006 PM 27764078 ER PT J AU Wang, A Hardy, C Rajasingham, A Martinsen, A Templin, L Kamwaga, S Sebunya, K Jhuthi, B Habtu, M Kiberiti, S Massa, K Quick, R Mulungu, J Eidex, R Handzel, T AF Wang, Alice Hardy, Colleen Rajasingham, Anangu Martinsen, Andrea Templin, Lindsay Kamwaga, Stanislaus Sebunya, Kiwe Jhuthi, Brenda Habtu, Michael Kiberiti, Stephen Massa, Khalid Quick, Rob Mulungu, Jane Eidex, Rachel Handzel, Thomas TI Chlorination Strategies for Drinking Water During a Cholera Epidemic - Tanzania, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Wang, Alice] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Wang, Alice] CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Hardy, Colleen; Rajasingham, Anangu; Martinsen, Andrea; Templin, Lindsay; Mulungu, Jane; Eidex, Rachel; Handzel, Thomas] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA. [Kamwaga, Stanislaus; Sebunya, Kiwe] United Nations Childrens Fund, New York, NY USA. [Jhuthi, Brenda] Int Federat Red Cross, Geneva, Switzerland. [Kiberiti, Stephen; Massa, Khalid] Tanzanian Minist Hlth Community Dev Gender Elderl, Dar Es Salaam, Tanzania. [Quick, Rob] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Mulungu, Jane; Eidex, Rachel] CDC Country Off Tanzania, Div Global Hlth Protect, Ctr Global Hlth, Dar Es Salaam, Tanzania. RP Wang, A (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Wang, A (reprint author), CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM ilm1@cdc.gov NR 3 TC 1 Z9 1 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 21 PY 2016 VL 65 IS 41 BP 1150 EP 1151 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA5EX UT WOS:000386643300007 PM 27764079 ER PT J AU Hernandez, SM Welch, CN Peters, VE Lipp, EK Curry, S Yabsley, MJ Sanchez, S Presotto, A Gerner-Smidt, P Hise, KB Hammond, E Kistler, WM Madden, M Conway, AL Kwan, T Maurer, JJ AF Hernandez, Sonia M. Welch, Catharine N. Peters, Valerie E. Lipp, Erin K. Curry, Shannon Yabsley, Michael J. Sanchez, Susan Presotto, Andrea Gerner-Smidt, Peter Hise, Kelley B. Hammond, Elizabeth Kistler, Whitney M. Madden, Marguerite Conway, April L. Kwan, Tiffany Maurer, John J. TI Urbanized White Ibises (Eudocimus albus) as Carriers of Salmonella enterica of Significance to Public Health and Wildlife SO PLOS ONE LA English DT Article ID FIELD GEL-ELECTROPHORESIS; SPARROWS PASSER-MONTANUS; UNITED-STATES; AVIAN WILDLIFE; MOLECULAR EPIDEMIOLOGY; TYPHIMURIUM INFECTION; MULTISTATE OUTBREAK; SUBSP ENTERICA; GULLS LARUS; BIRDS AB Worldwide, Salmonella spp. is a significant cause of disease for both humans and wildlife, with wild birds adapted to urban environments having different opportunities for pathogen exposure, infection, and transmission compared to their natural conspecifics. Food provisioning by people may influence these factors, especially when high-density mixed species flocks aggregate. White Ibises (Eudocimus albus), an iconic Everglades species in decline in Florida, are becoming increasingly common in urbanized areas of south Florida where most are hand-fed. We examined the prevalence of Salmonella shedding by ibises to determine the role of landscape characteristics where ibis forage and their behavior, on shedding rates. We also compared Salmonella isolated from ibises to human isolates to better understand non-foodborne human salmonellosis. From 2010-2013, 13% (n = 261) adult/subadult ibises and 35% (n = 72) nestlings sampled were shedding Salmonella. The prevalence of Salmonella shedding by ibises significantly decreased as the percent of Palustrine emergent wetlands and herbaceous grasslands increased, and increased as the proportion of open-developed land types (e.g. parks, lawns, golf courses) increased, suggesting that natural ecosystem land cover types supported birds with a lower prevalence of infection. A high diversity of Salmonella serotypes (n = 24) and strain types (43 PFGE types) were shed by ibises, of which 33% of the serotypes ranked in the top 20 of high significance for people in the years of the study. Importantly, 44% of the Salmonella Pulsed-Field Gel Electrophoresis patterns for ibis isolates (n = 43) matched profiles in the CDC PulseNet USA database. Of these, 20% came from Florida in the same three years we sampled ibis. Importantly, there was a negative relationship between the amount of Palustrine emergent wetland and the number of Salmonella isolates from ibises that matched human cases in the PulseNet database (p = 0.056). Together, our results indicate that ibises are good indicators of salmonellae strains circulating in their environment and they have both the potential and opportunity to transmit salmonellae to people. Finally, they may act as salmonellae carriers to natural environments where other more highly-susceptible groups (nestlings) may be detrimentally affected. C1 [Hernandez, Sonia M.; Welch, Catharine N.; Curry, Shannon; Yabsley, Michael J.; Conway, April L.] Univ Georgia, Warnell Sch Forestry & Nat Resources, Athens, GA 30602 USA. [Hernandez, Sonia M.; Yabsley, Michael J.; Kistler, Whitney M.] Univ Georgia, Coll Vet Med, Dept Populat Hlth, Southeastern Cooperat Wildlife Dis Study, Athens, GA 30602 USA. [Peters, Valerie E.] Miami Univ, Dept Zool, Inst Environm & Sustainabil, Columbia, OH USA. [Lipp, Erin K.] Univ Georgia, Dept Environm Hlth Sci, Athens, GA 30602 USA. [Sanchez, Susan] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA USA. [Presotto, Andrea; Madden, Marguerite] Univ Georgia, Dept Geog, Athens, GA 30602 USA. [Gerner-Smidt, Peter; Hise, Kelley B.] Ctr Dis Control & Prevent, US Dept Hlth & Human Serv, Atlanta, GA USA. [Hammond, Elizabeth] Lion Country Safari Pk, Loxahatchee, FL USA. [Kwan, Tiffany; Maurer, John J.] Univ Georgia, Coll Vet Med, Dept Populat Hlth, Poultry Diagnost & Res Ctr, Athens, GA USA. RP Hernandez, SM (reprint author), Univ Georgia, Warnell Sch Forestry & Nat Resources, Athens, GA 30602 USA.; Hernandez, SM (reprint author), Univ Georgia, Coll Vet Med, Dept Populat Hlth, Southeastern Cooperat Wildlife Dis Study, Athens, GA 30602 USA. EM shernz@uga.edu FU National Institutes of Health [1R15A1089565-01]; American Association of Zoo Veterinarians; University of Georgia; National Science Foundation [EEID 1518611] FX This research was funded by National Institutes of Health 1R15A1089565-01 to Erin K Lipp; American Association of Zoo Veterinarians to Dr Sonia M. Hernandez; University of Georgia to Dr Sonia Maria Hernandez; and National Science Foundation EEID 1518611 to Dr. Sonia M. Hernandez. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 69 TC 0 Z9 0 U1 9 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 21 PY 2016 VL 11 IS 10 AR e0164402 DI 10.1371/journal.pone.0164402 PG 22 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DZ9OE UT WOS:000386205400013 PM 27768705 ER PT J AU Teeter, LD Vempaty, P Nguyen, DTM Tapia, J Sharnprapai, S Ghosh, S Kammerer, JS Miramontes, R Cronin, WA Graviss, EA AF Teeter, Larry D. Vempaty, Padmaja Nguyen, Duc T. M. Tapia, Jane Sharnprapai, Sharon Ghosh, Smita Kammerer, J. Steven Miramontes, Roque Cronin, Wendy A. Graviss, Edward A. CA Tb Epidemiologic Studies TI Validation of genotype cluster investigations for Mycobacterium tuberculosis: application results for 44 clusters from four heterogeneous United States jurisdictions SO BMC INFECTIOUS DISEASES LA English DT Article DE Tuberculosis; Epidemiology; Genotype; Cluster investigation; MIRU-VNTR; Spoligotype; Contact investigation; Surveillance ID MOLECULAR EPIDEMIOLOGY; CONTACT INVESTIGATIONS; STRAIN DIFFERENTIATION; TRANSMISSION DYNAMICS; PERSPECTIVE AB Background: Tracking the dissemination of specific Mycobacterium tuberculosis (Mtb) strains using genotyped Mtb isolates from tuberculosis patients is a routine public health practice in the United States. The present study proposes a standardized cluster investigation method to identify epidemiologic-linked patients in Mtb genotype clusters. The study also attempts to determine the proportion of epidemiologic-linked patients the proposed method would identify beyond the outcome of the conventional contact investigation. Methods: The study population included Mtb culture positive patients from Georgia, Maryland, Massachusetts and Houston, Texas. Mtb isolates were genotyped by CDC's National TB Genotyping Service (NTGS) from January 2006 to October 2010. Mtb cluster investigations (CLIs) were conducted for patients whose isolates matched exactly by spoligotyping and 12-locus MIRU-VNTR. CLIs were carried out in four sequential steps: (1) Public Health Worker (PHW) Interview, (2) Contact Investigation (CI) Evaluation, (3) Public Health Records Review, and (4) CLI TB Patient Interviews. Comparison between patients whose links were identified through the study's CLI interviews (Step 4) and patients whose links were identified earlier in CLI (Steps 1-3) was conducted using logistic regression. Results: Forty-four clusters were randomly selected from the four study sites (401 patients in total). Epidemiologic links were identified for 189/401 (47 %) study patients in a total of 201 linked patient-pairs. The numbers of linked patients identified in each CLI steps were: Step 1 - 105/401 (26.2 %), Step 2 - 15/388 (3.9 %), Step 3 - 41/281 (14.6 %), and Step 4 - 28/119 (30 %). Among the 189 linked patients, 28 (14.8 %) were not identified in previous CI. No epidemiologic links were identified in 13/44 (30 %) clusters. Conclusions: We validated a standardized and practical method to systematically identify epidemiologic links among patients in Mtb genotype clusters, which can be integrated into the TB control and prevention programs in public health settings. The CLI interview identified additional epidemiologic links that were not identified in previous CI. One-third of the clusters showed no epidemiologic links despite being extensively investigated, suggesting that some improvement in the interviewing methods is still needed. C1 [Teeter, Larry D.; Nguyen, Duc T. M.; Graviss, Edward A.] Houston Methodist Res Inst, Houston, TX 77030 USA. [Vempaty, Padmaja; Ghosh, Smita; Kammerer, J. Steven; Miramontes, Roque] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tapia, Jane] Emory Sch Med, Atlanta, GA USA. [Sharnprapai, Sharon] Massachusetts Dept Publ Hlth, Jamaica Plain, MA USA. [Kammerer, J. Steven] Ctr Dis Control & Prevent, Northrop Grumman Corp, Atlanta, GA USA. [Cronin, Wendy A.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Teeter, Larry D.] Texas Dept State Hlth Serv, HSR 6-5, South Houston, TX USA. [Graviss, Edward A.] Houston Methodist Res Inst, Dept Pathol & Genom Med, Mail Stn R6-414,6670 Bertner, Houston, TX 77030 USA. RP Graviss, EA (reprint author), Houston Methodist Res Inst, Houston, TX 77030 USA.; Graviss, EA (reprint author), Houston Methodist Res Inst, Dept Pathol & Genom Med, Mail Stn R6-414,6670 Bertner, Houston, TX 77030 USA. EM eagraviss@houstonmethodist.org OI Miramontes, Roque/0000-0001-9535-460X FU Division of TB Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention [26] FX This project was funded by the Division of TB Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, through a task order announced and managed by the Tuberculosis Epidemiologic Studies Consortium (TBESC). The task order is designated as Task Order 26. NR 30 TC 0 Z9 0 U1 2 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD OCT 21 PY 2016 VL 16 AR 594 DI 10.1186/s12879-016-1937-9 PG 11 WC Infectious Diseases SC Infectious Diseases GA DZ7FP UT WOS:000386030600005 PM 27769182 ER PT J AU Crosby, AE Lyons, B AF Crosby, Alex E. Lyons, Bridget TI Assessing Homicides by and of US Law-Enforcement Officers SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID DEATH REPORTING SYSTEM C1 [Crosby, Alex E.; Lyons, Bridget] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30333 USA. RP Crosby, AE (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30333 USA. NR 5 TC 1 Z9 1 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 20 PY 2016 VL 375 IS 16 BP 1509 EP 1511 DI 10.1056/NEJMp1609905 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA EJ3HF UT WOS:000393102500003 PM 27537352 ER PT J AU Gilchuk, I Gilchuk, P Sapparapu, G Lampley, R Singh, V Kose, N Blum, DL Hughes, LJ Satheshkumar, PS Townsend, MB Kondas, AV Reed, Z Weiner, Z Olson, VA Hammarlund, E Raue, HP Slifka, MK Slaughter, JC Graham, BS Edwards, KM Eisenberg, RJ Cohen, GH Joyce, S Crowe, JE AF Gilchuk, Iuliia Gilchuk, Pavlo Sapparapu, Gopal Lampley, Rebecca Singh, Vidisha Kose, Nurgun Blum, David L. Hughes, Laura J. Satheshkumar, Panayampalli S. Townsend, Michael B. Kondas, Ashley V. Reed, Zachary Weiner, Zachary Olson, Victoria A. Hammarlund, Erika Raue, Hans-Peter Slifka, Mark K. Slaughter, James C. Graham, Barney S. Edwards, Kathryn M. Eisenberg, Roselyn J. Cohen, Gary H. Joyce, Sebastian Crowe, James E., Jr. TI Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections SO CELL LA English DT Article ID ATTENUATED SMALLPOX VACCINE; MONOCLONAL-ANTIBODIES; VIRUS-INFECTION; ENVELOPE PROTEIN; IMMUNE-RESPONSE; B-CELLS; MONKEYPOX; MICE; CHALLENGE; ANTIGEN AB Monkeypox (MPXV) and cowpox (CPXV) areemerging agents that cause severe human infections on an inter-mittentbasis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply. We generated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects to investigate the molecular basis of broadly neutralizing antibody responses for diverse orthopox-viruses. Detailed analysis revealed the principal neutralizing antibody specificities that are cross-reactive for VACV, CPXV, MPXV, and VARV and that are determinants of protection in murine challenge models. Optimal protection following respiratory or systemic infection required a mixture of Abs that targeted several membrane proteins, including proteins on enveloped and mature virion forms of virus. This work reveals orthopoxvirus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab therapeutic mixtures to replace VIG. C1 [Gilchuk, Iuliia; Sapparapu, Gopal; Lampley, Rebecca; Singh, Vidisha; Kose, Nurgun; Blum, David L.; Crowe, James E., Jr.] Vanderbilt Univ, Vanderbilt Vaccine Ctr, Med Ctr, Nashville, TN 37232 USA. [Gilchuk, Pavlo; Joyce, Sebastian; Crowe, James E., Jr.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA. [Gilchuk, Pavlo; Joyce, Sebastian] Vet Adm Tennessee Valley Healthcare Syst, Nashville, TN 37332 USA. [Sapparapu, Gopal; Edwards, Kathryn M.; Crowe, James E., Jr.] Vanderbilt Univ, Dept Pediat, Med Ctr, Nashville, TN 37232 USA. [Hughes, Laura J.; Satheshkumar, Panayampalli S.; Townsend, Michael B.; Kondas, Ashley V.; Reed, Zachary; Olson, Victoria A.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA 30329 USA. [Reed, Zachary; Weiner, Zachary] Ctr Dis Control & Prevent, Lab Leadership Serv, Atlanta, GA 30329 USA. [Hammarlund, Erika; Raue, Hans-Peter; Slifka, Mark K.] Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA. [Slaughter, James C.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA. [Graham, Barney S.] NIAID, Vaccine Res Ctr, Bethesda, MD 20892 USA. [Eisenberg, Roselyn J.] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA. [Cohen, Gary H.] Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA. RP Crowe, JE (reprint author), Vanderbilt Univ, Vanderbilt Vaccine Ctr, Med Ctr, Nashville, TN 37232 USA.; Crowe, JE (reprint author), Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA.; Crowe, JE (reprint author), Vanderbilt Univ, Dept Pediat, Med Ctr, Nashville, TN 37232 USA. EM james.crowe@vanderbilt.edu OI Sapparapu, Gopal/0000-0001-9670-1757 FU U.S. NIH [U01 AI48512, HHSN272200900047C, U19 AI109948, 8P51 OD 011092-53]; NCRR [UL1 RR024975-01]; National Center for Advancing Translational Sciences [2 UL1 TR000445-06, BX001444]; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH; NIH [P30 CA68485, DK058404] FX This project received support from the U.S. NIH (grants U01 AI48512 and contract HHSN272200900047C to J.E.C., and U19 AI109948 and 8P51 OD 011092-53 to M.K.S.). The project was supported by NCRR grant UL1 RR024975-01, and is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06, and VA Merit Award BX001444 (to S.J.). This work was supported by intramural funding from the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH. Flow cytometry experiments were performed in the Vanderbilt University Medical Center Flow Cytometry Shared Resource, supported by NIH P30 CA68485 and DK058404. We thank Jill Janssen and the Vanderbilt Clinical Trials Center for regulatory support, and Yingchun Yu, Patricia McGraw, Natalie Thornburg, Shane Crotty, Chwan Hong Foo, J. Charles Whitbeck, and Stuart Isaacs for technical contributions and advice. We thank Y. Xiang and Dirk Zajonc for providing recombinant D8 protein and Shane Crotty for providing H3 protein. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Centers for Disease Control and Prevention. I.G. and J.E.C. are named as co-inventors on a patent applied for that is associated with some of the antibodies described in this manuscript. NR 41 TC 0 Z9 0 U1 5 U2 5 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD OCT 20 PY 2016 VL 167 IS 3 BP 684 EP + DI 10.1016/j.cell.2016.09.049 PG 20 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA EA1HW UT WOS:000386344100016 PM 27768891 ER PT J AU Sawadogo, S Makumbi, B Purfield, A Ndjavera, C Mutandi, G Maher, A Kaindjee-Tjituka, F Kaplan, JE Park, BJ Lowrance, DW AF Sawadogo, Souleymane Makumbi, Boniface Purfield, Anne Ndjavera, Christophine Mutandi, Gram Maher, Andrew Kaindjee-Tjituka, Francina Kaplan, Jonathan E. Park, Benjamin J. Lowrance, David W. TI Estimated Prevalence of Cryptococcus Antigenemia (CrAg) among HIV-Infected Adults with Advanced Immunosuppression in Namibia Justifies Routine Screening and Preemptive Treatment SO PLOS ONE LA English DT Article ID ANTIRETROVIRAL THERAPY; EARLY MORTALITY; SERUM; MENINGITIS; UGANDA; DIAGNOSIS; TANZANIA; URINE AB Background Cryptococcal meningitis is common and associated with high mortality among HIV infected persons. The World Health Organization recommends that routine Cryptococcal antigen (CrAg) screening in ART-naive adults with a CD4(+) count <100 cells/mu L followed by preemptive antifungal therapy for CrAg-positive patients be considered where CrAg prevalence is >= 3%. The prevalence of CrAg among HIV adults in Namibia is unknown. We estimated CrAg prevalence among HIV-infected adults receiving care in Namibia for the purpose of informing routine screening strategies. Methods The study design was cross-sectional. De-identified plasma specimens collected for routine CD4(+) testing from HIV-infected adults enrolled in HIV care at 181 public health facilities from November 2013 to January 2014 were identified at the national reference laboratory. Remnant plasma from specimens with CD4(+) counts <200 cells/mu L were sampled and tested for CrAg using the IMMY (R) Lateral Flow Assay. CrAg prevalence was estimated and assessed for associations with age, sex, and CD4(+) count. Results A total of 825 specimens were tested for CrAg. The median (IQR) age of patients from whom specimens were collected was 38 (32-46) years, 45.9% were female and 62.9% of the specimens had CD4 <100 cells/mu L. CrAg prevalence was 3.3% overall and 3.9% and 2.3% among samples with CD4(+) counts of CD4(+)<100 cells/mu L and 100-200 cells/mu L, respectively. CrAg positivity was significantly higher among patients with CD4+ cells/mu L < 50 (7.2%, P = 0.001) relative to those with CD4 cells/mu L 50-200 (2.2%). Conclusion This is the first study to estimate CrAg prevalence among HIV-infected patients in Namibia. CrAg prevalence of >= 3.0% among patients with CD4(+)<100 cells/mu L justifies routine CrAg screening and preemptive treatment among HIV-infected in Namibia in line with WHO recommendations. Patients with CD4(+)<100 cells/mu L have a significantly greater risk for CrAg positivity. Revised guidelines for ART in Namibia now recommend routine screening for CrAg. C1 [Sawadogo, Souleymane; Mutandi, Gram; Lowrance, David W.] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Windhoek, Namibia. [Makumbi, Boniface; Ndjavera, Christophine] Namibia Inst Pathol, Windhoek, Namibia. [Purfield, Anne; Park, Benjamin J.] Ctr Dis Control & Prevent CDC, Mycot Dis Branch, Atlanta, GA USA. [Kaindjee-Tjituka, Francina] Minist Hlth & Social Serv, Directorate Special Programs, Windhoek, Namibia. [Kaplan, Jonathan E.] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Atlanta, GA USA. [Maher, Andrew] Univ Calif San Francisco, Global Hlth Sci, San Francisco, CA 94143 USA. RP Sawadogo, S (reprint author), Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Windhoek, Namibia. EM ssawadogo@cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention [UPS001094A] FX This research was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention under the terms of Award #UPS001094A. NR 32 TC 1 Z9 1 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 19 PY 2016 VL 11 IS 10 AR e0161830 DI 10.1371/journal.pone.0161830 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DZ9NW UT WOS:000386204000002 PM 27760140 ER PT J AU Alwis, KU Bailey, TL Patel, D Wang, LQ Blount, BC AF Alwis, K. Udeni Bailey, T. Liz Patel, Dhrusti Wang, Liqun Blount, Benjamin C. TI Measuring urinary N-acetyl-S-(4-hydroxy-2-methyl-2-buten-1-yl)-L-cysteine (IPMA3) as a potential biomarker of isoprene exposure SO ANALYTICA CHIMICA ACTA LA English DT Article DE Isoprene; Metabolism; Urinary metabolites; Tobacco smoke; UPLC/ESI-MSMS; Biomonitoring ID BUTADIENE MONOXIDE; IN-VITRO; LIVER-MICROSOMES; EXHALED BREATH; RATS; MICE; GLUTATHIONE; METABOLISM; MONOEPOXIDES; CONJUGATION AB Isoprene, the 2-methyl analog of 1,3-butadiene, is identified as a possible human carcinogen by the International Agency for Research on Cancer (IARC). Isoprene is ubiquitous in the environment with numerous natural and anthropogenic sources. Tobacco smoke is the main exogenous source of isoprene exposure in indoor environments. Among smoke constituents, isoprene is thought to contribute significantly to cancer risk; however, no selective urinary biomarkers of isoprene exposure have been identified for humans. In this manuscript, we measured the minor isoprene metabolite IPMA1 (mixture of N-acetyl-S-(1-[hydroxymethyl]-2-methyl-2-propen-1-yl)-L-cysteine and N-acetyl-S-(2-hydroxy-3methyl-3-buten-1-yl)-L-cysteine), and we identified IPMA3 (N-acetyl-S-(4-hydroxy-2-methyl-2-buten-1-yl)-L-cysteine) as a major isoprene metabolite and novel isoptene exposure biomarker for humans. Urinary isoprene metabolites were measured using ultra high performance liquid chrcimatography coupled with electrospray ionization triple quad tandem mass spectrometry (UPLC/ESI-MSMS). The detection rates of IPMA1 and IPMA3 are <20% and 82%, respectively. The selectivity and abundance of IPMA3 make it a useful urinary biomarker of isoprene exposure. The limit of detection of IPMA3 in urine was 0.5 ng mL(-1). IPMA3 was stable under different storage temperatures and following ten freeze-thaw cycles. The average recovery of urine spiked with IPMA3 at three different levels was 99%. IPMA3 was measured in urine samples received from 75 anonymous subjects; the median (25th percentile, 75th percentile) IPMA3 level in smokers was 36.2 (18.2, 56.8) ng mL(-1) and non-smokers 2.31 (2.31, 4.38) ng mL(-1). Application of this method to large population studies will help to characterize isoprene exposure and assess potential health impact. Published by Elsevier B.V. C1 [Alwis, K. Udeni; Bailey, T. Liz; Patel, Dhrusti; Wang, Liqun; Blount, Benjamin C.] Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Alwis, KU (reprint author), Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Div Sci Lab, MS F-44,4770 Buford Highway, Atlanta, GA 30341 USA. EM UAlwis@cdc.gov NR 25 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0003-2670 EI 1873-4324 J9 ANAL CHIM ACTA JI Anal. Chim. Acta PD OCT 19 PY 2016 VL 941 BP 61 EP 66 DI 10.1016/j.aca.2016.08.023 PG 6 WC Chemistry, Analytical SC Chemistry GA DY7RK UT WOS:000385326800007 PM 27692379 ER PT J AU Meyers, AFA Sandstrom, P Denny, TN Hurlston, M Ball, TB Peeling, RW Boeras, DI AF Meyers, Adrienne F. A. Sandstrom, Paul Denny, Thomas N. Hurlston, Mackenzie Ball, Terry B. Peeling, Rosanna W. Boeras, Debrah I. TI Quality assurance for HIV point-of-care testing and treatment monitoring assays SO AFRICAN JOURNAL OF LABORATORY MEDICINE LA English DT Article ID RESOURCE-POOR SETTINGS; PROGRAM; LABORATORIES; SYSTEMS; AFRICA AB In 2015, UNAIDS launched the 90-90-90 targets aimed at increasing the number of people infected with HIV to become aware of their status, access antiretroviral therapies and ultimately be virally suppressed. To achieve these goals, countries may need to scale up point-of-care (POC) testing in addition to strengthening central laboratory services. While decentralising testing increases patient access to diagnostics, it presents many challenges with regard to training and assuring the quality of tests and testing. To ensure synergies, the London School of Hygiene & Tropical Medicine held a series of consultations with countries with an interest in quality assurance and their implementing partners, and agreed on an external quality assessment (EQA) programme to ensure reliable results so that the results lead to the best possible care for HIV patients. As a result of the consultations, EQA International was established, bringing together EQA providers and implementers to develop a strategic plan for countries to establish national POC EQA programmes and to estimate the cost of setting up and maintaining the programme. With the dramatic increase in the number of proficiency testing panels required for thousands of POC testing sites across Africa, it is important to facilitate technology transfer from global EQA providers to a network of regional EQA centres in Africa for regional proficiency testing panel production. EQA International will continue to identify robust and cost-effective EQA technologies for quality POC testing, integrating novel technologies to support sustainable country-owned EQA programmes in Africa. C1 [Meyers, Adrienne F. A.; Sandstrom, Paul; Ball, Terry B.] Publ Hlth Agcy Canada, QASI, Natl HIV & Retrovirol Labs, JC Wilt Infect Dis Res Ctr, Winnipeg, MB, Canada. [Meyers, Adrienne F. A.; Sandstrom, Paul; Ball, Terry B.] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada. [Meyers, Adrienne F. A.; Ball, Terry B.] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya. [Denny, Thomas N.] Duke Univ, Dept Med, Durham, NC USA. [Hurlston, Mackenzie] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ball, Terry B.] Univ Manitoba, Dept Immunol, Winnipeg, MB, Canada. [Peeling, Rosanna W.; Boeras, Debrah I.] London Sch Hyg & Trop Med, London, England. RP Meyers, AFA (reprint author), Publ Hlth Agcy Canada, QASI, Natl HIV & Retrovirol Labs, JC Wilt Infect Dis Res Ctr, Winnipeg, MB, Canada.; Meyers, AFA (reprint author), Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada.; Meyers, AFA (reprint author), Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya. EM adrienne.meyers@phac-aspc.gc.ca NR 32 TC 0 Z9 0 U1 1 U2 1 PU AOSIS PI CAPE TOWN PA POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA SN 2225-2002 EI 2225-2010 J9 AFR J LAB MED JI Afr. J. Lab. Med. PD OCT 17 PY 2016 VL 5 IS 2 AR a557 DI 10.4102/ajlm.v5i2.557 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA ED1KY UT WOS:000388605500013 ER PT J AU Nkengsong, J Boeras, DI Abimiku, A Peeling, RW AF Nkengsong, John Boeras, Debrah I. Abimiku, Alash'le Peeling, Rosanna W. TI Assuring the quality of diagnostic testing: The future is now SO AFRICAN JOURNAL OF LABORATORY MEDICINE LA English DT Article C1 [Nkengsong, John] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Boeras, Debrah I.; Peeling, Rosanna W.] US Ctr Dis Control & Prevent, Int Lab Branch, Atlanta, GA USA. [Abimiku, Alash'le] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA. RP Boeras, DI (reprint author), US Ctr Dis Control & Prevent, Int Lab Branch, Atlanta, GA USA. EM dboeras@globalhealthig.com NR 4 TC 0 Z9 0 U1 0 U2 0 PU AOSIS PI CAPE TOWN PA POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA SN 2225-2002 EI 2225-2010 J9 AFR J LAB MED JI Afr. J. Lab. Med. PD OCT 17 PY 2016 VL 5 IS 2 AR a558 DI 10.4102/ajlm.v5i2.558 PG 2 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA ED1KY UT WOS:000388605500014 ER PT J AU Pushko, P Sun, XJ Tretyakova, I Hidajat, R Pulit-Penaloza, JA Belser, JA Maines, TR Tumpey, TM AF Pushko, Peter Sun, Xiangjie Tretyakova, Irina Hidajat, Rachmat Pulit-Penaloza, Joanna A. Belser, Jessica A. Maines, Taronna R. Tumpey, Terrence M. TI Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model SO VACCINE LA English DT Article DE Influenza; Virus-like particles; VLP; H10N8; Recombinant vaccine; Baculovirus ID AVIAN INFLUENZA; INTRANASAL VACCINATION; HEMAGGLUTININ; VACCINES; MICE; H5N1; IMMUNOGENICITY; INFECTION; RESPONSES; HUMANS AB Avian-origin influenza represents a global public health concern. In 2013, the H10N8 virus caused documented human infections for the first time. Currently, there is no approved vaccine against H10 influenza. Recombinant virus-like particles (VLPs) represent a promising vaccine approach. In this study, we evaluated H10 VLPs containing hemagglutinin from H10N8 virus as an experimental vaccine in a ferret challenge model. In addition, we evaluated quadri-subtype VLPs co-localizing H5, H7, H9 and H10 subtypes. Both vaccines elicited serum antibody that reacted with the homologous H10 derived from H1ON8 virus and cross-reacted with the heterologous H1ON1 virus. Quadri-subtype vaccine also elicited serum antibody to the homologous H5, H7, and H9 antigens and cross-reacted with multiple clades of H5N1 virus. After heterologous challenge with the H1ON1 virus, all vaccinated ferrets showed significantly reduced titers of replicating virus in the respiratory tract indicating protective effect of vaccination with either H10 VLPs or with quadri-subtype VLPs. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Pushko, Peter; Tretyakova, Irina; Hidajat, Rachmat] Medigen Inc, 8420 Gas House Pike,Suite S, Frederick, MD 21701 USA. [Sun, Xiangjie; Pulit-Penaloza, Joanna A.; Belser, Jessica A.; Maines, Taronna R.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE, Atlanta, GA USA. RP Pushko, P (reprint author), Medigen Inc, 8420 Gas House Pike,Suite S, Frederick, MD 21701 USA. EM ppushko@medigen-usa.com FU NIH NIAID [R01AI111532] FX This research was supported in part by grant R01AI111532 from the NIH NIAID. The authors declare no competing financial interests. The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the funding agencies. NR 46 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 17 PY 2016 VL 34 IS 44 BP 5235 EP 5242 DI 10.1016/j.vaccine.2016.09.012 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EA1BF UT WOS:000386322600004 PM 27663671 ER PT J AU Bautista-Marquez, A Velasquez, DE Esparza-Aguilar, M Luna-Cruz, M Ruiz-Moran, T Sugata, K Jiang, BM Parashar, U Patel, M Richardson, V AF Bautista-Marquez, Aurora Velasquez, Daniel E. Esparza-Aguilar, Marcelino Luna-Cruz, Maria Ruiz-Moran, Tatiana Sugata, Ken Jiang, Baoming Parashar, Umesh Patel, Manish Richardson, Vesta. TI Breastfeeding linked to the reduction of both rotavirus shedding and IgA levels after Rotarix (R) immunization in Mexican infants SO VACCINE LA English DT Article DE Rotavirus; Vaccines; Shedding; Immunogenicity; Breastfeeding; Infants ID VACCINE; IMMUNOGENICITY; EFFICACY; LIVE; ANTIBODY; MILK; METAANALYSIS; CHILDREN; DIARRHEA; MOTHERS AB We examined potential risk factors on vaccine virus shedding and antibody seroresponse to human rota virus vaccine (Rotarix) in Mexican infants. Two doses of Rotarix were administered to infants during the first two visits for their routine childhood immunization (similar to 8 and 15 weeks of age) in Mexico City. Infant's characteristics and socioeconomic indicators were obtained, including history of long-term feeding practices (exclusively/predominantly breastfed and exclusively/predominantly non-breastfed). Two serum specimens were collected, one during the second rotavirus vaccine visit and one 7 weeks later. Stool specimens were collected between days 4-7 after each of the two rotavirus vaccine doses. Rotavirus IgA and IgG titers in serum were determined by enzyme immunoassays (EIA) and rotavirus shedding in stool was assessed by EIA and confirmed by RT-PCR. The overall rotavirus IgA geometric mean titers (GMT) increased significantly post dose 2 from post dose 1 [176 (95%CI: 113-273) to 335 (238-471); p = 0.020). Infants who were exclusively/predominantly breastfed were less likely to shed vaccine virus in stool than those who were formula-fed (22% vs. 43%, p = 0.016). Infants who were breastfed had lower rotavirus IgA titers than those who were formula-fed after dose 1 [GMT: 145 (84-250) vs. 267 (126-566) p = 0.188] and dose 2 [236 (147-378) vs.578 (367-910), p = 0.007]. Infants who shed vaccine virus post dose 1 had significantly higher serum IgA GMT than those who did not shed [425 (188-965) vs. 150 (84-266), p = 0.038]. Breastfeeding was linked with the reduction of both stool vaccine shedding, and IgA seroresponse. The reduced rotavirus replication in the gut and shedding after dose 1 may explain in part the lower IgA response in serum. Published by Elsevier Ltd. C1 [Bautista-Marquez, Aurora; Esparza-Aguilar, Marcelino; Luna-Cruz, Maria; Ruiz-Moran, Tatiana; Richardson, Vesta.] Minist Hlth, Natl Ctr Child & Adolescent Hlth, Mexico City, DF, Mexico. [Velasquez, Daniel E.; Sugata, Ken; Jiang, Baoming; Parashar, Umesh; Patel, Manish] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30329 USA. RP Jiang, BM (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30329 USA. EM bxj4@cdc.gov NR 32 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 17 PY 2016 VL 34 IS 44 BP 5284 EP 5289 DI 10.1016/j.vaccine.2016.09.006 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EA1BF UT WOS:000386322600010 PM 27663670 ER PT J AU Stading, BR Osorio, JE Velasco-Villa, A Smotherman, M Kingstad-Bakke, B Rocke, TE AF Stading, Ben R. Osorio, Jorge E. Velasco-Villa, Andres Smotherman, Michael Kingstad-Bakke, Brock Rocke, Tonie E. TI Infectivity of attenuated poxvirus vaccine vectors and immunogenicity of a raccoonpox vectored rabies vaccine in the Brazilian Free-tailed bat (Tadarida brasiliensis) SO VACCINE LA English DT Article DE Poxvirus; Vaccine; Bat; Chiroptera; Rabies ID VAMPIRE BATS; VIRUS GLYCOPROTEIN; ORAL VACCINATION; RECOMBINANT VACCINE; DESMODUS-ROTUNDUS; PUBLIC-HEALTH; PROCYON-LOTOR; IMMUNIZATION; PROTECTION; TRANSMISSION AB Bats (Order Chiroptera) are an abundant group of mammals with tremendous ecological value as insectivores and plant dispersers, but their role as reservoirs of zoonotic diseases has received more attention in the last decade. With the goal of managing disease in free-ranging bats, we tested modified vaccinia Ankara (MVA) and raccoon poxvirus (RCN) as potential vaccine vectors in the Brazilian Free-tailed bat (Tadarida brasiliensis), using biophotonic in vivo imaging and immunogenicity studies. Animals were administered recombinant poxviral vectors expressing the luciferase gene (MVA-luc, RCN-luc) through oronasal (ON) or intramuscular (IM) routes. and subsequently monitored for bioluminescent signal indicative of viral infection. No clinical illness was noted after exposure to any of the vectors, and limited luciferase expression was observed. Higher and longer levels of expression were observed with the RCN-luc construct. When given IM, luciferase expression was limited to the site of injection, while ON exposure led to initial expression in the oral cavity, often followed by secondary replication at another location, likely the gastric mucosa or gastric associated lymphatic tissue. Viral DNA was detected in oral swabs up to 7 and 9 days post infection (dpi) for MVA and RCN, respectively. While no live virus was detected in oral swabs from MVA-infected bats, titers up to 3.88 x 10(4) PFU/ml were recovered from oral swabs of RCN-infected bats. Viral DNA was also detected in fecal samples from two bats inoculated IM with RCN, but no live virus was recovered. Finally, we examined the immunogenicity of a RCN based rabies vaccine (RCN-G) following ON administration. Significant rabies neutralizing antibody titers were detected in the serum of immunized bats using the rapid fluorescence focus inhibition test (RFFIT). These studies highlight the safety and immunogenicity of attenuated poxviruses and their potential use as vaccine vectors in bats. Published by Elsevier Ltd. C1 [Stading, Ben R.; Osorio, Jorge E.; Kingstad-Bakke, Brock] Univ Wisconsin, Sch Vet Med, 1656 Linden Dr, Madison, WI 53706 USA. [Stading, Ben R.; Rocke, Tonie E.] US Geol Survey, Natl Wildlife Hlth Ctr, 6006 Schroeder Rd, Madison, WI 53711 USA. [Velasco-Villa, Andres] Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. [Smotherman, Michael] Texas A&M Univ, 3258 TAMU, College Stn, TX 77843 USA. RP Rocke, TE (reprint author), US Geol Survey, Natl Wildlife Hlth Ctr, 6006 Schroeder Rd, Madison, WI 53711 USA. EM stading@wisc.edu; jorge.osorio@wisc.edu; dly3@cdc.gov; msmotherman@bio.tamu.edu; babakke@wisc.edu; trocke@usgs.gov OI Rocke, Tonie/0000-0003-3933-1563 FU USGS; National Institutes of Health, Ruth L. Kirschstein National Research Service Award Institutional Training Grant from the National Center for Research Resources [T32 RR023916] FX We would like to acknowledge the technical assistance of Jennifer Brunner, Elizabeth Falendysz, Nicole Ward, and the other employees at the NWHC that helped with bat care. Additionally, we are grateful to Robin Russell and Katie Richgels for assistance in statistical analysis, Erik Hofmeister for reviewing the manuscript, and David Blehert and Dave Redell for providing their knowledge and expertise. This work was supported by the USGS and the National Institutes of Health, Ruth L. Kirschstein National Research Service Award Institutional Training Grant T32 RR023916, from the National Center for Research Resources. The findings and conclusions in this report are those of the authors and do not represent the views of the Centers for Disease Control. The use of trade, firm, or product names is for descriptive purposes only and does not imply endorsement by the U.S. Government. NR 55 TC 0 Z9 0 U1 11 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 17 PY 2016 VL 34 IS 44 BP 5352 EP 5358 DI 10.1016/j.vaccine.2016.08.088 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EA1BF UT WOS:000386322600019 PM 27650872 ER PT J AU Brostoff, T Pesavento, PA Barker, CM Kenney, JL Dietrich, EA Duggal, NK Bosco-Lauth, AM Brault, AC AF Brostoff, Terza Pesavento, Patricia A. Barker, Christopher M. Kenney, Joan L. Dietrich, Elizabeth A. Duggal, Nisha K. Bosco-Lauth, Angela M. Brault, Aaron C. TI MicroRNA reduction of neuronal West Nile virus replication attenuates and affords a protective immune response in mice SO VACCINE LA English DT Article DE miRNA; Immunogenicity; WNV; Neurovirulence; Attenuation; Neuroinvasive ID CENTRAL-NERVOUS-SYSTEM; SECONDARY STRUCTURE; RNA VIRUSES; MIRNAS; DISEASE; PATHOGENICITY; EPIDEMIOLOGY; EXPRESSION; VIRULENCE; STRAIN AB West Nile virus (WNV) is an important agent of human encephalitis that has quickly become endemic across much of the United States since its identification in North America in 1999. While the majority (similar to 75%) of infections are subclinical, neurologic disease can occur in a subset of cases, with outcomes including permanent neurologic damage and death. Currently, there are no WNV vaccines approved for use in humans. This study introduces a novel vaccine platform for WNV to reduce viral replication in the central nervous system while maintaining peripheral replication to elicit strong neutralizing antibody titers. Vaccine candidates were engineered to incorporate microRNA (miRNA) target sequences for a cognate miRNA expressed only in neurons, allowing the host miRNAs to target viral transcription through endogenous RNA silencing. To maintain stability, these targets were incorporated in multiple locations within the 3'-untranslated region, flanking sequences essential for viral replication without affecting the viral open reading frame. All candidates replicated comparably to wild type WNV in vitro within cells that did not express the cognate miRNA. Insertional control viruses were also capable of neuroinvasion and neurovirulence in vivo in CD-1 mice. Vaccine viruses were safe at all doses tested and did not demonstrate mutations associated with a reversion to virulence when serially passaged in mice. All vaccine constructs were protective from lethal challenge in mice, producing 93-100% protection at the highest dose tested. Overall, this is a safe and effective attenuation strategy with broad potential application for vaccine development. Published by Elsevier Ltd. C1 [Brostoff, Terza; Pesavento, Patricia A.; Barker, Christopher M.] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA. [Kenney, Joan L.; Dietrich, Elizabeth A.; Duggal, Nisha K.; Bosco-Lauth, Angela M.; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Brault, AC (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. EM abrault@cdc.gov FU Pacific Southwest Regional Center for Excellence (PSWRCE) [U54 AI065359]; American Society for Microbiology postdoctoral fellowships; Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate, Department of Homeland Security and Fogarty International Center, National Institutes of Health FX This work was supported by a developmental proposal from the Pacific Southwest Regional Center for Excellence (PSWRCE) U54 AI065359. Funding for AMBL, JLK and EAD was provided American Society for Microbiology postdoctoral fellowships. CMB acknowledges financial support from the Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate, Department of Homeland Security and Fogarty International Center, National Institutes of Health. NR 32 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 17 PY 2016 VL 34 IS 44 BP 5366 EP 5375 DI 10.1016/j.vaccine.2016.08.063 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EA1BF UT WOS:000386322600021 PM 27637937 ER PT J AU Lopez-Rubio, A Suaza-Vasco, J Marcet, PL Ruiz-Molina, N Caceres, L Porter, C Uribe, S AF Lopez-Rubio, Andres Suaza-Vasco, Juan Marcet, Paula L. Ruiz-Molina, Natalia Caceres, Lorenzo Porter, Charles Uribe, Sandra TI Use of DNA barcoding to distinguish the malaria vector Anopheles neivai in Colombia SO ZOOTAXA LA English DT Article DE DNA Barcode; Malaria; Kerteszia; COI ID D-AND-K; DIPTERA-CULICIDAE; COI GENE; ANOPHELES-(KERTESZIA)-NEIVAI H; MOLECULAR DIVERGENCE; SPECIES COMPLEX; PACIFIC COAST; POPULATION; IDENTIFICATION; NYSSORHYNCHUS AB A reference 535 bp barcode sequence from a fragment of the mitochondrial gene cytochrome oxidase I (COI), acquired from specimens of An. neivai Howard, Dyar & Knab, 1913 from its type locality in Panama, was used as a tool for distinguishing this species from others in the subgenus Kerteszia. Comparisons with corresponding regions of COI between An. neivai and other species in the subgenus (An. bellator Dyar & Knab 1906, An. homunculus Komp 1937, An cruzii Dyar & Knab, 1908 and An. laneanus Correa & Cerqueira, 1944) produced K2P genetic distances of 8.3-12.6%, values well above those associated with intraspecific variation. In contrast, genetic distances among 55 specimens from five municipalities in the Colombian Pacific coastal state of Choco were all within the range of 0-2.5%, with an optimized barcode threshold of 1.3%, the limit for unambiguous differentiation of An. neivai. Among specimens from the Choco region, 18 haplotypes were detected, two of which were widely distributed over the municipalities sampled. The barcode sequence permits discrimination of An. neivai from sympatric species and indicates genetic variability within the species; aspects key to malaria surveillance and control as well as defining geographic distribution and dispersion patterns. C1 [Lopez-Rubio, Andres; Suaza-Vasco, Juan; Ruiz-Molina, Natalia; Uribe, Sandra] Univ Nacl Colombia, Sede Medell~i, Fac Ciencias, Escuela Biociencias,Grp Invest Sistemat Mol, Calle 53A 63-20, Medellin 050034, Colombia. [Marcet, Paula L.; Porter, Charles] Ctr Dis Control & Prevent, CDC, Div Parasit Dis & Malaria, Entomol Branch, Atlanta, GA USA. [Caceres, Lorenzo] Inst Conmemorat Gorgas Estudios Salud, Ave Justo Arosemena & Calle 35, Panama City, Panama. RP Lopez-Rubio, A (reprint author), Univ Nacl Colombia, Sede Medell~i, Fac Ciencias, Escuela Biociencias,Grp Invest Sistemat Mol, Calle 53A 63-20, Medellin 050034, Colombia. EM andreslop27@gmail.com OI Marcet, Paula/0000-0002-0676-3020 FU Amazon Malaria Initiative under the auspice of the US Agency for International Development (USAID); Programa de Estudio y Control de Enfermedades Tropicales (PECET) of the Universidad de Antioquia, COLCIENCIAS-COLFUTURO grant [Convocatoria 567] FX Partial funding for this work was provided by the Amazon Malaria Initiative under the auspice of the US Agency for International Development (USAID). Special thanks are given to Robert A. Wirtz and Audrey Lenhart (both at the Centers for Disease Control and Prevention) for support throughout this endeavor. We are grateful for partial funding from Programa de Estudio y Control de Enfermedades Tropicales (PECET) of the Universidad de Antioquia, COLCIENCIAS-COLFUTURO grant for PhD studies (Convocatoria 567) and also for logistic support from Fundacion Salud para el Tropico, Santa Marta, Colombia. We also express our appreciation to Rafael Vivero, Diego Puerta and David Gallo (members of Grupo de Investigacion en Sistematica Molecular - Universidad Nacional de Colombia sede Medellin and PECET) for their participation in the fieldwork. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 64 TC 1 Z9 1 U1 6 U2 6 PU MAGNOLIA PRESS PI AUCKLAND PA PO BOX 41383, AUCKLAND, ST LUKES 1030, NEW ZEALAND SN 1175-5326 EI 1175-5334 J9 ZOOTAXA JI Zootaxa PD OCT 17 PY 2016 VL 4175 IS 4 BP 377 EP 389 DI 10.11646/zootaxa.4175.4.7 PG 13 WC Zoology SC Zoology GA DY6QR UT WOS:000385253400007 PM 27811749 ER PT J AU Breman, JG Heymann, DL Lloyd, G McCormick, JB Miatudila, M Murphy, FA Muyembe-Tamfun, JJ Piot, P Ruppol, JF Sureau, P van der Groen, G Johnson, KM AF Breman, Joel G. Heymann, David L. Lloyd, Graham McCormick, Joseph B. Miatudila, Malonga Murphy, Frederick A. Muyembe-Tamfun, Jean-Jacques Piot, Peter Ruppol, Jean-Francois Sureau, Pierre van der Groen, Guido Johnson, Karl M. TI Discovery and Description of Ebola Zaire Virus in 1976 and Relevance to the West African Epidemic During 2013-2016 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Discovery of Ebola Zaire virus; Ebola virus disease; Ebola in 1976 and 2013-2016 ID HEMORRHAGIC-FEVER; SIERRA-LEONE; DISEASE; ANIMALS; GUINEA; CONGO AB Background. In 1976, the first cases of Ebola virus disease in northern Democratic Republic of the Congo (then referred to as Zaire) were reported. This article addresses who was responsible for recognizing the disease; recovering, identifying, and naming the virus; and describing the epidemic. Key scientific approaches used in 1976 and their relevance to the 3-country (Guinea, Sierra Leone, and Liberia) West African epidemic during 2013-2016 are presented. Methods.aEuro integral Field and laboratory investigations started soon after notification, in mid-September 1976, and included virus cell culture, electron microscopy (EM), immunofluorescence antibody (IFA) testing of sera, case tracing, containment, and epidemiological surveys. In 2013-2016, medical care and public health work were delayed for months until the Ebola virus disease epidemic was officially declared an emergency by World Health Organization, but research in pathogenesis, clinical presentation, including sequelae, treatment, and prevention, has increased more recently. Results.aEuro integral Filoviruses were cultured and observed by EM in Antwerp, Belgium (Institute of Tropical Medicine); Porton Down, United Kingdom (Microbiological Research Establishment); and Atlanta, Georgia (Centers for Disease Control and Prevention). In Atlanta, serological testing identified a new virus. The 1976 outbreak (280 deaths among 318 cases) stopped in < 11 weeks, and basic clinical and epidemiological features were defined. The recent massive epidemic during 2013-2016 (11 310 deaths among 28 616 cases) has virtually stopped after > 2 years. Transmission indices (R-0) are higher in all 3 countries than in 1976. Conclusions.aEuro integral An international commission working harmoniously in laboratories and with local communities was essential for rapid success in 1976. Control and understanding of the recent West African outbreak were delayed because of late recognition and because authorities were overwhelmed by many patients and poor community involvement. Despite obstacles, research was a priority in 1976 and recently. C1 [Breman, Joel G.] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA. [McCormick, Joseph B.] Univ Texas Sch Publ Hlth, Brownsville Campus, Houston, TX USA. [Murphy, Frederick A.] Univ Texas, Dept Pathol, Galveston, TX USA. [Miatudila, Malonga] World Bank, Hlth Populat & Nutr, 1818 H St NW, Washington, DC 20433 USA. [Johnson, Karl M.] Ctr Dis Control & Prevent, Special Pathogens Branch, Atlanta, GA USA. [Heymann, David L.] Chatham House Ctr Global Hlth Secur, Porton Down, England. [Heymann, David L.; Piot, Peter] London Sch Hyg & Trop Med, Porton Down, England. [Lloyd, Graham] Med Res Estab, Off Director, Porton Down, England. [Muyembe-Tamfun, Jean-Jacques] Inst Natl Rech Med, Kinshasa, DEM REP CONGO. [Ruppol, Jean-Francois] Fonds Med Trop, Kinshasa, DEM REP CONGO. [Sureau, Pierre] Inst Pasteur, Paris, France. [van der Groen, Guido] Inst Trop Med, Dept Microbiol, Antwerp, Belgium. RP Breman, JG (reprint author), NIH, Fogarty Int Ctr, Fogarty Ctr, Bldg 16,Rm 214,16 Ctr Dr,MSC 6705, Bethesda, MD 20892 USA. EM bremanj@nih.gov FU Fogarty International Center at the National Institutes of Health FX This work was supported by the Fogarty International Center at the National Institutes of Health. NR 40 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2016 VL 214 SU 3 BP S93 EP S101 DI 10.1093/infdis/jiw207 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8VA UT WOS:000386148800001 PM 27357339 ER PT J AU de Wit, E Rosenke, K Fischer, RJ Marzi, A Prescott, J Bushmaker, T van Doremalen, N Emery, SL Falzarano, D Feldmann, F Groseth, A Hoenen, T Juma, B McNally, KL Ochieng, M Omballa, V Onyango, CO Owuor, C Rowe, T Safronetz, D Self, J Williamson, BN Zemtsova, G Grolla, A Kobinger, G Rayfield, M Stroher, U Strong, JE Best, SM Ebihara, H Zoon, KC Nichol, ST Nyenswah, TG Bolay, FK Massaquoi, M Feldmann, H Fields, B AF de Wit, Emmie Rosenke, Kyle Fischer, Robert J. Marzi, Andrea Prescott, Joseph Bushmaker, Trenton van Doremalen, Neeltje Emery, Shannon L. Falzarano, Darryl Feldmann, Friederike Groseth, Allison Hoenen, Thomas Juma, Bonventure McNally, Kristin L. Ochieng, Melvin Omballa, Victor Onyango, Clayton O. Owuor, Collins Rowe, Thomas Safronetz, David Self, Joshua Williamson, Brandi N. Zemtsova, Galina Grolla, Allen Kobinger, Gary Rayfield, Mark Stroher, Ute Strong, James E. Best, Sonja M. Ebihara, Hideki Zoon, Kathryn C. Nichol, Stuart T. Nyenswah, Tolbert G. Bolay, Fatorma K. Massaquoi, Moses Feldmann, Heinz Fields, Barry TI Ebola Laboratory Response at the Eternal Love Winning Africa Campus, Monrovia, Liberia, 2014-2015 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Ebola virus; West Africa; epidemic; mobile laboratory; diagnostics ID SEXUAL TRANSMISSION; SIERRA-LEONE; WEST-AFRICA; VIRUS; OUTBREAK; MANAGEMENT; DISEASE AB West Africa experienced the first epidemic of Ebola virus infection, with by far the greatest number of cases in Guinea, Sierra Leone, and Liberia. The unprecedented epidemic triggered an unparalleled response, including the deployment of multiple Ebola treatment units and mobile/field diagnostic laboratories. The National Institute of Allergy and Infectious Diseases and the Centers for Disease Control and Prevention deployed a joint laboratory to Monrovia, Liberia, in August 2014 to support the newly founded Ebola treatment unit at the Eternal Love Winning Africa (ELWA) campus. The laboratory operated initially out of a tent structure but quickly moved into a fixed-wall building owing to severe weather conditions, the need for increased security, and the high sample volume. Until May 2015, when the laboratory closed, the site handled close to 6000 clinical specimens for Ebola virus diagnosis and supported the medical staff in case patient management. Laboratory operation and safety, as well as Ebola virus diagnostic assays, are described and discussed; in addition, lessons learned for future deployments are reviewed. C1 [de Wit, Emmie; Rosenke, Kyle; Fischer, Robert J.; Marzi, Andrea; Prescott, Joseph; Bushmaker, Trenton; van Doremalen, Neeltje; Falzarano, Darryl; Groseth, Allison; Hoenen, Thomas; McNally, Kristin L.; Safronetz, David; Williamson, Brandi N.; Best, Sonja M.; Ebihara, Hideki; Feldmann, Heinz] NIAID, Virol Lab, NIH, Hamilton, MT USA. [Feldmann, Friederike] NIAID, Rocky Mt Vet Branch, Div Intramural Res, NIH, Hamilton, MT USA. [Emery, Shannon L.; Rowe, Thomas; Self, Joshua; Zemtsova, Galina; Rayfield, Mark; Stroher, Ute; Nichol, Stuart T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Zoon, Kathryn C.] NIAID, Cytokine Biol Sect, Div Intramural Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Juma, Bonventure; Onyango, Clayton O.; Fields, Barry] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global Hlth Protect, Nairobi, Kenya. [Ochieng, Melvin; Omballa, Victor; Owuor, Collins] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Nairobi, Kenya. [Grolla, Allen; Kobinger, Gary; Strong, James E.] Publ Hlth Agcy Canada, Special Pathogens Program, Winnipeg, MB, Canada. [Nyenswah, Tolbert G.; Massaquoi, Moses] Minist Hlth & Social Welf, Monrovia, Liberia. [Bolay, Fatorma K.] Liberian Inst Biomed Res, Charlesville, Liberia. [Falzarano, Darryl] Univ Saskatchewan, Int Vaccine Ctr, Vaccine & Infect Dis Org, Saskatoon, SK, Canada. [Safronetz, David] Publ Hlth Agcy Canada, Winnipeg, MB, Canada. [Groseth, Allison; Hoenen, Thomas] Friedrich Loffler Inst, Greifswald, Germany. RP Feldmann, H (reprint author), NIAID, Virol Lab, DIR, NIH, 903 S 4th St, Hamilton, MT 59840 USA. EM feldmannh@niaid.nih.gov OI de Wit, Emmie/0000-0002-9763-7758 FU Intramural Research Program of the NIAID, NIH; CDC FX This work was supported by the Intramural Research Program of the NIAID, NIH, and by the CDC. NR 27 TC 3 Z9 3 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2016 VL 214 SU 3 BP S169 EP S176 DI 10.1093/infdis/jiw216 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8VA UT WOS:000386148800010 PM 27333914 ER PT J AU Erickson, BR Sealy, TK Flietstra, T Morgan, L Kargbo, B Matt-Lebby, VE Gibbons, A Chakrabarti, AK Graziano, J Presser, L Flint, M Bird, BH Brown, S Klena, JD Blau, DM Brault, AC Belser, JA Salzer, JS Schuh, AJ Lo, M Zivcec, M Priestley, RA Pyle, M Goodman, C Bearden, S Amman, BR Basile, A Bergeron, E Bowen, MD Dodd, KA Freeman, MM McMullan, LK Paddock, CD Russell, BJ Sanchez, AJ Towner, JS Wang, D Zemtsova, GE Stoddard, RA Turnsek, M Guerrero, LW Emery, SL Stovall, J Kainulainen, MH Perniciaro, JL Mijatovic-Rustempasic, S Shakirova, G Winter, J Sexton, C Liu, F Slater, K Anderson, R Andersen, L Chiang, CF Tzeng, WP Crowe, SJ Maenner, MJ Spiropoulou, CF Nichol, ST Stroher, U AF Erickson, Bobbie R. Sealy, Tara K. Flietstra, Tim Morgan, Laura Kargbo, Brima Matt-Lebby, Victor E. Gibbons, Aridth Chakrabarti, Ayan K. Graziano, James Presser, Lance Flint, Mike Bird, Brian H. Brown, Shelley Klena, John D. Blau, Dianna M. Brault, Aaron C. Belser, Jessica A. Salzer, Johanna S. Schuh, Amy J. Lo, Michael Zivcec, Marko Priestley, Rachael A. Pyle, Meredith Goodman, Christin Bearden, Scott Amman, Brian R. Basile, Alison Bergeron, Eric Bowen, Michael D. Dodd, Kimberly A. Freeman, Molly M. McMullan, Laura K. Paddock, Christopher D. Russell, Brandy J. Sanchez, Angela J. Towner, Jonathan S. Wang, David Zemtsova, Galina E. Stoddard, Robyn A. Turnsek, Maryann Guerrero, Lisa Wiggleton Emery, Shannon L. Stovall, Janae Kainulainen, Markus H. Perniciaro, Jamie L. Mijatovic-Rustempasic, Slavica Shakirova, Gulchekhra Winter, Jorn Sexton, Christopher Liu, Feng Slater, Kimetha Anderson, Raydel Andersen, Lauren Chiang, Cheng-Feng Tzeng, Wen-Pin Crowe, Samuel J. Maenner, Matthew J. Spiropoulou, Christina F. Nichol, Stuart T. Stroher, Ute TI Ebola Virus Disease Diagnostics, Sierra Leone: Analysis of Real-time Reverse Transcription-Polymerase Chain Reaction Values for Clinical Blood and Oral Swab Specimens SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Ebola virus; West Africa; qRT-PCR; housekeeping gene; endogenous control ID STABILITY; FLUID AB During the Ebola virus outbreak of 2013-2016, the Viral Special Pathogens Branch field laboratory in Sierra Leone tested approximately 26 000 specimens between August 2014 and October 2015. Analysis of the B2M endogenous control Ct values showed its utility in monitoring specimen quality, comparing results with different specimen types, and interpretation of results. For live patients, blood is the most sensitive specimen type and oral swabs have little diagnostic utility. However, swabs are highly sensitive for diagnostic testing of corpses. C1 [Erickson, Bobbie R.; Sealy, Tara K.; Flietstra, Tim; Morgan, Laura; Gibbons, Aridth; Chakrabarti, Ayan K.; Presser, Lance; Flint, Mike; Bird, Brian H.; Brown, Shelley; Schuh, Amy J.; Lo, Michael; Zivcec, Marko; Amman, Brian R.; Bergeron, Eric; McMullan, Laura K.; Towner, Jonathan S.; Guerrero, Lisa Wiggleton; Kainulainen, Markus H.; Chiang, Cheng-Feng; Spiropoulou, Christina F.; Nichol, Stuart T.; Stroher, Ute] Ctr Dis Control & Prevent CDC, Viral Special Pathogens Branch, Atlanta, GA USA. [Graziano, James; Stoddard, Robyn A.] Ctr Dis Control & Prevent CDC, Bacterial Special Pathogens Branch, Atlanta, GA USA. [Blau, Dianna M.] Ctr Dis Control & Prevent CDC, Infect Dis Pathol Branch, Atlanta, GA USA. [Belser, Jessica A.; Wang, David; Liu, Feng; Tzeng, Wen-Pin] Ctr Dis Control & Prevent CDC, Influenza Div, Immunol & Pathogenesis Branch, Atlanta, GA USA. [Salzer, Johanna S.] Ctr Dis Control & Prevent CDC, Pox & Rabies Branch, Atlanta, GA USA. [Priestley, Rachael A.; Paddock, Christopher D.; Zemtsova, Galina E.; Perniciaro, Jamie L.; Slater, Kimetha] Ctr Dis Control & Prevent CDC, Rickettsial Zoonoses Branch, Atlanta, GA USA. [Pyle, Meredith] Ctr Dis Control & Prevent CDC, Div Blood Disorders, Atlanta, GA USA. [Bowen, Michael D.; Mijatovic-Rustempasic, Slavica] Ctr Dis Control & Prevent CDC, Gastroenteritis & Resp Virus Lab Branch, Atlanta, GA USA. [Freeman, Molly M.; Turnsek, Maryann] Ctr Dis Control & Prevent CDC, Enter Dis Lab Branch, Atlanta, GA USA. [Sanchez, Angela J.] Ctr Dis Control & Prevent CDC, Off Technol & Innovat, Atlanta, GA USA. [Emery, Shannon L.; Winter, Jorn] Ctr Dis Control & Prevent CDC, Influenza Div, Virol Surveillance & Diag Branch, Atlanta, GA USA. [Shakirova, Gulchekhra] Ctr Dis Control & Prevent CDC, Inorgan & Radiat Analyt Toxicol Branch, Atlanta, GA USA. [Anderson, Raydel] Ctr Dis Control & Prevent CDC, Measles Mumps Rubella & Herpes Virus Lab Branch, Atlanta, GA USA. [Andersen, Lauren] Ctr Dis Control & Prevent CDC, Lab Preparedness & Response Branch, Atlanta, GA USA. [Crowe, Samuel J.] Ctr Dis Control & Prevent CDC, Enter Dis Epidemiol Branch, Atlanta, GA USA. [Maenner, Matthew J.] Ctr Dis Control & Prevent CDC, Dev Disabil Branch, Atlanta, GA USA. [Brault, Aaron C.; Goodman, Christin; Basile, Alison; Russell, Brandy J.; Stovall, Janae] CDC, Arboviral Dis Branch, Ft Collins, CO USA. [Bearden, Scott; Sexton, Christopher] CDC, Bacterial Dis Branch, Ft Collins, CO USA. [Dodd, Kimberly A.] Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA. [Kargbo, Brima; Matt-Lebby, Victor E.] Minist Hlth & Sanitat, Freetown, Sierra Leone. [Klena, John D.] CDC, Div Global Hlth Protect, Beijing, Peoples R China. [Graziano, James] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, 1600 Clifton Rd,MS G-14, Atlanta, GA 30329 USA. [Pyle, Meredith; Wang, David] Ctr Dis Control & Prevent, Div Select Agents & Toxins, 1600 Clifton Rd,MS G-14, Atlanta, GA 30329 USA. [Dodd, Kimberly A.] Metabiota, Washington, DC USA. [Bird, Brian H.] Univ Calif Davis, Sch Vet Med, Hlth Inst 1, Davis, CA 95616 USA. RP Stroher, U (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,MS G-14, Atlanta, GA 30329 USA. EM ixy8@cdc.gov OI Zivcec, Marko/0000-0003-4337-8487 FU CDC FX This work was supported by the CDC. NR 11 TC 1 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2016 VL 214 SU 3 BP S258 EP S262 DI 10.1093/infdis/jiw296 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8VA UT WOS:000386148800022 PM 27587631 ER PT J AU Schafer, IJ Knudsen, E McNamara, LA Agnihotri, S Rollin, PE Islam, A AF Schafer, Ilana J. Knudsen, Erik McNamara, Lucy A. Agnihotri, Sachin Rollin, Pierre E. Islam, Asad TI The Epi Info Viral Hemorrhagic Fever (VHF) Application: A Resource for Outbreak Data Management and Contact Tracing in the 2014-2016 West Africa Ebola Epidemic SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Ebola; viral hemorrhagic fever; outbreak; contact tracing; data management; software ID HEALTH-CARE WORKERS; VIRUS DISEASE; SIERRA-LEONE; SEPTEMBER 2014; UNITED-STATES; GUINEA; DISTRICT; CLUSTER; CONAKRY; UGANDA AB The Epi Info Viral Hemorrhagic Fever application (Epi Info VHF) was developed in response to challenges managing outbreak data during four 2012 filovirus outbreaks. Development goals included combining case and contact data in a relational database, facilitating data-driven contact tracing, and improving outbreak data consistency and use. The application was first deployed in Guinea, when the West Africa Ebola epidemic was detected, in March 2014, and has been used in 7 African countries and 2 US states. Epi Info VHF enabled reporting of compatible data from multiple countries, contributing to international Ebola knowledge. However, challenges were encountered in accommodating the epidemic's unexpectedly large magnitude, addressing country-specific needs within 1 software product, and using the application in settings with limited Internet access and information technology support. Use of Epi Info VHF in the West Africa Ebola epidemic highlighted the fundamental importance of good data management for effective outbreak response, regardless of the software used. C1 [Schafer, Ilana J.; Knudsen, Erik; Agnihotri, Sachin; Islam, Asad] Ctr Dis Control & Prevent, Epi Info Team, Div Hlth Informat & Surveillance, Atlanta, GA USA. [Schafer, Ilana J.; Rollin, Pierre E.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [McNamara, Lucy A.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Atlanta, GA USA. [Schafer, Ilana J.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Knudsen, Erik] Ctr Dis Control & Prevent, Off Associate Director Commun, Div Commun Serv, Atlanta, GA USA. RP Schafer, IJ (reprint author), 1600 Clifton Rd NE,MS A-30, Atlanta, GA 30329 USA. EM wii3@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention, through core and emergency budgets. NR 27 TC 0 Z9 0 U1 4 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2016 VL 214 SU 3 BP S122 EP S136 DI 10.1093/infdis/jiw272 PG 15 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8VA UT WOS:000386148800004 PM 27587635 ER PT J AU Spengler, JR Lavender, KJ Martellaro, C Carmody, A Kurth, A Keck, JG Saturday, G Scott, DP Nichol, ST Hasenkrug, KJ Spiropoulou, CF Feldmann, H Prescott, J AF Spengler, Jessica R. Lavender, Kerry J. Martellaro, Cynthia Carmody, Aaron Kurth, Andreas Keck, James G. Saturday, Greg Scott, Dana P. Nichol, Stuart T. Hasenkrug, Kim J. Spiropoulou, Christina F. Feldmann, Heinz Prescott, Joseph TI Ebola Virus Replication and Disease Without Immunopathology in Mice Expressing Transgenes to Support Human Myeloid and Lymphoid Cell Engraftment SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Ebola; virus; hemorrhagic fever; humanized NSG-SGM3 mice; myeloid cell; immune response; immunopathology; flow cytometry ID HEMATOPOIETIC STEM-CELLS; DENDRITIC CELLS; HEMORRHAGIC-FEVER; MOUSE MODEL; IMMUNE-RESPONSES; MARBURG VIRUSES; INFECTION; PATHOGENESIS; PATHOLOGY; MONKEYS AB The study of Ebola virus (EBOV) pathogenesis in vivo has been limited to nonhuman primate models or use of an adapted virus to cause disease in rodent models. Herein we describe wild-type EBOV (Makona variant) infection of mice engrafted with human hematopoietic CD34(+) stem cells (Hu-NSG (TM)-SGM3 mice; hereafter referred to as SGM3 HuMice). SGM3 HuMice support increased development of myeloid immune cells, which are primary EBOV targets. In SGM3 HuMice, EBOV replicated to high levels, and disease was observed following either intraperitoneal or intramuscular inoculation. Despite the high levels of viral antigen and inflammatory cell infiltration in the liver, the characteristic histopathology of Ebola virus disease was not observed, and this absence of severe immunopathology may have contributed to the recovery and survival of some of the animals. Future investigations into the underlying mechanisms of the atypical disease presentation in SGM3 HuMice will provide additional insights into the immunopathogenesis of severe EBOV disease. C1 [Spengler, Jessica R.; Nichol, Stuart T.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Lavender, Kerry J.; Hasenkrug, Kim J.] NIAID, Lab Persistent Viral Dis, NIH, Rocky Mt Labs, Hamilton, MT USA. [Martellaro, Cynthia; Feldmann, Heinz; Prescott, Joseph] NIAID, Lab Virol, NIH, Rocky Mt Labs, Hamilton, MT USA. [Carmody, Aaron] NIAID, Res Technol Branch, NIH, Rocky Mt Labs, Hamilton, MT USA. [Saturday, Greg; Scott, Dana P.] NIAID, Rocky Mt Vet Branch, NIH, Rocky Mt Labs, Hamilton, MT USA. [Keck, James G.] In Vivo Serv, Jackson Lab, Sacramento, CA USA. [Kurth, Andreas] Robert Koch Inst, Ctr Biol Threats & Special Pathogens, Berlin, Germany. RP Prescott, J (reprint author), Rocky Mt Labs, 903 S 4th St, Hamilton, MT 59840 USA. EM prescottjb@niaid.nih.gov OI Spengler, Jessica R./0000-0002-5383-0513 FU Centers for Disease Control and Prevention (CDC); CDC Research Participation Program; National Institutes of Health (NIH) Loan Repayment Program; Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH FX This work was supported by the Centers for Disease Control and Prevention (CDC; emerging infectious disease research core funds); the CDC Research Participation Program (to J. R. S., administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC); the National Institutes of Health (NIH) Loan Repayment Program (award to J. R. S.); and the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. NR 35 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2016 VL 214 SU 3 BP S308 EP S318 DI 10.1093/infdis/jiw248 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8VA UT WOS:000386148800031 PM 27601621 ER PT J AU Whitmer, SLM Albarino, C Shepard, SS Dudas, G Sheth, M Brown, SC Cannon, D Erickson, BR Gibbons, A Schuh, A Sealy, T Ervin, E Frace, M Uyeki, TM Nichol, ST Stroher, U AF Whitmer, Shannon L. M. Albarino, Cesar Shepard, Samuel S. Dudas, Gytis Sheth, Mili Brown, Shelley C. Cannon, Deborah Erickson, Bobbie R. Gibbons, Aridth Schuh, Amy Sealy, Tara Ervin, Elizabeth Frace, Mike Uyeki, Timothy M. Nichol, Stuart T. Stroher, Ute TI Preliminary Evaluation of the Effect of Investigational Ebola Virus Disease Treatments on Viral Genome Sequences SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE molecular epidemiology; antiviral agents; Ebola virus; high-throughput nucleotide sequencing; directed molecular evolution ID REPLICATION IN-VITRO; UNITED-STATES; ANTIVIRAL ACTIVITY; NONHUMAN-PRIMATES; MONOCLONAL-ANTIBODIES; CLINICAL MANAGEMENT; CONVALESCENT PLASMA; ALKOXYALKYL ESTERS; CYCLIC CIDOFOVIR; SIERRA-LEONE AB Background. Several patients with Ebola virus disease (EVD) managed in the United States have received ZMapp monoclonal antibodies, TKM-Ebola small interfering RNA, brincidofovir, and/or convalescent plasma as investigational therapeutics. Methods.aEuro integral To investigate whether treatment selected for Ebola virus (EBOV) mutations conferring resistance, viral sequencing was performed on RNA extracted from clinical blood specimens from patients with EVD following treatment, and putative viral targets were analyzed. Results.aEuro integral We observed no major or minor EBOV mutations within regions targeted by therapeutics. Conclusions.aEuro integral This small subset of patients and clinical specimens suggests that evolution of resistance is not a direct consequence of antiviral treatment. As EVD antiviral treatments are introduced into wider use, it is essential that continuous viral full-genome surveillance is performed, to monitor for the emergence of escape mutations. C1 [Whitmer, Shannon L. M.; Albarino, Cesar; Brown, Shelley C.; Cannon, Deborah; Erickson, Bobbie R.; Gibbons, Aridth; Schuh, Amy; Sealy, Tara; Ervin, Elizabeth; Nichol, Stuart T.; Stroher, Ute] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, 1600 Clifton Rd,NE Mailstop A26, Atlanta, GA 30333 USA. [Sheth, Mili; Frace, Mike] Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, Atlanta, GA USA. [Shepard, Samuel S.; Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Dudas, Gytis] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH8 9YL, Midlothian, Scotland. RP Stroher, U (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, 1600 Clifton Rd,NE Mailstop A26, Atlanta, GA 30333 USA. EM ixy8@cdc.gov FU CDC FX This work was supported by the CDC. NR 41 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2016 VL 214 SU 3 BP S333 EP S341 DI 10.1093/infdis/jiw177 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8VA UT WOS:000386148800034 PM 27521366 ER PT J AU Petrie, JG Ohmit, SE Cheng, CK Martin, ET Malosh, RE Lauring, AS Lamerato, LE Reyes, KC Flannery, B Ferdinands, JM Monto, AS AF Petrie, Joshua G. Ohmit, Suzanne E. Cheng, Caroline K. Martin, Emily T. Malosh, Ryan E. Lauring, Adam S. Lamerato, Lois E. Reyes, Katherine C. Flannery, Brendan Ferdinands, Jill M. Monto, Arnold S. TI Influenza Vaccine Effectiveness Against Antigenically Drifted Influenza Higher Than Expected in Hospitalized Adults: 2014-2015 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza vaccine effectiveness; hospital; antigenic drift; case test-negative design; influenza A (H3N2) ID LABORATORY-CONFIRMED INFLUENZA; TEST-NEGATIVE DESIGN; UNITED-STATES; OLDER-ADULTS; SEASON; VIRUS; RECOMMENDATIONS; OUTPATIENT; PREVENTION; PROTECTION AB Background. The 2014-2015 influenza season was severe, with circulating influenza A (H3N2) viruses that were antigenically drifted from the vaccine virus. Reported vaccine effectiveness (VE) estimates from ambulatory care settings were markedly decreased. Methods. Adults, hospitalized at 2 hospitals in southeast Michigan for acute respiratory illnesses, defined by admission diagnoses, of <= 10 days duration were prospectively enrolled. Throat and nasal swab specimens were collected, combined, and tested for influenza by real-time reverse transcription polymerase chain reaction. VE was estimated by comparing the vaccination status of those testing positive for influenza with those testing negative in logistic regression models adjusted for age, sex, hospital, calendar time, time from illness onset to specimen collection, frailty score, and Charlson comorbidity index (CCI). Results. Among 624 patients included in the analysis, 421 (68%) were vaccinated, 337 (54%) were female, 220 (35%) were age >= 65 years, and 92% had CCI >0, indicating >= 1 comorbid conditions. Ninety-eight (16%) patients tested positive for influenza A (H3N2); among 60 (61%) A (H3N2) viruses tested by pyrosequencing, 53 (88%) belonged to the drifted 3C.2a genetic group. Adjusted VE was 43% (95% confidence interval [CI], 4-67) against influenza A (H3N2); 40% (95% CI, -13 to 68) for those <65 years, and 48% (95% CI, -33 to 80) for those >= 65 years. Sensitivity analyses largely supported these estimates. Conclusions. VE estimates appeared higher than reports from similar studies in ambulatory care settings, suggesting that the 2014-2015 vaccine may have been more effective in preventing severe illness requiring hospitalization. C1 [Petrie, Joshua G.; Ohmit, Suzanne E.; Cheng, Caroline K.; Martin, Emily T.; Malosh, Ryan E.; Monto, Arnold S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Lauring, Adam S.] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA. [Lauring, Adam S.] Univ Michigan, Dept Internal Med, Div Infect Dis, Ann Arbor, MI 48109 USA. [Lamerato, Lois E.] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA. [Reyes, Katherine C.] Henry Ford Hlth Syst, Dept Med, Div Infect Dis, Detroit, MI USA. [Flannery, Brendan; Ferdinands, Jill M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Petrie, JG (reprint author), Univ Michigan, Sch Publ Hlth, 1415 Washington Hts, Ann Arbor, MI 48109 USA. EM jpetrie@umich.edu FU CDC [U01 IP000474] FX This work was supported by the CDC (U01 IP000474). NR 40 TC 1 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2016 VL 63 IS 8 BP 1017 EP 1025 DI 10.1093/cid/ciw432 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7KN UT WOS:000386044400007 PM 27369320 ER PT J AU Rosenke, K Adjemian, J Munster, VJ Marzi, A Falzarano, D Onyango, CO Ochieng, M Juma, B Fischer, RJ Prescott, JB Safronetz, D Omballa, V Owuor, C Hoenen, T Groseth, A Martellaro, C van Doremalen, N Zemtsova, G Self, J Bushmaker, T McNally, K Rowe, T Emery, SL Feldmann, F Williamson, BN Best, SM Nyenswah, TG Grolla, A Strong, JE Kobinger, G Bolay, FK Zoon, KC Stassijns, J Giuliani, R de Smet, M Nichol, ST Fields, B Sprecher, A Massaquoi, M Feldmann, H de Wit, E AF Rosenke, Kyle Adjemian, Jennifer Munster, Vincent J. Marzi, Andrea Falzarano, Darryl Onyango, Clayton O. Ochieng, Melvin Juma, Bonventure Fischer, Robert J. Prescott, Joseph B. Safronetz, David Omballa, Victor Owuor, Collins Hoenen, Thomas Groseth, Allison Martellaro, Cynthia van Doremalen, Neeltje Zemtsova, Galina Self, Joshua Bushmaker, Trenton McNally, Kristin Rowe, Thomas Emery, Shannon L. Feldmann, Friederike Williamson, Brandi N. Best, Sonja M. Nyenswah, Tolbert G. Grolla, Allen Strong, James E. Kobinger, Gary Bolay, Fatorma K. Zoon, Kathryn C. Stassijns, Jorgen Giuliani, Ruggero de Smet, Martin Nichol, Stuart T. Fields, Barry Sprecher, Armand Massaquoi, Moses Feldmann, Heinz de Wit, Emmie TI Plasmodium Parasitemia Associated With Increased Survival in Ebola Virus-Infected Patients SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE coinfection; ebolavirus; plasmodium; survival ID HEMORRHAGIC-FEVER; VIRAL LOAD; ARTEMISININ DERIVATIVES; CASE-MANAGEMENT; SIERRA-LEONE; MOUSE MODEL; MALARIA; DIAGNOSIS; MORTALITY; DISEASE AB Background. The ongoing Ebola outbreak in West Africa has resulted in 28 646 suspected, probable, and confirmed Ebola virus infections. Nevertheless, malaria remains a large public health burden in the region affected by the outbreak. A joint Centers for Disease Control and Prevention/National Institutes of Health diagnostic laboratory was established in Monrovia, Liberia, in August 2014, to provide laboratory diagnostics for Ebola virus. Methods. All blood samples from suspected Ebola virus-infected patients admitted to the Medecins Sans Frontieres ELWA3 Ebola treatment unit in Monrovia were tested by quantitative real-time polymerase chain reaction for the presence of Ebola virus and Plasmodium species RNA. Clinical outcome in laboratory-confirmed Ebola virus-infected patients was analyzed as a function of age, sex, Ebola viremia, and Plasmodium species parasitemia. Results. The case fatality rate of 1182 patients with laboratory-confirmed Ebola virus infections was 52%. The probability of surviving decreased with increasing age and decreased with increasing Ebola viral load. Ebola virus-infected patients were 20% more likely to survive when Plasmodium species parasitemia was detected, even after controlling for Ebola viral load and age; those with the highest levels of parasitemia had a survival rate of 83%. This effect was independent of treatment with antimalarials, as this was provided to all patients. Moreover, treatment with antimalarials did not affect survival in the Ebola virus mouse model. Conclusions. Plasmodium species parasitemia is associated with an increase in the probability of surviving Ebola virus infection. More research is needed to understand the molecular mechanism underlying this remarkable phenomenon and translate it into treatment options for Ebola virus infection. C1 [Rosenke, Kyle; Munster, Vincent J.; Marzi, Andrea; Falzarano, Darryl; Fischer, Robert J.; Prescott, Joseph B.; Safronetz, David; Hoenen, Thomas; Groseth, Allison; Martellaro, Cynthia; van Doremalen, Neeltje; Bushmaker, Trenton; McNally, Kristin; Williamson, Brandi N.; Best, Sonja M.; Feldmann, Heinz; de Wit, Emmie] NIAID, Virol Lab, Div Intramural Res, Rocky Mt Labs,NIH, 903 S 4th St, Hamilton, MT 59840 USA. [Adjemian, Jennifer] NIAID, Epidemiol Unit, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Adjemian, Jennifer] US PHS, Commissioned Corps, Rockville, MD USA. [Onyango, Clayton O.; Juma, Bonventure; Fields, Barry] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global Hlth Protect, Atlanta, GA USA. [Ochieng, Melvin; Omballa, Victor; Owuor, Collins] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Nairobi, Kenya. [Zemtsova, Galina; Self, Joshua; Rowe, Thomas; Emery, Shannon L.; Nichol, Stuart T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Feldmann, Friederike] NIAID, Rocky Mt Vet Branch, Div Intramural Res, Rocky Mt Labs,NIH, Hamilton, MT 59840 USA. [Nyenswah, Tolbert G.; Massaquoi, Moses] Minist Hlth & Social Welf Incident Management Sys, Monrovia, Liberia. [Grolla, Allen; Strong, James E.; Kobinger, Gary] Publ Hlth Agcy Canada, Special Pathogens Program, Winnipeg, MB, Canada. [Bolay, Fatorma K.] Liberian Inst Biomed Res, Charlesville, NS, Canada. [Zoon, Kathryn C.] NIAID, Cytokine Biol Sect, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Stassijns, Jorgen; Giuliani, Ruggero; de Smet, Martin; Sprecher, Armand] Med Sans Frontieres, Operat Ctr, Brussels, Belgium. [Falzarano, Darryl] Univ Saskatchewan, Vaccine & Infect Dis Org, Int Vaccine Ctr, Saskatoon, SK, Canada. [Safronetz, David] Publ Hlth Agcy Canada, Winnipeg, MB, Canada. [Hoenen, Thomas; Groseth, Allison] Friedrich Loeffler Inst, Greifswald, Germany. RP de Wit, E (reprint author), NIAID, Virol Lab, Div Intramural Res, Rocky Mt Labs,NIH, 903 S 4th St, Hamilton, MT 59840 USA. EM emmie.dewit@nih.gov OI de Wit, Emmie/0000-0002-9763-7758; Munster, Vincent/0000-0002-2288-3196 FU NIAID/NIH FX This work was partially funded by the Intramural Research Program of the NIAID/NIH. NR 28 TC 8 Z9 8 U1 5 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2016 VL 63 IS 8 BP 1026 EP 1033 DI 10.1093/cid/ciw452 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7KN UT WOS:000386044400008 PM 27531847 ER PT J AU Klevens, RM Canary, L Huang, XH Denniston, MM Yeo, AE Pesano, RL Ward, JW Holmberg, S AF Klevens, R. Monina Canary, Lauren Huang, Xiaohua Denniston, Maxine M. Yeo, Anthony E. Pesano, Rick L. Ward, John W. Holmberg, Scott TI The Burden of Hepatitis C Infection-Related Liver Fibrosis in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE hepatitis C virus; epidemiology; fibrosis ID ALL-CAUSE MORTALITY; VIRUS-INFECTION; COST-EFFECTIVENESS; VIRAL-HEPATITIS; COHORT; CARE; PROGRESSION; PREVALENCE; HCV AB Background. Knowledge of the estimated proportion of hepatitis C virus (HCV)-infected persons with advanced fibrosis or cirrhosis is critical to estimating healthcare needs. Methods. We analyzed HCV-related testing conducted by Quest Diagnostics from January 2010 through December 2013. Tests included hepatitis C antibody, HCV RNA, HCV genotype (nucleic acid tests [NAT]), liver function tests, and platelet counts; patient age was also determined. Aspartate aminotransferase (AST)-to-platelet ratio (APRI) was calculated as = 100*(aspartate aminotransferase [AST]/upper limit of AST)/platelet. Fibrosis-4 (FIB-4) was calculated as (age x AST)/(platelet x root alanine aminotransferase [ALT]). Persons were "currently infected" if they had >= 1 positive HCV NAT; "in care" if a positive RNA test was followed <6 months by >= 1 additional NAT(s), or ALT, AST, and platelets <90 days, or any test ordered by an infectious diseases or gastroenterology specialist; and "evaluated for treatment" if they had a genotype test. Results. Approximately 10 million HCV test results were analyzed, representing 5.6 million unique patients. Of the 2.6 million patients with data to estimate liver disease, 5% were currently infected. Among those currently infected, APRI and FIB-4 scores indicated that 23% overall-and 27% among the cohort born during 1945-1965-had advanced fibrosis or cirrhosis at first diagnosis. A total of 54% of infected were in care and 51% of infected with advanced fibrosis or cirrhosis were evaluated for treatment. Conclusions. Testing from a large US commercial laboratory indicates that about 1 in 4 HCV-infected persons have levels of liver disease put them at highest risk for complications and could benefit from immediate antiviral therapy. C1 [Klevens, R. Monina; Canary, Lauren; Denniston, Maxine M.; Ward, John W.; Holmberg, Scott] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Huang, Xiaohua; Yeo, Anthony E.; Pesano, Rick L.] Quest Diagnost, Madison, NJ USA. RP Klevens, RM (reprint author), Massachusetts Dept Publ Hlth, Bur Infect Dis & Lab Sci, 305 S St, Boston, MA 02130 USA. EM monina.klevens@state.ma.us FU Centers for Disease Control and Prevention Foundation; AbbVie FX This work was supported in part by the Centers for Disease Control and Prevention Foundation, which received a grant from AbbVie. NR 20 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2016 VL 63 IS 8 BP 1049 EP 1055 DI 10.1093/cid/ciw468 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7KN UT WOS:000386044400011 PM 27506688 ER PT J AU Self, WH Wunderink, RG Williams, DJ Waterer, GW Jain, S Edwards, KM Grijalva, CG AF Self, Wesley H. Wunderink, Richard G. Williams, Derek J. Waterer, Grant W. Jain, Seema Edwards, Kathryn M. Grijalva, Carlos G. TI Empirical Coverage of Methicillin-Resistant Staphylococcus aureus in Community-Acquired Pneumonia: Those Who Do Not Remember the Past Are Doomed to Repeat It Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID OUTCOMES C1 [Self, Wesley H.; Williams, Derek J.; Edwards, Kathryn M.; Grijalva, Carlos G.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Wunderink, Richard G.; Waterer, Grant W.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Jain, Seema] Ctr Dis Control & Prevent, Atlanta, GA USA. [Waterer, Grant W.] Univ Western Australia, Perth, WA, Australia. RP Self, WH (reprint author), Vanderbilt Univ, 1313 21st Ave S,703 Oxford House, Nashville, TN 37232 USA. EM wesley.self@vanderbilt.edu FU NCIRD CDC HHS [U18 IP000299]; NIA NIH HHS [R01 AG043471]; NIGMS NIH HHS [K23 GM110469] NR 7 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2016 VL 63 IS 8 BP 1146 EP U173 DI 10.1093/cid/ciw466 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7KN UT WOS:000386044400029 PM 27402823 ER PT J AU Petrie, JG Ohmit, SE Truscon, R Johnson, E Braun, TM Levine, MZ Eichelberger, MC Monto, AS AF Petrie, Joshua G. Ohmit, Suzanne E. Truscon, Rachel Johnson, Emileigh Braun, Thomas M. Levine, Min Z. Eichelberger, Maryna C. Monto, Arnold S. TI Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE influenza; influenza vaccine; efficacy; waning; hemagglutinin; neuraminidase; antibody persistence; longevity of antibody; serologic assays; immune correlates ID IMMUNIZATION PRACTICES ACIP; TEST-NEGATIVE DESIGN; ADVISORY-COMMITTEE; VIRUS NEURAMINIDASE; UNITED-STATES; PROTECTION; CHILDREN; RECOMMENDATIONS; PREVENTION; CORRELATE AB Background. Antibody titers decrease with time following influenza vaccination, raising concerns that vaccine efficacy might wane. However, the relationship between time since vaccination and protection is unclear. Methods. Time-varying vaccine efficacy (VE[t]) was examined in healthy adult participants (age range, 18-49 years) in a placebo-controlled trial of inactivated influenza vaccine (IIV) and live-attenuated influenza vaccine (LAIV) performed during the 2007-2008 influenza season. Symptomatic respiratory illnesses were laboratory-confirmed as influenza. VE(t) was estimated by fitting a smooth function based on residuals from Cox proportional hazards models. Subjects had blood samples collected immediately prior to vaccination, 30 days after vaccination, and at the end of the influenza season for testing by hemagglutination inhibition and neuraminidase inhibition assays. Results. Overall efficacy was 70% (95% confidence interval [CI], 50%-82%) for IIV and 38% (95% CI, 5%-59%) for LAIV. Statistically significant waning was detected for IIV (P = .03) but not LAIV (P = .37); however, IIV remained significantly efficacious until data became sparse at the end of the season. Similarly, antibody titers against influenza virus hemagglutinin and neuraminidase significantly decreased over the season among IIV recipients. Conclusions. Both vaccines were efficacious but LAIV less so. IIV efficacy decreased slowly over time, but the vaccine remained significantly efficacious for the majority of the season. C1 [Petrie, Joshua G.; Ohmit, Suzanne E.; Truscon, Rachel; Johnson, Emileigh; Monto, Arnold S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Braun, Thomas M.] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. [Levine, Min Z.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Eichelberger, Maryna C.] US FDA, Ctr Biol Evaluat & Res, Div Viral Prod, Silver Spring, MD USA. RP Petrie, JG (reprint author), Univ Michigan, Sch Publ Hlth, 1415 Washington Hts, Ann Arbor, MI 48109 USA. EM jpetrie@umich.edu FU Sanofi Pasteur; Center for Biologics Evaluation and Research (PanFlu funds) FX This work was supported by Sanofi Pasteur (unrestricted grant) and the Center for Biologics Evaluation and Research (PanFlu funds). NR 36 TC 2 Z9 2 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2016 VL 214 IS 8 BP 1142 EP 1149 DI 10.1093/infdis/jiw105 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8UL UT WOS:000386147200006 PM 27095420 ER PT J AU Hsu, CH Rokni, GR Aghazadeh, N Brinster, N Li, Y Muehlenbachs, A Goldsmith, CS Zhao, H Petersen, B McCollum, AM Reynolds, MG AF Hsu, Christopher H. Rokni, Ghasem Rahmatpour Aghazadeh, Nessa Brinster, Nooshin Li, Yu Muehlenbachs, Atis Goldsmith, Cynthia S. Zhao, Hui Petersen, Brett McCollum, Andrea M. Reynolds, Mary G. TI Unique Presentation of Orf Virus Infection in a Thermal-Burn Patient After Receiving an Autologous Skin Graft SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Orf virus; skin graft; thermal burn; Parapoxvirus ID ASSAYS AB We describe a burn patient who developed skin lesions on her skin-graft harvest and skin-graft recipient (burn) sites. Orf virus infection was confirmed by a combination of diagnostic assays, including molecular tests, immunohistochemical analysis, pathologic analysis, and electron microscopy. DNA sequence analysis grouped this orf virus isolate among isolates from India. Although no definitive source of infection was determined from this case, this is the first reported case of orf virus infection in a skin graft harvest. Skin graft recipients with exposures to animals may be at risk for this viral infection. C1 [Hsu, Christopher H.; Li, Yu; Zhao, Hui; Petersen, Brett; McCollum, Andrea M.; Reynolds, Mary G.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, 1600 Clifton Rd NE,MSE 30, Atlanta, GA 30329 USA. [Muehlenbachs, Atis; Goldsmith, Cynthia S.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. [Hsu, Christopher H.] Epidem Intelligence Serv, Atlanta, GA USA. [Brinster, Nooshin] NYU, Med Ctr, Dept Dermatol, New York, NY 10016 USA. [Rokni, Ghasem Rahmatpour] Bo Ali Sina Hosp, Dept Dermatol, Hamadan, Iran. [Aghazadeh, Nessa] Univ Tehran Med Sci, Razi Dermatol Hosp, Tehran, Iran. RP Hsu, CH (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, 1600 Clifton Rd NE,MSE 30, Atlanta, GA 30329 USA. EM chsu@cdc.gov NR 15 TC 0 Z9 0 U1 3 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2016 VL 214 IS 8 BP 1171 EP 1174 DI 10.1093/infdis/jiw307 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8UL UT WOS:000386147200010 PM 27456708 ER PT J AU Tchaparian, E Sambol, NC Arinaitwe, E McCormack, SA Bigira, V Wanzira, H Muhindo, M Creek, DJ Sukumar, N Blessborn, D Tappero, JW Kakuru, A Bergqvist, Y Aweeka, FT Parikh, S AF Tchaparian, Eskouhie Sambol, Nancy C. Arinaitwe, Emmanuel McCormack, Shelley A. Bigira, Victor Wanzira, Humphrey Muhindo, Mary Creek, Darren J. Sukumar, Nitin Blessborn, Daniel Tappero, Jordan W. Kakuru, Abel Bergqvist, Yngve Aweeka, Francesca T. Parikh, Sunil TI Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Malaria; population pharmacokinetics; lumefantrine; artemisinin combination therapy; antimalarial; nonlinear mixed effects modeling; pharmacodynamics; trimethoprim-sulfamethoxazole ID PLASMODIUM-FALCIPARUM MALARIA; DIHYDROARTEMISININ-PIPERAQUINE; CLINICAL PHARMACOKINETICS; ANTIRETROVIRAL THERAPY; AFRICAN CHILDREN; RANDOMIZED-TRIAL; TRIMETHOPRIM; EFFICACY; SULFAMETHOXAZOLE; BIOAVAILABILITY AB Background. The pharmacokinetics and pharmacodynamics of lumefantrine, a component of the most widely used treatment for malaria, artemether-lumefantrine, has not been adequately characterized in young children. Methods. Capillary whole-blood lumefantrine concentration and treatment outcomes were determined in 105 Ugandan children, ages 6 months to 2 years, who were treated for 249 episodes of Plasmodium falciparum malaria with artemether-lumefantrine. Results. Population pharmacokinetics for lumefantrine used a 2-compartment open model with first-order absorption. Age had a significant positive correlation with bioavailability in a model that included allometric scaling. Children not receiving trimethoprim-sulfamethoxazole with capillary whole blood concentrations <200 ng/mL had a 3-fold higher hazard of 28-day recurrent parasitemia, compared with those with concentrations >200 ng/mL (P = .0007). However, for children receiving trimethoprim-sulfamethoxazole, the risk of recurrent parasitemia did not differ significantly on the basis of this threshold. Day 3 concentrations were a stronger predictor of 28-day recurrence than day 7 concentrations. Conclusions. We demonstrate that age, in addition to weight, is a determinant of lumefantrine exposure, and in the absence of trimethoprim-sulfamethoxazole, lumefantrine exposure is a determinant of recurrent parasitemia. Exposure levels in children aged 6 months to 2 years was generally lower than levels published for older children and adults. Further refinement of artemether-lumefantrine dosing to improve exposure in infants and very young children may be warranted. C1 [Tchaparian, Eskouhie; Sambol, Nancy C.; McCormack, Shelley A.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA. [Arinaitwe, Emmanuel; Bigira, Victor; Wanzira, Humphrey; Muhindo, Mary; Kakuru, Abel] Infect Dis Res Collaborat, Kampala, Uganda. [Creek, Darren J.] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic, Australia. [Sukumar, Nitin; Parikh, Sunil] Yale Sch Publ Hlth, 60 Coll St,Rm 724, New Haven, CT 06520 USA. [Blessborn, Daniel; Bergqvist, Yngve] Dalarna Univ, Uppsala, Sweden. [Tappero, Jordan W.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Aweeka, Francesca T.] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA. [Blessborn, Daniel] Fac Trop Med, Mahidol Oxford Res Unit, Bangkok, Thailand. [Blessborn, Daniel] Univ Oxford, Ctr Trop Med, Nuffield Dept Clin Med, Oxford OX1 2JD, England. RP Parikh, S (reprint author), Yale Sch Publ Hlth, 60 Coll St,Rm 724, New Haven, CT 06520 USA. EM sunil.parikh@yale.edu FU Doris Duke Charitable Foundation [2007055]; Novartis Pharmaceuticals [COA566A 0940005]; President's Emergency Plan for AIDS Relief, through the Department of Health and Human Services/Centers for Disease Control and Prevention [U62P024421]; National Center for HIV, Viral Hepatitis, STD, and TB Prevention; National Institute of Child Health and Human Development [R01HD068174]; Global AIDS Program FX This work was supported by the Doris Duke Charitable Foundation (clinical scientist development award to S. P. [grant 2007055]); Novartis Pharmaceuticals, through a clinical services agreement (study number COA566A 0940005); the President's Emergency Plan for AIDS Relief, through the Department of Health and Human Services/Centers for Disease Control and Prevention (U62P024421); the National Center for HIV, Viral Hepatitis, STD, and TB Prevention; the National Institute of Child Health and Human Development (award R01HD068174); and the Global AIDS Program. NR 47 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2016 VL 214 IS 8 BP 1243 EP 1251 DI 10.1093/infdis/jiw338 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8UL UT WOS:000386147200021 PM 27471317 ER PT J AU Rao, S Seth, P Walker, T Wang, GS Mulatu, MS Gilford, J German, EJ AF Rao, Shubha Seth, Puja Walker, Tanja Wang, Guoshen Mulatu, Mesfin S. Gilford, John German, Emilio J. TI HIV Testing and Outcomes Among Hispanics/Latinos - United States, Puerto Rico, and US Virgin Islands, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Rao, Shubha; Seth, Puja; Walker, Tanja; Wang, Guoshen; Mulatu, Mesfin S.; Gilford, John] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Program Evaluat Branch, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [German, Emilio J.] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Hlth Equ, Div HIV AIDS Prevent, Atlanta, GA USA. RP Rao, S (reprint author), Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Program Evaluat Branch, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. EM srao1@cdc.gov NR 10 TC 0 Z9 0 U1 3 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 14 PY 2016 VL 65 IS 40 BP 1099 EP 1103 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA1AM UT WOS:000386320700002 PM 27736833 ER PT J AU Korhonen, LC DeGroote, NP Shouse, RL Valleroy, LA Prejean, J Bradley, H AF Korhonen, Lauren C. DeGroote, Nicholas P. Shouse, R. Luke Valleroy, Linda A. Prejean, Joseph Bradley, Heather TI Unmet Needs for Ancillary Services Among Hispanics/Latinos Receiving HIV Medical Care - United States, 2013-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Korhonen, Lauren C.; DeGroote, Nicholas P.; Shouse, R. Luke; Valleroy, Linda A.; Prejean, Joseph; Bradley, Heather] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Korhonen, Lauren C.; DeGroote, Nicholas P.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN 37830 USA. RP Korhonen, LC (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.; Korhonen, LC (reprint author), Oak Ridge Inst Sci & Educ, Oak Ridge, TN 37830 USA. EM xgc9@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 14 PY 2016 VL 65 IS 40 BP 1104 EP 1107 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA1AM UT WOS:000386320700003 PM 27736837 ER PT J AU Springer, YP Gerona, R Scheunemann, E Shafer, SL Lin, T Banister, SD Cooper, MP Castrodale, LJ Levy, M Butler, JC McLaughlin, JB AF Springer, Yuri P. Gerona, Roy Scheunemann, Erich Shafer, Sarah L. Lin, Thomas Banister, Samuel D. Cooper, Michael P. Castrodale, Louisa J. Levy, Michael Butler, Jay C. McLaughlin, Joseph B. TI Increase in Adverse Reactions Associated with Use of Synthetic Cannabinoids - Anchorage, Alaska, 2015-2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID AB-FUBINACA; 5F-AB-PINACA; CHMINACA; PINACA C1 [Springer, Yuri P.; Cooper, Michael P.; Castrodale, Louisa J.; McLaughlin, Joseph B.] Alaska Div Publ Hlth, Sect Epidemiol, Anchorage, AK 99504 USA. [Springer, Yuri P.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Gerona, Roy; Lin, Thomas; Banister, Samuel D.] Univ Calif San Francisco, Clin Toxicol & Environm Biomonitoring Lab, San Francisco, CA 94143 USA. [Scheunemann, Erich; Levy, Michael] Anchorage Fire Dept, Anchorage, AK USA. [Shafer, Sarah L.] Alaska Native Epidemiol Ctr, Anchorage, AK USA. [Banister, Samuel D.] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA. [Butler, Jay C.] Alaska Dept Hlth & Social Serv, Anchorage, AK USA. RP Castrodale, LJ (reprint author), Alaska Div Publ Hlth, Sect Epidemiol, Anchorage, AK 99504 USA. EM louisa.castrodale@alaska.gov OI Banister, Samuel/0000-0002-4690-4318 NR 9 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 14 PY 2016 VL 65 IS 40 BP 1108 EP 1111 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA1AM UT WOS:000386320700004 PM 27736839 ER PT J AU Hopkins, DR Ruiz-Tiben, E Eberhard, ML Roy, SL Weiss, AJ AF Hopkins, Donald R. Ruiz-Tiben, Ernesto Eberhard, Mark L. Roy, Sharon L. Weiss, Adam J. TI Progress Toward Global Eradication of Dracunculiasis - January 2015-June 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CHAD C1 [Hopkins, Donald R.; Ruiz-Tiben, Ernesto; Weiss, Adam J.] Carter Ctr, Atlanta, GA USA. [Eberhard, Mark L.] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Roy, Sharon L.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Roy, Sharon L.] CDC, World Hlth Org Collaborating Ctr Res Training & E, Atlanta, GA 30333 USA. RP Roy, SL (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.; Roy, SL (reprint author), CDC, World Hlth Org Collaborating Ctr Res Training & E, Atlanta, GA 30333 USA. EM slroy@cdc.gov NR 9 TC 1 Z9 1 U1 6 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 14 PY 2016 VL 65 IS 40 BP 1112 EP 1116 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA1AM UT WOS:000386320700005 PM 27736840 ER PT J AU Perkins, KM Lawsin, A Hasan, NA Strong, M Halpin, AL Rodger, RR Moulton-Meissner, H Crist, MB Schwartz, S Marders, J Daley, CL Salfinger, M Perz, JE AF Perkins, Kiran M. Lawsin, Adrian Hasan, Nabeeh A. Strong, Michael Halpin, Alison L. Rodger, Rachael R. Moulton-Meissner, Heather Crist, Matthew B. Schwartz, Suzanne Marders, Julia Daley, Charles L. Salfinger, Max Perz, Joseph E. TI Mycobacterium chimaera Contamination of Heater-Cooler Devices Used in Cardiac Surgery - United States SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Perkins, Kiran M.; Lawsin, Adrian; Halpin, Alison L.; Moulton-Meissner, Heather; Crist, Matthew B.; Perz, Joseph E.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Hasan, Nabeeh A.; Strong, Michael; Rodger, Rachael R.; Daley, Charles L.; Salfinger, Max] Natl Jewish Hlth, Denver, CO 80206 USA. [Schwartz, Suzanne; Marders, Julia] US FDA, Rockville, MD 20857 USA. RP Perkins, KM (reprint author), CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM kperkins@cdc.gov NR 6 TC 13 Z9 13 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 14 PY 2016 VL 65 IS 40 BP 1117 EP 1118 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA1AM UT WOS:000386320700006 PM 27740609 ER PT J AU Lukovsky-Akhsanov, N Keating, MK Spivey, P Lathrop, GW Powell, N Levine, ML AF Lukovsky-Akhsanov, Nicole Keating, M. Kelly Spivey, Pamela Lathrop, George W., Jr. Powell, Nathaniel Levine, Michael L. TI Assessment of Domestic Goats as Models for Experimental and Natural Infection with the North American Isolate of Rickettsia slovaca SO PLOS ONE LA English DT Article ID DERMACENTOR-MARGINATUS TICKS; MOUNTAIN-SPOTTED-FEVER; BORNE RICKETTSIOSES; VARIABILIS; RAOULTII AB Rickettsia slovaca is a tick-borne human pathogen that is associated with scalp eschars and neck lymphadenopathy known as tick-borne lymphadenopathy (TIBOLA) or Dermacentor-borne necrosis erythema and lymphadenopathy (DEBONEL). Originally, R. slovaca was described in Eastern Europe, but since recognition of its pathogenicity, human cases have been reported throughout Europe. European vertebrate reservoirs of R. slovaca remain unknown, but feral swine and domestic goats have been found infected or seropositive for this pathogen. Recently, a rickettsial pathogen identical to R. slovaca was identified in, and isolated from, the American dog tick, Dermacentor variabilis. In previous experimental studies, this organism was found infectious to guinea pigs and transovarially transmissible in ticks. In this study, domestic goats (Capra hircus) were experimentally inoculated with the North American isolate of this R. slovaca-like agent to assess their reservoir competence-the ability to acquire the pathogens and maintain transmission between infected and uninfected ticks. Goats were susceptible to infection as demonstrated by detection of the pathogen in skin biopsies and multiple internal tissues, but the only clinical sign of illness was transient fever noted in three out of four goats, and reactive lymphoid hyperplasia. On average, less than 5% of uninfected ticks acquired the pathogen while feeding upon infected goats. Although domestic goats are susceptible to the newly described North American isolate of R. slovaca, they are likely to play a minor role in the natural transmission cycle of this pathogen. Our results suggest that goats do not propagate the North American isolate of R. slovaca in peridomestic environments and clinical diagnosis of infection could be difficult due to the brevity and mildness of clinical signs. Further research is needed to elucidate the natural transmission cycle of R. slovaca both in Europe and North America, as well as to identify a more suitable laboratory model. C1 [Lukovsky-Akhsanov, Nicole; Lathrop, George W., Jr.; Powell, Nathaniel] Ctr Dis Control & Prevent, Comparat Med Branch, Div Sci Resources, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Levine, Michael L.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Viral & Rickettsia! Dis, Natl Ctr Infect Dis, Atlanta, GA USA. [Keating, M. Kelly; Spivey, Pamela] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Lukovsky-Akhsanov, N (reprint author), Ctr Dis Control & Prevent, Comparat Med Branch, Div Sci Resources, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM YJN2@cdc.gov NR 22 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 14 PY 2016 VL 11 IS 10 AR e0165007 DI 10.1371/journal.pone.0165007 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DZ0DG UT WOS:000385507000087 PM 27741322 ER PT J AU Shepard, SS Meno, S Bahl, J Wilson, MM Barnes, J Neuhaus, E AF Shepard, Samuel S. Meno, Sarah Bahl, Justin Wilson, Malania M. Barnes, John Neuhaus, Elizabeth TI Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler (vol 17, 708, 2016) SO BMC GENOMICS LA English DT Correction C1 [Shepard, Samuel S.; Meno, Sarah; Wilson, Malania M.; Barnes, John; Neuhaus, Elizabeth] Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd, Atlanta, GA 30329 USA. [Bahl, Justin] Univ Texas Houston, Sch Publ Hlth, Ctr Infect Dis, Houston, TX USA. [Wilson, Malania M.] Battelle Mem Res Inst, 1600 Clifton Rd, Atlanta, GA 30329 USA. RP Shepard, SS; Neuhaus, E (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM vfn4@cdc.gov; ebn9@cdc.gov NR 1 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2164 J9 BMC GENOMICS JI BMC Genomics PD OCT 13 PY 2016 VL 17 AR 801 DI 10.1186/s12864-016-3138-8 PG 2 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA DZ0ES UT WOS:000385510900001 PM 27737640 ER PT J AU Fletcher, R Jones, JD Shah, NS AF Fletcher, Reid Jones, Joshua D. Shah, Neha S. TI Treatment of Active Tuberculosis in Chicago, 2008-2011: The Role of Public Health Departments SO PLOS ONE LA English DT Article ID NEW-YORK-CITY; PULMONARY TUBERCULOSIS; CARE; ERA AB Objective Evaluate differences in TB outcomes among different provider types in Chicago, IL. Methods We retrospectively reviewed all TB cases reported to the Chicago Department of Public Health (CDPH) from 2008 through 2011. Provider type was stratified into three groups: public, public-private, and private providers. Multivariate regression was used to evaluate treatment duration and time to sputum culture conversion. A Cox proportional hazard model was used to assess treatment completion. Results Of 703 cases, 203 (28.9%), 314 (44.7%), and 186 (26.5%) were treated by public, publicprivate and private providers, respectively. Adjusted regression showed private provider patients had a 48-day (95% CI 22.0-74.3) increase in treatment duration and a 30-day (95% C.I. 9.5-51.1) increase in time to sputum culture conversion. Cox model showed increased risk of remaining on treatment was associated with extra-pulmonary TB (aHR 0.78, 95% C.I. 0.62-0.98), being foreign-born (aHR 0.74, 95% C.I. 0.58-0.95), and any drug resistance (aHR 0.59, 95% C.I. 0.46-0.76). There were no differences in outcomes between public and public-private providers. Conclusion Patients treated solely in the private sector had prolonged time to sputum culture conversion and treatment duration which lead to increased cost for treatment, prolonged infectiousness, potential for transmission, and the possibility for increased medication side effects. C1 [Fletcher, Reid] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Jones, Joshua D.; Shah, Neha S.] Chicago Dept Publ Hlth, Chicago, IL USA. [Shah, Neha S.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Fletcher, R (reprint author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. EM reidnf@gmail.com NR 24 TC 0 Z9 0 U1 4 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 12 PY 2016 VL 11 IS 10 AR e0164162 DI 10.1371/journal.pone.0164162 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DZ0CQ UT WOS:000385505300039 PM 27732650 ER PT J AU Frieden, TR Schuchat, A Petersen, LR AF Frieden, Thomas R. Schuchat, Anne Petersen, Lyle R. TI Zika Virus 6 Months Later SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Frieden, Thomas R.; Schuchat, Anne; Petersen, Lyle R.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS D-14, Atlanta, GA 30333 USA. RP Frieden, TR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS D-14, Atlanta, GA 30333 USA. EM tfrieden@cdc.gov NR 6 TC 2 Z9 2 U1 18 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 11 PY 2016 VL 316 IS 14 BP 1443 EP 1444 DI 10.1001/jama.2016.11941 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DY1TC UT WOS:000384876300011 PM 27532277 ER PT J AU Chehab, ET Anya, BPM Onyango, AW Tevi-Benissan, MC Okeibunor, J Mkanda, P Mihigo, R AF Chehab, Elizabeth Tangel Anya, Blanche-Philomene Melanga Onyango, Adelheid Werimo Tevi-Benissan, Mable Carole Okeibunor, Joseph Mkanda, Pascal Mihigo, Richard TI Experience of integrating vitamin A supplementation into polio campaigns in the African Region SO VACCINE LA English DT Article DE Polio; Supplementary immunization activities; Vitamin A; Integration of health services AB Introduction: Vitamin A deficiency is a public health problem that affects children across the WHO African Region. Countries have integrated vitamin A supplementation in different child health interventions, most notably with polio campaigns. The integration of vitamin A in polio campaigns was documented as a best practice in Angola, Chad, Cote d'Ivoire, Tanzania, and Togo. There are potential risks to vitamin A supplementation associated with the polio endgame and certification in the African Region. Methods: We reviewed the findings from the documentation of, best practices assessment that was conducted by the WHO Regional Office for Africa in 2014 and 2015 in the five countries that noted integration of vitamin A with polio as a best practice. In addition, we reviewed the coverage rates for oral poliovirus vaccine and vitamin A supplementation in Angola, Chad, Cote d'Ivoire, Tanzania, and Togo in 2014 and 2015. Results: Vitamin A deficiency in 2004 ranged from 35% in Togo to as high as 55% in Angola. All five countries integrated vitamin A supplementation in at least one campaign in 2013-2014 and all achieved over 80% coverage for vitamin A supplementation when it was integrated with polio. Discussion: Given the progress of the polio program, and decreasing campaigns, there is a risk that fewer children will be reached each year with vitamin A supplementation. We recommend that for countries strengthen the integration of vitamin A supplementation with routine immunization services. Published by Elsevier Ltd. C1 [Chehab, Elizabeth Tangel] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Anya, Blanche-Philomene Melanga; Onyango, Adelheid Werimo; Tevi-Benissan, Mable Carole; Okeibunor, Joseph; Mkanda, Pascal; Mihigo, Richard] World Hlth Org, Reg Off Africa, Brazzaville, Rep Congo. RP Chehab, ET (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM uvz0@cdc.gov FU World Health Organization [001] NR 13 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 10 PY 2016 VL 34 IS 43 SI SI BP 5199 EP 5202 DI 10.1016/j.vaccine.2016.05.056 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA DZ1KN UT WOS:000385597400013 PM 27364094 ER PT J AU Nguyen, KH Ma, L AF Nguyen, Kimberly H. Ma, LaTisha TI State-Specific Prevalence of Current Cigarette Smoking and Smokeless Tobacco Use Among Adults - United States, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Nguyen, Kimberly H.; Ma, LaTisha] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Nguyen, KH (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM uxp1@cdc.gov NR 10 TC 0 Z9 0 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 7 PY 2016 VL 65 IS 39 BP 1 EP 7 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ6SV UT WOS:000385993100001 ER PT J AU Barbour, KE Boring, M Helmick, CG Murphy, LB Qin, J AF Barbour, Kamil E. Boring, Michael Helmick, Charles G. Murphy, Louise B. Qin, Jin TI Prevalence of Severe Joint Pain Among Adults with Doctor-Diagnosed Arthritis - United States, 2002-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ATTRIBUTABLE ACTIVITY LIMITATION C1 [Barbour, Kamil E.; Boring, Michael; Helmick, Charles G.; Murphy, Louise B.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Qin, Jin] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Barbour, KE (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 7 PY 2016 VL 65 IS 39 BP 8 EP 12 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ6SV UT WOS:000385993100002 ER PT J AU Seither, R Calhoun, K Mellerson, J Knighton, CL Street, E Dietz, V Underwood, JM AF Seither, Ranee Calhoun, Kayla Mellerson, Jenelle Knighton, Cynthia L. Street, Erica Dietz, Vance Underwood, J. Michael TI Vaccination Coverage Among Children in Kindergarten - United States, 2015-16 School Year SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Seither, Ranee; Calhoun, Kayla; Mellerson, Jenelle; Knighton, Cynthia L.; Street, Erica; Dietz, Vance; Underwood, J. Michael] CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. [Street, Erica] Assoc Sch & Programs Publ Hlth, Denver, CO USA. RP Seither, R (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. EM rseither@cdc.gov NR 8 TC 0 Z9 0 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 7 PY 2016 VL 65 IS 39 BP 13 EP 20 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ6SV UT WOS:000385993100003 ER PT J AU Hill, HA Elam-Evans, LD Yankey, D Singleton, JA Dietz, V AF Hill, Holly A. Elam-Evans, Laurie D. Yankey, David Singleton, James A. Dietz, Vance TI Vaccination Coverage Among Children Aged 19-35 Months - United States, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID IMMUNIZATION C1 [Hill, Holly A.; Elam-Evans, Laurie D.; Yankey, David; Singleton, James A.; Dietz, Vance] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Hill, HA (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM hhill@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 7 PY 2016 VL 65 IS 39 BP 21 EP 27 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ6SV UT WOS:000385993100004 ER PT J AU Oh, DH Dabbagh, A Goodson, JL Strebel, PM Thapa, S Giri, JN Shakya, SR Khanal, S AF Oh, David H. Dabbagh, Alya Goodson, James L. Strebel, Peter M. Thapa, Sanjita Giri, Jagat Narain Shakya, Sagar Ratna Khanal, Sudhir TI Real-Time Monitoring of Vaccination Campaign Performance Using Mobile Phones - Nepal, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID MEASLES ELIMINATION; COVERAGE; PROGRESS C1 [Oh, David H.; Dabbagh, Alya; Strebel, Peter M.] World Hlth Org, Dept Immunizat Vaccines & Biol, Delhi, India. [Goodson, James L.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. [Thapa, Sanjita; Giri, Jagat Narain; Shakya, Sagar Ratna] World Hlth Org, Immunizat Preventable Dis, Nepal Country Off, Delhi, India. [Khanal, Sudhir] World Hlth Org, Immutlizat & Vaccine Dev, South East Asia Reg Off, Delhi, India. RP Dabbagh, A (reprint author), World Hlth Org, Dept Immunizat Vaccines & Biol, Delhi, India. EM dabbagha@who.int NR 6 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 7 PY 2016 VL 65 IS 39 BP 28 EP 32 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ6SV UT WOS:000385993100005 ER PT J AU Petersen, EE Meaney-Delman, D Neblett-Fanfair, R Havers, F Oduyebo, T Hills, SL Rabe, IB Lambert, A Abercrombie, J Martin, SW Gould, CV Oussayef, N Polen, KND Kuehnert, MJ Pillai, SK Petersen, LR Honein, MA Jamieson, DJ Brooks, JT AF Petersen, Emily E. Meaney-Delman, Dana Neblett-Fanfair, Robyn Havers, Fiona Oduyebo, Titilope Hills, Susan L. Rabe, Ingrid B. Lambert, Amy Abercrombie, Julia Martin, Stacey W. Gould, Carolyn V. Oussayef, Nadia Polen, Kara N. D. Kuehnert, Matthew J. Pillai, Satish K. Petersen, Lyle R. Honein, Margaret A. Jamieson, Denise J. Brooks, John T. TI Update: Interim Guidance for Preconception Counseling and Prevention of Sexual Transmission of Zika Virus for Persons with Possible Zika Virus Exposure - United States, September 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID EPIDEMIC AREA; SEMEN; INFECTION; PERSISTENCE; DISEASE; RNA C1 [Petersen, Emily E.; Meaney-Delman, Dana; Neblett-Fanfair, Robyn; Havers, Fiona; Oduyebo, Titilope; Hills, Susan L.; Rabe, Ingrid B.; Lambert, Amy; Abercrombie, Julia; Martin, Stacey W.; Gould, Carolyn V.; Oussayef, Nadia; Polen, Kara N. D.; Kuehnert, Matthew J.; Pillai, Satish K.; Petersen, Lyle R.; Honein, Margaret A.; Jamieson, Denise J.; Brooks, John T.] CDC, Zika Response, Atlanta, GA 30333 USA. RP Petersen, EE (reprint author), CDC, Zika Response, Atlanta, GA 30333 USA. EM zikamch@cdc.gov NR 42 TC 0 Z9 0 U1 136 U2 136 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 7 PY 2016 VL 65 IS 39 BP 33 EP 37 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ6SV UT WOS:000385993100006 ER PT J AU Goodman, AB Dziuban, EJ Powell, K Bitsko, RH Langley, G Lindsey, N Franks, JL Russell, K Dasgupta, S Barfield, WD Odom, E Kahn, E Martin, S Fischer, M Staples, JE AF Goodman, Alyson B. Dziuban, Eric J. Powell, Krista Bitsko, Rebecca H. Langley, Gayle Lindsey, Nicole Franks, Jessica L. Russell, Kate Dasgupta, Sharoda Barfield, Wanda D. Odom, Erika Kahn, Emily Martin, Stacey Fischer, Marc Staples, J. Erin TI Characteristics of Children Aged < 18 Years with Zika Virus Disease Acquired Postnatally - US States, January 2015-July 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Goodman, Alyson B.] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Dziuban, Eric J.; Bitsko, Rebecca H.; Franks, Jessica L.] CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Powell, Krista] CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Langley, Gayle] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Lindsey, Nicole; Martin, Stacey; Fischer, Marc; Staples, J. Erin] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Russell, Kate; Dasgupta, Sharoda] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Russell, Kate] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Dasgupta, Sharoda] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Barfield, Wanda D.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Odom, Erika] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Kahn, Emily] CDC, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Staples, JE (reprint author), CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM estaples@cdc.gov NR 10 TC 0 Z9 0 U1 45 U2 45 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 7 PY 2016 VL 65 IS 39 BP 38 EP 41 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ6SV UT WOS:000385993100007 ER PT J AU Fry, AM Flannery, B Olsen, SJ Grohskopf, L Bresee, J AF Fry, A. M. Flannery, B. Olsen, S. J. Grohskopf, L. Bresee, J. TI Letter to the editor: Regarding the editorial by Penttinen and Friede SO EUROSURVEILLANCE LA English DT Letter ID SEASONAL INFLUENZA; VACCINES C1 [Fry, A. M.; Flannery, B.; Olsen, S. J.; Grohskopf, L.; Bresee, J.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Fry, AM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM afry@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 0 PU EUR CENTRE DIS PREVENTION & CONTROL PI STOCKHOLM PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN SN 1560-7917 J9 EUROSURVEILLANCE JI Eurosurveillance PD OCT 6 PY 2016 VL 21 IS 40 BP 15 EP 16 AR 30366 DI 10.2807/1560-7917.ES.2016.21.40.30366 PG 2 WC Infectious Diseases SC Infectious Diseases GA DZ7BL UT WOS:000386018400003 ER PT J AU Gastanaduy, PA Budd, J Fisher, N Redd, SB Fletcher, J Miller, J McFadden, DJ Rota, J Rota, PA Hickman, C Fowler, B Tatham, L Wallace, GS de Fijter, S Fiebelkorn, AP DiOrio, M AF Gastanaduy, Paul A. Budd, Jeremy Fisher, Nicholas Redd, Susan B. Fletcher, Jackie Miller, Julie McFadden, Dwight J., III Rota, Jennifer Rota, Paul A. Hickman, Carole Fowler, Brian Tatham, Lilith Wallace, Gregory S. de Fijter, Sietske Fiebelkorn, Amy Parker DiOrio, Mary TI A Measles Outbreak in an Underimmunized Amish Community in Ohio SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID UNITED-STATES; VIRUS; ELIMINATION; VACCINATION; RUBELLA; PHILIPPINES; CHILDREN; DISEASE; GENE AB BACKGROUND Although measles was eliminated in the United States in 2000, importations of the virus continue to cause outbreaks. We describe the epidemiologic features of an outbreak of measles that originated from two unvaccinated Amish men in whom measles was incubating at the time of their return to the United States from the Philippines and explore the effect of public health responses on limiting the spread of measles. METHODS We performed descriptive analyses of data on demographic characteristics, clinical and laboratory evaluations, and vaccination coverage. RESULTS From March 24, 2014, through July 23, 2014, a total of 383 outbreak-related cases of measles were reported in nine counties in Ohio. The median age of case patients was 15 years (range, <1 to 53); a total of 178 of the case patients (46%) were female, and 340 (89%) were unvaccinated. Transmission took place primarily within households (68% of cases). The virus strain was genotype D9, which was circulating in the Philippines at the time of the reporting period. Measles-mumps-rubella (MMR) vaccination coverage with at least a single dose was estimated to be 14% in affected Amish households and more than 88% in the general (non-Amish) Ohio community. Containment efforts included isolation of case patients, quarantine of susceptible persons, and administration of the MMR vaccine to more than 10,000 persons. The spread of measles was limited almost exclusively to the Amish community (accounting for 99% of case patients) and affected only approximately 1% of the estimated 32,630 Amish persons in the settlement. CONCLUSIONS The key epidemiologic features of a measles outbreak in the Amish community in Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the Amish community who sought vaccination. As a result of targeted containment efforts, and high baseline coverage in the general community, there was limited spread beyond the Amish community. C1 [Gastanaduy, Paul A.; Redd, Susan B.; Rota, Jennifer; Rota, Paul A.; Hickman, Carole; Wallace, Gregory S.; Fiebelkorn, Amy Parker] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Budd, Jeremy; Fisher, Nicholas; Fowler, Brian; Tatham, Lilith; de Fijter, Sietske; DiOrio, Mary] Ohio Dept Hlth, Columbus, OH 43266 USA. [Fletcher, Jackie; Miller, Julie] Knox Cty Hlth Dept, Mt Vernon, OH USA. [McFadden, Dwight J., III] Holmes Cty Hlth Dept, Millersburg, OH USA. RP Gastanaduy, PA (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop A-47, Atlanta, GA 30333 USA. EM vid7@cdc.gov FU Ohio Department of Health; CDC; Centers for Disease Control and Prevention FX Funded by the Ohio Department of Health and the Centers for Disease Control and Prevention.; Supported by the Ohio Department of Health and the CDC. NR 38 TC 2 Z9 2 U1 3 U2 3 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 6 PY 2016 VL 375 IS 14 BP 1343 EP 1354 DI 10.1056/NEJMoa1602295 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA DY3EZ UT WOS:000384974900007 PM 27705270 ER PT J AU Jones, CM Baldwin, GT Tefera, L AF Jones, Christopher M. Baldwin, Grant T. Tefera, Lemeneh TI State Regulations and Opioid Use among Disabled Adults SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID DRUG-MONITORING PROGRAMS; REDUCTIONS C1 [Jones, Christopher M.] US Dept HHS, Washington, DC 20201 USA. [Baldwin, Grant T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tefera, Lemeneh] Ctr Medicare Serv, Baltimore, MD USA. [Tefera, Lemeneh] Ctr Medicaid Serv, Baltimore, MD USA. RP Jones, CM (reprint author), US Dept HHS, Washington, DC 20201 USA. EM christopher.jones@hhs.gov NR 4 TC 0 Z9 0 U1 1 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 6 PY 2016 VL 375 IS 14 BP 1396 EP 1397 DI 10.1056/NEJMc1610108 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DY3EZ UT WOS:000384974900021 PM 27705248 ER PT J AU Murphy, D McCulloch, CE Lin, F Banerjee, T Bragg-Gresham, JL Eberhardt, MS Morgenstern, H Pavkov, ME Saran, R Powe, NR Hsu, CY AF Murphy, Daniel McCulloch, Charles E. Lin, Feng Banerjee, Tanushree Bragg-Gresham, Jennifer L. Eberhardt, Mark S. Morgenstern, Hal Pavkov, Meda E. Saran, Rajiv Powe, Neil R. Hsu, Chi-yuan CA Ctr Dis Control Prevention TI Trends in Prevalence of Chronic Kidney Disease in the United States SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID GLOMERULAR-FILTRATION-RATE; STAGE RENAL-DISEASE; NUTRITION EXAMINATION SURVEY; BLOOD-PRESSURE CONTROL; DIABETIC-NEPHROPATHY; NATIONAL-HEALTH; TEMPORAL TRENDS; US ADULTS; RISK; INSUFFICIENCY AB Background: Trends in the prevalence of chronic kidney disease (CKD) are important for health care policy and planning. Objective: To update trends in CKD prevalence. Design: Repeated cross-sectional study. Setting: NHANES (National Health and Nutrition Examination Survey) for 1988 to 1994 and every 2 years from 1999 to 2012. Participants: Adults aged 20 years or older. Measurements: Chronic kidney disease (stages 3 and 4) was defined as an estimated glomerular filtration rate (eGFR) of 15 to 59 mL/min/1.73 m(2), estimated with the Chronic Kidney Disease Epidemiology Collaboration equation from calibrated serum creatinine measurements. An expanded definition of CKD also included persons with an eGFR of at least 60 mL/min/1.73 m(2) and a 1-time urine albumin-creatinine ratio of at least 30 mg/g. Results: The unadjusted prevalence of stage 3 and 4 CKD increased from the late 1990s to the early 2000s. Since 2003 to 2004, however, the overall prevalence has largely stabilized (for example, 6.9% prevalence in 2003 to 2004 and in 2011 to 2012). There was little difference in adjusted prevalence of stage 3 and 4 CKD overall in 2003 to 2004 versus 2011 to 2012 after age, sex, race/ethnicity, and diabetes mellitus status were controlled for (P = 0.26). Lack of increase in CKD prevalence since the early 2000s was observed in most subgroups and with an expanded definition of CKD that included persons with higher eGFRs and albuminuria. Limitation: Serum creatinine and albuminuria were measured only once in each person. Conclusion: In a reversal of prior trends, there has been no appreciable increase in the prevalence of stage 3 and 4 CKD in the U.S. population overall during the most recent decade. C1 [Murphy, Daniel] Univ Minnesota, Dept Med, MMC 284 Mayo,8284A Campus Delivery Code, Minneapolis, MN 55455 USA. [McCulloch, Charles E.; Lin, Feng] Univ Calif San Francisco, Epidemiol & Biostat, Sch Med, 550 16th St,Box 0560, San Francisco, CA 94158 USA. [Banerjee, Tanushree; Powe, Neil R.] Priscilla Chan & Mark Zuckerberg San Francisco Ge, 1001 Potrero Ave,ZFGH 10,Box 1364, San Francisco, CA 94110 USA. [Bragg-Gresham, Jennifer L.] Univ Michigan, Internal Med Nephrol, 1455 Washington Hts,Suite 3645, Ann Arbor, MI 48109 USA. [Eberhardt, Mark S.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. [Morgenstern, Hal] Univ Michigan, Sch Publ Hlth, M5164 SPH 2,1415 Washington Hts, Ann Arbor, MI 48109 USA. [Pavkov, Meda E.] Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30329 USA. [Saran, Rajiv] Univ Michigan, Internal Med Nephrol Kidney Epidemiol & Cost Ctr, 1415 Washington Hts,SPH 1,Suite 3645, Ann Arbor, MI 48109 USA. [Hsu, Chi-yuan] UCSF Sch Med, 533 Parnassus Ave,UC Hall 404,Box 0532, San Francisco, CA 94143 USA. RP Hsu, CY (reprint author), Univ Calif San Francisco, Div Nephrol, 533 Parnassus Ave,U-400,Box 0532, San Francisco, CA 94143 USA. EM Neil.Powe@ucsf.edu; hsuchi@medicine.ucsf.edu FU American Society of Nephrology Foundation for Kidney Research Student Scholar Grant Program; Centers for Disease Control and Prevention, and National Institutes of Health FX American Society of Nephrology Foundation for Kidney Research Student Scholar Grant Program, Centers for Disease Control and Prevention, and National Institutes of Health. NR 41 TC 8 Z9 8 U1 8 U2 8 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 4 PY 2016 VL 165 IS 7 BP 473 EP + DI 10.7326/M16-0273 PG 17 WC Medicine, General & Internal SC General & Internal Medicine GA DY0EY UT WOS:000384771300005 PM 27479614 ER PT J AU Khoury, MJ Galea, S AF Khoury, Muin J. Galea, Sandro TI Will Precision Medicine Improve Population Health? SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, 1600 Clifton Rd, Atlanta, GA 30329 USA. [Galea, Sandro] Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Khoury, MJ (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM muk1@cdc.gov NR 8 TC 6 Z9 6 U1 10 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 4 PY 2016 VL 316 IS 13 BP 1357 EP 1358 DI 10.1001/jama.2016.12260 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DX7TC UT WOS:000384591300012 PM 27541310 ER PT J AU Zhang, WQ He, Y Yu, Q Liu, HP Wang, DM Li, XB Luo, J Meng, X Qin, HJ Lucchi, NW Udhayakumar, V Iyer, SS Yang, Y Yu, P AF Zhang, Wen-Qiang He, Yun Yu, Qun Liu, Hai-Peng Wang, De-Min Li, Xiao-Bin Luo, Jian Meng, Xin Qin, Hai-Juan Lucchi, Naomi W. Udhayakumar, Venkatachalam Iyer, Suri S. Yang, Yang Yu, Peng TI Polyvalent effect enhances diglycosidic antiplasmodial activity SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article DE Antimalarial; Polyvalent effect; Glycosylation; Matayoside D; Chloroquine-resistant ID HIGH-AFFINITY; BINDING; LECTIN; GLYCOCLUSTERS; SELECTIVITY; CHEMISTRY; DESIGN AB An efficient and facile total synthesis of diglycoside Matayoside D isolated from the root bark of Matayba guiattensis with antiplasmodial activity have been accomplished in 11 steps with 5% overall yields starting from commercially available glucose and rhamnose. Furthermore, a class of the diglycosidic derivatives with different lengths of the linker and valences were also prepared and evaluated for their antiplasmodial activities against chloroquine-susceptible (3D7) and chloroquine-resistant (W2) strains of Plasmodium falciparum. Low valent and short linker attached diglycoside show no enhancement of the antiplasmodial activity while polyvalent conjugates showed enhanced antiplasmodial activity with IC50 value at least 20 fold better than that of the corresponding diglycosidic monomer. The polyvalent diglycoside were non-cytotoxic against normal mammalian cells under 50,000 g/L. (C) 2016 Elsevier Masson SAS. All rights reserved. C1 [Zhang, Wen-Qiang; Yu, Qun; Liu, Hai-Peng; Wang, De-Min; Li, Xiao-Bin; Luo, Jian; Meng, Xin; Yang, Yang; Yu, Peng] Tianjin Univ Sci & Technol, China Int Sci & Technol Cooperat Base Food Nutr S, Sino French Joint Lab Food Nutr Safety & Med,Coll, Key Lab Ind Fermentat Microbiol,Minist Educ,Tianj, Tianjin 300457, Peoples R China. [He, Yun] Atlanta Res & Educ Fdn, Atlanta, GA 30329 USA. [Liu, Hai-Peng] Tianjin Univ Sci & Technol, Res Ctr Modern Analyt Technol, Tianjin 300457, Peoples R China. [Lucchi, Naomi W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30329 USA. [Iyer, Suri S.] Georgia State Univ, Dept Chem, Ctr Diagnost & Therapeut, Atlanta, GA 30302 USA. RP Yang, Y; Yu, P (reprint author), Tianjin Univ Sci & Technol, China Int Sci & Technol Cooperat Base Food Nutr S, Sino French Joint Lab Food Nutr Safety & Med,Coll, Key Lab Ind Fermentat Microbiol,Minist Educ,Tianj, Tianjin 300457, Peoples R China. EM yyang@tust.edu.cn; yupeng@tust.edu.cn FU Natural Science Foundation of China [21402140, 21502139]; International Science & Technology Cooperation Program of China [2013DFA31160] FX This work was financially supported by the Natural Science Foundation of China (21402140, 21502139) and the International Science & Technology Cooperation Program of China (2013DFA31160). The authors are thankful to the Research Centre of Modern Analytical Technology, Tianjin University of Science and Technology for NMR measurements and MALDI-TOF analysis. NR 23 TC 1 Z9 1 U1 4 U2 4 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0223-5234 EI 1768-3254 J9 EUR J MED CHEM JI Eur. J. Med. Chem. PD OCT 4 PY 2016 VL 121 BP 640 EP 648 DI 10.1016/j.ejmech.2016.05.069 PG 9 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA DU5RT UT WOS:000382269700052 PM 27318984 ER PT J AU Bardenheier, BH Duffy, J Duderstadt, SK Higgs, JB Keith, MP Papadopoulos, PJ Gilliland, WR McNeil, MM AF Bardenheier, Barbara H. Duffy, Jonathan Duderstadt, Susan K. Higgs, Jay B. Keith, Michael P. Papadopoulos, Patricia J. Gilliland, William R. McNeil, Michael M. TI Anthrax Vaccine and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus in the US Military: A Case-Control Study SO MILITARY MEDICINE LA English DT Article ID REVISED CRITERIA; CHRONIC ARTHROPATHY; AMERICAN-COLLEGE; RANDOMIZED-TRIAL; ARMED-FORCES; CLASSIFICATION; IMMUNIZATION; VACCINATIONS; MINNESOTA; MORTALITY AB U.S. military personnel assigned to areas deemed to be at high risk for anthrax attack receive Anthrax Vaccine Adsorbed (AVA). Few cases of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) have been reported in persons who received AVA. Using a matched case-control study design, we assessed the relationship of RA and SLE with AVA vaccination using the Defense Medical Surveillance System. We identified potential cases using International Classification of Diseases, 9th Revision, Clinical Modification codes and confirmed cases with medical record review and rheumatologist adjudication. Using conditional logistic regression, we estimated odds ratios (OR) for AVA exposure during time intervals ranging from 90 to 1,095 days before disease onset. Among 77 RA cases, 13 (17%) had ever received AVA. RA cases were no more likely than controls to have received AVA when looking back 1,095 days (OR: 1.03; 95% confidence interval [CI]: 0.48-2.19) but had greater odds of exposure in the prior 90 days (OR: 3.93; 95% CI: 1.08-14.27). Among the 39 SLE cases, 5 (13%) had ever received AVA; no significant difference in receipt of AVA was found when compared with controls (OR: 0.91; 95% CI: 0.26-3.25). AVA was associated with recent onset RA, but did not increase the risk of developing RA in the long term. C1 [Bardenheier, Barbara H.; Duffy, Jonathan; Duderstadt, Susan K.; McNeil, Michael M.] Ctr Dis Control & Prevent, Immunizat Safety Off, MS D-26,1600 Clifton Rd NE, Atlanta, GA 30333 USA. [Higgs, Jay B.] Brooke Army Med Ctr, Rheumatol Serv, 3851 Roger Brooke Dr, San Antonio, TX 78234 USA. [Keith, Michael P.] Walter Reed Natl Mil Med Ctr, Rheumatol Serv, 4954 N Palmer Rd, Bethesda, MD 20889 USA. [Papadopoulos, Patricia J.] MultiCare Rheumatol Specialists, 1901 S Union Ave,Suite A221, Tacoma, WA 98405 USA. [Gilliland, William R.] Uniformed Serv Univ Hlth Sci, Dept Med, 4301 Jones Bridge Rd,Room A 1005, Bethesda, MD 20814 USA. RP Bardenheier, BH (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, MS D-26,1600 Clifton Rd NE, Atlanta, GA 30333 USA. FU CDC FX The authors gratefully acknowledge Tim Struttmann, MSPH, PMP, and Joan Jacobs, RN, of SRA International, Inc., for technical assistance; Angelia A. Eick-Cost, PhD, ScM, Armed Forces Health Surveillance Center, Silver Spring, MD, for assistance providing study data. The authors also thank Frank DeStefano, MD, MPH, for his critical review of the manuscript. The funding for this study was provided solely by the CDC. NR 29 TC 0 Z9 0 U1 0 U2 0 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD OCT PY 2016 VL 181 IS 10 BP 1348 EP 1356 DI 10.7205/MILMED-D-15-00485 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA EL3DB UT WOS:000394498700035 PM 27753574 ER PT J AU Florence, CS Zhou, C Luo, FJ Xu, LK AF Florence, Curtis S. Zhou, Chao Luo, Feijun Xu, Likang TI The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013 SO MEDICAL CARE LA English DT Article DE prescription opioid; overdose; abuse and dependence; economic burden ID MISUSE; INDIVIDUALS; COSTS AB Importance: It is important to understand the magnitude and distribution of the economic burden of prescription opioid overdose, abuse, and dependence to inform clinical practice, research, and other decision makers. Decision makers choosing approaches to address this epidemic need cost information to evaluate the cost effectiveness of their choices. Objective: To estimate the economic burden of prescription opioid overdose, abuse, and dependence from a societal perspective. Design, Setting, and Participants: Incidence of fatal prescription opioid overdose from the National Vital Statistics System, prevalence of abuse and dependence from the National Survey of Drug Use and Health. Fatal data are for the US population, nonfatal data are a nationally representative sample of the US civilian noninstitutionalized population ages 12 and older. Cost data are from various sources including health care claims data from the Truven Health MarketScan Research Databases, and cost of fatal cases from the WISQARS (Web-based Injury Statistics Query and Reporting System) cost module. Criminal justice costs were derived from the Justice Expenditure and Employment Extracts published by the Department of Justice. Estimates of lost productivity were based on a previously published study. Exposure: Calendar year 2013. Main Outcomes and Measures: Monetized burden of fatal overdose and abuse and dependence of prescription opioids. Results: The total economic burden is estimated to be $78.5 billion. Over one third of this amount is due to increased health care and substance abuse treatment costs ($28.9 billion). Approximately one quarter of the cost is borne by the public sector in health care, substance abuse treatment, and criminal justice costs. Conclusions and Relevance: These estimates can assist decision makers in understanding the magnitude of adverse health outcomes associated with prescription opioid use such as overdose, abuse, and dependence. C1 [Florence, Curtis S.; Zhou, Chao; Luo, Feijun; Xu, Likang] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop F-62, Atlanta, GA 30341 USA. RP Florence, CS (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop F-62, Atlanta, GA 30341 USA. EM cflorence@cdc.gov NR 26 TC 4 Z9 4 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD OCT PY 2016 VL 54 IS 10 BP 901 EP 906 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DW9RO UT WOS:000383999900003 PM 27623005 ER PT J AU Gopalani, SV Helgenberger, L Apaisam, C Donre, S Takiri, K Charley, J Yomai, A Judicpa, P Nakazono, N Johnson, E Setik, E Taulung, L Elias, A Barrow-Kohler, L AF Gopalani, Sameer V. Helgenberger, Louisa Apaisam, Carter Donre, Spencer Takiri, Keyleen Charley, Jocelyne Yomai, Anamaria Judicpa, Peter Nakazono, Naoki Johnson, Eliaser Setik, Eleanor Taulung, Livinson Elias, Augustus Barrow-Kohler, Lisa TI Measles outbreak response vaccination in the Federated States of Micronesia SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Editorial Material C1 [Gopalani, Sameer V.; Helgenberger, Louisa; Apaisam, Carter; Elias, Augustus; Barrow-Kohler, Lisa] Govt Federated States Micronesia Palikir, Dept Hlth & Social Affairs, Ponape, Micronesia. [Donre, Spencer; Johnson, Eliaser] Pohnpei State Div Primary Hlth Care, Nett Pohnpei, Micronesia. [Takiri, Keyleen; Yomai, Anamaria; Setik, Eleanor] Chuuk State Dept Hlth Serv, Chuuk, Micronesia. [Charley, Jocelyne; Taulung, Livinson] Kosrae State Dept Hlth Serv, Tofol, Kosrae, Micronesia. [Judicpa, Peter] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Nakazono, Naoki] Japan Int Cooperat Agcy, Tokyo, Japan. [Gopalani, Sameer V.] WHO, Country Liaison Off Northern Micronesia, Capitol St, FM-96941 Palikir, Pohnpei, Micronesia. RP Gopalani, SV (reprint author), WHO, Country Liaison Off Northern Micronesia, Capitol St, FM-96941 Palikir, Pohnpei, Micronesia. EM gopalani.sameer@gmail.com NR 4 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 EI 1464-3685 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD OCT PY 2016 VL 45 IS 5 BP 1394 EP 1400 DI 10.1093/ije/dyw111 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EJ4KA UT WOS:000393184400012 PM 27272184 ER PT J AU Zogg, CK Haring, RS Canner, JK AlSulaim, HA Scully, R Wolf, L Engineer, LD Haider, AH Schneider, EB AF Zogg, Cheryl K. Haring, R. Sterling Canner, Joseph K. AlSulaim, Hatim A. Scully, Rebecca Wolf, Lindsey Engineer, Lilly D. Haider, Adil H. Schneider, Eric B. TI Burden of Pediatric Traumatic Brain Injury Beyond the Emergency Department: The Untold Story of the Silent Epidemic SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 Ctr Surg & Publ Hlth, Boston, MA USA. CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S158 EP S158 PG 1 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500307 ER PT J AU Asay, GRB Roy, K Lang, JE Payne, RL Howard, DH AF Asay, Garrett R. Beeler Roy, Kakoli Lang, Jason E. Payne, Rebecca L. Howard, David H. TI Absenteeism and Employer Costs Associated With Chronic Diseases and Health Risk Factors in the US Workforce SO PREVENTING CHRONIC DISEASE LA English DT Article ID PRODUCTIVITY; WORKPLACE; OBESITY; PREVALENCE; TRENDS AB Introduction Employers may incur costs related to absenteeism among employees who have chronic diseases or unhealthy behaviors. We examined the association between employee absenteeism and 5 conditions: 3 risk factors (smoking, physical inactivity, and obesity) and 2 chronic diseases (hypertension and diabetes). Methods We identified 5 chronic diseases or risk factors from 2 data sources: MarketScan Health Risk Assessment and the Medical Expenditure Panel Survey (MEPS). Absenteeism was measured as the number of workdays missed because of sickness or injury. We used zero-inflated Poisson regression to estimate excess absenteeism as the difference in the number of days missed from work by those who reported having a risk factor or chronic disease and those who did not. Covariates included demographics (eg, age, education, sex) and employment variables (eg, industry, union membership). We quantified absenteeism costs in 2011 and adjusted them to reflect growth in employment costs to 2015 dollars. Finally, we estimated absenteeism costs for a hypothetical small employer (100 employees) and a hypothetical large employer (1,000 employees). Results Absenteeism estimates ranged from 1 to 2 days per individual per year depending on the risk factor or chronic disease. Except for the physical inactivity and obesity estimates, disease-and risk-factor- specific estimates were similar in MEPS and MarketScan. Absenteeism increased with the number of risk factors or diseases reported. Nationally, each risk factor or disease was associated with annual absenteeism costs greater than $ 2 billion. Absenteeism costs ranged from $ 16 to $ 81 (small employer) and $ 17 to $ 286 (large employer) per employee per year. Conclusion Absenteeism costs associated with chronic diseases and health risk factors can be substantial. Employers may incur these costs through lower productivity, and employees could incur costs through lower wages. C1 [Asay, Garrett R. Beeler; Roy, Kakoli; Payne, Rebecca L.] Ctr Dis Control & Prevent, Off Associate Director Policy, 1600 Clifton Rd,MS D-28, Atlanta, GA 30333 USA. [Lang, Jason E.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Howard, David H.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Asay, GRB (reprint author), Ctr Dis Control & Prevent, Off Associate Director Policy, 1600 Clifton Rd,MS D-28, Atlanta, GA 30333 USA. EM hrp9@cdc.gov FU Centers for Disease Control and Prevention Intergovernmental Personnel Act [1600867] FX We thank 2 anonymous reviewers for their comments on previous versions of this manuscript. David Howard was supported by Centers for Disease Control and Prevention Intergovernmental Personnel Act 1600867 for this work. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. The authors report no conflicts of interest relevant to this article. NR 29 TC 0 Z9 0 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2016 VL 13 AR E141 DI 10.5888/pcd13.150503 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EJ3JS UT WOS:000393109100002 PM 27710764 ER PT J AU Ansari, HR Templeton, TJ Subudhi, AK Ramaprasad, A Tang, JX Lu, F Naeem, R Hashish, Y Oguike, MC Benavente, ED Clark, TG Sutherland, CJ Barnwell, JW Culleton, R Cao, J Pain, A AF Ansari, Hifzur Rahman Templeton, Thomas J. Subudhi, Amit Kumar Ramaprasad, Abhinay Tang, Jianxia Lu, Feng Naeem, Raeece Hashish, Yasmeen Oguike, Mary C. Benavente, Ernest Diez Clark, Taane G. Sutherland, Colin J. Barnwell, John W. Culleton, Richard Cao, Jun Pain, Arnab TI Genome-scale comparison of expanded gene families in Plasmodium ovale wallikeri and Plasmodium ovale curtisi with Plasmodium malariae and with other Plasmodium species SO INTERNATIONAL JOURNAL FOR PARASITOLOGY LA English DT Article DE Plasmodium ovale spp.; Plasmodium ovale wallikeri; Plasmodium ovale curtisi; Plasmodium malariae; PIR; SURFIN; RBP-2; P25/27 ID RESPIRATORY-DISTRESS-SYNDROME; UGANDA I/CDC STRAIN; RED-BLOOD-CELL; INFECTED ERYTHROCYTES; P.-OVALE; SYMPATRIC DISTRIBUTION; PROTEIN FAMILIES; BINDING-PROTEIN; SEQUENCING DATA; FALCIPARUM AB Malaria in humans is caused by six species of Plasmodium parasites, of which the nuclear genome sequences for the two Plasmodium ovale spp., P. ovale curtisi and P. ovate wallikeri, and Plasmodium malariae have not yet been analyzed. Here we present an analysis of the nuclear genome sequences of these three parasites, and describe gene family expansions therein. Plasmodium ovale curtisi and P. ovale wallikeri are genetically distinct but morphologically indistinguishable and have sympatric ranges through the tropics of Africa, Asia and Oceania. Both P. ovale spp. show expansion of the surfin variant gene family, and an amplification of the Plasmodium interspersed repeat (pir) superfamily which results in an approximately 30% increase in genome size. For comparison, we have also analyzed the draft nuclear genome of P. malariae, a malaria parasite causing mild malaria symptoms with a quartan life cycle, long-term chronic infections, and wide geographic distribution. Plasmodium malariae shows only a moderate level of expansion of pir genes, and unique expansions of a highly diverged transmembrane protein family with over 550 members and the gamete P25/27 gene family. The observed diversity in the P. ovale wallikeri and P. ovale curtisi surface antigens, combined with their phylogenetic separation, supports consideration that the two parasites be given species status. (C) 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. C1 [Ansari, Hifzur Rahman; Subudhi, Amit Kumar; Ramaprasad, Abhinay; Naeem, Raeece; Hashish, Yasmeen; Pain, Arnab] King Abdullah Univ Sci & Technol, Biol & Environm Sci & Engn BESE Div, Pathogen Genom Lab, Jeddah 239556900, Saudi Arabia. [Templeton, Thomas J.] Nagasaki Univ, Inst Trop Med NEKKEN, Dept Protozool, 1-12-4 Sakamoto, Nagasaki 8528523, Japan. [Templeton, Thomas J.] Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA. [Tang, Jianxia; Lu, Feng; Cao, Jun] Jiangsu Inst Parasit Dis, Key Lab Natl Hlth & Family Planning Commiss Paras, Jiangsu Prov Key Lab Parasite & Vector Control Te, Wuxi, Jiangsu, Peoples R China. [Oguike, Mary C.; Sutherland, Colin J.] London Sch Hyg & Trop Med, Dept Immunol & Infect, Fac Infect & Trop Dis, London, England. [Benavente, Ernest Diez; Clark, Taane G.; Sutherland, Colin J.] London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, Fac Infect & Trop Dis, London, England. [Clark, Taane G.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Fac Epidemiol & Populat Hlth, London, England. [Sutherland, Colin J.] London Sch Hyg & Trop Med, Publ Hlth England Malaria Reference Lab, London, England. [Barnwell, John W.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Culleton, Richard] Nagasaki Univ, Inst Trop Med NEKKEN, Dept Pathol, Malaria Unit, 1-12-4 Sakamoto, Nagasaki 8528523, Japan. [Pain, Arnab] Hokkaido Univ, Global Stn Zoonosis Control, Global Inst Collaborat Res & Educ GI CoRE, Kita Ku, N20 W10, Sapporo, Hokkaido 0010020, Japan. RP Pain, A (reprint author), King Abdullah Univ Sci & Technol, Biol & Environm Sci & Engn BESE Div, Pathogen Genom Lab, Jeddah 239556900, Saudi Arabia.; Cao, J (reprint author), Jiangsu Inst Parasit Dis, Key Lab Natl Hlth & Family Planning Commiss Paras, Jiangsu Prov Key Lab Parasite & Vector Control Te, Wuxi, Jiangsu, Peoples R China.; Culleton, R (reprint author), Nagasaki Univ, Inst Trop Med NEKKEN, Dept Pathol, Malaria Unit, 1-12-4 Sakamoto, Nagasaki 8528523, Japan. EM richard@nagasaki-u.ac.jp; jipdjoe@163.com; arnab.pain@kaust.edu.sa OI Ramaprasad, Abhinay/0000-0001-9372-5526; Sutherland, Colin/0000-0003-1592-6407; Ansari, Hifzur Rahman/0000-0002-0646-1743 FU National Natural Science Foundation of China [81271870]; National Natural Science Foundation of Jiangsu Province, China [BK20150001]; King Abdullah University of Science and Technology (KAUST), Saudi Arabia; Global Institute for Collaborative Research and Education (GI-CORE) at the Research Center for Zoonosis Control, Hokkaido University, Japan; Japanese Society of Parasitology (JSPS), Japan [24255009, 25870525, 16K21233]; UK Medical Research Council [MR/L008661/1] FX TJT was supported by a visiting professorship to the Institute of Tropical Medicine, Nagasaki University, Japan. JC was supported by grants from the National Natural Science Foundation of China (No. 81271870) and the National Natural Science Foundation of Jiangsu Province, China (No. BK20150001). AP is supported by faculty baseline funding from the King Abdullah University of Science and Technology (KAUST), Saudi Arabia and the Global Institute for Collaborative Research and Education (GI-CORE) at the Research Center for Zoonosis Control, Hokkaido University, Japan. RC is supported by Japanese Society of Parasitology (JSPS), Japan Grant-in-Aid for Scientific Research Nos. 24255009, 25870525 and 16K21233. MCO, EDB, TGC and CJS are supported by UK Medical Research Council Project Grant MR/L008661/1 to CJS. The authors thank the staff of the Bioscience Core Laboratory in KAUST for sequencing the DNA libraries. Osamu Kaneko is thanked for discussions and critical reading of the manuscript. NR 89 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-7519 EI 1879-0135 J9 INT J PARASITOL JI Int. J. Parasit. PD OCT PY 2016 VL 46 IS 11 BP 685 EP 696 DI 10.1016/j.ijpara.2016.05.009 PG 12 WC Parasitology SC Parasitology GA EI5VE UT WOS:000392563600002 PM 27392654 ER PT J AU Smit, MR Ochomo, E Aljayyoussi, G Kwambai, T Abong'o, B Bayoh, N Gimnig, J Samuels, A Desai, M Phillips-Howard, PA Kariuki, S Wang, DL Ward, S ter Kuile, FO AF Smit, Menno R. Ochomo, Eric Aljayyoussi, Ghaith Kwambai, Titus Abong'o, Bernard Bayoh, Nabie Gimnig, John Samuels, Aaron Desai, Meghna Phillips-Howard, Penelope A. Kariuki, Simon Wang, Duolao Ward, Steve ter Kuile, Feiko O. TI Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya SO JMIR RESEARCH PROTOCOLS LA English DT Article DE malaria; Plasmodium falciparum; ivermectin; dihydroartemisinin-piperaquine; Anopheles gambiae s.s.; insecticide; clinical trial; pharmacokinetics; Kenya; study protocol ID ONCHOCERCA-VOLVULUS; ANOPHELES-GAMBIAE; PLASMODIUM-FALCIPARUM; MASS TREATMENT; PHARMACOKINETICS; MEDICINE; VECTOR; IMPACT AB Background: Innovative approaches are needed to complement existing tools for malaria elimination. Ivermectin is a broad spectrum antiparasitic endectocide clinically used for onchocerciasis and lymphatic filariasis control at single doses of 150 to 200 mcg/kg. It also shortens the lifespan of mosquitoes that feed on individuals recently treated with ivermectin. However, the effect after a 150 to 200 mcg/kg oral dose is short-lived (6 to 11 days). Modeling suggests higher doses, which prolong the mosquitocidal effects, are needed to make a significant contribution to malaria elimination. Ivermectin has a wide therapeutic index and previous studies have shown doses up to 2000 mcg/kg (ie, 10 times the US Food and Drug Administration approved dose) are well tolerated and safe; the highest dose used for onchocerciasis is a single dose of 800 mcg/kg. Objective: The aim of this study is to determine the safety, tolerability, and efficacy of ivermectin doses of 0, 300, and 600 mcg/kg/day for 3 days, when provided with a standard 3-day course of the antimalarial dihydroartemisinin-piperaquine (DP), on mosquito survival. Methods: This is a double-blind, randomized, placebo-controlled, parallel-group, 3-arm, dose-finding trial in adults with uncomplicated malaria. Monte Carlo simulations based on pharmacokinetic modeling were performed to determine the optimum dosing regimens to be tested. Modeling showed that a 3-day regimen of 600 mcg/kg/day achieved similar median (5 to 95 percentiles) maximum drug concentrations (Cmax) of ivermectin to a single of dose of 800 mcg/kg, while increasing the median time above the lethal concentration 50% (LC50, 16 ng/mL) from 1.9 days (1.0 to 5.7) to 6.8 (3.8 to 13.4) days. The 300 mcg/kg/day dose was chosen at 50% of the higher dose to allow evaluation of the dose response. Mosquito survival will be assessed daily up to 28 days in laboratory-reared Anopheles gambiae s.s. populations fed on patients' blood taken at days 0, 2 (Cmax), 7 (primary outcome), 10, 14, 21, and 28 after the start of treatment. Safety outcomes include QT-prolongation and mydriasis. The trial will be conducted in 6 health facilities in western Kenya and requires a sample size of 141 participants (47 per arm). Sub-studies include (1) rich pharmacokinetics and (2) direct skin versus membrane feeding assays. Results: Recruitment started July 20, 2015. Data collection was completed July 2, 2016. Unblinding and analysis will commence once the database has been completed, cleaned, and locked. Conclusions: High-dose ivermectin, if found to be safe and well tolerated, might offer a promising new tool for malaria elimination. C1 [Smit, Menno R.; Aljayyoussi, Ghaith; Phillips-Howard, Penelope A.; Wang, Duolao; Ward, Steve; ter Kuile, Feiko O.] Univ Liverpool Liverpool Sch Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England. [Ochomo, Eric; Kwambai, Titus; Abong'o, Bernard; Kariuki, Simon] Kenya Med Res Inst KEMRI, Ctr Global Hlth Res, Kisumu, Kenya. [Kwambai, Titus] Kenya Minist Hlth MoH, Kisumu Cty, Kisumu, Kenya. [Bayoh, Nabie; Gimnig, John; Samuels, Aaron; Desai, Meghna] US Ctr Dis Control & Prevent CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Smit, MR (reprint author), Univ Liverpool Liverpool Sch Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England. EM menno.smit@lstmed.ac.uk OI Smit, Menno/0000-0003-3405-6638; Ochomo, Eric/0000-0002-4042-4970 FU Malaria Eradication Scientific Alliance (MESA); Bill and Melinda Gates Foundation (BMGF) FX This study is funded by the Malaria Eradication Scientific Alliance (MESA), through a sub-grant from the Bill and Melinda Gates Foundation (BMGF). Neither MESA nor the BMGF has or will have any role in the design of the study, the collection, analysis, and interpretation of data, or in the writing the manuscript. NR 36 TC 0 Z9 0 U1 3 U2 3 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1929-0748 J9 JMIR RES PROTOC JI JMIR RES. Protoc. PD OCT-DEC PY 2016 VL 5 IS 4 AR e213 DI 10.2196/resprot.6617 PG 15 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EG4VR UT WOS:000391042300016 PM 27856406 ER PT J AU Allen, J Mansergh, G Herbst, J Mimiaga, M Denson, D Pitts, N Holman, J AF Allen, Jacob Mansergh, Gordon Herbst, Jeff Mimiaga, Matthew Denson, Damian Pitts, Nicole Holman, Jeremy TI MOBILE PHONE AND INTERNET SEX SEEKING: ASSOCIATIONS WITH RECENT STIs AMONG AFRICAN AMERICAN/BLACK AND LATINO MSM SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Allen, Jacob; Mansergh, Gordon; Denson, Damian] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Herbst, Jeff] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. [Mimiaga, Matthew] Brown Univ, Providence, RI 02912 USA. [Pitts, Nicole] ICF Int, Atlanta, GA USA. [Holman, Jeremy] Hlth Resources Act, Boston, MA USA. EM lax9@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 54 BP S170 EP S170 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900162 ER PT J AU Apostolou, A McCollum, J Person, M AF Apostolou, Andria McCollum, Jeffrey Person, Marissa TI USING ELECTRONIC HEALTH RECORDS TO EXAMINE RATES OF CHLAMYDIA AMONG AMERICAN INDIANS AND ALASKA NATIVES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Apostolou, Andria; McCollum, Jeffrey] Indian Hlth Serv, Div Epidemiol & Dis Prevent, Rockville, MD USA. [Person, Marissa] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. EM andria.apostolou@ihs.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 32 BP S163 EP S164 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900140 ER PT J AU Bakshi, R Gupta, K Brown, L Jordan, S Press, C Gorwitz, RJ Papp, J Geisler, W AF Bakshi, Rakesh Gupta, Kanupriya Brown, LaDraka Jordan, Stephen Press, Christen Gorwitz, Rachel J. Papp, John Geisler, William TI INVESTIGATING THE CLASSIFICATION OF SPONTANEOUS RESOLUTION OF CHLAMYDIA TRACHOMATIS INFECTION USING AN IMMUNOGLOBULIN-BASED MOLECULAR APPROACH SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Bakshi, Rakesh; Gupta, Kanupriya; Brown, LaDraka; Jordan, Stephen; Press, Christen; Geisler, William] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA. [Gorwitz, Rachel J.; Papp, John] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM rkb247@uab.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 116 BP S224 EP S224 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900356 ER PT J AU Barrow, R Workowski, K McKenzie, S Hogben, M Hoover, K Ham, DC Ahmed, F AF Barrow, Roxanne Workowski, Kimberly McKenzie, Sheila Hogben, Matthew Hoover, Karen Ham, D. Cal Ahmed, Faruque TI NEW CDC RECOMMENDATIONS FOR PROVIDING QUALITY STD CLINICAL SERVICES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Barrow, Roxanne; McKenzie, Sheila; Hogben, Matthew; Ahmed, Faruque] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Workowski, Kimberly] Emory Univ, Div Infect Dis, Atlanta, GA 30322 USA. [Hoover, Karen; Ham, D. Cal] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. EM rrb6@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 40 BP S165 EP S166 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900148 ER PT J AU Barton, J Madera, RT Bauer, H Nguyen, TQ Kohn, RP Hawrusik, R Klingler, E Han, E Bell, T Schumacher, C Stenger, M AF Barton, Jerusha Madera, Robbie Therese Bauer, Heidi Nguyen, Trang Q. Kohn, Robert P. Hawrusik, Rebecca Klingler, Ellen Han, Emily Bell, Teal Schumacher, Christina Stenger, Mark TI CONTRIBUTION OF REPEAT INFECTIONS TO THE GONORRHEA BURDEN IN THE STD SURVEILLANCE NETWORK (SSUN) SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Barton, Jerusha; Stenger, Mark] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Madera, Robbie Therese] Philadelphia Dept Publ Hlth, Div Dis Control, Philadelphia, PA USA. [Bauer, Heidi; Han, Emily] Calif Dept Publ Hlth, Sexually Transmitted Dis Control Branch, Richmond, CA USA. [Nguyen, Trang Q.; Kohn, Robert P.] San Francisco Dept Publ Hlth, Appl Res Community Hlth Epidemiol & Surveillance, Populat Hlth Div, San Francisco, CA USA. [Hawrusik, Rebecca] Massachusetts Dept Publ Hlth, Div STD Prevent, Jamaica Plain, MA USA. [Klingler, Ellen] New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, Long Isl City, NY USA. [Bell, Teal] Washington State Dept Hlth, Infect Dis Assessment Unit, Olympia, WA USA. [Schumacher, Christina] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA. EM kno1@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 94 BP S218 EP S218 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900334 ER PT J AU Becker, M Cheuk, E Gichangi, P Blanchard, J Aral, S Musyoki, H Bhattacharjee, P Isac, S Pavlova, D Balakireva, O Mishra, S AF Becker, Marissa Cheuk, Eve Gichangi, Peter Blanchard, James Aral, Sevgi Musyoki, Helgar Bhattacharjee, Parinita Isac, Shajy Pavlova, Daria Balakireva, Olga Mishra, Sharmistha TI RISKY FIRST SEX AMONG YOUNG WOMEN ENGAGED IN CASUAL, TRANSACTIONAL, AND FORMAL SEX WORK IN MOMBASA, KENYA SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Becker, Marissa; Cheuk, Eve; Blanchard, James] Univ Manitoba, Dept Community Hlth Sci, Ctr Global Publ Hlth, Winnipeg, MB, Canada. [Gichangi, Peter] Int Ctr Reprod Hlth Kenya, Nairobi, Kenya. [Aral, Sevgi] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Musyoki, Helgar] Natl AIDS & STI Control Programme, Nairobi, Kenya. [Bhattacharjee, Parinita] Univ Manitoba, Nairobi, Kenya. [Isac, Shajy] Karnataka Hlth Promot Trust, Bangalore, Karnataka, India. [Pavlova, Daria; Balakireva, Olga] Ukrainian Inst Social Res, Kiev, Ukraine. [Mishra, Sharmistha] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada. EM marissa.becker@umanitoba.ca NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 17 BP S159 EP S159 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900125 ER PT J AU Beltran, O Kachur, R Caccamo, A Habel, M AF Beltran, Oscar Kachur, Rachel Caccamo, Alexandra Habel, Melissa TI THE ROLE OF RELIGIOSITY ON SEXUAL BEHAVIORS AND THE PREVENTION OF STDs AMONG A NATIONALLY-REPRESENTATIVE SAMPLE OF ADOLESCENTS AND YOUNG ADULTS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Beltran, Oscar; Kachur, Rachel; Caccamo, Alexandra; Habel, Melissa] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM ybp8@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 33 BP S201 EP S201 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900273 ER PT J AU Bowen, V Lupoli, K Chipungu, G Danavall, D Chiwaula, M Nachamkin, E Chen, CY Routh, J Kamb, ML AF Bowen, Virginia Lupoli, Kathryn Chipungu, Geoffrey Danavall, Damien Chiwaula, Mabvuto Nachamkin, Eli Chen, Cheng Y. Routh, Janell Kamb, Mary L. TI A BUNDLE OF HEALTH: SYPHILIS TEST PERFORMANCE IN THE FIELD EVALUATION OF A NOVEL DUAL HIV/SYPHILIS RAPID TEST-MALAWI, 2014-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Bowen, Virginia; Danavall, Damien; Nachamkin, Eli; Chen, Cheng Y.; Kamb, Mary L.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Lupoli, Kathryn] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. [Chipungu, Geoffrey] Ctr Dis Control & Prevent, Div Global HIV AIDS, Lilongwe, Malawi. [Chiwaula, Mabvuto] Malawi Minist Hlth, Community Hlth Sci Unit, Lilongwe, Malawi. [Routh, Janell] Adm Children & Families, Washington, DC USA. EM xef3@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 113 BP S223 EP S223 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900353 ER PT J AU Brener, N Kann, L AF Brener, Nancy Kann, Laura TI SEXUALLY TRANSMITTED DISEASE (STD) PREVENTION EDUCATION AND SERVICES IN A NATIONALLY REPRESENTATIVE SAMPLE OF SCHOOLS - UNITED STATES, 2014 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Brener, Nancy; Kann, Laura] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. EM nad1@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 2C1 BP S133 EP S134 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900034 ER PT J AU Brookmeyer, K Beltran, O Abad, N AF Brookmeyer, Kate Beltran, Oscar Abad, Neetu TI UNDERSTANDING HOW SEXUAL COERCION AFFECTS STD TREATMENT PATHWAYS: FINDINGS FROM THE NATIONAL SURVEY OF FAMILY GROWTH (2011-2013) SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Brookmeyer, Kate; Beltran, Oscar; Abad, Neetu] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM guu1@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 6C2 BP S153 EP S153 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900103 ER PT J AU Brown, V Matthias, J AF Brown, Veronica Matthias, James TI CONGENITAL SYPHILIS IN FLORIDA: IDENTIFYING AT-RISK POPULATIONS IN A HIGH MORBIDITY STATE SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Brown, Veronica] Florida Dept Hlth, STD & Viral Hepatitis Sect, Bur Communicable Dis, Tallahassee, FL USA. [Matthias, James] Ctr Dis Control & Prevent, Epidemiol & Stat Branch, Div STD Prevent, Tallahassee, FL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 127 BP S190 EP S191 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900235 ER PT J AU Brown, V Matthias, J Alam, N AF Brown, Veronica Matthias, James Alam, Nushrat TI ARE THERE INCREASES IN SYPHILIS AMONG HETEROSEXUAL MEN IN FLORIDA? SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Brown, Veronica; Alam, Nushrat] Florida Dept Hlth, Bur Communicable Dis, STD & Viral Hepatitis Sect, Tallahassee, FL USA. [Matthias, James] Ctr Dis Control & Prevent, Div STD Prevent, Tallahassee, FL USA. EM veronica.brown2@flhealth.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 77 BP S176 EP S176 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900185 ER PT J AU Brown, V Matthias, J AF Brown, Veronica Matthias, James TI HIGH RATES OF STD AMONG MEN LIVING AT A SINGLE RESIDENCE SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Brown, Veronica] Florida Dept Hlth, STD & Viral Hepatitis Sect, Bur Communicable Dis, Tallahassee, FL USA. [Matthias, James] Ctr Dis Control & Prevent, Div STD Prevent, Tallahassee, FL USA. EM veronica.brown2@flhealth.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 4C5 BP S144 EP S144 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900072 ER PT J AU Caccamo, A Torrone, E Carter, M Hogben, M Aral, S AF Caccamo, Alexandra Torrone, Elizabeth Carter, Marion Hogben, Matthew Aral, Sevgi TI ANALYZING ABSTRACTS FROM THE 2014 STD PREVENTION CONFERENCE: ASSESSMENT OF THE STATE OF THE SCIENCE SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Caccamo, Alexandra; Torrone, Elizabeth; Carter, Marion; Hogben, Matthew; Aral, Sevgi] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM yfu3@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 93 BP S218 EP S218 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900333 ER PT J AU Caccamo, A Kachur, R Williams, SP AF Caccamo, Alexandra Kachur, Rachel Williams, Samantha P. TI STDs AND HOMELESS YOUTH - WHAT DO WE KNOW ABOUT STD PREVALENCE AND RISK? SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Caccamo, Alexandra; Kachur, Rachel; Williams, Samantha P.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM yfu3@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 4 BP S155 EP S156 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900112 ER PT J AU Caccamo, A Habel, M Beltran, O Becasen, J Pearson, W Dittus, P AF Caccamo, Alexandra Habel, Melissa Beltran, Oscar Becasen, Jeffrey Pearson, William Dittus, Patricia TI MAKING THE GRADE: ASSESSING THE PROVISION OF SEXUAL HEALTH SERVICES AT US COLLEGES AND UNIVERSITIES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Caccamo, Alexandra; Habel, Melissa; Beltran, Oscar; Pearson, William; Dittus, Patricia] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Becasen, Jeffrey] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. EM yfu3@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 2C4 BP S134 EP S134 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900037 ER PT J AU Castro, M Braunstein, S Blank, S Borges, C AF Castro, Michael Braunstein, Sarah Blank, Sue Borges, Christine TI DISCREPANT MEASURES OF HIV LINKAGE RATES: HIV SURVEILLANCE VERSUS MEDICAL RECORD DATA NEW YORK CITY (NYC) HEALTH DEPARTMENT SEXUALLY TRANSMITTED DISEASE (STD) CLINICS, 2014 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Castro, Michael; Borges, Christine] Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA. [Braunstein, Sarah] HIV Epidemiol & Field Serv, New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA. [Blank, Sue] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. EM mcastro3@health.nyc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 2A3 BP S131 EP S131 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900026 ER PT J AU Chavez, P Peters, P Wesolowski, L Johnson, C Nasrullah, M Oraka, E August, E DiNenno, E AF Chavez, Pollyanna Peters, Philip Wesolowski, Laura Johnson, Christopher Nasrullah, Muazzam Oraka, Emeka August, Euna DiNenno, Elizabeth TI HOW ARE US PRIMARY CARE PROVIDERS ASSESSING WHETHER THEIR MALE PATIENT HAS MALE SEX PARTNERS? SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Chavez, Pollyanna; Peters, Philip; Wesolowski, Laura; Johnson, Christopher; Nasrullah, Muazzam; August, Euna; DiNenno, Elizabeth] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Oraka, Emeka] ICF Int, Atlanta, GA USA. EM geo5@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 59 BP S171 EP S171 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900167 ER PT J AU Cheng, Q Moore, A Stein, R Williams, W Uhl, G AF Cheng, Qi Moore, Andrea Stein, Renee Williams, Weston Uhl, Gary TI CONDOM USE AMONG MEN WHO HAVE SEX WITH MEN RECEIVING SERVICES AT FOUR CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDED COMMUNITY-BASED ORGANIZATIONS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Cheng, Qi] Karna LLC, Atlanta, GA USA. [Moore, Andrea; Stein, Renee; Uhl, Gary] Ctr Dis Control & Prevent, Div HIV STD Prevent, Atlanta, GA USA. [Williams, Weston] Publ Hlth Analyt Consulting Serv Inc, Miami, FL USA. EM ycx6@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 74 BP S175 EP S175 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900182 ER PT J AU Chesson, H Torrone, E Gift, T Peterman, T AF Chesson, Harrell Torrone, Elizabeth Gift, Thomas Peterman, Thomas TI THE EXPECTED LIFETIME COST OF CHLAMYDIA AND GONORRHEA PER INFANT BORN IN THE UNITED STATES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Chesson, Harrell; Torrone, Elizabeth; Gift, Thomas; Peterman, Thomas] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM hbc7@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 122 BP S226 EP S226 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900362 ER PT J AU Chesson, H Kirkcaldy, B Gift, T Weinstock, HS AF Chesson, Harrell Kirkcaldy, Bob Gift, Thomas Weinstock, Hillard S. TI THE ESTIMATED MEDICAL COSTS AVERTED BY MAINTAINING THE PREVALENCE OF CEFTRIAXONE-RESISTANT NEISSERIA GONORRHOEAE BELOW 2% IN ACCORDANCE WITH THE TARGETS OF THE NATIONAL STRATEGY FOR COMBATING ANTIBIOTIC RESISTANT BACTERIA SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Chesson, Harrell; Kirkcaldy, Bob; Gift, Thomas; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM hbc7@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 96 BP S219 EP S219 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900336 ER PT J AU Cheuk, E Mishra, S Gichangi, P Blanchard, J Aral, S Musyoki, H Bhattacharjee, P Isac, S Mountain, E Pickles, M Boily, MC Pavlova, D Balakireva, O Becker, M AF Cheuk, Eve Mishra, Sharmistha Gichangi, Peter Blanchard, James Aral, Sevgi Musyoki, Helgar Bhattacharjee, Parinita Isac, Shajy Mountain, Elisa Pickles, Michael Boily, Marie-Claude Pavlova, Daria Balakireva, Olga Becker, Marissa TI SUBSTANCE USE AND EXPERIENCE OF VIOLENCE AMONG YOUNG WOMEN ENGAGED IN CASUAL, TRANSACTIONAL, AND FORMAL SEX WORK IN MOMBASA, KENYA SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Cheuk, Eve; Blanchard, James; Becker, Marissa] Univ Manitoba, Dept Community Hlth Sci, Ctr Global Publ Hlth, Winnipeg, MB, Canada. [Mishra, Sharmistha] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada. [Gichangi, Peter] Int Ctr Reprod Hlth Kenya, Mombasa, Kenya. [Aral, Sevgi] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Musyoki, Helgar] Natl AIDS & STI Control Programme, Nairobi, Kenya. [Bhattacharjee, Parinita] Univ Manitoba, Nairobi, Kenya. [Isac, Shajy] Karnataka Hlth Promot Trust, Bangalore, Karnataka, India. [Mountain, Elisa; Pickles, Michael; Boily, Marie-Claude] Imperial Coll London, Dept Infect Dis Epidemiol, Sch Publ Hlth, London, England. [Pavlova, Daria; Balakireva, Olga] Ukrainian Inst Social Res, Kiev, Ukraine. EM eve.cheuk@umanitoba.ca NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 11 BP S157 EP S158 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900119 ER PT J AU Choden, T Hennessy, R AF Choden, Tsering Hennessy, Robin TI EVALUATING THE CLASSIFICATION OF CONGENITAL SYPHILIS INVESTIGATIONS IN NYC, 2012 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Choden, Tsering] Bur Mental Hlth, Long Isl City, NY USA. [Hennessy, Robin] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM tchoden@health.nyc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 5C3 BP S148 EP S149 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900087 ER PT J AU Cope, A Mobley, V Larson, M Peterman, T Samoff, E AF Cope, Anna Mobley, Victoria Larson, Mara Peterman, Thomas Samoff, Erika TI IMMEDIATE TREATMENT IN EARLY SYPHILIS: AN OPPORTUNITY TO PREVENT TRANSMISSION SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Cope, Anna; Peterman, Thomas] Ctr Dis Control & Prevent, Epidemiol & Stat Branch, Div STD Prevent, Atlanta, GA USA. [Mobley, Victoria; Larson, Mara; Samoff, Erika] North Carolina Div Publ Hlth, Communicable Dis Branch, Raleigh, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 102 BP S183 EP S183 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900210 ER PT J AU Corrado, R Hennessy, R Lee, D Klingler, E Varma, J Vora, N AF Corrado, Rachel Hennessy, Robin Lee, David Klingler, Ellen Varma, Jay Vora, Neil TI UTILIZING DATA FROM A REGIONAL HEALTH INFORMATION ORGANIZATION (RHIO) TO SUPPORT GONORRHEA SURVEILLANCE - BRONX, 2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Corrado, Rachel; Lee, David] New York City Dept Hlth & Mental Hyg, Dis Control Adm, Long Isl City, NY USA. [Hennessy, Robin] Ctr Dis Control & Prevent, Atlanta, GA USA. [Klingler, Ellen] New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, Long Isl City, NY USA. [Varma, Jay] NYC Dept Hlth & Mental Hyg, Div Dis Control, Long Isl City, NY USA. [Vora, Neil] Ctr Dis Control & Prevent, Long Isl City, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 3C4 BP S139 EP S139 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900054 ER PT J AU Cuffe, K Habel, M Caccamo, A Beltran, O Leichliter, J AF Cuffe, Kendra Habel, Melissa Caccamo, Alexandra Beltran, Oscar Leichliter, Jami TI COLLEGE STUDENT HEALTH CARE COSTS, INSURANCE COVERAGE, AND MEASURES TO PROTECT CONFIDENTIALITY FOR SEXUALLY TRANSMITTED DISEASE SERVICES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Cuffe, Kendra; Habel, Melissa; Caccamo, Alexandra; Beltran, Oscar; Leichliter, Jami] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM kkn2@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 13 BP S196 EP S196 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900253 ER PT J AU de Voux, A Kidd, S Grey, J Rosenberg, E Gift, T Weinstock, HS Bernstein, K AF de Voux, Alex Kidd, Sarah Grey, Jeremy Rosenberg, Eli Gift, Thomas Weinstock, Hillard S. Bernstein, Kyle TI RATES OF PRIMARY AND SECONDARY SYPHILIS BY STATE AMONG MEN WHO HAVE SEX WITH MEN - UNITED STATES, 2014 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [de Voux, Alex; Kidd, Sarah; Gift, Thomas; Weinstock, Hillard S.; Bernstein, Kyle] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Grey, Jeremy; Rosenberg, Eli] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. EM yxj3@cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 4B1 BP S142 EP S142 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900063 ER PT J AU Demissie, Z Clayton, H Dunville, R AF Demissie, Zewditu Clayton, Heather Dunville, Richard TI IS CONTRACEPTIVE METHOD ASSOCIATED WITH HIV TESTING AMONG HIGH SCHOOL STUDENTS? - UNITED STATES, 2013 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Demissie, Zewditu; Clayton, Heather; Dunville, Richard] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. EM izj5@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 12 BP S158 EP S158 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900120 ER PT J AU Deutsch, J AF Deutsch, John TI DEVELOPMENT OF AN ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) FOR THE DETECTION OF NONTREPONEMAL ANTI-CARDIOLIPIN ANTIBODIES IN THE SERA OF PATIENTS WITH SYPHILIS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Deutsch, John] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM xgp7@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 98 BP S219 EP S219 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900338 ER PT J AU DiOrio, D Broussard, D Ross, A AF DiOrio, Dawne Broussard, Dawn Ross, Amara TI ESTIMATING THE IMPACT OF PUBLIC HEALTH ADVISORS AND STATE DIS IN RESOLVING INDIANA'S HIV OUTBREAK SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [DiOrio, Dawne] Ctr Dis Control & Prevent, Indiana State Dept Hlth, Div STD Prevent, Indianapolis, IN USA. [Broussard, Dawn] Ctr Dis Control & Prevent, Div STD Prevent, Chicago, IL USA. [Ross, Amara] Indiana State Dept Hlth, Epidemiol Resource Ctr, STD Program, Indianapolis, IN 46202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 94 BP S181 EP S181 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900202 ER PT J AU Elliott, R AF Elliott, Richard TI STD/HIV CRIMINALIZATION AND INCARCERATION-RELATED POLICIES: WHAT IS THE IMPACT ON STD PREVENTION? SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Elliott, Richard] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 2D BP S135 EP S135 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900039 ER PT J AU Elmore, L Ludovic, J Pitasi, M Poromon, L AF Elmore, Lori Ludovic, Jennifer Pitasi, Marc Poromon, Lydia TI AAPPS AND STD SAFETY NET CLINICAL PREVENTIVE SERVICES: A SUMMARY OF THE 2014 STD AAPPS ADMINISTRATIVE REPORTING RESULTS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Elmore, Lori; Ludovic, Jennifer; Poromon, Lydia] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Pitasi, Marc] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 110 BP S185 EP S186 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900218 ER PT J AU Flagg, EW AF Flagg, Elaine W. TI PREVALENCE OF ANOGENITAL WARTS AMONG PARTICIPANTS IN PRIVATE HEALTH PLANS IN THE UNITED STATES, 2006-2014: POTENTIAL IMPACT OF HPV VACCINATION SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Flagg, Elaine W.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM ewf2@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 1A1 BP S126 EP S126 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900007 ER PT J AU Folaranmi, T Whaley, M Kamiya, H MacNeil, J Kretz, C Blain, A Ngai, S Winter, K Pacilli, M Wang, X Bowen, V Patel, M Martin, SW Misegades, L Meyer, S AF Folaranmi, Temitope Whaley, Melissa Kamiya, Hajime MacNeil, Jessica Kretz, Cecilia Blain, Amy Ngai, Stephanie Winter, Kathleen Pacilli, Massimo Wang, Xin Bowen, Virginia Patel, Manisha Martin, Stacey W. Misegades, Lara Meyer, Sarah TI MENINGOCOCCAL DISEASE RISK AMONG MEN WHO HAVE SEX WITH MEN - UNITED STATES, 2012-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Folaranmi, Temitope; Whaley, Melissa; MacNeil, Jessica; Kretz, Cecilia; Blain, Amy; Wang, Xin; Martin, Stacey W.; Meyer, Sarah] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA. [Kamiya, Hajime] Natl Inst Hlth & Nutr, Tokyo, Japan. [Ngai, Stephanie] NYC Dept Hlth & Mental Hyg, New York, NY USA. [Winter, Kathleen] Calif Dept Publ Hlth, Immunizat Branch, Richmond, VA USA. [Pacilli, Massimo] Chicago Dept Publ Hlth, Chicago, IL USA. [Patel, Manisha] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Bowen, Virginia] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Misegades, Lara] HHS ACF Off Refugee Resettlement, Washington, DC USA. EM topefolaranmi@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 80 BP S177 EP S177 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900188 ER PT J AU Friedman, A Witbart, L Arrindel, D Wyand, F Barclay, L AF Friedman, Allison Witbart, Lauren Arrindel, Deborah Wyand, Fred Barclay, Lynn TI TOOLS AND INSIGHTS FOR REACHING YOUNG AFRICAN AMERICAN MEN WITH SEXUAL HEALTH MESSAGING SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Friedman, Allison] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Witbart, Lauren] Ctr Dis Control & Prevent, Off Associate Director Commun, Atlanta, GA USA. [Arrindel, Deborah; Wyand, Fred; Barclay, Lynn] Amer Sexual Hlth Assoc, Res Triangle Pk, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 52 BP S206 EP S207 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900292 ER PT J AU Friedman, A Harper, C Habel, M Hogben, M McFarlane, M Brookmeyer, K Kachur, R AF Friedman, Allison Harper, Christopher Habel, Melissa Hogben, Matthew McFarlane, Mary Brookmeyer, Kate Kachur, Rachel TI ARE STD CAMPAIGNS HAVING A PERCEIVED IMPACT ON YOUTH'S ATTITUDES, NORMS AND BEHAVIORS? SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Friedman, Allison; Habel, Melissa; Hogben, Matthew; McFarlane, Mary; Brookmeyer, Kate; Kachur, Rachel] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Harper, Christopher] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. EM alf8@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 6B3 BP S152 EP S152 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900099 ER PT J AU Furness, BW Apostolou, A Hirsch, S Salgado, RV Cicchinelli, M Gayles, T Kharfen, M AF Furness, Bruce W. Apostolou, Andria Hirsch, Shawn Salgado, Raydel Valdes Cicchinelli, Marty Gayles, Travis Kharfen, Michael TI CAN PUBLICLY-FUNDED SPECIALTY CLINICS PROVIDE MEDICAL HOMES FOR UNDERSERVED AT-RISK COMMUNITITIES IN THE ERA OF EXPANDED MEDICAID AND AFFORDABLE CARE ACT? SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Furness, Bruce W.] Ctr Dis Control & Prevent, DC DOH HIV AIDS Hepatitis STD & TB Adm, Div STD TB Control, DSTDP, Washington, DC USA. [Apostolou, Andria; Hirsch, Shawn; Salgado, Raydel Valdes; Cicchinelli, Marty] SciMetrika LLC, Durham, NC USA. [Gayles, Travis; Kharfen, Michael] DC Dept Hlth, HIV AIDS Hepatitis STD & TB Adm, Washington, DC USA. EM bff0@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 31 BP S201 EP S201 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900271 ER PT J AU Furness, BW Newman, DR Foster, B Troutman, K Urquilla, V Gayles, T Kharfen, M AF Furness, Bruce W. Newman, Daniel R. Foster, Bethany Troutman, Kenya Urquilla, Veronica Gayles, Travis Kharfen, Michael TI MEASURING THE IMPACT OF SCHOOL-BASED STD SCREENING, WASHINGTON, DC, 2013-2014 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Furness, Bruce W.; Foster, Bethany; Troutman, Kenya; Urquilla, Veronica; Gayles, Travis; Kharfen, Michael] DC DOH, HIV AIDS Hepatitis STD & TB Adm, Washington, DC USA. [Furness, Bruce W.; Gayles, Travis] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Newman, Daniel R.] Ctr Dis Control & Prevent, Epidemiol & Stat, Atlanta, GA USA. EM bff0@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 18 BP S197 EP S197 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900258 ER PT J AU Furness, BW Troutman, K Urquilla, V Gayles, T Kharfen, M AF Furness, Bruce W. Troutman, Kenya Urquilla, Veronica Gayles, Travis Kharfen, Michael TI INCORPORATING AND SUSTAINING HIV TESTING IN AN ESTABLISHED SCHOOL-BASED STD SCREENING PROGRAM SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Furness, Bruce W.] Ctr Dis Control & Prevent, DC DOH HIV AIDS Hepatitis STD & TB Adm, Div STD TB Control, Div STD Prevent, Washington, DC USA. [Troutman, Kenya; Urquilla, Veronica; Gayles, Travis; Kharfen, Michael] HIV AIDS Hepatitis STD & TB Adm, DC Dept Hlth, Washington, DC USA. EM bff0@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 2C2 BP S134 EP S134 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900035 ER PT J AU Gasiorowicz, M Stockman, L Schumann, C Kufalk, B Shrestha, D Reitl, I Oyervides, O AF Gasiorowicz, Mari Stockman, Lauren Schumann, Casey Kufalk, Brandon Shrestha, Dhana Reitl, Irmine Oyervides, Otilio TI INVESTIGATION OF LARGE NETWORKS OF HIV/SYPHILIS CASES IN YOUNG BLACK MEN WHO HAVE SEX WITH MEN (MSM) IN MILWAUKEE AND FOLLOW-UP BY DISEASE INTERVENTION SPECIALISTS (DIS) SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Gasiorowicz, Mari; Shrestha, Dhana] Wisconsin Div Publ Hlth, AIDS HIV Program, Madison, WI USA. [Stockman, Lauren] Wisconsin Div Publ Hlth, Hepatitis Program C, Madison, WI USA. [Schumann, Casey] AIDS HIV Program, Madison, WI USA. [Kufalk, Brandon] Wisconsin Div Publ Hlth, STD Program, Madison, WI USA. [Reitl, Irmine] City Milwaukee Hlth Dept, Keenean STD Clin, Milwaukee, WI USA. [Oyervides, Otilio] Milwaukee Hlth Dept, Ctr Dis Control & Prevent, Keenan STD Clin, Milwaukee, WI USA. EM mari.gasiorowicz@wi.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 78 BP S176 EP S177 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900186 ER PT J AU Gorwitz, RJ An, Q Hoots, B Bernstein, K Paz-Bailey, G AF Gorwitz, Rachel J. An, Qian Hoots, Brooke Bernstein, Kyle Paz-Bailey, Gabriela TI SELF-REPORTED HISTORY OF CHLAMYDIA TESTING IN HETEROSEXUAL WOMEN AT INCREASED RISK FOR HIV INFECTION - NATIONAL HIV BEHAVIORAL SURVEILLANCE (NHBS), 2013 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Gorwitz, Rachel J.; Bernstein, Kyle] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [An, Qian; Hoots, Brooke; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. EM RGorwitz@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 124 BP S226 EP S226 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900364 ER PT J AU Gorwitz, RJ Chen, PL Wiesenfeld, HC Hammond, KR Sereday, KA Haggerty, CL Johnson, RE Papp, J Kissin, DM Henning, TC Hook, N Steinkampf, MP Markowitz, L Geisler, W AF Gorwitz, Rachel J. Chen, Pai Lien Wiesenfeld, Harold C. Hammond, Karen R. Sereday, Karen A. Haggerty, Catherine L. Johnson, Robert E. Papp, John Kissin, Dmitry M. Henning, Tara C. Hook, Ned, III Steinkampf, Michael P. Markowitz, Lauri Geisler, William TI CHLAMYDIA TRACHOMATIS SEROPREVALENCE AND FRACTION OF TUBAL FACTOR INFERTILITY ATTRIBUTABLE TO CHLAMYDIA AMONG FEMALE PATIENTS AT TWO US INFERTILITY PRACTICES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Gorwitz, Rachel J.; Sereday, Karen A.; Johnson, Robert E.; Papp, John; Henning, Tara C.; Markowitz, Lauri] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Chen, Pai Lien] FHI360, Durham, NC USA. [Wiesenfeld, Harold C.] Univ Pittsburgh, Sch Med, Magee Womens Hosp, Div Gynecol Specialties,UPMC, Pittsburgh, PA USA. [Wiesenfeld, Harold C.] Univ Pittsburgh, Sch Med, Magee Womens Hosp, Div Reprod Infect Dis & Immunol,UPMC, Pittsburgh, PA USA. [Hammond, Karen R.; Steinkampf, Michael P.] Alabama Fertil Specialists, Birmingham, AL USA. [Haggerty, Catherine L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Haggerty, Catherine L.] Magee Womens Res Inst, Pittsburgh, PA USA. [Kissin, Dmitry M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Hook, Ned, III; Geisler, William] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 129 BP S191 EP S191 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900237 ER PT J AU Gupta, K Van der Pol, B Press, C Gorwitz, RJ Papp, J Geisler, W AF Gupta, Kanupriya Van der Pol, Barbara Press, Christen Gorwitz, Rachel J. Papp, John Geisler, William TI CHLAMYDIA TRACHOMATIS REINFECTION IS ASSOCIATED WITH LOWER ORGANISM LOAD SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Gupta, Kanupriya; Van der Pol, Barbara; Press, Christen; Geisler, William] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA. [Gorwitz, Rachel J.; Papp, John] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 132 BP S192 EP S192 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900240 ER PT J AU Habel, M Brookmeyer, K Haffner, S Oliver-Veronesi, R AF Habel, Melissa Brookmeyer, Kate Haffner, Shelley Oliver-Veronesi, Robin TI CREATING INNOVATIVE STD TESTING OPTIONS FOR UNIVERSITY STUDENTS: THE IMPACT OF A STD SELF-TESTING PROGRAM SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Habel, Melissa; Brookmeyer, Kate] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Haffner, Shelley] Penn State Univ, Infect Dis, University Pk, PA 16802 USA. [Oliver-Veronesi, Robin] Penn State Univ, Womens Hlth, University Pk, PA 16802 USA. EM mhabel@cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 2C5 BP S134 EP S135 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900038 ER PT J AU Harper, C Dittus, P Ethier, K Hoo, E AF Harper, Christopher Dittus, Patricia Ethier, Kathleen Hoo, Elizabeth TI PROFILES OF CHLAMYDIA INFECTION RISK AMONG URBAN HIGH SCHOOL STUDENTS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Harper, Christopher] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. [Dittus, Patricia] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Ethier, Kathleen; Hoo, Elizabeth] Ctr Dis Control & Prevent, Off Director, Atlanta, GA USA. EM xgj4@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 13 BP S158 EP S158 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900121 ER PT J AU Harper, C Friedman, A Brookmeyer, K Habel, M Hogben, M Kachur, R McFarlane, M AF Harper, Christopher Friedman, Allison Brookmeyer, Kate Habel, Melissa Hogben, Matthew Kachur, Rachel McFarlane, Mary TI TAKING THE STIGMA OUT OF STD TESTING: ASSOCIATIONS BETWEEN AN STD TESTING STIGMA-REDUCTION CAMPAIGN AND YOUTH ATTITUDES AND BEHAVIORS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Harper, Christopher] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. [Friedman, Allison; Brookmeyer, Kate; Habel, Melissa; Hogben, Matthew; Kachur, Rachel; McFarlane, Mary] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA USA. EM xgj4@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 6B2 BP S151 EP S152 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900098 ER PT J AU Hennessy, R Schillinger, J Klingler, E Toro, B AF Hennessy, Robin Schillinger, Julie Klingler, Ellen Toro, Brian TI OUTCOMES OF HIV PARTNER SERVICES FOR PEOPLE WITH PREVALENT HIV INFECTION AND NEWLY ACQUIRED SEXUALLY TRANSMITTED DISEASE INFECTION IN NYC, 2014 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Hennessy, Robin; Klingler, Ellen; Toro, Brian] New York City Dept Hlth & Mental Hyg, Bur STD Control & Prevent, Queens, NY USA. [Schillinger, Julie] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 3B2 BP S137 EP S137 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900047 ER PT J AU Hill-Whilton, Z Pathela, P Blank, S AF Hill-Whilton, Zachary Pathela, Preeti Blank, Sue TI DEMOGRAPHIC CORRELATES OF DRUG AND ALCOHOL USE AMONG NYC STD PATIENTS: WHO BENEFITS FROM INTERVENTIONS, AND HOW MANY ARE WE MISSING? SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Hill-Whilton, Zachary] Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Queens, NY USA. [Pathela, Preeti] Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA. [Blank, Sue] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 125 BP S190 EP S190 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900233 ER PT J AU Hogben, M Cramer, R Caccamo, A Beltran, O Habel, M AF Hogben, Matthew Cramer, Ryan Caccamo, Alexandra Beltran, Oscar Habel, Melissa TI USE OF PATIENT-DELIVERED PARTNER THERAPY IN US COLLEGE SETTINGS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Hogben, Matthew; Cramer, Ryan; Caccamo, Alexandra; Beltran, Oscar; Habel, Melissa] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM MHogben@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 51 BP S169 EP S169 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900159 ER PT J AU Holderman, J DiOrio, D Arno, J AF Holderman, Justin DiOrio, Dawne Arno, Janet TI REPEAT SYPHILIS INFECTIONS, 2008-2015, MARION COUNTY, INDIANAPOLIS, INDIANA SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Holderman, Justin; Arno, Janet] Marion Cty Publ Hlth Dept, Bell Flower Clin, Indianapolis, IN USA. [DiOrio, Dawne] Ctr Dis Control & Prevent, Indiana State Dept Hlth, Div STD Prevent, Indianapolis, IN USA. EM jholderman@marionhealth.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 84 BP S178 EP S178 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900192 ER PT J AU Hoots, B Bernstein, K An, Q Paz-Bailey, G AF Hoots, Brooke Bernstein, Kyle An, Qian Paz-Bailey, Gabriela TI CHLAMYDIA AND GONORRHEA TESTING AND DIAGNOSIS AMONG MEN WHO HAVE SEX WITH MEN-20 US CITIES, 2011 AND 2014 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Hoots, Brooke; An, Qian; Paz-Bailey, Gabriela] AIDS Prevent Centers Dis Control & Prevent, Div HIV, Atlanta, GA USA. [Bernstein, Kyle] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM vie2@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 1B5 BP S128 EP S128 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900016 ER PT J AU Hsieh, HL Patel, C Pearson, W Huppert, J Tao, GY AF Hsieh, Hsien-Lin Patel, Chirag Pearson, William Huppert, Jill Tao, Guoyu TI IMPACT OF PAP GUIDELINE CHANGES ON ANNUAL CHLAMYDIA TESTING AMONG YOUNG WOMEN: 2007 TO 2014 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Hsieh, Hsien-Lin; Patel, Chirag; Pearson, William; Tao, Guoyu] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Huppert, Jill] Agcy Healthcare Res & Qual, Ctr Evidence & Practice Improvement, Rockville, MD USA. EM yve5@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 6C5 BP S154 EP S154 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900106 ER PT J AU Hurd, J Collier, S Judd, M Bowen, A AF Hurd, Jacqueline Collier, Sarah Judd, Michael Bowen, Anna TI INCREASING RELATIVE BURDEN OF LABORATORY-CONFIRMED SHIGELLA FLEXNERI INFECTIONS AMONG US MEN, 2003-2013: AN EMERGING SEXUALLY TRANSMITTED DISEASE SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Hurd, Jacqueline; Collier, Sarah; Judd, Michael; Bowen, Anna] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. EM xyf2@cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 6A4 BP S151 EP S151 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900095 ER PT J AU Jamison, K Pathela, P Blank, S AF Jamison, Kelly Pathela, Preeti Blank, Sue TI LOW MENINGOCOCCAL VACCINE COMPLETION RATES AMONG HIV-INFECTED MEN-WHO-HAVE-SEX-WITH-MEN ATTENDING NEW YORK CITY SEXUALLY TRANSMITTED DISEASE CLINICS, 2012-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Jamison, Kelly; Pathela, Preeti] New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, Long Isl City, NY USA. [Blank, Sue] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. EM kjamison@health.nyc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 6A2 BP S150 EP S150 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900093 ER PT J AU Jamison, K Pathela, P Papadouka, V Markowitz, L Schillinger, J AF Jamison, Kelly Pathela, Preeti Papadouka, Vikki Markowitz, Lauri Schillinger, Julie TI ADOLESCENTS ATTENDING NEW YORK CITY SEXUALLY TRANSMITTED DISEASE CLINICS HAVE MISSED OPPORTUNITIES FOR RECEIVING HPV VACCINE WITH PRIMARY CARE, AND OTHER PROVIDERS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Jamison, Kelly; Pathela, Preeti] New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, Long Isl City, NY USA. [Papadouka, Vikki] NYC Dept Hlth & Mental Hyg, Bur Immunizat, Long Isl City, NY USA. [Markowitz, Lauri] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA. [Schillinger, Julie] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. EM kjamison@health.nyc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 5A2 BP S145 EP S145 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900076 ER PT J AU Jatlaoui, T Simmons, K Curtis, K AF Jatlaoui, Tara Simmons, Katharine Curtis, Kathryn TI THE SAFETY OF INTRAUTERINE CONTRACEPTION INITIATION AMONG WOMEN WITH ASYMPTOMATIC CERVICAL INFECTION OR AT HIGH RISK FOR SEXUALLY TRANSMITTED INFECTIONS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Jatlaoui, Tara; Simmons, Katharine; Curtis, Kathryn] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. EM kgz4@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 34 BP S201 EP S202 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900274 ER PT J AU Kachur, R AF Kachur, Rachel TI NEW DIRECTIONS IN ADDRESSING ADOLESCENT STD RISK SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Kachur, Rachel] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 1E BP S130 EP S130 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900023 ER PT J AU Kasaie, P Berry, S Shah, M Rosenberg, E Hoover, K Pennington, J German, D Flynn, C Beyrer, C Dowdy, D AF Kasaie, Parastu Berry, Stephen Shah, Maunank Rosenberg, Eli Hoover, Karen Pennington, Jeff German, Danielle Flynn, Colin Beyrer, Chris Dowdy, David TI DECREASING HIV INCIDENCE AMONG MSM IN BALTIMORE CITY VIA TARGETED PrEP PROVISION AT STI CLINICS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Kasaie, Parastu; Berry, Stephen; Shah, Maunank; Pennington, Jeff; German, Danielle; Beyrer, Chris; Dowdy, David] Johns Hopkins Univ, Baltimore, MD USA. [Rosenberg, Eli] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Hoover, Karen] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Flynn, Colin] Maryland Dept Hlth & Mental Hyg, Baltimore, MD 21201 USA. EM pkasaie@jhu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 74 BP S212 EP S213 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900314 ER PT J AU Klingler, E Pathela, P Blank, S Schillinger, J AF Klingler, Ellen Pathela, Preeti Blank, Sue Schillinger, Julie TI TRENDS IN REPEAT PRIMARY AND SECONDARY SYPHILIS AMONG NYC MEN, 2000-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Klingler, Ellen; Pathela, Preeti] New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, Long Isl City, NY USA. [Blank, Sue; Schillinger, Julie] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 3B1 BP S137 EP S137 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900046 ER PT J AU Klompas, M Kruskal, B Menchaca, J Hawrusik, R Zambrano, B Hsu, K Torrone, E AF Klompas, Michael Kruskal, Benjamin Menchaca, John Hawrusik, Rebecca Zambrano, Bob Hsu, Katherine Torrone, Elizabeth TI TEMPORAL PATTERNS IN CHLAMYDIA REPEAT TESTING IN PREGNANT WOMEN VS NON-PREGNANT WOMEN VS MEN IN EASTERN MASSACHUSETTS, 2007-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Klompas, Michael] Harvard Med Sch, Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA. [Klompas, Michael; Menchaca, John] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Kruskal, Benjamin] Atrius Hlth, Somerville, NJ USA. [Hawrusik, Rebecca; Hsu, Katherine] Massachusetts Dept Publ Hlth, Jamaica Plain, MA USA. [Zambrano, Bob] Commonwealth Informat, Waltham, MA USA. [Torrone, Elizabeth] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM mklompas@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 125 BP S226 EP S227 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900365 ER PT J AU Knust, B AF Knust, Barbara TI THE ROLE OF SEXUAL TRANSMISSION IN NON-STI PATHOGENS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Knust, Barbara] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 2E BP S135 EP S135 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900040 ER PT J AU Kreisel, K Weston, E Braxton, J Llata, E Torrone, E AF Kreisel, Kristen Weston, Emily Braxton, Jim Llata, Eloisa Torrone, Elizabeth TI KEEPING AN EYE ON CHLAMYDIA AND GONORRHEA CONJUNCTIVITIS IN THE UNITED STATES, 2010-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Kreisel, Kristen; Weston, Emily; Braxton, Jim; Llata, Eloisa; Torrone, Elizabeth] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM ltq1@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 5C5 BP S149 EP S149 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900089 ER PT J AU Lamb, L Matthias, J Kampert, K AF Lamb, Leah Matthias, James Kampert, Kenneth TI OCULAR SYPHILIS IN FLORIDA: EPIDEMIOLOGY OF REPORTED CASES IN 2014-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Lamb, Leah] Bur Communicable Dis, STD & Viral Hepatitis Sect, Div Dis Control & Hlth Protect, Florida Dept Hlth, Tallahassee, FL USA. [Matthias, James] Ctr Dis Control & Prevent, Epidemiol & Stat Branch, Div STD Prevent, Tallahassee, FL USA. [Kampert, Kenneth] Bur Communicable Dis, Sexually Transmitted Dis & Viral Hepatitis Sect, Div Dis Control & Hlth Protect, Florida Dept Hlth, Tallahassee, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 111 BP S186 EP S186 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900219 ER PT J AU Leichliter, J Beltran, O Cramer, R LaPollo, AB Hexem, S Loosier, P Dittus, P Chesson, H AF Leichliter, Jami Beltran, Oscar Cramer, Ryan LaPollo, Archana Bodas Hexem, Sarah Loosier, Penny Dittus, Patricia Chesson, Harrell TI SOCIAL CONTEXT AND ACCESS TO STI SERVICES AMONG GAY AND BISEXUAL MEN SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Leichliter, Jami; Beltran, Oscar; Cramer, Ryan; Loosier, Penny; Dittus, Patricia; Chesson, Harrell] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [LaPollo, Archana Bodas; Hexem, Sarah] Publ Hlth Management Corp, Philadelphia, PA USA. EM gzl3@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 64 BP S172 EP S173 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900172 ER PT J AU Lesesne, C Hebert, A Rasberry, C Adkins, SH Mezzo, J Steiner, R Rose, I AF Lesesne, Catherine Hebert, Andrew Rasberry, Catherine Adkins, Susan Hocevar Mezzo, Jennifer Steiner, Riley Rose, India TI STRUCTURAL MODELING OF SCHOOL-RELATED PREDICTORS OF HIV/STD TESTING AMONG SEXUALLY EXPERIENCED HIGH SCHOOL STUDENTS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Lesesne, Catherine] ICF Int, Publ Hlth Res & Evaluat, Atlanta, GA USA. [Hebert, Andrew; Mezzo, Jennifer; Rose, India] ICF Int, Atlanta, GA USA. [Rasberry, Catherine; Adkins, Susan Hocevar; Steiner, Riley] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. EM CLesesne@icfi.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 2C3 BP S134 EP S134 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900036 ER PT J AU Lewis, F Madera, RT Asbel, L Salmon, M AF Lewis, Felicia Madera, Robbie Therese Asbel, Lenore Salmon, Melinda TI BRIDGING IN PHILADELPHIA - DEMOGRAPHICS OF MSMW AND THEIR NAMED FEMALE PARTNERS IN CONTACT WITH PUBLIC HEALTH STD SERVICES IN PHILADELPHIA, 2010-2014 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Lewis, Felicia] Ctr Dis Control & Prevent, Div STD Prevent, Philadelphia, PA USA. [Madera, Robbie Therese] Philadelphia Dept Publ Hlth, Div Dis Control, Philadelphia, PA USA. [Asbel, Lenore] Philadelphia Dept Publ Hlth, STD Control Program, Philadelphia, PA USA. [Salmon, Melinda] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM felicia.lewis@phila.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 70 BP S174 EP S174 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900178 ER PT J AU Llata, E Braxton, J Asbel, L Murphy, R Pathela, P Schumacher, C Toevs, K Torrone, E AF Llata, Eloisa Braxton, Jim Asbel, Lenore Murphy, Ryan Pathela, Preeti Schumacher, Christina Toevs, Kim Torrone, Elizabeth TI THE BOTTOM LINE: POSSIBLE MISSED INFECTIONS AMONG WOMEN REPORTING RECTAL INTERCOURSE IN STD CLINICS, SEXUALLY TRANSMITTED DISEASES SURVEILLANCE NETWORK - UNITED STATES, 2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Llata, Eloisa; Braxton, Jim; Torrone, Elizabeth] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Asbel, Lenore] Philadelphia Dept Publ Hlth, STD Control Program, Philadelphia, PA USA. [Murphy, Ryan] Los Angeles Cty Dept Publ Hlth, Div HIV & STD Programs, Los Angeles, CA USA. [Pathela, Preeti] New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, Long Isl City, NY USA. [Schumacher, Christina] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA. [Toevs, Kim] Multnomah Cty Hlth Dept, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 4A2 BP S140 EP S141 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900059 ER PT J AU Loosier, P Cramer, R Tao, GY Hsieh, HL AF Loosier, Penny Cramer, Ryan Tao, Guoyu Hsieh, Hsien-Lin TI PRE- AND POST-AFFORDABLE CARE ACT PARTICIPATION IN INSURANCE AND UPTAKE OF SEXUAL HEALTH SERVICES BY SELF- OR PARENTALLY-INSURED FEMALES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Loosier, Penny; Cramer, Ryan; Tao, Guoyu; Hsieh, Hsien-Lin] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM plf4@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 1C3 BP S129 EP S129 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900019 ER PT J AU Maddox, B Wright, S Namadingo, H Bowen, V Chipungu, G Kamb, ML AF Maddox, Brandy Wright, Shaunta Namadingo, Hazel Bowen, Virginia Chipungu, Geoffrey Kamb, Mary L. TI NATIONAL SCALE-UP OF A NOVEL DUAL HIV/SYPHILIS RAPID DIAGNOSTIC TEST: PERSPECTIVES OF KEY STAKEHOLDERS IN MALAWI SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Maddox, Brandy; Wright, Shaunta; Bowen, Virginia; Kamb, Mary L.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Namadingo, Hazel] Malawi Epidemiol Intervent Res Unit, Lilongwe, Malawi. [Chipungu, Geoffrey] Ctr Dis Control & Prevent, Div Global HIV AIDS, Lilongwe, Malawi. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 3A5 BP S136 EP S137 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900045 ER PT J AU Mansergh, G Herbst, J Mimiaga, M Pitts, N Denson, D Landers, S Holman, J AF Mansergh, Gordon Herbst, Jeff Mimiaga, Matthew Pitts, Nicole Denson, Damian Landers, Stewart Holman, Jeremy TI VARIABLES ASSOCIATED WITH LESS CONCERN FOR HIV GIVEN EFFECTIVE TREATMENT IN AN ERA OF INCREASING HIV PREVENTION METHODS AMONG BLACK/AFRICAN AMERICAN AND LATINO MSM IN THREE US CITIES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Mansergh, Gordon; Denson, Damian] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Herbst, Jeff] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. [Mimiaga, Matthew] Brown Univ, Providence, RI 02912 USA. [Pitts, Nicole] ICF Int, Atlanta, GA USA. [Landers, Stewart] John Snow Inc, Boston, MA USA. [Holman, Jeremy] Hlth Resources Act, Boston, MA USA. EM gcm2@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 58 BP S171 EP S171 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900166 ER PT J AU Marcell, A Perin, J Gibbs, S Howard, S Heuklom, S Pilgrim, N Jennings, J Arrington-Sanders, R Page, K Loosier, P Dittus, P AF Marcell, Arik Perin, Jamie Gibbs, Susannah Howard, Shalynn Heuklom, Shannon Pilgrim, Nanlesta Jennings, Jacky Arrington-Sanders, Renata Page, Kathleen Loosier, Penny Dittus, Patricia TI DID A BRIEF INTERVENTION INCREASE COMMUNITY-BASED YOUTH-SERVING PROFESSIONALS' SEXUAL HEALTHCARE DISCUSSIONS AND REFERRALS WITH YOUNG MEN? SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Marcell, Arik; Heuklom, Shannon; Jennings, Jacky; Arrington-Sanders, Renata] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Gen Pediat & Adolescent Med, Baltimore, MD 21205 USA. [Perin, Jamie] Johns Hopkins Univ, Global Dis Epidemiol & Control, Baltimore, MD USA. [Howard, Shalynn] Johns Hopkins Univ, Ctr Child & Community Hlth Res, Baltimore, MD USA. [Pilgrim, Nanlesta] Populat Council, Washington, DC USA. [Page, Kathleen] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD USA. [Loosier, Penny; Dittus, Patricia] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM amarcell@jhu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 22 BP S160 EP S161 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900130 ER PT J AU Matthias, J Brown, V Keller, G AF Matthias, James Brown, Veronica Keller, Gayle TI IMPROVING DATA QUALITY IN FLORIDA'S STD SURVEILLANCE SYSTEM: AUTOMATION ENHANCEMENTS AND REQUIRED FIELDS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Matthias, James] Ctr Dis Control & Prevent, Div STD Prevent, Tallahassee, FL USA. [Brown, Veronica] Bur Communicable Dis, STD & Viral Hepatitis Sect, Florida Dept Hlth, Tallahassee, FL USA. [Keller, Gayle] Florida Dept Hlth, STD & Viral Hepatitis Sect, Tallahassee, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 95 BP S181 EP S181 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900203 ER PT J AU Matthias, J Keller, G Peterman, T AF Matthias, James Keller, Gayle Peterman, Thomas TI PREVALENCE AND RISKS FOR SYPHILIS REINFECTION IN FLORIDA, 2012-2014: IMPLICATIONS FOR RAPID SYPHILIS TESTING SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Matthias, James] Ctr Dis Control & Prevent, Div STD Prevent, Tallahassee, FL USA. [Keller, Gayle] Florida Dept Hlth, STD & Viral Hepatitis Sect, Tallahassee, FL USA. [Peterman, Thomas] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 98 BP S182 EP S182 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900206 ER PT J AU Meites, E McGinnis, E Meyerson, B Haderxhanaj, LT Saraiya, M Smith, W Markowitz, L AF Meites, Elissa McGinnis, Emily Meyerson, Beth Haderxhanaj, Laura T. Saraiya, Mona Smith, William (Bill) Markowitz, Lauri TI HPV VACCINATION OFFERED BY 78 SEXUALLY TRANSMITTED DISEASE CLINICS - UNITED STATES, 2014-15 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Meites, Elissa; Markowitz, Lauri] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [McGinnis, Emily; Smith, William (Bill)] Natl Coalit STD Directors, Washington, DC USA. [Meyerson, Beth; Haderxhanaj, Laura T.] Indiana Univ, Sch Publ Hlth Bloomington, Dept Appl Hlth Sci, Rural Ctr AIDS STD Prevent, Bloomington, IN USA. [Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. EM emeites@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 5A1 BP S145 EP S145 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900075 ER PT J AU Mobley, V Donovan, J Sutton, K Simmons, D Jones, C AF Mobley, Victoria Donovan, Jenna Sutton, Kimberly Simmons, Dee Jones, Constance TI BRIDGING THE GAP: TRANSITIONING HIV-POSITIVE INMATES FROM PRISON TO COMMUNITY HIV CARE SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Mobley, Victoria; Donovan, Jenna] US Dept HHS, North Carolina Div Publ Hlth, Communicable Dis Branch, Raleigh, NC USA. [Sutton, Kimberly] US Dept HHS, NC Div Publ Hlth, Communicable Dis Branch, Charlotte, NC USA. [Simmons, Dee] Ctr Dis Control & Prevent, North Carolina Dept Hlth & Human Serv, Raleigh, NC USA. [Jones, Constance] US Dept HHS, CPM, NC Div Publ Hlth, Communicable Dis Branch, Fayetteville, AR USA. EM victoria.mobley@dhhs.nc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 87 BP S216 EP S216 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900327 ER PT J AU Mobley, V Cope, A Rinsky, J Samoff, E AF Mobley, Victoria Cope, Anna Rinsky, Jessica Samoff, Erika TI THINK INSIDE THE BOX: OCULAR SYPHILIS SURVEILLANCE USING EXISTING DIS PROTOCOLS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Mobley, Victoria; Samoff, Erika] North Carolina Div Publ Hlth, Communicable Dis Branch, Raleigh, NC USA. [Cope, Anna] North Carolina Communicable Dis Branch, Raleigh, NC USA. [Cope, Anna] Ctr Dis Control & Prevent, Div STD Prevent, Raleigh, NC USA. [Rinsky, Jessica] Ctr Surveillance Epidemiol & Lab Serv, Div Sci Educ & Profess Dev, Raleigh, NC USA. EM victoria.mobley@dhhs.nc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 82 BP S215 EP S215 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900322 ER PT J AU Newman, DR Fratto, E Carlile, J Peterman, T AF Newman, Daniel R. Fratto, Erin Carlile, Jerry Peterman, Thomas TI PARTNER SERVICES FOR GONORRHEA IN UTAH 2009-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Newman, Daniel R.; Peterman, Thomas] Ctr Dis Control & Prevent, Epidemiol & Stat, Atlanta, GA USA. [Fratto, Erin; Carlile, Jerry] Utah Dept Hlth, Salt Lake City, UT USA. EM DNewman@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 15 BP S196 EP S196 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900255 ER PT J AU Okah, E Westheimer, E Jamison, K Schillinger, J AF Okah, Ebiere Westheimer, Emily Jamison, Kelly Schillinger, Julie TI DURATION OF NUCLEIC ACID AMPLIFICATION TEST POSITIVITY AMONG MEN WHO HAVE SEX WITH MEN RETURNING FOR A TEST-OF-CURE VISIT AFTER TREATMENT FOR LABORATORY-CONFIRMED NEISSERIA GONORRHEA INFECTION AT TWO PUBLIC STD CLINICS, NEW YORK CITY, 2013-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Okah, Ebiere] Icahn Sch Med Mt Sinai, Sch Med, New York, NY 10029 USA. [Westheimer, Emily] New York City Dept Hlth & Mental Hyg, Bur HIV AIDS Prevent & Control, Long Isl City, NY USA. [Jamison, Kelly] New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, Long Isl City, NY USA. [Schillinger, Julie] Ctr Dis Control & Prevent, Bur Sexually Transmitted Dis Control, NYC Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. EM eokah@health.nyc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 71 BP S212 EP S212 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900311 ER PT J AU Okah, E Rogers, M Kim, M Arya, V Schillinger, J AF Okah, Ebiere Rogers, Meighan Kim, Michelle Arya, Vibhuti Schillinger, Julie TI SENTINEL PHARMACY SURVEILLANCE FOR EXPEDITED PARTNER THERAPY PRESCRIPTIONS IN NEIGHBORHOODS WHERE PROVIDERS REGULARLY WRITE EXPEDITED PARTNER THERAPY PRESCRIPTIONS, NEW YORK CITY, 2016 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Okah, Ebiere] Icahn Sch Med Mt Sinai, Sch Med, New York, NY 10029 USA. [Rogers, Meighan] New York City Dept Hlth & Mental Hyg LIC, Bur STD Prevent & Control, New York, NY USA. [Kim, Michelle; Arya, Vibhuti] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY USA. [Schillinger, Julie] New York City Dept Hlth & Mental Hygiene, Bur STD Control & Prevent, Div STD Prevent, Ctr Dis Control & Prevent, Long Isl City, NY USA. EM ebiere.okah@icahn.mssm.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 1A5 BP S127 EP S127 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900011 ER PT J AU Olansky, E Mansergh, G Pitts, N Herbst, J Mimiaga, M Denson, D Landers, S Holman, J AF Olansky, Evelyn Mansergh, Gordon Pitts, Nicole Herbst, Jeff Mimiaga, Matthew Denson, Damian Landers, Stewart Holman, Jeremy TI HIV/AIDS CONSPIRACY BELIEFS AND PrEP UNAWARENESS AMONG BLACK/AFRICAN AMERICAN AND LATINO MSM IN THREE US CITIES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Olansky, Evelyn; Pitts, Nicole] ICF Int, Atlanta, GA USA. [Mansergh, Gordon; Denson, Damian] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Herbst, Jeff] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. [Mimiaga, Matthew] Brown Univ, Providence, RI 02912 USA. [Landers, Stewart] John Snow Inc, Boston, MA USA. [Holman, Jeremy] Hlth Resources Act, Boston, MA USA. EM ism9@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 79 BP S214 EP S214 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900319 ER PT J AU Oliver, A Schillinger, J Klingler, E AF Oliver, Ashley Schillinger, Julie Klingler, Ellen TI THE IMPACT OF PRESCRIPTIONS ON SEX PARTNER TREATMENT USING EXPEDITED PARTNER THERAPY FOR CHLAMYDIA TRACHOMATIS INFECTION, NEW YORK CITY, 2014-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Oliver, Ashley; Klingler, Ellen] New York City Dept Hlth & Mental Hyg, Bureau Sexually Transmitted Dis Prevent & Control, Queens, NY USA. [Schillinger, Julie] New York City Dept Hlth & Mental Hygiene, Bureau STD Control & Prevent, Div STD Prevent, Ctr Dis Control & Prevent, Long Isl City, NY USA. EM aoliver@health.nyc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 1A2 BP S126 EP S126 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900008 ER PT J AU Oliver, S AF Oliver, Sara TI INCREASE IN OCULAR SYPHILIS - NORTH CAROLINA, 2014-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Oliver, Sara] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. EM yxo4@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 4B2 BP S142 EP S142 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900064 ER PT J AU Oraka, E Abara, W Pitasi, M Van Handel, M DiNenno, E AF Oraka, Emeka Abara, Winston Pitasi, Marc Van Handel, Michelle DiNenno, Elizabeth TI PREVALENCE OF HIV TESTING AMONG ADULTS WITH A HEPATITIS C DIAGNOSIS: FINDINGS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 1999-2014 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Oraka, Emeka] ICF Int, Hlth Res Informat & Technol Div, Atlanta, GA USA. [Abara, Winston] Ctr Dis Control, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Pitasi, Marc; Van Handel, Michelle; DiNenno, Elizabeth] Ctr Dis Control, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM emeka.oraka@icfi.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 90 BP S217 EP S217 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900330 ER PT J AU Parikh, A Zaleski, N AF Parikh, Anjani Zaleski, Nicole TI THE IMPACT OF CONDOM DISTRIBUTION PROGRAMS ON TEEN CHLAMYDIA AND GONORRHEA RATES IN PHILADELPHIA, 2010-2014 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Parikh, Anjani] Philadelphia Dept Publ Hlth, STD Control Program, Philadelphia, PA USA. [Zaleski, Nicole] Ctr Dis Control & Prevent, Philadelphia Dept Publ Hlth, Philadelphia, PA USA. EM lgv4@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 45 BP S167 EP S167 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900153 ER PT J AU Park, I Fakile, Y Novak, S Schapiro, J Tran, A Gustafson, K Nomura, J Hoover, K Chow, J AF Park, Ina Fakile, Yetunde Novak, Susan Schapiro, Jeffrey Tran, Anthony Gustafson, Katie Nomura, Jim Hoover, Karen Chow, Joan TI COMPARATIVE TEST PERFORMANCE OF SEVEN TREPONEMAL TESTS FOR DIAGNOSIS OF SYPHILIS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Park, Ina; Chow, Joan] Calif Dept Publ Hlth, Sexually Transmitted Dis Control Branch, Richmond, CA USA. [Fakile, Yetunde] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Novak, Susan] Kaiser Permanente Southern Calif, Reg Lab, Atlanta, GA USA. [Schapiro, Jeffrey] Kaiser Permanente Northern Calif, Reg Lab, Berkeley, CA USA. [Tran, Anthony] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Gustafson, Katie] Calif Dept Publ Hlth, STD Control Branch, Sacramento, CA USA. [Nomura, Jim] Kaiser Permanente Los Angeles, Med Ctr, Los Angeles, CA USA. [Hoover, Karen] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. EM Ina.Park@cdph.ca.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 77 BP S213 EP S214 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900317 ER PT J AU Patel, C Huppert, J Kidd, S Tao, GY AF Patel, Chirag Huppert, Jill Kidd, Sarah Tao, Guoyu TI PROVIDER ADHERENCE TO SYPHILIS TESTING RECOMMENDATIONS FOR WOMEN WITH STILLBIRTH SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Patel, Chirag; Kidd, Sarah; Tao, Guoyu] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Huppert, Jill] Agcy Healthcare Res & Qual, Ctr Evidence & Practice Improvement, Rockville, MD USA. EM wyp3@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 5C4 BP S149 EP S149 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900088 ER PT J AU Patel, J AF Patel, Jean TI COMBATING ANTIBIOTIC RESISTANT BACTERIA/ADVANCED MOLECULAR DETECTION AND RESISTANT NEISSERIA GONORRHOEAE SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Patel, Jean] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 6D BP S154 EP S154 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900107 ER PT J AU Pathela, P Jamison, K Braunstein, S Schillinger, J Tymejczyk, O Nash, D AF Pathela, Preeti Jamison, Kelly Braunstein, Sarah Schillinger, Julie Tymejczyk, Olga Nash, Denis TI IDENTIFYING HIV CARE CONTINUUM GAPS AMONG PUBLIC STD CLINIC PATIENTS TO IMPROVE OUTCOMES AND REDUCE ONWARD HIV TRANSMISSION SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Pathela, Preeti; Jamison, Kelly] New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, Long Isl City, NY USA. [Braunstein, Sarah] New York City Dept Hlth & Mental Hyg, HIV Epidemiol & Field Serv, Long Isl City, NY USA. [Schillinger, Julie] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. [Tymejczyk, Olga; Nash, Denis] CUNY, Sch Publ Hlth, Epidemiol & Biostat Program, New York, NY 10021 USA. EM ppathela@health.nyc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 22 BP S198 EP S198 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900262 ER PT J AU Pathela, P Jamison, K Schillinger, J AF Pathela, Preeti Jamison, Kelly Schillinger, Julie TI LYMPHOGRANULOMA VENEREUM: AN INCREASINGLY COMMON ANORECTAL INFECTION AMONG MEN WHO HAVE SEX WITH MEN ATTENDING NEW YORK CITY STD CLINICS, 2012-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Pathela, Preeti; Jamison, Kelly] New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, Long Isl City, NY USA. [Schillinger, Julie] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. EM ppathela@health.nyc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 6A1 BP S150 EP S150 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900092 ER PT J AU Pearson, W Spicknall, I Bowen, V Hogben, M AF Pearson, William Spicknall, Ian Bowen, Virginia Hogben, Matthew TI HIV TEST SEEKING AT STD CLINICS: A TALE OF 21 CITIES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Pearson, William; Spicknall, Ian; Bowen, Virginia; Hogben, Matthew] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM wpearson@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 8 BP S157 EP S157 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900116 ER PT J AU Peterson, A Mansergh, G Herbst, J Mimiaga, M Pitts, N Denson, D Landers, S Holman, J AF Peterson, Alexa Mansergh, Gordon Herbst, Jeff Mimiaga, Matthew Pitts, Nicole Denson, Damian Landers, Stewart Holman, Jeremy TI GENERAL MEDICATION ADHERENCE, HEALTH INSURANCE TYPE, AND RECENT CONDOMLESS SEX: IMPLICATIONS FOR PrEP IMPLEMENTATION AMONG HIV-UNINFECTED BLACK/AFRICAN AMERICAN AND LATINO MSM IN THREE US CITIES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Peterson, Alexa] Gustavus Adolphus Coll, St Peter, MN 56082 USA. [Mansergh, Gordon; Denson, Damian] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Herbst, Jeff] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. [Mimiaga, Matthew] Brown Univ, Providence, RI 02912 USA. [Pitts, Nicole] ICF Int, Atlanta, GA USA. [Landers, Stewart] John Snow Inc, Boston, MA USA. [Holman, Jeremy] Hlth Resources Act, Boston, MA USA. EM apeter20@gustavus.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 61 BP S172 EP S172 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900169 ER PT J AU Romero-Severson, E Bulla, I Gromov, D Serea, OS Spicknall, I AF Romero-Severson, Ethan Bulla, Ingo Gromov, Dmitry Serea, Oana-Silvia Spicknall, Ian TI DYNAMIC ALLOCATION OF LIMITED HIV PREVENTION FUNDS USING CONTROL THEORETIC METHODS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Romero-Severson, Ethan] Los Alamos Natl Lab, Theoret Biol & Biophys, Los Alamos, NM USA. [Bulla, Ingo] Ernst Moritz Arndt Univ Greifswald, Greifswald, Germany. [Gromov, Dmitry] St Petersburg State Univ, St Petersburg 199034, Russia. [Serea, Oana-Silvia] Univ Perpignan, Perpignan, France. [Spicknall, Ian] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM eoromero@lanl.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 2B5 BP S133 EP S133 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900033 ER PT J AU Ronn, M Wolf, E Chesson, H Menzies, NA Galer, K Gorwitz, RJ Gift, T Hsu, K Salomon, JA AF Ronn, Minttu Wolf, Emory Chesson, Harrell Menzies, Nicolas A. Galer, Kara Gorwitz, Rachel J. Gift, Thomas Hsu, Katherine Salomon, Joshua A. TI A LITERATURE REVIEW: ADDRESSING PUBLIC HEALTH POLICY QUESTIONS WITH CHLAMYDIA TRANSMISSION MODELS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Ronn, Minttu; Wolf, Emory; Menzies, Nicolas A.; Galer, Kara; Salomon, Joshua A.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Prevent Policy Modeling Lab, Boston, MA USA. [Chesson, Harrell; Gorwitz, Rachel J.; Gift, Thomas] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Hsu, Katherine] Massachusetts Dept Publ Hlth, Div STD Prevent, Jamaica Plain, MA USA. [Hsu, Katherine] Massachusetts Dept Publ Hlth, Ratelle STD HIV Prevent Training Ctr New England, Jamaica Plain, MA USA. EM mronn@hsph.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 84 BP S215 EP S216 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900324 ER PT J AU Sanchez, D Okah, E Schillinger, J AF Sanchez, Diana Okah, Ebiere Schillinger, Julie TI FACTORS ASSOCIATED WITH EXPEDITED PARTNER THERAPY RECEIPT AMONG FEMALE ATTENDEES OF TWO COMMUNITY HEALTH ORGANIZATIONS SERVING NEIGHBORHOODS WITH HIGH RATES OF CHLAMYDIA TRACHOMATIS INFECTION IN NEW YORK CITY, 2014 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Sanchez, Diana] New York City Dept Hlth & Mental Hyg, Bureau Sexually Transmitted Dis, Long Isl City, NY USA. [Okah, Ebiere] Icahn Sch Med Mt Sinai, Sch Med, New York, NY 10029 USA. [Schillinger, Julie] Ctr Dis Control & Prevent, NYC Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, Long Isl City, NY USA. EM dsanchez@health.nyc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 28 BP S200 EP S200 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900268 ER PT J AU Sanchez, D Washburn, K Rogers, M Blank, S AF Sanchez, Diana Washburn, Kate Rogers, Meighan Blank, Sue TI CHLAMYDIA SCREENING COVERAGE ESTIMATES AMONG INSURED AND UNINSURED FEMALE PATIENTS ATTENDING TWO NEW YORK CITY HEALTH CENTERS SERVING NEIGHBORHOODS WITH HIGH RATES OF CHLAMYDIA TRACHOMATIS, 2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Sanchez, Diana; Washburn, Kate; Rogers, Meighan] Bur Sexually Transmitted Dis, New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA. [Blank, Sue] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. EM dsanchez@health.nyc.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 1C5 BP S130 EP S130 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900021 ER PT J AU Sandels, C Hennessy, R Hill-Whilton, Z AF Sandels, Cara Hennessy, Robin Hill-Whilton, Zachary TI GONORRHEA CASES REPORTED WITH NON-CDC RECOMMENDED TREATMENT REGIMENS IN NEW YORK CITY, 2013: GAPS IN PROVIDER KNOWLEDGE OR REPORTING ERRORS? SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Sandels, Cara; Hennessy, Robin] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hill-Whilton, Zachary] Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Queens, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 105 BP S184 EP S184 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900213 ER PT J AU Sarkar, N McKenney, S Moore, K Wilson, J Rogers, M Blank, S Schillinger, J AF Sarkar, Nihar McKenney, Sarah Moore, Kira Wilson, Joyce Rogers, Meighan Blank, Sue Schillinger, Julie TI PREDICTORS OF CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHEA SCREENING ACCEPTANCE IN A NEW YORK CITY SCHOOL-BASED STD PROGRAM SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Sarkar, Nihar; McKenney, Sarah; Moore, Kira; Wilson, Joyce; Rogers, Meighan] New York City Dept Hlth & Mental Hyg, Bur STD Prevent & Control, Long Isl City, NY USA. [Blank, Sue; Schillinger, Julie] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. EM nsarkar@health.nyc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 3 BP S155 EP S155 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900111 ER PT J AU Schillinger, J Okah, E Blank, S AF Schillinger, Julie Okah, Ebiere Blank, Sue TI POSSIBLE AZITHROMYCIN TREATMENT FAILURE AMONG 3 MEN WITH NEISSERIA GONORRHOEAE INFECTION TREATED SOLELY WITH AZITHROMYCIN, NEW YORK CITY HEALTH DEPARTMENT SEXUALLY TRANSMITTED DISEASE (NYC STD) CLINICS, 2015-2016 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Schillinger, Julie] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA. [Okah, Ebiere] Icahn Sch Med Mt Sinai, Sch Med, New York, NY 10029 USA. [Blank, Sue] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 104 BP S184 EP S184 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900212 ER PT J AU Schillinger, J Okah, E Lewis, F Anschuetz, G Cope, A Matthias, J Taylor, M Peterman, T AF Schillinger, Julie Okah, Ebiere Lewis, Felicia Anschuetz, Greta Cope, Anna Matthias, James Taylor, Melanie Peterman, Thomas TI REPORTING ONLY PRIMARY AND SECONDARY SYPHILIS GROSSLY UNDERESTIMATES INFECTIOUS SYPHILIS BURDEN; NEW YORK CITY, PHILADELPHIA, NORTH CAROLINA, FLORIDA, AND MARICOPA COUNTY ARIZONA, 2013-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Schillinger, Julie] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. [Okah, Ebiere] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Lewis, Felicia] Ctr Dis Control & Prevent, Philadelphia Dept Publ Hlth, Div STD Prevent, Philadelphia, PA USA. [Anschuetz, Greta] Philadelphia Dept Publ Hlth, STD Control Program, Philadelphia, PA USA. [Cope, Anna] Ctr Dis Control & Prevent, North Carolina Communicable Dis Branch, Div STD Prevent, Raleigh, NC USA. [Matthias, James] Ctr Dis Control & Prevent, Div STD Prevent, Tallahassee, FL USA. [Taylor, Melanie] Ctr Dis Control, Div STD Prevent, Phoenix, AZ USA. [Peterman, Thomas] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM Jschilli@health.nyc.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 27 BP S162 EP S162 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900135 ER PT J AU Shapiro, K Jamison, K Schillinger, J AF Shapiro, Katherine Jamison, Kelly Schillinger, Julie TI TRENDS IN MALE NEISSERIA GONORRHOEAE ISOLATES WITH REDUCED SUSCEPTIBILITY TO AZITHROMYCIN, AND CASE-PATIENT CHARACTERISTICS, NEW YORK CITY STD CLINICS, JANUARY 2013-DECEMBER 2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Shapiro, Katherine] NYU, New York, NY USA. [Jamison, Kelly] New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, Long Isl City, NY USA. [Schillinger, Julie] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. EM shapiro.katherine@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 6A3 BP S150 EP S151 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900094 ER PT J AU Snead, M Wiener, J Phillips, C Hylton-Kong, T Medley-Singh, N Legardy-Williams, J Costenbader, B Papp, J Warner, L Kourtis, A AF Snead, Margaret Wiener, Jeffrey Phillips, Christi Hylton-Kong, Tina Medley-Singh, Natalie Legardy-Williams, Jennifer Costenbader, Betsy Papp, John Warner, Lee Kourtis, Athena TI PREVALENCE AND PREDICTORS OF STIS AMONG WOMEN INITIATING CONTRACEPTIVE IMPLANTS IN KINGSTON, JAMAICA SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Snead, Margaret; Wiener, Jeffrey; Phillips, Christi; Legardy-Williams, Jennifer; Papp, John; Warner, Lee; Kourtis, Athena] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hylton-Kong, Tina] STD Clin, Kingston, NY USA. [Medley-Singh, Natalie] UWI, Kingston, NY USA. [Costenbader, Betsy] FHI360, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 130 BP S191 EP S191 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900238 ER PT J AU Soto, M Toro, B Ramon, A Blank, S Mikati, T AF Soto, Maria Toro, Brian Ramon, Alexander Blank, Sue Mikati, Tarek TI POOR PERFORMANCE OF A RAPID SYPHILIS TEST USED FOR SCREENING IN AN OUTREACH SETTING, NEW YORK CITY, 2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Soto, Maria; Ramon, Alexander; Mikati, Tarek] New York City Dept Mental Hlth & Hyg, Bur STD Prevent & Control, Queens, NY USA. [Toro, Brian] New York City Dept Hlth & Mental Hyg, Bur STD Prevent & Control, Long Isl City, NY USA. [Blank, Sue] Ctr Dis Control & Prevent, Bur STD Control & Prevent, New York City Dept Hlth & Mental Hyg, Div STD Prevent, Long Isl City, NY USA. EM msoto3@health.nyc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 73 BP S212 EP S212 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900313 ER PT J AU Spicknall, I Mercer, C Kang, J Beltran, O Gift, T Aral, S AF Spicknall, Ian Mercer, Catherine Kang, Joseph Beltran, Oscar Gift, Thomas Aral, Sevgi TI CROSS-NATIONAL AND TEMPORAL DIFFERENCES IN DISTRIBUTIONS OF HETEROSEXUAL PARTNERSHIP DURATION FROM 7 POPULATION SURVEYS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Spicknall, Ian; Kang, Joseph; Beltran, Oscar; Gift, Thomas; Aral, Sevgi] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Mercer, Catherine] UCL, Res Dept Infect & Populat Hlth, Ctr Sexual Hlth & HIV Res, London, England. EM xfu0@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 19 BP S160 EP S160 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900127 ER PT J AU Spicknall, I Huppert, J Gift, T AF Spicknall, Ian Huppert, Jill Gift, Thomas TI MODELING THE TRADE-OFF BETWEEN AZITHROMYCIN AND DOXYCYCLINE FOR TREATMENT OF UROGENITAL CHLAMYDIA IN WOMEN SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Spicknall, Ian; Gift, Thomas] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Huppert, Jill] Agcy Healthcare Res & Qual, Ctr Evidence & Practice Improvement, Rockville, MD USA. EM xfu0@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 4A5 BP S141 EP S142 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900062 ER PT J AU Steiner, R Swartzendruber, A Pazol, K Liddon, N Sales, J AF Steiner, Riley Swartzendruber, Andrea Pazol, Karen Liddon, Nicole Sales, Jessica TI STD SCREENING BY CONTRACEPTIVE TYPE: MISSED OPPORTUNITIES FOR ADOLESCENT AND YOUNG ADULT WOMEN SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Steiner, Riley; Liddon, Nicole] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. [Swartzendruber, Andrea; Sales, Jessica] Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA USA. [Pazol, Karen] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. EM vtc1@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 20 BP S197 EP S198 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900260 ER PT J AU Stenger, M Bauer, H Eaglin, M Jespersen, M Madera, RT Mohamed, M Kohn, RP Pugsley, R Tabidze, I Torrone, E AF Stenger, Mark Bauer, Heidi Eaglin, Margaret Jespersen, Megan Madera, Robbie Therese Mohamed, Mukhtar Kohn, Robert P. Pugsley, River Tabidze, Irina Torrone, Elizabeth TI JUST HOW GOOD IS YOUR RULE OF THUMB? VALIDATING MALE-TO-FEMALE GONORRHEA CASE RATIO AS A PROXY FOR MSM-INVOLVED EPIDEMICS AT THE COUNTY LEVEL SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Stenger, Mark; Torrone, Elizabeth] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Bauer, Heidi] Calif Dept Publ Hlth, Sexually Transmitted Dis Control Branch, Richmond, CA USA. [Eaglin, Margaret] HIV STI Bur, City Chicago Dept Publ Hlth, Chicago, IL USA. [Jespersen, Megan] LA Off Publ Hlth, Infect Dis Epidemiol Program, New Orleans, LA USA. [Madera, Robbie Therese] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. [Mohamed, Mukhtar] Connecticut Dept Publ Hlth, STD Control Program, Hartford, CT USA. [Kohn, Robert P.] San Francisco Dept Publ Hlth, Appl Res Community Hlth Epidemiol & Surveillance, Populat Hlth Div, San Francisco, CA USA. [Pugsley, River] Virginia Dept Hlth, Div Dis Prevent STD Surveillance Operat & Data Ad, Richmond, VA USA. [Tabidze, Irina] Chicago Dept Publ Hlth, Div STI HIV, Chicago, IL USA. EM zpl4@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 2A1 BP S130 EP S131 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900024 ER PT J AU Tabidze, I Varella, L Warren, E Henley, G Simmons, C AF Tabidze, Irina Varella, Lisa Warren, Eric Henley, Gabrielle Simmons, Cristal TI IMPLEMENTATION OF A NEW ELECTRONIC SEXUALLY TRANSMITTED DISEASE (STD) SURVEILLANCE SYSTEM IN CHICAGO, IL SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Tabidze, Irina; Henley, Gabrielle] Chicago Dept Publ Hlth, Div STI HIV, Chicago, IL USA. [Varella, Lisa] Ctr Dis Control & Prevent, Div STD Prevent, Chicago, IL USA. [Warren, Eric] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Simmons, Cristal] Chicago Dept Publ Hlth, Dept Epidemiol & Publ Hlth Informat, Chicago, IL USA. EM irina.tabidze@cityofchicago.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 88 BP S216 EP S217 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900328 ER PT J AU Tao, GY Gift, T AF Tao, Guoyu Gift, Thomas TI INCREASED NUMBER OF SEXUALLY-ACTIVE WOMEN AND WOMEN WHO HAD CHLAMYDIA TESTING IN HEDIS MEASURES, 2009-2014 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Tao, Guoyu; Gift, Thomas] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM gat3@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 21 BP S198 EP S198 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900261 ER PT J AU Taylor, L Pavlish, A Fuld, J Nagendra, G AF Taylor, Lauren Pavlish, April Fuld, Jennifer Nagendra, Gowri TI PROVIDING COMPREHENSIVE HEALTH CARE TO MEN WHO HAVE SEX WITH MEN: TRAINING PRIMARY CARE PROVIDERS IN NEW YORK CITY, 2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Taylor, Lauren] Ctr Dis Control & Prevent, New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA. [Pavlish, April; Nagendra, Gowri] Columbia Univ, New York, NY USA. [Fuld, Jennifer] New York City Dept Hlth & Mental Hyg, Div Dis Control, PCSI, Long Isl City, NY USA. EM gn103@cumc.columbia.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 72 BP S212 EP S212 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900312 ER PT J AU Taylor, M Newman, DR Mickey, T Bouton, E Peterman, T AF Taylor, Melanie Newman, Daniel R. Mickey, Tom Bouton, Erica Peterman, Thomas TI ARE WE FINDING THE INFECTED PARTNERS OF FEMALE SYPHILIS CASES? SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Taylor, Melanie] Ctr Dis Control, Div STD Prevent, Phoenix, AZ USA. [Newman, Daniel R.; Peterman, Thomas] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Mickey, Tom; Bouton, Erica] Maricopa Cty Dept Publ Hlth, STD Program, Phoenix, AZ USA. EM mdt7@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 120 BP S225 EP S225 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900360 ER PT J AU Tuite, A Ronn, M Wolf, E Menzies, NA Galer, K Gift, T Hsu, K Salomon, JA AF Tuite, Ashleigh Ronn, Minttu Wolf, Emory Menzies, Nicolas A. Galer, Kara Gift, Thomas Hsu, Katherine Salomon, Joshua A. TI CHARACTERIZING SEXUAL BEHAVIOR AND MIXING PATTERNS OF AMERICAN ADULTS OF DIFFERENT RACES/ETHNICITIES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Tuite, Ashleigh] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USA. [Ronn, Minttu; Wolf, Emory; Menzies, Nicolas A.; Galer, Kara; Salomon, Joshua A.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Prevent Policy Modeling Lab, Boston, MA USA. [Gift, Thomas] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Hsu, Katherine] Massachusetts Dept Publ Hlth, Div STD Prevent, Jamaica Plain, MA USA. [Hsu, Katherine] Massachusetts Dept Publ Hlth, Ratelle STD HIV Prevent Training Ctr New England, Jamaica Plain, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 116 BP S187 EP S187 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900224 ER PT J AU Turner, AN Maierhofer, C Licon, DB Kirkcaldy, B Briere, E Ervin, M Krauss, T Wang, X Fields, K Kretz, C Abrams, AJ Dennison, A Trees, D del Rio, C Stephens, DS Tzeng, YL Roberts, MW Bazan, JA AF Turner, Abigail Norris Maierhofer, Courtney Licon, Denisse B. Kirkcaldy, Bob Briere, Elizabeth Ervin, Melissa Krauss, Tiffany Wang, Xin Fields, Karen Kretz, Cecilia Abrams, A. Jeanine Dennison, Amanda Trees, David del Rio, Carlos Stephens, David S. Tzeng, Yih-Ling Roberts, Mysheika Williams Bazan, Jose A. TI AN OUTBREAK OF NEISSERIA MENINGITIDIS URETHRITIS AMONG MEN SEEKING STD CARE IN COLUMBUS, OHIO SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Turner, Abigail Norris] Ohio State Univ, Coll Med, Columbus, OH 43210 USA. [Maierhofer, Courtney; Bazan, Jose A.] Ohio State Univ, Coll Med, Div Infect Dis, Columbus, OH 43210 USA. [Licon, Denisse B.; Krauss, Tiffany; Fields, Karen; Roberts, Mysheika Williams] Columbus Publ Hlth, Columbus, OH USA. [Kirkcaldy, Bob; Briere, Elizabeth; Wang, Xin; Kretz, Cecilia; Abrams, A. Jeanine; Trees, David] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ervin, Melissa] Columbus Publ Hlth, Columbus, OH USA. [Dennison, Amanda] Ohio Dept Hlth, Columbus, OH 43266 USA. [del Rio, Carlos; Stephens, David S.; Tzeng, Yih-Ling] Emory Univ, Sch Med, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 109 BP S185 EP S185 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900217 ER PT J AU Wang, GS Seth, P Song, W Hogben, M Gilford, J AF Wang, Guoshen Seth, Puja Song, Wei Hogben, Matthew Gilford, John TI CDC-FUNDED HIV TESTING AND HIV SERVICE DELIVERY TO RACIAL AND ETHNIC MINORITY PATIENTS ATTENDING STD CLINICS IN THE UNITED STATES: ASSOCIATIONS WITH MEDICAID EXPANSION SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Wang, Guoshen; Seth, Puja; Song, Wei; Hogben, Matthew; Gilford, John] Ctr Dis Control & Prevent, Atlanta, GA USA. EM ifd1@cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 114 BP S223 EP S224 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900354 ER PT J AU Warner, L Williams, L Le, B Smith, R Pazol, K Harrison, L Kourtis, A Barfield, W AF Warner, Lee Williams, Letitia Le, Brenda Smith, Ruben Pazol, Karen Harrison, Leslie Kourtis, Athena Barfield, Wanda TI DUAL USE OF CONDOMS WITH LONG-ACTING REVERSIBLE CONTRACEPTION (LARC) VERSUS MODERATELY EFFECTIVE METHODS AMONG TEEN MOTHERS PARTICIPATING IN THE PREGNANCY RISK ASSESSMENT MONITORING SYSTEM (PRAMS) SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Warner, Lee; Williams, Letitia; Le, Brenda; Smith, Ruben; Pazol, Karen; Harrison, Leslie; Kourtis, Athena; Barfield, Wanda] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. EM DLW7@cdc.gov NR 0 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 6C3 BP S153 EP S153 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900104 ER PT J AU Weiss, G Smith, D Ye, JL Newman, S Kitlas, A AF Weiss, Gretchen Smith, Dawn Ye, Jiali Newman, Sarah Kitlas, Alyssa TI IMPLEMENTING PrEP IN STD CLINICS: FINDINGS FROM A 2015 ASSESSMENT OF LOCAL HEALTH DEPARTMENT ENGAGEMENT IN PrEP IMPLEMENTATION SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Weiss, Gretchen; Ye, Jiali; Newman, Sarah; Kitlas, Alyssa] Natl Assoc Cty & City Hlth Officials, Washington, DC USA. [Smith, Dawn] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. EM gweiss@naccho.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 2B1 BP S132 EP S132 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900029 ER PT J AU Wejnert, C An, Q Bernstein, K Paz-Bailey, G AF Wejnert, Cyprian An, Qian Bernstein, Kyle Paz-Bailey, Gabriela TI SYPHILIS SCREENING AND DIAGNOSIS AMONG MEN WHO HAVE SEX WITH MEN, 2008-2014, 20 US CITIES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Wejnert, Cyprian; An, Qian; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Bernstein, Kyle] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM dwy7@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA 4B4 BP S142 EP S143 PG 2 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900066 ER PT J AU Weston, E Kreisel, K Torrone, E AF Weston, Emily Kreisel, Kristen Torrone, Elizabeth TI THE CURIOUS CASE OF RATES OF GONORRHEA AND CHLAMYDIA AMONG ADOLESCENTS (15-19 YEARS) IN THE UNITED STATES, 2011-2015 SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Weston, Emily; Kreisel, Kristen; Torrone, Elizabeth] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM csi7@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 31 BP S163 EP S163 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900139 ER PT J AU White, C Barham, T AF White, Christina Barham, Terrika TI BEHAVIORAL INTERVENTIONS FOR HIV AND STD PREVENTION AMONG YOUTH AND YOUNG ADULTS IN THE COMPENDIUM OF EVIDENCE-BASED INTERVENTIONS AND BEST PRACTICES FOR HIV PREVENTION SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [White, Christina; Barham, Terrika] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, Atlanta, GA USA. EM cwhite2@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 19 BP S197 EP S197 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900259 ER PT J AU Wise, B McLaughlin, C Aarkoti, M Muse, A AF Wise, Benjamin McLaughlin, Colleen Aarkoti, Malathi Muse, Alison TI COMMUNITY SUPPORT FOR CONDOM AVAILABILITY IN NEW YORK STATE (NYS) LOCAL PUBLIC SCHOOLS SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Wise, Benjamin; McLaughlin, Colleen; Muse, Alison] New York State Dept Hlth, Bur STD Prevent & Epidemiol, Albany, NY 12237 USA. [Aarkoti, Malathi] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA THP 51 BP S206 EP S206 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900291 ER PT J AU Vaidyanathan, A Kegler, SR Saha, SS Mulholland, JA AF Vaidyanathan, Ambarish Kegler, Scott R. Saha, Shubhayu S. Mulholland, James A. TI A STATISTICAL FRAMEWORK TO EVALUATE EXTREME WEATHER DEFINITIONS FROM A HEALTH PERSPECTIVE A Demonstration Based on Extreme Heat Events SO BULLETIN OF THE AMERICAN METEOROLOGICAL SOCIETY LA English DT Article ID PHYSIOLOGICAL EQUIVALENT TEMPERATURE; UNITED-STATES; WARNING SYSTEM; MORTALITY; WAVE; CLIMATE; CLASSIFICATION; DISASTER; OUTCOMES; CHICAGO C1 [Vaidyanathan, Ambarish; Saha, Shubhayu S.] Ctr Dis Control & Prevent CDC, Natl Ctr Environm Hlth, Atlanta, GA USA. [Kegler, Scott R.] CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Mulholland, James A.] Georgia Inst Technol, Sch Civil & Environm Engn, Atlanta, GA 30332 USA. RP Vaidyanathan, A (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hgwy,MS F60, Atlanta, GA 30341 USA. EM rishv@cdc.gov NR 54 TC 0 Z9 0 U1 0 U2 0 PU AMER METEOROLOGICAL SOC PI BOSTON PA 45 BEACON ST, BOSTON, MA 02108-3693 USA SN 0003-0007 EI 1520-0477 J9 B AM METEOROL SOC JI Bull. Amer. Meteorol. Soc. PD OCT PY 2016 VL 97 IS 10 BP 1817 EP 1830 DI 10.1175/BAMS-D-15-00181.1 PG 14 WC Meteorology & Atmospheric Sciences SC Meteorology & Atmospheric Sciences GA ED9QR UT WOS:000389208100006 ER PT J AU McLone, SG Loharikar, A Sheehan, K Mason, M AF McLone, Suzanne G. Loharikar, Anagha Sheehan, Karen Mason, Maryann TI Suicide in Illinois, 2005-2010: A reflection of patterns and risks by age groups and opportunities for targeted prevention SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Article; Proceedings Paper CT 19th Annual Meeting of the Injury Free Coalition for Kids CY DEC 05-07, 2014 CL Fort Lauderdale, FL DE Suicide epidemiology; suicide by age; associated factors suicide ID DEATH REPORTING SYSTEM; UNITED-STATES; MILITARY PERSONNEL; OLDER-ADULTS; PRECIPITATING CIRCUMSTANCES; PHYSICIAN TRAINEES; MENTAL-HEALTH; SUBSTANCE USE; US MILITARY; VETERANS AB BACKGROUND: Suicide accounts for two thirds of all deaths from intentional or violence-related injury and is a leading cause of death in the United States. Patterns of suicide have been well described among high-risk groups, but few studies have compared the circumstances related to suicides across all age groups. We sought to understand the epidemiology of suicide cases in Illinois and to characterize the risks and patterns for suicide among different age groups. METHODS: We used suicide data collected from the Illinois Violent Death Reporting System to assess demographics, method of suicide, circumstances, and mental health status among different age groups. RESULTS: Between 2005 and 2010, 3,016 suicides were reported; 692 (23%) were female, and the median age (n = 3,013) was 45 years (range, 10-98 years). The most common method/weapon types were hanging/strangulation (33%), firearm (32%) and poisoning (21%). Hanging was more common (74%) among young people aged 10 to 19 years, while firearm use was more common among elderly persons age 65 years and older (55%). The percentage of victims within an age group experiencing a crisis within two weeks before committing suicide was highest among 10- to 14-year-olds, while the risk factor of having a family member or friend die in the past 5 years was highest among older victims. CONCLUSION: The final analysis demonstrated age-related trends in suicide in Illinois, suggesting prevention programs should tailor services by age. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. C1 [McLone, Suzanne G.; Sheehan, Karen; Mason, Maryann] Ann & Robert H Lurie Childrens Hosp Chicago, Injury Prevent & Res Ctr, 225 E Chicago Ave,Box 87, Chicago, IL 60611 USA. [Loharikar, Anagha] Ctr Dis Control & Prevent, Atlanta, GA USA. Global Hlth Global Immunizat Div, Atlanta, GA USA. [Sheehan, Karen; Mason, Maryann] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA. [Sheehan, Karen] Stanley Manne Childrens Res Inst, Smith Child Hlth Res Program, Chicago, IL USA. RP McLone, SG (reprint author), Ann & Robert H Lurie Childrens Hosp Chicago, Injury Prevent & Res Ctr, 225 E Chicago Ave,Box 87, Chicago, IL 60611 USA. EM smclone@luriechildrens.org NR 48 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0755 EI 2163-0763 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD OCT PY 2016 VL 81 IS 4 SU 1 BP S30 EP S35 DI 10.1097/TA.0000000000001141 PG 6 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA EF3XC UT WOS:000390257200007 PM 27244579 ER PT J AU Hancock-Allen, JB Janelle, SJ Lujan, K Bamberg, WM AF Hancock-Allen, Jessica B. Janelle, Sarah J. Lujan, Kate Bamberg, Wendy M. TI Outbreak of group A Streptococcus infections in an outpatient wound clinic-Colorado, 2014 SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Disease outbreak; infection; wound infection; epidemiology ID HEALTH-CARE; TRANSMISSION; FACILITIES; SETTINGS AB Background: In September 2014, wound clinic A reported a cluster of group A Streptococcus (GAS) infections to public health authorities. Although clinic providers were individually licensed, the clinic, affiliated with hospital A, was not licensed or subject to regulation. We investigated to identify cases, determine risk factors, and implement control measures. Methods: A case was defined as GAS isolation from a wound or blood specimen during March 28-November 19, 2014, from a patient treated at wound clinic A or by a wound clinic A provider within the previous 7 days. All wound clinic A staff were screened for GAS carriage. Wound care procedures were assessed for adherence to infection control principles and possible GAS transmission routes. Results: We identified 16 patients with 19 unique infections: 9 (56%) patients required hospitalization, and 7 (44%) required surgical debridement procedures. One patient died. Six (37%) patients received negative pressure wound therapy at GAS onset. Staff self-screening found no GAS carriers. Breaches in infection control and poor wound care practices were widespread. Conclusions: This GAS outbreak was associated with a wound care clinic not subject to state or federal regulation. Lapses in infection control practices and inadequate oversight contributed to the outbreak. Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Hancock-Allen, Jessica B.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA USA. [Hancock-Allen, Jessica B.; Janelle, Sarah J.; Lujan, Kate; Bamberg, Wendy M.] Colorado Dept Publ Hlth & Environm, Dis Control & Environm Epidemiol Div, 4300 Cherry Creek Dr S, Denver, CO 80246 USA. RP Bamberg, WM (reprint author), Colorado Dept Publ Hlth & Environm, Dis Control & Environm Epidemiol Div, 4300 Cherry Creek Dr S, Denver, CO 80246 USA. EM Wendy.Bamberg@state.co.us NR 17 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT 1 PY 2016 VL 44 IS 10 BP 1133 EP 1138 DI 10.1016/j.ajic.2016.03.058 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EE3QP UT WOS:000389510400013 PM 27307178 ER PT J AU Clark, SL Romero, R Dildy, GA Callaghan, WM Smiley, RM Bracey, AW Hankins, GD D'Alton, ME Foley, M Pacheco, LD Vadhera, RB Herlihy, JP Berkowitz, RL Belfort, MA AF Clark, Steven L. Romero, Roberto Dildy, Gary A. Callaghan, William M. Smiley, Richard M. Bracey, Arthur W. Hankins, Gary D. D'Alton, Mary E. Foley, Mike Pacheco, Luis D. Vadhera, Rakesh B. Herlihy, J. Patrick Berkowitz, Richard L. Belfort, Michael A. TI 3 Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE amniotic fluid embolism; critical care ID MATERNAL PULMONARY CIRCULATION; SEPTIC SHOCK; CELLS; PREGNANCY AB Amniotic fluid embolism is a leading cause of maternal mortality in developed countries. Our understanding of risk factors, diagnosis, treatment, and prognosis is hampered by a lack of uniform clinical case definition; neither histologic nor laboratory findings have been identified unique to this condition. Amniotic fluid embolism is often overdiagnosed in critically ill peripartum women, particularly when an element of coagulopathy is involved. Previously proposed case definitions for amniotic fluid embolism are nonspecific, and when viewed through the eyes of individuals with experience in critical care obstetrics, would include women with a number of medical conditions much more common than amniotic fluid embolism. We convened a working group under the auspices of a committee of the Society for Maternal-Fetal Medicine and the Amniotic Fluid Embolism Foundation whose task was to develop uniform diagnostic criteria for the research reporting of amniotic fluid embolism. These criteria rely on the presence of the classic triad of hemodynamic and respiratory compromise accompanied by strictly defined disseminated intravascular coagulopathy. It is anticipated that limiting research reports involving amniotic fluid embolism to women who meet these criteria will enhance the validity of published data and assist in the identification of risk factors, effective treatments, and possibly useful biomarkers for this condition. A registry has been established in conjunction with the Perinatal Research Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development to collect both clinical information and laboratory specimens of women with suspected amniotic fluid embolism in the hopes of identifying unique biomarkers of this condition. C1 [Clark, Steven L.] Baylor Coll Med, Houston, TX 77030 USA. Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Perinatol Res Branch, Div Obstet & Maternal Fetal Med, Div Intramural Res,NIH, Detroit, MI USA. Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Perinatol Res Branch, Div Obstet & Maternal Fetal Med, Div Intramural Res,NIH, Bethesda, MD USA. Columbia Univ, New York, NY USA. Ctr Dis Control & Prevent, Atlanta, GA USA. Banner Hlth, Phoenix, AZ USA. Univ Texas Med Branch, Galveston, TX 77555 USA. RP Clark, SL (reprint author), Baylor Coll Med, Houston, TX 77030 USA. EM slclark@bcm.edu FU Intramural CDC HHS [CC999999] NR 27 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2016 VL 215 IS 4 BP 408 EP 412 DI 10.1016/j.ajog.2016.06.037 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EE3RJ UT WOS:000389513600004 PM 27372270 ER PT J AU Ewing, AC Datwani, HM Flowers, LM Ellington, SR Jamieson, DJ Kourtis, AP AF Ewing, Alexander C. Datwani, Hema M. Flowers, Lisa M. Ellington, Sascha R. Jamieson, Denise J. Kourtis, Athena P. TI Trends in hospitalizations of pregnant HIV-infected women in the United States: 2004 through 2011 SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT Conference on Retroviruses and Opportunistic Infection (CROI) CY FEB 22-25, 2016 CL Boston, MA SP CROI Fdn, Int Antiviral Soc DE delivery; HIV; hospitalization; pregnancy; United States ID GESTATIONAL-DIABETES-MELLITUS; RECEIVING ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; PRETERM DELIVERY; INCREASED RISK; PREMATURE DELIVERY; PREECLAMPSIA; PREVENTION; HAART; RECOMMENDATIONS AB BACKGROUND: With the development and widespread use of combination antiretroviral therapy, HIV-infected women live longer, healthier lives. Previous research has shown that, since the adoption of combination antiretroviral therapy in the United States, rates of morbidity and adverse obstetric outcomes remained higher for HIV-infected pregnant women compared with HIV-uninfected pregnant women. Monitoring trends in the outcomes these women experience is essential, as recommendations for this special population continue to evolve with the progress of HIV treatment and prevention options. OBJECTIVE: We conducted an analysis comparing rates of hospitalizations and associated outcomes among HIV-infected and HIV-uninfected pregnant women in the United States from 2004 through 2011. STUDY DESIGN: We used cross-sectional hospital discharge data for girls and women age 15-49 from the 2004, 2007, and 2011 Nationwide Inpatient Sample, a nationally representative sample of US hospital discharges. Demographic characteristics, morbidity outcomes, and time trends were compared using chi(2) tests and multivariate logistic regression. Analyses were weighted to produce national estimates. RESULTS: In 2011, there were 4751 estimated pregnancy hospitalizations and 3855 delivery hospitalizations for HIV-infected pregnant women; neither increased since 2004. Compared with those of HIV-uninfected women, pregnancy hospitalizations of HIV-infected women were more likely to be longer, be in the South and Northeast, be covered by public insurance, and incur higher charges (all P <.005). Hospitalizations among pregnant women with HIV infection had higher rates for many adverse outcomes. Compared to 2004, hospitalizations of HIV-infected pregnant women in 2011 had higher odds of gestational diabetes (adjusted odds ratio, 1.81; 95% confidence interval, 1.16-2.84), preeclampsia/ hypertensive disorders of pregnancy (adjusted odds ratio, 1.58; 95% confidence interval, 1.12-2.24), viral/mycotic/parasitic infections (adjusted odds ratio, 1.90; 95% confidence interval, 1.69-2.14), and bacterial infections (adjusted odds ratio, 2.54; 95% confidence interval, 1.53-4.20). Bacterial infections did not increase among hospitalizations of HIV-uninfected pregnant women. CONCLUSION: The numbers of hospitalizations during pregnancy and delivery have not increased for HIV-infected women since 2004, a departure from previously estimated trends. Pregnancy hospitalizations of HIV-infected women remain more medically complex than those of HIVuninfected women. An increasing trend in infections among the delivery hospitalizations of HIV-infected pregnant women warrant further attention. C1 [Ewing, Alexander C.; Datwani, Hema M.; Flowers, Lisa M.; Ellington, Sascha R.; Jamieson, Denise J.; Kourtis, Athena P.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. RP Ewing, AC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. EM yhy4@cdc.gov NR 59 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2016 VL 215 IS 4 AR 499.e1-8 DI 10.1016/j.ajog.2016.05.048 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EE3RJ UT WOS:000389513600036 PM 27263995 ER PT J AU Henry-Akintobi, T Laster, N Trotter, J Jacobs, D Johnson, T Gordon, TK Miller, A AF Henry-Akintobi, Tabia Laster, Nastassia Trotter, Jennie Jacobs, DeBran Johnson, Tarita Gordon, Tandeca King Miller, Assia TI The Health, Enlightenment, Awareness, and Living (HEAL) Intervention: Outcome of an HIV and Hepatitis B and C Risk Reduction Intervention SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article DE health disparities; HIV/AIDS risk reduction; hepatitis risk reduction ID AFRICAN-AMERICAN WOMEN; SEXUALLY-TRANSMITTED INFECTIONS; BEHAVIORAL INTERVENTIONS; PREVENTION INTERVENTIONS; UNSAFE SEX; SOUTH; METAANALYSIS; COMMUNITIES; DISPARITIES; STRATEGIES AB African American women have among the highest HIV/AIDS and hepatitis B and C incidence rates in the United States, especially among those homeless or incarcerated. The objective of this study was to evaluate the Health Enlightenment, Awareness and Living Intervention, designed to decrease HIV/AIDS, hepatitis and related risky behaviors. The thirteen-session intervention was implemented among homeless and formerly incarcerated low-income African American women, ages 18 to 55, in Atlanta, Georgia from 2006 to 2010. A single group repeated measures study design was employed and consisted of a pre-test (n = 355) group, an immediate post-test (n = 228) group with a response rate of 64%, and a six-month follow up (n = 110) group with response rate of 48%, completing a 135-item survey. Paired-sample t-tests, McNemar tests, and repeated measures ANOVA were applied to compare survey results. Participants demonstrated statistically significant increases in hepatitis B and C knowledge over time (p < 0.001). Statistically significant decreases were also reported for unprotected sex in exchange for money, drugs or shelter (p = 0.008), and sex under the influence of drugs or alcohol (p < 0.001). Reported substance use decreased with statistical significance for alcohol (p = 0.011), marijuana (p = 0.011), illegal drugs (p = 0.002), and crack/cocaine (p = 0.003). Findings broaden the evidence base related to the effectiveness of HIV/AIDS and hepatitis risk reduction interventions designed for homeless and previously incarcerated African American women. C1 [Henry-Akintobi, Tabia; Gordon, Tandeca King] Morehouse Sch Med, Dept Community Hlth & Prevent Med, Prevent Res Ctr, 720 Westview Dr SW, Atlanta, GA 30310 USA. [Laster, Nastassia] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA 30329 USA. [Trotter, Jennie; Johnson, Tarita] Wholistic Stress Control Inst Inc, 2545 Benjamin E Mays Dr, Atlanta, GA 30311 USA. [Jacobs, DeBran] Univ Alabama Birmingham, Sch Educ, 1720 2nd Ave South, Birmingham, AL 35294 USA. [Miller, Assia] McKing Consulting Corp, 2900 Chamblee Tucker Rd,Bldg 10,Suite 100, Atlanta, GA 30341 USA. RP Henry-Akintobi, T (reprint author), Morehouse Sch Med, Dept Community Hlth & Prevent Med, Prevent Res Ctr, 720 Westview Dr SW, Atlanta, GA 30310 USA. EM takintobi@msm.edu; nlaster@cdc.gov; jt@wholistic1.com; djacobs@uab.edu; tjohnson@wholistic1.com; tgordon@msm.edu; amiller@msm.edu FU Substance Abuse and Mental Health Administration (SAMHSA) [5 SP 13435-04]; Centers for Disease Control and Prevention (CDC) Health Promotion and Disease Prevention Research Center [1U58DP005945-01]; National Institute on Minority Health and Health Disparities (NIMHHD) [S21MD000101]; National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000454] FX The Health, Enlightenment, Awareness and Living Intervention was funded by grant award #5 SP 13435-04 from the Substance Abuse and Mental Health Administration (SAMHSA) and through research infrastructure grants including the Centers for Disease Control and Prevention (CDC) Health Promotion and Disease Prevention Research Center (Grant #1U58DP005945-01), the National Institute on Minority Health and Health Disparities (NIMHHD) (Grant #S21MD000101) and the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000454. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIMHHD, NCATS, NIH or the CDC. Authors wish to acknowledge the communities, partners and women who helped to facilitate a broader understanding of HIV/AIDS hepatitis, and substance abuse prevention interventions. NR 42 TC 0 Z9 0 U1 1 U2 1 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD OCT PY 2016 VL 13 IS 10 AR 948 DI 10.3390/ijerph13100948 PG 14 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA EE4KF UT WOS:000389570100015 ER PT J AU Goddard, J Allerdice, MEJ Paddock, CD Portugal, JS AF Goddard, J. Allerdice, M. E. J. Paddock, C. D. Portugal, J. S., III TI Spotted Fever Group Rickettsiae in Immature Amblyomma maculatum (Acari: Ixodidae) from Mississippi SO JOURNAL OF ENTOMOLOGICAL SCIENCE LA English DT Article DE Amblyomma maculatum immatures; spotted fever group rickettsiae; Mississippi C1 [Goddard, J.; Allerdice, M. E. J.; Paddock, C. D.; Portugal, J. S., III] Mississippi State Univ, Dept Biochem Mol Biol Entomol & Plant Pathol, Starkville, MS 39762 USA. [Allerdice, M. E. J.; Paddock, C. D.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA. RP Goddard, J (reprint author), Mississippi State Univ, Dept Biochem Mol Biol Entomol & Plant Pathol, Starkville, MS 39762 USA. EM jgoddard@entomology.msstate.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU GEORGIA ENTOMOLOGICAL SOC INC PI TIFTON PA PO BOX 748 DEPT ENTOMOLOGY COASTAL PLAIN EXPT STATION, TIFTON, GA 31793-0748 USA SN 0749-8004 J9 J ENTOMOL SCI JI J. Entomol. Sci. PD OCT PY 2016 VL 51 IS 4 BP 329 EP 331 PG 3 WC Entomology SC Entomology GA EE4GT UT WOS:000389561000008 ER PT J AU Maslia, ML Aral, MM Ruckart, PZ Bove, FJ AF Maslia, Morris L. Aral, Mustafa M. Ruckart, Perri Z. Bove, Frank J. TI Reconstructing Historical VOC Concentrations in DrinkingWater for Epidemiological Studies at a US Military Base: Summary of Results SO WATER LA English DT Article DE historical reconstruction; modeling; drinking water; water quality; volatile organic compounds (VOC); epidemiological study; health risk; Camp Lejeune ID PLUME EVOLUTION; WATER; TRICHLOROETHYLENE; EXPOSURE AB A U.S. government health agency conducted epidemiological studies to evaluate whether exposures to drinking water contaminated with volatile organic compounds (VOC) at U.S. Marine Corps Base Camp Lejeune, North Carolina, were associated with increased health risks to children and adults. These health studies required knowledge of contaminant concentrations in drinking water-at monthly intervals-delivered to family housing, barracks, and other facilities within the study area. Because concentration data were limited or unavailable during much of the period of contamination (1950s-1985), the historical reconstruction process was used to quantify estimates of monthly mean contaminant-specific concentrations. This paper integrates many efforts, reports, and papers into a synthesis of the overall approach to, and results from, a drinking-water historical reconstruction study. Results show that at the Tarawa Terrace water treatment plant (WTP) reconstructed (simulated) tetrachloroethylene (PCE) concentrations reached a maximum monthly average value of 183 micrograms per liter (mu g/L) compared to a one-time maximum measured value of 215 mu g/L and exceeded the U.S. Environmental Protection Agency's current maximum contaminant level (MCL) of 5 mu g/L during the period November 1957-February 1987. At the Hadnot Point WTP, reconstructed trichloroethylene (TCE) concentrations reached a maximum monthly average value of 783 mu g/L compared to a one-time maximum measured value of 1400 mu g/L during the period August 1953-December 1984. The Hadnot Point WTP also provided contaminated drinking water to the Holcomb Boulevard housing area continuously prior to June 1972, when the Holcomb Boulevard WTP came on line (maximum reconstructed TCE concentration of 32 mu g/L) and intermittently during the period June 1972-February 1985 (maximum reconstructed TCE concentration of 66 mu g/L). Applying the historical reconstruction process to quantify contaminant-specific monthly drinking-water concentrations is advantageous for epidemiological studies when compared to using the classical exposed versus unexposed approach. C1 [Maslia, Morris L.; Ruckart, Perri Z.; Bove, Frank J.] Agcy Tox Subst & Dis Registry, Atlanta, GA 30341 USA. [Aral, Mustafa M.] Georgia Inst Technol, Sch Civil & Environm Engn, Multimedia Environm Simulat Lab, Atlanta, GA 30332 USA. RP Maslia, ML (reprint author), Agcy Tox Subst & Dis Registry, Atlanta, GA 30341 USA. EM mmaslia@cdc.gov; maral@ce.gatech.edu; pruckart@cdc.gov; fbove@cdc.gov OI Aral, Mustafa/0000-0003-4640-8717 NR 50 TC 0 Z9 0 U1 0 U2 0 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 2073-4441 J9 WATER-SUI JI Water PD OCT PY 2016 VL 8 IS 10 AR 449 DI 10.3390/w8100449 PG 23 WC Water Resources SC Water Resources GA EE5PD UT WOS:000389659200034 ER PT J AU Lanzieri, TM Kruszon-Moran, D Gambhir, M Bialek, SR AF Lanzieri, Tatiana M. Kruszon-Moran, Deanna Gambhir, Manoj Bialek, Stephanie R. TI Influence of parity and sexual history on cytomegalovirus seroprevalence among women aged 20-49 years in the USA SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS LA English DT Article DE Cytomegalovirus; Parity; Reproductive age; Seroprevalence ID PREGNANT-WOMEN; RISK-FACTORS; INFECTION; PREVALENCE AB Objective: To assess the influence of parity, as a proxy for exposure to children, and sexual history on cytomegalovirus (CMV) seroprevalence. Methods: Data were retrospectively analyzed from women aged 20-49 years who were tested for CMV immunoglobulin G antibodies in the 1999-2004 National Health and Nutrition Examination Survey, a nationally representative survey of the US population. Logistic regression was used to determine independent variables associated with CMV seroprevalence. Results: Among 3710 women, the age-adjusted CMV seroprevalence was 61.3% (95% CI 58.9%-63.6%). In age-adjusted univariate analysis, women who had given birth at least once had higher overall CMV seroprevalence (66.0%, 95% CI 63.1%-68.9%) than did those who had not given birth (49.0%, 95% CI 44.4%-53.7%; P < 0.001). In multivariate logistic analysis, higher CMV seroprevalence was independently associated with number of live births (each additional birth: adjusted odds ratio [a011] 1.2, 95% CI 1.1-1.3), age at first sexual intercourse (<18 vs >= 18 years: aOR 1.3, 95% CI 1.1-1.6), lifetime sexual partners (>= 10 vs <10: aOR 1.4, 95% CI 1.1-1.9), and herpes type 2 seropositivity (aOR 1.9, 95% CI 1.5-2.6) after controlling for age, race/Hispanic origin, place of birth, poverty index, and education. Conclusion: Among US women of reproductive age, parity and sexual exposures were independently associated with increased CMV seroprevalence. Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology and Obstetrics. C1 [Lanzieri, Tatiana M.; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop A-34, Atlanta, GA 30333 USA. [Kruszon-Moran, Deanna] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Gambhir, Manoj] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia. RP Lanzieri, TM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop A-34, Atlanta, GA 30333 USA. EM tmlanzieri@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0020-7292 EI 1879-3479 J9 INT J GYNECOL OBSTET JI Int. J. Gynecol. Obstet. PD OCT PY 2016 VL 135 IS 1 BP 82 EP 85 DI 10.1016/j.ijgo.2016.03.032 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DY0MA UT WOS:000384789700018 PM 27401134 ER PT J AU Flannery, B Zimmerman, RK Gubareva, LV Garten, RJ Chung, JR Nowalk, MP Jackson, ML Jackson, LA Monto, AS Ohmit, SE Belongia, EA McLean, HQ Gaglani, M Piedra, PA Mishin, VP Chesnokov, AP Spencer, S Thaker, SN Barnes, JR Foust, A Sessions, W Xu, X Katz, J Fry, AM AF Flannery, Brendan Zimmerman, Richard K. Gubareva, Larisa V. Garten, Rebecca J. Chung, Jessie R. Nowalk, Mary Patricia Jackson, Michael L. Jackson, Lisa A. Monto, Arnold S. Ohmit, Suzanne E. Belongia, Edward A. McLean, Huong Q. Gaglani, Manjusha Piedra, Pedro A. Mishin, Vasiliy P. Chesnokov, Anton P. Spencer, Sarah Thaker, Swathi N. Barnes, John R. Foust, Angie Sessions, Wendy Xu, Xiyan Katz, Jacqueline Fry, Alicia M. TI Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE influenza; genetic characterization; pyrosequencing; influenza vaccine; vaccine effectiveness ID TEST-NEGATIVE DESIGN; UNITED-STATES; SEASONAL INFLUENZA; RECOMMENDATIONS; HEMAGGLUTININ; METAANALYSIS; PROTECTION; FEBRUARY AB Background. During the 2014-2015 US influenza season, expanded genetic characterization of circulating influenza A(H3N2) viruses was used to assess the impact of the genetic variability of influenza A(H3N2) viruses on influenza vaccine effectiveness (VE). Methods. A novel pyrosequencing assay was used to determine genetic group, based on hemagglutinin (HA) gene sequences, of influenza A(H3N2) viruses from patients enrolled at US Influenza Vaccine Effectiveness Network sites. VE was estimated using a test-negative design comparing vaccination among patients infected with influenza A(H3N2) viruses and uninfected patients. Results. Among 9710 enrollees, 1868 (19%) tested positive for influenza A(H3N2) virus; genetic characterization of 1397 viruses showed that 1134 (81%) belonged to 1 HA genetic group (3C.2a) of antigenically drifted influenza A(H3N2) viruses. Effectiveness of 2014-2015 influenza vaccination varied by influenza A(H3N2) virus genetic group from 1% (95% confidence interval [CI], -14% to 14%) against illness caused by antigenically drifted influenza A(H3N2) virus group 3C.2a viruses versus 44% (95% CI, 16%-63%) against illness caused by vaccine-like influenza A(H3N2) virus group 3C.3b viruses. Conclusions. Effectiveness of 2014-2015 influenza vaccination varied by genetic group of influenza A(H3N2) virus. Changes in HA genes related to antigenic drift were associated with reduced VE. C1 [Flannery, Brendan; Gubareva, Larisa V.; Garten, Rebecca J.; Chung, Jessie R.; Mishin, Vasiliy P.; Chesnokov, Anton P.; Spencer, Sarah; Thaker, Swathi N.; Barnes, John R.; Foust, Angie; Sessions, Wendy; Xu, Xiyan; Katz, Jacqueline; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30329 USA. [Chung, Jessie R.; Spencer, Sarah] Atlanta Res & Educ Fdn, Decatur, GA USA. [Zimmerman, Richard K.; Nowalk, Mary Patricia] Univ Pittsburgh, Sch Hlth Sci, Pittsburgh, PA 15260 USA. [Jackson, Michael L.; Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA USA. [Monto, Arnold S.; Ohmit, Suzanne E.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Belongia, Edward A.; McLean, Huong Q.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Gaglani, Manjusha] Baylor Scott & White Hlth, Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA. [Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Piedra, Pedro A.] Baylor Coll Med, Pediat, Houston, TX 77030 USA. RP Flannery, B (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30329 USA. EM bflannery@cdc.gov FU CDC [U01IP000466, U01IP000467, U01IP000471, U01IP000473, U01IP000474] FX This work was supported by the CDC (cooperative agreements U01IP000466, U01IP000467, U01IP000471, U01IP000473, and U01IP000474). NR 31 TC 8 Z9 8 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2016 VL 214 IS 7 BP 1010 EP 1019 DI 10.1093/infdis/jiw181 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8RF UT WOS:000386137800007 PM 27190176 ER PT J AU Kim, JH Mishina, M Chung, JR Cole, KS Nowalk, MP Martin, JM Spencer, S Flannery, B Zimmerman, RK Sambhara, S AF Kim, Jin Hyang Mishina, Margarita Chung, Jessie R. Cole, Kelly Stefano Nowalk, Mary Patricia Martin, Judith M. Spencer, Sarah Flannery, Brendan Zimmerman, Richard K. Sambhara, Suryaprakash TI Cell-Mediated Immunity Against Antigenically Drifted Influenza A(H3N2) Viruses in Children During a Vaccine Mismatch Season SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE A(H3N2) drifted viruses; antigenic mismatch; influenza vaccines; cell-mediated immunity; young and adolescent children ID T-CELLS; PROTECTIVE EFFICACY; ANTIBODY-RESPONSES; A VIRUS; INFECTION; CORRELATE; IMMUNIZATION; HUMANS; TITERS AB Background. Emergence of antigenically drifted influenza A(H3N2) viruses resulted in reduced vaccine effectiveness in all age groups during the 2014-2015 influenza season. In children, inactivated influenza vaccine (IIV) elicited neutralizing antibodies (Abs) against drifted strains at significantly lower levels than against the vaccine strain. Little is known about the cross-reactivity of cell-mediated immunity against drifted strains in children. Methods. Children aged 3-17 years (n = 48) received IIV during the 2014-2015 influenza season. Peripheral blood mononuclear cells, collected before (on day 0) and after (on days 7 and 21) vaccination were evaluated for induction of cross-reactive plasmablasts, memory B cells, and cytokine-secreting CD4(+) and CD8(+) T cells against the vaccine and drifted A(H3N2) viruses by an enzyme-linked immunospot assay and flow cytometry. Results. IIV increased frequencies of plasmablasts and memory B cells. The overall induction of the T-cell response was not significant. Both B-cell and T-cell responses showed significant cross-reactivity against A(H3N2) viruses. Age and preexisting immunity affected virus-specific plasmablast responses and fold-change of T-cell responses, respectively. The proportion of T-helper type 1-prone (ie, interferon gamma- or tumor necrosis factor alpha-secreting) CD4(+) T cell responses also increased with age. Conclusions. In children aged 3-17 years, B-and T-cell responses following IIV receipt showed significant cross-reactivity against A(H3N2) viruses during a vaccine mismatch season. C1 [Kim, Jin Hyang; Flannery, Brendan; Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Mishina, Margarita] Battelle Mem Inst, Columbus, OH 43201 USA. [Chung, Jessie R.; Spencer, Sarah] Atlanta Res & Educ Fdn, Decatur, GA USA. [Cole, Kelly Stefano] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15260 USA. [Cole, Kelly Stefano] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA. [Nowalk, Mary Patricia; Zimmerman, Richard K.] Univ Pittsburgh, Dept Family Med, Pittsburgh, PA 15260 USA. [Martin, Judith M.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA. [Martin, Judith M.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA. RP Kim, JH (reprint author), Old Easton Rd, Doylestown, PA 18902 USA. EM jkim@arbutusbio.com FU CDC [U01 IP000467]; National Institutes of Health [UL1 RR024153, UL1TR000005] FX This work was supported by the CDC (U01 IP000467) and the National Institutes of Health (UL1 RR024153 and UL1TR000005). NR 34 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2016 VL 214 IS 7 BP 1030 EP 1038 DI 10.1093/infdis/jiw311 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8RF UT WOS:000386137800009 PM 27534687 ER PT J AU Mugwanya, K Baeten, J Celum, C Donnell, D Nickolas, T Mugo, N Branch, A Tappero, J Kiarie, J Ronald, A Yin, M Wyatt, C AF Mugwanya, Kenneth Baeten, Jared Celum, Connie Donnell, Deborah Nickolas, Thomas Mugo, Nelly Branch, Andrea Tappero, Jordan Kiarie, James Ronald, Allan Yin, Michael Wyatt, Christina CA Partners Prep Study Team TI Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE PrEP; TDF toxicity; proximal tubular dysfunction; TDF nephrotoxicity ID ACUTE-RENAL-FAILURE; ACUTE KIDNEY INJURY; HIV-INFECTION; ANTIRETROVIRAL PROPHYLAXIS; BANGKOK TENOFOVIR; AFRICAN WOMEN; PHOSPHATE; EXPOSURE; REABSORPTION; NOMOGRAM AB Objective. Tenofovir disoproxil fumarate (TDF) is associated with proximal tubular dysfunction (tubulopathy) when used in the treatment of human immunodeficiency virus (HIV) infection. We evaluated whether TDF causes tubulopathy when used as HIV preexposure prophylaxis (PrEP) and whether tubulopathy predicts clinically relevant decline (>= 25%) in the estimated glomerular filtration rate (eGFR). Methods. A subgroup analysis of the Partners PrEP Study, a randomized, placebo-controlled trial of daily oral TDF, alone or with emtricitabine (FTC), in HIV-uninfected African men and women (Clinicaltrials.gov NCT00557245). Tubulopathy was assessed in concurrently obtained urine and serum samples at the 24-month or last on-treatment visit, predefined as = 2 of the following: tubular proteinuria, euglycemic glycosuria, increased urinary phosphate, and uric acid excretion. Results. Of 1549 persons studied (776 receiving FTC-TDF, 773 receiving placebo), 64% were male, and the median age was 37 years. Over a median 24 months of study-drug exposure, the frequency of tubulopathy was 1.7% for FTC-TDF versus 1.3% for placebo (odds ratio, 1.30; 95% confidence interval,.52-3.33; P = .68); Tubulopathy occurred in 2 of 52 persons (3.8%) with versus 3 of 208 (1.4%) without >= 25% eGFR decline (adjusted odds ratio, 1.39; .10-14.0; P > .99). Conclusions. Daily oral FTC-TDF PrEP was not significantly associated with tubulopathy over the course of 24 months, nor did tubulopathy predict clinically relevant eGFR decline. C1 [Mugwanya, Kenneth; Baeten, Jared; Celum, Connie] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Mugwanya, Kenneth; Baeten, Jared; Celum, Connie; Mugo, Nelly] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Baeten, Jared; Celum, Connie] Univ Washington, Dept Med, Seattle, WA USA. [Donnell, Deborah] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA. [Nickolas, Thomas] Columbia Univ, Dept Med, Med Ctr, Div Nephrol, New York, NY USA. [Yin, Michael] Columbia Univ, Dept Med, Med Ctr, Div Infect Dis, New York, NY USA. [Branch, Andrea] Icahn Sch Med Mt Sinai, Dept Med, Div Liver Dis, New York, NY 10029 USA. [Wyatt, Christina] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA. [Tappero, Jordan] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. [Mugwanya, Kenneth] Makerere Univ, Sch Publ Hlth, Div Dis Control, Kampala, Uganda. [Mugo, Nelly] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Kiarie, James] Univ Nairobi, Dept Obstet & Gynecol, Nairobi, Kenya. [Ronald, Allan] Univ Manitoba, Dept Med, Winnipeg, MB, Canada. RP Mugwanya, K (reprint author), Univ Washington, 325 Ninth Ave,UW Box 359927, Seattle, WA 98104 USA. EM mugwanya@uw.edu RI Hendrix, Craig/G-4182-2014 OI Hendrix, Craig/0000-0002-5696-8665 FU Bill & Melinda Gates Foundation [OPP47674]; US NIH [R01MH095507, R01DK100272] FX This work was supported by the Bill & Melinda Gates Foundation (grant OPP47674) and the US NIH (grants R01MH095507 and R01DK100272). NR 27 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2016 VL 214 IS 7 BP 1050 EP 1057 DI 10.1093/infdis/jiw125 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8RF UT WOS:000386137800011 PM 27029778 ER PT J AU Massud, I Mitchell, J Babusis, D Deyounks, F Ray, AS Rooney, JF Heneine, W Miller, MD Garcia-Lerma, JG AF Massud, Ivana Mitchell, James Babusis, Darius Deyounks, Frank Ray, Adrian S. Rooney, James F. Heneine, Walid Miller, Michael D. Garcia-Lerma, J. Gerardo TI Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Preexposure prophylaxis; tenofovir alafenamide; macaques; SHIV ID HIV TRANSMISSION; PROPHYLAXIS; PRODRUG; PREVENTION; TISSUE; BLOOD AB Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir that efficiently delivers tenofovir diphosphate to lymphoid cells following oral administration. We investigated whether the combination of TAF and emtricitabine (FTC) could prevent simian/human immunodeficiency virus (SHIV) infection in macaques to determine the potential use of TAF for pre-exposure prophylaxis (PrEP) to prevent human immunodeficiency virus infection. Macaques were exposed rectally to SHIV once per week for up to 19 weeks and received saline or FTC/TAF 24 hours before and 2 hours after each virus inoculation. All 6 controls were infected, while the 6 PrEP-treated animals were protected from infection. Our results support the clinical investigation of FTC/TAF for PrEP. C1 [Massud, Ivana; Mitchell, James; Deyounks, Frank; Heneine, Walid; Garcia-Lerma, J. Gerardo] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Babusis, Darius; Ray, Adrian S.; Rooney, James F.; Miller, Michael D.] Gilead Sci, Foster City, CA USA. RP Garcia-Lerma, JG (reprint author), Div HIV AIDS Prevent, Branch Lab, MS G45,1600 Clifton Rd, Atlanta, GA 30329 USA. EM jng5@cdc.gov OI Ray, Adrian/0000-0002-3508-3008 FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention (intramural funds). NR 14 TC 1 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2016 VL 214 IS 7 BP 1058 EP 1062 DI 10.1093/infdis/jiw312 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8RF UT WOS:000386137800012 PM 27465645 ER PT J AU Rodriguez-Barraquer, I Arinaitwe, E Jagannathan, P Boyle, MJ Tappero, J Muhindo, M Kamya, MR Dorsey, G Drakeley, C Ssewanyana, I Smith, DL Greenhouse, B AF Rodriguez-Barraquer, Isabel Arinaitwe, Emmanuel Jagannathan, Prasanna Boyle, Michelle J. Tappero, Jordan Muhindo, Mary Kamya, Moses R. Dorsey, Grant Drakeley, Chris Ssewanyana, Isaac Smith, David L. Greenhouse, Bryan TI Quantifying Heterogeneous Malaria Exposure and Clinical Protection in a Cohort of Ugandan Children SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE malaria; epidemiology; immunity; heterogeneity in transmission ID PLASMODIUM-FALCIPARUM MALARIA; ENTOMOLOGICAL INOCULATION RATE; SUB-SAHARAN AFRICA; TRANSMISSION INTENSITY; AGE-PATTERNS; ACQUIRED-IMMUNITY; INFECTION; ENDEMICITY; MODEL; SEASONALITY AB Background. Plasmodium falciparum malaria remains a leading cause of childhood morbidity and mortality. There are important gaps in our understanding of the factors driving the development of antimalaria immunity as a function of age and exposure. Methods. We used data from a cohort of 93 children participating in a clinical trial in Tororo, Uganda, an area of very high exposure to P. falciparum. We jointly quantified individual heterogeneity in the risk of infection and the development of immunity against infection and clinical disease. Results. Results showed significant heterogeneity in the hazard of infection and independent effects of age and cumulative number of infections on the risk of infection and disease. The risk of developing clinical malaria upon infection decreased on average by 6% (95% confidence interval [CI], 0%-12%) for each additional year of age and by 2% (95% CI, 1%-3%) for each additional prior infection. Children randomly assigned to receive dihydroartemisinin-piperaquine for treatment appeared to develop immunity more slowly than those receiving artemether-lumefantrine. Conclusions. Heterogeneity in P. falciparum exposure and immunity can be independently evaluated using detailed longitudinal studies. Improved understanding of the factors driving immunity will provide key information to anticipate the impact of malaria-control interventions and to understand the mechanisms of clinical immunity. C1 [Rodriguez-Barraquer, Isabel] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Jagannathan, Prasanna; Boyle, Michelle J.; Dorsey, Grant; Greenhouse, Bryan] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA. [Tappero, Jordan] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA USA. Inst Hlth Metr & Evaluat, Seattle, WA USA. [Arinaitwe, Emmanuel; Muhindo, Mary; Ssewanyana, Isaac] Infect Dis Res Collaborat, Kampala, Uganda. [Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Dept Med, Kampala, Uganda. [Boyle, Michelle J.] Burnet Inst Med Res & Publ Hlth, Melbourne, Vic, Australia. [Drakeley, Chris; Smith, David L.] London Sch Hyg & Trop Med, London, England. RP Rodriguez-Barraquer, I (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, 615 N Wolfe St,E6610, Baltimore, MD 21205 USA. EM isabelr@jhu.edu FU Centers for Disease Control and Prevention [U62P024421]; Doris Duke Charitable Foundation; National Institutes of Health [U19AI089674]; National Health and Medical Research Council Australia; National Health and Medical Research Council Australia Infrastructure for Research Institutes Support Scheme; Victorian State Government Operational Infrastructure Support FX This work was supported by the Centers for Disease Control and Prevention, (cooperative agreement U62P024421), the Doris Duke Charitable Foundation the National Institutes of Health (U19AI089674), the National Health and Medical Research Council Australia (early career fellowship to M. J. B.), the National Health and Medical Research Council Australia Infrastructure for Research Institutes Support Scheme (to the Burnet Institute), and Victorian State Government Operational Infrastructure Support (to the Burnet Institute). NR 41 TC 1 Z9 1 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2016 VL 214 IS 7 BP 1072 EP 1080 DI 10.1093/infdis/jiw301 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8RF UT WOS:000386137800014 PM 27481862 ER PT J AU Evans, DP Anderson, M Shahpar, C del Rio, C Curran, JW AF Evans, Dabney P. Anderson, Mark Shahpar, Cyrus del Rio, Carlos Curran, James W. TI Innovation in Graduate Education for Health Professionals in Humanitarian Emergencies SO PREHOSPITAL AND DISASTER MEDICINE LA English DT Article DE disasters; global health; graduate education; humanitarian emergencies; public health ID PUBLIC-HEALTH AB The objective of this report was to show how the Center for Humanitarian Emergencies (the Center) at Emory University (Atlanta, Georgia USA) has trained graduate students to respond to complex humanitarian emergencies (CHEs) through innovative educational programs, with the goal of increasing the number of trained humanitarian workers. Natural disasters are on the rise with more than twice as many occurring from 2000-2009 as there were from 1980-1989. In 2012 alone, 144 million people were affected by a natural disaster or displaced by conflict worldwide. This has created an immense need for trained humanitarian workers to respond effectively to such disasters. The Center has developed a model for educational programming that targets learners along an educational continuum ranging from the undergraduate level through continuing professional education. These programs, based in the Rollins School of Public Health (RSPH) of Emory University, include: a competency-based graduate certificate program (the Certificate) in humanitarian emergencies; a fellowship program for mid-career professionals; and funded field practica. The competency-based Certificate program began in 2010 with a cohort of 14 students. Since then, 101 students have received the Certificate with 50 more due for completion in 2016 and 2017 combined. The fellowship program for mid-career professionals has hosted four fellows from conflict-affected or resource-poor countries, who have then gone on to assume leadership positions with humanitarian organizations. From 2009-2015, the field practicum program supported 34 students in international summer practicum experiences related to emergency response or preparedness. Students have participated in summer field experiences on every continent but Australia. Together the Certificate, funded field practicum opportunities, and the fellowship comprise current efforts in providing innovative education and training for graduate and post-graduate students of public health in humanitarian response. These modest efforts are just the beginning in terms of addressing the global shortage of skilled public health professionals that can coordinate humanitarian response. Evaluating existing programs will allow for refinement of current programs. Ultimately, these programs may influence the development of new programs and inform others interested in this area. C1 [Evans, Dabney P.; del Rio, Carlos] Emory Univ, Ctr Humanitarian Emergencies, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Anderson, Mark; Shahpar, Cyrus] US Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. [Curran, James W.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Evans, DP (reprint author), 1518 Clifton Rd NE,Mailstop 1518-002-7BB, Atlanta, GA 30322 USA. EM dabney.evans@emory.edu RI del Rio, Carlos/B-3763-2012 OI del Rio, Carlos/0000-0002-0153-3517 NR 8 TC 0 Z9 0 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1049-023X EI 1945-1938 J9 PREHOSPITAL DISASTER JI Prehospital Disaster Med. PD OCT PY 2016 VL 31 IS 5 BP 532 EP 538 DI 10.1017/S1049023X16000650 PG 7 WC Emergency Medicine SC Emergency Medicine GA DZ2IR UT WOS:000385666000012 PM 27492749 ER PT J AU Hu, L Li, Y Lu, Y Klena, JD Qiu, Y Lin, Y Jiang, M Shi, X Chen, L Liu, X Ma, H Cheng, J Wu, S Kan, B Hu, Q AF Hu, L. Li, Y. Lu, Y. Klena, J. D. Qiu, Y. Lin, Y. Jiang, M. Shi, X. Chen, L. Liu, X. Ma, H. Cheng, J. Wu, S. Kan, B. Hu, Q. TI Clinical characteristics, virulence factors and molecular typing of methicillin-resistant Staphylococcus aureus infections in Shenzhen City, China SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE CA-MRSA; clinical characteristics; HA-MRSA; HACO-MRSA; methicillin-resistant Staphylococcus aureus; molecular typing; virulence factors ID INTENSIVE-CARE-UNIT; ANTIMICROBIAL RESISTANCE; TOXIN GENES; COMMUNITY; EPIDEMIOLOGY; MRSA; CLONES; SPREAD; STATES; MEC AB Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a serious hospital and community-acquired infection and some strains are associated with greater severity. We investigated the clinical variability and molecular characteristics of MRSA infections in Shenzhen, China through a study at nine sentinel hospitals from January to December 2014. MRSA infections were classified as community-associated (CA-MRSA), healthcare-associated (HA-MRSA), and healthcare-associated community-onset (HACO-MRSA). In total, 812 MRSA isolates were collected and 183 of these were selected for further study. Patients with HA-MRSA infections were generally of greater age compared to other groups. Distinct body site and clinical presentations were evident in infected patients, e.g. CA-MRSA (skin and soft tissue, 53%), HA-MRSA (respiratory tract, 22%; surgical site, 20%; trauma wounds, 20%) and HACO-MRSA (mastitis, 47%). In contrast to HA-MRSA, other categories of strains were significantly more susceptible to gentamicin, sulfamethoxazole/trimethoprim, and tetracycline. No resistance to vancomycin or linezolid was recorded. The predominant clonal lineage within each strain category was CC59-t437-SCCmec IV/V-agr I (CA, 51.4%; HA, 28.9%; HACO, 52.9%) which exhibited characteristics of a traditional CA clone together with agr I which is more often associated with HA clones. In conclusion, for the three categories of MRSA infections, there were significant differences in clinical characteristics of patients, but the predominant clone in each category shared a similar genetic background which suggests that transmission of MRSA strains has occurred between the community and hospitals in Shenzhen. C1 [Hu, L.; Hu, Q.] Shenzhen Univ, Coll Life Sci, Shenzhen, Guangdong, Peoples R China. [Hu, L.; Li, Y.; Lu, Y.; Qiu, Y.; Lin, Y.; Jiang, M.; Shi, X.; Chen, L.; Liu, X.; Ma, H.; Cheng, J.; Hu, Q.] Shenzhen Ctr Dis Control & Prevent, Shenzhen Major Infect Dis Control Key Lab, Shenzhen, Guangdong, Peoples R China. [Klena, J. D.; Wu, S.] US Ctr Dis Control & Prevent, Beijing, Peoples R China. [Klena, J. D.] US Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. [Kan, B.] Chinese Ctr Dis Control & Prevent, Key Lab Surveillance & Early Warning Infect Dis, Div Infect Dis, Beijing, Peoples R China. RP Hu, Q (reprint author), Shenzhen Ctr Dis Control & Prevent, Shenzhen 518055, Guangdong, Peoples R China. EM huqinghua03@163.com FU US Centers for Disease Control and Prevention [5U2GGH000018]; Technology Major Projects Foundation in China [2012ZX10004215-003-005]; Shenzhen Municipal Science and Technology Programme [CXZZ20140411105636301] FX This study was supported by Cooperative Agreement no. 5U2GGH000018 from the US Centers for Disease Control and Prevention, Technology Major Projects Foundation in China (no. 2012ZX10004215-003-005) and the Shenzhen Municipal Science and Technology Programme (CXZZ20140411105636301). NR 33 TC 0 Z9 0 U1 6 U2 6 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD OCT PY 2016 VL 144 IS 14 BP 3037 EP 3045 DI 10.1017/S0950268816001552 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA ED1QB UT WOS:000388618900015 PM 27447826 ER PT J AU Nkengasong, JN Parekh, BS Hader, SL AF Nkengasong, John N. Parekh, Bharat S. Hader, Shannon L. TI HIV testing and human rights: the right to the right test SO LANCET HIV LA English DT Editorial Material C1 [Nkengasong, John N.; Parekh, Bharat S.; Hader, Shannon L.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV & TB, Atlanta, GA 30333 USA. RP Nkengasong, JN (reprint author), US Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV & TB, Atlanta, GA 30333 USA. EM jcn5@cdc.gov NR 11 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 2352-3018 J9 LANCET HIV JI Lancet HIV PD OCT PY 2016 VL 3 IS 10 BP E457 EP E458 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA ED7SY UT WOS:000389072000007 PM 27687035 ER PT J AU Moulton, AD AF Moulton, Anthony D. TI Toward a National Climate Change Health Coalition SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material C1 [Moulton, Anthony D.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Moulton, AD (reprint author), 1035 Elizabeth Ct, Atlanta, GA 30306 USA. EM anthonydmoulton@gmail.com NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2016 VL 106 IS 10 BP 1763 EP 1764 DI 10.2105/AJPH.2016.303331 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EC4DP UT WOS:000388076500034 PM 27626347 ER PT J AU Armour, BS Courtney-Long, EA Fox, MH Fredine, H Cahill, A AF Armour, Brian S. Courtney-Long, Elizabeth A. Fox, Michael H. Fredine, Heidi Cahill, Anthony TI Prevalence and Causes of Paralysis-United States, 2013 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SPINAL-CORD-INJURY; EPIDEMIOLOGY AB Objectives. To estimate the prevalence and causes of functional paralysis in the United States. Methods. We used the 2013 US Paralysis Prevalence & Health Disparities Survey to estimate the prevalence of paralysis, its causes, associated sociodemographic characteristics, and health effects among this population. Results. Nearly 5.4 million persons live with paralysis. Most persons with paralysis were younger than 65 years (72.1%), female (51.7%), White (71.4%), high school graduates (64.8%), married or living with a partner (47.4%), and unable to work (41.8%). Stroke is the leading cause of paralysis, affecting 33.7% of the population with paralysis, followed by spinal cord injury (27.3%), multiple sclerosis (18.6%), and cerebral palsy (8.3%). Conclusions. According to the functional definition, persons living with paralysis represent a large segment of the US population, and two thirds of them are between ages 18 and 64 years. Targeted health promotion that uses inclusion strategies to account for functional limitations related to paralysis can be undertaken in partnership with state and local health departments. C1 [Armour, Brian S.; Courtney-Long, Elizabeth A.; Fox, Michael H.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Atlanta, GA USA. [Fredine, Heidi; Cahill, Anthony] Univ New Mexico, Ctr Dev & Disabil, Albuquerque, NM 87131 USA. RP Armour, BS (reprint author), Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, 4770 Buford Hwy,Mailstop E-88, Atlanta, GA 30341 USA. EM barmour@cdc.gov FU Centers for Disease Control and Prevention (CDC); Christopher and Dana Reeve Foundation [U59-DD000838]; US Department of Health and Human Services; Administration for Community Living; CDC (ACL-CDC(PRC) [14-DD-ACL-001] FX Funding for this project was provided through a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Christopher and Dana Reeve Foundation (cooperative agreement U59-DD000838). Additional funding was provided by the US Department of Health and Human Services, Administration for Community Living, through an interagency agreement with the CDC (ACL-CDC(PRC)/tracking number: 14-DD-ACL-001). NR 8 TC 0 Z9 0 U1 2 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2016 VL 106 IS 10 BP 1855 EP 1857 DI 10.2105/AJPH.2016.303270 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EC4DP UT WOS:000388076500052 PM 27552260 ER PT J AU Koenig, LJ Purcell, DW Zaza, S Mermin, J AF Koenig, Linda J. Purcell, David W. Zaza, Stephanie Mermin, Jonathan TI DISPARITIES IN UPTAKE OF HIV PREEXPOSURE PROPHYLAXIS IN A LARGE INTEGRATED HEALTH CARE SYSTEM RESPONDS SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Letter C1 [Koenig, Linda J.; Purcell, David W.] Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Atlanta, GA USA. [Zaza, Stephanie] CDC, Div Adolescent & Sch Hlth, Atlanta, GA 30333 USA. [Mermin, Jonathan] CDC, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Koenig, LJ (reprint author), CDC, Prevent Res Branch, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E37, Atlanta, GA 30329 USA. EM LKoenig@cdc.gov NR 7 TC 0 Z9 0 U1 2 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2016 VL 106 IS 10 BP E3 EP E3 DI 10.2105/AJPH.2016.303340 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EC4DP UT WOS:000388076500004 PM 27626356 ER PT J AU Mitnick, CD White, RA Lu, CL Rodriguez, CA Bayona, J Becerra, MC Burgos, M Centis, R Cohen, T Cox, H D'Ambrosio, L Danilovitz, M Falzon, D Gelmanova, IY Gler, MT Grinsdale, JA Holtz, TH Keshavjee, S Leimane, V Menzies, D Migliori, GB Milstein, MB Mishustin, SP Pagano, M Quelapio, MI Shean, K Shin, SS Tolman, AW van der Walt, ML Van Deun, A Viiklepp, P AF Mitnick, Carole D. White, Richard A. Lu, Chunling Rodriguez, Carly A. Bayona, Jaime Becerra, Mercedes C. Burgos, Marcos Centis, Rosella Cohen, Theodore Cox, Helen D'Ambrosio, Lia Danilovitz, Manfred Falzon, Dennis Gelmanova, Irina Y. Gler, Maria T. Grinsdale, Jennifer A. Holtz, Timothy H. Keshavjee, Salmaan Leimane, Vaira Menzies, Dick Migliori, Giovanni Battista Milstein, Meredith B. Mishustin, Sergey P. Pagano, Marcello Quelapio, Maria I. Shean, Karen Shin, Sonya S. Tolman, Arielle W. van der Walt, Martha L. Van Deun, Armand Viiklepp, Piret CA Collaborative Grp Anal Bacteriolog TI Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article ID NEGATIVE PULMONARY TUBERCULOSIS; PATIENT DATA METAANALYSIS; TREATMENT OUTCOMES; INCOME COUNTRIES; HIV-INFECTION; SOUTH-AFRICA; IMPACT; COST; ELIMINATION; DEFINITION AB Debate persists about monitoring method (culture or smear) and interval (monthly or less frequently) during treatment for multidrug-resistant tuberculosis (MDR-TB). We analysed existing data and estimated the effect of monitoring strategies on timing of failure detection. We identified studies reporting microbiological response to MDR-TB treatment and solicited individual patient data from authors. Frailty survival models were used to estimate pooled relative risk of failure detection in the last 12 months of treatment; hazard of failure using monthly culture was the reference. Data were obtained for 5410 patients across 12 observational studies. During the last 12 months of treatment, failure detection occurred in a median of 3 months by monthly culture; failure detection was delayed by 2, 7, and 9 months relying on bimonthly culture, monthly smear and bimonthly smear, respectively. Risk (95% CI) of failure detection delay resulting from monthly smear relative to culture is 0.38 (0.34-0.42) for all patients and 0.33 (0.25-0.42) for HIV-co-infected patients. Failure detection is delayed by reducing the sensitivity and frequency of the monitoring method. Monthly monitoring of sputum cultures from patients receiving MDR-TB treatment is recommended. Expanded laboratory capacity is needed for high-quality culture, and for smear microscopy and rapid molecular tests. C1 [Mitnick, Carole D.; Lu, Chunling; Rodriguez, Carly A.; Becerra, Mercedes C.; Keshavjee, Salmaan; Milstein, Meredith B.; Shin, Sonya S.; Tolman, Arielle W.] Harvard Med Sch, Dept Global Hlth & Social Med, 641 Huntington Ave,3rd Floor, Boston, MA 02115 USA. [Mitnick, Carole D.; Becerra, Mercedes C.; Keshavjee, Salmaan; Shin, Sonya S.] Partners Hlth, Boston, MA USA. [White, Richard A.] Norwegian Inst Publ Hlth, Dept Infect Dis Epidemiol, Oslo, Norway. [White, Richard A.] Norwegian Inst Publ Hlth, Dept Hlth Stat, Oslo, Norway. [Lu, Chunling; Becerra, Mercedes C.; Keshavjee, Salmaan; Shin, Sonya S.] Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA. [Bayona, Jaime; Shin, Sonya S.] Socios Salud Sucursal, Lima, Peru. [Burgos, Marcos] Univ New Mexico, Sch Med, Dept Internal Med, Albuquerque, NM 87131 USA. [Centis, Rosella; D'Ambrosio, Lia; Migliori, Giovanni Battista] Fdn S Maugeri, Care & Res Inst, WHO Collaborating Ctr TB & Lung Dis, Tradate, Italy. [Cohen, Theodore] Yale Sch Publ Hlth, Epidemiol Microbial Dis, New Haven, CT USA. [Cox, Helen] Med Sans Frontieres, Cape Town, South Africa. [D'Ambrosio, Lia] Publ Hlth Consulting Grp, Lugano, Switzerland. [Danilovitz, Manfred] Tartu Univ Hosp, Lung Clin, Tartu, Estonia. [Falzon, Dennis] WHO, Global TB Programme, Geneva, Switzerland. [Gelmanova, Irina Y.] Partners Hlth Russia, Moscow, Russia. [Gler, Maria T.] Makati Med Ctr, Manila, Philippines. [Grinsdale, Jennifer A.] San Francisco Dept Publ Hlth, TB Control, San Francisco, CA USA. [Holtz, Timothy H.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Leimane, Vaira] State Agcy TB & Lung Dis TPSVA, Riga, Latvia. [Menzies, Dick] McGill Univ, Montreal Chest Inst, Montreal, PQ, Canada. [Milstein, Meredith B.] Northeastern Univ, Bouve Coll Hlth Sci, Boston, MA 02115 USA. [Mishustin, Sergey P.] Tomsk TB & Pulm Med Ctr, Tomsk Oblast, Russia. [Pagano, Marcello] Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Quelapio, Maria I.] Trop Dis Fdn, Philippine Inst TB, Makati, Philippines. [Shean, Karen] Univ Cape Town, Lung Infect & Immun Unit, Div Pulmonol, Cape Town, South Africa. [Shean, Karen] Univ Cape Town, UCT Lung Inst, Dept Med, Cape Town, South Africa. [van der Walt, Martha L.] South African Med Res Council, TB Res Platform, Pretoria, South Africa. [Van Deun, Armand] Inst Trop Med, Antwerp, Belgium. [Viiklepp, Piret] Natl Inst Heath Dev, Tallinn, Estonia. RP Mitnick, CD (reprint author), Harvard Med Sch, Dept Global Hlth & Social Med, 641 Huntington Ave,3rd Floor, Boston, MA 02115 USA. EM carole_mitnick@hms.harvard.edu RI Lange, Christoph/J-6289-2012; OI Hollm-Delgado, Maria-Graciela/0000-0003-1067-8520 FU Global Tuberculosis Programme of the World Health Organization; United States Agency for International Development; Bill and Melinda Gates Foundation; David Rockefeller Center for Latin American Studies at Harvard University; US National Institutes of Health [K01 A1065836, K01 HL080939]; Centers for Disease Control and Prevention Cooperative Agreement Funds; Fonds de Recherche en Sante de Quebec; European Community's Seventh Framework Programme (FP7) [FP7-223681]; South African Medical Research Council FX Funding for this study was provided in part by Global Tuberculosis Programme of the World Health Organization, through a grant from the United States Agency for International Development. Funding for data gathering at participating centres was provided as follows: in Peru from Thomas J. White, the Bill and Melinda Gates Foundation, David Rockefeller Center for Latin American Studies at Harvard University and from the US National Institutes of Health (K01 A1065836 (C.D. Mitnick) and K01 HL080939 (M.C. Becerra)); in the State of California from the Centers for Disease Control and Prevention Cooperative Agreement Funds; and in South Africa from the South African Medical Research Council funding. D. Menzies was supported by salary awards from the Fonds de Recherche en Sante de Quebec; and G.B. Migliori and R. Centis were funded by the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement FP7-223681. M.L. van der Walt was funded by the South African Medical Research Council. Funding information for this article has been deposited with the Open Funder Registry. NR 41 TC 4 Z9 4 U1 1 U2 1 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 EI 1399-3003 J9 EUR RESPIR J JI Eur. Resp. J. PD OCT PY 2016 VL 48 IS 4 BP 1160 EP 1170 DI 10.1183/13993003.00462-2016 PG 11 WC Respiratory System SC Respiratory System GA EC7HJ UT WOS:000388307500023 PM 27587552 ER PT J AU Lawman, HG Fryar, CD Gu, QP Ogden, CL AF Lawman, Hannah G. Fryar, Cheryl D. Gu, Qiuping Ogden, Cynthia L. TI The Role of Prescription Medications in the Association of Self-Reported Sleep Duration and Obesity in US Adults, 2007-2012 SO OBESITY LA English DT Article ID BODY-MASS INDEX; UNITED-STATES; HEALTH; WEIGHT; COHORT; MORTALITY; OUTCOMES; DRUGS AB Objective: Previous research has not investigated the role of prescription medication in sleep-obesity associations despite the fact that 56% of U.S. adults take at least one prescription medication. Methods: Data from n=16,622 adults in the National Health and Nutrition Examination Survey (2007-2012) were used to examine how the association between obesity and self-reported sleep duration varied by total number of prescription medications used in the past 30 days and by select classes of prescription medications including anxiolytics/sedatives/hypnotics, antidepressants, sleep aids, anticonvulsants, thyroid agents, and metabolic agents. Results: Logistic regression analyses showed a significant inverse linear association of sleep duration and obesity, regardless of the total number of prescription medications individuals were taking. Each additional hour of sleep was associated with a 10% decrease in the odds of obesity. Results suggest that increased sleep duration is associated with lower odds of having obesity overall, even for long-duration sleepers (>= 9 h), and this association does not differ for those taking antidepressants, thyroid agents, metabolic agents, and multiple prescription medications. Conclusions: The relationship between sleep duration and obesity was similar among all prescription medication users and nonusers. The potential for a nonlinear association between sleep duration and obesity may be important to examine in some specific prescription medication classes. C1 [Lawman, Hannah G.; Fryar, Cheryl D.; Gu, Qiuping; Ogden, Cynthia L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Lawman, HG (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM hannah.lawman@phila.gov NR 32 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD OCT PY 2016 VL 24 IS 10 BP 2210 EP 2216 DI 10.1002/oby.21600 PG 7 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA EC6WH UT WOS:000388276900031 PM 27601085 ER PT J AU Park, S Akinbami, LJ McGuire, LC Blanck, HM AF Park, Sohyun Akinbami, Lara J. McGuire, Lisa C. Blanck, Heidi M. TI Association of sugar-sweetened beverage intake frequency and asthma among US adults, 2013 SO PREVENTIVE MEDICINE LA English DT Article DE Sugar-sweetened beverage; Asthma; BRFSS; Adults ID HIGH-SCHOOL-STUDENTS; SULFUR-DIOXIDE; DENTAL-CARIES; CONSUMPTION; RISK; PREVALENCE; INCREASES; ADDITIVES; CHILDREN; OBESITY AB Objectives. Sugar-sweetened beverage (SSB) intake among U. S. adults is associated with obesity and type 2 diabetes. An association between SSB intake and asthma has been shown among U. S. children and Australian adults, but scant published information exists for U. S. adults. We examined associations between SSB intake and current asthma among U. S. adults, and the role of obesity in this association. Methods. We analyzed 2013 Behavioral Risk Factor Surveillance System data for 146,990 adults (>= 18 years) from23 states and the District of Columbia. We usedmultivariable logistic regression to estimate associations between current asthma and frequency (none, <1 time/day, once/day, >= 2 times/day) of SSB intake (soda, fruit drink, sweet tea, and sports/energy drink). SSB intake was measured using two questions. Covariates included age, sex, race/ethnicity, education, and smoking. Obesity, based on self-reported height andweight, was assessed as an effect modifier. Results. Overall, 9.1% of adults reported current asthma: 8.5% of adultswho did not consume SSBs had current asthma vs 12.1% of adultswho consumed SSBs >= 2 times/day. There was no difference in asthma prevalencewith SSB intake < 1 time/day (8.7%) or once/day (8.7%). Among non-obese adults, the odds of having current asthma were higher among thosewho consumed SSBs >= 2 times/day (aOR= 1.66, 95% CI= 1.39, 1.99) than non-SSB consumers. However, SSB intake frequency was not associated with asthma among obese adults. Conclusions. Frequent SSB consumption was associated with asthma among non-obese adults. Research on asthma prevention should further consider the potential adverse effects of high SSB intake among U. S. adults. Published by Elsevier Inc. C1 [Park, Sohyun; McGuire, Lisa C.; Blanck, Heidi M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,Mailstop F79 NE, Atlanta, GA 30341 USA. [Akinbami, Lara J.] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, ID USA. RP Park, S (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,Mailstop F79 NE, Atlanta, GA 30341 USA. EM spark3@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 1 Z9 1 U1 5 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2016 VL 91 BP 58 EP 61 DI 10.1016/j.ypmed.2016.08.004 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EC7ME UT WOS:000388322800009 PM 27496394 ER PT J AU Carlson, SA Paul, P Watson, KB Schmid, TL Fulton, JE AF Carlson, Susan A. Paul, Prabasaj Watson, Kathleen B. Schmid, Thomas L. Fulton, Janet E. TI How reported usefulness modifies the association between neighborhood supports and walking behavior SO PREVENTIVE MEDICINE LA English DT Article DE Behavior; Community; Commuting; Environment design; Safety; Physical activity; Recreation ID PHYSICAL-ACTIVITY; BUILT ENVIRONMENT; PUBLIC-TRANSIT; ADULTS; CRIME; WALKABILITY; HEALTH AB Neighborhood supports have been associated with walking, but this association may be modified by reports about the usefulness of these supports for promoting walking. This study examined the association between reported presence of neighborhood supports and walking and whether usefulness modified this association in a nationwide sample of U.S. adults. Measures of reported presence and use or potential use (i.e., usefulness) of neighborhood supports (shops within walking distance, transit stops, sidewalks, parks, interesting things to look at, well-lit at night, low crime rate, and cars following speed limit) were examined in 3973 adults who completed the 2014 SummerStyles survey. Multinomial regression models were used to examine the association between presence of supports with walking frequency (frequently, sometimes, rarely (referent)) and the role usefulness had on this association. The interaction term between reported presence and usefulness was significant for all supports (p < 0.05). For adults who reported a support as useful, a positive association between presence of the support and walking frequency was observed for all supports. For adults who did not report a support as useful, the association between presence of the support and walking frequency was null for most supports and negative for sidewalks, well-lit at night, and low crime rate. The association between presence of neighborhood supports and walking is modified by reported usefulness of the support. Tailoring initiatives to meet a community's supply of and affinity for neighborhood supports may help initiatives designed to promote walking and walkable communities succeed. Published by Elsevier Inc. C1 [Carlson, Susan A.; Paul, Prabasaj; Watson, Kathleen B.; Schmid, Thomas L.; Fulton, Janet E.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. RP Carlson, SA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,NE,Mailstop F-77, Atlanta, GA 30341 USA. EM scarlson1@cdc.gov NR 27 TC 0 Z9 0 U1 4 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2016 VL 91 BP 76 EP 81 DI 10.1016/j.ypmed.2016.07.020 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EC7ME UT WOS:000388322800012 PM 27471025 ER PT J AU Kim, SY Sharma, AJ Sappenfield, W Salihu, HM AF Kim, Shin Y. Sharma, Andrea J. Sappenfield, William Salihu, Hamisu M. TI Preventing large birth size in women with preexisting diabetes mellitus: The benefit of appropriate gestational weight gain SO PREVENTIVE MEDICINE LA English DT Article DE Gestational weight gain; LGA; Macrosomia; Preexisting diabetes ID PREGNANCY OUTCOMES; OBESITY; RISK; ASSOCIATION; TRENDS; STATES AB Objective. To estimate the percentage of infants with large birth size attributable to excess gestational weight gain (GWG), independent of prepregnancy body mass index, among mothers with preexisting diabetes mellitus (PDM). Study design. We analyzed 2004-2008 Florida linked birth certificate and maternal hospital discharge data of live, term (37-41 weeks) singleton deliveries (N = 641,857). We calculated prevalence of large-for-gestational age (LGA) (birth weight-for-gestational age >= 90th percentile) and macrosomia (birth weight > 4500 g) by GWG categories (inadequate, appropriate, or excess). We used multivariable logistic regression to estimate the relative risk (RR) of large birth size associated with excess compared to appropriate GWG among mothers with PDM. We then estimated the population attributable fraction (PAF) of large birth size due to excess GWG among mothers with PDM (n = 4427). Results. Regardless of diabetes status, half of mothers (51.2%) gained weight in excess of recommendations. Large birth size was higher in infants of mothers with PDM than in infants of mothers without diabetes (28.8% versus 9.4% for LGA, 5.8% versus 0.9% for macrosomia). Among women with PDM, the adjusted RR of having an LGA infant was 1.7 (95% CI 1.5, 1.9) for women with excess GWG compared to those with appropriate gain; the PAF was 27.7% (95% CI 22.0, 33.3). For macrosomia, the adjusted RR associated with excess GWG was 2.1 (95% CI 1.5, 2.9) and the PAF was 38.6% (95% CI 24.9, 52.4). Conclusion. Preventing excess GWG may avert over one-third of macrosomic term infants of mothers with PDM. Effective strategies to prevent excess GWG are needed. Published by Elsevier Inc. C1 [Kim, Shin Y.; Sharma, Andrea J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Prommt, Div Reprod Hlth, Atlanta, GA USA. [Sharma, Andrea J.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. [Sappenfield, William] Univ S Florida, Coll Publ Hlth, Tampa, FL USA. [Salihu, Hamisu M.] Baylor Coll Med, Dept Family & Community Med, Houston, TX 77030 USA. RP Kim, SY (reprint author), 4770 Buford Hwy,NE MS K-23, Atlanta, GA 30341 USA. EM skim1@cdc.gov OI Sharma, Andrea/0000-0003-0385-0011 FU Intramural CDC HHS [CC999999] NR 34 TC 0 Z9 0 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2016 VL 91 BP 164 EP 168 DI 10.1016/j.ypmed.2016.08.026 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EC7ME UT WOS:000388322800025 PM 27539071 ER PT J AU Watson, M Geller, AC Tucker, MA Guy, GP Weinstock, MA AF Watson, Meg Geller, Alan C. Tucker, Margaret A. Guy, Gery P. Weinstock, Martin A. TI Melanoma burden and recent trends among non-Hispanic whites aged 15-49 years, United States SO PREVENTIVE MEDICINE LA English DT Article DE Melanoma; Cancer incidence; Cancer mortality; Trends; Adolescent and young adult ID CUTANEOUS MELANOMA; CANCER REGISTRIES; REPORTING DELAY; INCIDENCE RATES; SUN EXPOSURE; SURVIVAL; US; ADULTS; WOMEN; RISK AB Melanoma is among the most common cancers for adolescents and young adults. Updated information on melanoma among adults <50 is needed. The objective of this study was to examine invasive melanoma in the United States among people aged 15-49 years for the group at highest risk, non-Hispanic whites. In 2015, we analyzed population-based cancer registry data from the Centers for Disease Control and Prevention's National Program of Cancer Registries and the National Cancer Institute's Surveillance, Epidemiology, and End Results program to examineme lanoma incidence and death rates and trends among non-Hispanic whites aged 15-49 years by sex and age. We also present incidence trends with regard to thickness and site on the body. Among non-Hispanic whites aged 15-49 years, rates were higher among females. Thin melanomas increased among both sexes during 19922006 and stabilized during 2006-2012. For the period 1992-2012, melanomas thicker than 4 mm increased among males and melanomas 1.01-2.00 mm thick increased among females. Melanomas were most commonly diagnosed on the trunk and lower extremity among females and on the trunk and upper extremity among males. Increases in melanoma incidence among non-Hispanic whites aged 15-49 years across various thicknesses suggest that melanoma trends are not solely related to increased screening but are, in part, related to true increases. Declines in melanoma rates of about 3% a year from the mid-2000s to 2012 in the youngest age groups offer hope that melanoma incidence may decline in future generations. Published by Elsevier Inc. C1 [Watson, Meg; Guy, Gery P.] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, 4770 Buford Hwy NE MS-F76, Atlanta, GA 30341 USA. [Geller, Alan C.] Harvard Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA. [Tucker, Margaret A.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Weinstock, Martin A.] Brown Univ, VA Med Ctr, Dept Dermatol, Providence, RI 02912 USA. [Weinstock, Martin A.] Brown Univ, VA Med Ctr, Dept Epidemiol, Providence, RI 02912 USA. RP Watson, M (reprint author), Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, 4770 Buford Hwy NE MS-F76, Atlanta, GA 30341 USA. EM Eze5@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 0 Z9 0 U1 2 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2016 VL 91 BP 294 EP 298 DI 10.1016/j.ypmed.2016.08.032 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EC7ME UT WOS:000388322800042 PM 27565055 ER PT J AU Ahluwalia, IB Arrazola, RA Ouma, AEO AF Ahluwalia, Indu B. Arrazola, Rene A. Ouma, Ahmed E. Ogwell TI Tobacco control in Africa SO PREVENTIVE MEDICINE LA English DT Editorial Material ID MIDDLE-INCOME COUNTRIES C1 [Ahluwalia, Indu B.; Arrazola, Rene A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30333 USA. [Ouma, Ahmed E. Ogwell] WHO, Reg Off Africa, Brazzaville, Congo. RP Ahluwalia, IB (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30333 USA. EM iaa2@cdc.gov FU World Health Organization [001] NR 11 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2016 VL 91 SU S BP S1 EP S1 DI 10.1016/j.ypmed.2016.07.001 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EC7KW UT WOS:000388318300001 PM 27384929 ER PT J AU Chandora, R Song, Y Chaussard, M Palipudi, KM Lee, KA Ramanandraibe, N Asma, S AF Chandora, Rachna Song, Yang Chaussard, Martine Palipudi, Krishna Mohan Lee, Kyung Ah Ramanandraibe, Nivo Asma, Samira CA GYTS Collaborative Grp TI Youth access to cigarettes in six sub-Saharan African countries SO PREVENTIVE MEDICINE LA English DT Article DE Accessibility; Adolescents; Cigarettes; Control; GYTS; Legislation; Smoking; Sub-Saharan Africa; Supply; Tobacco ID POLICIES; TOBACCO; MINORS; SALES AB Objective. Tobacco smoking is initiated and established mostly during adolescence. TheWorld Health Organization (WHO) Framework Convention on Tobacco Control (FCTC) Article 16 outlines the obligation of parties to prohibit the sale of tobacco products to minors. This study examined where and howstudent smokers obtain cigarettes. Methods. We examined Global Youth Tobacco Survey (GYTS) data from 2009 to 2011 on cigarette access among students aged 13-15 in six sub-Saharan African countries. Results. In all countries analyzed, over 20% of student smokers obtained their cigarettes in a store or shop (52.6% in South Africa, 37.7% in Republic of Congo, 28.2% in Swaziland, 27.4% in Cote d'Ivoire, 26.9% in Ghana, and 22.6% in Uganda). In Cote d'Ivoire and South Africa, 68.9% and 68.7% of student cigarette smokers, respectively, were not refused the sale of cigarettes because of age. The percentage of students whowere offered free cigarettes by a tobacco company representative ranged from 4.7% in Cote d'Ivoire to 12.1% in South Africa. Conclusions. The method of obtaining cigarettes and access to cigarettes among students varies among subSaharan African countries. Adopting and enforcing interventions that prevent youth from accessing tobacco products could be an effective strategy for reducing smoking initiation among youth in sub-Saharan African countries. (C) 2016 Published by Elsevier Inc. C1 [Chandora, Rachna] CDC Fdn, 55 Pk Pl,Suite 400, Atlanta, GA 30324 USA. [Song, Yang; Asma, Samira] Ctr Dis Control & Prevent CDC, Div Global Hlth Protect, Atlanta, GA USA. [Chaussard, Martine] Amer Canc Soc, Atlanta, GA 30329 USA. [Palipudi, Krishna Mohan; Lee, Kyung Ah] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30333 USA. [Ramanandraibe, Nivo] WHO, Reg Off Africa, Brazzaville, Congo. RP Chandora, R (reprint author), CDC Fdn, 55 Pk Pl,Suite 400, Atlanta, GA 30324 USA. EM rchandora@cdcfoundation.org FU Bloomberg Initiative to Reduce Tobacco Use through the CDC Foundation; Bloomberg Philanthropies; Bill & Melinda Gates Foundation FX Financial support for this research is provided by the Bloomberg Initiative to Reduce Tobacco Use through the CDC Foundation with grants from Bloomberg Philanthropies and the Bill & Melinda Gates Foundation. NR 24 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2016 VL 91 SU S BP S23 EP S27 DI 10.1016/j.ypmed.2016.01.018 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EC7KW UT WOS:000388318300005 PM 26845374 ER PT J AU English, LM Hsia, J Malarcher, A AF English, Lorna McLeod Hsia, Jason Malarcher, Ann TI Tobacco advertising, promotion, and sponsorship (TAPS) exposure, anti-TAPS policies, and students' smoking behavior in Botswana and South Africa SO PREVENTIVE MEDICINE LA English DT Article DE Tobacco marketing; Students smoking behavior; Africa; Anti-tobacco policies; Tobacco advertising; Promotion and sponsorship ID SUSCEPTIBILITY AB Objective. We examined the change over time in tobacco advertising, promotion and sponsorship exposure and the concurrent changes in cigarette smoking behavior among students age 13 to 15 years in two African countries with different anti-tobacco advertising, promotion and sponsorship policies. In South Africa, anti-tobacco advertising, promotion and sponsorship policies became more comprehensive over time and were more strictly enforced, whereas the partial anti-tobacco advertising, promotion and sponsorship policies adopted in Botswana were weakly enforced. Method. We analyzed two rounds of Global Youth Tobacco Survey data from South Africa (1999, n = 2342; 2011, n = 3713) and in Botswana (2001, n = 1073; 2008, n = 1605). We assessed several indicators of tobacco advertising, promotion and sponsorship exposure along with prevalence of current cigarette smoking and smoking susceptibility for each data round. Logistic regression was used to examine changes over time in tobacco advertising, promotion and sponsorship exposure and smoking behavior in both countries. Results. Between 1999 and 2011, South African students' exposure to tobacco advertising and sponsorship decreased significantly by 16% (p value, <0.0001) and 14% (p value, <0.0001), respectively. Exposure to tobacco promotion was lower and did not decrease significantly. Botswanan students' tobacco advertising, promotion and sponsorship exposure did not change significantly between 2001 and 2008. South African students' prevalence of cigarette smoking decreased over time (OR, 0.68) as did susceptibility to smoking (OR, 0.75), but declines did not remain significant after adjusting for parents' and friends' smoking. In Botswana, students' prevalence of cigarette smoking increased significantly over time (OR, 1.84), as did susceptibility to smoking (OR, 2.71). Conclusion. Enforcement of strong anti-tobacco advertising, promotion and sponsorship policies is a vital component of effective tobacco control programs in Africa. Such regulations, if effectively implemented, can reduce tobacco advertising, promotion and sponsorship exposure among adolescents and may influence cigarette smoking behavior. (C) 2016 Published by Elsevier Inc. C1 [English, Lorna McLeod; Hsia, Jason; Malarcher, Ann] Ctr Dis Control & Prevent, Off Smoking & Hlth, 4770 Buford Highway NE,Mailstop F-79, Atlanta, GA 30341 USA. RP English, LM (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, 4770 Buford Highway NE,Mailstop F-79, Atlanta, GA 30341 USA. EM lenglish@cdc.gov; zxx1@cdc.gov; aym8@cdc.gov NR 28 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2016 VL 91 SU S BP S28 EP S34 DI 10.1016/j.ypmed.2016.01.014 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EC7KW UT WOS:000388318300006 PM 26824891 ER PT J AU Husain, MJ English, LM Ramanandraibe, N AF Husain, Muhammad Jami English, Lorna McLeod Ramanandraibe, Nivo TI An overview of tobacco control and prevention policy status in Africa SO PREVENTIVE MEDICINE LA English DT Article DE WHO Framework Convention on Tobacco Control; WHO FCTC Articles; MPOWER; Tobacco control and prevention policy status in Africa; WHO FCTC and MPOWER implementation status; WHO African Region AB Tobacco smoking prevalence remains low in many African countries. However, growing economies and the increased presence of multinational tobacco companies in the African Region have the potential to contribute to increasing tobacco use rates in the future. This paper used data from the 2014 Global Progress Report on implementation of theWorld Health Organization Framework Convention on Tobacco Control (WHO FCTC), aswell as the 2015 WHO report on the global tobacco epidemic, to describe the status of tobacco control and prevention efforts in countries in theWHO African Region relative to the provisions of theWHO FCTC andMPOWER package. Among the 23 countries in the African Region analyzed, there are large variations in the overall WHO FCTC implementation rates, ranging from 9% in Sierra Leone to 78% in Kenya. The analysis of MPOWER implementation status indicates that opportunities exist for the African countries to enhance compliance withWHO recommended best practices for monitoring tobacco use, protecting people fromtobacco smoke, offering help to quit tobacco use, warning about the dangers of tobacco, enforcing bans on tobacco advertising and promotion, and raising taxes on tobacco products. If tobacco control interventions are successfully implemented, African nations could avert a tobacco-related epidemic, including premature death, disability, and the associated economic, development, and societal costs. Published by Elsevier Inc. C1 [Husain, Muhammad Jami; English, Lorna McLeod] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA USA. [Ramanandraibe, Nivo] WHO, Reg Off Africa, Brazzaville, Congo. RP Husain, MJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Global Tobacco Control Branch, 4770 Buford Highway NE,Mailstop F-79, Atlanta, GA 30341 USA. EM MHusain@cdc.gov FU Bloomberg Initiative to Reduce Tobacco Use through the CDC Foundation; Bloomberg Philanthropies FX This research is supported in part by the Bloomberg Initiative to Reduce Tobacco Use through the CDC Foundation with grants from Bloomberg Philanthropies. NR 24 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2016 VL 91 SU S BP S16 EP S22 DI 10.1016/j.ypmed.2016.02.017 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EC7KW UT WOS:000388318300004 PM 26876626 ER PT J AU Lee, KA Palipudi, KM English, LM Ramanandraibe, N Asma, S AF Lee, Kyung A. Palipudi, Krishna M. English, Lorna M. Ramanandraibe, Nivo Asma, Samira CA GYTS Collaborative Grp TI Secondhand smoke exposure and susceptibility to initiating cigarette smoking among never-smoking students in selected African countries: Findings from the Global Youth Tobacco Survey SO PREVENTIVE MEDICINE LA English DT Article DE Africa; Global Youth Tobacco Survey; SHS exposure; Students; Susceptibility andYouth ID NICOTINE DEPENDENCE; ADOLESCENTS; PREDICTORS AB Background. Exposure to secondhand smoke (SHS) causes premature death and illness in non-smokers. We examined SHS exposure at home and in public places, as well as susceptibility to initiate cigarette smoking among never cigarette smokers. We used 2006-2011 Global Youth Tobacco Survey (GYTS) data from 29 African countries (56,967 students). Methods. GYTS is a nationally representative, self-administered school-based survey, conducted among students aged 13-15 years. Prevalence ratio, estimates and 95% confidence intervals were computed for SHS exposure in the homes and public places separately. The two-sample t-test was used to assess the difference in susceptibility to smoking by SHS exposure among never-smoking students (alpha= 0.05). Results. Among never-smoking students, exposure to SHS at home ranged from 12.7% (Cape Verde) to 44.0% (Senegal). The prevalence ratio (PR) comparing susceptibility to smoking initiation among never smokers exposed to SHS at home to thosewho were not exposed at home ranged from1.2 to 2.6. Exposure to SHS in public places ranged from23.9% (Cape Verde) to 80.4% (Mali). Of the countries being studied, 8 countries showed a significant difference in susceptibility to smoking initiation among never smokers exposed to SHS in public places compared to those not exposed in public places. (PR ranged from 0.5-3.5). Conclusion. In many African countries in the study, a substantial proportion of students who never smoked are exposed to SHS at home and in public places. Majority of never smokers who were exposed to SHS at home and in public places had a higher prevalence of susceptibility to initiate smoking than those that were not exposed to SHS at home and in public places. Adoption and enforcement of smoke-free policies in public places and smoke-free rules at home could substantially contribute to reducing SHS exposure in many of these countries. (C) 2016 Elsevier Inc. All rights reserved. C1 [Lee, Kyung A.; Palipudi, Krishna M.; English, Lorna M.; GYTS Collaborative Grp] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30333 USA. [Lee, Kyung A.] Northrop Grumman Informat Syst, Atlanta, GA USA. [Ramanandraibe, Nivo] WHO, Reg Off Africa, Brazzaville, Congo. RP Lee, KA (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30333 USA.; Lee, KA (reprint author), Northrop Grumman Informat Syst, Atlanta, GA USA. FU World Health Organization [001] NR 30 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2016 VL 91 SU S BP S2 EP S8 DI 10.1016/j.ypmed.2016.04.017 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EC7KW UT WOS:000388318300002 PM 27138692 ER PT J AU Mbulo, L Ogbonna, N Olarewaju, I Musa, E Salandy, S Ramanandraibe, N Palipudi, K AF Mbulo, Lazarous Ogbonna, Nwokocha Olarewaju, Isiaka Musa, Emmanuel Salandy, Simone Ramanandraibe, Nivo Palipudi, Krishna CA GATS Collaborative Grp TI Preventing tobacco epidemic in LMICs with low tobacco use - Using Nigeria GATS to review WHO MPOWER tobacco indicators and prevention strategies SO PREVENTIVE MEDICINE LA English DT Review DE Tobacco control - Nigeria; Tobacco control and WHO MPOWER - Nigeria; Tobacco control - Low income countries; Tobacco control - Africa ID SMOKING; COUNTRIES; PREVALENCE AB Introduction. Tobacco is a major preventable cause of disease and death globally and increasingly shifting its burden to low and middle-income countries (LMICs) including African countries. We use Nigeria Global Adult Tobacco Survey data to examine indications of a potential tobacco epidemic in a LMIC setting and provide potential interventions to prevent the epidemic. Methodology. Global Adult Tobacco Survey data from Nigeria (2012; sample = 9765) were analyzed to examine key tobacco indicators. Estimates and confidence intervals for each indicator were computed using SPSS software version 21 for complex samples. Results. 5.5% of adult Nigerians use any tobacco and exposure to secondhand smoke was mainly high in bars (80.0%) and restaurants (29.3%). Two-thirds of smokers (66.3%) are interested in quitting. Among those who attempted to quit, 15.0% used counseling/advice and 5.2% pharmacotherapy. Awareness was high that tobacco use causes serious illnesses (82.4%), heart attack (76.8%) and lung cancer (73.0%) but only 51.4% for stroke. Awareness that secondhand smoke can cause serious illnesswas also high (74.5%). Overall 88.5% support tobacco products tax increase. Conclusion. Although tobacco use is relatively low in Nigeria as in other African countries, high smoking rate among men compared to women might indicate potential increase in prevalence. Challenges to preventing increasing smoking rate include limited use of evidence-based cessation methods among quit attempters, social acceptability of smoking particularly in bars and restaurants, and gap in knowledge on tobacco-related diseases. However, ratification of WHO FCTC and signing into law of the Tobacco Control law provide the impetus to implement evidence-based interventions. Published by Elsevier Inc. C1 [Mbulo, Lazarous; Salandy, Simone; Palipudi, Krishna] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Global Tobacco Control Branch, Atlanta, GA 30333 USA. [Ogbonna, Nwokocha] Nigeria Fed Minist Hlth, Abuja, Nigeria. [Olarewaju, Isiaka] Nigeria Natl Bur Stat NBS, Abuja, Nigeria. [Musa, Emmanuel] WHO, Country Off, Abuja, Nigeria. [Ramanandraibe, Nivo] WHO, Africa Reg Off, Brazzaville, Congo. RP Mbulo, L (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Global Tobacco Control Branch, 4770 Buford Highway,MS F-79, Atlanta, GA 30341 USA. EM vyp7@cdc.gov FU Bloomberg Philanthropies' Initiative to Reduce Tobacco Use FX Nigeria GATS was supported by the Bloomberg Philanthropies' Initiative to Reduce Tobacco Use. NR 39 TC 0 Z9 0 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2016 VL 91 SU S BP S9 EP S15 DI 10.1016/j.ypmed.2016.04.005 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EC7KW UT WOS:000388318300003 PM 27085992 ER PT J AU Zhao, LH Palipudi, KM Ramanandraibe, N Asma, S AF Zhao, Luhua Palipudi, Krishna M. Ramanandraibe, Nivo Asma, Samira TI Cigarette smoking and cigarette marketing exposure among students in selected African countries: Findings from the Global Youth Tobacco Survey SO PREVENTIVE MEDICINE LA English DT Article DE Exposure; Cigarette marketing; Tobacco advertising; Promotion and sponsorship; Youth ID ADOLESCENTS; FILMS AB Objective. To investigate cigarette smoking prevalence and exposure to various forms of cigarette marketing among students in 10 African countries. Methods. We used data collected during 2009-2011 from the Global Youth Tobacco Survey (GYTS), a school-based cross-sectional survey of students aged 13-15 years, to measure the prevalence of cigarette smoking and exposure to cigarette marketing; comparisons to estimates from 2005 to 2006 were conducted for five countries where data were available. Results. Current cigarette smoking ranged from 3.4% to 13.6% among students aged 13-15 in the 10 countries studied, although use of tobacco products other than cigarettes was more prevalent in all countries except in Cote D'Ivoire. Cigarette smoking was higher among boys than girls in seven out of the 10 countries. Among the five countries with two rounds of surveys, a significant decrease in cigarette smoking prevalence was observed in Mauritania and Niger; these two countries also experienced a decline in three measures of cigarette marketing exposure. It is also possible that smoking prevalence might have risen faster among girls than boys. Conclusion. Cigarette smoking among youth was noticeable in 10 African countries evaluated, with the prevalence over 10% in Cote D'Ivoire, Mauritania, and South Africa. Cigarette marketing exposure varied by the types of marketing; traditional venues such as TV, outdoor billboards, newspapers, and magazines were still prominent. Published by Elsevier Inc. C1 [Zhao, Luhua; Palipudi, Krishna M.; Asma, Samira] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. [Ramanandraibe, Nivo] WHO, Reg Off Africa, Brazzaville, Congo. RP Zhao, LH (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, MS F79,4770 Buford Highway, Chamblee, GA 30341 USA. EM itz8@cdc.gov; gou8@cdc.gov; ramanadraiben@afro.who.int; sea5@cdc.gov FU Bloomberg Initiative to Reduce Tobacco Use through the CDC Foundation; Bloomberg Philanthropies; Bill & Melinda Gates Foundation FX This research is supported in part by the Bloomberg Initiative to Reduce Tobacco Use through the CDC Foundation with grants from Bloomberg Philanthropies and the Bill & Melinda Gates Foundation. NR 17 TC 0 Z9 0 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2016 VL 91 SU S BP S35 EP S39 DI 10.1016/j.ypmed.2015.12.015 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EC7KW UT WOS:000388318300007 PM 26743632 ER PT J AU Dowell, D Zhang, K Noonan, RK Hockenberry, JM AF Dowell, Deborah Zhang, Kun Noonan, Rita K. Hockenberry, Jason M. TI Mandatory Provider Review And Pain Clinic Laws Reduce The Amounts Of Opioids Prescribed And Overdose Death Rates SO HEALTH AFFAIRS LA English DT Article ID UNITED-STATES; DRUG OVERDOSE; HEROIN USE; EPIDEMIC; ABUSE; FLORIDA; USERS AB To address the opioid overdose epidemic in the United States, states have implemented policies to reduce inappropriate opioid prescribing. These policies could affect the coincident heroin overdose epidemic by either driving the substitution of heroin for opioids or reducing simultaneous use of both substances. We used IMS Health's National Prescription Audit and government mortality data to examine the effect of these policies on opioid prescribing and on prescription opioid and heroin overdose death rates in the United States during 2006-13. The analysis revealed that combined implementation of mandated provider review of state-run prescription drug monitoring program data and pain clinic laws reduced opioid amounts prescribed by 8 percent and prescription opioid overdose death rates by 12 percent. We also observed relatively large but statistically insignificant reductions in heroin overdose death rates after implementation of these policies. This combination of policies was effective, but broader approaches to address these coincident epidemics are needed. C1 [Dowell, Deborah; Zhang, Kun] Ctr Dis Control & Prevent CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Zhang, Kun] CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Noonan, Rita K.] CDC, Natl Ctr Injury Prevent & Control, Hlth Syst & Trauma Syst Branch, Atlanta, GA USA. [Hockenberry, Jason M.] Emory Univ, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. RP Dowell, D (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM gdo7@cdc.gov NR 38 TC 4 Z9 4 U1 4 U2 4 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD OCT PY 2016 VL 35 IS 10 BP 1876 EP 1883 DI 10.1377/hlthaff.2016.0448 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA EB1NA UT WOS:000387118000020 PM 27702962 ER PT J AU Eke, PI Wei, L Thornton-Evans, GO Borrell, LN Borgnakke, WS Dye, B Genco, RJ AF Eke, Paul I. Wei, Liang Thornton-Evans, Gina O. Borrell, Luisa N. Borgnakke, Wenche S. Dye, Bruce Genco, Robert J. TI Risk Indicators for Periodontitis in US Adults: NHANES 2009 to 2012 SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE Diabetes mellitus; dental health surveys; epidemiology; periodontitis; population surveillance; smoking ID DISEASE SURVEILLANCE PROJECT; CURRENT CIGARETTE-SMOKING; UNITED-STATES; CASE DEFINITIONS; NATIONAL-HEALTH; POPULATION; ASSOCIATION; PREVALENCE; OBESITY; UPDATE AB Background: Through the use of optimal surveillance measures and standard case definitions, it is now possible to more accurately determine population-average risk profiles for severe (SP) and non-severe periodontitis (NSP) in adults (aged 30 years and older) in the United States. Methods: Data from the 2009 to 2012 National Health and Nutrition Examination Survey were used, which, for the first time, used the "gold standard'' full-mouth periodontitis surveillance protocol to classify severity of periodontitis following suggested Centers for Disease Control/American Academy of Periodontology case definitions. Probabilities of periodontitis by: 1) sociodemographics, 2) behavioral factors, and 3) comorbid conditions were assessed using prevalence ratios (PRs) estimated by predicted marginal probability from multivariable generalized logistic regression models. Analyses were further stratified by sex for each classification of periodontitis. Results: Likelihood of total periodontitis (TP) increased with age for overall and NSP relative to non-periodontitis. Compared with non-Hispanic whites, TP was more likely in Hispanics (adjusted [a] PR = 1.38; 95% confidence interval 95% CI: 1.26 to 1.52) and non-Hispanic blacks (aPR = 1.35; 95% CI: 1.22 to 1.50), whereas SP was most likely in non-Hispanic blacks (aPR = 1.82; 95% CI: 1.44 to 2.31). There was at least a 50% greater likelihood of TP in current smokers compared with non-smokers. In males, likelihood of TP in adults aged 65 years and older was greater (aPR = 2.07; 95% CI: 1.76 to 2.43) than adults aged 30 to 44 years. This probability was even greater in women (aPR = 3.15; 95% CI: 2.63 to 3.77). Likelihood of TP was higher in current smokers relative to non-smokers regardless of sex and periodontitis classification. TP was more likely in men with uncontrolled diabetes mellitus (DM) compared with adults without DM. Conclusions: Assessment of risk profiles for periodontitis in adults in the United States based on gold standard periodontal measures show important differences by severity of disease and sex. Cigarette smoking, specifically current smoking, remains an important modifiable risk for all levels of periodontitis severity. Higher likelihood of TP in older adults and in males with uncontrolled DM is noteworthy. These findings could improve identification of target populations for effective public health interventions to improve periodontal health of adults in the United States. C1 [Eke, Paul I.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA. [Wei, Liang] DB Consulting Grp, Atlanta, GA USA. [Thornton-Evans, Gina O.] Ctr Dis Control & Prevent, Div Oral Hlth, Atlanta, GA USA. [Borrell, Luisa N.] CUNY, Dept Epidemiol & Biostat, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10021 USA. [Borgnakke, Wenche S.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA. [Dye, Bruce] Natl Inst Dent & Craniofacial Res, Bethesda, MD USA. [Genco, Robert J.] SUNY Buffalo, UB Microbiome Ctr, Sch Dent Med, Buffalo, NY USA. [Genco, Robert J.] SUNY Buffalo, UB Microbiome Ctr, Sch Med, Buffalo, NY USA. [Genco, Robert J.] SUNY Buffalo, UB Microbiome Ctr, Sch Biomed Sci, Buffalo, NY USA. RP Eke, PI (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis & Hlth Promot, Atlanta, GA 30341 USA. EM peke@cdc.gov NR 41 TC 5 Z9 5 U1 6 U2 6 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 EI 1943-3670 J9 J PERIODONTOL JI J. Periodont. PD OCT PY 2016 VL 87 IS 10 BP 1174 EP 1185 DI 10.1902/jop.2016.160013 PG 12 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA EC3EV UT WOS:000388009400012 PM 27367420 ER PT J AU Meaney-Delman, D Oduyebo, T Polen, KND White, JL Bingham, AM Slavinski, SA Heberlein-Larson, L St George, K Rakeman, JL Hills, S Olson, CK Adamski, A Barlow, LC Lee, EH Likos, AM Munoz, JL Petersen, EE Dufort, EM Dean, AB Cortese, MM Santiago, GA Bhatnagar, J Powers, AM Zaki, S Petersen, LR Jamieson, DJ Honein, MA AF Meaney-Delman, Dana Oduyebo, Titilope Polen, Kara N. D. White, Jennifer L. Bingham, Andrea M. Slavinski, Sally A. Heberlein-Larson, Lea St George, Kirsten Rakeman, Jennifer L. Hills, Susan Olson, Christine K. Adamski, Alys Barlow, Lauren Culver Lee, Ellen H. Likos, Anna M. Munoz, Jorge L. Petersen, Emily E. Dufort, Elizabeth M. Dean, Amy B. Cortese, Margaret M. Santiago, Gilberto A. Bhatnagar, Julu Powers, Ann M. Zaki, Sherif Petersen, Lyle R. Jamieson, Denise J. Honein, Margaret A. CA US Zika Pregnancy Registry Prolong TI Prolonged Detection of Zika Virus RNA in Pregnant Women SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID UNITED-STATES; INFECTION; MICRONESIA; ANTIBODY AB OBJECTIVE:Zika virus infection during pregnancy is a cause of microcephaly and other fetal brain abnormalities. Reports indicate that the duration of detectable viral RNA in serum after symptom onset is brief. In a recent case report involving a severely affected fetus, Zika virus RNA was detected in maternal serum 10 weeks after symptom onset, longer than the duration of RNA detection in serum previously reported. This report summarizes the clinical and laboratory characteristics of pregnant women with prolonged detection of Zika virus RNA in serum that were reported to the U.S. Zika Pregnancy Registry.METHODS:Data were obtained from the U.S. Zika Pregnancy Registry, an enhanced surveillance system of pregnant women with laboratory evidence of confirmed or possible Zika virus infection. For this case series, we defined prolonged detection of Zika virus RNA as Zika virus RNA detection in serum by real-time reverse transcription-polymerase chain reaction (RT-PCR) 14 or more days after symptom onset or, for women not reporting signs or symptoms consistent with Zika virus disease (asymptomatic), 21 or more days after last possible exposure to Zika virus.RESULTS:Prolonged Zika virus RNA detection in serum was identified in four symptomatic pregnant women up to 46 days after symptom onset and in one asymptomatic pregnant woman 53 days postexposure. Among the five pregnancies, one pregnancy had evidence of fetal Zika virus infection confirmed by histopathologic examination of fetal tissue, three pregnancies resulted in live births of apparently healthy neonates with no reported abnormalities, and one pregnancy is ongoing.CONCLUSION:Zika virus RNA was detected in the serum of five pregnant women beyond the previously estimated timeframe. Additional real-time RT-PCR testing of pregnant women might provide more data about prolonged detection of Zika virus RNA and the possible diagnostic, epidemiologic, and clinical implications for pregnant women. C1 Ctr Dis Control & Prevent, Off Director, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Div Vector Borne Dis, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. New York State Dept Hlth, Bur Communicable Dis Control, Wadsworth Ctr, Albany, NY 12237 USA. New York State Dept Hlth, Viral Dis Lab, Wadsworth Ctr, Albany, NY 12237 USA. New York State Dept Hlth, Viral Encephalitis Lab Viral Dis, Wadsworth Ctr, Albany, NY 12237 USA. New York City Dept Hlth & Mental Hyg, Bur Communicable Dis, Div Dis Control, New York, NY USA. New York City Dept Hlth & Mental Hyg, Publ Hlth Lab, New York, NY USA. New York State Dept Hlth & Mental Hyg, New York, NY USA. Suffolk Cty Dept Hlth Serv, New York, NY USA. Florida Dept Hlth, Bur Epidemiol, Tallahassee, FL USA. Florida Dept Hlth, Div Dis Control & Hlth Protect, Tallahassee, FL USA. RP Meaney-Delman, D (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,Mailstop C-12, Atlanta, GA 30333 USA. EM vmo0@cdc.gov NR 26 TC 13 Z9 13 U1 7 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD OCT PY 2016 VL 128 IS 4 BP 724 EP 730 DI 10.1097/AOG.0000000000001625 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DX6VT UT WOS:000384523600007 PM 27479770 ER PT J AU Mactaggart, I Cappa, C Kuper, H Loeb, M Polack, S AF Mactaggart, Islay Cappa, Claudia Kuper, Hannah Loeb, Mitchell Polack, Sarah TI Field testing a draft version of the UNICEF/Washington Group Module on child functioning and disability. Background, methodology and preliminary findings from Cameroon and India SO ALTER-EUROPEAN JOURNAL OF DISABILITY RESEARCH LA English DT Article DE Child disability; Functioning; Measurement; Field testing ID HEALTH; IMPAIRMENT; BEHAVIOR AB Background. - Global child disability data are generally non comparable, comprising different tools, methodologies and disability definitions. UNICEF and The Washington Group on Disability Statistics (WG) have developed a new tool on child functioning and disability to address this need. Aims. - The aim of this paper is to describe the development of the new module, and to present an independent field test of the draft module in two contrasting settings. Methods. - UNICEF and the WG developed a parent -reported survey module to identify children aged 2-17 years with functional difficulties in population-based surveys through: review of existing documentation, consultation with experts and cognitive testing. A field test of the draft module was undertaken in Cameroon and India within a population-based survey. Functional limitation in each of 14 domains was scored on a scale comprising "no difficulty", "some difficulty", "a lot of difficulty" and "cannot do". Results. - In all, 1713 children in Cameroon and 1101 children in India were assessed. Sixty-four percent of children in Cameroon and 35% of children in India were reported to have at least some difficulty in one or more domain. The proportion reported to have either "a lot of difficulty" or "cannot do" was 9% in Cameroon and 4% in India. There were no significant differences in reported functional difficulties by sex but children aged 2-4 were reported to have fewer functional difficulties of any kind compared with older children in both countries. Conclusion. - Comparable estimates were generated between the two countries, providing an initial overview of the tool's outputs. The continued development of this standardised questionnaire for the collection of robust and reliable data on child disability is essential. (C) 2016 Association ALTER. Published by Elsevier Masson SAS. All rights reserved. C1 [Mactaggart, Islay; Kuper, Hannah; Polack, Sarah] London Sch Hyg & Trop Med, Int Ctr Evidence Disabil, London, England. [Cappa, Claudia] United Nations Childrens Fund New, Data & Analyt Sect, New York, NY USA. [Loeb, Mitchell] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Mactaggart, I (reprint author), London Sch Hyg & Trop Med, Int Ctr Evidence Disabil, London, England. EM Islay.mactaggart@lshtm.ac.uk NR 24 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER MASSON PI MILANO PA VIA PALEOCAPA 7, 20121 MILANO, ITALY SN 1875-0672 EI 1875-0680 J9 ALTER JI Alter PD OCT-DEC PY 2016 VL 10 IS 4 BP 345 EP 360 DI 10.1016/j.alter.2016.09.003 PG 16 WC Rehabilitation SC Rehabilitation GA EA8JL UT WOS:000386881000006 ER PT J AU Gu, JK Charles, LE Ma, CC Andrew, ME Fekedulegn, D Hartley, TA Violanti, JM Burchfiel, CM AF Gu, Ja K. Charles, Luenda E. Ma, Claudia C. Andrew, Michael E. Fekedulegn, Desta Hartley, Tara A. Violanti, John M. Burchfiel, Cecil M. TI Prevalence and trends of leisure-time physical activity by occupation and industry in US workers: the National Health Interview Survey 2004-2014 SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Prevalence; Leisure-time physical activity; Occupation; Industry ID UNITED-STATES; FITNESS; DISEASE; ASSOCIATION; OBESITY; ADULTS; RISK AB Purpose: Studies describing prevalence and trends of physical activity among workers in the United States are scarce. We aimed to estimate prevalence and trends of "sufficient" leisure-time physical activity (LTPA) during the 2004-2014 time period among U.S. workers. Methods: Data were collected for U.S. workers in the National Health Interview Survey. LTPA was categorized as sufficiently active (moderate intensity, >150 minutes per week), insufficiently active (10-149 minutes per week), and inactive (<10 minutes per week). Prevalence of LTPA was adjusted for age using 2010 U.S. working population as a standardized age distribution. Results: Prevalence trends of "sufficient" LTPA significantly increased from 2004 to 2014 (45.6% to 54.8%; P < .001). Among industry groups, the highest prevalence of "sufficient" LTPA was observed among workers in Professional/Scientific/Technical Services (62.1%). The largest increases were observed among workers in Public Administration (51.3%-63.4%). Among occupational groups, "sufficient" LTPA prevalence was lowest in farming/fishing/forestry (30.8%) and highest in life/physical/social science (66.4%). Prevalence of LTPA significantly increased from 2004 to 2014 in most occupational and industry groups. Conclusions: Among U.S. workers, trends of "sufficient" LTPA significantly increased between 2004 and 2014. Overall, a larger proportion of white-collar compared to blue-collar workers were engaged in "sufficient" LTPA. Published by Elsevier Inc. C1 [Gu, Ja K.; Charles, Luenda E.; Ma, Claudia C.; Andrew, Michael E.; Fekedulegn, Desta; Hartley, Tara A.; Burchfiel, Cecil M.] Ctr Dis Control & Prevent, Natl Hlth Inst Occupat Safety & Hlth, Hlth Effects Lab Div, Biostat & Epidemiol Branch, Morgantown, WV USA. [Violanti, John M.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY USA. RP Gu, JK (reprint author), HELD BEB, Natl Inst Occupat Safety & Hlth, Mailstop L-4050,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM jgu@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 0 Z9 0 U1 7 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD OCT PY 2016 VL 26 IS 10 BP 685 EP 692 DI 10.1016/j.annepidem.2016.08.004 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EB8HJ UT WOS:000387631800005 PM 27659584 ER PT J AU VanderEnde, K Mercy, J Shawa, M Kalanda, M Hamela, J Maksud, N Ross, B Gupta, S Wadonda-Kabondo, N Hillis, S AF VanderEnde, Kristin Mercy, James Shawa, Mary Kalanda, McKnight Hamela, Justin Maksud, Nankali Ross, Brendan Gupta, Sundeep Wadonda-Kabondo, Nellie Hillis, Susan TI Violent experiences in childhood are associated with men's perpetration of intimate partner violence as a young adult: a multistage cluster survey in Malawi SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Violence against children; Intimate partner violence; Domestic violence; Perpetration; Malawi; Violence Against Children Survey ID DOMESTIC VIOLENCE; RISK BEHAVIORS; WOMEN; METAANALYSES; CONSEQUENCES; PREVALENCE; PREGNANCY; ABUSE; DEATH; ACE AB Purpose: To examine the association between exposures to violence in childhood, including exposure to multiple forms of violence, with young men's perpetration of intimate partner violence (IPV) in Malawi. Methods: We analyzed data from 450 ever-partnered 18- to 24-year-old men interviewed in the Malawi Violence Against Children and Young Woman Survey, a nationally representative, multistage cluster survey conducted in 2013. We estimated the weighted prevalence for perpetration of physical and/or sexual IPV and retrospective reporting of experiences of violence in childhood and examined the associations between childhood experiences of violence and perpetration of IPV using logistic regression. Results: Among young men in Malawi, lifetime prevalence for perpetration of sexual IPV (24%) was higher than for perpetration of physical IPV (9%). In logistic regression analyses, the adjusted odds ratios for perpetration of sexual IPV increased in a statistically significant gradient fashion, from 1.2 to 1.4 to 3.7 to 4.3 for young men with exposures to one, two, three, and four or more forms of violence in childhood, respectively. Conclusions: Among young men in Malawi, exposure to violence in childhood is associated with an increased odds of perpetrating IPV, highlighting the need for programs and policies aimed at interrupting the intergenerational transmission of violence. (C) 2016 Elsevier Inc. All rights reserved. C1 [VanderEnde, Kristin] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [VanderEnde, Kristin; Mercy, James; Hillis, Susan] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Shawa, Mary; Kalanda, McKnight; Hamela, Justin] Malawi Minist Gender Children Disabil & Social We, Lilongwe, Malawi. [Maksud, Nankali; Ross, Brendan] United Nations Int Childrens Emergency Fund Malaw, Lilongwe, Malawi. [Gupta, Sundeep; Wadonda-Kabondo, Nellie] Ctr Dis Control & Prevent, Malawi, Lilongwe, Malawi. RP VanderEnde, K (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. EM ydj3@cdc.gov FU government of the United Kingdom; Ministry of Gender, Children, Disability and Social Welfare (MoGCDSW); Center for Social Research at the University of Malawi; United Nations Children's Fund in Malawi (UNICEF Malawi); President's Emergency Plan For Aids Relief (PEPFAR) FX The authors thank the survey participants who shared their experiences of violence so that this information might lead to the prevention of future violence. The authors thank the team leaders and interviewers who took great care in interviewing children and young adults, always placing the privacy and safety of the participants first. The authors thank Juliette Lee and Scott Kegler for their critical input. The Ministry of Gender, Children, Disability and Social Welfare (MoGCDSW), the Center for Social Research at the University of Malawi, the United Nations Children's Fund in Malawi (UNICEF Malawi), and the President's Emergency Plan For Aids Relief (PEPFAR) conducted the Violence Against Children and Young Women survey in Malawi (VACS Malawi), with funding provided by the government of the United Kingdom. The technical guidance and coordination of this study was provided by the Centers for Disease Control and Prevention (CDC) and implemented by the Center for Social Research at the University of Malawi. Funding for the implementation and coordination of the survey was provided by the government of the United Kingdom. NR 33 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD OCT PY 2016 VL 26 IS 10 BP 723 EP 728 DI 10.1016/j.annepidem.2016.08.007 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EB8HJ UT WOS:000387631800011 PM 27793275 ER PT J AU Croston, TL Nayak, AP Lemons, AR Goldsmith, WT Gu, JK Germolec, DR Beezhold, DH Green, BJ AF Croston, T. L. Nayak, A. P. Lemons, A. R. Goldsmith, W. T. Gu, J. K. Germolec, D. R. Beezhold, D. H. Green, B. J. TI Influence of Aspergillus fumigatus conidia viability on murine pulmonary microRNA and mRNA expression following subchronic inhalation exposure SO CLINICAL AND EXPERIMENTAL ALLERGY LA English DT Article DE allergens and epitopes; animal models; genetics ID HELICOBACTER-PYLORI INFECTION; ALLERGIC AIRWAYS DISEASE; BETA-GLUCAN RECEPTOR; CIGARETTE-SMOKE; MOUSE LUNG; CELLULAR MICRORNA; IMMUNE-RESPONSES; GENE-EXPRESSION; DOWN-REGULATION; T-CELLS AB Background Personal exposure to fungal bioaerosols derived from contaminated building materials or agricultural commodities may induce or exacerbate a variety of adverse health effects. The genomic mechanisms that underlie pulmonary immune responses to fungal bioaerosols have remained unclear. Objective The impact of fungal viability on the pulmonary microRNA and messenger RNA profiles that regulate murine immune responses was evaluated following subchronic inhalation exposure to Aspergillus fumigatus conidia. Methods Three groups of naive B6C3F1/N mice were exposed via nose-only inhalation to A. fumigatus viable conidia, heat-inactivated conidia (HIC), or HEPA-filtered air twice a week for 13 weeks. Total RNA was isolated from whole lung 24 and 48 h postfinal exposure and was further processed for gene expression and microRNA array analysis. The molecular network pathways between viable and HIC groups were evaluated. Results Comparison of data sets revealed increased Il4, Il13 and Il33 expression in mice exposed to viable vs. HIC. Of 415 microRNAs detected, approximately 50% were altered in mice exposed to viable vs. HIC 48 h postexposure. Significantly down-regulated (P <= 0.05) miR-29a-3p was predicted to regulate TGF-beta 3 and Clec7a, genes involved in innate responses to viable A. fumigatus. Also significantly down-regulated (P <= 0.05), miR-23b-3p regulates genes involved in pulmonary IL-13 and IL-33 responses and SMAD2, downstream of TGF-b signalling. Using Ingenuity Pathway Analysis, a novel interaction was identified between viable conidia and SMAD2/3. Conclusions and Clinical Relevance Examination of the pulmonary genetic profiles revealed differentially expressed genes and microRNAs following subchronic inhalation exposure to A. fumigatus. MicroRNAs regulating genes involved in the pulmonary immune responses were those with the greatest fold change. Specifically, germinating A. fumigatus conidia were associated with Clec7a and were predicted to interact with Il13 and Il33. Furthermore, altered microRNAs may serve as potential biomarkers to evaluate fungal exposure. C1 [Croston, T. L.; Nayak, A. P.; Lemons, A. R.; Green, B. J.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. [Goldsmith, W. T.] NIOSH, Engn & Control Technol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Gu, J. K.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Germolec, D. R.] NIEHS, Toxicol Branch, DNTP, POB 12233, Res Triangle Pk, NC 27709 USA. [Beezhold, D. H.] NIOSH, Off Director, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. RP Croston, TL (reprint author), NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM xzu9@cdc.gov OI Lemons, Angela/0000-0003-3057-9888 FU NIOSH [AES12007001-1-0-6]; NIEHS [AES12007001-1-0-6]; Centers for Disease Control and Prevention-NIOSH [927ZLCT] FX The authors acknowledge Dr. Michael Kashon in the Biostatistics and Epidemiology Branch, National Institute for Occupational Safety and Health (NIOSH), for assistance with statistical analysis and representation, as well as Brandon F. Law in the Allergy and Clinical Immunology Branch, NIOSH, for assistance in harvesting and processing samples. The authors would also thank Dr. Paivi Salo from the National Institute of Environmental Health Sciences (NIEHS) and Dr. John Noti, NIOSH for participating in the internal NIEHS and NIOSH review process. This study was supported in part by an interagency agreement between NIOSH and NIEHS (AES12007001-1-0-6) as a collaborative National Toxicology Program research activity. This study was also funded in part by Centers for Disease Control and Prevention-NIOSH intramural funds (927ZLCT). The findings and conclusions in this study are those of the authors and do not necessarily represent the views of National Institute for Occupational Safety and Health. NR 70 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0954-7894 EI 1365-2222 J9 CLIN EXP ALLERGY JI Clin. Exp. Allergy PD OCT PY 2016 VL 46 IS 10 BP 1315 EP 1327 DI 10.1111/cea.12783 PG 13 WC Allergy; Immunology SC Allergy; Immunology GA EA9IR UT WOS:000386956900007 PM 27473664 ER PT J AU Kardous, CA Shaw, PB AF Kardous, Chucri A. Shaw, Peter B. TI Evaluation of smartphone sound measurement applications (apps) using external microphones-A follow-up study SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article AB This follow-up study examines the accuracy of selected smartphone sound measurement applications (apps) using external calibrated microphones. The initial study examined 192 apps on the iOS and Android platforms and found four iOS apps with mean differences of +/- 2 dB of a reference sound level measurement system. This study evaluated the same four apps using external microphones. The results showed measurements within +/- 1 dB of the reference. This study suggests that using external calibrated microphones greatly improves the overall accuracy and precision of smartphone sound measurements, and removes much of the variability and limitations associated with the built-in smartphone microphones. C1 [Kardous, Chucri A.; Shaw, Peter B.] NIOSH, 1090 Tusculum Ave, Cincinnati, OH 45226 USA. RP Kardous, CA (reprint author), NIOSH, 1090 Tusculum Ave, Cincinnati, OH 45226 USA. EM ckardous@cdc.gov; pbs3@cdc.gov FU Intramural CDC HHS [CC999999] NR 7 TC 0 Z9 0 U1 0 U2 0 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 EI 1520-8524 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD OCT PY 2016 VL 140 IS 4 BP EL327 EP EL333 DI 10.1121/1.4964639 PG 7 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA EB3JN UT WOS:000387260600007 PM 27794313 ER PT J AU Palmer, A Painter, J Hassler, H Richards, VP Bruce, T Morrison, S Brown, E Kozak-Muiznieks, NA Lucas, C McNealy, TL AF Palmer, Allison Painter, Joseph Hassler, Hayley Richards, Vincent P. Bruce, Terri Morrison, Shatavia Brown, Ellen Kozak-Muiznieks, Natalia A. Lucas, Claressa McNealy, Tamara L. TI Legionella clemsonensis sp nov.: a green fluorescing Legionella strain from a patient with pneumonia SO MICROBIOLOGY AND IMMUNOLOGY LA English DT Article ID PNEUMOPHILA AB A novel Legionella species was identified based on sequencing, cellular fatty acid analysis, biochemical reactions, and biofilm characterization. Strain D5610 was originally isolated from the bronchial wash of a patient in Ohio, USA. The bacteria were gram-negative, rod-shaped, and exhibited green fluorescence under long wave UV light. Phylogenetic analysis and fatty acid composition revealed a distinct separation within the genus. The strain grows between 26-45 degrees C and forms biofilms equivalent to L. pneumophila Philadelphia 1. These characteristics suggest that this isolate is a novel Legionella species, for which the name Legionella clemsonensis sp nov. is proposed. C1 [Palmer, Allison; Painter, Joseph; Hassler, Hayley; Richards, Vincent P.; McNealy, Tamara L.] Clemson Univ, Dept Biol Sci, Life Sci Bldg,190 Collings St, Clemson, SC 29631 USA. [Bruce, Terri] Clemson Univ, Clemson Light Imaging Facil, 190 Collings St, Clemson, SC 29631 USA. [Morrison, Shatavia; Brown, Ellen; Kozak-Muiznieks, Natalia A.; Lucas, Claressa] Ctr Dis Control, 1600 Clifton Rd, Atlanta, GA 30333 USA. RP McNealy, TL (reprint author), Clemson Univ, Life Sci Bldg,Rm 157B,190 Collings St, Clemson, SC 29631 USA. EM tmcneal@clemson.edu FU Clemson University Creative Inquiry program FX Characterization of this novel strain was financially supported by the Clemson University Creative Inquiry program, a unique undergraduate research program providing inquiry-based, relevant research experiences for students. Biotype analysis was conducted at the Ernst Laboratory at the University of Maryland Baltimore, with special thanks to Allison Scott for assistance. The authors also acknowledge the support and efforts of the following members of the CU and CDC Creative Inquiry group: Kyle Toth, Rayphael Hardy, Scott Howard and Kasey Remillard. NR 18 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0385-5600 EI 1348-0421 J9 MICROBIOL IMMUNOL JI Microbiol. Immunol. PD OCT PY 2016 VL 60 IS 10 BP 694 EP 701 DI 10.1111/1348-0421.12439 PG 8 WC Immunology; Microbiology SC Immunology; Microbiology GA EB0AS UT WOS:000387006400005 PM 27619817 ER PT J AU Switzer, A Munson, L Beesley, C Wilkins, P Blackburn, JK Marker, L AF Switzer, Alexandra Munson, Linda Beesley, Cari Wilkins, Patricia Blackburn, Jason K. Marker, Laurie TI Namibian farmland cheetahs (Acinonyx jubatus) demonstrate seronegativity for antibodies against Bacillus anthracis SO AFRICAN JOURNAL OF WILDLIFE RESEARCH LA English DT Article ID ETOSHA-NATIONAL-PARK; WILDLIFE C1 [Switzer, Alexandra; Munson, Linda] Univ Calif Davis, Sch Vet Med, One Shields Ave, Davis, CA 95616 USA. [Switzer, Alexandra] Stanford Sch Med, 291 Campus Dr, Stanford, CA 94305 USA. [Beesley, Cari; Wilkins, Patricia] Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. [Blackburn, Jason K.] Univ Florida, Dept Geog, Spatial Epidemiol & Ecol Res Lab, 3141 Turlington Hall, Gainesville, FL 32611 USA. [Blackburn, Jason K.] Univ Florida, Emerging Pathogens Inst, 2055 Mowry Rd, Gainesville, FL 32611 USA. [Marker, Laurie] Cheetah Conservat Fund, POB 1755, Otjiwarongo, Namibia. RP Switzer, A (reprint author), Univ Calif Davis, Sch Vet Med, One Shields Ave, Davis, CA 95616 USA.; Switzer, A (reprint author), Stanford Sch Med, 291 Campus Dr, Stanford, CA 94305 USA. EM aswitzer@stanford.edu NR 18 TC 0 Z9 0 U1 0 U2 0 PU SOUTHERN AFRICAN WILDLIFE MANAGEMENT ASSOC PI BLOUBERGSTRAND PA P O BOX 217, BLOUBERGSTRAND 7437, SOUTH AFRICA SN 2410-7220 EI 2410-8200 J9 AFR J WILDL RES JI Afr. J. Wildl. Res. PD OCT PY 2016 VL 46 IS 2 BP 139 EP 143 DI 10.3957/056.046.0139 PG 5 WC Ecology; Zoology SC Environmental Sciences & Ecology; Zoology GA DZ7OD UT WOS:000386054700007 ER PT J AU Elmes, J Hess, K Silhol, R Anton, P Shacklett, B McGowan, I Paz-Bailey, G Boily, MC AF Elmes, Jocelyn Hess, Kristen Silhol, Romain Anton, Peter Shacklett, Barbara McGowan, Ian Paz-Bailey, Gabriela Boily, Marie-Claude CA NHBS Study Grp TI Meta-analysis and Modelling Study of Anal Sex Practices and Its Contribution to HIV Incidence among High-risk Women Across Twenty US Cities SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Elmes, Jocelyn; Silhol, Romain; Boily, Marie-Claude] Imperial Coll London, London, England. [Hess, Kristen; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Atlanta, GA USA. [Anton, Peter] Univ Calif Los Angeles, Los Angeles, CA USA. [Shacklett, Barbara] Univ Calif Davis, Davis, CA 95616 USA. [McGowan, Ian] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA05.02 BP 48 EP 48 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600075 ER PT J AU Wimonsate, W Pattanasin, S Luechai, P Sriporn, A Winaitham, S Mock, P Ungsedhapand, C Dunne, E Chitwarakorn, A Holtz, T AF Wimonsate, Wipas Pattanasin, Sarika Luechai, Pikunchai Sriporn, Anuwat Winaitham, Santi Mock, Philip Ungsedhapand, Chaiwat Dunne, Eileen Chitwarakorn, Anupong Holtz, Timothy TI HIV Incidence Factors and Trends in Voluntary Counseling and Testing, Silom Community Clinic, Bangkok, Thailand, 2005-2015 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Wimonsate, Wipas; Pattanasin, Sarika; Luechai, Pikunchai; Sriporn, Anuwat; Winaitham, Santi; Mock, Philip; Ungsedhapand, Chaiwat; Dunne, Eileen; Holtz, Timothy] Thailand MOPH US CDC Collaborat, Nonthaburi, Thailand. [Dunne, Eileen; Holtz, Timothy] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Chitwarakorn, Anupong] Minist Publ Hlth, Nonthaburi, Thailand. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA05.04 BP 49 EP 49 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600077 ER PT J AU Zhao, CX Gunawardana, M Villinger, F Baum, M Chan, R Moench, T Whaley, K Bohorov, O Smith, T Anderson, D Moss, J AF Zhao, Chunxia Gunawardana, Manjula Villinger, Francois Baum, Marc Chan, Remedios Moench, Thomas Whaley, Kevin Bohorov, Ognian Smith, Thomas Anderson, Deborah Moss, John TI Pharmacokinetics and Safety of Pod-intravaginal Rings Delivering VRC01-N for HIV Prophylaxis in a Macaque Model SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Zhao, Chunxia] Emory Univ, Atlanta, GA 30322 USA. [Zhao, Chunxia] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gunawardana, Manjula; Baum, Marc; Smith, Thomas; Moss, John] Oak Crest Inst Sci, Pasadena, CA USA. [Villinger, Francois] Univ Louisiana Lafayette, Lafayette, LA 70504 USA. [Chan, Remedios] Auritec Pharmaceut, Pasadena, CA USA. [Moench, Thomas] Reprotect Inc, Towson, MD USA. [Whaley, Kevin; Bohorov, Ognian] Mapp Biopharmaceut, San Diego, CA USA. [Anderson, Deborah] Boston Univ, Sch Med, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA06.02 BP 51 EP 51 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600081 ER PT J AU Massud, I Sykes, DC Cong, ME Ellis, S Kelley, K Heneine, W Kashuba, ADM Garcia-Lerma, JG AF Massud, Ivana Sykes, D. Craig Cong, Mian-Er Ellis, Shanon Kelley, Kristen Heneine, Walid Kashuba, Angela D. M. Garcia-Lerma, J. Gerardo TI Pharmacokinetic Profile of Lamivudine (3TC) in Macaques and Relative Drug Exposure in Rectal and Vaginal Tissues SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Massud, Ivana; Cong, Mian-Er; Ellis, Shanon; Kelley, Kristen; Heneine, Walid; Garcia-Lerma, J. Gerardo] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sykes, D. Craig; Kashuba, Angela D. M.] Univ N Carolina, Chapel Hill, NC 27515 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA06.03 BP 52 EP 52 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600082 ER PT J AU Mitchell, KM Hoots, B Dimitrov, D Farley, J Gelman, M German, D Flynn, C Adeyeye, A Remien, RH Beyrer, C Paz-Bailey, G Boily, MC AF Mitchell, Kate M. Hoots, Brooke Dimitrov, Dobromir Farley, Jason Gelman, Marcy German, Danielle Flynn, Colin Adeyeye, Adeola Remien, Robert H. Beyrer, Chris Paz-Bailey, Gabriela Boily, Marie-Claude TI Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV-positive MSM in Baltimore: Mathematical Modelling for HPTN 078 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Mitchell, Kate M.; Boily, Marie-Claude] Imperial Coll London, London, England. [Hoots, Brooke; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dimitrov, Dobromir] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Farley, Jason; German, Danielle; Beyrer, Chris] Johns Hopkins Univ, Baltimore, MD 21218 USA. [Gelman, Marcy] Fenway Inst, Boston, MA USA. [Flynn, Colin] Maryland Dept Hlth & Mental Hyg, Baltimore, MD 21201 USA. [Adeyeye, Adeola] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA. [Remien, Robert H.] NY State Psychiat Inst, New York, NY USA. [Remien, Robert H.] Columbia Univ, New York, NY 10027 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA10.04 BP 64 EP 64 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600107 ER PT J AU Smith, D Weiss, G Kitlas, A Newman, S Ye, JL AF Smith, Dawn Weiss, Gretchen Kitlas, Alyssa Newman, Sarah Ye, Jiali TI PrEP Implementation by Local Health Departments in US Cities and Counties: Findings from a 2015 Assessment of Local Health Departments SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Smith, Dawn] Ctr Dis Control & Prevent, Atlanta, GA USA. [Weiss, Gretchen; Kitlas, Alyssa; Newman, Sarah; Ye, Jiali] Natl Assoc Cty & City Hlth Officials, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA16.03 BP 82 EP 82 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600142 ER PT J AU Srinivasan, P Moss, JA Zhang, JN Gunawardana, M Marzinke, MA Li, B Baum, MM Smith, JM AF Srinivasan, Priya Moss, John A. Zhang, Jining Gunawardana, Manjula Marzinke, Mark A. Li, Bin Baum, Marc M. Smith, James M. TI Pharmacokinetics of a Multipurpose Prevention Technology Pod-intravaginal Ring for HIV-1, HSV, and Contraception SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Srinivasan, Priya; Li, Bin; Smith, James M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Moss, John A.; Gunawardana, Manjula; Baum, Marc M.] Oak Crest Inst Sci, Monrovia, CA USA. [Zhang, Jining] Total Solut Inc, Atlanta, GA USA. [Marzinke, Mark A.] Johns Hopkins Univ, Baltimore, MD 21218 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA PD03.04 BP 115 EP 115 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600207 ER PT J AU Ham, A Srinivasan, P Pereira, L Buckheit, K Martin, A Singletary, T Zhang, JN Katz, D Smith, J Buckheit, R AF Ham, Anthony Srinivasan, Priya Pereira, Lara Buckheit, Karen Martin, Amy Singletary, Tyana Zhang, Jining Katz, David Smith, James Buckheit, Robert, Jr. TI IQP-0528: The Pharmacokinetics of an Anti-HIV NNRTI in Non-human Primates from Various Dosage Forms SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Ham, Anthony; Buckheit, Karen; Buckheit, Robert, Jr.] ImQuest BioSci, Frederick, MD USA. [Srinivasan, Priya; Martin, Amy; Smith, James] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pereira, Lara] LifeSource BioMed, Herndon, VA USA. [Singletary, Tyana] Anyar, Herndon, VA USA. [Zhang, Jining] Total Solut, Davenport, IA USA. [Katz, David] Duke Univ, Durham, NC 27706 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA PD03.05 BP 116 EP 116 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600208 ER PT J AU Mukura, R Charalambous, S Mudzengi, D Chetty-Makkan, CM Grund, J Maraisane, M Bere, A Holmes, M AF Mukura, Rachel Charalambous, Salome Mudzengi, Don Chetty-Makkan, Candice M. Grund, Jonathan Maraisane, Mpho Bere, Alfred Holmes, Marionette TI Costs of Recruiting Men for Medical Male Circumcision in a Peri-urban Clinic in Johannesburg, South Africa: Results from the IMBIZO Study SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Mukura, Rachel] Wits Publ Hlth & Hlth Transit Unit, Johannesburg, South Africa. [Charalambous, Salome; Mudzengi, Don; Chetty-Makkan, Candice M.; Maraisane, Mpho] Aurum Inst, Johannesburg, South Africa. [Charalambous, Salome] Univ Witwatersrand, Sch Publ Hlth, ZA-2050 Johannesburg, South Africa. [Grund, Jonathan; Holmes, Marionette] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bere, Alfred] Ctr Dis Control & Prevent, Durban, South Africa. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P02.32 BP 165 EP 165 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600295 ER PT J AU Dobard, C Sharma, S Jhunjhunwala, K Dinh, C Martin, A Holder, A Garcia-Lerma, G Rohan, L Heneine, W AF Dobard, Charles Sharma, Sunita Jhunjhunwala, Kunal Dinh, Chuong Martin, Amy Holder, Angela Garcia-Lerma, Gerardo Rohan, Lisa Heneine, Walid TI Pharmacokinetic Evaluation of Rectal Tenofovir Suppositories in Macaques SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Dobard, Charles; Sharma, Sunita; Dinh, Chuong; Martin, Amy; Holder, Angela; Garcia-Lerma, Gerardo; Heneine, Walid] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Branch Lab, Atlanta, GA USA. [Jhunjhunwala, Kunal; Rohan, Lisa] Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P07.07 BP 211 EP 211 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600384 ER PT J AU Katz, D Ham, A Smith, J Guthrie, K Simons, M Gao, YJ Peters, J Yuan, A Henderson, M Pereira, L Singletary, T Fava, J Vargas, S Buckheit, K Murtha, A Buckheit, R AF Katz, David Ham, Anthony Smith, James Guthrie, Kate Simons, Morgan Gao, Yajing Peters, Jennifer Yuan, Andrew Henderson, Marcus Pereira, Lara Singletary, Tyana Fava, Joseph Vargas, Sara Buckheit, Karen Murtha, Amy Buckheit, Robert TI Do Microbicide Gel Volume and Properties Matter? Effects on Deployment, PK and User Sensory Perceptions and Experiences SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Katz, David; Simons, Morgan; Gao, Yajing; Peters, Jennifer; Yuan, Andrew; Henderson, Marcus; Murtha, Amy] Duke Univ, Durham, NC 27706 USA. [Ham, Anthony; Buckheit, Karen; Buckheit, Robert] ImQuest BioSci, Frederick, MD USA. [Smith, James] Ctr Dis Control & Prevent, Atlanta, GA USA. [Guthrie, Kate; Fava, Joseph; Vargas, Sara] Brown Univ, Providence, RI 02912 USA. [Pereira, Lara] LifeSource BioMed, Mountain View, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P07.09 BP 212 EP 212 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600386 ER PT J AU Halavaty, KK Ott, A Su, J Maric, D Matias, E Sung, S Pereira, L Smith, J Kiser, P Hope, T AF Halavaty, Katarina Kotnik Ott, Adina Su, Jonathan Maric, Danijela Matias, Edgar Sung, Samuel Pereira, Lara Smith, James Kiser, Patrick Hope, Thomas TI In Vivo PK/PD with Single Round Reporter Viruses: Drug Distribution and Infection Sites in Nonhuman Primates in the Presence of an Intravaginal Ring SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Halavaty, Katarina Kotnik; Ott, Adina; Su, Jonathan; Maric, Danijela; Matias, Edgar; Sung, Samuel; Kiser, Patrick; Hope, Thomas] Northwestern Univ, Evanston, IL 60208 USA. [Pereira, Lara] Lifesource Biomed LLC, Herndon, VA USA. [Smith, James] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P07.29 BP 222 EP 222 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600406 ER PT J AU Clark, MR Evanoff, AJ Anderson, SM Aesram, A Chandra, N Kimble, TD Kerr, B Abdelmawla, F Bushman, L Singletary, T Dietz-Ostergaard, S Pereira, L Smith, JM Anderson, PL Heneine, W Kiser, PF Doncel, GF AF Clark, Meredith R. Evanoff, Alexander J. Anderson, Sharon M. Aesram, Anisa Chandra, Neelima Kimble, Thomas D. Kerr, Becky Abdelmawla, Farah Bushman, Lane Singletary, Tyana Dietz-Ostergaard, Sharon Pereira, Lara Smith, James M. Anderson, Peter L. Heneine, Walid Kiser, Patrick F. Doncel, Gustavo F. TI Long-acting Intrauterine System Delivers Integrase Inhibitor Throughout the Reproductive Tract of Rabbits and Macaques SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Clark, Meredith R.; Anderson, Sharon M.; Chandra, Neelima; Kimble, Thomas D.; Doncel, Gustavo F.] Eastern Virginia Med Sch, CONRAD, Norfolk, VA 23501 USA. [Evanoff, Alexander J.; Aesram, Anisa; Kiser, Patrick F.] Northwestern Univ, Evanston, IL 60208 USA. [Kerr, Becky; Abdelmawla, Farah; Bushman, Lane; Anderson, Peter L.] Univ Colorado, Denver, CO 80202 USA. [Singletary, Tyana] Anyar Inc, Ft Walton Beach, FL USA. [Dietz-Ostergaard, Sharon; Smith, James M.; Heneine, Walid] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pereira, Lara] Lifesource Biomed LLC, Herndon, VA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P07.40 BP 227 EP 227 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600417 ER PT J AU Donnell, D Gray, KM Li, JM Wu, BH Benbow, N Schuette, S Brady, K Torian, L Xia, Q Saafir-Callaway, B Opoku, J Lum, G Meyer, J Hanscom, B Hall, I AF Donnell, Deborah Gray, Kristen Mahle Li, Jianmin Wu, Baohua Benbow, Nanette Schuette, Stephanie Brady, Kathleen Torian, Lucia Xia, Qiang Saafir-Callaway, Brittani Opoku, Jenevieve Lum, Garret Meyer, Jeffrey Hanscom, Brett Hall, Irene TI Encouraging Trends in HIV Diagnoses, Care and Viral Suppression in 5 US Cities, 2009-2013: Surveillance-based Data from HPTN 065 (TLC-plus) SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Donnell, Deborah; Hanscom, Brett] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Gray, Kristen Mahle; Li, Jianmin; Hall, Irene] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wu, Baohua] ICF Int, Fairfax, VA USA. [Benbow, Nanette; Schuette, Stephanie] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. [Brady, Kathleen] Chicago Dept Publ Hlth, Chicago, IL USA. [Torian, Lucia; Xia, Qiang] NYC Dept Hlth & Mental Hyg, New York, NY USA. [Saafir-Callaway, Brittani; Opoku, Jenevieve; Lum, Garret] Dist Columbia Dept Hlth HIV AIDS Hepatitis STD &, Washington, DC USA. [Meyer, Jeffrey] Houston Dept Hlth & Human Serv, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P09.06 BP 243 EP 243 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600448 ER PT J AU Pattanasin, S Chemnasiri, T Sukwicha, W Raengsakulrach, B Hengprasert, S Ungsephapand, C Sirivongrongson, P Holtz, TH Dunne, EF AF Pattanasin, Sarika Chemnasiri, Tareerat Sukwicha, Wichuda Raengsakulrach, Boonyos Hengprasert, Sumetha Ungsephapand, Chaiwat Sirivongrongson, Pachara Holtz, Timothy H. Dunne, Eileen F. TI Sex Work in the City: MSM and Transgender Women Who Receive Money or Goods for Sex, Bangkok, Thailand SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Pattanasin, Sarika; Chemnasiri, Tareerat; Sukwicha, Wichuda; Raengsakulrach, Boonyos; Hengprasert, Sumetha; Ungsephapand, Chaiwat; Holtz, Timothy H.; Dunne, Eileen F.] Thailand MOPH US CDC Collaborat, Bangkok, Thailand. [Sirivongrongson, Pachara] Minist Publ Hlth, Bangkok, Thailand. [Holtz, Timothy H.; Dunne, Eileen F.] US Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P09.18 BP 249 EP 249 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600460 ER PT J AU Vishwanathan, SA Aubert, RD Morris, MR Zhao, CX Philips, C Papp, JR Kersh, EN McNicholl, JM AF Vishwanathan, Sundaram Ajay Aubert, Rachael D. Morris, Monica R. Zhao, Chunxia Philips, Christi Papp, John R. Kersh, Ellen N. McNicholl, Janet M. TI A Macaque Model of Rectal Lymphogranuloma Venereum (LGV) and non-LGV Chlamydia trachomatis: Impact on Susceptibility to Rectal SHIV Acquisition SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Vishwanathan, Sundaram Ajay; Aubert, Rachael D.; Philips, Christi; Papp, John R.; Kersh, Ellen N.; McNicholl, Janet M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Morris, Monica R.; Zhao, Chunxia] Total Solut, Brighton, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P14.08 BP 280 EP 280 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600515 ER PT J AU Jenness, S Goodreau, S Rosenberg, E Sharma, A Hoover, K Smith, D Sullivan, P AF Jenness, Samuel Goodreau, Steven Rosenberg, Eli Sharma, Akshay Hoover, Karen Smith, Dawn Sullivan, Patrick TI Individual-Level HIV Risk versus Population-level Impact of Risk Compensation after PrEP Initiation among MSM in the US: A Modeling Study SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Jenness, Samuel; Rosenberg, Eli; Sharma, Akshay; Sullivan, Patrick] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Goodreau, Steven] Univ Washington, Seattle, WA 98195 USA. [Hoover, Karen; Smith, Dawn] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P15.20 BP 292 EP 292 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600539 ER PT J AU Pluff, L Broussard, D Johnson, T Quinn, L Caruso, J Bhatia, R AF Pluff, Lindsay Broussard, Dawn Johnson, Tameeka Quinn, Leah Caruso, Jennifer Bhatia, Ramona TI Pre-exposure Prophylaxis Knowledge and Beliefs in Chicago Department of Public Health Disease Intervention Specialists SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Pluff, Lindsay; Broussard, Dawn; Johnson, Tameeka] Ctr Dis Control & Prevent, Atlanta, GA USA. [Quinn, Leah; Caruso, Jennifer; Bhatia, Ramona] Chicago Dept Publ Hlth, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P15.24LB BP 294 EP 294 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600543 ER PT J AU Dimitrov, D Wood, D Mitchell, KM Li, MJ Hughes, JP Donnell, D Bekker, LG Mannheimer, S Holtz, TH Grant, RM Boily, MC AF Dimitrov, Dobromir Wood, Daniel Mitchell, Kate M. Li, Maoji Hughes, James P. Donnell, Deborah Bekker, Linda-Gail Mannheimer, Sharon Holtz, Timothy H. Grant, Robert M. Boily, Marie-Claude TI Predicted Effectiveness of Daily and Non-daily PrEP Based on Sex Coverage Data from HPTN 067 ADAPT Sites in South Africa, Thailand and US SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Dimitrov, Dobromir; Wood, Daniel; Li, Maoji; Hughes, James P.; Donnell, Deborah] Fred Hutchinson Canc Res Ctr, Seattle, WA USA. [Mitchell, Kate M.; Boily, Marie-Claude] Imperial Coll London, London, England. [Bekker, Linda-Gail] Univ Cape Town, ZA-7700 Rondebosch, South Africa. [Mannheimer, Sharon] Harlem Hosp Med Ctr, New York, NY USA. [Mannheimer, Sharon] Columbia Univ, New York, NY 10027 USA. [Holtz, Timothy H.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Holtz, Timothy H.] Thailand Minist Publ Hlth, US Ctr Dis Control & Prevent Collaborat, Nonthaburi, Thailand. [Grant, Robert M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P17.02 BP 298 EP 298 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600551 ER PT J AU Sheth, AN Swaims-Kohlmeier, A Haaland, RE Lahiri, CD Carlson, RD Aguierre, AJ Evans-Strickfaden, T Brown, NL Lupo, LD Mehta, CB Hart, CE Ofotokun, I AF Sheth, Anandi N. Swaims-Kohlmeier, Alison Haaland, Richard E. Lahiri, Cecile D. Carlson, Renee Donahue Aguierre, Alfredo J. Evans-Strickfaden, Tammy Brown, Nakita L. Lupo, L. Davis Mehta, Christina B. Hart, Clyde E. Ofotokun, Igho TI Oral Maraviroc Reduces CD4 T Cells at the Genital Mucosal Surface of HIV-seronegative Women SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Sheth, Anandi N.; Lahiri, Cecile D.; Carlson, Renee Donahue; Aguierre, Alfredo J.; Brown, Nakita L.; Ofotokun, Igho] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Swaims-Kohlmeier, Alison; Haaland, Richard E.; Evans-Strickfaden, Tammy; Lupo, L. Davis; Hart, Clyde E.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Mehta, Christina B.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P18.02 BP 305 EP 305 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600564 ER PT J AU Swaims-Kohlmeier, A Kelley, C Holder, A Heeke, S Fountain, J Evans-Strickfaden, T Hart, C Haaland, R AF Swaims-Kohlmeier, Alison Kelley, Colleen Holder, Angela Heeke, Sheila Fountain, Jeffrey Evans-Strickfaden, Tammy Hart, Clyde Haaland, Richard TI Repeated Rectal Application of a Hyperosmolar Lubricant Increases HIV Susceptibility Markers but Does Not Reduce Antiretroviral Drug Concentrations SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Swaims-Kohlmeier, Alison; Holder, Angela; Fountain, Jeffrey; Evans-Strickfaden, Tammy; Hart, Clyde; Haaland, Richard] CDC, Atlanta, GA 30333 USA. [Kelley, Colleen; Heeke, Sheila] Emory Univ, Sch Med, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P18.01 BP 305 EP 305 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600563 ER PT J AU Kelley, C de Man, T Ingersoll, J Mulligan, M Sullivan, P Tharp, G Bosinger, S Kraft, C Amara, R AF Kelley, Colleen de Man, Tom Ingersoll, Jessica Mulligan, Mark Sullivan, Patrick Tharp, Gregory Bosinger, Steven Kraft, Colleen Amara, Rama TI The Relationship of Condomless Receptive Anal Intercourse, Mucosal Injury, and the Rectal Microbiota in Men Who Have Sex with Men SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Kelley, Colleen; Ingersoll, Jessica; Mulligan, Mark; Kraft, Colleen] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [de Man, Tom] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sullivan, Patrick] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Tharp, Gregory; Bosinger, Steven; Amara, Rama] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P18.10 BP 309 EP 309 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600572 ER PT J AU Holder, A Haaland, R Evans-Strickfaden, T Pau, CP Nyagol, B Makanga, M Oyaro, B Humwa, F Williams, T Mclellan, E Desai, M Hart, C Huey, M AF Holder, Angela Haaland, Richard Evans-Strickfaden, Tammy Pau, Chou Pong Nyagol, Beatrice Makanga, Mumbi Oyaro, Boaz Humwa, Felix Williams, Tiffany Mclellan, Eleanor Desai, Mitesh Hart, Clyde Huey, Michael TI Residual Synthetic Estrogen and Progestin Levels in Used Intravaginal Rings of Women Participating in a Clinical Trial of Acceptability SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Holder, Angela; Haaland, Richard; Evans-Strickfaden, Tammy; Pau, Chou Pong; Williams, Tiffany; Mclellan, Eleanor; Desai, Mitesh; Hart, Clyde] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Nyagol, Beatrice; Makanga, Mumbi; Oyaro, Boaz; Humwa, Felix] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Huey, Michael] Emory Univ, Student Hlth Serv, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P24.01 BP 375 EP 375 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600698 ER PT J AU Yoon, SS Dillon, CF Illoh, K Carroll, M AF Yoon, Sung Sug (Sarah) Dillon, Charles F. Illoh, Kachi Carroll, Margaret TI Trends in the Prevalence of Coronary Heart Disease in the US National Health and Nutrition Examination Survey, 2001-2012 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID UNITED-STATES; BLOOD-PRESSURE; SELF-REPORTS; HYPERTENSION; ADULTS; MORTALITY; RISK; LIPOPROTEINS; POPULATION; VALIDITY AB Introduction: This study evaluated recent trends in the prevalence of coronary heart disease in the U.S. population aged >= 40 years. Methods: A total of 21,472 adults aged >= 40 years from the 2001-2012 National Health and Nutrition Examination Survey were included in the analysis. The analysis was conducted in 2015. Coronary heart disease included myocardial infarction, angina, and any other type of coronary heart disease, which were defined as a history of medical diagnosis of these specific conditions. Angina was also defined as currently taking anti-angina medication or having Rose Angina Questionnaire responses that scored with a Grade >= 1. Trends from 2001 to 2012 were analyzed overall, within demographic subgroups, and by major coronary heart disease risk factors. Results: Between 2001 and 2012, the overall prevalence of coronary heart disease significantly decreased from 10.3% to 8.0% (p-trend<0.05). The prevalence of angina significantly decreased from 7.8% to 5.5% and myocardial infarction prevalence decreased from 5.5% to 4.7% (p-trend <0.05 for both groups). Overall coronary heart disease prevalence significantly decreased among women, adults aged >60 years, non-Hispanic whites, non-Hispanic blacks, adults who did not complete high school, adults with more than a high school education, and adults who had health insurance (p-trend <0.05 for all groups). Conclusions: The overall prevalence of coronary heart disease including angina and myocardial infarction decreased significantly over the 12-year survey period. However, this reduction was seen mainly among persons without established coronary heart disease risk factors. There was no change in coronary heart disease prevalence among those with specific coronary heart disease risk factors. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Yoon, Sung Sug (Sarah)] NIH, Healthcare Delivery & Methodol IRG, Div AIDS Behav & Populat Sci, Ctr Sci Review, 6701 Rockledge Dr,Room 3152,MSC 7770, Bethesda, MD 20892 USA. [Dillon, Charles F.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Illoh, Kachi] US FDA, Off New Drugs Immediate Off, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [Carroll, Margaret] CDC, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Yoon, SS (reprint author), NIH, Healthcare Delivery & Methodol IRG, Div AIDS Behav & Populat Sci, Ctr Sci Review, 6701 Rockledge Dr,Room 3152,MSC 7770, Bethesda, MD 20892 USA. EM sarah.yoon@nih.gov NR 39 TC 2 Z9 2 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2016 VL 51 IS 4 BP 437 EP 445 DI 10.1016/j.amepre.2016.02.023 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7BX UT WOS:000386784200008 PM 27113539 ER PT J AU Sandhu, PK Elder, R Patel, M Saraiya, M Holman, DM Perna, F Smith, RA Buller, D Sinclair, C Reeder, A Makin, J McNoe, B Glanz, K AF Sandhu, Paramjit K. Elder, Randy Patel, Mona Saraiya, Mona Holman, Dawn M. Perna, Frank Smith, Robert A. Buller, David Sinclair, Craig Reeder, Anthony Makin, Jennifer McNoe, Bronwen Glanz, Karen CA Community Preventive Serv TI Community-wide Interventions to Prevent Skin Cancer Two Community Guide Systematic SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PROMOTE SUN PROTECTION; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; ULTRAVIOLET-RADIATION; DYSPLASTIC NEVI; UNITED-STATES; RISK-FACTORS; AUSTRALIA; METAANALYSIS; PREVALENCE AB Context: Skin cancer is a preventable and commonly diagnosed cancer in the U.S. Excessive ultraviolet radiation exposure is a known cause of skin cancer. This article presents updated results of two types of interventions evaluated in a previously published Community Guide systematic review: multicomponent community-wide interventions and mass media interventions when used alone. Evidence acquisition: Studies assessing multicomponent community-wide and mass media interventions to prevent skin cancer by reducing ultraviolet radiation exposure were evaluated using Community Guide systematic review methods. Relevant studies published between 1966 and 2013 were included and analyzed for this review. Evidence synthesis: Seven studies evaluating the effectiveness of multicomponent community-wide interventions showed a median increase in sunscreen use of 10.8 (interquartile interval=7.3, 23.2) percentage points, a small decrease in ultraviolet radiation exposure, a decrease in indoor tanning device use of 4.0 (95% CI=2.5, 5.5) percentage points, and mixed results for other protective behaviors. Four studies evaluating the effectiveness of mass media interventions found that they generally led to improved ultraviolet protection behaviors among children and adults. Conclusions: The available evidence showed that multicomponent community-wide interventions are effective in reducing the deleterious effects of ultraviolet radiation exposure by increasing sunscreen use. There was, however, insufficient evidence to determine the effectiveness of mass media interventions alone in reducing ultraviolet radiation exposure and increasing ultraviolet protection behaviors, indicating a continuing need for more research in this field to improve assessment of effectiveness. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine. C1 [Sandhu, Paramjit K.; Elder, Randy; Patel, Mona] Ctr Dis Control & Prevent CDC, Community Guide Branch, Div Publ Hlth Informat Disseminat, Atlanta, GA USA. [Saraiya, Mona; Holman, Dawn M.] CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA. [Perna, Frank] NCI, NIH, Bethesda, MD 20892 USA. [Smith, Robert A.] Amer Canc Soc, Atlanta, GA 30329 USA. [Buller, David] Klein Buendel, Lakewood, CO USA. [Sinclair, Craig] Canc Council Victoria, Ctr Behav Res Canc, Melbourne, Vic, Australia. [Reeder, Anthony; McNoe, Bronwen] Univ Otago, Dept Prevent & Social Med, Canc Soc Social & Behav Res Unit, Dunedin, New Zealand. [Makin, Jennifer] Univ Tasmania, Menzies Res Inst, Hobart, Tas 7001, Australia. [Glanz, Karen] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Glanz, Karen] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. RP Sandhu, PK (reprint author), Ctr Dis Control & Prevent CDC, Lab Res & Evaluat Branch, 1600 Clifton Rd,Mailstop E-69, Atlanta, GA 30329 USA. EM psandhu@cdc.gov FU Intramural CDC HHS [CC999999] NR 43 TC 1 Z9 1 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2016 VL 51 IS 4 BP 531 EP 539 DI 10.1016/j.amepre.2016.03.020 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7BX UT WOS:000386784200021 PM 27647053 ER PT J AU Elder, R AF Elder, Randy CA Community Preventive Serv TI Community-wide Interventions to Prevent Skin Cancer Recommendation of the Community Preventive Services Task Force Community Preventive Services Task Force SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SUN PROTECTION RP Elder, R (reprint author), CDC, Community Guide Branch, Div Publ Hlth Informat Dissemination, Ctr Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd,Mailstop E-69, Atlanta, GA 30329 USA. EM rfe3@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2016 VL 51 IS 4 BP 540 EP 541 DI 10.1016/j.amepre.2016.03.019 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7BX UT WOS:000386784200022 ER PT J AU Collins, CB Sapiano, TN AF Collins, Charles B., Jr. Sapiano, Tobey N. TI Lessons Learned From Dissemination of Evidence-Based Interventions for HIV Prevention SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID EFFECTIVE BEHAVIORAL INTERVENTIONS; INTERACTIVE SYSTEMS FRAMEWORK; AFRICAN-AMERICAN WOMEN; HIV/AIDS PREVENTION; CONTROLLED-TRIAL; RISK BEHAVIOR; MEN FINDINGS; BLACK-MEN; YOUNG MEN; DIFFUSION AB In 1999, IOM issued a report that recommended that the Centers for Disease Control and Prevention should disseminate evidence-based HIV prevention interventions (EBIs) to be implemented by health departments, community-based organizations, drug treatment centers, and clinics. Based on these recommendations, the Diffusion of Effective Behavioral Interventions Project was initiated in 2000 and began disseminating interventions into public health practice. For 15 years, the Centers for Disease Control and Prevention has disseminated 29 EBIs to more than 11,300 agencies. Lessons were identified during the 15 years of implementation regarding successful methods of dissemination of EBIs. Lessons around selecting interventions for dissemination, developing a dissemination infrastructure including a resource website (https://effectiveinterven tions.cdc.gov), and engagement with stakeholders are discussed. A continuous development approach ensured that intervention implementation materials, instructions, and technical assistance were all tailored to the needs of end users, focus populations, and agency capacities. Six follow-up studies demonstrated that adopters of EBIs were able to obtain comparable outcomes to those of the original efficacy research. The Diffusion of Effective Behavioral Interventions Project may offer guidance for other large, national, evidence-based public health dissemination projects. Published by Elsevier Inc. C1 [Collins, Charles B., Jr.; Sapiano, Tobey N.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Capac Bldg Branch, Atlanta, GA USA. RP Collins, CB (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E-40, Atlanta, GA 30333 USA. EM cwc4@cdc.gov FU Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention FX The activities described in this manuscript were funded and supported by the Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention. The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 42 TC 3 Z9 3 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2016 VL 51 IS 4 SU 2 BP S140 EP S147 DI 10.1016/j.amepre.2016.05.017 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7BM UT WOS:000386783100006 PM 27402185 ER PT J AU Coulthart, MB Geschwind, MD Qureshi, S Phielipp, N Demarsh, A Abrams, JY Belay, E Gambetti, P Jansen, GH Lang, AE Schonberger, LB AF Coulthart, Michael B. Geschwind, Michael D. Qureshi, Shireen Phielipp, Nicolas Demarsh, Alex Abrams, Joseph Y. Belay, Ermias Gambetti, Pierluigi Jansen, Gerard H. Lang, Anthony E. Schonberger, Lawrence B. TI A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia SO BRAIN LA English DT Article DE prion diseases; variant Creutzfeldt-Jakob disease; bovine spongiform encephalopathy; Saudi Arabia ID AGE CHARACTERISTICS; UNITED-KINGDOM; PRION DISEASES; CODON 219; BSE; EPIDEMIC; HUMANS; CJD; TRANSMISSION; PROTEIN AB The vast majority of reported cases of variant Creutzfeldt-Jakob disease have been in European countries. Coulthart et al. present evidence that human infections with bovine spongiform encephalopathy have also occurred in other regions of the world, specifically in the Kingdom of Saudi Arabia.The vast majority of reported cases of variant Creutzfeldt-Jakob disease have been in European countries. Coulthart et al. present evidence that human infections with bovine spongiform encephalopathy have also occurred in other regions of the world, specifically in the Kingdom of Saudi Arabia.As of mid-2016, 231 cases of variant Creutzfeldt-Jakob disease-the human form of a prion disease of cattle, bovine spongiform encephalopathy-have been reported from 12 countries. With few exceptions, the affected individuals had histories of extended residence in the UK or other Western European countries during the period (1980-96) of maximum global risk for human exposure to bovine spongiform encephalopathy. However, the possibility remains that other geographic foci of human infection exist, identification of which may help to foreshadow the future of the epidemic. We report results of a quantitative analysis of country-specific relative risks of infection for three individuals diagnosed with variant Creutzfeldt-Jakob disease in the USA and Canada. All were born and raised in Saudi Arabia, but had histories of residence and travel in other countries. To calculate country-specific relative probabilities of infection, we aligned each patient's life history with published estimates of probability distributions of incubation period and age at infection parameters from a UK cohort of 171 variant Creutzfeldt-Jakob disease cases. The distributions were then partitioned into probability density fractions according to time intervals of the patient's residence and travel history, and the density fractions were combined by country. This calculation was performed for incubation period alone, age at infection alone, and jointly for incubation and age at infection. Country-specific fractions were normalized either to the total density between the individual's dates of birth and symptom onset ('lifetime'), or to that between 1980 and 1996, for a total of six combinations of parameter and interval. The country-specific relative probability of infection for Saudi Arabia clearly ranked highest under each of the six combinations of parameter x interval for Patients 1 and 2, with values ranging from 0.572 to 0.998, respectively, for Patient 2 (age at infection x lifetime) and Patient 1 (joint incubation and age at infection x 1980-96). For Patient 3, relative probabilities for Saudi Arabia were not as distinct from those for other countries using the lifetime interval: 0.394, 0.360 and 0.378, respectively, for incubation period, age at infection and jointly for incubation and age at infection. However, for this patient Saudi Arabia clearly ranked highest within the 1980-96 period: 0.859, 0.871 and 0.865, respectively, for incubation period, age at infection and jointly for incubation and age at infection. These findings support the hypothesis that human infection with bovine spongiform encephalopathy occurred in Saudi Arabia. C1 [Coulthart, Michael B.] Publ Hlth Agcy Canada, Canadian Creutzfeldt Jakob Dis Surveillance Syst, Ctr Foodborne Environm & Zoonot Infect Dis, Ottawa, ON K1A 0K9, Canada. [Geschwind, Michael D.] Univ Calif San Francisco, Memory & Aging Ctr, Box 1207, San Francisco, CA 94143 USA. [Qureshi, Shireen] Dhahran Hlth Ctr, Dhahran, Saudi Arabia. [Phielipp, Nicolas] Univ Calif Irvine, Dept Neurol, Parkinsons & Movement Disorders Program, Irvine, CA 92697 USA. [Demarsh, Alex] Publ Hlth Agcy Canada, Ctr Foodborne Environm & Zoonot Infect Dis, Zoonoses Div, Ottawa, ON K1A 0K9, Canada. [Abrams, Joseph Y.; Belay, Ermias; Schonberger, Lawrence B.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Gambetti, Pierluigi] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA. [Jansen, Gerard H.] Ottawa Hosp, Eastern Ontario Reg Lab Assoc, Ottawa, ON K1Y 4E9, Canada. [Lang, Anthony E.] Univ Toronto, Morton & Gloria Shulman Movement Disorders Clin, Toronto, ON M5T 2S8, Canada. [Lang, Anthony E.] Univ Toronto, Edmond J Safra Program Parkinsons Dis, Univ Hlth Network, Div Neurol,Dept Med, Toronto, ON M5T 2S8, Canada. RP Coulthart, MB (reprint author), Publ Hlth Agcy Canada, 130 Colonnade Rd, Ottawa, ON K1A 0K9, Canada. EM michael.coulthart@canada.ca FU Public Health Agency of Canada; Charles F. Britton Fund; United States Centers for Disease Control and Prevention [CDC UR8/CCU515004]; NIH/NIA [R01AG031189, K23 AG021989, P01 AG02160]; NIH/NCRR UCSF-CTSI [UL1 RR024131] FX The Canadian Creutzfeldt-Jakob Disease Surveillance System is funded by the Prion Diseases Program of the Public Health Agency of Canada. The National Prion Disease Pathology Surveillance Center is supported by the Charles F. Britton Fund and cooperative agreement CDC UR8/CCU515004 with the United States Centers for Disease Control and Prevention. Funding to support study of patient 2 was received from NIH/NIA R01AG031189, K23 AG021989, and P01 AG02160, and NIH/NCRR UCSF-CTSI (UL1 RR024131). NR 31 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 EI 1460-2156 J9 BRAIN JI Brain PD OCT PY 2016 VL 139 BP 2609 EP 2616 DI 10.1093/brain/aww206 PN 10 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DZ7CZ UT WOS:000386023000013 PM 27671029 ER PT J AU Prudent, N Houghton, A Luber, G AF Prudent, Natasha Houghton, Adele Luber, George TI Assessing climate change and health vulnerability at the local level: Travis County, Texas SO DISASTERS LA English DT Article DE adaption; excessive heat; floods; health; mitigation; vulnerability mapping ID SOCIAL VULNERABILITY; FLOOD VULNERABILITY; HAZARDS AB We created a measure to help comprehend population vulnerability to potential flooding and excessive heat events using health, built environment and social factors. Through principal component analysis (PCA), we created non-weighted sum index scores of literature-reviewed social and built environment characteristics. We created baseline poor health measures using 1999-2005 age-adjusted cardiovascular and combined diabetes and hypertension mortality rates to correspond with social-built environment indices. We mapped US Census block groups by linked age-adjusted mortality and a PCA-created social-built environment index. The goal was to measure flooding and excessive heat event vulnerability as proxies for population vulnerability to climate change for Travis County, Texas. This assessment identified communities where baseline poor health, social marginalisation and built environmental impediments intersected. Such assessments may assist targeted interventions and improve emergency preparedness in identified vulnerable communities, while fostering resilience through the focus of climate change adaptation policies at the local level. C1 [Prudent, Natasha] US Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Luber, George] US Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Prudent, N (reprint author), US Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Sci Integrat & Appl Res Team, 1600 Clifton Rd Mail Stop D18, Atlanta, GA 30333 USA. EM nprudent@cdc.gov NR 22 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-3666 EI 1467-7717 J9 DISASTERS JI Disasters PD OCT PY 2016 VL 40 IS 4 BP 740 EP 752 DI 10.1111/disa.12177 PG 13 WC Planning & Development SC Public Administration GA DW5PI UT WOS:000383698000007 PM 26748543 ER PT J AU Mancuso, AC Boulet, SL Duran, E Munch, E Kissin, DM Van Voorhis, BJ AF Mancuso, Abigail C. Boulet, Sheree L. Duran, Eyup Munch, Erika Kissin, Dmitry M. Van Voorhis, Bradley J. TI Elective single embryo transfer in women less than age 38 years reduces multiple birth rates, but not live birth rates, in United States fertility clinics SO FERTILITY AND STERILITY LA English DT Article DE Elective single embryo transfer; live birth rate; multiple birth rate; IVF ID PREGNANCY RATES; TWIN PREGNANCIES; IVF; GESTATION; METAANALYSIS; MISCARRIAGE; PREDICTORS; PREVENTION; OUTCOMES; POLICY AB Objective: To determine the effect of elective single ET (eSET) on live birth and multiple birth rates by a cycle-level and clinic-level analysis. Design: Retrospective cohort study. Setting: Not applicable. Patient(s): Patient ages <35 and 35-37 years old. Intervention(s): None. Main Outcome Measure(s): Clinics were divided into groups based on eSET rate for each age group and aggregate rates of live birth per ET and multiple birth per delivery were calculated. A cycle-level analysis comparing eSET and double ET (DET) live birth and multiple birth rates was also performed, stratified based on total number (2, 3, or 4+) of embryos available, embryo stage, and patient age. Result(s): There was a linear decrease in multiple birth rate with increasing eSET rate and no significant difference in clinic-level live birth rates for each age group. Cycle-level analysis found slightly higher live birth rates with double ET, but this was mainly observed in women aged 35-37 years or with four or more embryos available for transfer, and confirmed the marked reduction in multiple births with eSET. Conclusion(s): Our study showed a marked and linear reduction in multiple birth rates, and important, little to no effect on clinic-level live birth rates with increasing rates of eSET supporting the growing evidence that eSET is effective in decreasing the high multiple birth rates associated with IVF and suggests that eSET should be used more frequently than is currently practiced. (C) 2016 by American Society for Reproductive Medicine. C1 [Mancuso, Abigail C.; Duran, Eyup; Munch, Erika; Van Voorhis, Bradley J.] Univ Iowa, Carver Coll Med, Dept Obstet & Gynecol, 200 Hawkins Dr, Iowa City, IA 52242 USA. [Boulet, Sheree L.; Kissin, Dmitry M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Mancuso, AC (reprint author), Univ Iowa, Carver Coll Med, Dept Obstet & Gynecol, 200 Hawkins Dr, Iowa City, IA 52242 USA. EM abigail-mancuso@uiowa.edu NR 26 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD OCT PY 2016 VL 106 IS 5 BP 1107 EP 1114 DI 10.1016/j.fertnstert.2016.06.017 PG 8 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA EA7RG UT WOS:000386828800024 PM 27376458 ER PT J AU Spradling, PR Xing, J Rupp, LB Moorman, AC Gordon, SC Lu, M Teshale, EH Boscarino, JA Daida, Y Schmidt, MA Holmberg, SD AF Spradling, Philip R. Xing, Jian Rupp, Loralee B. Moorman, Anne C. Gordon, Stuart C. Lu, Mei Teshale, Eyasu H. Boscarino, Joseph A. Daida, Yihe Schmidt, Mark A. Holmberg, Scott D. TI Uptake of and factors associated with direct-acting antiviral therapy among patients infected with hepatitis C virus in the Chronic Hepatitis Cohort Study, 2014-2015 SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Spradling, Philip R.; Xing, Jian; Moorman, Anne C.; Teshale, Eyasu H.; Holmberg, Scott D.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Rupp, Loralee B.; Gordon, Stuart C.; Lu, Mei] Henry Ford Hlth Syst, Detroit, MI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. [Daida, Yihe] Kaiser Permanente Hawaii, Honolulu, HI USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 20 BP 10A EP 11A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800021 ER PT J AU Lu, M Gordon, SC Li, J Rupp, LB Zhou, YR Moorman, AC Spradling, P Teshale, EH Boscarino, JA Daida, Y Schmidt, MA Trudeau, S Holmberg, SD AF Lu, Mei Gordon, Stuart C. Li, Jia Rupp, Loralee B. Zhou, Yueren Moorman, Anne C. Spradling, Phillip Teshale, Eyasu H. Boscarino, Joseph A. Daida, Yihe Schmidt, Mark A. Trudeau, Sheri Holmberg, Scott D. TI Hepatitis C Complications: Prevalence and Disparities in a Large US Cohort 2006-2014 SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Lu, Mei; Li, Jia; Zhou, Yueren; Trudeau, Sheri] Henry Ford Hlth Syst, Publ Hlth Sci, Detroit, MI USA. [Gordon, Stuart C.] Henry Ford Hlth Syst, Div Gastroenterol & Hepatol, Detroit, MI USA. [Rupp, Loralee B.] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA. [Moorman, Anne C.; Spradling, Phillip; Teshale, Eyasu H.; Holmberg, Scott D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Heaptitis STD & TB Prevent, Atlanta, GA USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Ctr Hlth Res, Danville, PA USA. [Daida, Yihe] Kaiser Permanente Hawaii, Ctr Hlth Res, Honolulu, HI USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 180 BP 95A EP 96A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800181 ER PT J AU Drobeniuc, J Greene-Montfort, T Tejada-Strop, A Hayden, TM Kamili, S AF Drobeniuc, Jan Greene-Montfort, Tracy Tejada-Strop, Alexandra Hayden, Tonya M. Kamili, Saleem TI Laboratory based surveillance identifies 227 cases of hepatitis E in the United States over a period of three years SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Drobeniuc, Jan; Greene-Montfort, Tracy; Tejada-Strop, Alexandra; Hayden, Tonya M.; Kamili, Saleem] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 228 BP 120A EP 120A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800229 ER PT J AU Hagan, L Kasradze, A Salyer, S Gamkrelidze, A Alkhazashvili, M Chanturia, G Chitadze, N Sukhiashvili, R Shakhnazarova, M Blanton, C Russell, S Kuchukhidze, G Baliashvili, D Hariri, S Drobeniuc, J Imnadze, P Morgan, J Averhoff, F AF Hagan, Liesl Kasradze, Ana Salyer, Stephanie Gamkrelidze, Amiran Alkhazashvili, Maia Chanturia, Gvantsa Chitadze, Nazi Sukhiashvili, Roena Shakhnazarova, Marina Blanton, Curtis Russell, Steven Kuchukhidze, Giorgi Baliashvili, Davit Hariri, Susan Drobeniuc, Jan Imnadze, Paata Morgan, Juliette Averhoff, Francisco TI Hepatitis C Virus Seroprevalence Survey in the Country of Georgia SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Hagan, Liesl; Hariri, Susan; Drobeniuc, Jan; Averhoff, Francisco] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Kasradze, Ana; Gamkrelidze, Amiran; Alkhazashvili, Maia; Chanturia, Gvantsa; Chitadze, Nazi; Sukhiashvili, Roena; Shakhnazarova, Marina; Kuchukhidze, Giorgi; Baliashvili, Davit; Imnadze, Paata] Natl Ctr Dis Control, Tbilisi, Rep of Georgia. [Salyer, Stephanie; Blanton, Curtis; Russell, Steven; Morgan, Juliette] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 777 BP 383A EP 384A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802047 ER PT J AU Spradling, PR Xing, J Rupp, LB Moorman, AC Gordon, SC Lu, M Teshale, EH Boscarino, JA Daida, Y Schmidt, MA Holmberg, SD AF Spradling, Philip R. Xing, Jian Rupp, Loralee B. Moorman, Anne C. Gordon, Stuart C. Lu, Mei Teshale, Eyasu H. Boscarino, Joseph A. Daida, Yihe Schmidt, Mark A. Holmberg, Scott D. TI Preliminary clinical outcome data among patients with hepatitis C virus infection receiving direct-acting antiviral therapy in the Chronic Hepatitis Cohort Study, 2014-2015 SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Spradling, Philip R.; Xing, Jian; Moorman, Anne C.; Teshale, Eyasu H.; Holmberg, Scott D.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Rupp, Loralee B.; Gordon, Stuart C.; Lu, Mei] Henry Ford Hlth Syst, Detroit, MI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. [Daida, Yihe] Kaiser Permanente Hawaii, Honolulu, HI USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 962 BP 487A EP 488A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802229 ER PT J AU Choi, Y Zhang, XG Tran, C Skinner, B AF Choi, Youkyung Zhang, Xiugen Tran, Coleen Skinner, Brianna TI Determination of the protective levels of IgG anti-HEV antibodies during hepatitis E virus reinfection in experimentally infected rhesus macaques SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Choi, Youkyung; Zhang, Xiugen; Tran, Coleen; Skinner, Brianna] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1023 BP 517A EP 517A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802290 ER PT J AU McMahon, BJ Townshend-Bulson, LJ Gounder, PP Barbour, Y Homan, CE Hewitt, A Bruden, DJ Espera, HG Plotnik, JN Gove, JE Bruce, M Spradling, P Simons, B AF McMahon, Brian J. Townshend-Bulson, Lisa J. Gounder, Prabhu P. Barbour, Youssef Homan, Chriss E. Hewitt, Annette Bruden, Dana J. Espera, Hannah G. Plotnik, Julia N. Gove, James E. Bruce, Michael Spradling, Phillip Simons, Brenna TI Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [McMahon, Brian J.; Townshend-Bulson, Lisa J.; Barbour, Youssef; Homan, Chriss E.; Hewitt, Annette; Espera, Hannah G.; Plotnik, Julia N.; Gove, James E.; Simons, Brenna] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. [McMahon, Brian J.; Gounder, Prabhu P.; Bruden, Dana J.; Bruce, Michael] Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. [Spradling, Phillip] Ctr Dis Control & Prevent, Div Viral Hepatitis, Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1744 BP 861A EP 862A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804106 ER PT J AU Teshale, EH Zhong, YN Moorman, AC Spradling, PR Holmberg, SD Rupp, LB Lu, M Gordon, SC Boscarino, JA Daida, Y Schmidt, MA AF Teshale, Eyasu H. Zhong, Yuna Moorman, Anne C. Spradling, Philip R. Holmberg, Scott D. Rupp, Loralee B. Lu, Mei Gordon, Stuart C. Boscarino, Joseph A. Daida, Yihe Schmidt, Mark A. TI Alcohol use disorder among chronic hepatitis C patients: prevalence and treatment outcome, CHeCS, 2006-2013 SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Teshale, Eyasu H.; Zhong, Yuna; Moorman, Anne C.; Spradling, Philip R.; Holmberg, Scott D.] CDC, Atlanta, GA 30333 USA. [Rupp, Loralee B.; Lu, Mei; Gordon, Stuart C.] Henry Ford Hlth Syst, Detroit, MI USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Portland, OR USA. [Daida, Yihe] Kaiser Permanente Hawaii, Honolulu, HI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1769 BP 873A EP 874A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804131 ER PT J AU Harris, AM Chandrasekar, E Wang, S Pong, P Bowlus, CL Chen, M Vellozzi, C AF Harris, Aaron M. Chandrasekar, Edwin Wang, Su Pong, Perry Bowlus, Christopher L. Chen, Moon Vellozzi, Claudia TI Community-Based Strategies to Improve Testing and Linkage to Care for Foreign-Born Persons with Chronic Hepatitis B Virus Infection SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Harris, Aaron M.; Vellozzi, Claudia] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Chandrasekar, Edwin] Asian Hlth Coalit, Chicago, IL USA. [Wang, Su] St Barnabas Hosp, Livingston, NJ USA. [Pong, Perry] Charles B Wang Community Hlth Ctr, New York, NY USA. [Bowlus, Christopher L.; Chen, Moon] Univ Calif Davis, Sacramento, CA 95817 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1773 BP 875A EP 876A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804135 ER PT J AU Bruce, M Gounder, PP Bulkow, L Snowball, M Negus, S Spradling, PR McMahon, BJ AF Bruce, Michael Gounder, Prabhu P. Bulkow, Lisa Snowball, Mary Negus, Susan Spradling, Philip R. McMahon, Brian J. TI Hepatitis B surface antigen (HBsAg) seroclearance, hepatocellular carcinoma (HCC) and liver-related death (LRD) risk among Alaska Native (AN) persons with indeterminate phase chronic hepatitis B virus infection (CHB) - Alaska, 2001-2014 SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Bruce, Michael; Gounder, Prabhu P.; Bulkow, Lisa] CDC, Anchorage, AK USA. [Snowball, Mary; Negus, Susan; McMahon, Brian J.] ANMC, Liver Dis & Hepatitis Program, Anchorage, AK USA. [Spradling, Philip R.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1804 BP 891A EP 891A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804166 ER PT J AU Gounder, PP Bulkow, L Snowball, M Negus, S Spradling, P McMahon, BJ AF Gounder, Prabhu P. Bulkow, Lisa Snowball, Mary Negus, Susan Spradling, Phillip McMahon, Brian J. TI Risk for progressing to immune active (IA) phase chronic hepatitis B virus infection (CHB) among Alaska Native (AN) persons in the inactive carrier (IC) and indeterminate CHB infection phases - Alaska, 2001-2014 SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Gounder, Prabhu P.; Bulkow, Lisa; McMahon, Brian J.] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK USA. [Snowball, Mary; Negus, Susan; McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. [Spradling, Phillip] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1806 BP 891A EP 892A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804168 ER PT J AU Orata, FD Xu, Y Gladney, LM Rishishwar, L Case, RJ Boucher, Y Jordan, IK Tarr, CL AF Orata, Fabini D. Xu, Yue Gladney, Lori M. Rishishwar, Lavanya Case, Rebecca J. Boucher, Yan Jordan, I. King Tarr, Cheryl L. TI Characterization of clinical and environmental isolates of Vibrio cidicii sp nov., a close relative of Vibrio navarrensis SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY LA English DT Article ID SPECIES DEFINITION; ESCHERICHIA-COLI; L-RHAMNOSE; IDENTIFICATION; TOOL; METABOLISM; EVOLUTION; SOFTWARE; GENOMES AB Four Vibrio spp. isolates from the historical culture collection at the Centers for Disease Control and Prevention, obtained from human blood specimens (n=3) and river water (n=1), show characteristics distinct from those of isolates of the most closely related species, Vibrio navarrensis and Vibrio vulnificus, based on phenotypic and genotypic tests. They are specifically adapted to survival in both freshwater and seawater, being able to grow in rich media without added salts as well as salinities above that of seawater. Phenotypically, these isolates resemble V. navarrensis, their closest known relative with a validly published name, but the group of isolates is distinguished from V. navarrensis by the ability to utilize L-rhamnose. Average nucleotide identity and percent DNA-DNA hybridization values obtained from the pairwise comparisons of whole-genome sequences of these isolates to V. navarrensis range from 95.4-95.8% and 61.9-64.3 %, respectively, suggesting that the group represents a different species. Phylogenetic analysis of the core genome, including four protein-coding housekeeping genes (pyrH, recA, rpoA and rpoB), places these four isolates into their own monophyletic clade, distinct from V. navarrensis and V. vulnificus. Based on these differences, we propose these isolates represent a novel species of the genus Vibrio, for which the name Vibrio cidicii sp. nov. is proposed; strain LMG 29267(T) (=CIP 111013(T) = 2756-81(T)), isolated from river water, is the type strain. C1 [Orata, Fabini D.; Xu, Yue; Case, Rebecca J.; Boucher, Yan] Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada. [Gladney, Lori M.; Tarr, Cheryl L.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA USA. [Gladney, Lori M.] IHRC Inc, Atlanta, GA USA. [Rishishwar, Lavanya; Jordan, I. King] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA. [Rishishwar, Lavanya; Jordan, I. King] Appl Bioinformat Lab, Atlanta, GA USA. [Rishishwar, Lavanya; Jordan, I. King] PanAmer Bioinformat Inst, Santiago De Cali, Valle Del Cauca, Colombia. RP Boucher, Y (reprint author), Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada. EM yboucher@ualberta.ca FU Alberta Innovates - Technology Futures; Natural Sciences and Engineering Research Council of Canada; Canadian Institute for Advanced Research; Georgia Institute of Technology (GIT) Bioinformatics Graduate Program; IHRC-GIT Applied Bioinformatics Laboratory FX F. D. O. was supported by Alberta Innovates - Technology Futures. R. J. C. and Y. B. were supported by the Natural Sciences and Engineering Research Council of Canada. Y. B. was also supported by the Canadian Institute for Advanced Research. L. R. and I. K. J. were supported by the Georgia Institute of Technology (GIT) Bioinformatics Graduate Program and the IHRC-GIT Applied Bioinformatics Laboratory. NR 38 TC 0 Z9 0 U1 0 U2 0 PU MICROBIOLOGY SOC PI LONDON PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND SN 1466-5026 EI 1466-5034 J9 INT J SYST EVOL MICR JI Int. J. Syst. Evol. Microbiol. PD OCT PY 2016 VL 66 BP 4148 EP 4155 DI 10.1099/ijsem.0.001327 PN 10 PG 8 WC Microbiology SC Microbiology GA EA8FV UT WOS:000386871600061 PM 27468862 ER PT J AU Chou, CF Beckles, GL Cheng, YJ Saaddine, JB AF Chou, Chiu-Fang Beckles, Gloria L. Cheng, Yiling J. Saaddine, Jinan B. TI Association Between County-Level Characteristics and Eye Care Use by US Adults in 22 States After Accounting for Individual-Level Characteristics Using a Conceptual Framework SO JAMA OPHTHALMOLOGY LA English DT Article ID QUALITY-OF-LIFE; UNITED-STATES; VISUAL IMPAIRMENT; DIABETIC-RETINOPATHY; MACULAR DEGENERATION; PREVENTIVE SERVICES; MULTILEVEL ANALYSIS; VISION LOSS; HEALTH; AGE AB IMPORTANCE Individual-level characteristics are associated with eye care use. The influence of contextual factors on vision and eye health, as well as health behavior, is unknown. OBJECTIVE To examine the association between county-level characteristics and eye care use after accounting for individual-level characteristics using a conceptual framework. DESIGN, SETTING, AND PARTICIPANTS This investigation was a cross-sectional study of respondents 40 years and older participating in the Behavioral Risk Factor Surveillance System surveys between 2006 and 2010 from 22 states that used the Visual Impairment and Access to Eye Care module. Multilevel regressions were used to examine the association between county-level characteristics and eye care use after adjusting for individual-level characteristics (age, sex, race/ethnicity, educational attainment, annual household income, employment status, health care insurance coverage, eye care insurance coverage, personal established physician, poor vision or eye health, and diabetes status). Data analysis was performed from March 23, 2014, to June 7, 2016. MAIN OUTCOMES AND MEASURES Eye care visit and receipt of a dilated eye examination in the past year. RESULTS Among 117 295 respondents who resided in 828 counties, individual-level data were obtained from the Behavioral Risk Factor Surveillance System surveys. All county-level variables were aggregated at the county level from the Behavioral Risk Factor Surveillance System surveys except for a high geographic density of eye care professionals, which was obtained from the 2010 Area Health Resource File. After controlling for individual-level characteristics, the odds of reporting an eye care visit in the past year were significantly higher among people living in counties with high percentages of black individuals (adjusted odds ratio [aOR], 1.12; 95% CI, 1.01-1.24; P = .04) or low-income households (aOR, 1.12; 95% CI, 1.00-1.25; P = .045) or with a high density of eye care professionals (aOR, 1.18; 95% CI, 1.07-1.29; P < .001) than among those living in counties with the lowest tertile of each county-level characteristic. The odds of reporting receipt of a dilated eye examination in the past year were also higher among people living in counties with the highest percentages of black individuals (aOR, 1.20; 95% CI, 1.07-1.34; P = .002) or low-income households (aOR, 1.17; 95% CI, 1.04-1.32; P = .01). However, the odds of reported receipt of a dilated eye examination in the past year were lower in counties with the highest percentages of people with poor vision and eye health compared with counties with lower percentages (aOR, 0.85; 95% CI, 0.77-0.94; P = .002). CONCLUSIONS AND RELEVANCE Contextual factors, measured at the county level, were associated with eye care use independent of individual-level characteristics. The findings suggest that, while individual characteristics influence health care use, it is also important to address contextual factors to improve eye care use and ultimately vision health. C1 [Chou, Chiu-Fang; Beckles, Gloria L.; Cheng, Yiling J.; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F-75, Atlanta, GA 30341 USA. RP Chou, CF (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F-75, Atlanta, GA 30341 USA. EM cchou@cdc.gov NR 45 TC 1 Z9 1 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD OCT 1 PY 2016 VL 134 IS 10 BP 1158 EP 1167 DI 10.1001/jamaophthalmol.2016.3007 PG 10 WC Ophthalmology SC Ophthalmology GA EA3FO UT WOS:000386486900021 PM 27561117 ER PT J AU Bilder, DA Bakian, AV Stevenson, DA Carbone, PS Cunniff, C Goodman, AB McMahon, WM Fisher, NP Viskochil, D AF Bilder, Deborah A. Bakian, Amanda V. Stevenson, David A. Carbone, Paul S. Cunniff, Christopher Goodman, Alyson B. McMahon, William M. Fisher, Nicole P. Viskochil, David TI Brief Report: The Prevalence of Neurofibromatosis Type 1 among Children with Autism Spectrum Disorder Identified by the Autism and Developmental Disabilities Monitoring Network SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Autism; Neurofibromatosis; Developmental disabilities; Children; Non-verbal communications ID POPULATION; ATTENTION; CRITERIA AB Neurofibromatosis type 1 (NF1) is an inherited neurocutaneous disorder associated with neurodevelopmental disorders including autism spectrum disorder (ASD). The frequency of ASD/NF1 co-occurrence has been subject to debate since the 1980s. This relationship was investigated in a large population-based sample of 8-year-old children identified with ASD (N = 12,271) by the Centers for Disease Control and Prevention's Autism and Developmental Disabilities Monitoring (ADDM) Network. Twenty-two (1-in-558) children with ASD had diagnosed NF1, exceeding NF1 general population estimates by four to five fold. Children with ASD/NF1 versus ASD without NF1 were significantly less likely to receive a community-based ASD diagnosis (p = 0.04) and understand non-verbal communication (p = 0.001). These findings underscore the importance of including social-communication ability among relevant developmental concerns in children with NF1. C1 [Bilder, Deborah A.; Bakian, Amanda V.] Univ Utah, Utah Autism Res Program, Dept Psychiat, 650 Komas Dr,Suite 206, Salt Lake City, UT 84108 USA. [Stevenson, David A.; Viskochil, David] Univ Utah, Div Med Genet, Salt Lake City, UT USA. [Carbone, Paul S.] Univ Utah, Dept Pediat, Salt Lake City, UT USA. [Cunniff, Christopher] Univ Arizona, Dept Pediat, Tucson, AZ 85721 USA. [Goodman, Alyson B.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [McMahon, William M.; Fisher, Nicole P.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA. [Stevenson, David A.] Stanford Univ, Div Med Genet, Stanford, CA 94305 USA. [Cunniff, Christopher] Weill Cornell Med Coll, Div Med Genet, New York, NY USA. RP Bilder, DA (reprint author), Univ Utah, Utah Autism Res Program, Dept Psychiat, 650 Komas Dr,Suite 206, Salt Lake City, UT 84108 USA. EM deborah.bilder@hsc.utah.edu FU Centers for Disease Control and Prevention [UR3 DD000685-04/DD10-1002, UR3 DD000685-04/dd10-1102]; Utah Department of Health; Utah State Office of Education FX Case identification was funded through a grant from the Centers for Disease Control and Prevention under Cooperative Agreement UR3 DD000685-04/DD10-1002 and the Utah Department of Health. This research was funded by the Centers for Disease Control and Prevention under Cooperative Agreement UR3 DD000685-04/dd10-1102 and the Utah Department of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. We thank the Utah Department of Health and Utah State Office of Education for their support of the Utah Registry of Autism and Developmental Disabilities. NR 34 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 EI 1573-3432 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD OCT PY 2016 VL 46 IS 10 BP 3369 EP 3376 DI 10.1007/s10803-016-2877-3 PG 8 WC Psychology, Developmental SC Psychology GA EA7BO UT WOS:000386783300017 PM 27465244 ER PT J AU Chang, OH Liu, F Knopp, E Muehlenbachs, A Cope, JR Ali, I Thompson, R George, E AF Chang, Oliver H. Liu, Fan Knopp, Eleanor Muehlenbachs, Atis Cope, Jennifer R. Ali, Ibne Thompson, Robert George, Evan TI Centrofacial Balamuthiasis: case report of a rare cutaneous amebic infection SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Article DE ameba; Balamuthia mandrillaris; cutaneous balamuthiasis; free living amebae; skin infections ID FREE-LIVING AMEBAS; MANDRILLARIS; ENCEPHALITIS; ACANTHAMOEBA AB Free-living amebae are ubiquitous in our environment, but rarely cause cutaneous infection. Balamuthia mandrillaris has a predilection for infecting skin of the central face. Infection may be restricted to the skin or associated with life-threatening central nervous system (CNS) involvement. We report a case of a 91-year-old woman, who presented with a non-healing red plaque over her right cheek. Several punch biopsies exhibited non-specific granulomatous inflammation without demonstrable fungi or mycobacteria in histochemical stains. She was treated empirically for granulomatous rosacea, but the lesion continued to progress. A larger incisional biopsy was performed in which amebae were observed in hematoxylin-eosin stained sections. These were retrospectively apparent in the prior punch biopsy specimens. Immunohistochemistry and polymerase chain reaction studies identified the organisms as Balamuthia mandrillaris. Cutaneous infection by B. mandrillaris is a rare condition that is sometimes complicated by life-threatening CNS involvement and which often evades timely diagnosis due to its rarity and nonspecific clinical manifestations. Moreover, these amebae are easily overlooked in histopathologic sections because of their small number and their resemblance to histiocytes. Dermatopathologists should be familiar with the histopathologic appearance of these organisms and include balamuthiasis and other amebic infections in the differential diagnosis of granulomatous dermatitis. C1 [Chang, Oliver H.; George, Evan] Univ Washington, Dept Anat Pathol, Box 357470,1959 NE Pacific St, Seattle, WA 98195 USA. [Liu, Fan; Knopp, Eleanor] Univ Washington, Dept Med, Div Dermatol, Box 357470,1959 NE Pacific St, Seattle, WA 98195 USA. [Knopp, Eleanor; Thompson, Robert] Grp Hlth Capitol Hill Campus, Seattle, WA USA. [Cope, Jennifer R.; Ali, Ibne] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Atlanta, GA USA. [Muehlenbachs, Atis] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Chang, OH (reprint author), Univ Washington, Dept Anat Pathol, Box 357470,1959 NE Pacific St, Seattle, WA 98195 USA. EM ochang@uw.edu FU Intramural CDC HHS [CC999999] NR 20 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0303-6987 EI 1600-0560 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD OCT PY 2016 VL 43 IS 10 BP 892 EP 897 DI 10.1111/cup.12748 PG 6 WC Dermatology; Pathology SC Dermatology; Pathology GA EA6ZT UT WOS:000386778500013 PM 27251900 ER PT J AU Taylor, EM Painter, J Posey, DL Zhou, WG Shetty, S AF Taylor, Eboni M. Painter, John Posey, Drew L. Zhou, Weigong Shetty, Sharmila TI Latent Tuberculosis Infection Among Immigrant and Refugee Children Arriving in the United States: 2010 SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Pediatric; Tuberculin skin test; Interferon gamma release assay; Migrants ID COMPLETION AB Immigrants and refugees age 2-14 years entering the United States from countries with estimated tuberculosis (TB) incidence rate C20 per 100,000 population are screened for TB. Children with TB disease are treated before US arrival. Children with positive tuberculin skin tests (TST), but negative TB evaluation during their pre-immigration examination, are classified with latent TB infection (LTBI) and are recommended for re-evaluation post-arrival. We examined post-immigration TB evaluation and therapy for children arriving with LTBI. We reviewed medical exam data from immigrant children with medical conditions and all refugee children arriving during 2010. Medical examination data were available for 67,334 children. Of these, 8231 (12 %) had LTBI pre-immigration; 5749 (70 %) were re-evaluated for TB post-immigration, and 64 % were retested by TST or IGRA. The pre-immigration LTBI diagnosis was changed for 38 % when retested by TST and for 71 % retested by IGRA. Estimated LTBI therapy initiation and completion rates were 68 and 12 %. In this population, testing with IGRA may limit the number of children targeted for therapy. Increased pre-immigration TB screening with post-immigration follow-up evaluation leading to completion of LTBI therapy should be encouraged to prevent TB reactivation. C1 [Taylor, Eboni M.; Painter, John; Posey, Drew L.; Zhou, Weigong; Shetty, Sharmila] US Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging Zoonot & Infect Dis, 1600 Clifton Rd NE,Mailstop E-04, Atlanta, GA 30333 USA. [Taylor, Eboni M.; Painter, John; Posey, Drew L.; Zhou, Weigong; Shetty, Sharmila] US Publ Hlth Serv Commissioned Corps, Washington, DC USA. RP Taylor, EM (reprint author), US Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging Zoonot & Infect Dis, 1600 Clifton Rd NE,Mailstop E-04, Atlanta, GA 30333 USA.; Taylor, EM (reprint author), US Publ Hlth Serv Commissioned Corps, Washington, DC USA. EM ETaylor1@cdc.gov NR 20 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD OCT PY 2016 VL 18 IS 5 BP 966 EP 970 DI 10.1007/s10903-015-0273-2 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA3KR UT WOS:000386501700006 PM 26364054 ER PT J AU Ao, T Shetty, S Sivilli, T Blanton, C Ellis, H Geltman, PL Cochran, J Taylor, E Lankau, EW Cardozo, BL AF Ao, Trong Shetty, Sharmila Sivilli, Teresa Blanton, Curtis Ellis, Heidi Geltman, Paul L. Cochran, Jennifer Taylor, Eboni Lankau, Emily W. Cardozo, Barbara Lopes TI Suicidal Ideation and Mental Health of Bhutanese Refugees in the United States (vol 18, pg 828, 2016) SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Correction C1 [Ao, Trong; Sivilli, Teresa; Blanton, Curtis; Lankau, Emily W.; Cardozo, Barbara Lopes] Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, Ctr Global Hlth, 1600 Clifton Rd,Mailstop E-22, Atlanta, GA 30329 USA. [Ellis, Heidi] Boston Childrens Hosp, Boston, MA USA. [Ellis, Heidi; Geltman, Paul L.] Harvard Med Sch, Boston, MA USA. [Geltman, Paul L.; Cochran, Jennifer] Massachusetts Dept Publ Hlth, Boston, MA USA. [Lankau, Emily W.] LandCow Consulting, Athens, GA USA. [Lankau, Emily W.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA. [Shetty, Sharmila; Taylor, Eboni] Ctr Dis Control & Prevent, Immigrant Refugee & Migrant Hlth Branch, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. RP Cardozo, BL (reprint author), Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, Ctr Global Hlth, 1600 Clifton Rd,Mailstop E-22, Atlanta, GA 30329 USA. EM tfa8@cdc.gov; acq1@cdc.gov; teri.sivilli@gmail.com; cgb9@cdc.gov; Heidi.Ellis@childrens.harvard.edu; paul.geltman@state.ma.us; jennifer.cochran@state.ma.us; jyo1@cdc.gov; emily.wheeler@alumni.rice.edu; bhc8@cdc.gov NR 1 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD OCT PY 2016 VL 18 IS 5 BP 1256 EP 1256 DI 10.1007/s10903-016-0343-0 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA3KR UT WOS:000386501700043 PM 27085882 ER PT J AU Azevedo, J dos Anjos, ES Cordeiro, SM dos Santos, MS Escobar, EC Lobo, PR Carvalho, MD Reis, MG Reis, JN Campos, LC AF Azevedo, Jailton dos Anjos, Eder Silva Cordeiro, Soraia M. dos Santos, Milena S. Escobar, Eliane C. Lobo, Paulo R. Carvalho, Maria da Gloria Reis, Mitermayer G. Reis, Joice N. Campos, Leila C. TI Genetic profiles and antimicrobial resistance of Streptococcus pneumoniae non-PCV10 serotype isolates recovered from meningitis cases in Salvador, Brazil SO JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Article ID INVASIVE PNEUMOCOCCAL DISEASE; NONTYPABLE HAEMOPHILUS-INFLUENZAE; CONJUGATE VACCINE IMPLEMENTATION; CAPSULAR SEROTYPES; CHILDREN; SURVEILLANCE; VARIABILITY; CARRIAGE; IMPACT; AGE AB In 2010, the 10-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Brazilian childhood vaccination programme. Concerns have been raised that non-vaccine serotypes could increase in prevalence and reduce the benefits of vaccination; therefore, we examined non-PCV10 isolates recovered from meningitis during pre- (January 2008-May 2010) and post-vaccine (June 2010-December 2012) periods. Surveillance for pneumococcal meningitis was established at the Reference Hospital of Infectious Diseases in Salvador, Brazil. Serotypes were determined by multiplex PCR and/or Quellung reaction. Antimicrobial susceptibility testing was conducted by E-test and broth microdilution. Genotyping used PFGE and multi-locus sequence typing. A total of 148 cases of meningitis were identified from January 2008 to December 2012, 77 (52 %) of which were due to non-PCV10 isolates, with 50 (52.1 %) from pre-vaccine and 27 (52 %) from post-vaccine periods. In the post-vaccine period, the non-PCV10 serotypes 12F (n=6; 22.2 %), 10A (n=3; 11.1 %), 15B (n=2; 7.4 %) and 18B (n=2; 7.4 %) were the most prevalent. Forty-three isolates (55.8 %) were non-susceptible to one or more antibiotics. Non-susceptibility to penicillin was observed among serotypes 19A (three isolates), 9N (one isolate) and 12F (one isolate). PFGE and multi-locus sequence typing results demonstrated a wide genetic diversity among the isolates. During the early period following PCV10 introduction, no obvious emergence of a particular serotype was evident among non-PCV10 strains. This study underscores the importance of monitoring any changes among non-PCV10 cases after the introduction of PCV10. C1 [Azevedo, Jailton; dos Anjos, Eder Silva; Escobar, Eliane C.; Lobo, Paulo R.; Reis, Mitermayer G.; Reis, Joice N.; Campos, Leila C.] Fundacao Oswaldo Cruz, Inst Goncalo Moniz, BR-40296710 Salvador, BA, Brazil. [Cordeiro, Soraia M.; Reis, Joice N.] Univ Fed Bahia, Fac Farm, BR-40170115 Salvador, BA, Brazil. [dos Santos, Milena S.] Univ Fed Bahia, Inst Multidisciplinar Saude, Campus Anisio Teixeira, BR-45029094 Vitoria Da Conquista, BA, Brazil. [Carvalho, Maria da Gloria] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30333 USA. RP Campos, LC (reprint author), Fundacao Oswaldo Cruz, Inst Goncalo Moniz, BR-40296710 Salvador, BA, Brazil. EM lccampos@bahia.fiocruz.br OI Azevedo, Jailton /0000-0002-0801-8673 NR 32 TC 0 Z9 0 U1 1 U2 1 PU MICROBIOLOGY SOC PI LONDON PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND SN 0022-2615 EI 1473-5644 J9 J MED MICROBIOL JI J. Med. Microbiol. PD OCT PY 2016 VL 65 BP 1164 EP 1170 DI 10.1099/jmm.0.000346 PN 10 PG 7 WC Microbiology SC Microbiology GA EA5IN UT WOS:000386653000017 PM 27599851 ER PT J AU Boylan, B Rice, AS Neff, AT Manco-Johnson, MJ Kempton, CL Miller, CH AF Boylan, B. Rice, A. S. Neff, A. T. Manco-Johnson, M. J. Kempton, C. L. Miller, C. H. CA Hemophilia Inhibitor Res Study TI Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Article DE factor IX; factor IX deficiency; hemophilia B; immunoassay; inherited blood coagulation disorders ID IMMUNE TOLERANCE INDUCTION; FACTOR-VIII; IMMUNOCHEMICAL CHARACTERIZATION; UNITED-STATES; INHIBITORS; ANAPHYLAXIS; ANTIBODIES; MUTATIONS; REGISTRY; THERAPY AB Background Hemophilia B (HB) is an inherited bleeding disorder caused by the absence or dysfunction of coagulation factor IX (FIX). A subset of patients who have HB develop neutralizing alloantibodies (inhibitors) against FIX after infusion therapy. HB prevalence and the proportion of patients who develop inhibitors are much lower than those for hemophilia A (HA), which makes studies of inhibitors in patients with HB challenging due to the limited availability of samples. As a result, there is a knowledge gap regarding HB inhibitors. Objective Evaluate the largest group of patients with inhibitor-positive HB studied to date to assess the relationship between anti-FIX antibody profiles and inhibitor formation. Methods A fluorescence immunoassay was used to detect anti-FIX antibodies in plasma samples from 37 patients with HB. Results Assessments of antibody profiles showed that anti-FIX IgG(1-4), IgA, and IgE were detected significantly more often in patients with a positive Nijmegen-Bethesda assay (NBA). All NBA-positive samples were positive for IgG(4). Anti-FIX IgG(4) demonstrated a strong correlation with the NBA, while correlations were significant, yet more moderate, for anti-FIX IgG(1-2) and IgA. Conclusions The anti-FIX antibody profile in HB patients who develop inhibitors is diverse and correlates well with the NBA across immunoglobulin (sub)class, and anti-FIX IgG(4) is particularly relevant to functional inhibition. The anti-FIX fluorescence immunoassay may serve as a useful tool to confirm the presence of antibodies in patients who have low positive NBA results and to more clearly define, predict, and treat alloantibody formation against FIX. C1 [Boylan, B.; Rice, A. S.; Miller, C. H.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Neff, A. T.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Manco-Johnson, M. J.] Univ Colorado, Hemophilia & Thrombosis Ctr, Aurora, CO USA. [Manco-Johnson, M. J.] Childrens Hosp, Aurora, CO USA. [Kempton, C. L.] Emory Univ, Sch Med, Dept Hematol Oncol, Atlanta, GA USA. [Miller, C. H.] Cleveland Clin, Cleveland, OH 44106 USA. RP Boylan, B (reprint author), Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, 1600 Clifton Rd,MS D-02, Atlanta, GA 30333 USA. EM bboylan@cdc.gov FU CDC Foundation through Pfizer Pharmaceuticals FX This work was supported by the CDC Foundation through a grant from Pfizer Pharmaceuticals. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC. NR 38 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD OCT PY 2016 VL 14 IS 10 BP 1931 EP 1940 DI 10.1111/jth.13438 PG 10 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA EA9IL UT WOS:000386956200005 PM 27501440 ER PT J AU Braekkan, SK Grosse, SD Okoroh, EM Tsai, J Cannegieter, SC Naess, IA Krokstad, S Hansen, JB Skjeldestad, FE AF Braekkan, S. K. Grosse, S. D. Okoroh, E. M. Tsai, J. Cannegieter, S. C. Naess, I. A. Krokstad, S. Hansen, J. -B. Skjeldestad, F. E. TI Venous thromboembolism and subsequent permanent work-related disability SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Article DE deep vein thrombosis; disability; risk; venous thromboembolism ID DEEP-VEIN THROMBOSIS; QUALITY-OF-LIFE; ACUTE PULMONARY-EMBOLISM; POSTTHROMBOTIC SYNDROME; RISK-FACTORS; 1ST EPISODE; COHORT PROFILE; POPULATION; HYPERTENSION; HEALTH AB Background The burden of venous thromboembolism (VTE) related to permanent work-related disability has never been assessed among a general population. Therefore, we aimed to estimate the risk of work-related disability in subjects with incident VTE compared with those without VTE in a population-based cohort. Methods From the TromsO Study and the Nord-TrOndelag Health Study (HUNT), Norway, 66 005 individuals aged 20-65 years were enrolled in 1994-1997 and followed to 31 December 2008. Incident VTE events among the study participants were identified and validated, and information on work-related disability was obtained from the Norwegian National Insurance Administration database. Cox-regression models using age as time-scale and VTE as time-varying exposure were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) adjusted for sex, body mass index, smoking, education level, marital status, history of cancer, diabetes, cardiovascular disease and self-rated general health. Results During follow-up, 384 subjects had a first VTE and 9862 participants were granted disability pension. The crude incidence rate of work-related disability after VTE was 37.5 (95% CI, 29.7-47.3) per 1000 person-years, vs. 13.5 (13.2-13.7) per 1000 person-years among those without VTE. Subjects with unprovoked VTE had a 52% higher risk of work-related disability than those without VTE (HR, 1.52; 95% CI, 1.09-2.14) after multivariable adjustment, and the association appeared to be driven by deep vein thrombosis. Conclusion VTE was associated with subsequent work-related disability in a cohort recruited from the general working-age population. Our findings suggest that indirect costs because of loss of work time may add to the economic burden of VTE. C1 [Braekkan, S. K.; Hansen, J. -B.] UiT, KG Jebsen Thrombosis Res & Expertise Ctr TREC, Dept Clin Med, Tromso, Norway. [Braekkan, S. K.; Hansen, J. -B.] UiT, Hematol Res Grp HERG, Dept Clin Med, Tromso, Norway. [Braekkan, S. K.; Hansen, J. -B.] Univ Hosp North Norway, Div Internal Med, Tromso, Norway. [Grosse, S. D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Okoroh, E. M.; Tsai, J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Cannegieter, S. C.] Leiden Univ, Dept Clin Epidemiol, Med Ctr, Leiden, Netherlands. [Naess, I. A.] Univ Trondheim Hosp, Dept Hematol, Trondheim, Norway. [Krokstad, S.] Norwegian Univ Sci & Technol, HUNT Res Ctr, Dept Publ Hlth & Gen Practice, Levanger, Norway. [Skjeldestad, F. E.] UiT, Res Grp Epidemiol Chron Dis, Dept Community Med, Tromso, Norway. RP Braekkan, SK (reprint author), Univ Tromso, Dept Clin Med, KG Jebsen Thrombosis Res & Expertise Ctr TREC, N-9001 Tromso, Norway. EM sigrid.brakkan@uit.no FU Intramural CDC HHS [CC999999] NR 46 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD OCT PY 2016 VL 14 IS 10 BP 1978 EP 1987 DI 10.1111/jth.13411 PG 10 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA EA9IL UT WOS:000386956200010 PM 27411161 ER PT J AU Cooper, CP Gelb, CA AF Cooper, Crystale Purvis Gelb, Cynthia A. TI Opportunities to Expand Colorectal Cancer Screening Participation SO JOURNAL OF WOMENS HEALTH LA English DT Article DE colorectal cancer; screening; prevention; health knowledge; attitudes; United States ID GENDER-DIFFERENCES; BARRIERS; WOMEN AB The Centers for Disease Control and Prevention's Screen for Life: National Colorectal Cancer Action Campaign has operated continuously since 1999 to promote colorectal cancer screening. The campaign's most recent formative research cycle was conducted in 2015 and included 16 focus groups in four United States cities with adults aged 50-75 years who had not received colorectal cancer screening as recommended. The most common reason for screening nonparticipation was aversion to some aspect of colonoscopy, such as preparation, the invasive nature of the test, or the possibility of complications. Other reasons for screening nonparticipation were absence of symptoms, lack of screening awareness/provider recommendation, and lack of family history. Screening promotion messages that resonated with participants included the following: multiple screening tests are available; colorectal cancer may not cause symptoms; screening should begin at age 50; and most cases of colorectal cancer occur in individuals with no family history of the disease. Efforts to increase colorectal cancer screening participation may be supported by disseminating messages that counter common concerns about screening. Raising awareness of the range of colorectal cancer screening options may be especially critical given that many unscreened individuals were unwilling to undergo a colonoscopy. C1 [Cooper, Crystale Purvis] Soltera Ctr Canc Prevent & Control, Tucson, AZ USA. [Gelb, Cynthia A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 3719 North Peachtree,MS F75,Chamblee Bldg 107, Atlanta, GA 30341 USA. RP Gelb, CA (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 3719 North Peachtree,MS F75,Chamblee Bldg 107, Atlanta, GA 30341 USA. EM cgelb@cdc.gov FU Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention FX The authors thank Wendy Child for her assistance in development of the discussion guide and facilitating the focus groups. Funding for this study was provided by the Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. NR 13 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD OCT PY 2016 VL 25 IS 10 BP 990 EP 995 DI 10.1089/jwh.2016.6049 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA EA3BH UT WOS:000386472300004 PM 27749190 ER PT J AU Tong, VT Kissin, DM Bernson, D Copeland, G Boulet, SL Zhang, YJ Jamieson, DJ England, LJ AF Tong, Van T. Kissin, Dmitry M. Bernson, Dana Copeland, Glenn Boulet, Sheree L. Zhang, Yujia Jamieson, Denise J. England, Lucinda J. TI Maternal Smoking Among Women With and Without Use of Assisted Reproductive Technologies SO JOURNAL OF WOMENS HEALTH LA English DT Article DE smoking; pregnancy; surveillance; assisted reproductive technology ID UNITED-STATES; CIGARETTE-SMOKING; PREGNANCY; AGE AB Objective: To estimate smoking prevalence during the year before pregnancy and during pregnancy and adverse outcomes among women who delivered infants with and without assisted reproductive technology (ART) using linked birth certificates (BC) and National ART Surveillance System (NASS) data. Methods: Data were analyzed for 384,390 women and 392,248 infants born in Massachusetts and Michigan during 2008-2009. Maternal smoking prevalence was estimated using smoking indicated from BC by ART status. For ART users, to evaluate underreporting, prepregnancy smoking was estimated from BC, NASS, or both sources. Effect of prenatal smoking on preterm and mean birthweight (term only) for singleton infants were examined by ART status. Results: Maternal smoking prevalence estimates were significantly lower for ART users than nonusers (prepregnancy=3.2% vs. 16.7%; prenatal=1.0% vs. 11.1%, p<0.05). When combining smoking information from BC and NASS, prepregnancy smoking prevalence estimates for ART users could be as high as 4.4% to 6.1%. Adverse effects of smoking on infant outcomes in ART pregnancies were consistent with the effects seen in non-ART pregnancies, specifically decline in infant birthweight and increase in preterm delivery, although association between smoking and preterm was not significant. Conclusion: A low, but substantial proportion of ART users smoked before and during pregnancy. As ART users are highly motivated to get pregnant, it should be clearly communicated that smoking can decrease fertility and adversely affect pregnancy outcomes. Continued efforts are needed to encourage smoking cessation and maintain tobacco abstinence among all women of reproductive age. C1 [Tong, Van T.; Kissin, Dmitry M.; Boulet, Sheree L.; Zhang, Yujia; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,NE,MS F74, Atlanta, GA 30341 USA. [Bernson, Dana] Massachusetts Dept Publ Hlth, Boston, MA USA. [Copeland, Glenn] Michigan Dept Hlth, Ann Arbor, MI USA. [England, Lucinda J.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Tong, VT (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,NE,MS F74, Atlanta, GA 30341 USA. EM vtong@cdc.gov FU Centers for Disease Control and Prevention, Department of Health and Human Services FX Financial support for this analysis was provided by the Centers for Disease Control and Prevention, Department of Health and Human Services. NR 14 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD OCT PY 2016 VL 25 IS 10 BP 1066 EP 1072 DI 10.1089/jwh.2015.5662 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA EA3BH UT WOS:000386472300014 PM 27243366 ER PT J AU Cao, WP Davis, WG Kim, JH De La Cruz, JA Taylor, A Hendrickson, GR Kumar, A Ranjan, P Lyon, LA Katz, JM Gangappa, S Sambhara, S AF Cao, Weiping Davis, William G. Kim, Jin Hyang De La Cruz, Juan A. Taylor, Andrew Hendrickson, Grant R. Kumar, Amrita Ranjan, Priya Lyon, L. Andrew Katz, Jacqueline M. Gangappa, Shivaprakash Sambhara, Suryaprakash TI An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE LA English DT Article DE Oil-in-water nanoemulsion; Adjuvant; H5N1 vaccine; Innate immunity; Adaptive immunity; Influenza ID PANDEMIC INFLUENZA VACCINE; PHASE-I; RANDOMIZED-TRIAL; HEALTHY-ADULTS; ANTIBODY-RESPONSES; ALUMINUM-HYDROXIDE; LETHAL CHALLENGE; DENDRITIC CELLS; ELDERLY ADULTS; CLINICAL-TRIAL AB To enhance the immunogenicity of the Influenza H5N1 vaccine, we developed an oil-in-water nanoemulsion ( NE) adjuvant. NE displayed good temperature stability and maintained particle size. More importantly, it significantly enhanced IL-6 and MCP-1 production to recruit innate cells, including neutrophils, monocytes/macrophages and dendritic cells to the local environment. Furthermore, NE enhanced dendritic cell function to induce robust antigen-specific T and B cell immune responses. NE-adjuvanted H5N1 vaccine not only elicited significantly higher and long-lasting antibody responses, but also conferred enhanced protection against homologous clade 1 as well as heterologous clade 2 H5N1 virus challenge in young as well as in aged mice. The pre-existing immunity to seasonal influenza did not affect the immunogenicity of NE-adjuvanted H5N1 vaccine. Published by Elsevier Inc. C1 [Cao, Weiping; Davis, William G.; Kim, Jin Hyang; De La Cruz, Juan A.; Taylor, Andrew; Kumar, Amrita; Ranjan, Priya; Katz, Jacqueline M.; Gangappa, Shivaprakash; Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Hendrickson, Grant R.; Lyon, L. Andrew] Georgia Inst Technol, Sch Chem & Biochem, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA. [Lyon, L. Andrew] Chapman Univ, Schmid Coll Sci & Technol, Orange, CA USA. RP Cao, WP (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM wcao@cdc.gov RI Lyon, Andrew/A-4082-2009 OI Lyon, Andrew/0000-0001-7828-7345 FU Influenza Division, Centers for Disease Control and Prevention FX the Influenza Division, Centers for Disease Control and Prevention. NR 41 TC 0 Z9 0 U1 7 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1549-9634 EI 1549-9642 J9 NANOMED-NANOTECHNOL JI Nanomed.-Nanotechnol. Biol. Med. PD OCT PY 2016 VL 12 IS 7 BP 1909 EP 1917 DI 10.1016/j.nano.2016.04.005 PG 9 WC Nanoscience & Nanotechnology; Medicine, Research & Experimental SC Science & Technology - Other Topics; Research & Experimental Medicine GA EA1JJ UT WOS:000386348000017 PM 27112307 ER PT J AU Bloch, D Roth, NM Caraballo, EV Munoz-Jordan, J Hunsperger, E Rivera, A Perez-Padilla, J Garcia, BR Sharp, TM AF Bloch, Danielle Roth, Nicole M. Caraballo, Elba V. Munoz-Jordan, Jorge Hunsperger, Elizabeth Rivera, Aidsa Perez-Padilla, Janice Garcia, Brenda Rivera Sharp, Tyler M. TI Use of Household Cluster Investigations to Identify Factors Associated with Chikungunya Virus Infection and Frequency of Case Reporting in Puerto Rico SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID DENGUE VIRUS; PERSISTENT ARTHRALGIA; SEROPREVALENCE SURVEY; REUNION-ISLAND; TRANSMISSION; EPIDEMIC; MALAYSIA; CANDLES AB Background Chikungunya virus (CHIKV) is transmitted by Aedes species mosquitoes and is the cause of an acute febrile illness characterized by potentially debilitating arthralgia. After emerging in the Caribbean in late 2013, the first locally-acquired case reported to public health authorities in Puerto Rico occurred in May 2014. During June-August 2014, household-based cluster investigations were conducted to identify factors associated with infection, development of disease, and case reporting. Methodology/Principal Findings Residents of households within a 50-meter radius of the residence of laboratory-positive chikungunya cases that had been reported to Puerto Rico Department of Health (PRDH) were offered participation in the investigation. Participants provided a serum specimen and answered a questionnaire that collected information on demographic factors, household characteristics, recent illnesses, healthcare seeking behaviors, and clinical diagnoses. Current CHIKV infection was identified by rRT-PCR, and recent CHIKV infection was defined by detection of either anti-CHIKV IgM or IgG antibody. Among 250 participants, 74 (30%) had evidence of CHIKV infection, including 12 (5%) with current and 62 (25%) with recent CHIKV infection. All specimens from patients with CHIKV infection that were collected within four days, two weeks, and three weeks of illness onset were positive by RT-PCR, IgM ELISA, and IgG ELISA, respectively. Reporting an acute illness in the prior three months was strongly associated with CHIKV infection (adjusted odds ratio [aOR] = 21.6, 95% confidence interval [CI]: 9.24-50.3). Use of air conditioning (aOR = 0.50, 95% CI = 0.3-0.9) and citronella candles (aOR = 0.4, 95% CI = 0.1-0.9) were associated with protection from CHIKV infection. Multivariable analysis indicated that arthralgia (aOR = 51.8, 95% CI = 3.8-700.8) and skin rash (aOR = 14.2, 95% CI = 2.4-84.7) were strongly associated with CHIKV infection. Hierarchical cluster analysis of signs and symptoms reported by CHIKV-infected participants demonstrated that fever, arthralgia, myalgia, headache, and chills tended to occur simultaneously. Rate of symptomatic CHIKV infection (defined by arthralgia with fever or skin rash) was 62.5%. Excluding index case-patients, 22 (63%) participants with symptomatic CHIKV infection sought medical care, of which 5 (23%) were diagnosed with chikungunya and 2 (9%) were reported to PRDH. Conclusions/Significance This investigation revealed high rates of CHIKV infection among household members and neighbors of chikungunya patients, and that behavioral interventions such as use of air conditioning were associated with prevention of CHIKV infection. Nearly two-thirds of patients with symptomatic CHIKV infection sought medical care, of which less than one-quarter were reportedly diagnosed with chikungunya and one-in-ten were reported to public health authorities. These findings emphasize the need for point-of-care rapid diagnostic tests to optimize identification and reporting of chikungunya patients. C1 [Bloch, Danielle; Roth, Nicole M.; Caraballo, Elba V.; Munoz-Jordan, Jorge; Hunsperger, Elizabeth; Rivera, Aidsa; Perez-Padilla, Janice; Sharp, Tyler M.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00937 USA. [Bloch, Danielle] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA. [Roth, Nicole M.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Garcia, Brenda Rivera] Puerto Rico Dept Hlth, San Juan, PR USA. RP Sharp, TM (reprint author), Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00937 USA. EM tsharp@cdc.gov NR 43 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2016 VL 10 IS 10 AR e0005075 DI 10.1371/journal.pntd.0005075 PG 17 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EA5QH UT WOS:000386676200052 PM 27764085 ER PT J AU Lemoine, JF Desormeaux, AM Monestime, F Fayette, CR Desir, L Direny, AN Carciunoiu, S Miller, L Knipes, A Lammie, P Smith, P Stockton, M Trofimovich, L Bhandari, K Reithinger, R Crowley, K Ottesen, E Baker, M AF Lemoine, Jean Frantz Desormeaux, Anne Marie Monestime, Franck Fayette, Carl Renad Desir, Luccene Direny, Abdel Nasser Carciunoiu, Sarah Miller, Lior Knipes, Alaine Lammie, Patrick Smith, Penelope Stockton, Melissa Trofimovich, Lily Bhandari, Kalpana Reithinger, Richard Crowley, Kathryn Ottesen, Eric Baker, Margaret TI Controlling Neglected Tropical Diseases (NTDs) in Haiti: Implementation Strategies and Evidence of Their Success SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID LYMPHATIC FILARIASIS; BANCROFTIAN FILARIASIS; LYMPHEDEMA MANAGEMENT; ELIMINATION; PROGRAM; LEOGANE; INDIA; TRANSMISSION; DISTRICT; CAMPAIGN AB Lymphatic filariasis (LF) and soil-transmitted helminths (STH) have been targeted since 2000 in Haiti, with a strong mass drug administration (MDA) program led by the Ministry of Public Health and Population and its collaborating international partners. By 2012, Haiti's neglected tropical disease (NTD) program had reached full national scale, and with such consistently good epidemiological coverage that it is now able to stop treatment for LF throughout almost all of the country. Essential to this success have been in the detail of how MDAs were implemented. These key programmatic elements included ensuring strong community awareness through an evidence-based, multi-channel communication and education campaign facilitated by voluntary drug distributors; strengthening community trust of the drug distributors by ensuring that respected community members were recruited and received appropriate training, supervision, identification, and motivation; enforcing a "directly observed treatment" strategy; providing easy access to treatment though numerous distribution posts and a strong drug supply chain; and ensuring quality data collection that was used to guide and inform MDA strategies. The evidence that these strategies were effective lies in both the high treatment coverage obtained- 100% geographical coverage reached in 2012, with almost all districts consistently achieving well above the epidemiological coverage targets of 65% for LF and 75% for STH-and the significant reduction in burden of infection-45 communes having reached the target threshold for stopping treatment for LF. By taking advantage of sustained international financial and technical support, especially during the past eight years, Haiti's very successful MDA campaign resulted in steady progress toward LF elimination and development of a strong foundation for ongoing STH control. These efforts, as described, have not only helped establish the global portfolio of "best practices" for NTD control but also are poised to help solve two of the most important future NTD challenges-how to maintain control of STH infections after the community-based LF "treatment platform" ceases and how to ensure appropriate morbidity management for patients currently suffering from lymphatic filarial disease. C1 [Lemoine, Jean Frantz; Desormeaux, Anne Marie] Minist Publ Hlth & Populat, Port Au Prince, Haiti. [Monestime, Franck; Fayette, Carl Renad] IMA World Hlth, Port Au Prince, Haiti. [Desir, Luccene] Hop St Croix, Leogane, Haiti. [Desir, Luccene] Univ Notre Dame, Leogane, Haiti. [Direny, Abdel Nasser; Stockton, Melissa; Bhandari, Kalpana; Reithinger, Richard; Crowley, Kathryn; Ottesen, Eric; Baker, Margaret] RTI Int, Washington, DC 20005 USA. [Carciunoiu, Sarah; Miller, Lior] IMA World Hlth, Washington, DC USA. [Knipes, Alaine; Lammie, Patrick] Ctr Dis Control & Prevent, Atlanta, GA USA. [Smith, Penelope] US Agcy Int Dev, Washington, DC 20523 USA. [Trofimovich, Lily] RTI Int Consultancy, Washington, DC USA. RP Direny, AN (reprint author), RTI Int, Washington, DC 20005 USA. EM adireny@rti.org FU United States Agency for International Development [AID-OAA-A-11-00048]; National NTD Control Program; US Centers for Disease Control and Prevention FX This study was led by RTI International as part of the ENVISION project, a global project funded by the United States Agency for International Development (www.neglecteddiseases.gov) under cooperative agreement No. AID-OAA-A-11-00048. The ENVISION project provides technical and financial assistance in support of the National NTD Control Program and in partnerships with the US Centers for Disease Control and Prevention. The funder had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript. The author's views expressed in this publication do not necessarily reflect the views of the United States Agency for International Development or the United States Government. NR 40 TC 1 Z9 1 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2016 VL 10 IS 10 AR e0004954 DI 10.1371/journal.pntd.0004954 PG 20 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EA5QH UT WOS:000386676200006 PM 27706162 ER PT J AU Lutomiah, J Barrera, R Makio, A Mutisya, J Koka, H Owaka, S Koskei, E Nyunja, A Eyase, F Coldren, R Sang, R AF Lutomiah, Joel Barrera, Roberto Makio, Albina Mutisya, James Koka, Hellen Owaka, Samuel Koskei, Edith Nyunja, Albert Eyase, Fredrick Coldren, Rodney Sang, Rosemary TI Dengue Outbreak in Mombasa City, Kenya, 2013-2014: Entomologic Investigations SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID AEDES-AEGYPTI; 1ST REPORT; VECTOR; VIRUS; FEVER; ALBOPICTUS; AFRICA; TRANSMISSION; INFECTIONS; CULICIDAE AB Dengue outbreaks were first reported in East Africa in the late 1970s to early 1980s including the 1982 outbreak on the Kenyan coast. In 2011, dengue outbreaks occurred in Mandera in northern Kenya and subsequently in Mombasa city along the Kenyan coast in 2013-2014. Following laboratory confirmation of dengue fever cases, an entomologic investigation was conducted to establish the mosquito species, and densities, causing the outbreak. Affected parts of the city were identified with the help of public health officials. Adult Ae. aegypti mosquitoes were collected using various tools, processed and screened for dengue virus (DENV) by cell culture and RT-PCR. All containers in every accessible house and compound within affected suburbs were inspected for immatures. A total of 2,065 Ae. aegypti adults were collected and 192 houses and 1,676 containers inspected. An overall house index of 22%, container index, 31.0% (indoor = 19; outdoor = 43) and Breteau index, 270.1, were observed, suggesting that the risk of dengue transmission was high. Overall, jerry cans were the most productive containers (18%), followed by drums (17%), buckets (16%), tires (14%) and tanks (10%). However, each site had specific most-productive container-types such as tanks (17%) in Kizingo; Drums in Nyali (30%) and Changamwe (33%), plastic basins (35%) in Nyali-B and plastic buckets (81%) in Ganjoni. We recommend that for effective control of the dengue vector in Mombasa city, all container types would be targeted. Measures would include proper covering of water storage containers and eliminating discarded containers outdoors through a public participatory environmental clean-up exercise. Providing reliable piped water to all households would minimize the need for water storage and reduce aquatic habitats. Isolation of DENV from male Ae. aegypti mosquitoes is a first observation in Kenya and provides further evidence that transovarial transmission may have a role in DENV circulation and/or maintenance in the environment. C1 [Lutomiah, Joel; Sang, Rosemary] Kenya Med Res Inst KEMRI, Ctr Virus Res, Arbovirus Viral Hemorrhag Fever Lab, Nairobi, Kenya. [Barrera, Roberto] Ctr Dis Control & Prevent, Entomol & Ecol Act, Dengue Branch, San Juan, PR USA. [Lutomiah, Joel; Makio, Albina; Mutisya, James; Koka, Hellen; Owaka, Samuel; Koskei, Edith; Nyunja, Albert; Eyase, Fredrick; Coldren, Rodney; Sang, Rosemary] US Army Med Res Directorate Kenya USAMRD K, Nairobi, Kenya. RP Lutomiah, J (reprint author), Kenya Med Res Inst KEMRI, Ctr Virus Res, Arbovirus Viral Hemorrhag Fever Lab, Nairobi, Kenya.; Lutomiah, J (reprint author), US Army Med Res Directorate Kenya USAMRD K, Nairobi, Kenya. EM joel.lutomiah@usamru-k.org FU Global Emerging Infection Surveillance and Response System (GEIS) of the US Armed Forces Health Surveillance Center (AFHSC) under the United States Department of Defense (DoD) FX This work was funded by the Global Emerging Infection Surveillance and Response System (GEIS) of the US Armed Forces Health Surveillance Center (AFHSC) under the United States Department of Defense (DoD) and supported by the Director, KEMRI. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript NR 66 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2016 VL 10 IS 10 AR e0004981 DI 10.1371/journal.pntd.0004981 PG 16 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EA5QH UT WOS:000386676200007 PM 27783626 ER PT J AU Padgett, KA Bonilla, D Eremeeva, ME Glaser, C Lane, RS Porse, CC Castro, MB Messenger, S Espinosa, A Hacker, J Kjemtrup, A Ryan, B Scott, JJ Hu, RJ Yoshimizu, MH Dasch, GA Kramer, V AF Padgett, Kerry A. Bonilla, Denise Eremeeva, Marina E. Glaser, Carol Lane, Robert S. Porse, Charsey Cole Castro, Martin B. Messenger, Sharon Espinosa, Alex Hacker, Jill Kjemtrup, Anne Ryan, Bonnie Scott, Jamesina J. Hu, Renjie Yoshimizu, Melissa Hardstone Dasch, Gregory A. Kramer, Vicki TI The Eco-epidemiology of Pacific Coast Tick Fever in California SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID DERMACENTOR-OCCIDENTALIS ACARI; ESCHAR-ASSOCIATED ILLNESS; MOUNTAIN-SPOTTED-FEVER; RICKETTSIA-RICKETTSII; RHIPICEPHALUS-SANGUINEUS; METEOROLOGICAL FACTORS; NORTHERN CALIFORNIA; IXODES-PACIFICUS; UNITED-STATES; HOST-SEEKING AB Rickettsia philipii (type strain "Rickettsia 364D"), the etiologic agent of Pacific Coast tick fever (PCTF), is transmitted to people by the Pacific Coast tick, Dermacentor occidentalis. Following the first confirmed human case of PCTF in 2008, 13 additional human cases have been reported in California, more than half of which were pediatric cases. The most common features of PCTF are the presence of at least one necrotic lesion known as an eschar (100%), fever (85%), and headache (79%); four case-patients required hospitalization and four had multiple eschars. Findings presented here implicate the nymphal or larval stages of D. occidentalis as the primary vectors of R. philipii to people. Peak transmission risk from ticks to people occurs in late summer. Rickettsia philipii DNA was detected in D. occidentalis ticks from 15 of 37 California counties. Similarly, non-pathogenic Rickettsia rhipicephali DNA was detected in D. occidentalis in 29 of 38 counties with an average prevalence of 12.0% in adult ticks. In total, 5,601 ticks tested from 2009 through 2015 yielded an overall R. philipii infection prevalence of 2.1% in adults, 0.9% in nymphs and a minimum infection prevalence of 0.4% in larval pools. Although most human cases of PCTF have been reported from northern California, acarological surveillance suggests that R. philipii may occur throughout the distribution range of D. occidentalis. C1 [Padgett, Kerry A.; Bonilla, Denise; Glaser, Carol; Porse, Charsey Cole; Castro, Martin B.; Messenger, Sharon; Espinosa, Alex; Hacker, Jill; Kjemtrup, Anne; Hu, Renjie; Yoshimizu, Melissa Hardstone; Kramer, Vicki] Calif Dept Publ Hlth, Div Communicable Dis Control, Richmond, CA 94804 USA. [Eremeeva, Marina E.] Georgia Southern Univ, Jian Ping Hsu Coll Publ Hlth, Statesboro, GA USA. [Lane, Robert S.] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA. [Ryan, Bonnie; Scott, Jamesina J.] Lake Cty Vector Control Dist, Lakeport, CA USA. [Dasch, Gregory A.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA USA. RP Padgett, KA (reprint author), Calif Dept Publ Hlth, Div Communicable Dis Control, Richmond, CA 94804 USA. EM Kerry.Padgett@cdph.ca.gov OI Padgett, Kerry/0000-0002-9535-3401 NR 38 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2016 VL 10 IS 10 AR e0005020 DI 10.1371/journal.pntd.0005020 PG 17 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EA5QH UT WOS:000386676200015 PM 27706171 ER PT J AU Pereira, TA Syn, WK Amancio, FF Cunha, PHD Caporali, JFM Trindade, GVD Santos, ET Souza, MM Andrade, ZA Witek, RP Secor, WE Pereira, FEL Lambertucci, JR Diehl, AM AF Pereira, Thiago Almeida Syn, Wing-Kin Amancio, Frederico Figueiredo Diniz Cunha, Pedro Henrique Morais Caporali, Julia Fonseca de Melo Trindade, Guilherme Vaz Santos, Elisangela Trindade Souza, Marcia Maria Andrade, Zilton Araujo Witek, Rafal P. Secor, William Evan Lima Pereira, Fausto Edmundo Lambertucci, Jose Roberto Diehl, Anna Mae TI Osteopontin Is Upregulated in Human and Murine Acute Schistosomiasis Mansoni SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID GRANULOMA-FORMATION; LIVER; INFLAMMATION; INFECTION; RESPONSES; FIBROSIS; INJURY; CELLS AB Background Symptomatic acute schistosomiasis mansoni is a systemic hypersensitivity reaction against the migrating schistosomula and mature eggs after a primary infection. The mechanisms involved in the pathogenesis of acute schistosomiasis are not fully elucidated. Osteopontin has been implicated in granulomatous reactions and in acute hepatic injury. Our aims were to evaluate if osteopontin plays a role in acute Schistosoma mansoni infection in both human and experimentally infected mice and if circulating OPN levels could be a novel biomarker of this infection. Methodology/Principal Findings Serum/plasma osteopontin levels were measured by ELISA in patients with acute (n = 28), hepatointestinal (n = 26), hepatosplenic (n = 39) schistosomiasis and in uninfected controls (n = 21). Liver osteopontin was assessed by immunohistochemistry in needle biopsies of 5 patients. Sera and hepatic osteopontin were quantified in the murine model of schistosomiasis mansoni during acute (7 and 8 weeks post infection, n = 10) and chronic (30 weeks post infection, n = 8) phase. Circulating osteopontin levels are increased in patients with acute schistosomiasis (p = 0.0001). The highest levels of OPN were observed during the peak of clinical symptoms (7-11 weeks post infection), returning to baseline level once the granulomas were modulated (>12 weeks post infection). The plasma levels in acute schistosomiasis were even higher than in hepatosplenic patients. The murine model mirrored the human disease. Macrophages were the major source of OPN in human and murine acute schistosomiasis, while the ductular reaction maintains OPN production in hepatosplenic disease. Soluble egg antigens from S. mansoni induced OPN expression in primary human kupffer cells. Conclusions/Significance S. mansoni egg antigens induce the production of OPN by macrophages in the necroticexudative granulomas characteristic of acute schistosomiasis mansoni. Circulating OPN levels are upregulated in human and murine acute schistosomiasis and could be a noninvasive biomarker of this form of disease. C1 [Pereira, Thiago Almeida; Diehl, Anna Mae] Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA. [Pereira, Thiago Almeida; Amancio, Frederico Figueiredo; Diniz Cunha, Pedro Henrique; Morais Caporali, Julia Fonseca; de Melo Trindade, Guilherme Vaz; Lambertucci, Jose Roberto] Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Lab Doencas Infecciosas & Parasitarias, Belo Horizonte, MG, Brazil. [Pereira, Thiago Almeida; Santos, Elisangela Trindade; Souza, Marcia Maria; Andrade, Zilton Araujo] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Lab Patol Expt, Salvador, BA, Brazil. [Pereira, Thiago Almeida] NIAID, Immunopathogesis Sect, Parasit Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Syn, Wing-Kin] Ralph H Johnson Vet Affairs Med Ctr, Gastroenterol Sect, Charleston, SC USA. [Syn, Wing-Kin] Med Univ South Carolina, Div Gastroenterol & Hepatol, Charleston, SC USA. [Syn, Wing-Kin] Fdn Liver Res, Inst Hepatol, Liver Regenerat & Repair Res Grp, London, England. [de Melo Trindade, Guilherme Vaz] Natl Univ Ireland, Sch Med, Dept Physiol, Galway, Ireland. [Witek, Rafal P.] Thermo Fisher Sci, Frederick, MD USA. [Secor, William Evan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lima Pereira, Fausto Edmundo] Univ Fed Espirito Santo, Nucleo Doencas Infecciosas, Vitoria, ES, Brazil. RP Diehl, AM (reprint author), Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA.; Lambertucci, JR (reprint author), Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Lab Doencas Infecciosas & Parasitarias, Belo Horizonte, MG, Brazil. EM jrlambertu@gmail.com; annamae.diehl@duke.edu FU National Institutes of Health [R01-DK-077794]; National Institutes of Health (Division of Intramural Research, NIAID, NIH); Duke University; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Ministry of Science, Technology and Innovation of Brazil (CNPq); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) FX This work was supported by National Institutes of Health (grant number R01-DK-077794 (to AMD); Division of Intramural Research, NIAID, NIH (to TAP)); the Duke University Endowment (the Florence McAlister Professorship) (to AMD), the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Ministry of Science, Technology and Innovation of Brazil (CNPq) (to TAP, FELP, JRL and ZAA); and Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) (to JRL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2016 VL 10 IS 10 AR e0005057 DI 10.1371/journal.pntd.0005057 PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EA5QH UT WOS:000386676200038 PM 27755536 ER PT J AU Requena, P Rui, E Padilla, N Martinez-Espinosa, FE Castellanos, ME Botto-Menezes, C Malheiro, A Arevalo-Herrera, M Kochar, S Kochar, SK Kochar, DK Umbers, AJ Ome-Kaius, M Wangnapi, R Hans, D Menegon, M Mateo, F Sanz, S Desai, M Mayor, A Chitnis, CC Bardaji, A Mueller, I Rogerson, S Severini, C Fernandez-Becerra, C Menendez, C del Portillo, H Dobano, C AF Requena, Pilar Rui, Edmilson Padilla, Norma Martinez-Espinosa, Flor E. Eugenia Castellanos, Maria Botto-Menezes, Camila Malheiro, Adriana Arevalo-Herrera, Myriam Kochar, Swati Kochar, Sanjay K. Kochar, Dhanpat K. Umbers, Alexandra J. Ome-Kaius, Maria Wangnapi, Regina Hans, Dhiraj Menegon, Michela Mateo, Francesca Sanz, Sergi Desai, Meghna Mayor, Alfredo Chitnis, Chetan C. Bardaji, Azucena Mueller, Ivo Rogerson, Stephen Severini, Carlo Fernandez-Becerra, Carmen Menendez, Clara del Portillo, Hernando Dobano, Carlota TI Plasmodium vivax VIR Proteins Are Targets of Naturally-Acquired Antibody and T Cell Immune Responses to Malaria in Pregnant Women SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID CHONDROITIN SULFATE; FALCIPARUM; PARASITE; EXPRESSION; PHENOTYPE; GENES; PURIFICATION; CYTOADHESION; EXPOSURE; RECEPTOR AB P. vivax infection during pregnancy has been associated with poor outcomes such as anemia, low birth weight and congenital malaria, thus representing an important global health problem. However, no vaccine is currently available for its prevention. Vir genes were the first putative virulent factors associated with P. vivax infections, yet very few studies have examined their potential role as targets of immunity. We investigated the immunogenic properties of five VIR proteins and two long synthetic peptides containing conserved VIR sequences (PvLP1 and PvLP2) in the context of the PregVax cohort study including women from five malaria endemic countries: Brazil, Colombia, Guatemala, India and Papua New Guinea (PNG) at different timepoints during and after pregnancy. Antibody responses against all antigens were detected in all populations, with PNG women presenting the highest levels overall. P. vivax infection at sample collection time was positively associated with antibody levels against PvLP1 (fold-increase: 1.60 at recruitment-first antenatal visit-) and PvLP2 (fold-increase: 1.63 at delivery), and P. falciparum co-infection was found to increase those responses (for PvLP1 at recruitment, fold-increase: 2.25). Levels of IgG against two VIR proteins at delivery were associated with higher birth weight (27 g increase per duplicating antibody levels, p<0.05). Peripheral blood mononuclear cells from PNG uninfected pregnant women had significantly higher antigen-specific IFN-gamma T(H)1 responses (p=0.006) and secreted less pro-inflammatory cytokines TNF and IL-6 after PvLP2 stimulation than P. vivax-infected women (p<0.05). These data demonstrate that VIR antigens induce the natural acquisition of antibody and T cell memory responses that might be important in immunity to P. vivax during pregnancy in very diverse geographical settings. C1 [Requena, Pilar; Rui, Edmilson; Mateo, Francesca; Sanz, Sergi; Mayor, Alfredo; Bardaji, Azucena; Mueller, Ivo; Fernandez-Becerra, Carmen; Menendez, Clara; del Portillo, Hernando; Dobano, Carlota] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Spain. [Requena, Pilar] Univ Liverpool Liverpool Sch Trop Med, Dept Parasitol, Liverpool, Merseyside, England. [Padilla, Norma; Eugenia Castellanos, Maria] Univ Valle Guatemala, Ctr Estudios Salud, Guatemala City, Guatemala. [Martinez-Espinosa, Flor E.; Botto-Menezes, Camila] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil. [Martinez-Espinosa, Flor E.] Inst Leonidas & Maria Deane ILMD Fiocruz Amazonia, Manaus, Amazonas, Brazil. [Botto-Menezes, Camila] Univ Estado Amazonas, Manaus, Amazonas, Brazil. [Malheiro, Adriana] Univ Fed Amazonas, Inst Ciencias Biol, Manaus, Amazonas, Brazil. [Arevalo-Herrera, Myriam] Univ Valle, Caucaseco Sci Res Ctr, Cali, Colombia. [Kochar, Swati; Kochar, Sanjay K.; Kochar, Dhanpat K.] Coll Med, Dept Med, Bikaner, Rajasthan, India. [Umbers, Alexandra J.; Rogerson, Stephen] Univ Melbourne, Dept Med, Melbourne, Vic, Australia. [Ome-Kaius, Maria; Wangnapi, Regina] Papua New Guinea Inst Med Res, Madang, Papua N Guinea. [Hans, Dhiraj; Chitnis, Chetan C.] Int Ctr Genet Engn & Biotechnol, Delhi, India. [Menegon, Michela; Severini, Carlo] Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, Rome, Italy. [Desai, Meghna] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA. [Mueller, Ivo] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia. [del Portillo, Hernando] ICREA, Barcelona, Spain. RP del Portillo, H; Dobano, C (reprint author), Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Spain.; del Portillo, H (reprint author), ICREA, Barcelona, Spain. EM Hernandoa.delportillo@isglobal.org; Carlota.dobano@isglobal.org RI Requena, Pilar/B-1919-2017; Dobano, Carlota/N-4119-2014 OI Requena, Pilar/0000-0002-2298-4085; Dobano, Carlota/0000-0002-6751-4060 FU European Union [201588]; Ministerio de Economia y Competitividad (National R&D Internationalisation Programme, EUROSALUD, Spain) [EUS2009-03560]; CDC Foundation; Malaria in Pregnancy Consortium (MiPc) through Bill & Melinda Gates Foundation [46099]; MiPc; Ministerio de Economia y Competitividad [RYC-2008-02631]; Institute de Salud Carlos III [CES10/021-I3SNS]; National Health and Medical Research Council [GNT1043345] FX The PREGVAX project received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement 201588, and co-funding from the Ministerio de Economia y Competitividad (National R&D Internationalisation Programme, EUROSALUD 2008, Spain) under grant agreement EUS2009-03560. The Latin American sites received co-funding from the CDC Foundation, who received a grant from the Malaria in Pregnancy Consortium (MiPc) which is partially funded through a grant from the Bill & Melinda Gates Foundation to the Liverpool School of Tropical Medicine (46099). The studies in PNG also received co-funding from the MiPc. CD was supported by a fellowship from the Ministerio de Economia y Competitividad (RYC-2008-02631), AMay was supported by Institute de Salud Carlos III (CES10/021-I3SNS) and IM was supported by a National Health and Medical Research Council Senior Research Fellowship (GNT1043345). CD and HdP were affiliate and full member, respectively, of the EU FP7 Network of Excellence EviMalaR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 1 Z9 1 U1 3 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2016 VL 10 IS 10 AR e0005009 DI 10.1371/journal.pntd.0005009 PG 20 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EA5QH UT WOS:000386676200011 PM 27711158 ER PT J AU Sikulu-Lord, MT Milali, MP Henry, M Wirtz, RA Hugo, LE Dowell, FE Devine, GJ AF Sikulu-Lord, Maggy T. Milali, Masabho P. Henry, Michael Wirtz, Robert A. Hugo, Leon E. Dowell, Floyd E. Devine, Gregor J. TI Near-Infrared Spectroscopy, a Rapid Method for Predicting the Age of Male and Female Wild-Type and Wolbachia Infected Aedes aegypti SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID MOSQUITO AGE; TRANSCRIPTIONAL PROFILES; CUTICULAR HYDROCARBONS; ZIKA VIRUS; VECTOR; DENGUE; CHIKUNGUNYA; CULICIDAE; DIPTERA AB Estimating the age distribution of mosquito populations is crucial for assessing their capacity to transmit disease and for evaluating the efficacy of available vector control programs. This study reports on the capacity of the near-infrared spectroscopy (NIRS) technique to rapidly predict the ages of the principal dengue and Zika vector, Aedes aegypti. The age of wild-type males and females, and males and females infected with wMel and wMelPop strains of Wolbachia pipientis were characterized using this method. Calibrations were developed using spectra collected from their heads and thoraces using partial least squares (PLS) regression. A highly significant correlation was found between the true and predicted ages of mosquitoes. The coefficients of determination for wild-type females and males across all age groups were R-2 = 0.84 and 0.78, respectively. The coefficients of determination for the age of wMel and wMelPop infected females were 0.71 and 0.80, respectively (P<0.001 in both instances). The age of wild-type female Ae. aegypti could be identified as < or >= 8 days old with an accuracy of 91% (N = 501), whereas female Ae. aegypti infected with wMel and wMelPop were differentiated into the two age groups with an accuracy of 83% (N = 284) and 78% (N = 229), respectively. Our results also indicate NIRS can distinguish between young and old male wild-type, wMel and wMelPop infected Ae. aegypti with accuracies of 87% (N = 253), 83% (N = 277) and 78% (N = 234), respectively. We have demonstrated the potential of NIRS as a predictor of the age of female and male wild-type and Wolbachia infected Ae. aegypti mosquitoes under laboratory conditions. After field validation, the tool has the potential to offer a cheap and rapid alternative for surveillance of dengue and Zika vector control programs. C1 [Sikulu-Lord, Maggy T.; Hugo, Leon E.; Devine, Gregor J.] QIMR Berghofer Med Res Inst, Mosquito Control Lab, Brisbane, Qld, Australia. [Sikulu-Lord, Maggy T.; Milali, Masabho P.; Henry, Michael] Ifakara Hlth Inst, Environm Hlth & Ecol Sci Themat Grp, Ifakara, Tanzania. [Wirtz, Robert A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dowell, Floyd E.] ARS, Stored Prod Insect & Engn Res Unit, Ctr Grain & Anim Hlth Res, USDA, Manhattan, KS USA. RP Sikulu-Lord, MT (reprint author), QIMR Berghofer Med Res Inst, Mosquito Control Lab, Brisbane, Qld, Australia.; Sikulu-Lord, MT (reprint author), Ifakara Hlth Inst, Environm Hlth & Ecol Sci Themat Grp, Ifakara, Tanzania. EM maggy.sikulu@qimrberghofer.edu.au FU Grand Challenges Canada Stars for Global Health - Government of Canada [0439-01] FX This study was supported by Grand Challenges Canada Stars for Global Health funded by the Government of Canada (grant 0439-01) awarded to MTSL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 41 TC 0 Z9 0 U1 11 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2016 VL 10 IS 10 AR e0005040 DI 10.1371/journal.pntd.0005040 PG 11 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EA5QH UT WOS:000386676200028 PM 27768689 ER PT J AU Tomashek, KM Rivera, A Torres-Velasquez, B Hunsperger, EA Munoz-Jordan, JL Sharp, TM Rivera, I Sanabria, D Blau, DM Galloway, R Torres, J Rodriguez, R Serrano, J Chavez, C Davila, F Perez-Padilla, J Ellis, EM Caballero, G Wright, L Zaki, SR Deseda, C Rodriguez, E Margolis, HS AF Tomashek, Kay M. Rivera, Aidsa Torres-Velasquez, Brenda Hunsperger, Elizabeth A. Munoz-Jordan, Jorge L. Sharp, Tyler M. Rivera, Irma Sanabria, Dario Blau, Dianna M. Galloway, Renee Torres, Jose Rodriguez, Rosa Serrano, Javier Chavez, Carlos Davila, Francisco Perez-Padilla, Janice Ellis, Esther M. Caballero, Gladys Wright, Laura Zaki, Sherif R. Deseda, Carmen Rodriguez, Edda Margolis, Harold S. TI Enhanced Surveillance for Fatal Dengue-Like Acute Febrile Illness in Puerto Rico, 2010-2012 SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID LINKED-IMMUNOSORBENT-ASSAY; CONSENSUS CONFERENCE; HEMORRHAGIC-FEVER; CASE-MANAGEMENT; SHOCK SYNDROME; PCR ASSAY; RT-PCR; DIAGNOSIS; VIRUS; EPIDEMIC AB Background Dengue is a leading cause of morbidity throughout the tropics; however, accurate population- based estimates of mortality rates are not available. Methods/Principal Findings We established the Enhanced Fatal Acute Febrile Illness Surveillance System (EFASS) to estimate dengue mortality rates in Puerto Rico. Healthcare professionals submitted serum and tissue specimens from patients who died from a dengue-like acute febrile illness, and death certificates were reviewed to identify additional cases. Specimens were tested for markers of dengue virus (DENV) infection by molecular, immunologic, and immunohistochemical methods, and were also tested for West Nile virus, Leptospira spp., and other pathogens based on histopathologic findings. Medical records were reviewed and clinical data abstracted. A total of 311 deaths were identified, of which 58 (19%) were DENV laboratory-positive. Dengue mortality rates were 1.05 per 100,000 population in 2010, 0.16 in 2011 and 0.36 in 2012. Dengue mortality was highest among adults 19-64 years and seniors >= 65 years (1.17 and 1.66 deaths per 100,000, respectively). Other pathogens identified included 34 Leptospira spp. cases and one case of Burkholderia pseudomallei and Neisseria meningitidis. Conclusions/Significance EFASS showed that dengue mortality rates among adults were higher than reported for influenza, and identified a leptospirosis outbreak and index cases of melioidosis and meningitis. C1 [Tomashek, Kay M.; Rivera, Aidsa; Torres-Velasquez, Brenda; Hunsperger, Elizabeth A.; Munoz-Jordan, Jorge L.; Sharp, Tyler M.; Perez-Padilla, Janice; Ellis, Esther M.; Margolis, Harold S.] Ctr Dis Control & Prevent CDC, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00920 USA. [Rivera, Irma; Sanabria, Dario; Torres, Jose; Rodriguez, Rosa; Serrano, Javier; Chavez, Carlos; Davila, Francisco; Rodriguez, Edda] Puerto Rico Inst Forens Sci, San Juan, PR USA. [Blau, Dianna M.; Zaki, Sherif R.] CDC, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Galloway, Renee] CDC, Bacterial Special Pathogens Branch, Div High Consequence Pathogens, Atlanta, GA 30333 USA. [Caballero, Gladys] Demog Registry Puerto Rico, San Juan, PR USA. [Wright, Laura] ATSDR, Geospatial Res Anal & Serv Program, Div Toxicol & Human Hlth Sci, Atlanta, GA USA. [Deseda, Carmen] Puerto Rico Dept Hlth, San Juan, PR USA. [Tomashek, Kay M.] NIAID, Off Clin Res Resources, Div Microbiol & Infect Dis, NIH, Rockville, MD USA. RP Tomashek, KM (reprint author), Ctr Dis Control & Prevent CDC, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00920 USA.; Tomashek, KM (reprint author), NIAID, Off Clin Res Resources, Div Microbiol & Infect Dis, NIH, Rockville, MD USA. EM kay.tomashek@nih.gov FU CDC Dengue Branch programmatic FX The authors received CDC Dengue Branch programmatic funding for this project. No additional sources of funding were received. The funders had no role in the system design, data collection and analysis, decision to publish or preparation of the manuscript. NR 61 TC 0 Z9 0 U1 2 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2016 VL 10 IS 10 AR e0005025 DI 10.1371/journal.pntd.0005025 PG 19 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EA5QH UT WOS:000386676200018 PM 27727271 ER PT J AU O'Keefe, LC Brown, KC Frith, KH Heaton, KL Maples, EH Phillips, JA Vance, DE AF O'Keefe, Louise C. Brown, Kathleen C. Frith, Karen H. Heaton, Karen L. Maples, Elizabeth H. Phillips, Jennan A. Vance, David E. TI Obesity, Prediabetes, and Perceived Stress in Municipal Workers SO WORKPLACE HEALTH & SAFETY LA English DT Article DE disease prevention; research; workforce; work; chronic illnesses; health promotion; occupational hazards ID SERVICES TASK-FORCE; US ADULTS; POLICE FORCE; PREVALENCE; HEALTH; TRENDS; PREVENTION; EXERCISE; GENDER AB The primary cause of death for men and women in the United States is heart disease. Obesity and diabetes are major contributors to heart disease, and the risk is worsened in the presence of stress. It is clinically useful to identify predictors of obesity and prediabetes in a working population. The purpose of this current cross-sectional, correlational study was to examine relationships among obesity, prediabetes, and perceived stress in municipal workers using a subset of worksite wellness program data from employees screened in 2010 and 2011. Multiple regression models indicated that age, gender, race, HA1c, shift schedule, physical activity, and occupation were significant predictors of obesity in municipal workers (p < .01). Prediabetes in municipal workers was predicted by age, Black race, and body mass index (BMI; p < .01). Perceived stress was not a significant predictor of obesity or prediabetes in municipal workers. Overall, the findings of this study provide guidance to occupational health nurses when evaluating individuals in an occupational health setting. Further research is needed to examine relationships among the variables and validate the models. C1 [O'Keefe, Louise C.; Frith, Karen H.] Univ Alabama, 301 Sparkman Dr, Huntsville, AL 35899 USA. [Brown, Kathleen C.; Heaton, Karen L.; Phillips, Jennan A.; Vance, David E.] Univ Alabama Birmingham, Birmingham, AL USA. [Maples, Elizabeth H.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP O'Keefe, LC (reprint author), Univ Alabama, 301 Sparkman Dr, Huntsville, AL 35899 USA. EM louise.okeefe@uah.edu OI Heaton, Karen/0000-0002-9532-1573; Vance, David/0000-0002-0498-6263 FU National Institute for Occupational Safety and Health (NIOSH) FX Dr. O'Keefe acknowledges the National Institute for Occupational Safety and Health (NIOSH) for the fellowship award during her doctoral studies, the Good Health Program, the City of Birmingham, and the University of Alabama at Birmingham. NR 36 TC 0 Z9 0 U1 3 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 2165-0799 EI 2165-0969 J9 WORKPLACE HEALTH SAF JI Workplace Health Saf. PD OCT PY 2016 VL 64 IS 10 BP 453 EP 461 DI 10.1177/2165079916632771 PG 9 WC Nursing SC Nursing GA EA8AB UT WOS:000386853800002 ER PT J AU Mimiaga, MJ Closson, EF Battle, S Herbst, JH Denson, D Pitts, N Holman, J Landers, S Mansergh, G AF Mimiaga, Matthew J. Closson, Elizabeth F. Battle, Shanice Herbst, Jeffrey H. Denson, Damian Pitts, Nicole Holman, Jeremy Landers, Stewart Mansergh, Gordon TI Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities SO AIDS PATIENT CARE AND STDS LA English DT Article DE MSM; HIV; PrEP; racial; ethnic minority; messaging ID CONSPIRACY BELIEFS; RISK; PREP AB Men who have sex with men (MSM) of color are disproportionately affected by HIV in the United States. Pre-exposure prophylaxis (PrEP) using antiretroviral medications is a newer biomedical prevention modality with established efficacy for reducing the risk of acquiring HIV. We conducted formative qualitative research to explore audience reactions and receptivity to message concepts on PrEP as part of the development of prevention messages to promote PrEP awareness among black and Latino MSM in the United States. In 2013, 48 black and 42 Latino (total study sample=90) mixed HIV serostatus MSM from Chicago, Ft. Lauderdale, and Kansas City participated in either an individual interview or focus group discussion. Men were recruited online and at community-based organizations in each city. We elicited feedback on the comprehensibility, credibility, and relevance of two draft messages on PrEP. The messages included efficacy estimates from iPrEx, a phase III clinical trial to ascertain whether the antiretroviral medication tenofovir/emtricitabine disoproxil fumarate (commercially known as Truvada((R))) could safely and effectively prevent HIV acquisition through sex among MSM and transgender women. With participants' consent, the interviews and focus groups were recorded and transcribed. The data were then summarized and analyzed using a qualitative descriptive approach. The majority of men were unfamiliar with PrEP. It was suggested that additional information about the medication and clinical trials establishing efficacy was needed to enhance the legitimacy and relevancy of the messages. Participants sought to form an opinion of PrEP that was grounded in their own interpretation of the efficacy data. However, confusion about nonadherence among clinical trial subjects and individual versus average risk limited comprehension of these messages. Thematic overlaps suggest that message believability was connected to participants' ability to derive meaning from the PrEP efficacy data. Despite being concerned that other MSM would interpret the messages to mean that condom use was unnecessary while taking PrEP, participants themselves primarily understood PrEP as a supplement rather than a replacement for condoms. Based on their experience with taking antiretroviral medication, HIV-positive men considered condom use a more feasible form of HIV prevention than PrEP. Participants' responses suggest that more information about PrEP and the clinical trial would support the legitimacy of PrEP and the messages as a whole. These details may enhance believability in the concept of PrEP and reinforce confidence in the validity of the efficacy result. C1 [Mimiaga, Matthew J.] Brown Univ, Dept Psychiat & Human Behav, Dept Epidemiol, Sch Publ Hlth,Alpert Med Sch, Providence, RI 02912 USA. [Mimiaga, Matthew J.] Brown Univ, Dept Psychiat & Human Behav, Dept Social & Behav Sci, Sch Publ Hlth,Alpert Med Sch, Providence, RI 02912 USA. [Mimiaga, Matthew J.] Brown Univ, Inst Community Hlth Promot, Providence, RI 02912 USA. [Mimiaga, Matthew J.; Holman, Jeremy; Landers, Stewart] John Snow Inc, Boston, MA USA. [Closson, Elizabeth F.] London Sch Hyg & Trop Med, Dept Social & Environm Hlth Res, London, England. [Battle, Shanice; Herbst, Jeffrey H.; Denson, Damian; Mansergh, Gordon] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Pitts, Nicole] ICF Int, Atlanta, GA USA. RP Mimiaga, MJ (reprint author), Brown Univ, Sch Publ Hlth, Dept Epidemiol & Behav & Social Hlth Sci, 121 South Main St,8th Floor, Providence, RI 02912 USA. EM matthew_mimiaga@brown.edu FU Centers for Disease Control and Prevention [U01PS0053307-01] FX This research was supported by the Centers for Disease Control and Prevention grant number U01PS0053307-01 (PI: M.M). NR 22 TC 0 Z9 0 U1 2 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 EI 1557-7449 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD OCT PY 2016 VL 30 IS 10 BP 484 EP 489 DI 10.1089/apc.2016.0123 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EA3BL UT WOS:000386472800006 PM 27749110 ER PT J AU Wertheim, JO Oster, AM Hernandez, AL Saduvala, N Ocfemia, MCB Hall, HI AF Wertheim, Joel O. Oster, Alexandra M. Hernandez, Angela L. Saduvala, Neeraja Ocfemia, M. Cheryl Banez Hall, H. Irene TI The International Dimension of the US HIV Transmission Network and Onward Transmission of HIV Recently Imported into the United States SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article DE HIV; transmission network; cluster; surveillance; molecular clock ID SURVEILLANCE DATA; PREVALENCE; HIV/AIDS; SUBTYPES; MEN; SEX AB The majority of HIV infections in the United States can be traced back to a single introduction in late 1960s or early 1970s. However, it remains unclear whether subsequent introductions of HIV into the United States have given rise to onward transmission. Genetic transmission networks can aid in understanding HIV transmission. We constructed a genetic distance-based transmission network using HIV-1 pol sequences reported to the U.S. National HIV Surveillance System (n=41,539) and all publicly available non-U.S. HIV-1 pol sequences (n=86,215). Of the 13,145 U.S. persons clustered in the network, 457 (3.5%) were genetically linked to a potential transmission partner outside the United States. For internationally connected persons residing in but born outside the United States, 61% had a connection to their country of birth or to another country that shared a language with their country of birth. Bayesian molecular clock phylogenetic analyses indicate that introduced nonsubtype B infections have resulted in onward transmission within the United States. C1 [Wertheim, Joel O.] Univ Calif San Diego, Dept Med, 9500 Gilman Dr, San Diego, CA 92093 USA. [Wertheim, Joel O.; Saduvala, Neeraja] ICF Int, Atlanta, GA USA. [Oster, Alexandra M.; Hernandez, Angela L.; Ocfemia, M. Cheryl Banez; Hall, H. Irene] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Wertheim, JO (reprint author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, San Diego, CA 92093 USA. EM jwertheim@ucsd.edu FU NIH [K01AI110181] FX We acknowledge the local and state health department staff instrumental in collecting HIV sequence data and other present and past members of CDC Incidence and Molecular Epidemiology Team, including Qian An, David Kim, Magan Pearson, Rebecca Ziebell, and Joseph "Buzz'' Prejean. We also thank N. Lance Hepler and Sergei L. Kosakovsky Pond for their work on HIV-TRACE. JOW was funded in part by an NIH Career Development Award (K01AI110181). NR 32 TC 4 Z9 4 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT-NOV PY 2016 VL 32 IS 10-11 BP 1046 EP 1053 DI 10.1089/aid.2015.0272 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DZ9RL UT WOS:000386216200014 PM 27105549 ER PT J AU Feldblum, PJ Chen, PL Fischer, SJ Sexton, CJ AF Feldblum, Paul J. Chen, Pai-Lien Fischer, Shelly J. Sexton, Connie J. TI Evaluation of SMARTube to Detect HIV Infection Before Seroconversion Using Standard Methods SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article DE SMARTube; HIV infection; seroconversion; acute infection ID ETHIOPIAN IMMIGRANTS; WINDOW PERIOD; TYPE-1; TRANSMISSION; ANTIBODIES; ISRAEL; DONORS AB The acute phase of HIV infection carries substantial risk of transmission; identification of acute-phase infections may offer opportunities to reduce that risk. SMARTube incubation of blood specimens is designed to stimulate in vivo-primed HIV-specific lymphocytes to produce HIV antibodies in vitro. The resulting supernatant (S-plasma) can be tested to identify acute infections with commercially available HIV assays. We assessed the performance of the SMARTube to identify acute HIV infections in studies at three developing country sites. We conducted HIV incidence studies in Ho Chi Minh City, Vietnam, and Bloemfontein and Rustenburg, South Africa. We estimated HIV incidence in cross-sectional samples and measured prospective incidence in uninfected women followed for up to 12 months. We incorporated SMARTube into the HIV testing algorithm at cross-sectional screening and monthly follow-up visits. We tested 1,384 persons in Vietnam, 1,145 women in Bloemfontein, and 538 persons in Rustenburg. Cross-sectional samples from 11 participants that tested positive with SMARTube after an initial unincubated negative test result (11 of 2,472; 0.4% of all specimens) were considered potential acute infections. Matching samples from 3 of the 11 (27.3%) were confirmed by polymerase chain reaction (PCR) testing. In follow-up of 355, 401, and 223 uninfected women in Vietnam, Bloemfontein, and Rustenburg, respectively, 11 seroconversions occurred in Bloemfontein and Rustenburg. In four of these incident infections (36.4%), SMARTube testing had resulted in earlier detection of HIV infection than the eventual seroconversion visits. In our field studies, pretreatment with SMARTube allowed the identification of acute HIV-1 infection in some new infections, but with a positive predictive value of 27%. Larger studies are needed to evaluate SMARTube as an alternative to technically challenging and costly enzyme immunoassay and PCR testing to detect acute HIV infection. C1 [Feldblum, Paul J.; Chen, Pai-Lien] FHI 360, Dept Global Hlth Res, 359 Blackwell St, Durham, NC 27701 USA. [Fischer, Shelly J.; Sexton, Connie J.] FHI 360, Durham, NC USA. [Sexton, Connie J.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Feldblum, PJ (reprint author), FHI 360, Dept Global Hlth Res, 359 Blackwell St, Durham, NC 27701 USA. EM pfeldblum@fhi360.org FU U.S. Agency for International Development (USAID) [GPO-A-00-05-00022-00]; Contraceptive and Reproductive Health Technologies Research and Utilization (CRTU) Program; Preventive Technology Agreement; Centers for Disease Control and Prevention (CDC) [200-20074-05314]; [GHO-A-00-05-00022-00] FX The authors thank the developer of the SMARTube technology, Tamar Jehuda-Cohen, for helpful discussions and training on the use of the SMARTube. We also thank our FHI 360 colleague Timothy Mastro for valuable discussions and review of the article. The HIV incidence studies were funded by the U.S. Agency for International Development (USAID) under Cooperative Agreement No. GPO-A-00-05-00022-00, the Contraceptive and Reproductive Health Technologies Research and Utilization (CRTU) Program, and Cooperative Agreement No. GHO-A-00-05-00022-00, the Preventive Technology Agreement. Additional funding was provided by the Centers for Disease Control and Prevention (CDC) under contract no. 200-20074-05314, Task Order #7. The contents are the responsibility of FHI 360 and do not necessarily reflect the views of USAID or the CDC. We are grateful to the study participants. In Vietnam, we thank the Provincial AIDS Committee of Ho Chi Minh City, the People's Committee, and the Center for Preventive Medicine laboratory. In South Africa, we thank the The Aurum Institute and JOSHA, staff at PathCare Laboratories and the Mangaung University Community Partnership Program in Bloemfontein, and the Departments of Health in North West and Free State provinces. We thank Nguyen Thi Hoang Lan and Le Truong Giang in Vietnam; John Lombaard, Sharne Foulkes, Ilse Reblin, and Gustav Venter in Bloemfontein; and Mary Latka and Candice Chetty in Rustenburg. We are also grateful to numerous current and former FHI 360 colleagues in the North Carolina, Vietnam, and Bangkok offices. NR 17 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT-NOV PY 2016 VL 32 IS 10-11 BP 1067 EP 1071 DI 10.1089/aid.2015.0284 PG 5 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DZ9RL UT WOS:000386216200016 PM 27004993 ER PT J AU Hodara, VL Parodi, LM Keckler, MS Giavedoni, LD AF Hodara, Vida L. Parodi, Laura M. Keckler, M. Shannon Giavedoni, Luis D. TI Increases in NKG2C Expression on T Cells and Higher Levels of Circulating CD8(+) B Cells Are Associated with Sterilizing Immunity Provided by a Live Attenuated SIV Vaccine SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article DE acute; macaques; lymphocytes; cytokines; SIV; sterilizing; immunity; NKG2C; inflammation; rhesus; vaccine; challenge ID SIMIAN-IMMUNODEFICIENCY-VIRUS; MULTIPLE-SCLEROSIS PATIENTS; RHESUS MACAQUES; SIVMAC251 INFECTION; PROTECTIVE IMMUNITY; NONHUMAN-PRIMATES; VIRAL REPLICATION; TETHERING SYSTEM; CHALLENGE; CD4(+) AB Vaccines based on live attenuated viruses are highly effective immunogens in the simian immunodeficiency virus (SIV)/rhesus macaque animal model and offer the possibility of studying correlates of protection against infection with virulent virus. We utilized a tether system for studying, in naive macaques and animals vaccinated with a live-attenuated vaccine, the acute events after challenge with pathogenic SIV. This approach allowed for the frequent sampling of small blood volumes without sedation or restraining of the animals, thus reducing the confounding effect of sampling stress. Before challenge, vaccinated animals presented significantly higher levels of proliferating and activated B cells than naive macaques, which were manifested by high expression of CD8 on B cells. After SIV challenge, the only changes observed in protected vaccinated macaques were significant increases in expression of the NK marker NKG2C on CD4 and CD8 T cells. We also identified that infection of naive macaques with SIV resulted in a transient peak of expression of CD20 on CD8 T cells and a constant rise in the number of B cells expressing CD8. Finally, analysis of a larger cohort of vaccinated animals identified that, even when circulating levels of vaccine virus are below the limit of detection, live attenuated vaccines induce systemic increases of IP-10 and perforin. These studies indicate that components of both the innate and adaptive immune systems of animals inoculated with a live-attenuated SIV vaccine respond to and control infection with virulent virus. Persistence of the vaccine virus in tissues may explain the elevated cytokine and B-cell activation levels. In addition, our report underpins the utility of the tether system for the intensive study of acute immune responses to viral infections. C1 [Hodara, Vida L.; Parodi, Laura M.; Giavedoni, Luis D.] Texas Biomed Res Inst, Dept Virol & Immunol, 7620 NW Loop 410, San Antonio, TX 78227 USA. [Hodara, Vida L.; Giavedoni, Luis D.] Texas Biomed Res Inst, Southwest Natl Primate Res Ctr, San Antonio, TX USA. [Keckler, M. Shannon] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Giavedoni, LD (reprint author), Texas Biomed Res Inst, Dept Virol & Immunol, 7620 NW Loop 410, San Antonio, TX 78227 USA. EM lgiavedoni@txbiomed.org FU US National Institutes of Health [R01 AI41923, R21 AI44363, P51 OD011133] FX The authors thank the veterinary personnel from the Southwest National Primate Research Center of the Texas Biomedical Research Institute for assistance with the animal manipulations. This work was supported by the US National Institutes of Health (grant nos. R01 AI41923, R21 AI44363, and P51 OD011133). NR 56 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT-NOV PY 2016 VL 32 IS 10-11 BP 1125 EP 1134 DI 10.1089/aid.2015.0300 PG 10 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DZ9RL UT WOS:000386216200023 PM 26986800 ER PT J AU Cely-Garcia, MF Curriero, FC Giraldo, M Mendez, L Breysse, PN Duran, M Torres-Duque, CA Gonzalez-Garcia, M Perez, C Parada, P Ramos-Bonilla, JP AF Fernanda Cely-Garcia, Maria Curriero, Frank C. Giraldo, Margarita Mendez, Lorena Breysse, Patrick N. Duran, Mauricio Torres-Duque, Carlos A. Gonzalez-Garcia, Mauricio Perez, Carolina Parada, Patricia Pablo Ramos-Bonilla, Juan TI Factors Associated With Non-compliance of Asbestos Occupational Standards in Brake Repair Workers SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE asbestos exposures; brake mechanics; compliance; occupational standards ID EXPOSURE; HEALTH AB Asbestos and non-asbestos containing brake products are currently used in low- and middle-income countries like Colombia. Because brake products are distributed detached from their supports, they require manipulation before installation, which release fibers and expose workers. Previous studies of our research group have documented exposures in excess of the widely accepted 0.1 f/cm(3) exposure guideline. The aim of this study is to identify factors associated with non-compliance of the 8-h time weighted average (TWA) 0.1 f/cm(3) asbestos occupational limit among brake mechanics (i.e. riveters). Eighteen brake repair shops (BRS) located in Bogota (Colombia) were sampled during 3 to 6 consecutive days for the entire work-shift. Personal and short-term personal samples were collected following NIOSH methods 7400 and 7402. Longitudinal based logistic regression models were used to determine the association between the odds of exceeding the 8-h TWA 0.1 f/cm(3) asbestos occupational limit and variables such as type of tasks performed by workers, workload (number of products manipulated daily), years of experience as riveters, and shop characteristics. These models can be used to estimate the odds of being currently or historically overexposed when sampling data do not exist. Since the information required to run the models can vary for both retrospective and current asbestos occupational exposure studies, three models were constructed with different information requirements. The first model evaluated the association between the odds of non-compliance with variables related to the workload, the second model evaluated the association between the odds of non-compliance with variables related to the manipulation tasks, and the third model evaluated the association between the odds of non-compliance with variables related with both the type of tasks performed by workers and the workload. Variables associated with the odds of non-compliance included conducting at least one manipulation activity with beveling and grinding of asbestos and non-asbestos containing brake products during the work shift, the location of the worker in the shop during non-manipulation activities, cleaning activities of the manipulation area, the years of experience working as riveters, and the number of asbestos and non-asbestos containing brake products manipulated daily. These models could be useful for current and retrospective occupational studies, in determining the odds of non-compliance of the asbestos occupational limit among brake mechanics. C1 [Fernanda Cely-Garcia, Maria; Giraldo, Margarita; Mendez, Lorena; Pablo Ramos-Bonilla, Juan] Univ Los Andes, Dept Civil & Environm Engn, Carrera 1 Este 19A-40 ML328, Bogota 111711, Colombia. [Curriero, Frank C.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA. [Breysse, Patrick N.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St, Baltimore, MD 21205 USA. [Duran, Mauricio; Torres-Duque, Carlos A.; Gonzalez-Garcia, Mauricio; Perez, Carolina] Fdn Neumol Colombiana, Dept Med, Cra 13B 161-85, Bogota 110131, Colombia. [Torres-Duque, Carlos A.; Parada, Patricia] Fdn Neumol Colombiana, Res Dept, Cra 13B 161-85, Bogota 110131, Colombia. [Breysse, Patrick N.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Ramos-Bonilla, JP (reprint author), Univ Los Andes, Dept Civil & Environm Engn, Carrera 1 Este 19A-40 ML328, Bogota 111711, Colombia. EM jramos@uniandes.edu.co FU Colombian Departamento Administrativo de Ciencia, Tecnologia e Innovacion (Colciencias) [760-2013, 120456933509, 567-2012]; Department of Civil and Environmental Engineering; School of Engineering from Universidad de Los Andes; Fundacion MAPFRE FX This study was funded with a grant from the Colombian Departamento Administrativo de Ciencia, Tecnologia e Innovacion (Colciencias) (Contract 760-2013, project code 120456933509), and grant 567-2012 for doctoral students from the same institution. Financial support was also obtained from the Department of Civil and Environmental Engineering and the School of Engineering from Universidad de Los Andes, and Fundacion MAPFRE. NR 35 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 EI 1475-3162 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD OCT PY 2016 VL 60 IS 8 BP 1020 EP 1035 DI 10.1093/annhyg/mew028 PG 16 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA DZ7BD UT WOS:000386017300010 PM 27234376 ER PT J AU Nahid, P Dorman, SE Alipanah, N Barry, PM Brozek, JL Cattamanchi, A Chaisson, LH Chaisson, RE Daley, CL Grzemska, M Higashi, JM Ho, CS Hopewell, PC Keshavjee, SA Lienhardt, C Menzies, R Merrifield, C Narita, M O'Brien, R Peloquin, CA Raftery, A Saukkonen, J Schaaf, HS Sotgiu, G Starke, JR Migliori, GB Vernon, A AF Nahid, Payam Dorman, Susan E. Alipanah, Narges Barry, Pennan M. Brozek, Jan L. Cattamanchi, Adithya Chaisson, Lelia H. Chaisson, Richard E. Daley, Charles L. Grzemska, Malgosia Higashi, Julie M. Ho, Christine S. Hopewell, Philip C. Keshavjee, Salmaan A. Lienhardt, Christian Menzies, Richard Merrifield, Cynthia Narita, Masahiro O'Brien, Rick Peloquin, Charles A. Raftery, Ann Saukkonen, Jussi Schaaf, H. Simon Sotgiu, Giovanni Starke, Jeffrey R. Migliori, Giovanni Battista Vernon, Andrew TI Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Mycobacterium tuberculosis; HIV infections; antitubercular agents; case management; public health ID RANDOMIZED CONTROLLED-TRIAL; HIV-INFECTED ADULTS; RECONSTITUTION INFLAMMATORY SYNDROME; ACQUIRED RIFAMYCIN RESISTANCE; DIRECTLY OBSERVED THERAPY; PULMONARY TUBERCULOSIS; ANTITUBERCULOSIS THERAPY; INTERNATIONAL STANDARDS; ANTIRETROVIRAL THERAPY; TREATMENT COMPLETION AB The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US National Tuberculosis Controllers Association. Representatives from the American Academy of Pediatrics, the Canadian Thoracic Society, the International Union Against Tuberculosis and Lung Disease, and the World Health Organization also participated in the development of the guideline. This guideline provides recommendations on the clinical and public health management of tuberculosis in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis. For all recommendations, literature reviews were performed, followed by discussion by an expert committee according to the Grading of Recommendations, Assessment, Development and Evaluation methodology. Given the public health implications of prompt diagnosis and effective management of tuberculosis, empiric multidrug treatment is initiated in almost all situations in which active tuberculosis is suspected. Additional characteristics such as presence of comorbidities, severity of disease, and response to treatment influence management decisions. Specific recommendations on the use of case management strategies (including directly observed therapy), regimen and dosing selection in adults and children (daily vs intermittent), treatment of tuberculosis in the presence of HIV infection (duration of tuberculosis treatment and timing of initiation of antiretroviral therapy), as well as treatment of extrapulmonary disease (central nervous system, pericardial among other sites) are provided. The development of more potent and better-tolerated drug regimens, optimization of drug exposure for the component drugs, optimal management of tuberculosis in special populations, identification of accurate biomarkers of treatment effect, and the assessment of new strategies for implementing regimens in the field remain key priority areas for research. See the full-text online version of the document for detailed discussion of the management of tuberculosis and recommendations for practice. C1 [Nahid, Payam; Alipanah, Narges; Cattamanchi, Adithya; Chaisson, Lelia H.; Hopewell, Philip C.; Merrifield, Cynthia; Raftery, Ann] Univ Calif San Francisco, San Francisco, CA 94110 USA. [Dorman, Susan E.; Chaisson, Richard E.] Johns Hopkins Univ, Baltimore, MD USA. [Barry, Pennan M.] Calif Dept Publ Hlth, Richmond, CA USA. [Brozek, Jan L.] McMaster Univ, Hamilton, ON, Canada. [Daley, Charles L.] Natl Jewish Hlth, Denver, CO USA. [Grzemska, Malgosia; Lienhardt, Christian] WHO, Geneva, Switzerland. [Higashi, Julie M.] San Francisco Dept Publ Hlth, TB Control Sect, San Francisco, CA USA. [Ho, Christine S.; Vernon, Andrew] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Keshavjee, Salmaan A.] Harvard Med Sch, Boston, MA USA. [Menzies, Richard] McGill Univ, Montreal, PQ, Canada. [Migliori, Giovanni Battista] Fdn S Maugeri Care & Res Inst, WHO Collaborating Ctr TB & Lung Dis, Tradate, Italy. [Narita, Masahiro] Seattle & King Cty Publ Hlth, TB Control Program, Seattle, WA USA. [Narita, Masahiro] Univ Washington, Seattle, WA 98195 USA. [O'Brien, Rick] Int Union TB & Lung Dis, Eth Advisory Grp, Paris, France. [Peloquin, Charles A.] Univ Florida, Gainesville, FL USA. [Saukkonen, Jussi] Boston Univ, Boston, MA 02215 USA. [Schaaf, H. Simon] Univ Stellenbosch, Dept Paediat & Child Hlth, Cape Town, South Africa. [Sotgiu, Giovanni] Univ Sassari, Sassari, Italy. [Starke, Jeffrey R.] Baylor Coll Med, Houston, TX 77030 USA. RP Nahid, P (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Pulm & Crit Care Med, 1001 Potrero Ave,5K1, San Francisco, CA 94110 USA. EM pnahid@ucsf.edu FU American Thoracic Society; IDSA; CDC FX Support for this guideline was provided by the American Thoracic Society, the IDSA, and the CDC. NR 92 TC 4 Z9 4 U1 4 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2016 VL 63 IS 7 BP 853 EP 867 DI 10.1093/cid/ciw566 PG 15 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7JL UT WOS:000386041100008 PM 27621353 ER PT J AU Farnon, EC Kokko, KE Budge, PJ Mbaeyi, C Lutterloh, EC Qvarnstrom, Y da Silva, AJ Shieh, WJ Roy, SL Paddock, CD Sriram, R Zaki, SR Visvesvara, GS Kuehnert, MJ AF Farnon, Eileen C. Kokko, Kenneth E. Budge, Philip J. Mbaeyi, Chukwuma Lutterloh, Emily C. Qvarnstrom, Yvonne da Silva, Alexandre J. Shieh, Wun-Ju Roy, Sharon L. Paddock, Christopher D. Sriram, Rama Zaki, Sherif R. Visvesvara, Govinda S. Kuehnert, Matthew J. CA Balamuthia Transplant Invest Teams TI Transmission of Balamuthia mandrillaris by Organ Transplantation SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE organ transplantation; Balamuthia; encephalitis; donor-derived infection; transplant-transmitted ID FREE-LIVING AMEBAS; SOLID-ORGAN; NAEGLERIA-FOWLERI; ACANTHAMOEBA SPP.; ENCEPHALITIS; MENINGOENCEPHALITIS; VIRUS; ANTIBODIES; RECIPIENTS; INFECTION AB We describe the first recognized clusters of transplant-transmitted Balamuthia mandrillaris. We describe the detection of this rare cause of encephalitis in each cluster, the clinical management and public health response, and recommendations to detect and defer potential donors with encephalitis.Methods.aEuro integral We investigated all recipients and the 2 donors through interview, medical record review, and testing of available specimens retrospectively. Surviving recipients were tested and treated prospectively. Results.aEuro integral In the 2009 cluster of illness, 2 kidney recipients were infected and 1 died. The donor had Balamuthia encephalitis confirmed on autopsy. In the 2010 cluster, the liver and kidney-pancreas recipients developed Balamuthia encephalitis and died. The donor had a clinical syndrome consistent with Balamuthia infection and serologic evidence of infection. In both clusters, the 2 asymptomatic recipients were treated expectantly and survived; 1 asymptomatic recipient in each cluster had serologic evidence of exposure that decreased over time. Both donors had been presumptively diagnosed with other neurologic diseases prior to organ procurement. Conclusions.aEuro integral Balamuthia can be transmitted through organ transplantation with an observed incubation time of 17-24 days. Clinicians should be aware of Balamuthia as a cause of encephalitis with high rate of fatality, and should notify public health departments and evaluate transplant recipients from donors with signs of possible encephalitis to facilitate early diagnosis and targeted treatment. Organ procurement organizations and transplant centers should be aware of the potential for Balamuthia infection in donors with possible encephalitis and also assess donors carefully for signs of neurologic infection that may have been misdiagnosed as stroke or as noninfectious forms of encephalitis. C1 [Farnon, Eileen C.; Budge, Philip J.; Mbaeyi, Chukwuma; Lutterloh, Emily C.; Qvarnstrom, Yvonne; da Silva, Alexandre J.; Shieh, Wun-Ju; Roy, Sharon L.; Paddock, Christopher D.; Sriram, Rama; Zaki, Sherif R.; Visvesvara, Govinda S.; Kuehnert, Matthew J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kokko, Kenneth E.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. [Lutterloh, Emily C.] Kentucky Dept Publ Hlth, Frankfort, KY USA. RP Farnon, EC (reprint author), Philadelphia Dept Publ Hlth, 500 S Broad St,2nd Flr, Philadelphia, PA 19146 USA. EM eileen.farnon@phila.gov NR 39 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2016 VL 63 IS 7 BP 878 EP 888 DI 10.1093/cid/ciw422 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7JL UT WOS:000386041100011 PM 27358357 ER PT J AU Weiser, J Beer, L West, BT Duke, CC Gremel, GW Skarbinski, J AF Weiser, John Beer, Linda West, Brady T. Duke, Christopher C. Gremel, Garrett W. Skarbinski, Jacek TI Qualifications, Demographics, Satisfaction, and Future Capacity of the HIV Care Provider Workforce in the United States, 2013-2014 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HIV provider; workforce survey; capacity ID HEALTH-CARE; EXPERIENCE; THERAPY; CHOICE AB Projected growth of the HIV care provider workforce by 2019 will not accommodate the increase in HIV-infected persons requiring care. Ryan White Program-funded facilities may face provider attrition. Dissatisfaction with salary/reimbursement is substantial, and black and Hispanic providers are underrepresented.Methods.aEuro integral We surveyed a probability sample of 2023 US HIV care providers in 2013-2014, including those at Ryan White HIV/AIDS Program (RWHAP)-funded facilities and in private practices. We estimated future patient care capacity by comparing counts of providers entering and planning to leave practice within 5 years, and the number of patients under their care. Results.aEuro integral Of surveyed providers, 1234 responded (adjusted response rate, 64%): 63% were white, 11% black, 11% Hispanic, and 16% other race/ethnicity; 37% were satisfied/very satisfied with salary/reimbursement, and 33% were satisfied/very satisfied with administrative time. Compared with providers in private practice, more providers at RWHAP-funded facilities were HIV specialists (71% vs 43%; P < .0001) and planned to leave HIV practice within 5 years (11% vs 4%; P = .0004). An estimated 190 more full-time equivalent providers (defined as 40 HIV clinical care hours per week) entered practice in the past 5 years than are expected to leave in the next 5 years. If these rates continue, by 2019 patient care capacity will increase by 65 000, compared with an increased requirement of at least 100 000. Conclusions.aEuro integral Projected workforce growth by 2019 will not accommodate the increased number of HIV-infected persons requiring care. RWHAP-funded facilities may face attrition of highly qualified providers. Dissatisfaction with salary/reimbursement and administrative burden is substantial, and black and Hispanic providers are underrepresented relative to HIV patients. C1 [Weiser, John; Beer, Linda; Skarbinski, Jacek] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS-E46, Atlanta, GA 30329 USA. [West, Brady T.] Univ Michigan, Survey Res Ctr, Ann Arbor, MI 48109 USA. [Duke, Christopher C.; Gremel, Garrett W.] Altarum Inst, Ann Arbor, MI USA. RP Weiser, J (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS-E46, Atlanta, GA 30329 USA. EM jweiser@cdc.gov FU CDC FX This work was funded by the CDC. Funding for the MMP is provided by the CDC. NR 32 TC 1 Z9 1 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2016 VL 63 IS 7 BP 966 EP 975 DI 10.1093/cid/ciw442 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7JL UT WOS:000386041100025 PM 27358352 ER PT J AU Crepaz, N Tang, T Marks, G Mugavero, MJ Espinoza, L Hall, HI AF Crepaz, Nicole Tang, Tian Marks, Gary Mugavero, Michael J. Espinoza, Lorena Hall, H. Irene TI Durable Viral Suppression and Transmission Risk Potential Among Persons With Diagnosed HIV Infection: United States, 2012-2013 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE durable viral suppression; viral burden; HIV transmission risk; HIV-diagnosed persons; disparity ID WHITE HIV/AIDS PROGRAM; ANTIRETROVIRAL THERAPY; CARE CONTINUUM; PREVENTION; INTERVENTIONS; OUTCOMES; VIREMIA; LOAD AB Using national human immunodeficiency virus (HIV) surveillance data from 17 jurisdictions, 38% of HIV-diagnosed persons in care did not sustain viral suppression in 2012-2013, spending 60% and 30% of observation time with viral load above 200 and 10 000 copies/mL.Methods.aEuro integral Using data from the National HIV Surveillance System from 17 jurisdictions with complete reporting of VL test results, we determined the percentage of persons in HIV care who achieved durable viral suppression (all VL results < 200 copies/mL) and examined viremia copy-years and time spent above VL levels that increase the risk of HIV transmission during 2012-2013. Results.aEuro integral Of 265 264 persons in HIV care in 2011, 238 641 had at least 2 VLs in 2012-2013. The median number of VLs per individual during the 2-year period was 5. Approximately 62% had durable viral suppression. The remaining 38% had high VL burden (geometric mean of viremia copy-years, 7261) and spent an average of 438 days, 316 days, and 215 days (60%, 43.2%, and 29.5% of the 2-year period) above 200, 1500, and 10 000 copies/mL. Women, blacks/African Americans, Hispanics/Latinos, persons with HIV infection attributed to transmission other than male-to-male sexual contact, younger age groups, and persons with gaps in care had higher viral burden and transmission risk potential. Conclusions.aEuro integral Two-thirds of persons in HIV care had durable viral suppression during a 2-year period. One-third had high VL burden and spent substantial time above VL levels with increased risk of onward transmission. More intervention efforts are needed to improve retention in care and medication adherence so that more persons in HIV care achieve durable viral suppression. C1 [Crepaz, Nicole; Marks, Gary; Espinoza, Lorena; Hall, H. Irene] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,E-47, Atlanta, GA 30329 USA. [Tang, Tian] ICF Int, Atlanta, GA USA. [Mugavero, Michael J.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. RP Crepaz, N (reprint author), US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,E-47, Atlanta, GA 30329 USA. EM ncrepaz@cdc.gov FU Division of Human immunodeficiency Virus/AIDS Prevention at the CDC FX This work was supported by the Division of Human immunodeficiency Virus/AIDS Prevention at the CDC and was not funded by any other organization. NR 21 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2016 VL 63 IS 7 BP 976 EP 983 DI 10.1093/cid/ciw418 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7JL UT WOS:000386041100026 PM 27358354 ER PT J AU Nahid, P Dorman, SE Alipanah, N Barry, PM Brozek, JL Cattamanchi, A Chaisson, LH Chaisson, RE Daley, CL Grzemska, M Higashi, JM Ho, CS Hopewell, PC Keshavjee, SA Lienhardt, C Menzies, R Merrifield, C Narita, M O'Brien, R Peloquin, CA Raftery, A Saukkonen, J Schaaf, HS Sotgiu, G Starke, JR Migliori, GB Vernon, A AF Nahid, Payam Dorman, Susan E. Alipanah, Narges Barry, Pennan M. Brozek, Jan L. Cattamanchi, Adithya Chaisson, Lelia H. Chaisson, Richard E. Daley, Charles L. Grzemska, Malgosia Higashi, Julie M. Ho, Christine S. Hopewell, Philip C. Keshavjee, Salmaan A. Lienhardt, Christian Menzies, Richard Merrifield, Cynthia Narita, Masahiro O'Brien, Rick Peloquin, Charles A. Raftery, Ann Saukkonen, Jussi Schaaf, H. Simon Sotgiu, Giovanni Starke, Jeffrey R. Migliori, Giovanni Battista Vernon, Andrew TI Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Mycobacterium tuberculosis; HIV infections; antitubercular agents; case management; public health AB The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US National Tuberculosis Controllers Association. Representatives from the American Academy of Pediatrics, the Canadian Thoracic Society, the International Union Against Tuberculosis and Lung Disease, and the World Health Organization also participated in the development of the guideline. This guideline provides recommendations on the clinical and public health management of tuberculosis in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis. For all recommendations, literature reviews were performed, followed by discussion by an expert committee according to the Grading of Recommendations, Assessment, Development and Evaluation methodology. Given the public health implications of prompt diagnosis and effective management of tuberculosis, empiric multidrug treatment is initiated in almost all situations in which active tuberculosis is suspected. Additional characteristics such as presence of comorbidities, severity of disease, and response to treatment influence management decisions. Specific recommendations on the use of case management strategies (including directly observed therapy), regimen and dosing selection in adults and children (daily vs intermittent), treatment of tuberculosis in the presence of HIV infection (duration of tuberculosis treatment and timing of initiation of antiretroviral therapy), as well as treatment of extrapulmonary disease (central nervous system, pericardial among other sites) are provided. The development of more potent and better-tolerated drug regimens, optimization of drug exposure for the component drugs, optimal management of tuberculosis in special populations, identification of accurate biomarkers of treatment effect, and the assessment of new strategies for implementing regimens in the field remain key priority areas for research. See the full-text online version of the document for detailed discussion of the management of tuberculosis and recommendations for practice. C1 [Nahid, Payam; Alipanah, Narges; Cattamanchi, Adithya; Chaisson, Lelia H.; Hopewell, Philip C.; Merrifield, Cynthia; Raftery, Ann] Univ Calif San Francisco, San Francisco, CA 94110 USA. [Dorman, Susan E.; Chaisson, Richard E.] Johns Hopkins Univ, Baltimore, MD USA. [Barry, Pennan M.] Calif Dept Publ Hlth, Richmond, CA USA. [Brozek, Jan L.] McMaster Univ, Hamilton, ON, Canada. [Daley, Charles L.] Natl Jewish Hlth, Denver, CO USA. [Grzemska, Malgosia; Lienhardt, Christian] WHO, Geneva, Switzerland. [Higashi, Julie M.] San Francisco Dept Publ Hlth, TB Control Sect, San Francisco, CA USA. [Ho, Christine S.; Vernon, Andrew] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Keshavjee, Salmaan A.] Harvard Med Sch, Boston, MA USA. [Menzies, Richard] McGill Univ, Montreal, PQ, Canada. [Migliori, Giovanni Battista] Fdn S Maugeri Care & Res Inst, WHO Collaborating Ctr TB & Lung Dis, Tradate, Italy. [Narita, Masahiro] Seattle & King Cty Publ Hlth, TB Control Program, Seattle, WA USA. [Narita, Masahiro] Univ Washington, Seattle, WA 98195 USA. [O'Brien, Rick] Int Union TB & Lung Dis, Eth Advisory Grp, Paris, France. [Peloquin, Charles A.] Univ Florida, Gainesville, FL USA. [Saukkonen, Jussi] Boston Univ, Boston, MA 02215 USA. [Schaaf, H. Simon] Univ Stellenbosch, Dept Paediat & Child Hlth, Cape Town, South Africa. [Sotgiu, Giovanni] Univ Sassari, Sassari, Italy. [Starke, Jeffrey R.] Baylor Coll Med, Houston, TX 77030 USA. RP Nahid, P (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Pulm & Crit Care Med, 1001 Potrero Ave 5K1, San Francisco, CA 94110 USA. EM pnahid@ucsf.edu FU American Thoracic Society; IDSA; CDC FX Support for this guideline was provided by the American Thoracic Society, the IDSA, and the CDC. NR 0 TC 19 Z9 19 U1 7 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2016 VL 63 IS 7 BP e147 EP e195 DI 10.1093/cid/ciw376 PG 49 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7JL UT WOS:000386041100007 PM 27516382 ER PT J AU Tong, X George, MG Gillespie, C Merritt, R AF Tong, Xin George, Mary G. Gillespie, Cathleen Merritt, Robert TI Trends in hospitalizations and cost associated with stroke by age, United States 2003-2012 SO INTERNATIONAL JOURNAL OF STROKE LA English DT Article DE Hospitalization rate; subarachnoid hemorrhage stroke; intracerebral hemorrhage stroke; acute ischemic stroke; trends ID ISCHEMIC-STROKE; YOUNG-ADULTS; OUTCOMES; RATES AB Background The disease burden associated with stroke by age is not well known. Aim To assess the trends in stroke hospitalizations and associated cost among adults aged 18 years by age groups in the United States. Methods The study population consisted of 2003-2012 adult hospitalizations from the National Inpatient Sample of the Healthcare Cost and Utilization Project. Subarachnoid hemorrhage, intracerebral hemorrhage, and acute ischemic stroke hospitalizations were identified by the principal diagnosis ICD-9-CM code. We estimated national hospitalization rates and inflation-adjusted hospital costs across five consecutive 2-year time intervals, stratified by seven age groups. Results Hospitalization rates for subarachnoid hemorrhage decreased significantly from 2003-2004 to 2011-2012 for ages 35-44 (relative percent change (RPC): -23%) and 45-54 (RPC: -22%), respectively. For intracerebral hemorrhage, the rates decreased significantly for ages 65 years. Acute ischemic stroke hospitalization rates increased significantly for ages 18-54 and decreased significantly for ages 65-84 years. The average per-hospitalization cost for subarachnoid hemorrhage increased 7-35% among all age groups, except those aged 65-74, and increased 10-29% for intracerabral hemorrhage except those aged 75-84, and increased 6-19% among all ages for acute ischemic stroke, respectively. Overall, the estimated total national cost increased 7% for subarachnoid hemorrhage, 10% for intracerebral hemorrhage, and 18% for acute ischemic stroke from 2003-2004 to 2011-2012. Conclusions From 2003 to 2012, subarachnoid hemorrhage and intracerabral hemorrhage stroke hospitalization rates declined across all age groups. While US acute ischemic stroke hospitalizations among ages 65-84 declined significantly, the hospitalization rates increased significantly among ages 18-54. The estimated hospital costs increased across all stroke subtypes during the study period. C1 [Tong, Xin; George, Mary G.; Gillespie, Cathleen; Merritt, Robert] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Tong, X (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy,MS-F77, Atlanta, GA 30341 USA. EM xtong@cdc.gov FU Intramural CDC HHS [CC999999] NR 16 TC 0 Z9 0 U1 2 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1747-4930 EI 1747-4949 J9 INT J STROKE JI Int. J. Stroke PD OCT PY 2016 VL 11 IS 8 SI SI BP 874 EP 881 DI 10.1177/1747493016654490 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DZ6YI UT WOS:000386008400011 PM 27312679 ER PT J AU Guy, GP Holman, DM Watson, M AF Guy, Gery P., Jr. Holman, Dawn M. Watson, Meg TI The Important Role of Schools in the Prevention of Skin Cancer SO JAMA DERMATOLOGY LA English DT Editorial Material C1 [Guy, Gery P., Jr.; Holman, Dawn M.; Watson, Meg] Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,Mailstop F76, Atlanta, GA 30341 USA. RP Guy, GP (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,Mailstop F76, Atlanta, GA 30341 USA. EM irm2@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD OCT 1 PY 2016 VL 152 IS 10 BP 1083 EP 1084 DI 10.1001/jamadermatol.2016.3453 PG 2 WC Dermatology SC Dermatology GA DZ8KJ UT WOS:000386119000002 PM 27580085 ER PT J AU Martin, C Chang, JN Boulet, S Jamieson, DJ Kissin, D AF Martin, Caitlin Chang, Jeani Boulet, Sheree Jamieson, Denise J. Kissin, Dmitry TI Factors predicting double embryo implantation following double embryo transfer in assisted reproductive technology: implications for elective single embryo transfer SO JOURNAL OF ASSISTED REPRODUCTION AND GENETICS LA English DT Article DE Double embryo transfer; In vitro fertilization; Double embryo implantation; Multiple birth pregnancy; Elective single embryo transfer ID IN-VITRO FERTILIZATION; MULTIPLE BIRTHS; UNITED-STATES; LIVE BIRTH; TWIN PREGNANCY; OUTCOMES; QUALITY; CYCLES; RISK; CRYOPRESERVATION AB The aim of this study was to identify factors associated with double embryo implantation following double embryo transfer (DET) during assisted reproductive technology (ART) procedures and to evaluate the implications of findings in selecting candidates for elective single embryo transfer (eSET). Factors predicting double embryo implantation, defined as embryo transfers with two or more heartbeats on 6-week ultrasound following DET, were assessed using the US National ART Surveillance System data from 2000 to 2012 (n = 1,793,067 fresh, autologous transfers). Adjusted risk ratios (aRRs) were estimated after stratifying by prognosis. Favorable prognosis was defined as first-time ART with supernumerary embryo(s) cryopreserved. Average prognosis was defined as first-time ART without supernumerary embryo(s) cryopreserved, prior unsuccessful ART with supernumerary embryo(s) cryopreserved, or prior ART with previous birth(s) conceived with ART or naturally. Rates and factors associated with double embryo implantation were compared with single embryo implantation following DET among both prognosis groups. Double embryo implantation was positively associated with blastocyst (versus cleavage) transfer in favorable (aRR = 1.58 (1.51-1.65)) and average (aRR = 1.67 (1.60-1.75)) prognosis groups and negatively associated with age > 35 years in both prognosis groups. For average prognosis patients, double embryo implantation was associated with retrieving > 10 oocytes (aRR = 1.22 (1.18-1.24)). Regardless of prognosis, patients aged < 35 years with blastocyst-stage embryos and average prognosis patients from whom > 10 oocytes were retrieved may be good candidates for eSET. Physicians may consider using these data to counsel patients on eSET, which would reduce multiple gestations and associated complications. C1 [Martin, Caitlin; Chang, Jeani; Boulet, Sheree; Jamieson, Denise J.; Kissin, Dmitry] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F-74, Atlanta, GA 30341 USA. [Martin, Caitlin] Emory Univ, Dept Gynecol & Obstet, Glenn Bldg,4th Floor,69 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA. RP Martin, C (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F-74, Atlanta, GA 30341 USA.; Martin, C (reprint author), Emory Univ, Dept Gynecol & Obstet, Glenn Bldg,4th Floor,69 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA. EM Caitlin.Martin@emory.edu; zsj9@cdc.gov; sbu1@cdc.gov; djj0@cdc.gov; dtk3@cdc.gov FU Marianne Ruby Award in Obstetrics and Gynecology from the Department of Gynecology and Obstetrics of Emory University FX Caitlin Martin received support from the Marianne Ruby Award in Obstetrics and Gynecology from the Department of Gynecology and Obstetrics of Emory University. We acknowledge Dr. Luca Gianaroli for his help with the initial concept of the study and Dr. Jennifer Kawwass for her critical evaluation of the manuscript. NR 33 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1058-0468 EI 1573-7330 J9 J ASSIST REPROD GEN JI J. Assist. Reprod. Genet. PD OCT PY 2016 VL 33 IS 10 BP 1343 EP 1353 DI 10.1007/s10815-016-0770-9 PG 11 WC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology SC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology GA EA1SW UT WOS:000386373200011 PM 27416834 ER PT J AU Ching, LK Gounder, PP Bulkow, L Spradling, PR Bruce, MG Negus, S Snowball, M McMahon, BJ AF Ching, Lance K. Gounder, Prabhu P. Bulkow, Lisa Spradling, Philip R. Bruce, Michael G. Negus, Susan Snowball, Mary McMahon, Brian J. TI Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people SO LIVER INTERNATIONAL LA English DT Article DE epidemiology; genomics; liver cancer; Native American; risk factors ID CORE PROMOTER MUTATIONS; SURFACE-ANTIGEN; LIVER-DISEASE; INFECTION; SUBGENOTYPE; SEQUELAE; CARRIERS; PROGRAM; RISK AB Background & AimsMost regions of the world have 3 co-circulating hepatitis B virus (HBV) genotypes, which limits direct comparisons of hepatocellular carcinoma (HCC) risk among HBV-infected persons by genotype. We evaluated HCC incidence by HBV genotype in a cohort of Alaska Native (AN) persons where five HBV genotypes (A, B, C, D, F) have been identified. MethodsOur cohort comprised AN persons with chronic HBV infection identified during 1983-2012 who consented to participate in this study. Cohort persons were offered annual hepatitis B e antigen (HBeAg) testing and semi-annual HCC screening. We developed a logistic regression model to compare HCC risk by genotype, adjusting for age, sex, region and HBeAg status. ResultsAmong the 1235 consenting study participants, 711 (57.6%) were male, 510 (41.3%) were HBeAg positive at cohort entry and 43 (3.5%) developed HCC. The HBV genotype was known for 1142 (92.5%) persons (13.5% A, 3.9% B, 6.7% C, 56.9% D, 19.0% F). The HCC incidence/1000 person-years of follow-up for genotypes A, B, C, D and F was 1.3, 0, 5.5, 0.4 and 4.2 respectively. Compared with persons with HBV genotype B/D infection, the HCC risk was higher for persons with genotypes A [adjusted odds ratio (aOR): 3.9, 95% confidence interval (CI): 1.14-13.74], C (aOR: 16.3, 95% CI: 5.20-51.11) and F (aOR: 13.9, 95% CI: 5.30-36.69). ConclusionHBV genotype is independently associated with HCC risk. AN persons with genotypes A, C and F are at higher risk compared with genotypes B or D. C1 [Ching, Lance K.; Gounder, Prabhu P.; Bulkow, Lisa; Bruce, Michael G.; McMahon, Brian J.] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. [Ching, Lance K.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Spradling, Philip R.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Negus, Susan; Snowball, Mary; McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. RP Gounder, PP (reprint author), CDC, Arctic Invest Program, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM PGounder@cdc.gov FU Centers for Disease Control and Prevention, NCHHSTP, Division of Viral Hepatitis (CA) [1U01P S004113] FX This work was supported by the Centers for Disease Control and Prevention, NCHHSTP, Division of Viral Hepatitis (CA# 1U01P S004113). NR 32 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1478-3223 EI 1478-3231 J9 LIVER INT JI Liver Int. PD OCT PY 2016 VL 36 IS 10 BP 1507 EP 1515 DI 10.1111/liv.13129 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DW3UI UT WOS:000383568200015 PM 27009849 ER PT J AU Ifeonu, OO Chibucos, MC Orvis, J Su, Q Elwin, K Guo, FG Zhang, HL Xiao, LH Sun, MF Chalmers, RM Fraser, CM Zhu, G Kissinger, JC Widmer, G Silva, JC AF Ifeonu, Olukemi O. Chibucos, Marcus C. Orvis, Joshua Su, Qi Elwin, Kristin Guo, Fengguang Zhang, Haili Xiao, Lihua Sun, Mingfei Chalmers, Rachel M. Fraser, Claire M. Zhu, Guan Kissinger, Jessica C. Widmer, Giovanni Silva, Joana C. TI Annotated draft genome sequences of three species of Cryptosporidium: Cryptosporidium meleagridis isolate UKMEL1, C. baileyi isolate TAMU-09Q1 and C. hominis isolates TU502 2012 and UKH1 SO PATHOGENS AND DISEASE LA English DT Article DE Cryptosporidium; C. hominis TU502_2012; Cryptosporidium meleagridis; Cryptosporidium baileyi; genome assembly; annotation ID PARVUM; APICOMPLEXAN AB Human cryptosporidiosis is caused primarily by Cryptosporidium hominis, C. parvum and C. meleagridis. To accelerate research on parasites in the genus Cryptosporidium, we generated annotated, draft genome sequences of human C. hominis isolates TU502_2012 and UKH1, C. meleagridis UKMEL1, also isolated from a human patient, and the avian parasite C. baileyi TAMU-09Q1. The annotation of the genome sequences relied in part on RNAseq data generated from the oocyst stage of both C. hominis and C. baileyi. The genome assembly of C. hominis is significantly more complete and less fragmented than that available previously, which enabled the generation of a much-improved gene set for this species, with an increase in average gene length of 500 bp relative to the protein-encoding genes in the 2004 C. hominis annotation. Our results reveal that the genomes of C. hominis and C. parvum are very similar in both gene density and average gene length. These data should prove a valuable resource for the Cryptosporidium research community.The release of the draft genome sequence, and corresponding annotation, of Cryptosporidium baileyi, C. hominis isolates TU502_2012 and UKH1, and C. meleagridis, will accelerate research on Cryptosporidium parasites.The release of the draft genome sequence, and corresponding annotation, of Cryptosporidium baileyi, C. hominis isolates TU502_2012 and UKH1, and C. meleagridis, will accelerate research on Cryptosporidium parasites. C1 [Ifeonu, Olukemi O.; Chibucos, Marcus C.; Orvis, Joshua; Su, Qi; Fraser, Claire M.; Silva, Joana C.] Univ Maryland, Inst Genome Sci, Sch Med, 801 W Baltimore St,Biopk 2,Rm 645, Baltimore, MD 21201 USA. [Elwin, Kristin; Chalmers, Rachel M.] Singleton Hosp, Publ Hlth Wales Microbiol, Cryptosporidium Reference Unit, Swansea SA2 8QA, W Glam, Wales. [Guo, Fengguang; Zhang, Haili; Zhu, Guan] Texas A&M Univ, Dept Vet Pathobiol, College Stn, TX 77843 USA. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. [Sun, Mingfei] Guangdong Acad Agr Sci, Inst Anim Hlth, Guangzhou 510640, Guangdong, Peoples R China. [Kissinger, Jessica C.] Univ Georgia, Inst Bioinformat, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA. [Kissinger, Jessica C.] Univ Georgia, Dept Genet, Athens, GA 30602 USA. [Widmer, Giovanni] Tufts Univ, Dept Infect Dis & Global Hlth, Cummings Sch Vet Med, North Grafton, MA 01536 USA. [Silva, Joana C.] Univ Maryland, Dept Microbiol & Immunol, Sch Med, Baltimore, MD 21201 USA. RP Silva, JC (reprint author), Univ Maryland, Inst Genome Sci, Sch Med, 801 W Baltimore St,Biopk 2,Rm 645, Baltimore, MD 21201 USA. EM jcsilva@som.umaryland.edu OI Kissinger, Jessica/0000-0002-6413-1101 FU National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIAID, NIH) [HHSN272200900009C] FX This work was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIAID, NIH), under contract number HHSN272200900009C. Genome sequencing was carried out by the Genome Resource Center at the Institute for Genome Sciences, University of Maryland School of Medicine. NR 23 TC 2 Z9 2 U1 5 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 2049-632X J9 PATHOG DIS JI Pathog. Dis. PD OCT PY 2016 VL 74 IS 7 AR ftw080 DI 10.1093/femspd/ftw080 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7LW UT WOS:000386048200009 ER PT J AU Oktay, J Rohan, E Schapmire, T Callahan, C Burruss, K Zebrack, B AF Oktay, Julianne Rohan, Elizabeth Schapmire, Tara Callahan, Christine Burruss, Karen Zebrack, Brad TI Oncology social work activities following distress screening: First steps in the development of an instrument to capture social work response. SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Oktay, Julianne; Callahan, Christine; Burruss, Karen] Univ Maryland, Sch Social Work, 525 W Redwood St, Baltimore, MD 21201 USA. [Rohan, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA USA. [Schapmire, Tara] Univ Louisville, Sch Social Work, Louisville, KY 40292 USA. [Zebrack, Brad] Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD OCT PY 2016 VL 25 IS SP. S3 MA 254 BP 88 EP 88 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA DZ6AA UT WOS:000385942700190 ER PT J AU Minguez-Alarcon, L Gaskins, AJ Chiu, YH Souter, I Williams, PL Calafat, AM Hauser, R Chavarro, JE AF Minguez-Alarcon, Lidia Gaskins, Audrey J. Chiu, Yu-Han Souter, Irene Williams, Paige L. Calafat, Antonia M. Hauser, Russ Chavarro, Jorge E. CA EARTH Study Team TI Dietary folate intake and modification of the association of urinary bisphenol A concentrations with in vitro fertilization outcomes among women from a fertility clinic SO REPRODUCTIVE TOXICOLOGY LA English DT Article DE Bisphenol A; In vitro fertilization; Folate; Methyl donors ID FOOD-FREQUENCY QUESTIONNAIRE; ASSISTED REPRODUCTIVE TECHNOLOGIES; ESTROGEN-RECEPTOR-ALPHA; OF-THE-LITERATURE; SEMEN QUALITY; US ADULTS; PHTHALATE METABOLITES; NURSES HEALTH; EXPOSURE; OBESITY AB Experimental data in rodents suggest that the effects of bisphenol A (BPA) on oocyte development may be modified by dietary methyl donors. Whether the same interaction exists in humans is unknown. We evaluated whether intake of methyl donors modified the associations between urinary BPA concentrations and treatment outcomes among 178 women who underwent 248 IVF cycles at a fertility center in Boston between 2007 and 2012. Participants completed a validated food frequency questionnaire and provided up to two urine samples per treatment cycle. High urinary BPA concentrations were associated with a 66% lower probability of implantation (p = 0.007) among women who consumed <400 mu g/day of food folate, but not among women consuming >= 400 mu g/day (21% higher probability of implantation, p=0.18) (p,interaction=0.04). A similar pattern was observed for probability of clinical pregnancy (p,interaction=0.07) and live birth (p,interaction=0.16). These results are consistent with previous animal data but further evaluation in other human populations is needed. (C) 2016 Elsevier Inc. All rights reserved. C1 [Minguez-Alarcon, Lidia; Hauser, Russ] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA. [Gaskins, Audrey J.; Chiu, Yu-Han; Chavarro, Jorge E.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Gaskins, Audrey J.; Chiu, Yu-Han; Williams, Paige L.; Hauser, Russ; Chavarro, Jorge E.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Souter, Irene; Hauser, Russ] Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA. [Souter, Irene; Hauser, Russ; Chavarro, Jorge E.] Harvard Med Sch, Boston, MA 02114 USA. [Williams, Paige L.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Chavarro, Jorge E.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. RP Minguez-Alarcon, L (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA. EM lminguez@hsph.harvard.edu FU NIH from the National Institute for Environmental Health Sciences [R01ES022955, R01ES009718, R01ES000002]; National Institute of Diabetes and Digestive and Kidney Diseases [T32DK007703-16, P30DK46200] FX NIH grants R01ES022955, R01ES009718, R01ES000002 from the National Institute for Environmental Health Sciences, T32DK007703-16 and P30DK46200 from the National Institute of Diabetes and Digestive and Kidney Diseases. NR 72 TC 1 Z9 1 U1 5 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0890-6238 J9 REPROD TOXICOL JI Reprod. Toxicol. PD OCT PY 2016 VL 65 BP 104 EP 112 DI 10.1016/j.reprotox.2016.07.012 PG 9 WC Reproductive Biology; Toxicology SC Reproductive Biology; Toxicology GA DZ6RZ UT WOS:000385990900013 PM 27423903 ER PT J AU Smith, DK Maier, E Betts, J Gray, S Kolodziejski, B Hoover, KW AF Smith, Dawn K. Maier, Emily Betts, Joshua Gray, Simone Kolodziejski, Brian Hoover, Karen W. TI WHAT COMMUNITY-BASED HIV PREVENTION ORGANIZATIONS SAY ABOUT THEIR ROLE IN BIOMEDICAL HIV PREVENTION SO AIDS EDUCATION AND PREVENTION LA English DT Article ID PREEXPOSURE PROPHYLAXIS; ANTIRETROVIRAL THERAPY; INFECTION; CAPACITY; INTERVENTIONS; TRANSMISSION; MEN; IMPLEMENTATION; SERVICES; WOMEN AB Community-based organizations (CBOs) are critical to delivery of effective HIV prevention because of their reach to key populations. This online survey of a national sample of CBOs assessed their awareness of, interest in, and resources needed to provide nonoccupational postexposure prophylaxis (nPEP), preexposure prophylaxis (PrEP), and HIV treatment as prevention (TasP). One hundred seventy-five CBOs participated: 87 clinical and 88 nonclinical CBOs. For nPEP, PrEP, and TasP, program managers reported that awareness was high (94%, 90%, 85%), meeting current client need was low (20%, 13%, 18%), and the likelihood of increasing their current provision with additional resources was somewhat high (62%, 64%, 62%). Clinical CBOs were more prepared to support expansion of these biomedical interventions than nonclinical CBOs. Meeting the information, training, and resource needs of CBOs is critical for effective collaboration to reduce the number of new HIV infections through expanded delivery of PrEP, nPEP, and TasP. C1 [Smith, Dawn K.; Betts, Joshua; Gray, Simone; Kolodziejski, Brian; Hoover, Karen W.] CDC, Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent NCH, Div HIV AIDS Prevent, Atlanta, GA USA. [Maier, Emily] Emory Rollins Sch Publ Hlth, Atlanta, GA USA. RP Smith, DK (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,Mail Stop E-45, Atlanta, GA 30333 USA. EM dsmith1@cdc.gov NR 30 TC 0 Z9 0 U1 3 U2 3 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA SN 0899-9546 EI 1943-2755 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD OCT PY 2016 VL 28 IS 5 BP 426 EP 439 PG 14 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA DZ1NE UT WOS:000385604300006 PM 27710082 ER PT J AU Lehman, EJ Hein, MJ Gersic, CM AF Lehman, Everett J. Hein, Misty J. Gersic, Christine M. TI Suicide Mortality Among Retired National Football League Players Who Played 5 or More Seasons SO AMERICAN JOURNAL OF SPORTS MEDICINE LA English DT Article DE suicide; football; National Football League; concussion ID CHRONIC TRAUMATIC ENCEPHALOPATHY; TABLE ANALYSIS SYSTEM; BRAIN-INJURY; RISK; DEPRESSION; CONCUSSION AB Background: There is current disagreement in the scientific literature about the relationship between playing football and suicide risk, particularly among professional players in the National Football League (NFL). While some research indicates players are at high risk of football-related concussions, which may lead to chronic traumatic encephalopathy and suicide, other research finds such a connection to be speculative and unsupported by methodologically sound research. Purpose: To compare the suicide mortality of a cohort of NFL players to what would be expected in the general population of the United States. Study Design: Cohort study; Level of evidence, 3. Methods: A cohort of 3439 NFL players with at least 5 credited playing seasons between 1959 and 1988 was assembled for statistical analysis. The vital status for this cohort was updated through 2013. Standardized mortality ratios (SMRs), the ratio of observed deaths to expected deaths, and 95% CIs were computed for the cohort; 95% CIs that excluded unity were considered statistically significant. For internal comparison purposes, standardized rate ratios were calculated to compare mortality results between players stratified into speed and nonspeed position types. Results: Suicide among this cohort of professional football players was significantly less than would be expected in comparison with the United States population (SMR = 0.47; 95% CI, 0.24-0.82). There were no significant differences in suicide mortality between speed and nonspeed position players. Conclusion: There is no indication of elevated suicide risk in this cohort of professional football players with 5 or more credited seasons of play. Because of the unique nature of this cohort, these study results may not be applicable to professional football players who played fewer than 5 years or to college or high school players. C1 [Lehman, Everett J.; Hein, Misty J.; Gersic, Christine M.] Ctr Dis Control & Prevent, NIOSH, Cincinnati, OH USA. RP Lehman, EJ (reprint author), Care of Trout D, Ctr Dis Control & Prevent, NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,R-12, Cincinnati, OH 45226 USA. EM DYT1@cdc.gov FU United States government FX One or more of the authors has declared the following potential conflict of interest or source of funding: This study was fully supported by funding from the United States government to the Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NR 34 TC 1 Z9 1 U1 11 U2 11 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0363-5465 EI 1552-3365 J9 AM J SPORT MED JI Am. J. Sports Med. PD OCT PY 2016 VL 44 IS 10 BP 2486 EP 2491 DI 10.1177/0363546516645093 PG 6 WC Orthopedics; Sport Sciences SC Orthopedics; Sport Sciences GA DY8JC UT WOS:000385374900010 PM 27159317 ER PT J AU Kennedy, AE Khoury, MJ Ioannidis, JPA Brotzman, M Miller, A Lane, C Lai, GY Rogers, SD Harvey, C Elena, JW Seminara, D AF Kennedy, Amy E. Khoury, Muin J. Ioannidis, John P. A. Brotzman, Michelle Miller, Amy Lane, Crystal Lai, Gabriel Y. Rogers, Scott D. Harvey, Chinonye Elena, Joanne W. Seminara, Daniela TI The Cancer Epidemiology Descriptive Cohort Database: A Tool to Support Population-Based Interdisciplinary Research SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID GENOME-WIDE ASSOCIATION; PROSTATE-CANCER; PRECISION MEDICINE; PANCREATIC-CANCER; CLINICAL-TRIALS; PUBLIC-HEALTH; CONSORTIUM; RISK; TRANSFORMATION; BREAST AB Background: We report on the establishment of a web-based Cancer Epidemiology Descriptive Cohort Database (CEDCD). The CEDCD's goals are to enhance awareness of resources, facilitate interdisciplinary research collaborations, and support existing cohorts for the study of cancer-related outcomes. Methods: Comprehensive descriptive data were collected from large cohorts established to study cancer as primary outcome using a newly developed questionnaire. These included an inventory of baseline and follow-up data, biospecimens, genomics, policies, and protocols. Additional descriptive data extracted from publicly available sources were also collected. This information was entered in a searchable and publicly accessible database. We summarized the descriptive data across cohorts and reported the characteristics of this resource. Results: As of December 2015, the CEDCD includes data from 46 cohorts representing more than 6.5 million individuals (29% ethnic/racial minorities). Overall, 78% of the cohorts have collected blood at least once, 57% at multiple time points, and 46% collected tissue samples. Genotyping has been performed by 67% of the cohorts, while 46% have performed whole-genome or exome sequencing in subsets of enrolled individuals. Information on medical conditions other than cancer has been collected in more than 50% of the cohorts. More than 600,000 incident cancer cases and more than 40,000 prevalent cases are reported, with 24 cancer sites represented. Conclusions: The CEDCD assembles detailed descriptive information on a large number of cancer cohorts in a searchable database. Impact: Information from the CEDCD may assist the interdisciplinary research community by facilitating identification of well-established population resources and large-scale collaborative and integrative research. (C) 2016 AACR. C1 [Kennedy, Amy E.; Lai, Gabriel Y.; Rogers, Scott D.; Harvey, Chinonye; Elena, Joanne W.] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, NIH, Rockville, MD USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Ioannidis, John P. A.] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Dept Stat, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Meta Res Innovat Ctr Stanford METRICS, Stanford, CA 94305 USA. [Brotzman, Michelle; Miller, Amy] Westat Corp, Rockville, MD USA. [Lane, Crystal] US Hlth Resources & Serv Adm, Off Epidemiol & Res, Maternal & Child Hlth Bur, Rockville, MD 20857 USA. [Seminara, Daniela] NCI, Div Canc Control & Populat Sci, NIH, Rockville, MD USA. RP Seminara, D (reprint author), NCI, 9609 Med Ctr Dr,Room 3E336,MSC 9763, Bethesda, MD 20850 USA. EM seminard@mail.nih.gov OI Kennedy, Amy/0000-0001-9589-5510 NR 34 TC 0 Z9 0 U1 2 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD OCT PY 2016 VL 25 IS 10 BP 1392 EP 1401 DI 10.1158/1055-9965.EPI-16-0412 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DZ2AA UT WOS:000385642800004 PM 27439404 ER PT J AU Berkowitz, Z Zhang, XY Richards, TB Peipins, L Henley, J Holt, J AF Berkowitz, Zahava Zhang, Xingyou Richards, Thomas B. Peipins, Lucy Henley, Jane Holt, James TI Multilevel Small-Area Estimation of Multiple Cigarette Smoking Status Categories Using the 2012 Behavioral Risk Factor Surveillance System SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID UNITED-STATES; LUNG-CANCER; POSTSTRATIFICATION; PREVALENCE; ADULTS; REGRESSION AB Background: Smoking is the leading preventable cause of death; however, small-area estimates for detailed smoking status are limited. We developed multilevel small-area estimate mixed models to generate county-level estimates for six smoking status categories: current, some days, every day, former, ever, and never. Method: Using 2012 Behavioral Risk Factor Surveillance System (BRFSS) data (our sample size = 405,233 persons), we constructed and fitted a series of multilevel logistic regression models and applied them to the U.S. Census population to generate county-level prevalence estimates. We mapped the estimates by sex and aggregated them into state and national estimates. We conducted comparisons for internal consistency with BRFSS states' estimates using Pearson correlation coefficients, and external validation with the 2012 National Health Interview Survey current smoking prevalence. Results: Correlation coefficients ranged from 0.908 to 0.982, indicating high internal consistency. External validation indicated complete agreement (prevalence = 18.06%). We found large variations in current and former smoking status between and within states and by sex. County prevalence of former smokers was highest among men in the Northeast, North, and West. Utah consistently had the lowest smoking prevalence. Conclusions: Our models, which include demographic and geographic characteristics, provide reliable estimates that can be applied to multiple category outcomes and any demographic group. County and state estimates may help understand the variation in smoking prevalence in the United States and provide information for control and prevention. Impact: Detailed county and state smoking category estimates can help identify areas in need of tobacco control and prevention and potentially allow planning for health care. (C) 2016 AACR. C1 [Berkowitz, Zahava; Zhang, Xingyou; Richards, Thomas B.; Peipins, Lucy; Henley, Jane; Holt, James] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Chamblee, GA USA. RP Berkowitz, Z (reprint author), CDC, Ctr Dis Control & Prevent, 4770 Buford Highway,Mailstop F-76, Chamblee, GA 30341 USA. EM zab3@cdc.gov NR 30 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD OCT PY 2016 VL 25 IS 10 BP 1402 EP 1410 DI 10.1158/1055-9965.EPI-16-0244 PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DZ2AA UT WOS:000385642800005 PM 27697795 ER PT J AU Self, WH Grijalva, CG Williams, DJ Woodworth, A Balk, RA Fakhran, S Zhu, YW Courtney, DM Chappell, J Anderson, EJ Qi, C Waterer, GW Trabue, C Bramley, AM Jain, S Edwards, KM Wunderink, RG AF Self, Wesley H. Grijalva, Carlos G. Williams, Derek J. Woodworth, Alison Balk, Robert A. Fakhran, Sherene Zhu, Yuwei Courtney, D. Mark Chappell, James Anderson, Evan J. Qi, Chao Waterer, Grant W. Trabue, Christopher Bramley, Anna M. Jain, Seema Edwards, Kathryn M. Wunderink, Richard G. TI Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired Pneumonia SO CHEST LA English DT Article DE biomarkers; pneumonia; prognosis; respiratory failure; septic shock ID INTENSIVE-CARE-UNIT; TRACT INFECTIONS; PREDICTION RULE; EMERGENCY-DEPARTMENT; PROGNOSTIC VALUE; LOW-RISK; SEVERITY; ADMISSION; CRITERIA; METAANALYSIS AB BACKGROUND: Predicting the need for intensive care among adults with community-acquired pneumonia (CAP) remains challenging. METHODS: Using a multicenter prospective cohort study of adults hospitalized with CAP, we evaluated the association of serum procalcitonin (PCT) concentration at hospital presentation with the need for invasive respiratory or vasopressor support (IRVS), or both, within 72 h. Logistic regression was used to model this association, with results reported as the estimated risk of IRVS for a given PCT concentration. We also assessed whether the addition of PCT changed the performance of established pneumonia severity scores, including the pneumonia severity index and the American Thoracic Society minor criteria, for prediction of IRVS. RESULTS: Of 1,770 enrolled patients, 115 required IRVS (6.5%). Using the logistic regression model, PCT concentration had a strong association with IRVS risk. Undetectable PCT (< 0.05 ng/mL) was associated with a 4% (95% CI, 3.1%-5.1%) risk of IRVS. For concentrations< 10 ng/mL, PCT had an approximate linear association with IRVS risk: for each 1 ng/mL increase in PCT, there was a 1% to 2% absolute increase in the risk of IRVS. With a PCT concentration of 10 ng/mL, the risk of IRVS was 22.4% (95% CI, 16.3%-30.1%) and remained relatively constant for all concentrations > 10 ng/mL. When added to each pneumonia severity score, PCT contributed significant additional risk information for the prediction of IRVS. CONCLUSIONS: Serum PCT concentration was strongly associated with the risk of requiring IRVS among adults hospitalized with CAP and is potentially useful for guiding decisions about ICU admission. C1 [Self, Wesley H.] Vanderbilt Univ, Med Ctr, Dept Emergency Med, 1313 21st Ave S,703 Oxford House, Nashville, TN 37232 USA. [Grijalva, Carlos G.] Vanderbilt Univ, Med Ctr, Dept Hlth Policy, Nashville, TN USA. [Williams, Derek J.; Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA. [Woodworth, Alison; Chappell, James] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA. [Zhu, Yuwei] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA. [Balk, Robert A.] Rush Univ, Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA. [Fakhran, Sherene] John H Stroger Jr Hosp Cook Cty, Div Pulm, Dept Med, Chicago, IL USA. [Courtney, D. Mark] Northwestern Univ, Dept Emergency Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Qi, Chao] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA. [Waterer, Grant W.; Wunderink, Richard G.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Pulm & Crit Care, Chicago, IL 60611 USA. [Anderson, Evan J.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA. [Waterer, Grant W.] Univ Western Australia, Dept Med, Perth, WA, Australia. [Waterer, Grant W.] Univ Western Australia, Dept Pharmacol, Perth, WA, Australia. [Trabue, Christopher] Univ Tennessee, St Thomas Hlth, Hlth Sci Ctr, Dept Med, Nashville, TN USA. [Bramley, Anna M.; Jain, Seema] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Self, WH (reprint author), Vanderbilt Univ, Med Ctr, Dept Emergency Med, 1313 21st Ave S,703 Oxford House, Nashville, TN 37232 USA. EM wesley.self@vanderbilt.edu OI Wunderink, Richard/0000-0002-8527-4195 FU Centers for Disease Control and Prevention [U18 IP000299]; National Institute of General Medical Sciences [K23GM110469]; BioMerieux, Inc. FX This work was supported by a cooperative agreement with the Centers for Disease Control and Prevention (U18 IP000299). Investigators from the Centers for Disease Control and Prevention participated in the study as authors. W.H.S. was supported in part by K23GM110469 from the National Institute of General Medical Sciences. Materials and funds to perform procalcitonin measurements were provided by BioMerieux, Inc. NR 35 TC 1 Z9 1 U1 2 U2 2 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2016 VL 150 IS 4 BP 819 EP 828 DI 10.1016/j.chest.2016.04.010 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DY0FN UT WOS:000384772800016 PM 27107491 ER PT J AU Levine, MZ Martin, JM Gross, FL Jefferson, S Cole, KS Archibald, CA Nowalk, MP Susick, M Moehling, K Spencer, S Chung, JR Flannery, B Zimmerman, RK AF Levine, Min Z. Martin, Judith M. Gross, F. Liaini Jefferson, Stacie Cole, Kelly Stefano Archibald, Crystal Ann Nowalk, Mary Patricia Susick, Michael Moehling, Krissy Spencer, Sarah Chung, Jessie R. Flannery, Brendan Zimmerman, Richard K. TI Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID HEMAGGLUTINATION-INHIBITING ANTIBODY; UNITED-STATES; SEASONAL INFLUENZA; VACCINES RECOMMENDATIONS; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; PROTECTION; INFECTION; PREVENTION; TITERS AB Human influenza A(H3N2) viruses that predominated during the moderately severe 2014-2015 influenza season differed antigenically from the vaccine component, resulting in reduced vaccine effectiveness (VE). To examine antibody responses to 20142015 inactivated influenza vaccine (IIV) and live-attenuated influenza vaccine (LAIV) among children and adolescents, we collected sera before and after vaccination from 150 children aged 3 to 17 years enrolled at health care facilities. Hemagglutination inhibition (HI) assays were used to assess the antibody responses to vaccine strains. We evaluated cross-reactive antibody responses against two representative A(H3N2) viruses that had antigenically drifted from the A(H3N2) vaccine component using microneutralization (MN) assays. Postvaccination antibody titers to drifted A(H3N2) viruses were higher following receipt of IIV (MN geometric mean titers [GMTs], 63 to 68; 38 to 45% achieved seroconversion) versus LAIV (MN GMT, 22; only 3 to 5% achieved seroconversion). In 9-to 17-year-olds, the highest MN titers were observed among IIV-vaccinated individuals who had received LAIV in the previous season. Among all IIV recipients aged 3 to 17 years, the strongest predictor of antibody responses to the drifted viruses was the prevaccination titers to the vaccine strain. The results of our study suggest that in an antigenically drifted influenza season, vaccination still induced cross-reactive antibody responses to drifted circulating A(H3N2) viruses, although higher antibody titers may be required for protection. Antibody responses to drifted A(H3N2) viruses following vaccination were influenced by multiple factors, including vaccine type and preexisting immunity from prior exposure. C1 [Levine, Min Z.; Gross, F. Liaini; Jefferson, Stacie; Spencer, Sarah; Chung, Jessie R.; Flannery, Brendan] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Martin, Judith M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA. [Cole, Kelly Stefano] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA. [Cole, Kelly Stefano; Archibald, Crystal Ann; Zimmerman, Richard K.] Univ Pittsburgh, Sch Med, Ctr Vaccine Res, Pittsburgh, PA USA. [Nowalk, Mary Patricia; Susick, Michael; Moehling, Krissy; Zimmerman, Richard K.] Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA USA. [Archibald, Crystal Ann; Zimmerman, Richard K.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Spencer, Sarah; Chung, Jessie R.] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Gross, F. Liaini] Battelle Mem Inst, Atlanta, GA USA. RP Levine, MZ (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM mwl2@cdc.gov FU HHS \ National Institutes of Health (NIH) [UL1 RR024153, UL1TR000005]; HHS \ Centers for Disease Control and Prevention (CDC) [U01 IP000467] FX Part of this work conducted at University of Pittsburgh, including the efforts of Richard Zimmerman, was funded by HHS vertical bar National Institutes of Health (NIH) (UL1 RR024153 and UL1TR000005). Part of this work conducted at University of Pittsburgh, including the efforts of Richard Zimmerman, was funded by HHS vertical bar Centers for Disease Control and Prevention (CDC) (U01 IP000467). Research conducted by University of Pittsburgh was funded through the two funders listed; research conducted by Centers for Disease Control and Prevention was not supported by any grant funding. NR 45 TC 0 Z9 0 U1 3 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD OCT PY 2016 VL 23 IS 10 BP 831 EP 839 DI 10.1128/CVI.00297-16 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ2FR UT WOS:000385658200004 PM 27558294 ER PT J AU Levy, B Spelke, B Paulozzi, LJ Bell, JM Nolte, KB Lathrop, S Sugerman, DE Landen, M AF Levy, Benjamin Spelke, Bridget Paulozzi, Leonard J. Bell, Jeneita M. Nolte, Kurt B. Lathrop, Sarah Sugerman, David E. Landen, Michael TI Recognition and response to opioid overdose deaths-New Mexico, 2012 SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Overdose deaths; Drug abuse; Opioid pain relievers; Heroin; Naloxone; Respiratory depression ID EMERGENCY MEDICAL-SERVICES; OBSTRUCTIVE SLEEP-APNEA; DRUG OVERDOSE; UNITED-STATES; CHRONIC PAIN; NALOXONE; PREVENTION; MORTALITY; HEROIN; TRENDS AB Purpose: Drug overdose deaths are epidemic in the U.S. Prescription opioid pain relievers (OPR) and heroin account for the majority of drug overdoses. Preventing death after an opioid overdose by naloxone administration requires the rapid identification of the overdose by witnesses. This study used a state medical examiner database to characterize fatal overdoses, evaluate witness-reported signs of overdose, and identify opportunities for intervention. Methods: We reviewed all unintentional drug overdose deaths that occurred in New Mexico during 2012. Data were abstracted from medical examiner records at the New Mexico Office of the Medical Investigator. We compared mutually exclusive groups of OPR and heroin-related deaths. Results: Of the 489 overdose deaths reviewed, 49.3% involved OPR, 21.7% involved heroin, 4.7% involved a mixture of OPR and heroin, and 24.3% involved only non-opioid substances. The majority of OPR-related deaths occurred in non-Hispanic whites (57.3%), men (58.5%), persons aged 40-59 years (55.2%), and those with chronic medical conditions (89.2%). Most overdose deaths occurred in the home (68.7%) and in the presence of bystanders (67.7%). OPR and heroin deaths did not differ with respect to paramedic dispatch and CPR delivery, however, heroin overdoses received naloxone twice as often (20.8% heroin vs. 10.0% OPR; p < 0.01). Conclusion: OPR overdose deaths differed by age, health status, and the presence of bystanders, yet received naloxone less often when compared to heroin overdose deaths. These findings suggest that naloxone education and distribution should be targeted in future prevention efforts. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Levy, Benjamin; Bell, Jeneita M.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, 4770 Buford Highway MS-F62, Chamblee, GA 30341 USA. [Spelke, Bridget] Brown Univ, Warrren Alpert Med Sch, Women & Infants Hosp Rhode Isl, Providence, RI 02912 USA. [Paulozzi, Leonard J.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, 601 Sunland Pk Dr,Suite 200, El Paso, TX 79912 USA. [Nolte, Kurt B.] Univ New Mexico, 1101 Camino Salud NE, Albuquerque, NM 87102 USA. [Lathrop, Sarah] Univ New Mexico, Albuquerque, NM 87131 USA. [Sugerman, David E.] Ctr Dis Control & Prevent, Ctr Global Hlth, 1600 Clifton Rd, Atlanta, GA 30329 USA. [Landen, Michael] New Mexico Dept Hlth, 1190 S St Francis Dr, Santa Fe, NM 87505 USA. RP Levy, B (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, 4770 Buford Highway MS-F62, Chamblee, GA 30341 USA. EM benalevy@hotmail.com; mspelke@wihri.org; lbp4@cdc.gov; hqp8@cdc.gov; knolte@salud.unm.edu; slathrop@salud.unm.edu; ggi4@cdc.gov; Michael.Landen@state.nm.us OI Spelke, Bridget/0000-0002-5950-8197 FU Centers for Disease Control and Prevention FX All funding was provided by the Centers for Disease Control and Prevention independent of project design, data analysis, or the decision to submit this report for publication. NR 28 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD OCT 1 PY 2016 VL 167 BP 29 EP 35 DI 10.1016/j.drugalcdep.2016.07.011 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DY7QT UT WOS:000385325100005 PM 27507658 ER PT J AU Rim, SH Guy, GP Yabroff, KR McGraw, KA Ekwueme, DU AF Rim, Sun Hee Guy, Gery P., Jr. Yabroff, K. Robin McGraw, Kathleen A. Ekwueme, Donatus U. TI The impact of chronic conditions on the economic burden of cancer survivorship: a systematic review SO EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH LA English DT Review DE Cancer survivors; chronic conditions; economic burden; systematic review ID MULTIPLE CHRONIC CONDITIONS; CARE EXPENDITURE BURDEN; UNITED-STATES; MEDICARE POPULATION; ELDERLY-PATIENTS; LONG-TERM; COSTS; PREVALENCE; COMORBIDITY; ADULTS AB Introduction: This systematic review examines the excess cost of chronic conditions on the economic burden of cancer survivorship among adults in the US.Areas covered: Twelve published studies were identified. Although studies varied substantially in populations, comorbidities examined, methods, and types of cost reported, costs for cancer survivors with comorbidities generally increased with greater numbers of comorbidities or an increase in comorbidity index score. Survivors with comorbidities incurred significantly more in total medical costs, out-of-pocket costs, and costs by service type compared to cancer survivors without additional comorbidities.Expert commentary: Cancer survivors with comorbidities bear significant excess out-of-pocket costs and their care is also more expensive to the healthcare system. On-going evaluation of different payment models, care coordination, and disease management programs for cancer survivors with comorbidities will be important in monitoring impact on healthcare costs. C1 [Rim, Sun Hee; Guy, Gery P., Jr.; Ekwueme, Donatus U.] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Yabroff, K. Robin] US Dept HHS, Off Hlth Policy, Planning & Evaluat, Washington, DC 20201 USA. [McGraw, Kathleen A.] Univ North Carolina Chapel Hill, Hlth Sci Lib, Chapel Hill, NC USA. RP Rim, SH (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,MS F-76, Atlanta, GA 30341 USA. EM srim@cdc.gov FU Intramural CDC HHS [CC999999] NR 52 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1473-7167 EI 1744-8379 J9 EXPERT REV PHARM OUT JI Expert Rev. Pharmacoecon. Outcomes Res. PD OCT PY 2016 VL 16 IS 5 BP 579 EP 589 DI 10.1080/14737167.2016.1239533 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA DZ5ZY UT WOS:000385942500005 PM 27649815 ER PT J AU Burnett, E Yen, C Tate, JE Parashar, UD AF Burnett, Eleanor Yen, Catherine Tate, Jacqueline E. Parashar, Umesh D. TI Rotavirus vaccines: current global impact and future perspectives SO FUTURE VIROLOGY LA English DT Review DE rotavirus; rotavirus vaccine; vaccines prophylactic ID CONTROLLED CASE-SERIES; PLACEBO-CONTROLLED TRIAL; INTUSSUSCEPTION RISK; UNITED-STATES; GASTROENTERITIS HOSPITALIZATIONS; DIARRHEAL HOSPITALIZATIONS; SOUTH-AFRICA; DOUBLE-BLIND; VACCINATION; CHILDREN AB As of May 2016, 81 countries have introduced Rotarix or RotaTeq rotavirus vaccines into their national immunization program. Despite initially slow uptake in some countries and differences in vaccine effectiveness (VE) between high-, low- and middle-income countries, impact of the vaccines has been swift and striking in all settings, with good VE against vaccine-type and nonvaccine-type strains. Newly published research indicates poor nutrition is associated with decreased VE and breastfeeding at the time of vaccination does not affect vaccine response. Vaccines in development and proposed alternate schedules also promise to address limitations of the current vaccines and optimize rotavirus disease prevention. C1 [Burnett, Eleanor; Yen, Catherine; Tate, Jacqueline E.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. RP Burnett, E (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM wwg7@cdc.gov FU Intramural CDC HHS [CC999999] NR 61 TC 1 Z9 1 U1 4 U2 4 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1746-0794 EI 1746-0808 J9 FUTURE VIROL JI Future Virol. PD OCT PY 2016 VL 11 IS 10 BP 699 EP 708 DI 10.2217/fvl-2016-0082 PG 10 WC Virology SC Virology GA DY8PE UT WOS:000385391500006 PM 27840654 ER PT J AU Reidy, DE Berke, DS Gentile, B Zeichner, A AF Reidy, Dennis E. Berke, Danielle S. Gentile, Brittany Zeichner, Amos TI Masculine discrepancy stress, substance use, assault and injury in a survey of US men SO INJURY PREVENTION LA English DT Article ID VIOLENCE AB To understand and ultimately prevent injury and behavioural health outcomes associated with masculinity, we assessed the influence of masculine discrepancy stress (stress that occurs when men perceive themselves as falling short of the traditional gender norms) on the propensity to engage in stereotypically masculine behaviours (eg, substance use, risk taking and violence) as a means of demonstrating masculinity. Six-hundred men from the USA were recruited via Amazon's Mechanical Turk (MTurk) online data collection site to complete surveys assessing self-perceptions of gender role discrepancy and consequent discrepancy stress, substance use/abuse, driving while intoxicated (DWI) and violent assaults. Negative binomial regression analyses indicated significant interactive effects wherein men high on gender role discrepancy and attendant discrepancy stress reported significantly more assaults with a weapon (B=1.01; SE=0.63; IRR=2.74; p=0.05) and assaults causing injury (B=1.01; SE=0.51; IRR=2.74; p<0.05). There was no association of discrepancy stress to substance abuse, but there was a protective effect of gender role discrepancy for DWI among men low on discrepancy stress (B=-1.19, SE=0.48; IRR=0.30; p=0.01). These findings suggest that gender role discrepancy and associated discrepancy stress, in particular, represent important injury risk factors and that prevention of discrepancy stress may prevent acts of violence with the greatest consequences and costs to the victim, offender and society. C1 [Reidy, Dennis E.] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. [Berke, Danielle S.; Gentile, Brittany; Zeichner, Amos] Univ Georgia, Dept Psychol, Athens, GA 30602 USA. RP Reidy, DE (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. EM dreidy@cdc.gov NR 17 TC 1 Z9 1 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 EI 1475-5785 J9 INJURY PREV JI Inj. Prev. PD OCT PY 2016 VL 22 IS 5 BP 370 EP 374 DI 10.1136/injuryprev-2015-041599 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DZ6CE UT WOS:000385948400012 PM 26303670 ER PT J AU Stover, PJ Berry, RJ Field, MS AF Stover, Patrick J. Berry, Robert J. Field, Martha S. TI Time to Think About Nutrient Needs in Chronic Disease SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; FOLIC-ACID; MORTALITY; THERAPY C1 [Stover, Patrick J.; Field, Martha S.] Cornell Univ, Div Nutr Sci, 127 Savage Hall,244 Garden Ave, Ithaca, NY 14853 USA. [Berry, Robert J.] CDC, Div Birth Defects & Dev Disabil, NCBDDD, Atlanta, GA 30333 USA. RP Stover, PJ (reprint author), Cornell Univ, Div Nutr Sci, 127 Savage Hall,244 Garden Ave, Ithaca, NY 14853 USA. EM pjs13@cornell.edu FU NIDDK NIH HHS [P30 DK020541, R01 DK058144] NR 9 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT PY 2016 VL 176 IS 10 BP 1451 EP 1452 DI 10.1001/jamainternmed.2016.4699 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DZ1ZU UT WOS:000385642000009 PM 27548386 ER PT J AU Wassilak, SGF Vertefeuille, JF Martin, RM AF Wassilak, Steven G. F. Vertefeuille, John F. Martin, Rebecca M. TI The Globally Synchronized Switch-Another Milestone Toward Achieving Polio Eradication SO JAMA PEDIATRICS LA English DT Editorial Material ID VACCINE; ENDGAME C1 [Wassilak, Steven G. F.; Vertefeuille, John F.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. [Martin, Rebecca M.] Ctr Dis Control & Prevent, Ctr Global Hlth, 1600 Clifton Rd NE,Mailstop D69, Atlanta, GA 30333 USA. RP Martin, RM (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, 1600 Clifton Rd NE,Mailstop D69, Atlanta, GA 30333 USA. EM rtm4@cdc.gov NR 8 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD OCT PY 2016 VL 170 IS 10 BP 927 EP 928 DI 10.1001/jamapediatrics.2016.1718 PG 2 WC Pediatrics SC Pediatrics GA DZ2AB UT WOS:000385643000006 PM 27479244 ER PT J AU Ellington, SR Devine, O Bertolli, J Quinones, AM Shapiro-Mendoza, CK Perez-Padilla, J Rivera-Garcia, B Simeone, RM Jamieson, DJ Valencia-Prado, M Gilboa, SM Honein, MA Johansson, MA AF Ellington, Sascha R. Devine, Owen Bertolli, Jeanne Quinones, Alma Martinez Shapiro-Mendoza, Carrie K. Perez-Padilla, Janice Rivera-Garcia, Brenda Simeone, Regina M. Jamieson, Denise J. Valencia-Prado, Miguel Gilboa, Suzanne M. Honein, Margaret A. Johansson, Michael A. TI Estimating the Number of Pregnant Women Infected With Zika Virus and Expected Infants With Microcephaly Following the Zika Virus Outbreak in Puerto Rico, 2016 SO JAMA PEDIATRICS LA English DT Article ID AEDES-AEGYPTI; CHIKUNGUNYA VIRUS; INTERIM GUIDANCE; UNITED-STATES; FOLIC-ACID; COMMUNITIES; PREVENTION; DISPERSAL; DEFECTS; BIRTH AB IMPORTANCE Zika virus (ZIKV) infection during pregnancy is a cause of congenital microcephaly and severe fetal brain defects, and it has been associated with other adverse pregnancy and birth outcomes. OBJECTIVE To estimate the number of pregnant women infected with ZIKV in Puerto Rico and the number of associated congenital microcephaly cases. DESIGN, SETTING, AND PARTICIPANTS We conducted a modeling study from April to July 2016. Using parameters derived from published reports, outcomes were modeled probabilistically using Monte Carlo simulation. We used uncertainty distributions to reflect the limited information available for parameter values. Given the high level of uncertainty in model parameters, interquartile ranges (IQRs) are presented as primary results. Outcomes were modeled for pregnant women in Puerto Rico, which currently has more confirmed ZIKV cases than any other US location. EXPOSURE Zika virus infection in pregnant women. MAIN OUTCOMES AND MEASURES Number of pregnant women infected with ZIKV and number of congenital microcephaly cases. RESULTS We estimated an IQR of 5900 to 10 300 pregnant women (median, 7800) might be infected during the initial ZIKV outbreak in Puerto Rico. Of these, an IQR of 100 to 270 infants (median, 180) may be born with microcephaly due to congenital ZIKV infection from mid-2016 to mid-2017. In the absence of a ZIKV outbreak, an IQR of 9 to 16 cases (median, 12) of congenital microcephaly are expected in Puerto Rico per year. CONCLUSIONS AND RELEVANCE The estimate of 5900 to 10 300 pregnant women that might be infected with ZIKV provides an estimate for the number of infants that could potentially have ZIKV-associated adverse outcomes. Including baseline cases of microcephaly, we estimated that an IQR of 110 to 290 total cases of congenital microcephaly, mostly attributable to ZIKV infection, could occur from mid-2016 to mid-2017 in the absence of effective interventions. The primary limitation in this analysis is uncertainty in model parameters. Multivariate sensitivity analyses indicated that the cumulative incidence of ZIKV infection and risk of microcephaly given maternal infection in the first trimester were the primary drivers of both magnitude and uncertainty in the estimated number of microcephaly cases. Increased information on these parameters would lead to more precise estimates. Nonetheless, the results underscore the need for urgent actions being undertaken in Puerto Rico to prevent congenital ZIKV infection and prepare for affected infants. C1 [Ellington, Sascha R.; Devine, Owen; Bertolli, Jeanne; Shapiro-Mendoza, Carrie K.; Perez-Padilla, Janice; Simeone, Regina M.; Jamieson, Denise J.; Gilboa, Suzanne M.; Honein, Margaret A.; Johansson, Michael A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ellington, Sascha R.] Univ Georgia, Athens, GA 30602 USA. [Devine, Owen] Carter Consulting Inc, Atlanta, GA USA. [Quinones, Alma Martinez; Rivera-Garcia, Brenda; Valencia-Prado, Miguel] Puerto Rico Dept Hlth, San Juan, PR USA. RP Ellington, SR (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, MS F74,Chamblee Campus,4770 Buford Hwy, Atlanta, GA 30341 USA. EM sellington@cdc.gov NR 43 TC 5 Z9 5 U1 12 U2 12 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD OCT PY 2016 VL 170 IS 10 BP 940 EP 945 DI 10.1001/jamapediatrics.2016.2974 PG 6 WC Pediatrics SC Pediatrics GA DZ2AB UT WOS:000385643000012 PM 27544075 ER PT J AU Pazol, K Daniels, K Romero, L Warner, L Barfield, W AF Pazol, Karen Daniels, Kimberly Romero, Lisa Warner, Lee Barfield, Wanda TI Trends in Long-Acting Reversible Contraception Use in Adolescents and Young Adults: New Estimates Accounting for Sexual Experience SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE LARC (long-acting reversible contraception); NSFG (National Survey of Family Growth); Youth-friendly services; Sexual experience ID UNITED-STATES; INTRAUTERINE CONTRACEPTION; UNINTENDED PREGNANCY; PROVISION; DECLINES; NEEDS; WOMEN AB Purpose: The purposes of the analysis were to compare long-acting reversible contraception (LARC) use estimates that include all reproductive age women with estimates that are limited to women at risk for unintended pregnancy and to examine trends for adolescents (15-19 years) and young adults (20-24 years). Methods: Using the 2006-2010 and 2011-2013 National Surveys of Family Growth, we compared LARC estimates for all women with estimates limited to women at risk for unintended pregnancy (those who were sexually experienced, and neither pregnant, seeking pregnancy, postpartum or infecund). We used t tests to detect differences according to the population included and to evaluate trends for adolescents and young adults. Results: Among adolescents and young adults, 56% and 14%, respectively, have never had vaginal intercourse, versus 1%-4% for women aged 25-44 years. Given the high percentage of adolescents and young adults who never had vaginal intercourse, LARC estimates were higher for these age groups (p < .05), but not for women aged 25-44 years, when limited to those at risk for unintended pregnancy. Among adolescents at risk, the increase in LARC use from 2006-2008 (1.1%) to 2008-2010 (3.6%) was not significant (p = .07), and no further increase occurred from 2008-2010 to 2011-2013 (3.2%); by contrast, among young adults at risk, LARC use increased from 2006-2008 (3.2%) to 2008-2010 (6.9%) and from 2008-2010 to 2011-2013 (11.1%). Conclusions: Because many adolescents and young adult women have never had vaginal intercourse, for these groups, including all women underestimates LARC use for pregnancy prevention. Among young adults, use of LARC for pregnancy prevention has increased but remains low among adolescents. (C) Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Pazol, Karen; Romero, Lisa; Warner, Lee; Barfield, Wanda] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Daniels, Kimberly] Ctr Dis Control & Prevent, Div Vital Stat, Reprod Stat Branch, Natl Ctr Hlth Stat, Atlanta, GA USA. RP Pazol, K (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,F74, Atlanta, GA 30341 USA. EM kpazol@cdc.gov NR 24 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD OCT PY 2016 VL 59 IS 4 BP 438 EP 442 DI 10.1016/j.jadohealth.2016.05.018 PG 5 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA DY9HI UT WOS:000385444100013 PM 27449328 ER PT J AU Breakwell, L Vogt, TM Fleming, D Ferris, M Briere, E Cohn, A Liang, JL AF Breakwell, Lucy Vogt, Tara M. Fleming, Debbie Ferris, Mary Briere, Elizabeth Cohn, Amanda Liang, Jennifer L. TI Understanding Factors Affecting University A Students' Decision to Receive an Unlicensed Serogroup B Meningococcal Vaccine SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Meningococcal disease; KAP survey; University students; Serogroup B meningococcal vaccine ID COLLEGE-STUDENTS; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; DISEASE RECOMMENDATIONS; INFLUENZA VACCINE; YOUNG-ADULTS; RISK; PERCEPTIONS; PREVALENCE; INTENTIONS AB Purpose: During March-November 2013, five cases of serogroup B meningococcal disease occurred among University A undergraduates. The Centers for Disease Control and Prevention used the unlicensed MenB-4C (Bexsero, Novartis Vaccines), a serogroup B meningococcal vaccine, to control the outbreak. All undergraduates (n = 19,257) were offered two doses; 51% of undergraduates received >= 1 dose of MenB-4C. We conducted a knowledge, attitudes, and practice survey to understand which factors and sources of information impacted their decision on whether or not to receive vaccine. Methods: An anonymous online survey was sent to University A undergraduates. The survey was implemented in June 2-30, 2014, and covered demographics, MenB-4C vaccination decision, and sources of information. Descriptive analyses were conducted. Results: A total of 1,341 students completed the survey (response rate = 7.0%), of these 873 received >= 1 dose of MenB-4C. Among vaccinated respondents, the predominant reasons for receiving vaccine were knowledge of disease severity, parental recommendation, and believing that vaccination offered the best protection. Among unvaccinated respondents, the predominant reasons for not receiving vaccine were perception of low disease risk and concern over vaccine newness and safety. Respondents' top primary sources of information were e-mails from the university followed by their parents. Conclusions: Reasons behind respondents' decision to receive an unlicensed vaccine were similar to those reported for routinely recommended vaccines. Given the challenges around communicating the importance of receiving a vaccine that is not routinely recommended, respondents' primary sources of information, the university and their parents, could be targeted to improve coverage rates. (C) Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Breakwell, Lucy; Briere, Elizabeth; Liang, Jennifer L.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Breakwell, Lucy] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Div Sci Educ & Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Vogt, Tara M.; Cohn, Amanda] Ctr Dis Control & Prevent, Off Director, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Fleming, Debbie] Univ Calif Santa Barbara, Div Student Affairs, Santa Barbara, CA 93106 USA. [Ferris, Mary] Univ Calif Santa Barbara, UCSB Student Hlth, Santa Barbara, CA 93106 USA. RP Breakwell, L (reprint author), Ctr Dis Control & Prevent, Accelerated Dis Control & Vaccine Preventable Dis, Global Immunizat Div, Ctr Global Hlth, 1825 Century Blvd NE, Atlanta, GA 30345 USA. EM xdc3@cdc.gov NR 26 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD OCT PY 2016 VL 59 IS 4 BP 457 EP 464 DI 10.1016/j.jadohealth.2016.06.004 PG 8 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA DY9HI UT WOS:000385444100016 PM 27523976 ER PT J AU Pukuta, E Waku-Kouomou, D Abernathy, E Illunga, BK Obama, R Mondonge, V Dahl, BA Maresha, BG Icenogle, J Muyembe, JJ AF Pukuta, Elizabeth Waku-Kouomou, Diane Abernathy, Emily Illunga, Benoit Kebela Obama, Ricardo Mondonge, Vital Dahl, Benjamin A. Maresha, Balcha G. Icenogle, Joseph Muyembe, Jean-Jacques TI Genotypes of Rubella Virus and the Epidemiology of Rubella Infections in the Democratic Republic of the Congo, 2004-2013 SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE rubella; genotyping; DRC; Africa ID SURVEILLANCE AB Rubella is a viral infection that may cause fetal death or congenital defects, known as congenital rubella syndrome (CRS), during early pregnancy. The World Health Organization (WHO) recommends that countries assess the burden of rubella and CRS, including the determination of genotypes of circulating viruses. The goal of this study was to identify the genotypes of rubella viruses in the Democratic Republic of the Congo (DRC). Serum or throat swab samples were collected through the measles surveillance system. Sera that tested negative for measles IgM antibody were tested for rubella IgM antibody. Serum collected within 4 days of rash onset and throat swabs were screened by real-time RT-PCR for rubella virus RNA. For positive samples, an amplicon of the E1 glycoprotein gene was amplified by RT-PCR and sequenced. 11733 sera were tested for rubella IgM and 2816 (24%) were positive; 145 (5%) were tested for the presence of rubella RNA by real-time RTPCR and 10 (7%) were positive. Seventeen throat swabs were analyzed by RT-PCR and three were positive. Sequences were obtained from eight of the positive samples. Phylogenetic analysis showed that the DRC rubella viruses belonged to genotypes 1B, 1E, 1G, and 2B. This report provides the first information on the genotypes of rubella virus circulating in the DRC. These data contribute to a better understanding of rubella burden and the dynamics of rubella virus circulation in Africa. Efforts to establish rubella surveillance in the DRC are needed to support rubella elimination in Africa. (C) 2016 Wiley Periodicals, Inc. C1 [Pukuta, Elizabeth; Muyembe, Jean-Jacques] Inst Natl Rech Biomed, Kinshasa, DEM REP CONGO. [Waku-Kouomou, Diane; Abernathy, Emily; Icenogle, Joseph] US Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS C-22, Atlanta, GA 30333 USA. [Illunga, Benoit Kebela] Minist Publ Hlth, Off Dis Prevent, Kinshasa, DEM REP CONGO. [Obama, Ricardo] World Hlth Org, Expanded Program Immunizat, Kinshasa, DEM REP CONGO. [Mondonge, Vital] World Hlth Org, Kinshasa, DEM REP CONGO. [Dahl, Benjamin A.] US Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. [Maresha, Balcha G.] World Hlth Org, Immunizat & Vaccines Dev, African Reg Off, Brazzaville, DEM REP CONGO. RP Waku-Kouomou, D (reprint author), US Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS C-22, Atlanta, GA 30333 USA. EM irf6@cdc.gov FU Bill and Melinda Gates Foundation through the SURVAC Project; World Health Organization; U.S. Centers for Diseases Control and Prevention; CDC Foundation; Ministry of Health of the Democratic Republic of the Congo FX Grant sponsor: The Bill and Melinda Gates Foundation through the SURVAC Project; Grant sponsor: The World Health Organization; Grant sponsor: The U.S. Centers for Diseases Control and Prevention; Grant sponsor: The CDC Foundation; Grant sponsor: The Ministry of Health of the Democratic Republic of the Congo NR 17 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0146-6615 EI 1096-9071 J9 J MED VIROL JI J. Med. Virol. PD OCT PY 2016 VL 88 IS 10 BP 1677 EP 1684 DI 10.1002/jmv.24517 PG 8 WC Virology SC Virology GA DZ3BZ UT WOS:000385720200006 PM 27479298 ER PT J AU Bai, Y Gilbert, A Fox, K Osikowicz, L Kosoy, M AF Bai, Ying Gilbert, Amy Fox, Karen Osikowicz, Lynn Kosoy, Michael TI BARTONELLA ROCHALIMAE AND B. VINSONII SUBSP BERKHOFFII IN WILD CARNIVORES FROM COLORADO, USA SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE Bartonella vinsonii subsp berkhoffii; Bartonella rochalimae; Colorado; wild carnivores; wildlife diseases ID CITRATE SYNTHASE GENE; PHYLOGENETIC ANALYSIS; GRAY FOXES; CALIFORNIA; INFECTION; SEQUENCES; DOGS; DIFFERENTIATION; ENDOCARDITIS; RESERVOIR AB Spleen samples from 292 wild carnivores from Colorado, US were screened for Bartonella infection. Bartonella DNA was detected in coyotes (Canis latrans) (28%), striped skunks (Mephitis mephitis) (23%), red foxes (Vulpes vulpes) (27%), and raccoons (Procyon lotor) (8%) but not in black bears (Ursus americanus), gray foxes (Urocyon cinereoargenteus), and mountain lions (Puma concolor). Two Bartonella species, B. vinsonii subsp. berkhoffii and B. rochalimae, were identified. All 10 infected striped skunks exclusively carried B. rochalimae while coyotes, red foxes, and raccoons could be infected with both Bartonella species. Five of seven infected coyotes carried B. v. berkhoffii whereas five of seven infected red foxes and 11 of 14 infected raccoons carried B. rochalimae. Further studies are needed to understand relationships between Bartonella species, wild carnivores, and their ectoparasites. C1 [Bai, Ying; Osikowicz, Lynn; Kosoy, Michael] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. [Gilbert, Amy] APHIS, Natl Wildlife Res Ctr, USDA, Wildlife Serv, 4101 Laporte Ave, Ft Collins, CO 80521 USA. [Fox, Karen] Colorado Pk & Wildlife, 317 W Prospect Rd, Ft Collins, CO 80525 USA. RP Bai, Y (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM bby5@cdc.gov NR 26 TC 1 Z9 1 U1 3 U2 3 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 EI 1943-3700 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD OCT PY 2016 VL 52 IS 4 BP 844 EP 849 DI 10.7589/2016-01-015 PG 6 WC Veterinary Sciences SC Veterinary Sciences GA DZ4RG UT WOS:000385846300009 PM 27529290 ER PT J AU Pan, L Grummer-Strawn, LM McGuire, LC Park, S Blanck, HM AF Pan, L. Grummer-Strawn, L. M. McGuire, L. C. Park, S. Blanck, H. M. TI Trends in state/territorial obesity prevalence by race/ethnicity among US low-income, preschool-aged children SO PEDIATRIC OBESITY LA English DT Article DE Childhood obesity; trends; low-income; state; race; ethnicity ID UNITED-STATES; CHILDHOOD OBESITY; ENVIRONMENT; POPULATIONS; FAMILIES; RISK AB BackgroundUnderstanding state/territorial trends in obesity by race/ethnicity helps focus resources on populations at risk. ObjectiveThis study aimed to examine trends in obesity prevalence among low-income, preschool-aged children from 2008 through 2011 in U.S. states and territories by race/ethnicity. MethodsWe used measured weight and height records of 11.1 million children aged 2-4 years who participated in federally funded health and nutrition programmes in 40 states, the District of Columbia and two U.S. territories. We used logistic regression to examine obesity prevalence trends, controlling for age and sex. ResultsFrom 2008 through 2011, the aggregated obesity prevalence declined among all racial/ethnic groups (decreased by 0.4-0.9%) except American Indians/Alaska Natives (AI/ANs); the largest decrease was among Asians/Pacific Islanders (A/PIs). Declines were significant among non-Hispanic whites in 14 states, non-Hispanic blacks in seven states/territories, Hispanics in 13 states, A/PIs in five states and AI/ANs in one state. Increases were significant among non-Hispanic whites in four states, non-Hispanic blacks in three states, Hispanics in two states and A/PIs in one state. The majority of the states/territories had no change in obesity prevalence. ConclusionsOur findings indicate slight reductions in obesity prevalence and variations in obesity trends, but disparities exist for some states and racial/ethnic groups. C1 [Pan, L.; McGuire, L. C.; Park, S.; Blanck, H. M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Highway,Mail Stop F-77, Atlanta, GA 30341 USA. [Grummer-Strawn, L. M.] WHO, Geneva, Switzerland. RP Pan, L (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Highway,Mail Stop F-77, Atlanta, GA 30341 USA. EM lpan@cdc.gov FU World Health Organization [001] NR 28 TC 0 Z9 0 U1 7 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-6310 EI 2047-6302 J9 PEDIATR OBES JI Pediatr. Obes. PD OCT PY 2016 VL 11 IS 5 BP 397 EP 402 DI 10.1111/ijpo.12078 PG 6 WC Pediatrics SC Pediatrics GA DY8KM UT WOS:000385378800015 PM 26463118 ER PT J AU Horton, KC Fahmy, NT Watany, N Zayed, A Mohamed, A Ahmed, AA Rollin, PE Dueger, EL AF Horton, Katherine C. Fahmy, Nermeen T. Watany, Noha Zayed, Alia Mohamed, Abro Ahmed, Ammar Abdo Rollin, Pierre E. Dueger, Erica L. TI Crimean Congo Hemorrhagic Fever Virus and Alkhurma (Alkhumra) Virus in Ticks in Djibouti SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Bunyaviridae; Crimean Congo hemorrhagic fever virus; Flaviviridae; tick(s) ID DIVERSITY AB Crimean Congo hemorrhagic fever virus and Alkhumra virus, not previously reported in Djibouti, were detected among 141 (infection rate = 15.7 per 100, 95% CI: 13.4-18.1) tick pools from 81 (37%) cattle and 2 (infection rate = 0.2 per 100, 95% CI: 0.0-0.7) tick pools from 2 (1%) cattle, respectively, collected at an abattoir in 2010 and 2011. C1 [Horton, Katherine C.; Dueger, Erica L.] US Ctr Dis Control & Prevent, Global Dis Detect Program, Cairo, Egypt. [Fahmy, Nermeen T.; Watany, Noha; Zayed, Alia] US Naval Med Res Unit 3, Vector Biol Res Program, Cairo, Egypt. [Mohamed, Abro; Ahmed, Ammar Abdo] Minist Hlth, Dept Epidemiol & Informat Serv, Djibouti, Djibouti. [Rollin, Pierre E.] US Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Dueger, Erica L.] US Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. RP Horton, KC (reprint author), US Ctr Dis Control & Prevent, Global Dis Detect Program, PSC 452 Box 5000, FPO, AE 09835 USA. EM katherinehorton12@gmail.com FU Department of Defense Global Emerging Infections System (GEIS), work unit [847705.82000.25GB.E0018]; Global Disease Detection Branch, Division of Global Health Protection, Center for Global Health, U.S. Centers for Disease Control and Prevention FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Department of the Navy, U.S. Department of Defense, or the U.S. Centers for Disease Control. This project was funded by the Department of Defense Global Emerging Infections System (GEIS), work unit 847705.82000.25GB.E0018, and the Global Disease Detection Branch, Division of Global Health Protection, Center for Global Health, U.S. Centers for Disease Control and Prevention. No competing financial interests exist. NR 10 TC 1 Z9 1 U1 9 U2 9 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD OCT PY 2016 VL 16 IS 10 BP 680 EP 682 DI 10.1089/vbz.2016.1951 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DY8QO UT WOS:000385395100010 PM 27508862 ER PT J AU Liepkalns, JS Pandey, A Hofstetter, AR Kumar, A Jones, EN Cao, WP Liu, F Levine, MZ Sambhara, S Gangappa, S AF Liepkalns, Justine S. Pandey, Aseem Hofstetter, Amelia R. Kumar, Amrita Jones, Enitra N. Cao, Weiping Liu, Feng Levine, Min Z. Sambhara, Suryaprakash Gangappa, Shivaprakash TI Rapamycin Does Not Impede Survival or Induction of Antibody Responses to Primary and Heterosubtypic Influenza Infections in Mice SO VIRAL IMMUNOLOGY LA English DT Article ID MAMMALIAN TARGET; PROTECTIVE IMMUNITY; VIRUS-INFECTION; MTOR; TRANSPLANTATION; MEMORY; CELLS; SUPPRESSION; METABOLISM; ACTIVATION AB Impairment of immune defenses can contribute to severe influenza infections. Rapamycin is an immunosuppressive drug often used to prevent transplant rejection and is currently undergoing clinical trials for treating cancers and autoimmune diseases. We investigated whether rapamycin has deleterious effects during lethal influenza viral infections. We treated mice with two concentrations of rapamycin and infected them with A/Puerto Rico/8/1934 (A/PR8), followed by a heterosubtypic A/Hong Kong/1/68 (A/HK68) challenge. Our data show similar morbidity, mortality, and lung viral titer with both rapamycin treatment doses compared to untreated controls, with a delay in morbidity onset in rapamycin high dose recipients during primary infection. Rapamycin treatment at high dose also led to increase in percent cytokine producing T cells in the spleen. However, all infected animals had similar serum antibody responses against A/PR8. Post-A/HK68 challenge, rapamycin had no impeding effect on morbidity or mortality and had similar serum antibody levels against A/PR8 and A/HK68. We conclude that rapamycin treatment does not adversely affect morbidity, mortality, or antibody production during lethal influenza infections. C1 [Liepkalns, Justine S.; Pandey, Aseem; Hofstetter, Amelia R.; Kumar, Amrita; Jones, Enitra N.; Cao, Weiping; Liu, Feng; Levine, Min Z.; Sambhara, Suryaprakash; Gangappa, Shivaprakash] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Bldg 17 Room 5205,MS-G16, Atlanta, GA 30333 USA. [Hofstetter, Amelia R.] Emory Univ, Pathol & Lab Med, Atlanta, GA 30322 USA. RP Gangappa, S (reprint author), Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Bldg 17 Room 5205,MS-G16, Atlanta, GA 30333 USA. EM sgangappa@cdc.gov OI Hofstetter, Amelia/0000-0003-4113-5473 FU Association of Public Health Laboratories (APHL); Institutional Research and Academic Career Development Award (IRACDA) FX The authors acknowledge the Atlanta Research and Education Foundation (AREF) (Atlanta VA Medical Center, 1670 Clairmont Road, Decatur, GA 30033). The authors also acknowledge the Association of Public Health Laboratories (APHL) (8515 Georgia Avenue, Suite 700, Silver Spring, MD 20910) for the Emerging Infectious Disease (EID) Fellowship awarded to E.N.J. and the Institutional Research and Academic Career Development Award (IRACDA) for the Fellowships in Research and Science Teaching (FIRST) (Whitehead Biomedical Research Bldg., Suite 648, Atlanta, GA 30323) awarded to J.S.L. The authors thank the animal facilities' technicians, as well as Dr. Samuel Amoah, for their assistance in caring for and treating animals. NR 32 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0882-8245 EI 1557-8976 J9 VIRAL IMMUNOL JI Viral Immunol. PD OCT PY 2016 VL 29 IS 8 BP 487 EP 493 DI 10.1089/vim.2016.0056 PG 7 WC Immunology; Virology SC Immunology; Virology GA DY8PC UT WOS:000385391300007 ER PT J AU Ahluwalia, N Herrick, KA Rossen, LM Rhodes, D Kit, B Moshfegh, A Dodd, KW AF Ahluwalia, Namanjeet Herrick, Kirsten A. Rossen, Lauren M. Rhodes, Donna Kit, Brian Moshfegh, Alanna Dodd, Kevin W. TI Usual nutrient intakes of US infants and toddlers generally meet or exceed Dietary Reference Intakes: findings from NHANES 2009-2012 SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE infants and toddlers; nationally representative sample; nutrient adequacy; recommended intakes; usual nutrient intake ID NATIONAL-HEALTH; PRESCHOOL-CHILDREN; FEEDING INFANTS; TOTAL-ENERGY; NUTRITION; COLLECTION; AMERICA; BIRTH; FOODS; B-24 AB Background: To our knowledge, few studies have described the usual nutrient intakes of US children aged <2 y or assessed the nutrient adequacy of their diets relative to the recommended Dietary Reference Intakes (DRIs). Objective: We estimated the usual nutrient intake of US children aged 6-23 mo examined in NHANES 2009-2012 and compared them to age-specific DRIs as applicable. Design: Dietary intake was assessed with two 24-h recalls for infants aged 6-11 mo (n = 381) and toddlers aged 12-23 mo (n = 516) with the use of the USDA's Automated Multiple-Pass Method. Estimates of usual nutrient intakes from food and beverages were obtained with the use of the National Cancer Institute method. The proportions of children with intakes below and above the DRI were also estimated. Results: The estimated usual intakes of infants were adequate for most nutrients; however, 10% had an iron intake below the Estimated Average Requirement (EAR), and only 21% had a vitamin D intake that met or exceeded the recommended Adequate Intake (AI). More nutrient inadequacies were noted among toddlers; 1 in 4 had a lower-than-recommended fat intake (percentage of energy), and most had intakes that were below the EAR for vitamins E (82%) and D (74%). Few toddlers (<1%) met or exceeded the AI for fiber and potassium. In contrast, 1 in 2 had sodium intakes that exceeded the Tolerable Upper Intake Level (UL); >= 16% and 41% of the children had excessive intakes (greater than the ULs) of vitamin A and zinc, respectively. Conclusions: The estimated usual intakes of infants were adequate for most nutrients. Most toddlers were at risk for inadequate intakes of vitamins D and E and had diets low in fiber and potassium. The sources contributing to excessive intakes of vitamin A and zinc among infants and toddlers may need further evaluation. C1 [Ahluwalia, Namanjeet; Herrick, Kirsten A.; Kit, Brian] CDC, Div Hlth & Nutr Examinat Survey, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Rossen, Lauren M.] CDC, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Rhodes, Donna; Moshfegh, Alanna] USDA, Food Surveys Res Grp, Beltsville, MD 20705 USA. [Dodd, Kevin W.] NCI, NIH, Rockville, MD USA. RP Ahluwalia, N (reprint author), CDC, Div Hlth & Nutr Examinat Survey, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM n.ahluwalia@cdc.gov NR 40 TC 2 Z9 2 U1 8 U2 8 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD OCT PY 2016 VL 104 IS 4 BP 1167 EP 1174 DI 10.3945/ajcn.116.137752 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DY1SO UT WOS:000384874900029 PM 27629049 ER PT J AU Garrison, LE Kunz, JM Cooley, LA Moore, MR Lucas, C Schrag, S Sarisky, J Whitney, CG AF Garrison, L. E. Kunz, J. M. Cooley, L. A. Moore, M. R. Lucas, C. Schrag, S. Sarisky, J. Whitney, C. G. TI Vital Signs: Deficiencies in Environmental Control Identified in Outbreaks of Legionnaires' Disease-North America, 2000-2014 (Reprinted from vol 65, pg 576-584, 2016) SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Reprint ID UNITED-STATES; LEGIONELLA; TRANSMISSION AB Background: The number of reported cases of Legionnaires' disease, a severe pneumonia caused by the bacterium Legionella, is increasing in the United States. During 2000-2014, the rate of reported legionellosis cases increased from 0.42 to 1.62 per 100 000 persons; 4% of reported cases were outbreak-associated. Legionella is transmitted through aerosolization of contaminated water. A new industry standard for prevention of Legionella growth and transmission in water systems in buildings was published in 2015. CDC investigated outbreaks of Legionnaires' disease to identify gaps in building water system maintenance and guide prevention efforts. Methods: Information from summaries of CDC Legionnaires' disease outbreak investigations during 2000-2014 was systematically abstracted, and water system maintenance deficiencies from land-based investigations were categorized as process failures, human errors, equipment failures, or unmanaged external changes. Results: During 2000-2014, CDC participated in 38 field investigations of Legionnaires' disease. Among 27 land-based outbreaks, the median number of cases was 10 (range = 3-82) and median outbreak case fatality rate was 7% (range = 0-80%). Sufficient information to evaluate maintenance deficiencies was available for 23 (85%) investigations. Of these, all had at least one deficiency; 11 (48%) had deficiencies in >= 2 categories. Fifteen cases (65%) were linked to process failures, 12 (52%) to human errors, eight (35%) to equipment failures, and eight (35%) to unmanaged external changes. Conclusions and Implications for Public Health Practice: Multiple common preventable maintenance deficiencies were identified in association with disease outbreaks, highlighting the importance of comprehensive water management programs for water systems in buildings. Properly implemented programs, as described in the new industry standard, could reduce Legionella growth and transmission, preventing Legionnaires' disease outbreaks and reducing disease. C1 [Garrison, L. E.; Cooley, L. A.; Moore, M. R.; Lucas, C.; Schrag, S.; Whitney, C. G.] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Kunz, J. M.; Sarisky, J.] CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Cooley, LA (reprint author), CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM lcooley@cdc.gov NR 17 TC 0 Z9 0 U1 7 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD OCT PY 2016 VL 16 IS 10 BP 3049 EP 3058 DI 10.1111/ajt.14024 PG 10 WC Surgery; Transplantation SC Surgery; Transplantation GA DY0UA UT WOS:000384810500033 ER PT J AU Yang, GY Jones, J Jang, YH Davis, CT AF Yang, Genyan Jones, Joyce Jang, Yunho Davis, C. Todd TI Multiplex assay for subtyping avian influenza A viruses by cDNA hybridization and adapter-mediated amplification SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY LA English DT Article DE Influenza; Subtyping; AmASIV; Surveillance ID IDENTIFICATION; PATHOGENS; PCR AB Multiple subtypes of influenza A viruses circulating in animals must be closely monitored to understand their risk to humans and animal populations. Many molecular-based subtyping methods require constant monitoring of viral genomes for primer and/or probe mismatches and are prone to primer-primer interactions. This report presents a new approach that involves target enrichment through cDNA hybridization followed by adapter-mediated amplification for subtyping influenza virus (AmASIV). As a proof of concept, the AmASIV assay was multiplexed to specifically detect and differentiate influenza A virus subtypes (H5, N5, N7, and N9) in a single reaction without cross-recognition of nontarget subtypes or influenza B virus. The limit of detection (LOD) of AmASIV, as measured by 50 % egg-infective dose per reaction (EID50/reaction), was comparable to that of singleplex TaqMan (R) qPCR assays with LODs of 10(-0.6) (H5), 10(2) (N5), 10(-0.3) (N7), and 10(-0.5) (N9) EID50/reaction. The AmASIV will strengthen animal influenza virus surveillance and laboratory capacity to improve prevention and control of influenza. C1 [Yang, Genyan; Jones, Joyce; Jang, Yunho; Davis, C. Todd] Ctr Dis Control & Prevent, Influenza Div, Virol Surveillance & Diag Branch, 1600 Clifton Rd NE,MS D30, Atlanta, GA 30333 USA. RP Davis, CT (reprint author), Ctr Dis Control & Prevent, Influenza Div, Virol Surveillance & Diag Branch, 1600 Clifton Rd NE,MS D30, Atlanta, GA 30333 USA. EM eou8@cdc.gov NR 26 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0175-7598 EI 1432-0614 J9 APPL MICROBIOL BIOT JI Appl. Microbiol. Biotechnol. PD OCT PY 2016 VL 100 IS 20 BP 8809 EP 8818 DI 10.1007/s00253-016-7664-8 PG 10 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA DY5GS UT WOS:000385128000016 PM 27372075 ER PT J AU Casanova, LM Teal, LJ Sickbert-Bennett, EE Anderson, DJ Sexton, DJ Rutala, WA Weber, DJ AF Casanova, Lisa M. Teal, Lisa J. Sickbert-Bennett, Emily E. Anderson, Deverick J. Sexton, Daniel J. Rutala, William A. Weber, David J. CA CDC Prevention Epictr Program TI Assessment of Self-Contamination During Removal of Personal Protective Equipment for Ebola Patient Care SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID VIRUS TRANSFER; EFFICACY; WORKERS; HANDS; RECOVERY; SYSTEMS; SKIN AB OBJECTIVE. Ebola virus disease (EVD) places healthcare personnel (HCP) at high risk for infection during patient care, and personal protective.equipment (PPE) is critical. Protocols for EVD PPE doffing have not been validated for prevention of viral self-contamination. Using surrogate viruses (non-enveloped MS2 and enveloped 406), we assessed self-contamination of skin and clothes when trained HCP doffed EVD PPE using a standardized protocol. METHODS. A total of 15 HCP donned EVD PPE for this study. Virus was applied to PPE, and a trained monitor guided them through the doffing protocol. Of the 15 participants, 10 used alcohol-based hand rub (ABHR) for glove and hand hygiene and 5 used hypochlorite for glove hygiene and ABHR for hand hygiene. Inner gloves, hands, face, and scrubs were sampled after doffing. RESULTS. After doffing, MS2 virus was detected on the inner glove worn on the dominant hand for 8 of 15 participants, on the non-dominant inner glove for 6 of 15 participants, and on scrubs for 2 of 15 participants. All MS2 on inner gloves was observed when ABHR was used for glove hygiene; none was observed when hypochlorite was used. When using hypochlorite for glove hygiene, 1 participant had MS2 on hands, and 1 had MS2 on scrubs. CONCLUSIONS. A structured doffing protocol using a trained monitor and ABHR protects against enveloped virus self-contamination. Non-enveloped virus (MS2) contamination was detected on inner gloves, possibly due to higher resistance to ABHR. Doffing protocols protective against all viruses need to incorporate highly effective glove and hand hygiene agents. C1 [Casanova, Lisa M.] Georgia State Univ, Sch Publ Hlth, Div Environm Hlth, POB 3984, Atlanta, GA 30303 USA. [Teal, Lisa J.; Sickbert-Bennett, Emily E.; Rutala, William A.; Weber, David J.] Univ North Carolina Healthcare, Hosp Epidemiol, Chapel Hill, NC USA. [Anderson, Deverick J.; Sexton, Daniel J.] Duke Univ, Med Ctr, Div Infect Dis, Durham, NC USA. [CDC Prevention Epictr Program] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Casanova, LM (reprint author), Georgia State Univ, Sch Publ Hlth, Div Environm Hlth, POB 3984, Atlanta, GA 30303 USA. EM lcasanova@gsu.edu FU Centers for Disease Control and Prevention's Prevention Epicenters Program [U54CK000164] FX This work was supported by the Centers for Disease Control and Prevention's Prevention Epicenters Program (Grant no. U54CK000164). The funding source played no role in the study design, the collection, analysis, and interpretation of data, the writing of the report, or in the decision to submit the paper for publication. NR 24 TC 1 Z9 1 U1 6 U2 6 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD OCT PY 2016 VL 37 IS 10 BP 1156 EP 1161 DI 10.1017/ice.2016.169 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DY4GS UT WOS:000385057600004 PM 27477451 ER EF